"Molecule ChEMBL ID";"Molecule Name";"Molecule Max Phase";"Molecular Weight";"#RO5 Violations";"AlogP";"Compound Key";"Smiles";"Standard Type";"Standard Relation";"Standard Value";"Standard Units";"pChEMBL Value";"Data Validity Comment";"Comment";"Uo Units";"Ligand Efficiency BEI";"Ligand Efficiency LE";"Ligand Efficiency LLE";"Ligand Efficiency SEI";"Potential Duplicate";"Assay ChEMBL ID";"Assay Description";"Assay Type";"BAO Format ID";"BAO Label";"Assay Organism";"Assay Tissue ChEMBL ID";"Assay Tissue Name";"Assay Cell Type";"Assay Subcellular Fraction";"Target ChEMBL ID";"Target Name";"Target Organism";"Target Type";"Document ChEMBL ID";"Source ID";"Source Description";"Document Journal";"Document Year";"Cell ChEMBL ID"
"CHEMBL1773577";"";"0";"443.49";"0";"3.65";"40";"CC(=O)Nc1nc2ccc(-c3ccnc(NS(=O)(=O)c4ccccc4F)n3)cc2s1";"IC50";"'='";"45.0";"nM";"7.35";"";"";"UO_0000065";"16.57";"0.33";"3.70";"6.45";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773561";"";"0";"390.47";"0";"4.60";"24";"CC(=O)Nc1nc2ccc(-c3ccnc(OCc4cccc(C)c4)n3)cc2s1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773077";"";"0";"406.47";"0";"4.30";"25";"COc1cccc(COc2nccc(-c3ccc4nc(NC(C)=O)sc4c3)n2)c1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773580";"";"0";"443.49";"0";"3.65";"43";"CC(=O)Nc1nc2ccc(-c3ccnc(NS(=O)(=O)c4ccc(F)cc4)n3)cc2s1";"IC50";"'='";"719.0";"nM";"6.14";"";"";"UO_0000065";"13.85";"0.28";"2.49";"5.39";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773578";"";"0";"457.51";"0";"3.68";"41";"CC(=O)Nc1nc2ccc(-c3ccnc(N(C)S(=O)(=O)c4ccccc4F)n3)cc2s1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773601";"";"0";"453.55";"0";"4.73";"60";"COc1ccc(S(=O)(=O)Nc2cccc(-c3ccc4nc(NC(C)=O)sc4c3)c2)cc1";"IC50";"'='";"1500.0";"nM";"5.82";"";"";"UO_0000065";"12.84";"0.26";"1.09";"5.98";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773606";"";"0";"526.95";"2";"5.79";"72";"CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccccc4C(F)(F)F)c3)cc2s1";"IC50";"'<'";"1.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1945792";"";"0";"312.33";"0";"1.84";"21";"O=c1[nH]c2ncc(-c3ccc(O)cc3)nc2n1C1CCOCC1";"IC50";"'='";"1670.0";"nM";"5.78";"";"";"UO_0000065";"18.50";"0.34";"3.94";"6.21";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1945950";"";"0";"366.47";"0";"3.59";"39";"CC(C)(O)c1ccc(-c2cnc3[nH]c(=O)n(CC4CCCCC4)c3n2)cc1";"IC50";"'='";"30.0";"nM";"7.52";"";"";"UO_0000065";"20.53";"0.38";"3.93";"8.98";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1946264";"";"0";"363.43";"0";"2.83";"58";"Nc1nc2cc(-c3cnc4[nH]c(=O)n(CC5CCCCC5)c4n3)ccc2[nH]1";"IC50";"'='";"92.0";"nM";"7.04";"";"";"UO_0000065";"19.36";"0.36";"4.21";"5.95";"False";"CHEMBL1949073";"Inhibition of mTOR-mediated Akt phosphorylation in human PC3 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";"CHEMBL3307570"
"CHEMBL1946266";"";"0";"349.39";"0";"2.69";"60";"O=c1[nH]c2ncc(-c3ccc4[nH]ccc4c3)nc2n1CC1CCOCC1";"IC50";"'='";"50.0";"nM";"7.30";"";"";"UO_0000065";"20.90";"0.38";"4.61";"8.24";"False";"CHEMBL1949073";"Inhibition of mTOR-mediated Akt phosphorylation in human PC3 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";"CHEMBL3307570"
"CHEMBL409427";"";"0";"532.63";"1";"1.75";"Table S1, S1";"COC[C@H]1OC(=O)/C(=C/N(C)CCN(C)C)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"1470.0";"nM";"5.83";"";"";"UO_0000065";"10.95";"0.21";"4.08";"4.63";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL1256461";"";"0";"604.63";"2";"7.80";"40";"CCC(=O)N1CC=C(c2ccc(-n3c(=O)ccc4cnc5ccc(-c6cnc7ccccc7c6)cc5c43)cc2C(F)(F)F)CC1";"IC50";"'='";"21.4";"nM";"7.67";"";"";"UO_0000065";"12.68";"0.23";"-0.13";"11.26";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1256458";"";"0";"691.76";"2";"5.67";"36";"CN1CCN(CC(=O)N2CCN(c3ccc(-n4c(=O)ccc5cnc6ccc(-c7cnc8ccccc8c7)cc6c54)cc3C(F)(F)F)CC2)CC1";"IC50";"'='";"0.57";"nM";"9.24";"";"";"UO_0000065";"13.36";"0.25";"3.57";"11.88";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1259105";"";"0";"547.64";"1";"4.35";"31";"O=c1ccc2cnc3ccc(-c4cnc5ccccc5c4)cc3c2n1-c1ccc(S(=O)(=O)N2CCNCC2)cc1";"IC50";"'='";"239.0";"nM";"6.62";"";"";"UO_0000065";"12.09";"0.23";"2.27";"6.81";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1256452";"";"0";"550.58";"2";"6.79";"25";"O=c1ccc2cnc3ccc(-c4ccc5ccccc5c4)cc3c2n1-c1ccc(N2CCNCC2)c(C(F)(F)F)c1";"IC50";"'='";"213.0";"nM";"6.67";"";"";"UO_0000065";"12.12";"0.22";"-0.12";"13.30";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1762774";"";"0";"395.43";"0";"4.40";"2";"Oc1cccc(Nc2nc3ccccc3n2-c2ncnc(Nc3ccccc3)n2)c1";"IC50";"'>'";"25000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1370";"BUDESONIDE";"4";"430.54";"0";"2.72";"Budesonide";"CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL829473";"Inhibitory activity against macrophilin (FKBP-12)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1138768";"1";"Scientific Literature";"J. Med. Chem.";"2004";""
"CHEMBL188678";"";"0";"413.50";"1";"5.66";"22g";"O=c1cc(N2CCOCC2)oc2c(-c3cccc4c3sc3ccccc34)cccc12";"IC50";"'='";"1700.0";"nM";"5.77";"";"";"UO_0000065";"13.95";"0.26";"0.11";"13.52";"False";"CHEMBL830270";"Inhibition of Mammalian target of Rapamycin mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1138727";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2004";""
"CHEMBL469202";"";"0";"406.51";"0";"4.11";"22d";"Cc1ccc(-c2ccc3c(c2)N(c2nc4c(s2)C(=O)NC(C)(C)C4)CCO3)cn1";"IC50";"'>'";"15000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1001369";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1155924";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2008";""
"CHEMBL1760160";"";"0";"357.33";"0";"2.44";"34";"Cc1nc(N)nc(-n2c(Nc3ccn(C(F)F)n3)nc3ccccc32)n1";"IC50";"'='";"340.0";"nM";"6.47";"";"";"UO_0000065";"18.10";"0.34";"4.03";"5.76";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760161";"";"0";"308.31";"0";"1.83";"35";"Cc1nc(N)nc(-n2c(Nc3ccon3)nc3ccccc32)n1";"IC50";"'='";"150.0";"nM";"6.82";"";"";"UO_0000065";"22.13";"0.41";"4.99";"5.66";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1773585";"";"0";"362.41";"0";"4.50";"8";"CC(=O)Nc1nc2ccc(-c3ccnc(Oc4ccccc4)n3)cc2s1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1201182";"TEMSIROLIMUS";"4";"1030.30";"";"";"2";"CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C";"IC50";"'='";"1760.0";"nM";"5.75";"";"";"UO_0000065";"5.59";"";"";"";"False";"CHEMBL1777505";"Inhibition of FKBP12-independent human recombinant mTOR expressed in HEK293 cells using His6-S6K1 as a substrate by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1772963";"1";"Scientific Literature";"J. Nat. Prod.";"2011";"CHEMBL3307715"
"CHEMBL2172638";"";"0";"401.41";"0";"3.35";"3";"Cc1nc(N)nc(-c2c(Nc3cc[nH]n3)nc3ccc(-c4ccccc4F)cn23)n1";"IC50";"'='";"15.0";"nM";"7.82";"";"";"UO_0000065";"19.49";"0.36";"4.47";"6.38";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1773574";"";"0";"455.52";"0";"3.52";"37";"COc1ccc(S(=O)(=O)Nc2nccc(-c3ccc4nc(NC(C)=O)sc4c3)n2)cc1";"IC50";"'='";"57.0";"nM";"7.24";"";"";"UO_0000065";"15.90";"0.32";"3.72";"5.88";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773579";"";"0";"443.49";"0";"3.65";"42";"CC(=O)Nc1nc2ccc(-c3ccnc(NS(=O)(=O)c4cccc(F)c4)n3)cc2s1";"IC50";"'='";"47.0";"nM";"7.33";"";"";"UO_0000065";"16.52";"0.33";"3.68";"6.43";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1762783";"";"0";"347.38";"0";"2.80";"12";"CCc1nc(N)nc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"6300.0";"nM";"5.20";"";"";"UO_0000065";"14.97";"0.27";"2.40";"4.53";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762788";"";"0";"333.36";"0";"2.55";"23";"Cc1nc(N)nc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"150.0";"nM";"6.82";"";"";"UO_0000065";"20.47";"0.37";"4.27";"5.95";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1773595";"";"0";"392.51";"1";"5.17";"18";"CC(=O)Nc1nc2ccc(-c3ccnc(Sc4cccc(C)c4)n3)cc2s1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773560";"";"0";"394.43";"0";"4.43";"23";"CC(=O)Nc1nc2ccc(-c3ccnc(OCc4cccc(F)c4)n3)cc2s1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773570";"";"0";"399.48";"0";"2.42";"34";"CC(=O)Nc1nc2ccc(-c3ccnc(OCCN4CCOCC4)n3)cc2s1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1762789";"";"0";"317.36";"0";"2.84";"24";"Cc1nc(N)nc(-n2c(Nc3ccccc3)nc3ccccc32)n1";"IC50";"'='";"190.0";"nM";"6.72";"";"";"UO_0000065";"21.18";"0.38";"3.88";"7.11";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760168";"";"0";"321.35";"0";"2.03";"42";"CNc1nc(C)nc(-n2c(Nc3cc[nH]n3)nc3ccccc32)n1";"IC50";"'='";"100.0";"nM";"7.00";"";"";"UO_0000065";"21.78";"0.40";"4.97";"6.41";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1615182";"";"0";"358.36";"0";"2.60";"1";"N#CCNc1ncnc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"97.0";"nM";"7.01";"";"";"UO_0000065";"19.57";"0.35";"4.41";"5.63";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL591358";"";"0";"515.58";"1";"3.09";"33";"CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)N(C)C)cc4)cc3)nc21";"IC50";"'='";"0.75";"nM";"9.12";"";"";"UO_0000065";"17.70";"0.33";"6.03";"7.00";"False";"CHEMBL1068073";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157707";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1081312";"";"0";"319.37";"0";"3.07";"33";"Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"25.05";"0.46";"4.93";"8.14";"True";"CHEMBL1111492";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1155389";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1808989";"";"0";"616.72";"1";"3.40";"20";"O=C(Nc1ccc(C(=O)NCCN2CCCCC2)cc1)Nc1ccc(-c2nc(O[C@H]3CCOC3)nc(N3CCOCC3)n2)cc1";"IC50";"'='";"0.4";"nM";"9.40";"";"";"UO_0000065";"15.24";"0.29";"6.00";"6.57";"False";"CHEMBL1810297";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1806467";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1808992";"";"0";"558.64";"1";"3.12";"24";"CN1C2CCC1CC(Oc1nc(-c3ccc(NC(=O)Nc4ccc(C(N)=O)cc4)cc3)nc(N3CCOCC3)n1)C2";"IC50";"'='";"5.3";"nM";"8.28";"";"";"UO_0000065";"14.81";"0.28";"5.16";"5.60";"False";"CHEMBL1810297";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1806467";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL592445";"GEDATOLISIB";"2";"615.74";"1";"3.02";"1, PKI-587";"CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1";"IC50";"'='";"0.4";"nM";"9.40";"";"";"UO_0000065";"15.26";"0.29";"6.38";"7.33";"False";"CHEMBL1810297";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1806467";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762788";"";"0";"333.36";"0";"2.55";"23";"Cc1nc(N)nc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"7.0";"nM";"8.15";"";"";"UO_0000065";"24.46";"0.45";"5.60";"7.11";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL601073";"";"0";"462.54";"0";"3.77";"23";"O=C(Nc1ccc(-c2nc(N3CCOCC3)c3nnn(C4CC4)c3n2)cc1)Nc1cccs1";"IC50";"'='";"3.05";"nM";"8.52";"";"";"UO_0000065";"18.41";"0.35";"4.75";"7.74";"False";"CHEMBL1068073";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157707";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1615183";"";"0";"307.32";"0";"1.57";"32";"Cc1nc(N)nc(-n2c(Nc3cc[nH]n3)nc3ccccc32)n1";"IC50";"'='";"27.0";"nM";"7.57";"";"";"UO_0000065";"24.63";"0.45";"6.00";"6.14";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760164";"";"0";"321.35";"0";"1.58";"38";"Cc1nc(N)nc(-n2c(Nc3ccnn3C)nc3ccccc32)n1";"IC50";"'>'";"50000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762790";"";"0";"349.35";"0";"2.26";"25";"Cc1nc(N)nc(-n2c(Nc3cc(O)cc(O)c3)nc3ccccc32)n1";"IC50";"'='";"0.2";"nM";"9.70";"";"";"UO_0000065";"27.76";"0.51";"7.44";"7.18";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760166";"";"0";"308.31";"0";"0.96";"40";"Cc1nc(N)nc(-n2c(Nc3nc[nH]n3)nc3ccccc32)n1";"IC50";"'='";"33100.0";"nM";"4.48";"";"";"UO_0000065";"14.53";"0.27";"3.52";"3.29";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760168";"";"0";"321.35";"0";"2.03";"42";"CNc1nc(C)nc(-n2c(Nc3cc[nH]n3)nc3ccccc32)n1";"IC50";"'='";"81.0";"nM";"7.09";"";"";"UO_0000065";"22.07";"0.40";"5.06";"6.49";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL568259";"";"0";"520.59";"1";"3.02";"24";"CNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(C4CCN(C(=O)OC)CC4)c3n2)cc1";"IC50";"'='";"0.22";"nM";"9.66";"";"";"UO_0000065";"18.55";"0.35";"6.64";"7.62";"True";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL567172";"";"0";"524.51";"1";"4.46";"35";"O=C(Nc1ccc(-c2nc(N3C4CCC3COC4)c3cnn(CC(F)(F)F)c3n2)cc1)Nc1cccnc1";"IC50";"'='";"0.2";"nM";"9.70";"";"";"UO_0000065";"18.49";"0.35";"5.24";"8.81";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL578645";"";"0";"522.61";"1";"3.26";"22";"CCNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)OCC)CC4)c3n2)cc1";"IC50";"'='";"0.17";"nM";"9.77";"";"";"UO_0000065";"18.69";"0.35";"6.51";"7.71";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL1957502";"";"0";"377.41";"0";"1.47";"25b";"CNC(=O)c1cn2cc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)c2n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1959594";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1955823";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1762774";"";"0";"395.43";"0";"4.40";"2";"Oc1cccc(Nc2nc3ccccc3n2-c2ncnc(Nc3ccccc3)n2)c1";"IC50";"'='";"870.0";"nM";"6.06";"";"";"UO_0000065";"15.33";"0.28";"1.66";"6.01";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1256465";"";"0";"638.65";"2";"5.53";"44";"CCC(=O)N1CCN(c2ccc(-n3c(=O)n(C)c(=O)c4cnc5ccc(-c6cnc7ccccc7c6)cc5c43)cc2C(F)(F)F)CC1";"IC50";"'='";"230.0";"nM";"6.64";"";"";"UO_0000065";"10.39";"0.19";"1.11";"7.11";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1760166";"";"0";"308.31";"0";"0.96";"40";"Cc1nc(N)nc(-n2c(Nc3nc[nH]n3)nc3ccccc32)n1";"IC50";"'='";"4600.0";"nM";"5.34";"";"";"UO_0000065";"17.31";"0.32";"4.38";"3.92";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL597814";"";"0";"475.55";"0";"3.16";"12";"Cc1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4CCOCC4)n3)cc2)cc1";"IC50";"'='";"6.3";"nM";"8.20";"";"";"UO_0000065";"17.24";"0.32";"5.04";"7.83";"False";"CHEMBL1065057";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157610";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1256468";"";"0";"611.62";"2";"7.32";"47";"CCC(=O)N1CCN(c2ccc(N3C(=O)OCc4cnc5ccc(-c6cnc7ccccc7c6)cc5c43)cc2C(F)(F)F)CC1";"IC50";"'='";"336.0";"nM";"6.47";"";"";"UO_0000065";"10.58";"0.20";"-0.85";"8.21";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1257839";"";"0";"501.59";"1";"3.70";"8c";"Cc1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4C5CCC4COC5)n3)cc2)cc1";"IC50";"'='";"1.3";"nM";"8.89";"";"";"UO_0000065";"17.72";"0.33";"5.19";"8.48";"False";"CHEMBL1259905";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255533";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1760167";"";"0";"325.38";"0";"1.69";"41";"Cc1nc(N)nc(-n2c(NC3CCOCC3)nc3ccccc32)n1";"IC50";"'>'";"25000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1091350";"";"0";"584.73";"1";"4.20";"21";"CN1CCN(c2ccc(NC(=O)Nc3ccc(-c4nc(C5CCOCC5)nc(N5C6CCC5COC6)n4)cc3)cc2)CC1";"IC50";"'='";"0.52";"nM";"9.28";"";"";"UO_0000065";"15.88";"0.29";"5.08";"8.60";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091359";"";"0";"573.70";"1";"4.38";"30";"CN(C)CCOc1ccc(NC(=O)Nc2ccc(-c3nc(C4CCOCC4)nc(N4C5CCC4COC5)n3)cc2)cc1";"IC50";"'='";"0.7";"nM";"9.15";"";"";"UO_0000065";"15.96";"0.30";"4.77";"8.03";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091711";"";"0";"627.79";"1";"4.31";"33";"CC(C)N1CCN(c2ccc(NC(=O)Nc3ccc(-c4nc(N5C6CCC5COC6)nc(N5CCOC[C@H]5C)n4)cc3)cc2)CC1";"IC50";"'='";"1.25";"nM";"8.90";"";"";"UO_0000065";"14.18";"0.26";"4.59";"8.00";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1256467";"";"0";"624.67";"2";"7.23";"46";"CCC(=O)N1CCN(c2ccc(N3C(=O)N(C)Cc4cnc5ccc(-c6cnc7ccccc7c6)cc5c43)cc2C(F)(F)F)CC1";"IC50";"'='";"287.0";"nM";"6.54";"";"";"UO_0000065";"10.47";"0.19";"-0.69";"8.98";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1085177";"";"0";"504.64";"2";"0.95";"20";"Cc1nc(N)ncc1-c1nc(N2CCOCC2)c2sc(CN3CCN(S(C)(=O)=O)CC3)cc2n1";"IC50";"'='";"880.0";"nM";"6.06";"";"";"UO_0000065";"12.00";"0.24";"5.11";"4.63";"False";"CHEMBL1103322";"Inhibition of human recombinant mTOR by FRET";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154879";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1098242";"";"0";"568.65";"1";"3.99";"27b";"CC(C)(C)OC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)NCCF)cc4)nc32)CC1";"IC50";"'='";"0.5";"nM";"9.30";"";"";"UO_0000065";"16.36";"0.31";"5.31";"7.34";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL561907";"";"0";"526.57";"1";"2.82";"25b";"COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)NCCF)cc4)nc32)CC1";"IC50";"'='";"0.6";"nM";"9.22";"";"";"UO_0000065";"17.51";"0.33";"6.40";"7.28";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1097900";"";"0";"588.72";"2";"5.81";"16m";"O=C(Nc1ccccc1)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)cc1";"IC50";"'='";"2.4";"nM";"8.62";"";"";"UO_0000065";"14.64";"0.27";"2.81";"8.58";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1098301";"";"0";"527.63";"1";"4.35";"13c";"COC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)cc1";"IC50";"'='";"12.0";"nM";"7.92";"";"";"UO_0000065";"15.01";"0.28";"3.57";"8.11";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1098245";"";"0";"600.68";"1";"3.91";"25f";"COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)Nc5ccc(CCO)cc5)cc4)nc32)CC1";"IC50";"'='";"0.1";"nM";"10.00";"";"";"UO_0000065";"16.65";"0.31";"6.09";"6.80";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1094981";"";"0";"554.63";"1";"3.60";"26b";"CC(C)OC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)NCCF)cc4)nc32)CC1";"IC50";"'='";"0.3";"nM";"9.52";"";"";"UO_0000065";"17.17";"0.33";"5.92";"7.51";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1762788";"";"0";"333.36";"0";"2.55";"23";"Cc1nc(N)nc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"9.0";"nM";"8.05";"";"";"UO_0000065";"24.14";"0.44";"5.50";"7.01";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1258296";"";"0";"531.62";"1";"2.92";"8g";"O=C(Nc1ccc(CCO)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1";"IC50";"'='";"0.32";"nM";"9.49";"";"";"UO_0000065";"17.86";"0.33";"6.57";"7.60";"False";"CHEMBL1259905";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255533";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1256447";"";"0";"585.63";"2";"6.90";"16";"COCCC(=O)N1CCN(c2ccc(Nc3ccnc4ccc(-c5cnc6ccccc6c5)cc34)cc2C(F)(F)F)CC1";"IC50";"'='";"966.0";"nM";"6.01";"";"";"UO_0000065";"10.27";"0.19";"-0.88";"8.52";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1259050";"";"0";"562.55";"1";"4.44";"24";"COc1ncc(-c2ccc3ncc4ccc(=O)n(-c5ccc(N6CCNCC6)c(C(F)(F)F)c5)c4c3c2)c(OC)n1";"IC50";"'='";"662.0";"nM";"6.18";"";"";"UO_0000065";"10.98";"0.21";"1.74";"6.55";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1084926";"";"0";"372.45";"0";"1.79";"5, GNE-493";"CC(C)(O)c1cc2nc(-c3cnc(N)nc3)nc(N3CCOCC3)c2s1";"IC50";"'='";"30.0";"nM";"7.52";"";"";"UO_0000065";"20.20";"0.40";"5.73";"6.82";"False";"CHEMBL1103322";"Inhibition of human recombinant mTOR by FRET";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154879";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL270553";"";"0";"591.70";"1";"4.13";"Table S1, S24";"COC[C@H]1OC(=O)/C(=C/N2CCC(c3ccccc3)CC2)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"2450.0";"nM";"5.61";"";"";"UO_0000065";"9.48";"0.18";"1.48";"4.58";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL271982";"";"0";"629.75";"2";"1.20";"Table S1, S22";"COC[C@H]1OC(=O)/C(=C/N2CCN(CCN3CCOCC3)CC2)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"619.0";"nM";"6.21";"";"";"UO_0000065";"9.86";"0.19";"5.01";"4.49";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL271430";"";"0";"613.75";"2";"1.96";"Table S1, S16";"COC[C@H]1OC(=O)/C(=C/N2CCN(C3CCN(C)CC3)CC2)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"961.0";"nM";"6.02";"";"";"UO_0000065";"9.80";"0.19";"4.06";"4.66";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL439319";"";"0";"966.23";"3";"6.05";"4";"CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@H](n3ncnn3)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C";"IC50";"'='";"4.8";"nM";"8.32";"";"";"UO_0000065";"8.61";"0.16";"2.27";"3.80";"False";"CHEMBL871328";"Inhibitory activity against FKBP12";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1141950";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2005";""
"CHEMBL1258635";"";"0";"489.54";"0";"2.18";"8p";"O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1)Nc1cncnc1";"IC50";"'='";"0.73";"nM";"9.14";"";"";"UO_0000065";"18.66";"0.35";"6.96";"7.00";"False";"CHEMBL1259905";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255533";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1242292";"";"0";"386.24";"0";"4.49";"PP218";"Nc1ncnc2[nH]nc(-c3cccc(OCc4c(Cl)cccc4Cl)c3)c12";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242850";"";"0";"287.33";"0";"3.27";"PP220";"Nc1ncnc2[nH]nc(-c3ccc(-c4ccccc4)cc3)c12";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241674";"";"0";"308.35";"0";"2.84";"PP242";"CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21";"IC50";"'='";"8.0";"nM";"8.10";"";"";"UO_0000065";"26.26";"0.48";"5.26";"7.66";"True";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241487";"";"0";"310.36";"0";"2.48";"PP281";"Nc1ccc(-c2nn(C3CCCC3)c3ncnc(N)c23)cc1O";"IC50";"'='";"911.0";"nM";"6.04";"";"";"UO_0000065";"19.46";"0.36";"3.56";"5.21";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241943";"";"0";"372.86";"0";"2.82";"PP391";"Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2CCC1CCCNC1";"IC50";"'='";"3600.0";"nM";"5.44";"";"";"UO_0000065";"14.60";"0.29";"2.62";"5.34";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL222102";"KU-55933";"0";"395.51";"0";"4.76";"1, KU-55933";"O=c1cc(-c2cccc3c2Sc2ccccc2S3)oc(N2CCOCC2)c1";"IC50";"'='";"9300.0";"nM";"5.03";"";"";"UO_0000065";"12.72";"0.25";"0.27";"11.79";"False";"CHEMBL1767684";"Inhibition of mTOR by radiometric phosphate incorporation assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1765064";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1242656";"";"0";"327.36";"0";"3.28";"PP421";"CC1CCC(n2nc(-c3ccc(F)c(O)c3)c3c(N)ncnc32)C1";"IC50";"'='";"815.0";"nM";"6.09";"";"";"UO_0000065";"18.60";"0.35";"2.81";"6.78";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241583";"";"0";"292.35";"0";"2.72";"PP46";"CC(C)n1nc(-c2cccc(CC#N)c2)c2c(N)ncnc21";"IC50";"'='";"12000.0";"nM";"4.92";"";"";"UO_0000065";"16.83";"0.31";"2.20";"5.27";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242117";"";"0";"293.29";"0";"1.72";"PP148";"Cn1nc(-c2ccc3occc(=O)c3c2)c2c(N)ncnc21";"IC50";"'='";"100000.0";"nM";"4.00";"";"";"UO_0000065";"13.64";"0.25";"2.28";"4.01";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242844";"";"0";"342.38";"0";"1.92";"PP377";"Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2CC1CCNCC1";"IC50";"'='";"100000.0";"nM";"4.00";"";"";"UO_0000065";"11.68";"0.22";"2.08";"3.93";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242573";"";"0";"311.32";"0";"2.67";"PP159";"CC(C)n1nc(-c2cc(F)c3cn[nH]c3c2)c2c(N)ncnc21";"IC50";"'='";"7000.0";"nM";"5.16";"";"";"UO_0000065";"16.56";"0.31";"2.48";"5.24";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242384";"";"0";"306.37";"0";"3.15";"PP135";"CC(C)n1nc(-c2ccc3c(ccn3C)c2)c2c(N)ncnc21";"IC50";"'='";"457.0";"nM";"6.34";"";"";"UO_0000065";"20.69";"0.38";"3.19";"8.50";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1773734";"";"0";"515.06";"2";"6.07";"79";"CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(C(C)(C)C)cc4)c3)cc2s1";"IC50";"'='";"2.1";"nM";"8.68";"";"";"UO_0000065";"16.85";"0.35";"2.61";"8.59";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1822059";"";"0";"402.84";"0";"3.99";"15";"O=S(=O)(Nc1cc(-c2ccc3nccn3c2)cnc1Cl)c1ccc(F)cc1";"IC50";"'='";"229.0";"nM";"6.64";"";"";"UO_0000065";"16.48";"0.34";"2.65";"8.70";"False";"CHEMBL1828260";"Inhibition of recombinant N-terminal GST-tagged mTOR-mediated 4E-BP1 phosphorylation after 60 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1821651";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1822060";"";"0";"459.89";"0";"4.18";"16";"CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)cc2[nH]1";"IC50";"'='";"20.0";"nM";"7.70";"";"";"UO_0000065";"16.74";"0.34";"3.52";"6.59";"False";"CHEMBL1828260";"Inhibition of recombinant N-terminal GST-tagged mTOR-mediated 4E-BP1 phosphorylation after 60 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1821651";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773602";"";"0";"479.54";"0";"4.00";"63";"COc1ccc(S(=O)(=O)Nc2cc(-c3ccc4nc(NC(C)=O)sc4c3)cnc2C#N)cc1";"IC50";"'='";"1.6";"nM";"8.80";"";"";"UO_0000065";"18.34";"0.36";"4.80";"6.56";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1615189";"";"0";"476.94";"0";"4.91";"82";"CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)cc2s1";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"18.24";"0.38";"3.79";"8.61";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1822212";"";"0";"403.82";"0";"4.48";"20";"O=S(=O)(Nc1cc(-c2ccc3ncoc3c2)cnc1Cl)c1ccc(F)cc1";"IC50";"'='";"76.0";"nM";"7.12";"";"";"UO_0000065";"17.63";"0.36";"2.64";"8.37";"False";"CHEMBL1828260";"Inhibition of recombinant N-terminal GST-tagged mTOR-mediated 4E-BP1 phosphorylation after 60 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1821651";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1242024";"";"0";"283.34";"0";"2.67";"PP60";"Cc1cc(O)ccc1-c1nn(C(C)C)c2ncnc(N)c12";"IC50";"'='";"2100.0";"nM";"5.68";"";"";"UO_0000065";"20.04";"0.37";"3.01";"6.32";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242468";"";"0";"302.31";"0";"1.44";"PP454";"C[C@@H](CN)n1nc(-c2ccc(F)c(O)c2)c2c(N)ncnc21";"IC50";"'='";"2900.0";"nM";"5.54";"";"";"UO_0000065";"18.32";"0.34";"4.10";"4.78";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241947";"";"0";"301.38";"0";"2.84";"PP34";"Cc1cc(-c2nn(C(C)C)c3ncnc(N)c23)sc1C=O";"IC50";"'='";"934.0";"nM";"6.03";"";"";"UO_0000065";"20.01";"0.39";"3.19";"6.96";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1762778";"";"0";"319.33";"0";"2.24";"6";"Nc1ncnc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"34.0";"nM";"7.47";"";"";"UO_0000065";"23.39";"0.42";"5.23";"6.51";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1774374";"";"0";"455.56";"0";"3.29";"29b";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)[C@@](C)(CCOC)OC3)cc1";"IC50";"'='";"41.0";"nM";"7.39";"";"";"UO_0000065";"16.22";"0.31";"4.10";"7.55";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774378";"";"0";"413.48";"0";"1.86";"29f";"CCNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3c(n2)[C@@](C)(CO)OC3)cc1";"IC50";"'='";"140.0";"nM";"6.85";"";"";"UO_0000065";"16.58";"0.31";"4.99";"6.30";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774361";"";"0";"451.57";"0";"4.06";"21a";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)[C@@](C)(CC2CC2)OC3)cc1";"IC50";"'='";"5.0";"nM";"8.30";"";"";"UO_0000065";"18.38";"0.34";"4.24";"9.37";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774364";"";"0";"427.51";"0";"2.25";"22b";"CCNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3c(n2)[C@](C)(CCO)OC3)cc1";"IC50";"'='";"2.6";"nM";"8.59";"";"";"UO_0000065";"20.08";"0.38";"6.34";"7.89";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774370";"";"0";"450.54";"0";"3.56";"23b";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)[C@](C)(CCC#N)OC3)cc1";"IC50";"'='";"15.0";"nM";"7.82";"";"";"UO_0000065";"17.37";"0.32";"4.26";"6.96";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774378";"";"0";"413.48";"0";"1.86";"29f";"CCNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3c(n2)[C@@](C)(CO)OC3)cc1";"IC50";"'='";"234.0";"nM";"6.63";"";"";"UO_0000065";"16.04";"0.30";"4.77";"6.09";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774379";"";"0";"469.59";"0";"3.42";"29g";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)[C@](C)(CC(C)(C)O)OC3)cc1";"IC50";"'='";"6.3";"nM";"8.20";"";"";"UO_0000065";"17.46";"0.33";"4.78";"7.53";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774381";"";"0";"469.59";"0";"3.42";"29i";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)[C@@](C)(CC(C)(C)O)OC3)cc1";"IC50";"'='";"24.0";"nM";"7.62";"";"";"UO_0000065";"16.23";"0.31";"4.20";"7.00";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774354";"";"0";"411.46";"0";"2.53";"13c";"CCNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3c(n2)C(C)(C)OC3=O)cc1";"IC50";"'='";"16.0";"nM";"7.80";"";"";"UO_0000065";"18.95";"0.35";"5.27";"7.38";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1241481";"";"0";"398.47";"0";"4.01";"PP20";"COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1NC(=O)OC(C)(C)C";"IC50";"'>'";"50000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241355";"";"0";"227.23";"0";"1.31";"PP133";"Nc1ncnc2[nH]nc(-c3ccccc3O)c12";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242569";"";"0";"325.37";"0";"2.67";"PP361";"C=CCn1nc(-c2ccc(OCC)c(OC)c2)c2c(N)ncnc21";"IC50";"'='";"4800.0";"nM";"5.32";"";"";"UO_0000065";"16.35";"0.30";"2.65";"6.04";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241679";"";"0";"278.32";"0";"2.53";"PP39";"CC(C)n1nc(-c2cccc(C#N)c2)c2c(N)ncnc21";"IC50";"'='";"40000.0";"nM";"4.40";"";"";"UO_0000065";"15.80";"0.29";"1.87";"4.71";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242287";"";"0";"360.22";"0";"3.27";"PP491";"Nc1ncnc2c1c(-c1ccc(Br)c(O)c1)nn2C1CCC1";"IC50";"'='";"127.0";"nM";"6.90";"";"";"UO_0000065";"19.14";"0.43";"3.63";"7.68";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241580";"";"0";"315.76";"0";"3.16";"PP463";"Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2C1CCC1";"IC50";"'='";"230.0";"nM";"6.64";"";"";"UO_0000065";"21.02";"0.41";"3.48";"7.39";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1091708";"";"0";"628.69";"2";"5.50";"6y";"CN(C(=O)C1CCN(c2ccnc3c2c(/C=C2\Oc4ccc(NC(=O)Nc5cccnc5)cc4C2=O)cn3C)CC1)c1cccnc1";"IC50";"'='";"13.0";"nM";"7.89";"";"";"UO_0000065";"12.54";"0.23";"2.39";"5.86";"False";"CHEMBL1107893";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156282";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091695";"";"0";"607.67";"1";"4.30";"6l";"Cn1cc(/C=C2\Oc3ccc(NC(=O)Nc4cccnc4)cc3C2=O)c2c(N3CCC(C(=O)N4CCOCC4)CC3)ccnc21";"IC50";"'='";"18.0";"nM";"7.75";"";"";"UO_0000065";"12.74";"0.24";"3.44";"5.92";"False";"CHEMBL1107893";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156282";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1774358";"";"0";"463.54";"0";"3.51";"13g";"C[C@H]1COCCN1c1nc(-c2ccc(NC(=O)Nc3cnn(C)c3)cc2)nc2c1COC2(C)C";"IC50";"'='";"4.3";"nM";"8.37";"";"";"UO_0000065";"18.05";"0.34";"4.86";"7.86";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774365";"";"0";"453.54";"0";"2.78";"22c";"CCNC(=O)Nc1ccc(-c2nc(N3C[C@@H]4CC[C@H](C3)O4)c3c(n2)[C@](C)(CCO)OC3)cc1";"IC50";"'='";"1.4";"nM";"8.85";"";"";"UO_0000065";"19.52";"0.37";"6.07";"8.13";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774379";"";"0";"469.59";"0";"3.42";"29g";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)[C@](C)(CC(C)(C)O)OC3)cc1";"IC50";"'='";"4.4";"nM";"8.36";"";"";"UO_0000065";"17.80";"0.34";"4.94";"7.68";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774362";"";"0";"451.57";"0";"4.06";"21b";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)[C@](C)(CC2CC2)OC3)cc1";"IC50";"'='";"5.0";"nM";"8.30";"";"";"UO_0000065";"18.38";"0.34";"4.24";"9.37";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774360";"";"0";"433.51";"0";"3.57";"13i";"C[C@H]1COCCN1c1nc(-c2ccc(Nc3cccc(=O)[nH]3)cc2)nc2c1COC2(C)C";"IC50";"'='";"15.0";"nM";"7.82";"";"";"UO_0000065";"18.05";"0.33";"4.25";"8.47";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1946131";"";"0";"376.42";"0";"2.40";"52";"O=c1[nH]c2ncc(-c3ccc(-n4cccn4)cc3)nc2n1CC1CCOCC1";"IC50";"'='";"170.0";"nM";"6.77";"";"";"UO_0000065";"17.98";"0.33";"4.37";"7.47";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1946261";"";"0";"350.38";"0";"2.09";"55";"O=c1[nH]c2ncc(-c3ccc4[nH]cnc4c3)nc2n1CC1CCOCC1";"IC50";"'='";"30.0";"nM";"7.52";"";"";"UO_0000065";"21.47";"0.40";"5.43";"7.41";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1945492";"";"0";"348.36";"0";"2.55";"11";"COc1ccc(Cn2c(=O)[nH]c3ncc(-c4ccc(O)cc4)nc32)cc1";"IC50";"'='";"630.0";"nM";"6.20";"";"";"UO_0000065";"17.80";"0.33";"3.65";"6.67";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1946130";"";"0";"374.45";"0";"3.76";"51";"O=c1[nH]c2ncc(-c3ccc(-c4cn[nH]c4)cc3)nc2n1CC1CCCCC1";"IC50";"'='";"120.0";"nM";"6.92";"";"";"UO_0000065";"18.48";"0.34";"3.16";"7.50";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1946265";"";"0";"379.42";"0";"2.13";"59";"CNc1nc2cc(-c3cnc4[nH]c(=O)n(CC5CCOCC5)c4n3)ccc2[nH]1";"IC50";"'='";"6.0";"nM";"8.22";"";"";"UO_0000065";"21.67";"0.40";"6.09";"7.24";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1946266";"";"0";"349.39";"0";"2.69";"60";"O=c1[nH]c2ncc(-c3ccc4[nH]ccc4c3)nc2n1CC1CCOCC1";"IC50";"'='";"21.0";"nM";"7.68";"";"";"UO_0000065";"21.97";"0.40";"4.99";"8.67";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1774366";"";"0";"441.53";"0";"2.64";"22d";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)[C@@](C)(CCO)OC3)cc1";"IC50";"'='";"40.0";"nM";"7.40";"";"";"UO_0000065";"16.76";"0.32";"4.76";"6.80";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774355";"";"0";"427.51";"0";"2.25";"13d";"C[C@H]1COCCN1c1nc(-c2ccc(NC(=O)NCCO)cc2)nc2c1COC2(C)C";"IC50";"'='";"4.0";"nM";"8.40";"";"";"UO_0000065";"19.64";"0.37";"6.15";"7.72";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774360";"";"0";"433.51";"0";"3.57";"13i";"C[C@H]1COCCN1c1nc(-c2ccc(Nc3cccc(=O)[nH]3)cc2)nc2c1COC2(C)C";"IC50";"'='";"9.3";"nM";"8.03";"";"";"UO_0000065";"18.53";"0.34";"4.46";"8.69";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1257716";"";"0";"512.57";"1";"3.26";"8d";"N#Cc1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4C5CCC4COC5)n3)cc2)cc1";"IC50";"'='";"3.3";"nM";"8.48";"";"";"UO_0000065";"16.55";"0.30";"5.22";"6.60";"False";"CHEMBL1259905";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255533";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1255813";"";"0";"585.71";"1";"3.14";"8i";"CN1CCN(c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5C6CCC5COC6)n4)cc3)cc2)CC1";"IC50";"'='";"1.1";"nM";"8.96";"";"";"UO_0000065";"15.30";"0.28";"5.82";"8.05";"False";"CHEMBL1259905";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255533";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1255815";"";"0";"599.74";"1";"3.13";"8k";"CN1CCN(Cc2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5C6CCC5COC6)n4)cc3)cc2)CC1";"IC50";"'='";"0.8";"nM";"9.10";"";"";"UO_0000065";"15.17";"0.28";"5.97";"8.18";"False";"CHEMBL1259905";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255533";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL6683";"";"0";"372.47";"0";"2.28";"S1M3M'1";"CC(CN1CCCCC1)OC(=O)[C@@H]1CCCN1C(=O)C(=O)c1ccccc1";"IC50";"'<'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL682171";"The inhibitory activity by using FK506 binding protein 12 SPA binding assay.";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1132865";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2000";""
"CHEMBL1242034";"";"0";"319.37";"0";"2.79";"PP147";"CC(C)n1nc(-c2ccc3nccc(N)c3c2)c2c(N)ncnc21";"IC50";"'='";"10000.0";"nM";"5.00";"";"";"UO_0000065";"15.66";"0.28";"2.21";"4.61";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241684";"";"0";"337.41";"0";"3.68";"PP42";"CC(C)n1nc(-c2cc3cc(C=O)ccc3s2)c2c(N)ncnc21";"IC50";"'='";"4500.0";"nM";"5.35";"";"";"UO_0000065";"15.85";"0.30";"1.67";"6.17";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242851";"";"0";"289.34";"0";"3.25";"PP224";"CCn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241682";"";"0";"318.38";"0";"3.51";"PP118";"Cc1ccc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2n1";"IC50";"'='";"565.0";"nM";"6.25";"";"";"UO_0000065";"19.62";"0.36";"2.74";"7.57";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241776";"";"0";"321.34";"0";"1.89";"PP158";"CC(C)n1nc(-c2ccc3nc[nH]c(=O)c3c2)c2c(N)ncnc21";"IC50";"'='";"20.0";"nM";"7.70";"";"";"UO_0000065";"23.96";"0.44";"5.81";"6.67";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242665";"";"0";"293.33";"0";"2.30";"PP161";"CC(C)n1nc(-c2ccn3ccnc3c2)c2c(N)ncnc21";"IC50";"'='";"7600.0";"nM";"5.12";"";"";"UO_0000065";"17.45";"0.32";"2.82";"5.89";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241492";"";"0";"295.31";"0";"2.19";"PP44";"CC(C)n1nc(-c2ccc3nonc3c2)c2c(N)ncnc21";"IC50";"'='";"100000.0";"nM";"4.00";"";"";"UO_0000065";"13.55";"0.25";"1.81";"3.69";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241585";"";"0";"351.41";"0";"4.28";"PP229";"Nc1ncnc2c1c(-c1ccc3ccccc3c1)nn2Cc1ccccc1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242205";"";"0";"303.32";"0";"3.39";"PP215";"Nc1ncnc2[nH]nc(-c3cccc(Oc4ccccc4)c3)c12";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1336";"SORAFENIB";"4";"464.83";"1";"5.55";"sorafenib";"CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1";"IC50";"'>'";"50000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL540695";"";"0";"604.68";"1";"4.24";"26";"O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)c5cccnc5)CC4)c3n2)cc1";"IC50";"'='";"0.83";"nM";"9.08";"";"";"UO_0000065";"15.02";"0.28";"4.84";"6.34";"False";"CHEMBL1058638";"Inhibition of flag-tagged truncated human mTOR (1360-2549) expressed in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1151963";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL561708";"";"0";"495.54";"0";"2.91";"19";"COC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)OC)CC4)c3n2)cc1";"IC50";"'='";"4.3";"nM";"8.37";"";"";"UO_0000065";"16.88";"0.32";"5.46";"6.75";"False";"CHEMBL1058638";"Inhibition of flag-tagged truncated human mTOR (1360-2549) expressed in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1151963";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL564404";"";"0";"525.57";"2";"2.27";"20";"COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)OCCO)cc4)nc32)CC1";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"17.12";"0.32";"6.73";"6.24";"False";"CHEMBL1058638";"Inhibition of flag-tagged truncated human mTOR (1360-2549) expressed in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1151963";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1242030";"";"0";"346.42";"0";"2.03";"PP40";"CC(C)n1nc(-c2ccc(NS(C)(=O)=O)cc2)c2c(N)ncnc21";"IC50";"'='";"3800.0";"nM";"5.42";"";"";"UO_0000065";"15.65";"0.31";"3.39";"4.68";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242115";"";"0";"381.47";"0";"2.49";"PP30";"CC(C)n1nc(-c2cccc(C(=O)NC3=NCCS3)c2)c2c(N)ncnc21";"IC50";"'='";"80.0";"nM";"7.10";"";"";"UO_0000065";"18.60";"0.36";"4.61";"6.39";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1256466";"";"0";"610.64";"2";"6.89";"45";"CCC(=O)N1CCN(c2ccc(N3C(=O)NCc4cnc5ccc(-c6cnc7ccccc7c6)cc5c43)cc2C(F)(F)F)CC1";"IC50";"'='";"396.0";"nM";"6.40";"";"";"UO_0000065";"10.48";"0.19";"-0.49";"7.84";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1256469";"";"0";"593.61";"2";"6.44";"18";"CC(=O)N1CCN(c2ccc(-n3c(=O)ccc4cnc5ccc(-c6cnc7ccccc7c6)cc5c43)cc2C(F)(F)F)CC1";"IC50";"'='";"5.4";"nM";"8.27";"";"";"UO_0000065";"13.93";"0.26";"1.83";"11.59";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1256454";"";"0";"593.63";"2";"5.01";"28";"CS(=O)(=O)Nc1ccc(-c2ccc3ncc4ccc(=O)n(-c5ccc(N6CCNCC6)c(C(F)(F)F)c5)c4c3c2)cc1";"IC50";"'='";"45.9";"nM";"7.34";"";"";"UO_0000065";"12.36";"0.24";"2.33";"7.62";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1256448";"";"0";"598.67";"2";"6.81";"17";"CN(C)CCC(=O)N1CCN(c2ccc(Nc3ccnc4ccc(-c5cnc6ccccc6c5)cc34)cc2C(F)(F)F)CC1";"IC50";"'='";"3810.0";"nM";"5.42";"";"";"UO_0000065";"9.05";"0.17";"-1.39";"8.39";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1259070";"";"0";"544.53";"2";"5.36";"27";"O=c1ccc2cnc3ccc(-c4ccc5c(c4)OCO5)cc3c2n1-c1ccc(N2CCNCC2)c(C(F)(F)F)c1";"IC50";"'='";"82.6";"nM";"7.08";"";"";"UO_0000065";"13.01";"0.24";"1.72";"10.32";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1256457";"";"0";"650.71";"2";"6.37";"35";"CN(C)CCC(=O)N1CCN(c2ccc(-n3c(=O)ccc4cnc5ccc(-c6cnc7ccccc7c6)cc5c43)cc2C(F)(F)F)CC1";"IC50";"'='";"3.6";"nM";"8.44";"";"";"UO_0000065";"12.98";"0.24";"2.07";"11.32";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL566216";"";"0";"499.58";"0";"4.02";"35";"CCn1ncc2c(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(CO)cc4)cc3)nc21";"IC50";"'='";"0.1";"nM";"10.00";"";"";"UO_0000065";"20.02";"0.37";"5.98";"8.52";"False";"CHEMBL1039195";"Inhibition of human FLAG-tagged mTOR expressed in HEK293 cells after 2 hrs by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156748";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307715"
"CHEMBL478980";"";"0";"283.33";"0";"2.46";"AMA37";"O=C(c1ccccc1)c1ccc(N2CCOCC2)cc1O";"IC50";"'>'";"100000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL941421";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156476";"1";"Scientific Literature";"J. Biol. Chem.";"2007";""
"CHEMBL570635";"";"0";"556.67";"1";"4.47";"34";"CCn1ncc2c(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(OCCN(C)C)cc4)cc3)nc21";"IC50";"'='";"0.8";"nM";"9.10";"";"";"UO_0000065";"16.34";"0.30";"4.63";"8.29";"False";"CHEMBL1039195";"Inhibition of human FLAG-tagged mTOR expressed in HEK293 cells after 2 hrs by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156748";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307715"
"CHEMBL567694";"";"0";"499.58";"0";"3.96";"20";"CCn1ncc2c(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(NC)nc4)cc3)nc21";"IC50";"'='";"0.9";"nM";"9.05";"";"";"UO_0000065";"18.11";"0.33";"5.09";"7.41";"False";"CHEMBL1039195";"Inhibition of human FLAG-tagged mTOR expressed in HEK293 cells after 2 hrs by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156748";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307715"
"CHEMBL585126";"";"0";"464.57";"0";"2.56";"15";"CCNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(CCN(C)C)c3n2)cc1";"IC50";"'='";"13.0";"nM";"7.89";"";"";"UO_0000065";"16.97";"0.32";"5.33";"7.85";"False";"CHEMBL1039195";"Inhibition of human FLAG-tagged mTOR expressed in HEK293 cells after 2 hrs by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156748";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307715"
"CHEMBL2064334";"";"0";"343.36";"0";"1.22";"12";"Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2ccc(F)cc21";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064333";"";"0";"343.36";"0";"1.22";"11";"Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2cc(F)ccc21";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064414";"";"0";"389.42";"0";"2.40";"42";"O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4ccccn4)cccc3o2)[nH]1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064410";"";"0";"391.23";"0";"2.10";"38";"O=c1cc(N2CCOCC2)nc(Cc2nc3c(Br)cccc3o2)[nH]1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064418";"";"0";"312.33";"0";"1.34";"7";"O=c1cc(N2CCOCC2)nc(Cc2nc3ccccc3o2)[nH]1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064415";"";"0";"389.42";"0";"2.40";"43";"O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4cccnc4)cccc3o2)[nH]1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL594218";"";"0";"339.36";"0";"1.63";"11";"c1nc2c(N3CCOCC3)nc(-c3ccc4c(c3)OCCO4)nc2[nH]1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1074731";"Inhibition of human TOR in HEK293 cells by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153204";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL596298";"";"0";"306.33";"0";"1.73";"17";"N#Cc1cccc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1074731";"Inhibition of human TOR in HEK293 cells by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153204";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL592747";"";"0";"498.63";"0";"3.73";"22";"OCc1cccc(-c2nc(N3CCOCC3)c3ncn(CC4CCN(Cc5ccccc5)CC4)c3n2)c1";"IC50";"'='";"10500.0";"nM";"4.98";"";"";"UO_0000065";"9.98";"0.18";"1.25";"6.26";"False";"CHEMBL1074731";"Inhibition of human TOR in HEK293 cells by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153204";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL601895";"";"0";"429.51";"1";"5.20";"28";"O=C(Nc1ccc(-c2nc(C3=CCOCC3)c3sccc3n2)cc1)Nc1cccnc1";"IC50";"'='";"1.1";"nM";"8.96";"";"";"UO_0000065";"20.86";"0.39";"3.76";"10.06";"False";"CHEMBL1074679";"Inhibition of mTOR in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153200";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL574680";"";"0";"498.47";"0";"3.93";"10";"O=C(Nc1ccc(-c2nc(N3CCOCC3)c3cnn(CC(F)(F)F)c3n2)cc1)Nc1cccnc1";"IC50";"'='";"0.2";"nM";"9.70";"";"";"UO_0000065";"19.46";"0.37";"5.77";"8.81";"False";"CHEMBL1074679";"Inhibition of mTOR in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153200";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL589858";"";"0";"432.41";"0";"3.61";"11";"CNC(=O)Nc1ccc(-c2nc(C3=CCOCC3)c3cnn(CC(F)(F)F)c3n2)cc1";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"20.12";"0.38";"5.09";"9.26";"False";"CHEMBL1074679";"Inhibition of mTOR in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153200";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL1242119";"";"0";"347.38";"0";"3.30";"PP144";"Nc1ncnc2c1c(-c1ccc3occc(=O)c3c1)nn2C1CCCC1";"IC50";"'='";"426.0";"nM";"6.37";"";"";"UO_0000065";"18.34";"0.33";"3.07";"6.38";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241301";"";"0";"271.28";"0";"1.33";"PP337";"COc1ccc(-c2nn(C)c3ncnc(N)c23)cc1O";"IC50";"'='";"98.0";"nM";"7.01";"";"";"UO_0000065";"25.84";"0.48";"5.68";"7.07";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242662";"";"0";"319.37";"0";"3.52";"PP17";"CC(C)n1nc(-c2ccc3cc(O)ccc3c2)c2c(N)ncnc21";"IC50";"'='";"109.0";"nM";"6.96";"";"";"UO_0000065";"21.80";"0.40";"3.44";"7.75";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242754";"";"0";"304.36";"0";"3.20";"PP105";"CC(C)n1nc(-c2cnc3ccccc3c2)c2c(N)ncnc21";"IC50";"'='";"1900.0";"nM";"5.72";"";"";"UO_0000065";"18.80";"0.34";"2.52";"6.93";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1760162";"";"0";"357.38";"0";"2.72";"36";"Cc1nc(N)nc(-n2c(Nc3n[nH]c4ccccc34)nc3ccccc32)n1";"IC50";"'='";"60.0";"nM";"7.22";"";"";"UO_0000065";"20.21";"0.37";"4.50";"5.86";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1631902";"";"0";"220.24";"0";"1.75";"20";"C(#Cc1n[nH]c2ncccc12)c1ccncc1";"IC50";"'='";"19100.0";"nM";"4.72";"";"";"UO_0000065";"21.43";"0.38";"2.97";"8.67";"False";"CHEMBL1633336";"Inhibition of mTORC1 expressed in HEK293 cells assessed as PRAS40 Ser183 phosphorylation level by LanthaScreen cellular assay";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";"CHEMBL3307715"
"CHEMBL1631897";"";"0";"182.23";"0";"2.32";"15";"C(#CC1CC1)c1n[nH]c2ccccc12";"IC50";"'>'";"50000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1633336";"Inhibition of mTORC1 expressed in HEK293 cells assessed as PRAS40 Ser183 phosphorylation level by LanthaScreen cellular assay";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";"CHEMBL3307715"
"CHEMBL1631890";"";"0";"254.24";"0";"3.24";"8";"Fc1cc(F)cc(C#Cc2n[nH]c3ccccc23)c1";"IC50";"'>'";"200000.0";"nM";"";"Outside typical range";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1633336";"Inhibition of mTORC1 expressed in HEK293 cells assessed as PRAS40 Ser183 phosphorylation level by LanthaScreen cellular assay";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";"CHEMBL3307715"
"CHEMBL1631888";"";"0";"233.27";"0";"2.54";"6";"Nc1ccc(C#Cc2n[nH]c3ccccc23)cc1";"IC50";"'='";"10800.0";"nM";"4.97";"";"";"UO_0000065";"21.29";"0.38";"2.43";"9.08";"False";"CHEMBL1633336";"Inhibition of mTORC1 expressed in HEK293 cells assessed as PRAS40 Ser183 phosphorylation level by LanthaScreen cellular assay";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";"CHEMBL3307715"
"CHEMBL1242025";"";"0";"331.38";"0";"3.49";"PP318";"Cc1ccc(-c2n[nH]c3ncnc(N)c23)cc1OCc1ccccc1";"IC50";"'='";"1200.0";"nM";"5.92";"";"";"UO_0000065";"17.87";"0.32";"2.43";"6.60";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL503885";"";"0";"1013.32";"";"";"iRap";"CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C@@H](c3cccc4c(C)c[nH]c34)C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)CC[C@H]1O";"IC50";"'='";"5.0";"nM";"8.30";"";"";"UO_0000065";"8.19";"";"";"";"False";"CHEMBL997061";"Inhibition of mTOR kinase expressed in human HEK293 cells by Western blot analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156445";"1";"Scientific Literature";"J. Biol. Chem.";"2007";"CHEMBL3307715"
"CHEMBL1241142";"";"0";"225.25";"0";"1.91";"PP201";"Cc1ccc(-c2n[nH]c3ncnc(N)c23)cc1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241143";"";"0";"225.25";"0";"1.91";"PP204";"Cc1cccc(-c2n[nH]c3ncnc(N)c23)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL272197";"";"0";"503.59";"1";"2.59";"5";"CCN(/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)[C@@H](O)CC[C@@H]12)CC";"IC50";"'='";"14000.0";"nM";"4.85";"";"";"UO_0000065";"9.64";"0.18";"2.26";"3.96";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL271184";"";"0";"592.69";"1";"3.07";"Table S1, S19";"COC[C@H]1OC(=O)/C(=C/N2CCN(c3ccccc3)CC2)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"692.0";"nM";"6.16";"";"";"UO_0000065";"10.39";"0.20";"3.09";"4.90";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL405157";"";"0";"590.67";"1";"3.67";"Table S1, S15";"COC[C@H]1OC(=O)/C(=C/N(CCC#N)Cc2ccccc2)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'>'";"1690.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL409620";"";"0";"535.59";"2";"0.54";"Table S1, S14";"COC[C@H]1OC(=O)/C(=C/N(C)CC(O)CO)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"1870.0";"nM";"5.73";"";"";"UO_0000065";"10.70";"0.21";"5.19";"3.51";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL272595";"";"0";"617.78";"2";"2.46";"Table S1, S6";"COC[C@H]1OC(=O)/C(=C/N(CCCN(C)C)CCCN(C)C)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"3560.0";"nM";"5.45";"";"";"UO_0000065";"8.82";"0.17";"2.99";"4.22";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL272898";"";"0";"546.66";"1";"2.14";"Table S1, S2";"CCN(/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)[C@@H](O)CC[C@@H]12)CCN(C)C";"IC50";"'='";"878.0";"nM";"6.06";"";"";"UO_0000065";"11.08";"0.21";"3.92";"4.81";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL410643";"";"0";"546.66";"1";"2.14";"13";"COC[C@H]1OC(=O)/C(=C/N(C)CCCN(C)C)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"2920.0";"nM";"5.54";"";"";"UO_0000065";"10.12";"0.19";"3.39";"4.40";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL1242568";"";"0";"313.34";"0";"3.04";"PP379";"Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2C1CCCC1";"IC50";"'='";"1800.0";"nM";"5.75";"";"";"UO_0000065";"18.33";"0.34";"2.70";"6.39";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242379";"";"0";"327.39";"0";"2.85";"PP485";"COc1ccc(-c2nn(C(C)(C)C)c3ncnc(N)c23)cc1OC";"IC50";"'='";"100000.0";"nM";"4.00";"";"";"UO_0000065";"12.22";"0.23";"1.15";"4.54";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241678";"";"0";"331.76";"0";"2.40";"PP428";"Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2[C@H]1CCOC1";"IC50";"'='";"377.0";"nM";"6.42";"";"";"UO_0000065";"19.36";"0.38";"4.02";"6.48";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242853";"";"0";"418.50";"0";"4.93";"PP88";"CC(C)(C)OC(=O)n1ccc2cc(-c3nn(C4CCCC4)c4ncnc(N)c34)ccc21";"IC50";"'='";"576.0";"nM";"6.24";"";"";"UO_0000065";"14.91";"0.27";"1.31";"6.19";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241587";"";"0";"295.35";"0";"2.59";"PP95";"CC(C)n1nc(-c2ccc3c(c2)CCO3)c2c(N)ncnc21";"IC50";"'='";"4500.0";"nM";"5.35";"";"";"UO_0000065";"18.10";"0.33";"2.76";"6.78";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241770";"";"0";"344.81";"0";"2.04";"PP389";"Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2CC1CCNC1";"IC50";"'='";"4800.0";"nM";"5.32";"";"";"UO_0000065";"15.43";"0.30";"3.28";"5.22";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241858";"";"0";"358.83";"0";"2.43";"PP369";"Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2CC1CCCNC1";"IC50";"'='";"3200.0";"nM";"5.50";"";"";"UO_0000065";"15.31";"0.30";"3.06";"5.39";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241439";"";"0";"271.28";"0";"2.06";"PP35";"CC(C)n1nc(-c2cc(C=O)co2)c2c(N)ncnc21";"IC50";"'='";"766.0";"nM";"6.12";"";"";"UO_0000065";"22.54";"0.42";"4.06";"6.13";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241485";"";"0";"298.35";"0";"2.25";"PP202";"COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1N";"IC50";"'='";"100000.0";"nM";"4.00";"";"";"UO_0000065";"13.41";"0.25";"1.75";"3.81";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242750";"";"0";"341.39";"0";"3.82";"PP465";"Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2C1CCCCCC1";"IC50";"'='";"1100.0";"nM";"5.96";"";"";"UO_0000065";"17.45";"0.33";"2.14";"6.63";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241579";"";"0";"318.77";"0";"1.95";"PP452";"C[C@H](CN)n1nc(-c2ccc(Cl)c(O)c2)c2c(N)ncnc21";"IC50";"'='";"2000.0";"nM";"5.70";"";"";"UO_0000065";"17.88";"0.35";"3.75";"4.92";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1233882";"";"0";"304.36";"0";"3.20";"PP102";"CC(C)n1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21";"IC50";"'='";"140.0";"nM";"6.85";"";"";"UO_0000065";"22.52";"0.41";"3.65";"8.31";"True";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242660";"";"0";"343.39";"0";"2.68";"PP64";"COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)cc(OC)c1OC";"IC50";"'='";"100000.0";"nM";"4.00";"";"";"UO_0000065";"11.65";"0.22";"1.32";"4.11";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242116";"";"0";"406.45";"0";"4.52";"PP149";"Nc1ncnc2[nH]nc(-c3ccc(NC(=O)c4ccc(-c5ccccc5)cc4)cc3)c12";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242295";"";"0";"318.38";"0";"3.67";"PP94";"Nc1ncnc2c1c(-c1ccc3[nH]ccc3c1)nn2C1CCCC1";"IC50";"'='";"407.0";"nM";"6.39";"";"";"UO_0000065";"20.07";"0.36";"2.72";"7.48";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241950";"";"0";"334.39";"0";"2.49";"PP142";"CC(C)n1nc(-c2ccc3nc(NN)ccc3c2)c2c(N)ncnc21";"IC50";"'='";"783.0";"nM";"6.11";"";"";"UO_0000065";"18.26";"0.33";"3.62";"5.06";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242380";"";"0";"343.39";"0";"1.72";"PP495";"COc1ccc(-c2nn(C[C@H](C)CO)c3ncnc(N)c23)cc1OC";"IC50";"'='";"1700.0";"nM";"5.77";"";"";"UO_0000065";"16.80";"0.32";"4.05";"5.33";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1240553";"";"0";"339.40";"0";"3.21";"PP90";"COc1ccc(-c2nn(C3CCCC3)c3ncnc(N)c23)cc1OC";"IC50";"'='";"2500.0";"nM";"5.60";"";"";"UO_0000065";"16.51";"0.31";"2.39";"6.36";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242753";"";"0";"329.36";"0";"1.48";"PP306";"CCOc1cc(-c2nn(CCO)c3ncnc(N)c23)ccc1OC";"IC50";"'='";"100000.0";"nM";"4.00";"";"";"UO_0000065";"12.14";"0.23";"2.52";"3.69";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242293";"";"0";"293.33";"0";"2.53";"PP108";"CC(C)n1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc21";"IC50";"'='";"60.0";"nM";"7.22";"";"";"UO_0000065";"24.62";"0.45";"4.69";"7.35";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242112";"";"0";"299.33";"0";"2.37";"PP15";"COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1O";"IC50";"'='";"1200.0";"nM";"5.92";"";"";"UO_0000065";"19.78";"0.37";"3.55";"5.98";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242385";"";"0";"332.41";"0";"3.68";"PP136";"Cn1ccc2cc(-c3nn(C4CCCC4)c4ncnc(N)c34)ccc21";"IC50";"'='";"205.0";"nM";"6.69";"";"";"UO_0000065";"20.12";"0.37";"3.01";"8.97";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241358";"";"0";"256.23";"0";"1.51";"PP213";"Nc1ncnc2[nH]nc(-c3ccc([N+](=O)[O-])cc3)c12";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242570";"";"0";"377.45";"0";"4.94";"PP167";"Nc1ncnc2c1c(-c1ccc3ccccc3c1)nn2C/C=C/c1ccccc1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1230790";"";"0";"269.31";"0";"2.36";"S1";"CC(C)n1nc(-c2cccc(O)c2)c2c(N)ncnc21";"IC50";"'='";"2100.0";"nM";"5.68";"";"";"UO_0000065";"21.08";"0.39";"3.32";"6.32";"True";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242026";"";"0";"283.34";"0";"2.67";"PP323";"Cc1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1O";"IC50";"'='";"33.0";"nM";"7.48";"";"";"UO_0000065";"26.40";"0.49";"4.81";"8.33";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242472";"";"0";"327.39";"0";"3.06";"PP343";"CCOc1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1OC";"IC50";"'='";"3300.0";"nM";"5.48";"";"";"UO_0000065";"16.74";"0.31";"2.42";"6.22";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241946";"";"0";"295.35";"0";"2.86";"PP55";"CC(=O)c1cccc(-c2nn(C(C)C)c3ncnc(N)c23)c1";"IC50";"'='";"16000.0";"nM";"4.80";"";"";"UO_0000065";"16.24";"0.30";"1.94";"5.53";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL266941";"";"0";"395.48";"0";"1.61";"S1M2M'3";"CC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)OCCS(=O)(=O)c1ccccc1";"IC50";"'<'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL682171";"The inhibitory activity by using FK506 binding protein 12 SPA binding assay.";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1132865";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2000";""
"CHEMBL584362";"";"0";"380.45";"0";"1.96";"5a";"Oc1cccc(-c2nc(N3CCOCC3)c3cnn(C4CCNCC4)c3n2)c1";"IC50";"'='";"215.0";"nM";"6.67";"";"";"UO_0000065";"17.53";"0.33";"4.71";"7.55";"True";"CHEMBL1063861";"Inhibition of human mTOR by DELFIA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154644";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL575710";"";"0";"484.56";"0";"3.51";"5c";"O=C(c1ccccc1)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4cccc(O)c4)nc32)CC1";"IC50";"'='";"4.0";"nM";"8.40";"";"";"UO_0000065";"17.33";"0.32";"4.89";"8.69";"False";"CHEMBL1063861";"Inhibition of human mTOR by DELFIA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154644";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL563985";"";"0";"494.56";"0";"2.48";"2";"CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)OC)CC4)c3n2)cc1";"IC50";"'='";"0.46";"nM";"9.34";"";"";"UO_0000065";"18.88";"0.35";"6.86";"7.37";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL575576";"";"0";"534.62";"1";"3.41";"29";"CCNC(=O)Nc1ccc(-c2nc(N3C4CCC3COC4)c3cnn(C4CCN(C(=O)OC)CC4)c3n2)cc1";"IC50";"'='";"0.62";"nM";"9.21";"";"";"UO_0000065";"17.22";"0.32";"5.80";"7.26";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL573662";"";"0";"585.67";"1";"4.55";"38";"CCOC(=O)N1CCC(n2ncc3c(N4CCOC[C@@H]4C)nc(-c4ccc(NC(=O)Nc5ccncc5)cc4)nc32)CC1";"IC50";"'='";"0.58";"nM";"9.24";"";"";"UO_0000065";"15.77";"0.29";"4.69";"6.62";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL565583";"";"0";"498.59";"0";"3.98";"32";"CCn1ncc2c(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(CN)cc4)cc3)nc21";"IC50";"'='";"0.2";"nM";"9.70";"";"";"UO_0000065";"19.45";"0.36";"5.72";"7.87";"False";"CHEMBL1039195";"Inhibition of human FLAG-tagged mTOR expressed in HEK293 cells after 2 hrs by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156748";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307715"
"CHEMBL573157";"";"0";"583.65";"1";"4.30";"26";"COC(=O)N1CCC(n2ncc3c(N4CC5CCC(C4)O5)nc(-c4ccc(NC(=O)Nc5cccnc5)cc4)nc32)CC1";"IC50";"'='";"0.11";"nM";"9.96";"";"";"UO_0000065";"17.06";"0.32";"5.66";"7.13";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL576090";"";"0";"581.68";"1";"4.27";"38";"CCn1ncc2c(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)NN5CCCC5)cc4)cc3)nc21";"IC50";"'='";"0.2";"nM";"9.70";"";"";"UO_0000065";"16.67";"0.31";"5.43";"7.49";"False";"CHEMBL1039195";"Inhibition of human FLAG-tagged mTOR expressed in HEK293 cells after 2 hrs by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156748";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307715"
"CHEMBL1242290";"";"0";"313.36";"0";"2.67";"PP23";"COc1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1OC";"IC50";"'='";"3100.0";"nM";"5.51";"";"";"UO_0000065";"17.58";"0.33";"2.84";"6.25";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL590104";"";"0";"464.42";"0";"3.95";"12";"O=C(NCCF)Nc1ccc(-c2nc(C3=CCOCC3)c3cnn(CC(F)(F)F)c3n2)cc1";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"19.38";"0.37";"5.05";"9.58";"False";"CHEMBL1074679";"Inhibition of mTOR in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153200";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL1241391";"";"0";"255.29";"0";"1.45";"PP53";"CC(C)n1nc(-c2cncnc2)c2c(N)ncnc21";"IC50";"'='";"50000.0";"nM";"4.30";"";"";"UO_0000065";"16.85";"0.31";"2.85";"4.51";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241104";"";"0";"211.23";"0";"1.60";"PP200";"Nc1ncnc2[nH]nc(-c3ccccc3)c12";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL574207";"";"0";"470.58";"0";"3.87";"5e";"Oc1cccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)c1";"IC50";"'='";"78.0";"nM";"7.11";"";"";"UO_0000065";"15.10";"0.28";"3.24";"8.94";"False";"CHEMBL1063861";"Inhibition of human mTOR by DELFIA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154644";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL586051";"";"0";"493.62";"0";"4.65";"5n";"c1ccc(CN2CCC(n3ncc4c(N5CCOCC5)nc(-c5cc6ccccc6[nH]5)nc43)CC2)cc1";"IC50";"'='";"130.0";"nM";"6.89";"";"";"UO_0000065";"13.95";"0.25";"2.24";"9.17";"False";"CHEMBL1063861";"Inhibition of human mTOR by DELFIA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154644";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL584734";"";"0";"421.51";"0";"3.02";"14";"CCNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(CC)c3n2)cc1";"IC50";"'='";"0.6";"nM";"9.22";"";"";"UO_0000065";"21.88";"0.41";"6.20";"9.49";"False";"CHEMBL1039195";"Inhibition of human FLAG-tagged mTOR expressed in HEK293 cells after 2 hrs by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156748";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307715"
"CHEMBL585480";"";"0";"513.60";"1";"4.06";"36";"CCn1ncc2c(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(CCO)cc4)cc3)nc21";"IC50";"'='";"0.1";"nM";"10.00";"";"";"UO_0000065";"19.47";"0.36";"5.94";"8.52";"False";"CHEMBL1039195";"Inhibition of human FLAG-tagged mTOR expressed in HEK293 cells after 2 hrs by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156748";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307715"
"CHEMBL605915";"";"0";"396.47";"0";"3.90";"8h";"COC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3sccc3n2)cc1";"IC50";"'='";"11.0";"nM";"7.96";"";"";"UO_0000065";"20.07";"0.39";"4.06";"10.39";"False";"CHEMBL1067293";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153098";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL595053";"";"0";"409.52";"0";"3.87";"9b";"CCNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3sccc3n2)cc1";"IC50";"'='";"0.7";"nM";"9.15";"";"";"UO_0000065";"22.36";"0.43";"5.28";"11.53";"False";"CHEMBL1067293";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153098";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL591101";"";"0";"436.52";"0";"2.01";"23";"CC(=O)N1CCC(n2cnc3c(N4CCOCC4)nc(-c4cccc(CO)c4)nc32)CC1";"IC50";"'='";"2100.0";"nM";"5.68";"";"";"UO_0000065";"13.01";"0.24";"3.67";"5.88";"False";"CHEMBL1068429";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153170";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL594549";"";"0";"634.79";"1";"3.84";"16c";"CS(=O)(=O)N1CCN(Cc2cc3nc(-c4ccc(NC(=O)Nc5cccnc5)cc4)nc(N4CC5CCC(C4)O5)c3s2)CC1";"IC50";"'='";"0.6";"nM";"9.22";"";"";"UO_0000065";"14.53";"0.29";"5.38";"6.94";"False";"CHEMBL1067293";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153098";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL576768";"";"0";"508.59";"1";"3.68";"5v";"O=C(c1cccnc1)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc5[nH]ccc5c4)nc32)CC1";"IC50";"'='";"4.0";"nM";"8.40";"";"";"UO_0000065";"16.51";"0.30";"4.72";"7.99";"False";"CHEMBL1063861";"Inhibition of human mTOR by DELFIA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154644";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL550286";"";"0";"471.57";"0";"3.27";"5f";"Oc1cccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5cccnc5)CC4)c3n2)c1";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"16.96";"0.31";"4.73";"8.66";"False";"CHEMBL1063861";"Inhibition of human mTOR by DELFIA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154644";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL575935";"";"0";"455.57";"0";"3.56";"5i";"c1ccc(CN2CCC(n3ncc4c(N5CCOCC5)nc(-c5cccnc5)nc43)CC2)cc1";"IC50";"'='";"695.0";"nM";"6.16";"";"";"UO_0000065";"13.52";"0.25";"2.60";"8.53";"False";"CHEMBL1063861";"Inhibition of human mTOR by DELFIA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154644";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL575929";"";"0";"505.63";"1";"4.72";"5l";"c1ccc(CN2CCC(n3ncc4c(N5CCOCC5)nc(-c5ccc6ncccc6c5)nc43)CC2)cc1";"IC50";"'='";"5950.0";"nM";"5.22";"";"";"UO_0000065";"10.33";"0.19";"0.51";"7.24";"False";"CHEMBL1063861";"Inhibition of human mTOR by DELFIA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154644";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL1256459";"TORIN1";"0";"607.64";"2";"6.83";"37";"CCC(=O)N1CCN(c2ccc(-n3c(=O)ccc4cnc5ccc(-c6cnc7ccccc7c6)cc5c43)cc2C(F)(F)F)CC1";"IC50";"'='";"0.29";"nM";"9.54";"";"";"UO_0000065";"15.70";"0.29";"2.71";"13.37";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1204014";"";"0";"624.15";"1";"2.24";"25";"CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1.Cl";"IC50";"'='";"1.4";"nM";"8.85";"";"";"UO_0000065";"15.07";"0.28";"6.61";"6.90";"False";"CHEMBL1065057";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157610";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL592445";"GEDATOLISIB";"2";"615.74";"1";"3.02";"26, PKI-587";"CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1";"IC50";"'='";"1.6";"nM";"8.80";"";"";"UO_0000065";"14.29";"0.27";"5.78";"6.86";"True";"CHEMBL1065057";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157610";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL592461";"";"0";"641.78";"1";"3.56";"27";"O=C(Nc1ccc(C(=O)N2CCC(N3CCCC3)CC2)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1";"IC50";"'='";"0.8";"nM";"9.10";"";"";"UO_0000065";"14.17";"0.26";"5.54";"7.09";"False";"CHEMBL1065057";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157610";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL597004";"";"0";"491.55";"0";"2.35";"15";"O=C(Nc1ccc(CO)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1";"IC50";"'='";"1.9";"nM";"8.72";"";"";"UO_0000065";"17.74";"0.33";"6.37";"6.98";"False";"CHEMBL1065057";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157610";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL592619";"";"0";"655.80";"1";"3.95";"28";"O=C(Nc1ccc(C(=O)N2CCC(N3CCCCC3)CC2)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1";"IC50";"'='";"0.7";"nM";"9.15";"";"";"UO_0000065";"13.96";"0.26";"5.20";"7.14";"False";"CHEMBL1065057";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157610";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL269775";"";"0";"352.48";"0";"2.01";"S1M3M'3";"CC(CN1CCCCC1)OC(=O)[C@@H]1CCCN1C(=O)C(=O)C(C)(C)C";"IC50";"'<'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL682171";"The inhibitory activity by using FK506 binding protein 12 SPA binding assay.";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1132865";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2000";""
"CHEMBL1259013";"";"0";"530.55";"2";"5.64";"20";"COc1ccc(-c2ccc3ncc4ccc(=O)n(-c5ccc(N6CCNCC6)c(C(F)(F)F)c5)c4c3c2)cc1";"IC50";"'='";"78.9";"nM";"7.10";"";"";"UO_0000065";"13.39";"0.25";"1.46";"11.96";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1259120";"";"0";"527.63";"2";"5.69";"32";"COc1cc(N2CCC(N)CC2)ccc1-n1c(=O)ccc2cnc3ccc(-c4cnc5ccccc5c4)cc3c21";"IC50";"'='";"95.0";"nM";"7.02";"";"";"UO_0000065";"13.31";"0.24";"1.33";"8.14";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1259136";"";"0";"511.63";"2";"5.50";"33";"CN1CCN(Cc2ccc(-n3c(=O)ccc4cnc5ccc(-c6cnc7ccccc7c6)cc5c43)cc2)CC1";"IC50";"'='";"66.0";"nM";"7.18";"";"";"UO_0000065";"14.03";"0.25";"1.68";"13.23";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1255816";"";"0";"565.64";"1";"3.84";"8o";"O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1)Nc1ccc(-c2cccnc2)nc1";"IC50";"'='";"3.45";"nM";"8.46";"";"";"UO_0000065";"14.96";"0.28";"4.62";"6.48";"False";"CHEMBL1259905";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255533";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL583874";"";"0";"546.63";"1";"3.55";"27";"COC(=O)N1CCC(n2ncc3c(N4CC5CCC(C4)O5)nc(-c4ccc(NC(=O)NC5CC5)cc4)nc32)CC1";"IC50";"'='";"0.62";"nM";"9.21";"";"";"UO_0000065";"16.84";"0.31";"5.66";"7.26";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL576782";"";"0";"554.63";"1";"3.60";"48";"CCOC(=O)N1CCC(n2ncc3c(N4CCOC[C@@H]4C)nc(-c4ccc(NC(=O)NCCF)cc4)nc32)CC1";"IC50";"'='";"1.8";"nM";"8.74";"";"";"UO_0000065";"15.77";"0.30";"5.14";"6.90";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL576305";"";"0";"599.70";"2";"3.63";"23";"CCn1ncc2c(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(OCCN5CCOCC5)nc4)cc3)nc21";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"15.01";"0.28";"5.37";"6.83";"False";"CHEMBL1039195";"Inhibition of human FLAG-tagged mTOR expressed in HEK293 cells after 2 hrs by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156748";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307715"
"CHEMBL557895";"";"0";"511.63";"1";"4.13";"8";"CC(=O)Nc1cccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)c1";"IC50";"'='";"2450.0";"nM";"5.61";"";"";"UO_0000065";"10.97";"0.20";"1.48";"6.35";"False";"CHEMBL1058638";"Inhibition of flag-tagged truncated human mTOR (1360-2549) expressed in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1151963";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL550972";"";"0";"526.65";"1";"3.92";"13";"CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)cc1";"IC50";"'='";"0.52";"nM";"9.28";"";"";"UO_0000065";"17.63";"0.33";"5.36";"9.24";"True";"CHEMBL1058638";"Inhibition of flag-tagged truncated human mTOR (1360-2549) expressed in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1151963";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1631889";"";"0";"218.26";"0";"2.96";"7";"C(#Cc1n[nH]c2ccccc12)c1ccccc1";"IC50";"'>'";"50000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1633336";"Inhibition of mTORC1 expressed in HEK293 cells assessed as PRAS40 Ser183 phosphorylation level by LanthaScreen cellular assay";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";"CHEMBL3307715"
"CHEMBL1631895";"";"0";"233.27";"0";"2.54";"13";"Nc1cccc(C#Cc2n[nH]c3ccccc23)c1";"IC50";"'>'";"100000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1633333";"Inhibition of mTOR by LanthaScreen Eu kinase binding assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1631893";"";"0";"199.26";"0";"1.48";"11";"CN(C)CC#Cc1n[nH]c2ccccc12";"IC50";"'>'";"50000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1633336";"Inhibition of mTORC1 expressed in HEK293 cells assessed as PRAS40 Ser183 phosphorylation level by LanthaScreen cellular assay";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";"CHEMBL3307715"
"CHEMBL1631893";"";"0";"199.26";"0";"1.48";"11";"CN(C)CC#Cc1n[nH]c2ccccc12";"IC50";"'>'";"100000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1633333";"Inhibition of mTOR by LanthaScreen Eu kinase binding assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL3781971";"";"0";"598.63";"2";"6.84";"24";"CC(=O)Nc1cnc2ccc(-c3cnc4ccccc4c3)cc2c1Nc1ccc(N2CCN(C(C)=O)CC2)c(C(F)(F)F)c1";"IC50";"'='";"30.0";"nM";"7.52";"";"";"UO_0000065";"12.57";"0.23";"0.68";"8.32";"False";"CHEMBL3784491";"Inhibition of human mTOR using ULight-4E-BP1 peptide as substrate after 1 hr by Lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3779897";"1";"Scientific Literature";"MedChemComm";"2016";""
"CHEMBL3781495";"";"0";"629.11";"2";"5.99";"18";"CS(=O)(=O)Nc1cnc2ccc(-c3cnc4ccccc4c3)cc2c1Nc1ccc(N2CCNCC2)c(C(F)(F)F)c1.Cl";"IC50";"'='";"340.0";"nM";"6.47";"";"";"UO_0000065";"10.91";"0.21";"0.48";"6.52";"False";"CHEMBL3784491";"Inhibition of human mTOR using ULight-4E-BP1 peptide as substrate after 1 hr by Lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3779897";"1";"Scientific Literature";"MedChemComm";"2016";""
"CHEMBL521851";"PICTILISIB";"2";"513.65";"1";"2.15";"GDC-0941";"CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1";"IC50";"'='";"580.0";"nM";"6.24";"";"";"UO_0000065";"12.14";"0.24";"4.09";"5.80";"True";"CHEMBL3795347";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide substrate incubated for 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3792291";"1";"Scientific Literature";"Eur. J. Med. Chem.";"2016";""
"CHEMBL3407721";"";"0";"523.60";"2";"2.87";"II";"N#Cc1cccc(Cn2cc(/C=N/Nc3nc(N4CCOCC4)nc(N4CCOCC4)n3)c3ccccc32)c1";"IC50";"'='";"16620.0";"nM";"4.78";"";"";"UO_0000065";"9.13";"0.17";"1.91";"4.09";"False";"CHEMBL3414045";"Inhibition of mTOR kinase (unknown origin) using ULight-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407441";"1";"Scientific Literature";"Eur. J. Med. Chem.";"2015";""
"CHEMBL1834657";"INFIGRATINIB PHOSPHATE";"0";"658.48";"2";"5.35";"1h, NVP-BGJ398";"CCN1CCN(c2ccc(Nc3cc(N(C)C(=O)Nc4c(Cl)c(OC)cc(OC)c4Cl)ncn3)cc2)CC1.O=P(O)(O)O";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1839856";"Inhibition of recombinant mTOR by luminescent kinase assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1833940";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL521851";"PICTILISIB";"2";"513.65";"1";"2.15";"GDC0941";"CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1";"IC50";"'='";"410.0";"nM";"6.39";"";"";"UO_0000065";"12.43";"0.25";"4.24";"5.94";"True";"CHEMBL3377242";"Inhibition of human mTOR by non-radiometric ADP-Glo assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352433";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL1090143";"";"0";"476.48";"1";"6.69";"11b";"O=C(Nc1cccc(-c2ncnc3sc(-c4ccncc4)cc23)c1)c1cccc(C(F)(F)F)c1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1117090";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156181";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091352";"";"0";"598.75";"1";"4.59";"23";"CCN1CCN(c2ccc(NC(=O)Nc3ccc(-c4nc(C5CCOCC5)nc(N5C6CCC5COC6)n4)cc3)cc2)CC1";"IC50";"'='";"0.56";"nM";"9.25";"";"";"UO_0000065";"15.45";"0.29";"4.66";"8.57";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091353";"";"0";"612.78";"1";"4.97";"24";"CC(C)N1CCN(c2ccc(NC(=O)Nc3ccc(-c4nc(C5CCOCC5)nc(N5C6CCC5COC6)n4)cc3)cc2)CC1";"IC50";"'='";"0.88";"nM";"9.06";"";"";"UO_0000065";"14.78";"0.27";"4.09";"8.39";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091354";"";"0";"612.78";"1";"4.97";"25";"CN(C)C1CCN(c2ccc(NC(=O)Nc3ccc(-c4nc(C5CCOCC5)nc(N5C6CCC5COC6)n4)cc3)cc2)CC1";"IC50";"'='";"0.56";"nM";"9.25";"";"";"UO_0000065";"15.10";"0.28";"4.28";"8.57";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091357";"";"0";"640.79";"1";"4.61";"28";"CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(C5CCOCC5)nc(N5C6CCC5COC6)n4)cc3)cc2)CC1";"IC50";"'='";"0.34";"nM";"9.47";"";"";"UO_0000065";"14.78";"0.28";"4.86";"7.57";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091358";"";"0";"600.72";"1";"3.74";"29";"CN(C)CCNC(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(C4CCOCC4)nc(N4C5CCC4COC5)n3)cc2)cc1";"IC50";"'='";"0.14";"nM";"9.85";"";"";"UO_0000065";"16.40";"0.31";"6.11";"7.36";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1256462";"";"0";"677.73";"2";"6.81";"41";"O=C(CN1CCOCC1)N1CCC(c2ccc(-n3c(=O)ccc4cnc5ccc(-c6cnc7ccccc7c6)cc5c43)cc2C(F)(F)F)CC1";"IC50";"'='";"4.25";"nM";"8.37";"";"";"UO_0000065";"12.35";"0.23";"1.56";"10.39";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1092396";"";"0";"655.80";"2";"3.54";"7";"CN1CCN(CCOc2ccc(NC(=O)Nc3ccc(-c4nc(N5C6CCC5COC6)nc(N5C6CCC5COC6)n4)cc3)cc2)CC1";"IC50";"'='";"0.9";"nM";"9.05";"";"";"UO_0000065";"13.79";"0.26";"5.51";"7.51";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1092394";"";"0";"556.67";"1";"3.64";"5";"CNCc1ccc(NC(=O)Nc2ccc(-c3nc(N4C5CCC4COC5)nc(N4C5CCC4COC5)n3)cc2)cc1";"IC50";"'='";"0.89";"nM";"9.05";"";"";"UO_0000065";"16.26";"0.30";"5.41";"7.75";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1256456";"";"0";"619.65";"2";"6.83";"34";"O=C(C1CC1)N1CCN(c2ccc(-n3c(=O)ccc4cnc5ccc(-c6cnc7ccccc7c6)cc5c43)cc2C(F)(F)F)CC1";"IC50";"'='";"6.84";"nM";"8.16";"";"";"UO_0000065";"13.18";"0.24";"1.33";"11.45";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1259137";"";"0";"394.48";"0";"4.33";"38";"CN(C)CCn1c(=O)ccc2cnc3ccc(-c4cnc5ccccc5c4)cc3c21";"IC50";"'='";"389.0";"nM";"6.41";"";"";"UO_0000065";"16.25";"0.29";"2.08";"12.56";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1256463";"";"0";"621.66";"2";"7.14";"42";"CCC(=O)N1CCN(c2ccc(-n3c(=O)c(C)cc4cnc5ccc(-c6cnc7ccccc7c6)cc5c43)cc2C(F)(F)F)CC1";"IC50";"'='";"26.6";"nM";"7.58";"";"";"UO_0000065";"12.19";"0.22";"0.44";"10.62";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1762783";"";"0";"347.38";"0";"2.80";"12";"CCc1nc(N)nc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"390.0";"nM";"6.41";"";"";"UO_0000065";"18.45";"0.34";"3.61";"5.58";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1089818";"";"0";"296.33";"0";"2.17";"18";"Oc1cccc(-c2nc(N3CCOCC3)c3cc[nH]c3n2)c1";"IC50";"'='";"64.0";"nM";"7.19";"";"";"UO_0000065";"24.28";"0.45";"5.02";"9.69";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL561103";"";"0";"528.62";"1";"3.74";"22a";"COC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5cccnc5)CC4)c3n2)cc1";"IC50";"'='";"4.6";"nM";"8.34";"";"";"UO_0000065";"15.77";"0.29";"4.60";"7.54";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1256449";"";"0";"551.57";"2";"6.18";"19";"O=c1ccc2cnc3ccc(-c4cnc5ccccc5c4)cc3c2n1-c1ccc(N2CCNCC2)c(C(F)(F)F)c1";"IC50";"'='";"13.5";"nM";"7.87";"";"";"UO_0000065";"14.27";"0.26";"1.69";"12.48";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1092547";"";"0";"486.58";"0";"3.54";"24";"CN(C)CCn1ccc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4cccnc4)cc3)nc21";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"17.52";"0.32";"4.98";"8.49";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1092073";"";"0";"610.64";"1";"4.43";"47";"CN(C)CCNC(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)c4ccn(CC(F)(F)F)c4n3)cc2)cc1";"IC50";"'='";"0.4";"nM";"9.40";"";"";"UO_0000065";"15.39";"0.29";"4.97";"8.06";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1092402";"";"0";"556.67";"1";"3.89";"50";"CCn1ccc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)NCCN(C)C)cc4)cc3)nc21";"IC50";"'='";"0.5";"nM";"9.30";"";"";"UO_0000065";"16.71";"0.31";"5.41";"7.97";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL562999";"";"0";"520.59";"1";"3.02";"23";"COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)NC5CC5)cc4)nc32)CC1";"IC50";"'='";"0.45";"nM";"9.35";"";"";"UO_0000065";"17.95";"0.34";"6.33";"7.37";"False";"CHEMBL1058638";"Inhibition of flag-tagged truncated human mTOR (1360-2549) expressed in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1151963";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1257955";"";"0";"487.56";"0";"3.39";"8a";"O=C(Nc1ccccc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"17.84";"0.33";"5.31";"8.31";"False";"CHEMBL1259905";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255533";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1257840";"";"0";"505.55";"1";"3.53";"8b";"O=C(Nc1ccc(F)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1";"IC50";"'='";"1.9";"nM";"8.72";"";"";"UO_0000065";"17.25";"0.32";"5.19";"8.33";"False";"CHEMBL1259905";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255533";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1762782";"";"0";"372.39";"0";"2.90";"10";"Cc1nc(NCC#N)nc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"8.0";"nM";"8.10";"";"";"UO_0000065";"21.74";"0.39";"5.20";"6.50";"True";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760156";"";"0";"374.41";"0";"2.80";"29";"CC(=O)Nc1cccc(Nc2nc3ccccc3n2-c2nc(C)nc(N)n2)c1";"IC50";"'='";"290.0";"nM";"6.54";"";"";"UO_0000065";"17.46";"0.32";"3.74";"5.29";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762786";"";"0";"317.35";"0";"3.57";"15";"Cc1nccc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"8900.0";"nM";"5.05";"";"";"UO_0000065";"15.91";"0.29";"1.48";"6.66";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1258743";"";"0";"489.54";"0";"2.18";"8q";"O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1)Nc1ccnnc1";"IC50";"'='";"1.55";"nM";"8.81";"";"";"UO_0000065";"18.00";"0.33";"6.63";"6.75";"False";"CHEMBL1259905";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255533";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1762778";"";"0";"319.33";"0";"2.24";"6";"Nc1ncnc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"710.0";"nM";"6.15";"";"";"UO_0000065";"19.26";"0.35";"3.91";"5.36";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1615182";"";"0";"358.36";"0";"2.60";"1";"N#CCNc1ncnc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"700.0";"nM";"6.16";"";"";"UO_0000065";"17.18";"0.31";"3.55";"4.94";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762785";"";"0";"332.37";"0";"3.16";"14";"Cc1nc(N)cc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"87.0";"nM";"7.06";"";"";"UO_0000065";"21.24";"0.39";"3.90";"6.93";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760170";"";"0";"360.39";"0";"2.31";"44";"Cc1nc(NCCC#N)nc(-n2c(Nc3cc[nH]n3)nc3ccccc32)n1";"IC50";"'='";"60.0";"nM";"7.22";"";"";"UO_0000065";"20.04";"0.37";"4.91";"5.43";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL104468";"";"0";"281.31";"0";"2.78";"2, NU-7026";"O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12";"IC50";"'='";"6400.0";"nM";"5.19";"";"";"UO_0000065";"18.46";"0.34";"2.41";"12.17";"False";"CHEMBL1767684";"Inhibition of mTOR by radiometric phosphate incorporation assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1765064";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1615182";"";"0";"358.36";"0";"2.60";"1";"N#CCNc1ncnc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"1700.0";"nM";"5.77";"";"";"UO_0000065";"16.10";"0.29";"3.17";"4.63";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL2206921";"";"0";"470.35";"0";"2.49";"3j";"Cc1nc(N)nc(-c2cc(Cl)cnc2Nc2cnc(Cl)c(NS(=O)(=O)N(C)C)c2)n1";"IC50";"'='";"163.0";"nM";"6.79";"";"";"UO_0000065";"14.43";"0.31";"4.30";"4.47";"True";"CHEMBL2211629";"Inhibition of recombinant N-terminal GST-tagged mTOR using GFP-4EBP as substrate after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2203208";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1822054";"";"0";"460.88";"0";"3.34";"10";"CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1";"IC50";"'='";"0.4";"nM";"9.40";"";"";"UO_0000065";"20.39";"0.41";"6.06";"7.94";"False";"CHEMBL1828260";"Inhibition of recombinant N-terminal GST-tagged mTOR-mediated 4E-BP1 phosphorylation after 60 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1821651";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773732";"";"0";"493.40";"1";"5.42";"77";"CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(Cl)cc4)c3)cc2s1";"IC50";"'<'";"1.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL2172478";"";"0";"470.54";"0";"3.98";"21f";"CC(=O)Nc1cc(-c2c(Nc3ccn(C)n3)nc3ccc(-c4cnn(C(C)C)c4)cn23)nc(C)n1";"IC50";"'='";"16.0";"nM";"7.80";"";"";"UO_0000065";"16.57";"0.30";"3.82";"6.50";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1760163";"";"0";"307.32";"0";"1.57";"37";"Cc1nc(N)nc(-n2c(Nc3cn[nH]c3)nc3ccccc32)n1";"IC50";"'='";"180.0";"nM";"6.75";"";"";"UO_0000065";"21.95";"0.40";"5.17";"5.47";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760167";"";"0";"325.38";"0";"1.69";"41";"Cc1nc(N)nc(-n2c(NC3CCOCC3)nc3ccccc32)n1";"IC50";"'='";"680.0";"nM";"6.17";"";"";"UO_0000065";"18.95";"0.35";"4.48";"5.94";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762774";"";"0";"395.43";"0";"4.40";"2";"Oc1cccc(Nc2nc3ccccc3n2-c2ncnc(Nc3ccccc3)n2)c1";"IC50";"'='";"2300.0";"nM";"5.64";"";"";"UO_0000065";"14.26";"0.26";"1.24";"5.59";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760167";"";"0";"325.38";"0";"1.69";"41";"Cc1nc(N)nc(-n2c(NC3CCOCC3)nc3ccccc32)n1";"IC50";"'='";"21400.0";"nM";"4.67";"";"";"UO_0000065";"14.35";"0.27";"2.98";"4.50";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762790";"";"0";"349.35";"0";"2.26";"25";"Cc1nc(N)nc(-n2c(Nc3cc(O)cc(O)c3)nc3ccccc32)n1";"IC50";"'='";"97.0";"nM";"7.01";"";"";"UO_0000065";"20.08";"0.37";"4.75";"5.19";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760159";"";"0";"321.35";"0";"1.58";"33";"Cc1nc(N)nc(-n2c(Nc3ccn(C)n3)nc3ccccc32)n1";"IC50";"'='";"5300.0";"nM";"5.28";"";"";"UO_0000065";"16.42";"0.30";"3.70";"4.70";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760160";"";"0";"357.33";"0";"2.44";"34";"Cc1nc(N)nc(-n2c(Nc3ccn(C(F)F)n3)nc3ccccc32)n1";"IC50";"'='";"770.0";"nM";"6.11";"";"";"UO_0000065";"17.11";"0.32";"3.67";"5.44";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760171";"";"0";"345.37";"0";"2.03";"45";"C#CCNc1nc(C)nc(-n2c(Nc3cc[nH]n3)nc3ccccc32)n1";"IC50";"'='";"150.0";"nM";"6.82";"";"";"UO_0000065";"19.76";"0.36";"4.79";"6.25";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL413";"SIROLIMUS";"4";"914.19";"3";"6.18";"Rapamycin";"CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C";"IC50";"'='";"3.467";"nM";"8.46";"";"";"UO_0000065";"9.25";"0.18";"2.28";"4.33";"False";"CHEMBL677281";"The inhibitory activity by using FK506 binding protein 12 SPA binding assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1132865";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2000";""
"CHEMBL1242029";"";"0";"283.34";"0";"2.67";"PP49";"COc1cccc(-c2nn(C(C)C)c3ncnc(N)c23)c1";"IC50";"'='";"8000.0";"nM";"5.10";"";"";"UO_0000065";"17.99";"0.33";"2.43";"6.46";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242571";"";"0";"299.34";"0";"2.86";"PP168";"C#CCn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242661";"";"0";"319.37";"0";"3.16";"PP116";"CCOc1ccc2cc(-c3nn(C)c4ncnc(N)c34)ccc2c1";"IC50";"'='";"100000.0";"nM";"4.00";"";"";"UO_0000065";"12.52";"0.23";"0.84";"5.07";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242475";"";"0";"319.37";"0";"3.07";"PP138";"Nc1ncnc2c1c(-c1ccc3[nH]ncc3c1)nn2C1CCCC1";"IC50";"'='";"1100.0";"nM";"5.96";"";"";"UO_0000065";"18.66";"0.34";"2.89";"6.06";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242849";"";"0";"301.35";"0";"3.28";"PP219";"Cn1nc(-c2cccc(-c3ccccc3)c2)c2c(N)ncnc21";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242476";"";"0";"308.35";"0";"2.11";"PP154";"CC(C)n1nc(-c2ccc3c(N)n[nH]c3c2)c2c(N)ncnc21";"IC50";"'='";"1640.0";"nM";"5.79";"";"";"UO_0000065";"18.76";"0.34";"3.68";"4.65";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL568156";"";"0";"383.41";"0";"1.89";"13";"COc1cc(-c2cn(-c3nccc(N4CCOCC4)n3)cn2)cc(OC)c1O";"IC50";"'='";"570.0";"nM";"6.24";"";"";"UO_0000065";"16.29";"0.30";"4.35";"6.59";"False";"CHEMBL1049650";"Inhibition of mTOR kinase in human HeLa cells by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HeLa";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156040";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3308376"
"CHEMBL585397";"";"0";"538.66";"2";"5.13";"26";"CCn1ncc2c(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(N5CCCC5)cc4)cc3)nc21";"IC50";"'='";"6.0";"nM";"8.22";"";"";"UO_0000065";"15.26";"0.28";"3.09";"8.19";"False";"CHEMBL1039195";"Inhibition of human FLAG-tagged mTOR expressed in HEK293 cells after 2 hrs by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156748";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307715"
"CHEMBL590386";"";"0";"298.31";"0";"0.96";"30";"Oc1cncc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)c1";"IC50";"'='";"620.0";"nM";"6.21";"";"";"UO_0000065";"20.81";"0.39";"5.25";"6.20";"False";"CHEMBL1068429";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153170";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL599667";"";"0";"467.56";"0";"2.92";"17";"O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1)Nc1cccs1";"IC50";"'='";"1.7";"nM";"8.77";"";"";"UO_0000065";"18.76";"0.36";"5.85";"8.37";"False";"CHEMBL1065057";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157610";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1242207";"";"0";"304.36";"0";"3.20";"PP129";"CC(C)n1nc(-c2ccc3cnccc3c2)c2c(N)ncnc21";"IC50";"'='";"2200.0";"nM";"5.66";"";"";"UO_0000065";"18.59";"0.34";"2.46";"6.86";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242209";"";"0";"318.38";"0";"3.51";"PP133";"Cc1ccc2ccc(-c3nn(C(C)C)c4ncnc(N)c34)cc2n1";"IC50";"'='";"1100.0";"nM";"5.96";"";"";"UO_0000065";"18.72";"0.34";"2.45";"7.22";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242756";"";"0";"276.30";"0";"2.16";"PP111";"Cn1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21";"IC50";"'='";"3000.0";"nM";"5.52";"";"";"UO_0000065";"19.99";"0.36";"3.36";"6.69";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241489";"";"0";"303.37";"0";"3.81";"PP226";"CC(C)n1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242027";"";"0";"319.31";"0";"2.94";"PP63";"COc1cc(F)c(-c2nn(C(C)C)c3ncnc(N)c23)cc1F";"IC50";"'='";"404.0";"nM";"6.39";"";"";"UO_0000065";"20.02";"0.38";"3.45";"8.11";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242028";"";"0";"305.29";"0";"2.64";"PP93";"CC(C)n1nc(-c2cc(F)c(O)cc2F)c2c(N)ncnc21";"IC50";"'='";"1130.0";"nM";"5.95";"";"";"UO_0000065";"19.48";"0.37";"3.31";"6.62";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242663";"";"0";"338.80";"0";"3.86";"PP134";"CC(C)n1nc(-c2cc3ccccc3nc2Cl)c2c(N)ncnc21";"IC50";"'='";"2200.0";"nM";"5.66";"";"";"UO_0000065";"16.70";"0.32";"1.80";"6.86";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241683";"";"0";"338.80";"0";"3.86";"PP130";"CC(C)n1nc(-c2ccc3nc(Cl)ccc3c2)c2c(N)ncnc21";"IC50";"'='";"113.0";"nM";"6.95";"";"";"UO_0000065";"20.50";"0.40";"3.09";"8.42";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242033";"";"0";"419.49";"0";"4.55";"PP145";"CC(C)n1nc(-c2ccc3nccc(NC(=O)OC(C)(C)C)c3c2)c2c(N)ncnc21";"IC50";"'='";"3200.0";"nM";"5.50";"";"";"UO_0000065";"13.10";"0.24";"0.94";"4.55";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241300";"";"0";"257.25";"0";"1.32";"PP321";"COc1ccc(-c2n[nH]c3ncnc(N)c23)cc1O";"IC50";"'='";"710.0";"nM";"6.15";"";"";"UO_0000065";"23.90";"0.44";"4.83";"5.59";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL6367";"GPI-1046";"0";"360.45";"0";"2.55";"GPI-1046";"CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)OCCCc1cccnc1";"IC50";"'='";"20892.96";"nM";"4.68";"";"";"UO_0000065";"12.98";"0.25";"2.13";"6.11";"False";"CHEMBL677281";"The inhibitory activity by using FK506 binding protein 12 SPA binding assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1132865";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2000";""
"CHEMBL1231371";"";"0";"317.40";"0";"3.98";"PP227";"CC(C)(C)n1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242114";"";"0";"299.33";"0";"2.37";"PP325";"COc1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1O";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"28.47";"0.53";"6.15";"8.60";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242202";"";"0";"339.40";"0";"3.15";"PP423";"COc1ccc(-c2nn(C3CCC(C)C3)c3ncnc(N)c23)cc1O";"IC50";"'='";"170.0";"nM";"6.77";"";"";"UO_0000065";"19.95";"0.37";"3.62";"6.83";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL2058166";"";"0";"398.43";"0";"-0.02";"5";"COCCNC(=O)c1cn2cc(-c3cnc(N)nc3)nc(N3CCOCC3)c2n1";"IC50";"'='";"2290.0";"nM";"5.64";"";"";"UO_0000065";"14.16";"0.27";"5.66";"4.25";"False";"CHEMBL2060320";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2057167";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2058164";"";"0";"411.47";"0";"-0.10";"3";"CN(C)CCNC(=O)c1cn2cc(-c3cnc(N)nc3)nc(N3CCOCC3)c2n1";"IC50";"'>'";"5000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2060320";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2057167";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1091344";"";"0";"629.77";"2";"2.62";"15";"CN1CCN(c2ccc(NC(=O)Nc3ccc(-c4nc(N5C6CCC5COC6)nc(N5[C@H](CO)CC[C@@H]5CO)n4)cc3)cc2)CC1";"IC50";"'='";"0.7";"nM";"9.15";"";"";"UO_0000065";"14.54";"0.27";"6.53";"6.43";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091712";"";"0";"627.79";"1";"4.31";"34";"C[C@@H]1COCCN1c1nc(-c2ccc(NC(=O)Nc3ccc(N4CCC(N(C)C)CC4)cc3)cc2)nc(N2C3CCC2COC3)n1";"IC50";"'='";"0.9";"nM";"9.05";"";"";"UO_0000065";"14.41";"0.27";"4.74";"8.13";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091715";"";"0";"588.71";"1";"3.72";"39";"C[C@@H]1COCCN1c1nc(-c2ccc(NC(=O)Nc3ccc(OCCN(C)C)cc3)cc2)nc(N2C3CCC2COC3)n1";"IC50";"'='";"1.7";"nM";"8.77";"";"";"UO_0000065";"14.90";"0.28";"5.05";"7.48";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1242657";"";"0";"314.32";"0";"1.45";"PP403";"Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2[C@H]1CCNC1";"IC50";"'='";"6500.0";"nM";"5.19";"";"";"UO_0000065";"16.50";"0.31";"3.74";"5.09";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242110";"";"0";"287.30";"0";"2.50";"PP77";"CC(C)n1nc(-c2cccc(O)c2F)c2c(N)ncnc21";"IC50";"'='";"192.0";"nM";"6.72";"";"";"UO_0000065";"23.38";"0.44";"4.22";"7.48";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242200";"";"0";"362.23";"0";"3.43";"PP85";"COc1cc(Br)cc(-c2nn(C(C)C)c3ncnc(N)c23)c1";"IC50";"'='";"10000.0";"nM";"5.00";"";"";"UO_0000065";"13.80";"0.31";"1.57";"6.34";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241271";"";"0";"255.28";"0";"1.63";"PP333";"Cc1ccc(-c2nn(C)c3ncnc(N)c23)cc1O";"IC50";"'='";"861.0";"nM";"6.07";"";"";"UO_0000065";"23.76";"0.44";"4.43";"6.75";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242378";"";"0";"302.31";"0";"1.44";"PP450";"C[C@H](CN)n1nc(-c2ccc(F)c(O)c2)c2c(N)ncnc21";"IC50";"'='";"11000.0";"nM";"4.96";"";"";"UO_0000065";"16.40";"0.31";"3.52";"4.28";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242847";"";"0";"283.34";"0";"2.67";"PP48";"COc1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1";"IC50";"'='";"4300.0";"nM";"5.37";"";"";"UO_0000065";"18.94";"0.35";"2.70";"6.81";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241861";"";"0";"317.30";"0";"2.75";"PP149";"CC(C)n1nc(-c2cc(F)c(C=O)c(F)c2)c2c(N)ncnc21";"IC50";"'='";"30000.0";"nM";"4.52";"";"";"UO_0000065";"14.25";"0.27";"1.77";"5.22";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241270";"";"0";"241.25";"0";"1.62";"PP320";"Cc1ccc(-c2n[nH]c3ncnc(N)c23)cc1O";"IC50";"'='";"4000.0";"nM";"5.40";"";"";"UO_0000065";"22.37";"0.41";"3.78";"5.36";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL2058167";"";"0";"412.45";"0";"0.37";"6";"COCCCNC(=O)c1cn2cc(-c3cnc(N)nc3)nc(N3CCOCC3)c2n1";"IC50";"'>'";"5000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2060320";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2057167";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2064342";"";"0";"387.42";"0";"1.33";"20";"COCCn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2cc(F)ccc21";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064407";"";"0";"326.36";"0";"1.65";"35";"Cc1ccc2oc(Cc3nc(N4CCOCC4)cc(=O)[nH]3)nc2c1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064352";"";"0";"330.32";"0";"1.48";"30";"O=c1cc(N2CCOCC2)nc(Cc2nc3cc(F)ccc3o2)[nH]1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064338";"";"0";"341.37";"0";"1.08";"16";"COc1ccc2[nH]c(Cc3nc(N4CCOCC4)cc(=O)[nH]3)nc2c1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064335";"";"0";"390.24";"0";"1.84";"13";"O=c1cc(N2CCOCC2)nc(Cc2nc3cc(Br)ccc3[nH]2)[nH]1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064419";"";"0";"314.35";"0";"0.79";"5";"O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccccc1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064330";"";"0";"325.37";"0";"1.08";"8";"Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2ccccc21";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL1760157";"";"0";"356.39";"0";"3.33";"30";"Cc1nc(N)nc(-n2c(Nc3ccc4cc[nH]c4c3)nc3ccccc32)n1";"IC50";"'='";"28.0";"nM";"7.55";"";"";"UO_0000065";"21.19";"0.38";"4.22";"6.85";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL604247";"";"0";"485.59";"0";"3.58";"33";"Cc1ccc(CN2CCC(n3cnc4c(N5CCOCC5)nc(-c5cncc(O)c5)nc43)CC2)cc1";"IC50";"'='";"590.0";"nM";"6.23";"";"";"UO_0000065";"12.83";"0.24";"2.65";"6.74";"False";"CHEMBL1068429";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153170";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL510164";"";"0";"313.38";"0";"2.90";"1";"Oc1cccc(-c2nc(N3CCOCC3)c3sccc3n2)c1";"IC50";"'='";"49.0";"nM";"7.31";"";"";"UO_0000065";"23.33";"0.45";"4.41";"12.50";"False";"CHEMBL1067293";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153098";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL594244";"";"0";"597.77";"1";"3.09";"16b";"CS(=O)(=O)N1CCN(Cc2cc3nc(-c4ccc(NC(=O)NC5CC5)cc4)nc(N4CC5CCC(C4)O5)c3s2)CC1";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"15.06";"0.30";"5.91";"7.50";"False";"CHEMBL1067293";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153098";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL593156";"";"0";"339.42";"0";"3.43";"8a";"Oc1cccc(-c2nc(N3CC4CCC(C3)O4)c3sccc3n2)c1";"IC50";"'='";"58.0";"nM";"7.24";"";"";"UO_0000065";"21.32";"0.41";"3.81";"12.37";"False";"CHEMBL1067293";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153098";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL593186";"";"0";"362.46";"0";"4.21";"8f";"c1cc2cc(-c3nc(N4CC5CCC(C4)O5)c4sccc4n3)ccc2[nH]1";"IC50";"'='";"22.0";"nM";"7.66";"";"";"UO_0000065";"21.13";"0.40";"3.45";"14.17";"False";"CHEMBL1067293";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153098";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL593157";"";"0";"425.51";"0";"2.84";"9d";"O=C(NCCO)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3sccc3n2)cc1";"IC50";"'='";"0.34";"nM";"9.47";"";"";"UO_0000065";"22.25";"0.43";"6.63";"9.51";"False";"CHEMBL1067293";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153098";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL572944";"";"0";"461.45";"0";"3.17";"40";"CNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(CC(F)(F)F)c3n2)cc1";"IC50";"'='";"0.5";"nM";"9.30";"";"";"UO_0000065";"20.16";"0.38";"6.13";"9.57";"True";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL575539";"";"0";"473.46";"0";"3.32";"44";"O=C(Nc1ccc(-c2nc(N3C[C@@H]4C[C@H]3CO4)c3cnn(CC(F)(F)F)c3n2)cc1)NC1CC1";"IC50";"'='";"1.9";"nM";"8.72";"";"";"UO_0000065";"18.42";"0.35";"5.40";"8.97";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL577137";"";"0";"534.62";"1";"3.41";"25";"CCNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(C4CCN(C(=O)OC)CC4)c3n2)cc1";"IC50";"'='";"0.2";"nM";"9.70";"";"";"UO_0000065";"18.14";"0.34";"6.29";"7.65";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL269732";"TACROLIMUS";"4";"804.03";"2";"4.64";"FK-506";"C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC";"IC50";"'='";"3.162";"nM";"8.50";"";"";"UO_0000065";"10.57";"0.20";"3.86";"4.77";"False";"CHEMBL677281";"The inhibitory activity by using FK506 binding protein 12 SPA binding assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1132865";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2000";""
"CHEMBL600367";"";"0";"582.67";"1";"4.76";"8f";"O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(C4CCC5(CC4)OCCO5)c3n2)cc1";"IC50";"'='";"0.12";"nM";"9.92";"";"";"UO_0000065";"17.03";"0.32";"5.16";"7.72";"False";"CHEMBL1068272";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156873";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL603498";"";"0";"475.55";"0";"3.30";"14";"CNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(C4CCC(=O)CC4)c3n2)cc1";"IC50";"'='";"0.22";"nM";"9.66";"";"";"UO_0000065";"20.31";"0.38";"6.36";"8.45";"False";"CHEMBL1068272";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156873";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL565787";"";"0";"469.55";"0";"4.52";"24";"CCn1ncc2c(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccccc4)cc3)nc21";"IC50";"'='";"0.3";"nM";"9.52";"";"";"UO_0000065";"20.28";"0.37";"5.00";"9.80";"False";"CHEMBL1039195";"Inhibition of human FLAG-tagged mTOR expressed in HEK293 cells after 2 hrs by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156748";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307715"
"CHEMBL568259";"";"0";"520.59";"1";"3.02";"4a";"CNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(C4CCN(C(=O)OC)CC4)c3n2)cc1";"IC50";"'='";"0.22";"nM";"9.66";"";"";"UO_0000065";"18.55";"0.35";"6.64";"7.62";"False";"CHEMBL1068272";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156873";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL602276";"";"0";"491.60";"0";"3.74";"12";"CNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn([C@H]4CC[C@H](OC)CC4)c3n2)cc1";"IC50";"'='";"0.38";"nM";"9.42";"";"";"UO_0000065";"19.16";"0.36";"5.68";"8.85";"False";"CHEMBL1068272";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156873";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL413";"SIROLIMUS";"4";"914.19";"3";"6.18";"267, Rapamycin";"CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C";"IC50";"'='";"0.45";"nM";"9.35";"";"";"UO_0000065";"10.22";"0.20";"3.17";"4.78";"False";"CHEMBL881403";"Inhibitory concentration against FKBP12 receptor";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143652";"1";"Scientific Literature";"J. Med. Chem.";"2005";""
"CHEMBL2030437";"";"0";"426.50";"0";"1.32";"18";"O=S(=O)(CCc1cnccn1)Cc1cc(N2CCOCC2)nc(-c2ccccn2)n1";"IC50";"'='";"3160.0";"nM";"5.50";"";"";"UO_0000065";"12.90";"0.25";"4.18";"4.95";"False";"CHEMBL2033327";"Inhibition of recombinant FLAG-tagged mTOR kinase expressed in HEK293 cells using Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2 as substrate after 90 mins";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2029234";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";"CHEMBL3307715"
"CHEMBL2030446";"";"0";"386.48";"0";"2.39";"26";"C[C@H]1COCCN1c1cc(CS(C)(=O)=O)nc(-c2ccc3[nH]ccc3c2)n1";"IC50";"'='";"303.0";"nM";"6.52";"";"";"UO_0000065";"16.87";"0.33";"4.13";"7.39";"False";"CHEMBL2033327";"Inhibition of recombinant FLAG-tagged mTOR kinase expressed in HEK293 cells using Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2 as substrate after 90 mins";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2029234";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";"CHEMBL3307715"
"CHEMBL410071";"";"0";"559.61";"1";"2.05";"Table S1, S26";"COC[C@H]1OC(=O)/C(=C/N2CCC(C(=O)O)CC2)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"822.0";"nM";"6.08";"";"";"UO_0000065";"10.87";"0.21";"4.04";"3.81";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL429577";"";"0";"574.72";"1";"2.92";"Table S1, S5";"CCN(/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)[C@@H](O)CC[C@@H]12)CCN(CC)CC";"IC50";"'='";"1480.0";"nM";"5.83";"";"";"UO_0000065";"10.14";"0.19";"2.91";"4.63";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL2087479";"";"0";"541.56";"2";"0.70";"19";"CS(=O)(=O)N1CCN(Cc2cn3cc(-c4cnc(N)nc4C(F)(F)F)nc(N4CCOCC4)c3n2)CC1";"IC50";"'='";"10000000.0";"nM";"";"Outside typical range";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2092092";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2086238";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL260313";"";"0";"529.59";"1";"1.92";"Table S1, S29";"COC[C@H]1OC(=O)/C(=C/N2CCC(=O)CC2)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"960.0";"nM";"6.02";"";"";"UO_0000065";"11.36";"0.22";"4.10";"4.31";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL271413";"";"0";"544.65";"1";"1.89";"Table S1, S10";"COC[C@H]1OC(=O)/C(=C/N(C)C2CCN(C)C2)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"1210.0";"nM";"5.92";"";"";"UO_0000065";"10.86";"0.21";"4.03";"4.70";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL407214";"";"0";"601.74";"2";"1.82";"Table S1, S7";"COC[C@H]1OC(=O)/C(=C/N(C)CCCN2CCN(C)CC2)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"2330.0";"nM";"5.63";"";"";"UO_0000065";"9.36";"0.18";"3.81";"4.36";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL409671";"";"0";"560.69";"1";"2.53";"Table S1, S4";"CCN(CC)CCN(C)/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)[C@@H](O)CC[C@@H]12";"IC50";"'='";"767.0";"nM";"6.12";"";"";"UO_0000065";"10.91";"0.21";"3.59";"4.86";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL272816";"";"0";"588.74";"1";"3.30";"16";"COC[C@H]1OC(=O)/C(=C/N(CCCN(C)C)C(C)(C)C)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"816.0";"nM";"6.09";"";"";"UO_0000065";"10.34";"0.20";"2.79";"4.84";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL1095627";"";"0";"479.59";"0";"3.48";"24c";"CC(C)(C)OC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(N)cc4)nc32)CC1";"IC50";"'='";"0.4";"nM";"9.40";"";"";"UO_0000065";"19.60";"0.37";"5.92";"8.42";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1092120";"";"0";"507.55";"1";"4.57";"9f";"Cn1cc(/C=C2\Oc3cccc(O)c3C2=O)c2c(-c3ccc(C(=O)N4CC5CCC(C4)O5)cc3)ccnc21";"IC50";"'='";"0.56";"nM";"9.25";"";"";"UO_0000065";"18.23";"0.33";"4.68";"9.85";"False";"CHEMBL1107897";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156283";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL589258";"";"0";"570.66";"1";"2.78";"3, PKI-402";"CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)N5CCN(C)CC5)cc4)cc3)nc21";"IC50";"'='";"1.7";"nM";"8.77";"";"";"UO_0000065";"15.37";"0.29";"5.99";"6.56";"False";"CHEMBL1068073";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157707";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL589103";"";"0";"445.49";"0";"2.78";"17";"CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4cccnc4)cc3)nc21";"IC50";"'='";"0.89";"nM";"9.05";"";"";"UO_0000065";"20.32";"0.37";"6.27";"7.36";"False";"CHEMBL1068073";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157707";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL589600";"";"0";"436.50";"0";"2.97";"21";"Cn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4cccs4)cc3)nc21";"IC50";"'='";"3.7";"nM";"8.43";"";"";"UO_0000065";"19.32";"0.37";"5.46";"7.66";"False";"CHEMBL1068073";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157707";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL591759";"";"0";"487.52";"0";"2.49";"27";"CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(N)=O)cc4)cc3)nc21";"IC50";"'='";"0.39";"nM";"9.41";"";"";"UO_0000065";"19.30";"0.36";"6.92";"6.14";"False";"CHEMBL1068073";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157707";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1094017";"";"0";"406.44";"0";"2.35";"18";"CN1CCN(c2ccnc3c2c(/C=C2\Oc4cc(O)cc(O)c4C2=O)cn3C)CC1";"IC50";"'='";"0.94";"nM";"9.03";"";"";"UO_0000065";"22.21";"0.41";"6.68";"9.91";"False";"CHEMBL1107897";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156283";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL592064";"";"0";"485.59";"0";"3.05";"5";"OCc1cccc(-c2nc(N3CCOCC3)c3nnn(C4CCN(Cc5ccccc5)CC4)c3n2)c1";"IC50";"'='";"250.0";"nM";"6.60";"";"";"UO_0000065";"13.60";"0.25";"3.55";"7.14";"False";"CHEMBL1068073";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157707";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL590587";"";"0";"558.65";"1";"2.68";"35";"CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)NCCN(C)C)cc4)cc3)nc21";"IC50";"'='";"0.5";"nM";"9.30";"";"";"UO_0000065";"16.65";"0.31";"6.62";"6.53";"False";"CHEMBL1068073";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157707";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL591357";"";"0";"515.58";"1";"3.14";"32";"CCNC(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)c4nnn(CC)c4n3)cc2)cc1";"IC50";"'='";"0.56";"nM";"9.25";"";"";"UO_0000065";"17.94";"0.33";"6.11";"6.65";"False";"CHEMBL1068073";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157707";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL2170089";"";"0";"531.62";"2";"2.14";"59";"COc1ncc(Nc2ncc([C@H](C)N3CCN(S(C)(=O)=O)C[C@@H]3C)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2173749";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169865";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2170099";"";"0";"517.59";"2";"1.75";"30";"COc1ncc(Nc2ncc([C@H](C)N3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2173749";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169865";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2170094";"";"0";"523.55";"1";"2.06";"20";"Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2ccc(C(F)(F)F)nc2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2173749";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169865";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2172476";"";"0";"362.40";"0";"2.54";"21d";"CC(=O)Nc1cc(-c2c(Nc3ccn(C)n3)nc3ccccn23)nc(C)n1";"IC50";"'='";"67.0";"nM";"7.17";"";"";"UO_0000065";"19.80";"0.36";"4.63";"7.03";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2172485";"";"0";"385.39";"0";"2.00";"12";"Cc1nc(N)nc(-c2c(Nc3cc[nH]n3)nc3ccc(-c4cncnc4)cn23)n1";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"22.57";"0.41";"6.70";"5.86";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1631901";"";"0";"243.27";"0";"2.83";"19";"N#Cc1ccc(C#Cc2n[nH]c3ccccc23)cc1";"IC50";"'>'";"50000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1633336";"Inhibition of mTORC1 expressed in HEK293 cells assessed as PRAS40 Ser183 phosphorylation level by LanthaScreen cellular assay";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";"CHEMBL3307715"
"CHEMBL1631900";"";"0";"224.29";"0";"3.02";"18";"C(#Cc1n[nH]c2ccccc12)c1ccsc1";"IC50";"'>'";"100000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1633336";"Inhibition of mTORC1 expressed in HEK293 cells assessed as PRAS40 Ser183 phosphorylation level by LanthaScreen cellular assay";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";"CHEMBL3307715"
"CHEMBL1631892";"";"0";"219.25";"0";"2.36";"10";"C(#Cc1n[nH]c2ccccc12)c1ccncc1";"IC50";"'='";"13600.0";"nM";"4.87";"";"";"UO_0000065";"22.20";"0.39";"2.51";"11.71";"False";"CHEMBL1633336";"Inhibition of mTORC1 expressed in HEK293 cells assessed as PRAS40 Ser183 phosphorylation level by LanthaScreen cellular assay";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";"CHEMBL3307715"
"CHEMBL1631896";"";"0";"210.28";"0";"3.10";"14";"C(#CC1CCCC1)c1n[nH]c2ccccc12";"IC50";"'>'";"100000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1633333";"Inhibition of mTOR by LanthaScreen Eu kinase binding assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL2172628";"";"0";"292.31";"0";"1.96";"19c";"Cc1nccc(-c2c(Nc3cc[nH]n3)nc3cccnn23)n1";"IC50";"'='";"141.0";"nM";"6.85";"";"";"UO_0000065";"23.44";"0.43";"4.89";"7.09";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2206913";"";"0";"406.86";"0";"1.99";"3b";"Cc1nc(N)nc(-c2cccnc2Nc2cnc(Cl)c(NS(C)(=O)=O)c2)n1";"IC50";"'='";"198.0";"nM";"6.70";"";"";"UO_0000065";"16.48";"0.34";"4.71";"4.51";"False";"CHEMBL2211629";"Inhibition of recombinant N-terminal GST-tagged mTOR using GFP-4EBP as substrate after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2203208";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1914736";"";"0";"543.02";"1";"4.03";"18l";"O=S(=O)(Nc1cc(-c2ccc3ncc(NCCN4CCOCC4)nc3c2)cnc1Cl)c1ccc(F)cc1";"IC50";"'='";"5.3";"nM";"8.28";"";"";"UO_0000065";"15.24";"0.31";"4.25";"7.57";"False";"CHEMBL1919685";"Inhibition of mTOR using GFP-tagged 4E-BP1 after 1 hr by spectrophotometric analysis";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1914426";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1945795";"";"0";"308.39";"0";"3.37";"31";"O=c1[nH]c2ncc(-c3ccccc3)nc2n1CC1CCCCC1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1945800";"";"0";"365.44";"0";"2.73";"36";"CNC(=O)c1ccc(-c2cnc3[nH]c(=O)n(CC4CCCCC4)c3n2)cc1";"IC50";"'='";"120.0";"nM";"6.92";"";"";"UO_0000065";"18.94";"0.35";"4.19";"7.47";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1945952";"";"0";"375.44";"0";"3.15";"43";"O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CC1CCCCC1";"IC50";"'='";"9.0";"nM";"8.05";"";"";"UO_0000065";"21.43";"0.39";"4.90";"7.65";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1945796";"";"0";"338.41";"0";"2.86";"32";"O=c1[nH]c2ncc(-c3ccc(CO)cc3)nc2n1CC1CCCCC1";"IC50";"'='";"60.0";"nM";"7.22";"";"";"UO_0000065";"21.34";"0.39";"4.36";"8.62";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1945956";"";"0";"376.42";"0";"2.60";"46";"O=c1[nH]c2ncc(-c3ccc(-c4cnc[nH]4)cc3)nc2n1CC1CCOCC1";"IC50";"'='";"2020.0";"nM";"5.70";"";"";"UO_0000065";"15.13";"0.28";"3.09";"5.61";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1631894";"";"0";"219.25";"0";"2.36";"12";"C(#Cc1n[nH]c2ccccc12)c1ccccn1";"IC50";"'>'";"50000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1633336";"Inhibition of mTORC1 expressed in HEK293 cells assessed as PRAS40 Ser183 phosphorylation level by LanthaScreen cellular assay";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";"CHEMBL3307715"
"CHEMBL1242208";"";"0";"304.36";"0";"3.20";"PP131";"CC(C)n1nc(-c2ccc3ccncc3c2)c2c(N)ncnc21";"IC50";"'='";"1500.0";"nM";"5.82";"";"";"UO_0000065";"19.13";"0.35";"2.62";"7.06";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241768";"";"0";"331.76";"0";"2.40";"PP430";"Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2[C@@H]1CCOC1";"IC50";"'='";"450.0";"nM";"6.35";"";"";"UO_0000065";"19.13";"0.38";"3.95";"6.41";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241677";"";"0";"330.78";"0";"1.97";"PP409";"Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2[C@@H]1CCNC1";"IC50";"'='";"2400.0";"nM";"5.62";"";"";"UO_0000065";"16.99";"0.33";"3.65";"5.52";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241864";"";"0";"346.39";"0";"3.03";"PP141";"Nc1ncnc2c1c(-c1ccc3[nH]c(=O)ccc3c1)nn2C1CCCC1";"IC50";"'='";"100000.0";"nM";"4.00";"";"";"UO_0000065";"11.55";"0.21";"0.97";"3.90";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241774";"";"0";"305.35";"0";"2.60";"PP132";"CC(C)n1nc(-c2ccc3nccnc3c2)c2c(N)ncnc21";"IC50";"'='";"632.0";"nM";"6.20";"";"";"UO_0000065";"20.30";"0.37";"3.60";"6.50";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1808991";"";"0";"588.67";"1";"2.57";"22";"CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(O[C@H]5CCOC5)nc(N5CCOCC5)n4)cc3)cc2)CC1";"IC50";"'='";"1.7";"nM";"8.77";"";"";"UO_0000065";"14.90";"0.28";"6.20";"6.53";"False";"CHEMBL1810297";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1806467";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1774356";"";"0";"436.52";"0";"3.17";"13e";"C[C@H]1COCCN1c1nc(-c2ccc(NC(=O)NCCC#N)cc2)nc2c1COC2(C)C";"IC50";"'='";"26.0";"nM";"7.58";"";"";"UO_0000065";"17.38";"0.32";"4.42";"6.75";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774373";"";"0";"455.56";"0";"3.29";"29a";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)[C@](C)(CCOC)OC3)cc1";"IC50";"'='";"15.0";"nM";"7.82";"";"";"UO_0000065";"17.17";"0.32";"4.53";"8.00";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773728";"";"0";"526.95";"2";"5.79";"73";"CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4cccc(C(F)(F)F)c4)c3)cc2s1";"IC50";"'<'";"1.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773571";"";"0";"358.42";"0";"3.13";"35";"COCCCOc1nccc(-c2ccc3nc(NC(C)=O)sc3c2)n1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773573";"";"0";"419.47";"0";"3.97";"48";"COc1ccc(C(=O)Nc2nccc(-c3ccc4nc(NC(C)=O)sc4c3)n2)cc1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL604303";"";"0";"495.97";"0";"3.51";"13";"O=C(Nc1ccc(Cl)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1";"IC50";"'='";"6.7";"nM";"8.17";"";"";"UO_0000065";"16.48";"0.32";"4.66";"7.80";"False";"CHEMBL1065057";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157610";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL594606";"";"0";"570.72";"1";"4.51";"13c";"CN1CCN(Cc2cc3nc(-c4ccc(NC(=O)Nc5cccnc5)cc4)nc(N4CC5CCC(C4)O5)c3s2)CC1";"IC50";"'='";"4.7";"nM";"8.33";"";"";"UO_0000065";"14.59";"0.28";"3.82";"8.43";"False";"CHEMBL1067293";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153098";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL592522";"";"0";"490.54";"0";"2.80";"34";"Oc1cncc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccc(F)nc5)CC4)c3n2)c1";"IC50";"'='";"570.0";"nM";"6.24";"";"";"UO_0000065";"12.73";"0.24";"3.44";"5.93";"False";"CHEMBL1068429";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153170";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL601864";"";"0";"393.45";"0";"2.15";"3a";"CNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(C)c3n2)cc1";"IC50";"'='";"1.34";"nM";"8.87";"";"";"UO_0000065";"22.55";"0.42";"6.72";"9.13";"False";"CHEMBL1068272";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156873";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL606621";"";"0";"477.57";"0";"3.09";"16";"CNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn([C@H]4CC[C@@H](O)CC4)c3n2)cc1";"IC50";"'='";"0.3";"nM";"9.52";"";"";"UO_0000065";"19.94";"0.37";"6.43";"8.11";"False";"CHEMBL1068272";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156873";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL601660";"";"0";"521.62";"1";"3.72";"17";"CNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(C4CCC(OC)(OC)CC4)c3n2)cc1";"IC50";"'='";"0.74";"nM";"9.13";"";"";"UO_0000065";"17.50";"0.33";"5.41";"7.89";"False";"CHEMBL1068272";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156873";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL601661";"";"0";"519.61";"1";"3.47";"8a";"CNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(C4CCC5(CC4)OCCO5)c3n2)cc1";"IC50";"'='";"0.21";"nM";"9.68";"";"";"UO_0000065";"18.63";"0.35";"6.21";"8.37";"False";"CHEMBL1068272";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156873";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL601876";"";"0";"533.63";"1";"3.86";"18";"CNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(C4CCC5(CC4)OCCCO5)c3n2)cc1";"IC50";"'='";"1.19";"nM";"8.92";"";"";"UO_0000065";"16.72";"0.31";"5.06";"7.72";"False";"CHEMBL1068272";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156873";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL600368";"";"0";"582.67";"1";"4.76";"8g";"O=C(Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(C4CCC5(CC4)OCCO5)c3n2)cc1)Nc1cccnc1";"IC50";"'='";"0.12";"nM";"9.92";"";"";"UO_0000065";"17.03";"0.32";"5.16";"7.72";"False";"CHEMBL1068272";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156873";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL590619";"";"0";"381.44";"0";"1.35";"31";"Oc1cncc(-c2nc(N3CCOCC3)c3ncn(C4CCNCC4)c3n2)c1";"IC50";"'='";"970.0";"nM";"6.01";"";"";"UO_0000065";"15.76";"0.29";"4.66";"5.94";"False";"CHEMBL1068429";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153170";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL604988";"";"0";"502.59";"1";"3.80";"25";"OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccccc5F)CC4)c3n2)c1";"IC50";"'='";"160.0";"nM";"6.80";"";"";"UO_0000065";"13.52";"0.25";"3.00";"8.54";"False";"CHEMBL1068429";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153170";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL590620";"";"0";"506.01";"1";"3.92";"32";"Oc1cncc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccc(Cl)cc5)CC4)c3n2)c1";"IC50";"'='";"160.0";"nM";"6.80";"";"";"UO_0000065";"13.43";"0.26";"2.88";"7.35";"False";"CHEMBL1068429";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153170";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL604167";"";"0";"571.73";"1";"2.55";"16a";"CNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3sc(CN4CCN(S(C)(=O)=O)CC4)cc3n2)cc1";"IC50";"'='";"1.4";"nM";"8.85";"";"";"UO_0000065";"15.49";"0.31";"6.30";"7.38";"False";"CHEMBL1067293";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153098";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1774358";"";"0";"463.54";"0";"3.51";"13g";"C[C@H]1COCCN1c1nc(-c2ccc(NC(=O)Nc3cnn(C)c3)cc2)nc2c1COC2(C)C";"IC50";"'='";"6.0";"nM";"8.22";"";"";"UO_0000065";"17.74";"0.33";"4.71";"7.73";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773085";"";"0";"425.49";"0";"2.92";"13b";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)C(C)(C)OC3=O)cc1";"IC50";"'='";"13.0";"nM";"7.89";"";"";"UO_0000065";"18.53";"0.35";"4.97";"7.46";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774368";"";"0";"453.54";"0";"2.78";"22f";"CCNC(=O)Nc1ccc(-c2nc(N3C[C@@H]4CC[C@H](C3)O4)c3c(n2)[C@@](C)(CCO)OC3)cc1";"IC50";"'='";"27.0";"nM";"7.57";"";"";"UO_0000065";"16.69";"0.31";"4.79";"6.95";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL593515";"";"0";"297.32";"0";"1.56";"15";"Oc1cccc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)c1";"IC50";"'='";"2383.0";"nM";"5.62";"";"";"UO_0000065";"18.91";"0.35";"4.06";"6.45";"False";"CHEMBL1074731";"Inhibition of human TOR in HEK293 cells by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153204";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL589864";"";"0";"374.43";"0";"1.23";"19";"CS(=O)(=O)Nc1cccc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1074731";"Inhibition of human TOR in HEK293 cells by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153204";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL574207";"";"0";"470.58";"0";"3.87";"34";"Oc1cccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)c1";"IC50";"'='";"83.0";"nM";"7.08";"";"";"UO_0000065";"15.05";"0.28";"3.21";"8.90";"False";"CHEMBL1074731";"Inhibition of human TOR in HEK293 cells by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153204";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL573178";"";"0";"403.49";"0";"2.74";"5t";"c1cc2cc(-c3nc(N4CCOCC4)c4cnn(C5CCNCC5)c4n3)ccc2[nH]1";"IC50";"'='";"170.0";"nM";"6.77";"";"";"UO_0000065";"16.78";"0.31";"4.03";"8.07";"False";"CHEMBL1063861";"Inhibition of human mTOR by DELFIA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154644";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL573424";"";"0";"555.69";"1";"4.09";"15";"CNC(=O)Nc1ccc(-c2nc(N3C[C@H](C)O[C@H](C)C3)c3cnn(C4CCN(Cc5cccnc5)CC4)c3n2)cc1";"IC50";"'='";"84.0";"nM";"7.08";"";"";"UO_0000065";"12.73";"0.24";"2.99";"6.24";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL594571";"";"0";"457.56";"1";"5.37";"9f";"O=C(Nc1ccccc1)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3sccc3n2)cc1";"IC50";"'='";"1.25";"nM";"8.90";"";"";"UO_0000065";"19.46";"0.37";"3.53";"11.22";"False";"CHEMBL1067293";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153098";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL580212";"";"0";"553.67";"1";"3.84";"23";"CNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(C4CCN(Cc5cccnc5)CC4)c3n2)cc1";"IC50";"'='";"0.48";"nM";"9.32";"";"";"UO_0000065";"16.83";"0.31";"5.48";"8.22";"True";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL574905";"";"0";"493.47";"0";"3.51";"32";"O=C(NCCF)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(CC(F)(F)F)c3n2)cc1";"IC50";"'='";"0.23";"nM";"9.64";"";"";"UO_0000065";"19.53";"0.38";"6.13";"9.92";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL575989";"";"0";"510.48";"1";"4.07";"36";"O=C(Nc1ccc(-c2nc(N3C[C@@H]4C[C@H]3CO4)c3cnn(CC(F)(F)F)c3n2)cc1)Nc1cccnc1";"IC50";"'='";"1.2";"nM";"8.92";"";"";"UO_0000065";"17.48";"0.33";"4.85";"8.10";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL573171";"";"0";"571.64";"1";"4.16";"18";"COC(=O)N1CCC(n2ncc3c(N4CCOC(C)C4)nc(-c4ccc(NC(=O)Nc5cccnc5)cc4)nc32)CC1";"IC50";"'='";"0.62";"nM";"9.21";"";"";"UO_0000065";"16.11";"0.30";"5.05";"6.59";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL538378";"";"0";"557.62";"1";"3.77";"20";"COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)Nc5cccnc5)cc4)nc32)CC1";"IC50";"'='";"0.2";"nM";"9.70";"";"";"UO_0000065";"17.39";"0.32";"5.93";"6.95";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL567822";"";"0";"461.45";"0";"3.17";"41";"CNC(=O)Nc1ccc(-c2nc(N3C4CCC3COC4)c3cnn(CC(F)(F)F)c3n2)cc1";"IC50";"'='";"0.56";"nM";"9.25";"";"";"UO_0000065";"20.05";"0.38";"6.08";"9.52";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL551440";"";"0";"527.63";"1";"3.31";"14";"CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5cccnc5)CC4)c3n2)cc1";"IC50";"'='";"0.38";"nM";"9.42";"";"";"UO_0000065";"17.85";"0.33";"6.11";"8.31";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL574211";"";"0";"505.63";"1";"4.72";"5k";"c1ccc(CN2CCC(n3ncc4c(N5CCOCC5)nc(-c5cnc6ccccc6c5)nc43)CC2)cc1";"IC50";"'='";"120.0";"nM";"6.92";"";"";"UO_0000065";"13.69";"0.25";"2.20";"9.59";"False";"CHEMBL1063861";"Inhibition of human mTOR by DELFIA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154644";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL576979";"";"0";"447.42";"0";"2.78";"43";"CNC(=O)Nc1ccc(-c2nc(N3C[C@H]4C[C@@H]3CO4)c3cnn(CC(F)(F)F)c3n2)cc1";"IC50";"'='";"91.0";"nM";"7.04";"";"";"UO_0000065";"15.74";"0.30";"4.26";"7.24";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL594350";"";"0";"338.44";"0";"3.31";"8e";"Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3sccc3n2)cc1";"IC50";"'='";"100.0";"nM";"7.00";"";"";"UO_0000065";"20.68";"0.40";"3.69";"10.89";"False";"CHEMBL1067293";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153098";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL594173";"";"0";"570.72";"1";"4.51";"13d";"CN1CCN(Cc2cc3nc(-c4ccc(NC(=O)Nc5ccncc5)cc4)nc(N4CC5CCC(C4)O5)c3s2)CC1";"IC50";"'='";"3.7";"nM";"8.43";"";"";"UO_0000065";"14.77";"0.28";"3.92";"8.54";"False";"CHEMBL1067293";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153098";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL589258";"";"0";"570.66";"1";"2.78";"2, PKI-402";"CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)N5CCN(C)CC5)cc4)cc3)nc21";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"15.24";"0.28";"5.92";"6.51";"False";"CHEMBL1810297";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1806467";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1241241";"";"0";"269.31";"0";"2.36";"PP56";"CC(C)n1nc(-c2ccc(O)cc2)c2c(N)ncnc21";"IC50";"'='";"6000.0";"nM";"5.22";"";"";"UO_0000065";"19.39";"0.36";"2.86";"5.81";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL597815";"";"0";"497.51";"0";"3.13";"14";"O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1)Nc1ccc(F)cc1F";"IC50";"'='";"9.3";"nM";"8.03";"";"";"UO_0000065";"16.14";"0.30";"4.90";"7.67";"False";"CHEMBL1065057";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157610";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1241942";"";"0";"283.34";"0";"2.82";"PP209";"CNc1ncnc2c1c(-c1cccc(O)c1)nn2C(C)C";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241356";"";"0";"226.24";"0";"1.18";"PP211";"Nc1ccc(-c2n[nH]c3ncnc(N)c23)cc1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL590356";"";"0";"398.46";"0";"4.25";"26";"O=C(NCCF)Nc1ccc(-c2nc(C3=CCOCC3)c3sccc3n2)cc1";"IC50";"'='";"2.5";"nM";"8.60";"";"";"UO_0000065";"21.59";"0.42";"4.35";"11.30";"False";"CHEMBL1074679";"Inhibition of mTOR in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153200";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL589622";"";"0";"428.52";"1";"5.81";"27";"O=C(Nc1ccccc1)Nc1ccc(-c2nc(C3=CCOCC3)c3sccc3n2)cc1";"IC50";"'='";"7.2";"nM";"8.14";"";"";"UO_0000065";"19.00";"0.36";"2.33";"10.69";"False";"CHEMBL1074679";"Inhibition of mTOR in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153200";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL435507";"";"0";"295.34";"0";"3.17";"48";"CC1CN(c2cc(=O)c3ccc4ccccc4c3o2)CCO1";"IC50";"'='";"4800.0";"nM";"5.32";"";"";"UO_0000065";"18.01";"0.33";"2.15";"12.46";"False";"CHEMBL830918";"Inhibition of mTOR protein isolated from HeLa cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HeLa";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1141182";"1";"Scientific Literature";"J. Med. Chem.";"2005";"CHEMBL3308376"
"CHEMBL1945955";"";"0";"376.42";"0";"2.60";"45";"O=c1[nH]c2ncc(-c3ccc(-c4ncc[nH]4)cc3)nc2n1CC1CCOCC1";"IC50";"'='";"5.0";"nM";"8.30";"";"";"UO_0000065";"22.05";"0.40";"5.70";"8.18";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1946262";"";"0";"348.41";"0";"3.24";"56";"O=c1[nH]c2ncc(-c3ccc4[nH]cnc4c3)nc2n1CC1CCCCC1";"IC50";"'='";"21.0";"nM";"7.68";"";"";"UO_0000065";"22.04";"0.40";"4.44";"8.32";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1945950";"";"0";"366.47";"0";"3.59";"39";"CC(C)(O)c1ccc(-c2cnc3[nH]c(=O)n(CC4CCCCC4)c3n2)cc1";"IC50";"'='";"1350.0";"nM";"5.87";"";"";"UO_0000065";"16.02";"0.30";"2.28";"7.00";"False";"CHEMBL1949072";"Inhibition of mTOR-mediated S6 phosphorylation in human PC3 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";"CHEMBL3307570"
"CHEMBL1946265";"";"0";"379.42";"0";"2.13";"59";"CNc1nc2cc(-c3cnc4[nH]c(=O)n(CC5CCOCC5)c4n3)ccc2[nH]1";"IC50";"'>'";"5000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1949072";"Inhibition of mTOR-mediated S6 phosphorylation in human PC3 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";"CHEMBL3307570"
"CHEMBL1946262";"";"0";"348.41";"0";"3.24";"56";"O=c1[nH]c2ncc(-c3ccc4[nH]cnc4c3)nc2n1CC1CCCCC1";"IC50";"'='";"137.0";"nM";"6.86";"";"";"UO_0000065";"19.70";"0.36";"3.62";"7.44";"False";"CHEMBL1949073";"Inhibition of mTOR-mediated Akt phosphorylation in human PC3 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";"CHEMBL3307570"
"CHEMBL489058";"";"0";"558.15";"2";"6.43";"5m";"CCN1CCN(CC/C=C/c2ccc3c(Nc4ccc(Sc5nccn5C)c(Cl)c4)c(C#N)cnc3c2)CC1";"IC50";"'>'";"30000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL991664";"Inhibition of mTOR in presence of 100 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1142456";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2008";""
"CHEMBL1808980";"";"0";"520.59";"1";"2.32";"10";"COc1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)NCCN(C)C)cc3)cc2)nc(N2CCOCC2)n1";"IC50";"'='";"5.6";"nM";"8.25";"";"";"UO_0000065";"15.85";"0.30";"5.93";"6.17";"False";"CHEMBL1810297";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1806467";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL593768";"";"0";"380.45";"0";"1.96";"15";"Oc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCNCC4)c3n2)c1";"IC50";"'='";"950.0";"nM";"6.02";"";"";"UO_0000065";"15.83";"0.29";"4.06";"6.82";"False";"CHEMBL1068429";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153170";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL593064";"";"0";"506.01";"1";"3.92";"19";"Oc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5cncc(Cl)c5)CC4)c3n2)c1";"IC50";"'='";"200.0";"nM";"6.70";"";"";"UO_0000065";"13.24";"0.25";"2.78";"7.25";"False";"CHEMBL1068429";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153170";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL3327012";"";"0";"422.47";"0";"2.79";"2n";"COc1ncc(-c2cnc3nc(N)nc(C)c3c2)cc1NS(=O)(=O)c1ccccc1";"IC50";"'='";"79.2";"nM";"7.10";"";"";"UO_0000065";"16.81";"0.32";"4.31";"5.34";"False";"CHEMBL3380578";"Inhibition of mTOR (unknown origin) assessed as inhibition of 4EBP-1 phosphorylation preincubated for 15 mins before substrate addition by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3351642";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL1808979";"";"0";"534.62";"1";"2.66";"9";"COc1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)N(C)CCN(C)C)cc3)cc2)nc(N2CCOCC2)n1";"IC50";"'='";"7.7";"nM";"8.11";"";"";"UO_0000065";"15.18";"0.28";"5.45";"6.49";"False";"CHEMBL1810297";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1806467";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1808985";"";"0";"560.66";"1";"3.19";"15";"CC(C)Oc1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)N4CCN(C)CC4)cc3)cc2)nc(N2CCOCC2)n1";"IC50";"'='";"1.3";"nM";"8.89";"";"";"UO_0000065";"15.85";"0.30";"5.70";"7.11";"False";"CHEMBL1810297";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1806467";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1808990";"";"0";"602.70";"1";"3.01";"21";"O=C(Nc1ccc(C(=O)NCCN2CCCC2)cc1)Nc1ccc(-c2nc(O[C@H]3CCOC3)nc(N3CCOCC3)n2)cc1";"IC50";"'='";"0.3";"nM";"9.52";"";"";"UO_0000065";"15.80";"0.30";"6.51";"6.66";"False";"CHEMBL1810297";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1806467";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760159";"";"0";"321.35";"0";"1.58";"33";"Cc1nc(N)nc(-n2c(Nc3ccn(C)n3)nc3ccccc32)n1";"IC50";"'='";"270.0";"nM";"6.57";"";"";"UO_0000065";"20.44";"0.37";"4.99";"5.85";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762779";"";"0";"304.31";"0";"2.66";"7";"Oc1cccc(Nc2nc3ccccc3n2-c2ncncn2)c1";"IC50";"'='";"3000.0";"nM";"5.52";"";"";"UO_0000065";"18.15";"0.33";"2.86";"6.22";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762784";"";"0";"361.41";"0";"3.19";"13";"CCCc1nc(N)nc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"4700.0";"nM";"5.33";"";"";"UO_0000065";"14.74";"0.27";"2.14";"4.64";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1774364";"";"0";"427.51";"0";"2.25";"22b";"CCNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3c(n2)[C@](C)(CCO)OC3)cc1";"IC50";"'='";"2.2";"nM";"8.66";"";"";"UO_0000065";"20.25";"0.38";"6.41";"7.95";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773085";"";"0";"425.49";"0";"2.92";"13b";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)C(C)(C)OC3=O)cc1";"IC50";"'='";"7.6";"nM";"8.12";"";"";"UO_0000065";"19.08";"0.36";"5.20";"7.68";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774361";"";"0";"451.57";"0";"4.06";"21a";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)[C@@](C)(CC2CC2)OC3)cc1";"IC50";"'='";"2.8";"nM";"8.55";"";"";"UO_0000065";"18.94";"0.35";"4.49";"9.65";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1928541";"";"0";"398.40";"0";"2.08";"5x";"Cc1ccc([N+](=O)[O-])cc1S(=O)(=O)N(C)/N=C/c1cnn2ccc(C#N)cc12";"IC50";"'='";"300.0";"nM";"6.52";"";"";"UO_0000065";"16.37";"0.32";"4.44";"4.87";"False";"CHEMBL1932537";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1926509";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2012";""
"CHEMBL2158855";"";"0";"438.51";"0";"2.30";"9m";"NS(=O)(=O)c1cccc(Nc2nccc(-c3ccnc(N4CC5CCC(C4)O5)c3)n2)c1";"IC50";"'='";"200.0";"nM";"6.70";"";"";"UO_0000065";"15.28";"0.30";"4.40";"5.43";"False";"CHEMBL2161544";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2157945";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2158854";"";"0";"438.51";"0";"2.30";"9l";"NS(=O)(=O)c1cccc(Nc2nccc(-c3ccnc(N4C5CCC4COC5)c3)n2)c1";"IC50";"'='";"3200.0";"nM";"5.50";"";"";"UO_0000065";"12.53";"0.24";"3.19";"4.46";"False";"CHEMBL2161544";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2157945";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2158866";"";"0";"566.09";"2";"5.38";"11j";"CCN(CC)S(=O)(=O)c1cc(Nc2nccc(-c3ccnc(-c4ccc(NC(=O)NC)cc4)c3)n2)ccc1Cl";"IC50";"'='";"50.0";"nM";"7.30";"";"";"UO_0000065";"12.90";"0.26";"1.92";"5.65";"False";"CHEMBL2161544";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2157945";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1773599";"";"0";"454.53";"0";"4.13";"54";"COc1ccc(S(=O)(=O)Nc2cncc(-c3ccc4nc(NC(C)=O)sc4c3)c2)cc1";"IC50";"'='";"11.0";"nM";"7.96";"";"";"UO_0000065";"17.51";"0.35";"3.83";"7.22";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1242758";"";"0";"318.38";"0";"3.67";"PP92";"Nc1ncnc2c1c(-c1cccc3[nH]ccc13)nn2C1CCCC1";"IC50";"'='";"5400.0";"nM";"5.27";"";"";"UO_0000065";"16.55";"0.30";"1.60";"6.17";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1240594";"";"0";"281.34";"0";"2.83";"PP234";"Cn1nc(-c2cc3ccccc3s2)c2c(N)ncnc21";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1421";"DASATINIB";"4";"488.02";"0";"3.31";"Dasatinib";"Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1";"IC50";"'='";"35000.0";"nM";"4.46";"";"";"UO_0000065";"9.13";"0.18";"1.15";"4.18";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1760154";"";"0";"389.42";"0";"2.60";"27";"CNC(=O)Nc1ccc(Nc2nc3ccccc3n2-c2nc(C)nc(N)n2)cc1";"IC50";"'='";"340.0";"nM";"6.47";"";"";"UO_0000065";"16.61";"0.30";"3.87";"4.77";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL604123";"";"0";"421.51";"0";"3.19";"3c";"CNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(C(C)C)c3n2)cc1";"IC50";"'='";"0.12";"nM";"9.92";"";"";"UO_0000065";"23.54";"0.44";"6.73";"10.21";"False";"CHEMBL1068272";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156873";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL572944";"";"0";"461.45";"0";"3.17";"3d";"CNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(CC(F)(F)F)c3n2)cc1";"IC50";"'='";"0.5";"nM";"9.30";"";"";"UO_0000065";"20.16";"0.38";"6.13";"9.57";"False";"CHEMBL1068272";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156873";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL600213";"";"0";"545.64";"1";"4.00";"8d";"O=C(Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(C4CCC5(CC4)OCCO5)c3n2)cc1)NC1CC1";"IC50";"'='";"0.22";"nM";"9.66";"";"";"UO_0000065";"17.70";"0.33";"5.66";"8.35";"False";"CHEMBL1068272";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156873";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL597012";"";"0";"468.56";"0";"1.73";"29";"O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1)NN1CCCCC1";"IC50";"'='";"460.0";"nM";"6.34";"";"";"UO_0000065";"13.52";"0.25";"4.61";"5.87";"False";"CHEMBL1065057";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157610";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1091070";"";"0";"307.31";"0";"3.21";"1";"Cn1cc(/C=C2\Oc3cc(O)cc(O)c3C2=O)c2ccccc21";"IC50";"'='";"800.0";"nM";"6.10";"";"";"UO_0000065";"19.84";"0.36";"2.89";"8.50";"True";"CHEMBL1107897";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156283";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1089767";"";"0";"310.36";"0";"1.95";"4";"OCc1cccc(-c2nc(N3CCOCC3)c3[nH]ccc3n2)c1";"IC50";"'='";"1625.0";"nM";"5.79";"";"";"UO_0000065";"18.65";"0.34";"3.84";"7.79";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1090781";"";"0";"503.56";"1";"3.59";"33";"COC(Cn1ccc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccncc4)cc3)nc21)OC";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"17.87";"0.33";"5.41";"7.78";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1095625";"";"0";"469.59";"0";"3.75";"13a";"Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)cc1";"IC50";"'='";"200.0";"nM";"6.70";"";"";"UO_0000065";"14.27";"0.26";"2.95";"7.85";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL3112712";"";"0";"571.61";"1";"3.91";"9v";"COc1ncc(-c2cc3c(C)nc(N)cc3n([C@H]3CC[C@H](O)CC3)c2=O)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"28.68";"nM";"7.54";"";"";"UO_0000065";"13.20";"0.26";"3.63";"5.05";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3112709";"";"0";"523.59";"1";"4.41";"9s";"COc1ncc(-c2cc3c(C)nc(N)cc3n(C3CCCC3)c2=O)cc1NS(=O)(=O)c1cccc(F)c1";"IC50";"'='";"13.88";"nM";"7.86";"";"";"UO_0000065";"15.01";"0.29";"3.45";"6.08";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3112730";"";"0";"615.66";"1";"3.93";"9k";"COc1ncc(-c2cc3c(C)nc(N)cc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"8.55";"nM";"8.07";"";"";"UO_0000065";"13.10";"0.26";"4.14";"5.09";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3112726";"";"0";"373.46";"0";"3.96";"9g";"Cc1nc(N)cc2c1cc(-c1cnc3c(ccn3C)c1)c(=O)n2C1CCCC1";"IC50";"'='";"82.12";"nM";"7.09";"";"";"UO_0000065";"18.97";"0.35";"3.13";"9.00";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3112724";"";"0";"368.41";"0";"3.61";"9e";"COc1ncc(-c2cc3c(C)nc(N)cc3n(C3CCCC3)c2=O)cc1F";"IC50";"'='";"159.96";"nM";"6.80";"";"";"UO_0000065";"18.45";"0.34";"3.19";"8.18";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL1234354";"PF-04691502";"2";"425.49";"0";"2.25";"PF-04691502";"COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1";"IC50";"'='";"7.9";"nM";"8.10";"";"";"UO_0000065";"19.04";"0.36";"5.85";"6.46";"True";"CHEMBL3380578";"Inhibition of mTOR (unknown origin) assessed as inhibition of 4EBP-1 phosphorylation preincubated for 15 mins before substrate addition by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3351642";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL7237";"";"0";"346.43";"0";"2.16";"S1M1M'2";"CC(C)CC(=O)C(=O)N1CCC[C@H]1C(=O)OCCCc1cccnc1";"IC50";"'<'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL682171";"The inhibitory activity by using FK506 binding protein 12 SPA binding assay.";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1132865";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2000";""
"CHEMBL551440";"";"0";"527.63";"1";"3.31";"10";"CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5cccnc5)CC4)c3n2)cc1";"IC50";"'='";"0.38";"nM";"9.42";"";"";"UO_0000065";"17.85";"0.33";"6.11";"8.31";"True";"CHEMBL1058638";"Inhibition of flag-tagged truncated human mTOR (1360-2549) expressed in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1151963";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL2030445";"";"0";"373.44";"0";"1.40";"24";"CS(=O)(=O)Cc1cc(N2CCOCC2)nc(-c2ccc3[nH]cnc3c2)n1";"IC50";"'='";"285.0";"nM";"6.54";"";"";"UO_0000065";"17.53";"0.34";"5.15";"6.48";"False";"CHEMBL2033327";"Inhibition of recombinant FLAG-tagged mTOR kinase expressed in HEK293 cells using Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2 as substrate after 90 mins";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2029234";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";"CHEMBL3307715"
"CHEMBL2030442";"";"0";"372.45";"0";"2.01";"21";"CS(=O)(=O)Cc1cc(N2CCOCC2)nc(-c2cccc3[nH]ccc23)n1";"IC50";"'='";"1460.0";"nM";"5.84";"";"";"UO_0000065";"15.67";"0.31";"3.83";"6.62";"False";"CHEMBL2033327";"Inhibition of recombinant FLAG-tagged mTOR kinase expressed in HEK293 cells using Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2 as substrate after 90 mins";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2029234";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";"CHEMBL3307715"
"CHEMBL271544";"";"0";"598.74";"1";"3.20";"Table S1, S17";"COC[C@H]1OC(=O)/C(=C/N2CCN(C3CCCCC3)CC2)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"820.0";"nM";"6.09";"";"";"UO_0000065";"10.16";"0.19";"2.89";"4.84";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL1774942";"HOMOTEMSIROLIMUS C";"0";"1044.33";"";"";"2c";"CC[C@@H]1/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C@@H](OC)C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC1=O";"IC50";"'='";"2100.0";"nM";"5.68";"";"";"UO_0000065";"5.44";"";"";"";"False";"CHEMBL1777505";"Inhibition of FKBP12-independent human recombinant mTOR expressed in HEK293 cells using His6-S6K1 as a substrate by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1772963";"1";"Scientific Literature";"J. Nat. Prod.";"2011";"CHEMBL3307715"
"CHEMBL1795875";"";"0";"683.73";"2";"8.26";"10";"CN1CCC(NC(=O)c2ccc(-c3ccc(-n4c(=O)ccc5cnc6ccc(-c7cnc8ccccc8c7)cc6c54)cc3C(F)(F)F)cc2)CC1";"IC50";"'='";"3.01";"nM";"8.52";"";"";"UO_0000065";"12.46";"0.23";"0.26";"10.64";"False";"CHEMBL1799287";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1795255";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL2030436";"";"0";"372.45";"0";"2.01";"19";"CS(=O)(=O)Cc1cc(N2CCOCC2)nc(-c2ccc3[nH]ccc3c2)n1";"IC50";"'='";"288.0";"nM";"6.54";"";"";"UO_0000065";"17.56";"0.34";"4.53";"7.42";"True";"CHEMBL2033327";"Inhibition of recombinant FLAG-tagged mTOR kinase expressed in HEK293 cells using Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2 as substrate after 90 mins";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2029234";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";"CHEMBL3307715"
"CHEMBL273038";"";"0";"573.64";"2";"2.14";"Table S1, S25";"COC[C@H]1OC(=O)/C(=C/N2CCC(C(=O)OC)CC2)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"1690.0";"nM";"5.77";"";"";"UO_0000065";"10.06";"0.19";"3.63";"3.88";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL271190";"";"0";"547.65";"1";"2.35";"8";"COC[C@H]1OC(=O)/C(=C/N(CCO)C(C)(C)C)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"28600.0";"nM";"4.54";"";"";"UO_0000065";"8.30";"0.16";"2.19";"3.18";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL1808982";"";"0";"532.61";"1";"2.42";"12";"COc1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)N4CCN(C)CC4)cc3)cc2)nc(N2CCOCC2)n1";"IC50";"'='";"22.5";"nM";"7.65";"";"";"UO_0000065";"14.36";"0.27";"5.23";"6.12";"False";"CHEMBL1810297";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1806467";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL2165270";"";"0";"293.33";"0";"2.88";"13";"Cc1nc(N)cc(-c2cccnc2Nc2cccc(O)c2)n1";"IC50";"'='";"360.0";"nM";"6.44";"";"";"UO_0000065";"21.97";"0.40";"3.56";"6.65";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2172636";"";"0";"384.41";"0";"2.61";"6";"Cc1nc(N)nc(-c2c(Nc3cc[nH]n3)nc3ccc(-c4cccnc4)cn23)n1";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"22.17";"0.40";"5.91";"6.29";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2206906";"";"0";"480.94";"1";"2.01";"3q";"COCCOc1cnc(Nc2cnc(Cl)c(NS(C)(=O)=O)c2)c(-c2nc(C)nc(N)n2)c1";"IC50";"'='";"32.0";"nM";"7.50";"";"";"UO_0000065";"15.58";"0.32";"5.48";"4.48";"False";"CHEMBL2211629";"Inhibition of recombinant N-terminal GST-tagged mTOR using GFP-4EBP as substrate after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2203208";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2206904";"";"0";"465.93";"0";"1.84";"3o";"COc1cnc(Nc2cnc(Cl)c(NS(=O)(=O)N(C)C)c2)c(-c2nc(C)nc(N)n2)c1";"IC50";"'='";"74.0";"nM";"7.13";"";"";"UO_0000065";"15.30";"0.31";"5.29";"4.43";"False";"CHEMBL2211629";"Inhibition of recombinant N-terminal GST-tagged mTOR using GFP-4EBP as substrate after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2203208";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2170091";"";"0";"471.55";"0";"0.33";"2";"Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2ccc(=O)[nH]c2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2173749";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169865";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL410637";"";"0";"530.62";"1";"1.50";"Table S1, S20";"COC[C@H]1OC(=O)/C(=C/N2CCN(C)CC2)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"829.0";"nM";"6.08";"";"";"UO_0000065";"11.46";"0.22";"4.58";"4.83";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL1242566";"";"0";"299.31";"0";"2.65";"PP461";"Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2C1CCC1";"IC50";"'='";"1500.0";"nM";"5.82";"";"";"UO_0000065";"19.46";"0.36";"3.17";"6.48";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1946266";"";"0";"349.39";"0";"2.69";"60";"O=c1[nH]c2ncc(-c3ccc4[nH]ccc4c3)nc2n1CC1CCOCC1";"IC50";"'='";"231.0";"nM";"6.64";"";"";"UO_0000065";"18.99";"0.35";"3.95";"7.49";"False";"CHEMBL1949072";"Inhibition of mTOR-mediated S6 phosphorylation in human PC3 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";"CHEMBL3307570"
"CHEMBL1945957";"";"0";"374.45";"0";"3.55";"47";"O=c1[nH]c2ncc(-c3ccc(-n4ccnc4)cc3)nc2n1CC1CCCCC1";"IC50";"'='";"580.0";"nM";"6.24";"";"";"UO_0000065";"16.66";"0.30";"2.69";"7.66";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1946263";"";"0";"365.40";"0";"1.67";"57";"Nc1nc2cc(-c3cnc4[nH]c(=O)n(CC5CCOCC5)c4n3)ccc2[nH]1";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"21.89";"0.40";"6.33";"6.27";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1946267";"";"0";"347.42";"0";"3.85";"61";"O=c1[nH]c2ncc(-c3ccc4[nH]ccc4c3)nc2n1CC1CCCCC1";"IC50";"'='";"63.0";"nM";"7.20";"";"";"UO_0000065";"20.73";"0.38";"3.35";"9.07";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1957497";"";"0";"496.60";"0";"1.19";"19";"CS(=O)(=O)N1CCN(Cc2cn3cc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3n2)CC1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1959594";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1955823";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1957500";"";"0";"531.04";"1";"1.84";"22";"CS(=O)(=O)N1CCN(Cc2cn3c(Cl)c(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3n2)CC1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1959594";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1955823";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL179242";"";"0";"281.31";"0";"1.68";"401";"O=c1cc(N2CCOCC2)nc2c3ccccc3ccn12";"IC50";"'='";"5300.0";"nM";"5.28";"";"";"UO_0000065";"18.75";"0.34";"3.60";"11.26";"False";"CHEMBL941421";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156476";"1";"Scientific Literature";"J. Biol. Chem.";"2007";""
"CHEMBL1760153";"";"0";"360.38";"0";"1.94";"26";"Cc1nc(N)nc(-n2c(Nc3cccc(C(N)=O)c3)nc3ccccc32)n1";"IC50";"'='";"175.0";"nM";"6.76";"";"";"UO_0000065";"18.75";"0.34";"4.82";"4.91";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760158";"";"0";"357.38";"0";"2.72";"31";"Cc1nc(N)nc(-n2c(Nc3ccc4cn[nH]c4c3)nc3ccccc32)n1";"IC50";"'='";"27.0";"nM";"7.57";"";"";"UO_0000065";"21.18";"0.38";"4.85";"6.14";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760163";"";"0";"307.32";"0";"1.57";"37";"Cc1nc(N)nc(-n2c(Nc3cn[nH]c3)nc3ccccc32)n1";"IC50";"'='";"190.0";"nM";"6.72";"";"";"UO_0000065";"21.87";"0.40";"5.15";"5.45";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL428496";"WORTMANNIN";"0";"428.44";"0";"2.54";"Wortmannin";"COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C(C3=O)[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O";"IC50";"'='";"40.0";"nM";"7.40";"";"";"UO_0000065";"17.27";"0.33";"4.86";"6.78";"False";"CHEMBL872196";"Inhibitory activity against MTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143469";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2005";""
"CHEMBL1760155";"";"0";"374.41";"0";"2.80";"28";"CC(=O)Nc1ccc(Nc2nc3ccccc3n2-c2nc(C)nc(N)n2)cc1";"IC50";"'='";"340.0";"nM";"6.47";"";"";"UO_0000065";"17.28";"0.32";"3.67";"5.23";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760157";"";"0";"356.39";"0";"3.33";"30";"Cc1nc(N)nc(-n2c(Nc3ccc4cc[nH]c4c3)nc3ccccc32)n1";"IC50";"'='";"960.0";"nM";"6.02";"";"";"UO_0000065";"16.89";"0.30";"2.69";"5.45";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760162";"";"0";"357.38";"0";"2.72";"36";"Cc1nc(N)nc(-n2c(Nc3n[nH]c4ccccc34)nc3ccccc32)n1";"IC50";"'='";"4200.0";"nM";"5.38";"";"";"UO_0000065";"15.04";"0.27";"2.66";"4.36";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760169";"";"0";"346.36";"0";"1.92";"43";"Cc1nc(NCC#N)nc(-n2c(Nc3cc[nH]n3)nc3ccccc32)n1";"IC50";"'='";"600.0";"nM";"6.22";"";"";"UO_0000065";"17.96";"0.33";"4.30";"4.68";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762790";"";"0";"349.35";"0";"2.26";"25";"Cc1nc(N)nc(-n2c(Nc3cc(O)cc(O)c3)nc3ccccc32)n1";"IC50";"'='";"5.0";"nM";"8.30";"";"";"UO_0000065";"23.76";"0.44";"6.04";"6.15";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760172";"";"0";"343.30";"0";"1.85";"46";"Cc1nc(N)nc(-n2c(Nc3cc[nH]n3)nc3cc(F)c(F)cc32)n1";"IC50";"'='";"45.0";"nM";"7.35";"";"";"UO_0000065";"21.40";"0.40";"5.50";"5.96";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL575976";"";"0";"524.51";"1";"4.46";"34";"O=C(Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(CC(F)(F)F)c3n2)cc1)Nc1cccnc1";"IC50";"'='";"0.19";"nM";"9.72";"";"";"UO_0000065";"18.53";"0.35";"5.26";"8.83";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL1773597";"";"0";"408.51";"0";"4.87";"20";"COc1ccccc1Sc1nccc(-c2ccc3nc(NC(C)=O)sc3c2)n1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773736";"";"0";"476.94";"0";"4.91";"81";"CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4cccc(F)c4)c3)cc2s1";"IC50";"'='";"2.3";"nM";"8.64";"";"";"UO_0000065";"18.11";"0.38";"3.73";"8.55";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL576091";"";"0";"554.66";"1";"4.36";"39";"CCn1ncc2c(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(N5CCOCC5)cc4)cc3)nc21";"IC50";"'='";"0.2";"nM";"9.70";"";"";"UO_0000065";"17.49";"0.32";"5.34";"8.84";"False";"CHEMBL1039195";"Inhibition of human FLAG-tagged mTOR expressed in HEK293 cells after 2 hrs by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156748";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307715"
"CHEMBL269732";"TACROLIMUS";"4";"804.03";"2";"4.64";"FK-506";"C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC";"IC50";"'='";"0.95";"nM";"9.02";"";"";"UO_0000065";"11.22";"0.22";"4.38";"5.06";"False";"CHEMBL829473";"Inhibitory activity against macrophilin (FKBP-12)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1138768";"1";"Scientific Literature";"J. Med. Chem.";"2004";""
"CHEMBL1684800";"";"0";"572.98";"2";"6.40";"7c";"COc1ccc(Cn2ncc(NC(=O)c3cc(NC(=O)Nc4ccc(Cl)c(C(F)(F)F)c4)ccc3C)c2N)cc1";"IC50";"'='";"3018.0";"nM";"5.52";"";"";"UO_0000065";"9.63";"0.19";"-0.88";"4.48";"False";"CHEMBL1687369";"inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1681781";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2011";""
"CHEMBL3693506";"";"0";"526.64";"1";"4.20";"BDBM174669";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCC(c5ccncc5)CC4)nc3n2)cc1CO";"IC50";"'='";"320.0";"nM";"6.50";"";"319949";"UO_0000065";"12.33";"0.23";"2.29";"6.71";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693511";"";"0";"453.54";"0";"2.86";"BDBM174674";"COC[C@@H](C)Nc1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(OC)c(CO)c3)nc2n1";"IC50";"'='";"58.0";"nM";"7.24";"";"319955";"UO_0000065";"15.96";"0.30";"4.38";"7.10";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693520";"";"0";"439.52";"0";"2.21";"BDBM174683";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N[C@@H](C)CO)nc3n2)cc1CO";"IC50";"'='";"35.0";"nM";"7.46";"";"319964";"UO_0000065";"16.96";"0.32";"5.25";"6.61";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693533";"";"0";"465.55";"0";"2.38";"BDBM174696";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCC[C@H]4CO)nc3n2)cc1CO";"IC50";"'='";"23.0";"nM";"7.64";"";"319978";"UO_0000065";"16.41";"0.31";"5.26";"7.34";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693567";"";"0";"531.53";"1";"3.69";"BDBM174733";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(-c4cc(C(=O)O)cc([N+](=O)[O-])c4)nc3n2)cc1CO";"IC50";"'='";"8.7";"nM";"8.06";"";"320012";"UO_0000065";"15.16";"0.28";"4.37";"5.01";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693577";"";"0";"413.48";"0";"3.47";"BDBM174743";"C[C@H]1COCCN1c1nc(-c2ccncc2)nc2nc(-c3cccc(CO)c3)ccc12";"IC50";"'='";"140.0";"nM";"6.85";"";"320022";"UO_0000065";"16.58";"0.30";"3.38";"8.13";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693583";"";"0";"444.54";"0";"3.43";"BDBM174749";"Cc1nn(C)c(C)c1-c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(CO)c3)nc2n1";"IC50";"'='";"86.0";"nM";"7.07";"";"320028";"UO_0000065";"15.89";"0.29";"3.64";"7.92";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701054";"";"0";"455.54";"0";"3.49";"BDBM172188";"Cc1nccc(-c2ccc(C(=O)N3CCN(C4CC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"317112";"UO_0000065";"19.10";"0.35";"5.21";"11.54";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701078";"";"0";"443.53";"0";"3.21";"BDBM172212";"CCc1nccc(-c2ccc(C(=O)N3CCN(C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"317136";"UO_0000065";"19.61";"0.36";"5.49";"11.54";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701095";"";"0";"376.85";"0";"3.45";"BDBM172230";"CNC(=O)c1cc(-c2ccnc(C)c2C#Cc2ccc(N)nc2)ccc1Cl";"IC50";"'='";"42.0";"nM";"7.38";"";"317154";"UO_0000065";"19.57";"0.37";"3.93";"9.12";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701097";"";"0";"390.87";"0";"3.79";"BDBM172232";"Cc1nccc(-c2ccc(Cl)c(C(=O)N(C)C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.0";"nM";"8.30";"";"317156";"UO_0000065";"21.24";"0.40";"4.51";"11.51";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688933";"";"0";"514.61";"1";"1.75";"BDBM174407";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(NS(C)(=O)=O)c3)[n+]([O-])c2n1";"IC50";"'='";"37.0";"nM";"7.43";"";"319716";"UO_0000065";"14.44";"0.28";"5.68";"6.00";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701120";"";"0";"412.50";"0";"2.22";"BDBM172255";"Cc1nccc(-c2ccc(C(=O)N3CCN(C)CC3)nc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"28.0";"nM";"7.55";"";"317179";"UO_0000065";"18.31";"0.33";"5.33";"8.56";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL404630";"";"0";"389.84";"0";"3.30";"13";"Oc1cc(O)c(-c2noc3ccc(NCCN4CCOCC4)cc23)cc1Cl";"IC50";"'>'";"20000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL944948";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1140740";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL1773587";"";"0";"361.43";"0";"4.46";"10";"CC(=O)Nc1nc2ccc(-c3ccnc(Nc4ccccc4)n3)cc2s1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL2165053";"";"0";"318.34";"0";"2.44";"BDBM50394890";"Cc1nc(N)nc(-c2cccnc2Nc2cccc3[nH]ncc23)n1";"IC50";"'>'";"50000.0";"nM";"";"";"254939";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165035";"";"0";"335.35";"0";"3.19";"BDBM50394885";"Cc1nc(N)c(F)c(-c2cccnc2Nc2cccc3[nH]ncc23)n1";"IC50";"'>'";"50000.0";"nM";"";"";"254943";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643927";"";"0";"332.37";"0";"2.75";"BDBM125240";"Cc1cnc(Nc2cccc3[nH]ncc23)c(-c2nc(C)nc(N)n2)c1";"IC50";"'>'";"50000.0";"nM";"";"";"254958";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643928";"";"0";"323.36";"0";"2.36";"BDBM125241";"CCOc1ccc(Nc2ncccc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"14240.0";"nM";"4.85";"";"254960";"UO_0000065";"14.99";"0.28";"2.49";"4.34";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643931";"";"0";"313.75";"0";"2.62";"BDBM125247";"Cc1nc(N)nc(-c2cccnc2Nc2ccc(Cl)nc2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"254962";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646433";"";"0";"489.54";"0";"2.75";"BDBM125274";"COC(=O)N1CCN(Cc2cnc(Nc3ccc(OC)nc3)c(-c3nc(C)nc4[nH]cnc34)c2)CC1";"IC50";"'='";"346.0";"nM";"6.46";"";"254986";"UO_0000065";"13.20";"0.25";"3.71";"4.81";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646442";"";"0";"454.49";"0";"4.62";"BDBM125284";"COc1cccc(Nc2cnc(Nc3ccc(OC)nc3)c(-c3nc(C)nc4[nH]cnc34)c2)c1";"IC50";"'>'";"10000.0";"nM";"";"";"254996";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646444";"";"0";"418.46";"0";"2.44";"BDBM125286";"COc1ccc(Nc2ncc(N3CCC(O)C3)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"254998";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646449";"";"0";"501.57";"1";"3.86";"BDBM125291";"COc1ccc(Nc2ncc(Cc3ccc(S(C)(=O)=O)cc3)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'='";"245.0";"nM";"6.61";"";"255003";"UO_0000065";"13.18";"0.25";"2.75";"4.87";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646456";"";"0";"318.34";"0";"2.44";"BDBM125298";"Cc1nc(N)cc(-c2nccnc2Nc2cccc3[nH]ncc23)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255012";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165021";"";"0";"309.33";"0";"1.97";"BDBM50394869";"COc1ccc(Nc2nccnc2-c2cc(N)nc(C)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255016";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646460";"";"0";"395.43";"1";"1.20";"BDBM125302";"COc1ccc(Nc2nc(N3CCOCC3)ncc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255020";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646470";"";"0";"426.46";"0";"1.94";"BDBM125312";"COc1ncc(Nc2ncc(CN3CCOCC3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255030";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646478";"";"0";"517.57";"1";"3.36";"BDBM125320";"COc1ccc(Nc2ncc(C(O)c3ccc(S(C)(=O)=O)cc3)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255039";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646487";"";"0";"517.55";"2";"0.83";"BDBM125329";"COc1ncc(Nc2ncc(C(=O)N3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255052";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646488";"";"0";"410.44";"0";"1.35";"BDBM125330";"COCCNC(=O)c1cnc(Nc2ccc(OC)nc2)c(-c2nc(C)nc(N)n2)c1";"IC50";"'>'";"10000.0";"nM";"";"";"255053";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646493";"";"0";"499.60";"1";"1.51";"BDBM125335";"CNc1nc(C)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2ccc(OC)nc2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255063";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649447";"";"0";"403.83";"0";"3.38";"BDBM122470";"O=S(=O)(Nc1cc(-c2cnc3ncccn23)cnc1Cl)c1ccc(F)cc1";"IC50";"'>'";"50000.0";"nM";"";"";"251071";"UO_0000065";"";"";"";"";"False";"CHEMBL3705287";"In Vitro mTOR Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP 1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639163";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646504";"";"0";"293.33";"0";"2.27";"BDBM125346";"Cc1cncc(Nc2ncccc2-c2nc(C)nc(N)n2)c1";"IC50";"'>'";"10000.0";"nM";"";"";"255074";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649426";"";"0";"481.73";"0";"4.75";"BDBM122449";"O=S(=O)(Nc1cc(-c2cnc3ccc(Br)cn23)cnc1Cl)c1ccc(F)cc1";"IC50";"'='";"39.0";"nM";"7.41";"";"251053";"UO_0000065";"15.38";"0.36";"2.66";"9.70";"False";"CHEMBL3705287";"In Vitro mTOR Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP 1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639163";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649427";"";"0";"479.92";"1";"5.05";"BDBM122450";"O=S(=O)(Nc1cc(-c2cnc3ccc(-c4ccncc4)cn23)cnc1Cl)c1ccc(F)cc1";"IC50";"'='";"36.0";"nM";"7.44";"";"251054";"UO_0000065";"15.51";"0.31";"2.39";"8.34";"False";"CHEMBL3705287";"In Vitro mTOR Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP 1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639163";"37";"BindingDB Database";"";"2014";""
"CHEMBL1774377";"";"0";"427.51";"0";"2.25";"29e";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)[C@@](C)(CO)OC3)cc1";"IC50";"'='";"48.0";"nM";"7.32";"";"";"UO_0000065";"17.12";"0.32";"5.07";"6.72";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774382";"";"0";"455.56";"0";"3.03";"29j";"CCNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3c(n2)[C@@](C)(CC(C)(C)O)OC3)cc1";"IC50";"'='";"43.0";"nM";"7.37";"";"";"UO_0000065";"16.17";"0.30";"4.34";"6.77";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774354";"";"0";"411.46";"0";"2.53";"13c";"CCNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3c(n2)C(C)(C)OC3=O)cc1";"IC50";"'='";"20.0";"nM";"7.70";"";"";"UO_0000065";"18.71";"0.35";"5.17";"7.29";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774365";"";"0";"453.54";"0";"2.78";"22c";"CCNC(=O)Nc1ccc(-c2nc(N3C[C@@H]4CC[C@H](C3)O4)c3c(n2)[C@](C)(CCO)OC3)cc1";"IC50";"'='";"1.9";"nM";"8.72";"";"";"UO_0000065";"19.23";"0.36";"5.94";"8.01";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774374";"";"0";"455.56";"0";"3.29";"29b";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)[C@@](C)(CCOC)OC3)cc1";"IC50";"'='";"69.0";"nM";"7.16";"";"";"UO_0000065";"15.72";"0.30";"3.87";"7.32";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774375";"";"0";"427.51";"0";"2.25";"29c";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)[C@](C)(CO)OC3)cc1";"IC50";"'='";"12.0";"nM";"7.92";"";"";"UO_0000065";"18.53";"0.35";"5.67";"7.28";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL3646530";"";"0";"509.60";"2";"0.93";"BDBM125373";"Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2cnc3c(c2)ncn3C)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255102";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646506";"";"0";"454.47";"0";"1.71";"BDBM125348";"COc1ncc(Nc2ncc(C(=O)N3CCC(O)CC3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255076";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646508";"";"0";"368.40";"0";"3.60";"BDBM125351";"Cc1nc(N)cc(-c2nc3ccccc3nc2Nc2cccc3[nH]ncc23)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255079";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649429";"";"0";"487.94";"0";"3.83";"BDBM122452";"O=S(=O)(Nc1cc(-c2cnc3ccc(N4CCOCC4)cn23)cnc1Cl)c1ccc(F)cc1";"IC50";"'='";"364.0";"nM";"6.44";"";"251056";"UO_0000065";"13.20";"0.27";"2.61";"7.25";"False";"CHEMBL3705287";"In Vitro mTOR Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP 1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639163";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649444";"";"0";"509.95";"1";"4.20";"BDBM122467";"O=c1n(Cc2ccccc2)ccc2ncc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)n12";"IC50";"'='";"180.0";"nM";"6.75";"";"251064";"UO_0000065";"13.23";"0.26";"2.54";"6.86";"False";"CHEMBL3705287";"In Vitro mTOR Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP 1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639163";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646499";"";"0";"416.45";"0";"3.04";"BDBM125341";"COc1ccc(Nc2ncc(-c3ccc(OC)nc3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255069";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL1773568";"";"0";"404.50";"0";"4.72";"32";"CC(=O)Nc1nc2ccc(-c3ccnc(OCCCc4ccccc4)n3)cc2s1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773572";"";"0";"403.51";"1";"5.06";"36";"CC(=O)Nc1nc2ccc(-c3ccnc(NC(C)(C)c4ccccc4)n3)cc2s1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL3937842";"";"0";"370.42";"0";"2.58";"BDBM245472";"Cn1c(=O)n(C2CNC2)c2c3cc(-c4cnc5[nH]ccc5c4)ccc3ncc21";"IC50";"'='";"177.0";"nM";"6.75";"";"427983";"UO_0000065";"18.23";"0.33";"4.17";"8.38";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL1773590";"";"0";"374.47";"0";"4.50";"13";"CC(=O)Nc1nc2ccc(-c3ccnc(CCc4ccccc4)n3)cc2s1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773593";"";"0";"396.47";"1";"5.00";"16";"CC(=O)Nc1nc2ccc(-c3ccnc(Sc4ccc(F)cc4)n3)cc2s1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773591";"";"0";"396.47";"1";"5.00";"14";"CC(=O)Nc1nc2ccc(-c3ccnc(Sc4ccccc4F)n3)cc2s1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773729";"";"0";"526.95";"2";"5.79";"74";"CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(C(F)(F)F)cc4)c3)cc2s1";"IC50";"'='";"1.6";"nM";"8.80";"";"";"UO_0000065";"16.69";"0.35";"3.01";"8.70";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL3936804";"";"0";"514.60";"1";"2.67";"BDBM251611";"COc1cc(-c2nc3c(c(C4(S(C)(=O)=O)CCOCC4)n2)OCCC2COCCN32)c2cc[nH]c2c1";"IC50";"'='";"808.0";"nM";"6.09";"";"438507";"UO_0000065";"11.84";"0.23";"3.42";"5.26";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL586702";"";"0";"417.42";"0";"1.82";"ZSTK474";"FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1";"IC50";"'='";"370.0";"nM";"6.43";"";"";"UO_0000065";"15.41";"0.29";"4.61";"7.90";"True";"CHEMBL3377242";"Inhibition of human mTOR by non-radiometric ADP-Glo assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352433";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL1774357";"";"0";"439.52";"0";"2.65";"13f";"C[C@H]1COCCN1c1nc(-c2ccc(NC(=O)NC3COC3)cc2)nc2c1COC2(C)C";"IC50";"'='";"37.0";"nM";"7.43";"";"";"UO_0000065";"16.91";"0.32";"4.78";"7.60";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL3218581";"";"0";"393.54";"0";"3.35";"A-66";"Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(C(C)(C)C)n1";"IC50";"'>'";"5000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3377242";"Inhibition of human mTOR by non-radiometric ADP-Glo assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352433";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL3977516";"";"0";"508.55";"1";"3.61";"BDBM222581";"COc1cnc(-c2ccc(NC(=O)Nc3ccc(N4CCOCC4)c(F)c3)cc2)nc1N1CCOCC1";"IC50";"'='";"107.2";"nM";"6.97";"";"389370";"UO_0000065";"13.71";"0.26";"3.36";"6.90";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3960323";"";"0";"501.63";"1";"4.55";"BDBM245505";"CO[C@H]1C[C@@H](n2c(=O)n(C)c3cnc4ccc(-c5ccc(OCCCN6CCCCC6)nc5)cc4c32)C1";"IC50";"'='";"2870.0";"nM";"5.54";"";"427916";"UO_0000065";"11.05";"0.20";"0.99";"7.45";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3908805";"";"0";"405.46";"0";"3.63";"BDBM222549";"COc1cnc(-c2ccc(NC(=O)Nc3ccccc3)cc2)nc1N1CCOCC1";"IC50";"'='";"253.4";"nM";"6.60";"";"389338";"UO_0000065";"16.27";"0.30";"2.97";"7.44";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3946028";"";"0";"454.55";"0";"3.03";"BDBM251581";"CC(C)(c1nc(-c2cccc3[nH]ccc23)nc2c1OCC1COCCN21)S(=O)(=O)C1CC1";"IC50";"'='";"274.0";"nM";"6.56";"";"438477";"UO_0000065";"14.44";"0.28";"3.53";"6.74";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3941839";"";"0";"484.58";"0";"2.66";"BDBM251600";"CS(=O)(=O)C1(c2nc(-c3cccc4[nH]ccc34)nc3c2OCC[C@H]2COCCN32)CCOCC1";"IC50";"'='";"10000.0";"nM";"5.00";"";"438496";"UO_0000065";"10.32";"0.20";"2.34";"4.69";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3913852";"";"0";"442.54";"0";"2.89";"BDBM251601";"CC(C)(c1nc(-c2cccc3[nH]ccc23)nc2c1OCC[C@H]1COCCN21)S(C)(=O)=O";"IC50";"'='";"1670.0";"nM";"5.78";"";"438497";"UO_0000065";"13.05";"0.25";"2.89";"5.93";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3908347";"";"0";"472.57";"0";"2.12";"BDBM251608";"CNc1nc2ccccc2n1-c1nc2c(c(C(C)(C)S(C)(=O)=O)n1)OCCC1COCCN21";"IC50";"'='";"586.0";"nM";"6.23";"";"438504";"UO_0000065";"13.19";"0.26";"4.11";"5.59";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3968531";"";"0";"440.53";"0";"2.65";"BDBM251630";"CS(=O)(=O)C1(c2nc(-c3cccc4[nH]ccc34)nc3c2OC[C@@H]2COCCN32)CCC1";"IC50";"'='";"151.0";"nM";"6.82";"";"438526";"UO_0000065";"15.48";"0.30";"4.17";"7.00";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL4114341";"";"0";"515.62";"1";"0.95";"BDBM251636";"CC(C)(c1nc(-[n+]2c(N3CCOCC3)[nH]c3ccccc32)nc2c1OC[C@@H]1COCCN21)S(C)(=O)=O";"IC50";"'='";"10000.0";"nM";"5.00";"";"438532";"UO_0000065";"9.70";"0.19";"4.05";"4.40";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3968026";"";"0";"472.57";"0";"1.76";"BDBM251642";"CN(C)c1nc2ccccc2n1-c1nc2c(c(C(C)(C)S(C)(=O)=O)n1)OC[C@@H]1COCCN21";"IC50";"'='";"10000.0";"nM";"5.00";"";"438538";"UO_0000065";"10.58";"0.21";"3.24";"4.87";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3957443";"";"0";"492.99";"0";"2.39";"BDBM251660";"CNc1nc2ccc(Cl)cc2n1-c1nc2c(c(C(C)(C)S(C)(=O)=O)n1)OC[C@@H]1COCCN21";"IC50";"'='";"5550.0";"nM";"5.26";"";"438540";"UO_0000065";"10.66";"0.22";"2.87";"4.71";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3950397";"";"0";"476.53";"0";"1.87";"BDBM251661";"CNc1nc2ccc(F)cc2n1-c1nc2c(c(C(C)(C)S(C)(=O)=O)n1)OC[C@@H]1COCCN21";"IC50";"'='";"2470.0";"nM";"5.61";"";"438542";"UO_0000065";"11.77";"0.23";"3.74";"5.03";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3980140";"";"0";"442.54";"0";"2.81";"BDBM251652";"Cc1cc2c(-c3nc4c(c(C(C)(C)S(C)(=O)=O)n3)OC[C@@H]3COCCN43)cccc2[nH]1";"IC50";"'='";"58.0";"nM";"7.24";"";"438553";"UO_0000065";"16.35";"0.32";"4.43";"7.43";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3910010";"";"0";"538.55";"1";"3.29";"BDBM251653";"CS(=O)(=O)C1(c2nc(-c3cc(C(F)(F)F)cc4[nH]ccc34)nc3c2OC[C@@H]2COCCN32)CCOCC1";"IC50";"'='";"1990.0";"nM";"5.70";"";"438554";"UO_0000065";"10.59";"0.21";"2.41";"5.35";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3924355";"";"0";"444.49";"0";"2.40";"BDBM251657";"CS(=O)(=O)C1(c2nc(-c3ccc(F)c4[nH]ccc34)nc3c2OC[C@@H]2COCCN32)CC1";"IC50";"'='";"10000.0";"nM";"5.00";"";"438558";"UO_0000065";"11.25";"0.22";"2.60";"5.13";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3956323";"";"0";"483.59";"0";"2.19";"BDBM251613";"CN1CCC(c2nc(-c3cccc4[nH]ccc34)nc3c2OCC2COCCN32)(S(C)(=O)=O)CC1";"IC50";"'='";"10000.0";"nM";"5.00";"";"438509";"UO_0000065";"10.34";"0.20";"2.81";"4.97";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3909601";"";"0";"366.42";"0";"2.45";"BDBM251621";"CC(C)(O)c1nc(-c2cccc3[nH]ccc23)nc2c1OC[C@@H]1COCCN21";"IC50";"'='";"44.0";"nM";"7.36";"";"438517";"UO_0000065";"20.08";"0.37";"4.91";"8.81";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3919612";"";"0";"454.55";"0";"3.03";"BDBM251624";"CC(C)(c1nc(-c2cccc3[nH]ccc23)nc2c1OC[C@@H]1COCCN21)S(=O)(=O)C1CC1";"IC50";"'='";"228.0";"nM";"6.64";"";"438520";"UO_0000065";"14.61";"0.28";"3.61";"6.82";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3944712";"";"0";"486.60";"0";"2.51";"BDBM251626";"CC(C)Nc1nc2ccccc2n1-c1nc2c(c(C(C)(C)S(C)(=O)=O)n1)OC[C@@H]1COCCN21";"IC50";"'='";"252.0";"nM";"6.60";"";"438522";"UO_0000065";"13.56";"0.27";"4.09";"5.92";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL410644";"";"0";"504.62";"1";"1.57";"15";"COC[C@H]1OC(=O)/C(=C/N(C)CCCN(C)C)C2=C(O)C(=O)C3=C([C@H](O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'>'";"20000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL271191";"";"0";"475.54";"0";"1.86";"7";"CCN/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)[C@@H](O)CC[C@@H]12";"IC50";"'>'";"20000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL409294";"";"0";"532.63";"1";"1.79";"14";"COC[C@H]1OC(=O)/C(=C/NCCCN(C)C)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'>'";"20000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL558486";"";"0";"508.58";"1";"2.87";"21";"CCNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)OC)CC4)c3n2)cc1";"IC50";"'='";"0.32";"nM";"9.49";"";"";"UO_0000065";"18.67";"0.35";"6.62";"7.49";"True";"CHEMBL1058638";"Inhibition of flag-tagged truncated human mTOR (1360-2549) expressed in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1151963";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL557963";"";"0";"557.62";"1";"3.77";"25";"COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)Nc5ccncc5)cc4)nc32)CC1";"IC50";"'='";"0.3";"nM";"9.52";"";"";"UO_0000065";"17.08";"0.32";"5.75";"6.82";"False";"CHEMBL1058638";"Inhibition of flag-tagged truncated human mTOR (1360-2549) expressed in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1151963";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1088791";"";"0";"324.38";"0";"1.96";"10";"Cn1ccc2nc(-c3cccc(CO)c3)nc(N3CCOCC3)c21";"IC50";"'>'";"4000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL594670";"";"0";"324.34";"0";"0.96";"8";"NC(=O)c1ccc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)cc1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1074731";"Inhibition of human TOR in HEK293 cells by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153204";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL608095";"";"0";"287.35";"0";"1.92";"13";"c1nc2c(N3CCOCC3)nc(-c3ccsc3)nc2[nH]1";"IC50";"'='";"3900.0";"nM";"5.41";"";"";"UO_0000065";"18.82";"0.37";"3.49";"8.08";"False";"CHEMBL1074731";"Inhibition of human TOR in HEK293 cells by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153204";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL1631888";"";"0";"233.27";"0";"2.54";"6";"Nc1ccc(C#Cc2n[nH]c3ccccc23)cc1";"IC50";"'='";"4970.0";"nM";"5.30";"";"";"UO_0000065";"22.74";"0.40";"2.76";"9.70";"False";"CHEMBL1633333";"Inhibition of mTOR by LanthaScreen Eu kinase binding assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL599259";"";"0";"519.56";"1";"2.64";"21";"COC(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4CCOCC4)n3)cc2)cc1";"IC50";"'='";"2.5";"nM";"8.60";"";"";"UO_0000065";"16.56";"0.31";"5.96";"6.56";"False";"CHEMBL1065057";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157610";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL592615";"";"0";"575.67";"1";"2.15";"24";"CN(C)CCNC(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4CCOCC4)n3)cc2)cc1";"IC50";"'='";"0.5";"nM";"9.30";"";"";"UO_0000065";"16.16";"0.30";"7.15";"6.79";"False";"CHEMBL1065057";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157610";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL591576";"";"0";"506.56";"1";"3.94";"28";"OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(c5ccc(F)cc5F)CC4)c3n2)c1";"IC50";"'='";"2050.0";"nM";"5.69";"";"";"UO_0000065";"11.23";"0.21";"1.75";"7.15";"False";"CHEMBL1068429";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153170";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL576507";"";"0";"555.69";"1";"4.50";"29";"CCn1ncc2c(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(NCCN(C)C)cc4)cc3)nc21";"IC50";"'='";"1.7";"nM";"8.77";"";"";"UO_0000065";"15.78";"0.29";"4.27";"7.80";"False";"CHEMBL1039195";"Inhibition of human FLAG-tagged mTOR expressed in HEK293 cells after 2 hrs by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156748";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307715"
"CHEMBL266660";"";"0";"395.48";"0";"1.61";"S1M2M'2";"CC(C)CC(=O)C(=O)N1CCC[C@H]1C(=O)OCCS(=O)(=O)c1ccccc1";"IC50";"'<'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL682171";"The inhibitory activity by using FK506 binding protein 12 SPA binding assay.";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1132865";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2000";""
"CHEMBL269154";"";"0";"366.42";"0";"2.43";"S1M1M'1";"O=C(C(=O)N1CCC[C@H]1C(=O)OCCCc1cccnc1)c1ccccc1";"IC50";"'<'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL682171";"The inhibitory activity by using FK506 binding protein 12 SPA binding assay.";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1132865";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2000";""
"CHEMBL3951467";"";"0";"575.63";"1";"2.59";"BDBM222619";"CCOc1c(C(=O)N2CCOCC2)nc(-c2ccc(NC(=O)Nc3ccc(C(N)=O)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"70.4";"nM";"7.15";"";"389408";"UO_0000065";"12.43";"0.23";"4.56";"4.44";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3978068";"";"0";"499.60";"0";"4.80";"BDBM222653";"CSc1c(-c2ccncc2)nc(-c2ccc(NC(=O)Nc3ccncc3)cc2)nc1N1CCOCC1";"IC50";"'='";"30.2";"nM";"7.52";"";"389442";"UO_0000065";"15.05";"0.29";"2.72";"7.15";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3904061";"";"0";"422.51";"0";"3.74";"BDBM222659";"CSc1cnc(-c2ccc(NC(=O)Nc3ccncc3)cc2)nc1N1CCOCC1";"IC50";"'='";"101.1";"nM";"7.00";"";"389448";"UO_0000065";"16.56";"0.32";"3.26";"7.58";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3894462";"";"0";"440.89";"0";"3.68";"BDBM222666";"COc1c(Cl)nc(-c2ccc(NC(=O)Nc3ccncc3)cc2)nc1N1CCOCC1";"IC50";"'='";"175.9";"nM";"6.75";"";"389455";"UO_0000065";"15.32";"0.30";"3.07";"6.65";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL1914743";"";"0";"499.96";"0";"4.12";"18d";"O=S(=O)(Nc1cc(-c2ccc3ncc(N4CCOCC4)nc3c2)cnc1Cl)c1ccc(F)cc1";"IC50";"'='";"5.0";"nM";"8.30";"";"";"UO_0000065";"16.60";"0.33";"4.18";"8.53";"False";"CHEMBL1919685";"Inhibition of mTOR using GFP-tagged 4E-BP1 after 1 hr by spectrophotometric analysis";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1914426";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1914742";"";"0";"541.05";"1";"4.82";"18q";"CC(C)N1CCN(c2cnc3ccc(-c4cnc(Cl)c(NS(=O)(=O)c5ccc(F)cc5)c4)cc3n2)CC1";"IC50";"'='";"37.0";"nM";"7.43";"";"";"UO_0000065";"13.74";"0.27";"2.61";"8.14";"False";"CHEMBL1919685";"Inhibition of mTOR using GFP-tagged 4E-BP1 after 1 hr by spectrophotometric analysis";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1914426";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL6809";"";"0";"415.47";"0";"1.88";"S1M2M'1";"O=C(C(=O)N1CCC[C@H]1C(=O)OCCS(=O)(=O)c1ccccc1)c1ccccc1";"IC50";"'<'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL682171";"The inhibitory activity by using FK506 binding protein 12 SPA binding assay.";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1132865";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2000";""
"CHEMBL1258634";"";"0";"523.00";"1";"3.44";"8n";"O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1)Nc1ccnc(Cl)c1";"IC50";"'='";"1.26";"nM";"8.90";"";"";"UO_0000065";"17.02";"0.33";"5.46";"7.57";"False";"CHEMBL1259905";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255533";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1256453";"";"0";"558.56";"2";"5.41";"26";"O=c1ccc2cnc3ccc(-c4ccc5c(c4)OCCO5)cc3c2n1-c1ccc(N2CCNCC2)c(C(F)(F)F)c1";"IC50";"'='";"66.5";"nM";"7.18";"";"";"UO_0000065";"12.85";"0.24";"1.77";"10.46";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1259086";"";"0";"506.55";"2";"5.70";"29";"O=c1ccc2cnc3ccc(-c4ccsc4)cc3c2n1-c1ccc(N2CCNCC2)c(C(F)(F)F)c1";"IC50";"'='";"214.0";"nM";"6.67";"";"";"UO_0000065";"13.17";"0.25";"0.97";"13.30";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1256460";"";"0";"669.71";"2";"7.83";"39";"CN1CCN(C(=O)c2ccc(-c3ccc(-n4c(=O)ccc5cnc6ccc(-c7cnc8ccccc8c7)cc6c54)cc3C(F)(F)F)cc2)CC1";"IC50";"'='";"1.26";"nM";"8.90";"";"";"UO_0000065";"13.29";"0.24";"1.07";"12.48";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL3357870";"";"0";"385.40";"0";"2.21";"9";"COc1ncc(Nc2ncc([C@@H](C)CO)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"15000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3379685";"Inhibition of recombinant N-terminally GST-tagged mTOR (1360 to 2549 aa) (unknown origin) assessed as inhibition of 27BP1 phosphorylation after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352452";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3961688";"";"0";"475.59";"0";"3.81";"BDBM245480";"CN(C)CCCOc1ccc(-c2ccc3ncc4c(c3c2)n(C2(C)CCOCC2)c(=O)n4C)cn1";"IC50";"'='";"266.0";"nM";"6.58";"";"427890";"UO_0000065";"13.83";"0.26";"2.77";"8.84";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3912673";"";"0";"479.56";"0";"3.77";"BDBM245484";"CN(C)CCCOc1ccc(-c2cc3c(cc2F)ncc2c3n([C@H]3CCCOC3)c(=O)n2C)cn1";"IC50";"'='";"9290.0";"nM";"5.03";"";"427894";"UO_0000065";"10.49";"0.20";"1.26";"6.76";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3932205";"";"0";"501.63";"1";"4.56";"BDBM245503";"Cn1c(=O)n([C@H]2CCCOC2)c2c3cc(-c4ccc(OCCCN5CCCCC5)nc4)ccc3ncc21";"IC50";"'='";"19500.0";"nM";"4.71";"";"427914";"UO_0000065";"9.39";"0.17";"0.15";"6.33";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL1258744";"";"0";"504.55";"1";"1.75";"9";"O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4COCC3[C@@H](O)C4)n2)cc1";"IC50";"'='";"0.8";"nM";"9.10";"";"";"UO_0000065";"18.03";"0.34";"7.35";"6.60";"False";"CHEMBL1259905";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255533";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1255814";"";"0";"574.69";"1";"3.33";"8j";"CN(C)CCOc1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4C5CCC4COC5)n3)cc2)cc1";"IC50";"'='";"1.85";"nM";"8.73";"";"";"UO_0000065";"15.20";"0.28";"5.40";"7.45";"False";"CHEMBL1259905";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255533";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL3944816";"";"0";"456.96";"0";"4.39";"BDBM222560";"CSc1c(Cl)nc(-c2ccc(NC(=O)Nc3cccnc3)cc2)nc1N1CCOCC1";"IC50";"'='";"110.4";"nM";"6.96";"";"389349";"UO_0000065";"15.22";"0.31";"2.57";"7.54";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3640926";"";"0";"353.43";"0";"3.63";"BDBM115576";"Cc1ncnc(-c2ccc(C(C)(C)C#N)cc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"24.0";"nM";"7.62";"";"240213";"UO_0000065";"21.56";"0.39";"3.99";"8.61";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640938";"";"0";"378.46";"0";"2.49";"BDBM115588";"CCc1ncnc(-c2ccc(S(C)(=O)=O)cc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"18.0";"nM";"7.75";"";"240225";"UO_0000065";"20.46";"0.39";"5.25";"7.84";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640951";"";"0";"327.39";"0";"3.10";"BDBM115601";"Cc1ncnc(-c2ccc(C3CC3)nc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"57.0";"nM";"7.24";"";"240238";"UO_0000065";"22.13";"0.40";"4.14";"9.34";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640955";"";"0";"331.38";"0";"2.49";"BDBM115605";"CCc1ncnc(-c2ccc(OC)nc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"51.0";"nM";"7.29";"";"240242";"UO_0000065";"22.01";"0.40";"4.80";"8.40";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640959";"";"0";"344.42";"0";"2.54";"BDBM115609";"CCc1ncnc(-c2ccc(N(C)C)nc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"79.0";"nM";"7.10";"";"240246";"UO_0000065";"20.62";"0.37";"4.56";"8.79";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640962";"";"0";"399.45";"0";"2.30";"BDBM115612";"Cc1ncnc(-c2cccc(C(=O)N3CCOCC3)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"90.0";"nM";"7.05";"";"240249";"UO_0000065";"17.64";"0.32";"4.75";"7.48";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640967";"";"0";"431.93";"0";"4.11";"BDBM115617";"Cc1ncnc(-c2ccc(Cl)c(C(=O)N3CCCCC3)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"13.0";"nM";"7.89";"";"240254";"UO_0000065";"18.26";"0.35";"3.78";"9.28";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640968";"";"0";"361.38";"0";"2.33";"BDBM115618";"CNC(=O)c1cc(-c2ncnc(C)c2C#Cc2ccc(N)nc2)ccc1F";"IC50";"'='";"32.0";"nM";"7.50";"";"240255";"UO_0000065";"20.74";"0.38";"5.16";"7.99";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640978";"";"0";"472.57";"0";"3.39";"BDBM115628";"CCc1ncnc(-c2ccc(C(=O)N(C)C3CCN(C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"33.0";"nM";"7.48";"";"240265";"UO_0000065";"15.83";"0.29";"4.09";"8.48";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640981";"";"0";"419.46";"0";"2.29";"BDBM115631";"CCc1ncnc(-c2ccc(C(=O)N(C)CCO)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"240268";"UO_0000065";"20.74";"0.38";"6.41";"8.27";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640983";"";"0";"444.51";"0";"2.61";"BDBM115633";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"240270";"UO_0000065";"19.57";"0.36";"6.09";"9.86";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640986";"";"0";"445.95";"0";"4.36";"BDBM115636";"CCc1ncnc(-c2ccc(C(=O)N3CCCCC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"240273";"UO_0000065";"19.51";"0.37";"4.34";"10.23";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640991";"";"0";"528.63";"1";"3.47";"BDBM115641";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CC4CCCO4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1C";"IC50";"'='";"5.0";"nM";"8.30";"";"240278";"UO_0000065";"15.70";"0.29";"4.83";"8.52";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3641004";"";"0";"463.97";"0";"3.84";"BDBM115655";"CCc1ncnc(-c2ccc(C(=O)N(C)CCCOC)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"240292";"UO_0000065";"18.37";"0.35";"4.68";"9.04";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3641010";"";"0";"491.00";"0";"2.49";"BDBM115661";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CCO)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.6";"nM";"9.22";"";"240298";"UO_0000065";"18.78";"0.36";"6.73";"8.50";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643069";"";"0";"456.51";"0";"1.66";"BDBM115684";"CCc1ncnc(-c2ccc(C(=O)N3CCNC(=O)C3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.0";"nM";"9.00";"";"240321";"UO_0000065";"19.71";"0.36";"7.34";"7.30";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643080";"";"0";"445.50";"0";"2.82";"BDBM115696";"CCc1ncnc(-c2ccc(C(=O)N3CCC(O)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.0";"nM";"9.00";"";"240333";"UO_0000065";"20.20";"0.37";"6.18";"8.55";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643081";"";"0";"486.60";"0";"3.64";"BDBM115697";"CCc1ncnc(-c2ccc(C(=O)N(C)CC3CCCN(C)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"24.0";"nM";"7.62";"";"240334";"UO_0000065";"15.66";"0.29";"3.98";"8.64";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643082";"";"0";"472.57";"0";"3.29";"BDBM115698";"CCc1ncnc(-c2ccc(C(=O)NCC3CCCN(C)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"33.0";"nM";"7.48";"";"240335";"UO_0000065";"15.83";"0.29";"4.19";"7.71";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643085";"";"0";"472.57";"0";"3.29";"BDBM115701";"CCc1ncnc(-c2ccc(C(=O)NCC3CCN(C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"28.0";"nM";"7.55";"";"240338";"UO_0000065";"15.98";"0.29";"4.26";"7.78";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643091";"";"0";"486.60";"0";"3.78";"BDBM115707";"CCCCN1CCN(C(=O)c2ccc(-c3ncnc(CC)c3C#Cc3ccc(N)nc3)cc2F)CC1";"IC50";"'='";"4.0";"nM";"8.40";"";"240344";"UO_0000065";"17.26";"0.32";"4.62";"9.52";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643092";"";"0";"514.61";"1";"3.16";"BDBM115708";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C4CCOCC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"240345";"UO_0000065";"16.56";"0.31";"5.36";"8.74";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643119";"";"0";"430.49";"0";"2.27";"BDBM115735";"CCc1ncnc(-c2ccc(C(=O)N3CCNCC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"13.0";"nM";"7.89";"";"240372";"UO_0000065";"18.32";"0.34";"5.62";"8.13";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643138";"";"0";"458.50";"0";"2.14";"BDBM115754";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C)C(=O)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"240391";"UO_0000065";"18.97";"0.35";"6.56";"8.26";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3639420";"";"0";"502.59";"1";"3.06";"BDBM115817";"CCc1ncnc(-c2ccc(C(=O)NC3CCN(CCOC)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"11.0";"nM";"7.96";"";"240429";"UO_0000065";"15.84";"0.29";"4.90";"7.49";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643181";"";"0";"567.71";"1";"4.04";"BDBM115824";"CCc1ncnc(-c2ccc(C(=O)NC3CC(N4CCC(N5CCCC5)CC4)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"8.0";"nM";"8.10";"";"240436";"UO_0000065";"14.26";"0.26";"4.06";"8.08";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643187";"";"0";"445.50";"0";"2.99";"BDBM115830";"CCc1ncnc(-c2ccc(C(=O)NCC3(C)COC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.0";"nM";"9.00";"";"240442";"UO_0000065";"20.20";"0.37";"6.01";"8.74";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643213";"";"0";"427.51";"0";"1.87";"BDBM115856";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C)CC3)nc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"24.0";"nM";"7.62";"";"240468";"UO_0000065";"17.82";"0.33";"5.75";"7.53";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643223";"";"0";"407.42";"0";"3.06";"BDBM115866";"CCc1ncnc(-c2cc(F)c(C(=O)N(C)C)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.49";"nM";"8.60";"";"240478";"UO_0000065";"21.12";"0.39";"5.54";"10.12";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643227";"";"0";"448.48";"0";"2.41";"BDBM115870";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCNCC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.02";"nM";"8.99";"";"240482";"UO_0000065";"20.05";"0.37";"6.58";"9.27";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645769";"";"0";"510.64";"1";"3.33";"BDBM115947";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCOCC4)CC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.43";"nM";"8.46";"";"240559";"UO_0000065";"16.58";"0.30";"5.13";"8.68";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645771";"";"0";"429.48";"0";"2.14";"BDBM115949";"CCc1ncnc(-c2ccc(C(=O)N3CC(O)CO3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.82";"nM";"8.74";"";"240561";"UO_0000065";"20.35";"0.37";"6.60";"7.64";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645856";"";"0";"541.68";"1";"3.53";"BDBM116035";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCN(C)CC4)CC3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"2.81";"nM";"8.55";"";"240647";"UO_0000065";"15.79";"0.29";"5.02";"11.04";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645874";"";"0";"545.42";"1";"4.41";"BDBM116053";"CCc1ncnc(-c2cc(Cl)c(C(=O)N3CCN(CC(F)F)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.27";"nM";"8.64";"";"240665";"UO_0000065";"15.85";"0.32";"4.23";"9.80";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645886";"";"0";"519.60";"1";"4.44";"BDBM116065";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCC(C(C)(C)O)CC3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"3.49";"nM";"8.46";"";"240677";"UO_0000065";"16.28";"0.30";"4.02";"9.27";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645891";"";"0";"490.51";"0";"2.73";"BDBM116070";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(C=O)CC3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"3.2";"nM";"8.49";"";"240682";"UO_0000065";"17.32";"0.32";"5.76";"9.30";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645936";"";"0";"512.63";"1";"4.38";"BDBM116115";"CCNc1ccc(C#Cc2c(CC)ncnc2-c2ccc(C(=O)N3CCN(C4CCC4)CC3)c(F)c2)cn1";"IC50";"'='";"1.64";"nM";"8.79";"";"240727";"UO_0000065";"17.14";"0.32";"4.41";"11.83";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3639448";"";"0";"500.58";"1";"2.69";"BDBM116126";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C4COC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1C";"IC50";"'='";"16.96";"nM";"7.77";"";"240738";"UO_0000065";"15.52";"0.29";"5.08";"7.97";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645948";"";"0";"521.00";"1";"3.03";"BDBM116128";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(C4COC4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.83";"nM";"8.42";"";"240740";"UO_0000065";"16.16";"0.31";"5.39";"8.64";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645950";"";"0";"490.01";"0";"2.45";"BDBM116130";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CCN)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"8.45";"nM";"8.07";"";"240742";"UO_0000065";"16.48";"0.32";"5.62";"7.07";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645961";"";"0";"478.53";"0";"3.82";"BDBM116141";"CCc1ncnc(-c2ccc(C(=O)N3CCc4ncccc4C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.09";"nM";"8.96";"";"240753";"UO_0000065";"18.73";"0.34";"5.14";"9.16";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645962";"";"0";"488.57";"0";"2.36";"BDBM116142";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CC(C)O)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.56";"nM";"8.81";"";"240754";"UO_0000065";"18.03";"0.33";"6.45";"8.12";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645971";"";"0";"537.04";"1";"3.67";"BDBM116151";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(C(C)COC)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.68";"nM";"9.17";"";"240763";"UO_0000065";"17.07";"0.33";"5.50";"9.41";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645975";"";"0";"523.01";"1";"3.01";"BDBM116155";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(CC(C)O)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.56";"nM";"9.25";"";"240767";"UO_0000065";"17.69";"0.34";"6.24";"8.53";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645981";"";"0";"556.07";"1";"4.30";"BDBM116161";"CCc1ncnc(-c2ccc(C(=O)N3CCN(Cc4nc(C)c(C)o4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.5";"nM";"8.82";"";"240773";"UO_0000065";"15.87";"0.30";"4.52";"7.72";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645984";"";"0";"535.05";"1";"2.50";"BDBM116164";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CCOCCO)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.28";"nM";"8.89";"";"240776";"UO_0000065";"16.62";"0.32";"6.39";"7.56";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645989";"";"0";"556.64";"1";"4.31";"BDBM116169";"CCc1ncnc(-c2ccc(C(=O)N3CCC4(CN(C(=O)OC(C)(C)C)C4)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"9.67";"nM";"8.02";"";"240781";"UO_0000065";"14.40";"0.27";"3.70";"7.00";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3648873";"";"0";"507.43";"1";"3.78";"BDBM116179";"CCc1ncnc(-c2cc(Cl)c(C(=O)N3CC4(CN(C)C4)C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"9.74";"nM";"8.01";"";"240791";"UO_0000065";"15.79";"0.31";"4.23";"9.08";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3648884";"";"0";"475.00";"0";"3.51";"BDBM116190";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C)C[C@@H]3C)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.84";"nM";"8.55";"";"240802";"UO_0000065";"17.99";"0.34";"5.04";"9.69";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3648886";"";"0";"512.55";"1";"2.56";"BDBM116192";"CCc1ncnc(-c2ccc(C(=O)N3CCN(Cc4ncon4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.45";"nM";"9.35";"";"240804";"UO_0000065";"18.24";"0.34";"6.79";"7.35";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3916652";"";"0";"464.53";"0";"1.86";"BDBM60571";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOCC4)nc3n2)cc1C(N)=O";"IC50";"'='";"6.7";"nM";"8.17";"";"235368";"UO_0000065";"17.60";"0.33";"6.31";"7.05";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3645972";"";"0";"523.01";"1";"3.01";"BDBM116152";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(C(C)CO)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.01";"nM";"9.00";"";"240764";"UO_0000065";"17.20";"0.33";"5.99";"8.29";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3670268";"";"0";"355.45";"0";"2.98";"BDBM111744";"CCc1ncnc(N2CCc3ccccc3C2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"68.0";"nM";"7.17";"";"232567";"UO_0000065";"20.16";"0.36";"4.19";"10.55";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670265";"";"0";"429.55";"0";"0.09";"BDBM111741";"CCc1ncnc(N2CCN(CCNS(C)(=O)=O)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"18.0";"nM";"7.75";"";"232564";"UO_0000065";"18.03";"0.35";"7.65";"6.60";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670253";"";"0";"321.43";"0";"2.87";"BDBM111729";"CCc1ncnc(N2CCCCC2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"55.0";"nM";"7.26";"";"232552";"UO_0000065";"22.59";"0.41";"4.39";"13.46";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670262";"";"0";"357.42";"0";"1.77";"BDBM111738";"CCc1ncnc(N2CCc3ncncc3C2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"27.0";"nM";"7.57";"";"232561";"UO_0000065";"21.18";"0.38";"5.80";"8.08";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670252";"";"0";"433.56";"0";"2.44";"BDBM111728";"CCc1ncnc(N2CCC3(CCN(C(=O)NC)CC3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"35.0";"nM";"7.46";"";"232551";"UO_0000065";"17.20";"0.32";"5.02";"7.44";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670263";"";"0";"392.51";"0";"1.72";"BDBM111739";"CCc1ncnc(N2CCN(C3CCOCC3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"77.0";"nM";"7.11";"";"232562";"UO_0000065";"18.12";"0.34";"5.39";"8.85";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670279";"";"0";"417.52";"0";"2.34";"BDBM111755";"CCc1ncnc(N2CCN(Cc3nc(C)c(C)o3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"258.0";"nM";"6.59";"";"232578";"UO_0000065";"15.78";"0.29";"4.25";"6.78";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670260";"";"0";"421.55";"0";"0.87";"BDBM111736";"CCc1ncnc(N2CCN(CCN3CCOCC3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"127.0";"nM";"6.90";"";"232559";"UO_0000065";"16.36";"0.30";"6.03";"8.25";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3586398";"";"0";"411.51";"0";"2.73";"31";"CO[C@H]1CC[C@H](CN2CC(=O)Nc3ncc(-c4ccc(C(C)(C)O)nc4)nc32)CC1";"IC50";"'='";"170.0";"nM";"6.77";"";"";"UO_0000065";"16.45";"0.31";"4.04";"6.74";"False";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3586384";"";"0";"419.49";"0";"2.81";"16";"Cc1cc(-c2nc[nH]n2)ccc1-c1cnc2c(n1)N(CCC1CCOCC1)C(=O)CN2";"IC50";"'='";"5.0";"nM";"8.30";"";"";"UO_0000065";"19.79";"0.37";"5.49";"7.62";"False";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL1091698";"";"0";"620.71";"1";"4.22";"6o";"CN1CCN(C(=O)C2CCN(c3ccnc4c3c(/C=C3\Oc5ccc(NC(=O)Nc6cccnc6)cc5C3=O)cn4C)CC2)CC1";"IC50";"'='";"70.0";"nM";"7.16";"";"";"UO_0000065";"11.53";"0.21";"2.93";"5.73";"False";"CHEMBL1107893";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156282";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091596";"";"0";"543.63";"1";"3.41";"10";"O=C(Nc1ccc(CO)cc1)Nc1ccc(-c2nc(N3C4CCC3COC4)nc(N3C4CCC3COC4)n2)cc1";"IC50";"'='";"0.18";"nM";"9.74";"";"";"UO_0000065";"17.93";"0.33";"6.33";"7.80";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091355";"";"0";"612.73";"1";"3.83";"26";"CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(C5CCOCC5)nc(N5C6CCC5COC6)n4)cc3)cc2)CC1";"IC50";"'='";"0.81";"nM";"9.09";"";"";"UO_0000065";"14.84";"0.28";"5.26";"7.27";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091356";"";"0";"640.79";"1";"4.61";"27";"CC(C)N1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(C5CCOCC5)nc(N5C6CCC5COC6)n4)cc3)cc2)CC1";"IC50";"'='";"0.46";"nM";"9.34";"";"";"UO_0000065";"14.57";"0.27";"4.73";"7.47";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1098306";"";"0";"540.67";"1";"4.31";"16f";"CCNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)cc1";"IC50";"'='";"0.8";"nM";"9.10";"";"";"UO_0000065";"16.83";"0.31";"4.79";"9.06";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL3909894";"";"0";"630.73";"1";"4.92";"BDBM178247";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(N5CCCC5)nc4)c(F)c3)c2C1=O";"IC50";"'='";"84.0";"nM";"7.08";"";"324267";"UO_0000065";"11.22";"0.21";"2.16";"5.66";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL1098300";"";"0";"430.47";"0";"3.50";"6i";"COC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(-c4ccccc4)c3n2)cc1";"IC50";"'='";"20.0";"nM";"7.70";"";"";"UO_0000065";"17.89";"0.33";"4.20";"8.16";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1879463";"DACTOLISIB";"2";"469.55";"1";"5.89";"1, NVP-BEZ235";"Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21";"IC50";"'='";"5.0";"nM";"8.30";"";"";"UO_0000065";"17.68";"0.31";"2.41";"10.85";"False";"CHEMBL3291527";"Inhibition of human recombinant mTOR assessed as inhibition of 4EBP1 phosphorylation after 30 mins by TR-FRET analysis";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3286093";"1";"Scientific Literature";"J. Med. Chem.";"2014";""
"CHEMBL565061";"";"0";"454.41";"0";"4.84";"1";"CCOC(=O)c1cnn2c(-c3cccc(NC(=O)c4cccc(C(F)(F)F)c4)c3)ccnc12";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1034666";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1151868";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";""
"CHEMBL1089140";"";"0";"423.52";"0";"2.25";"28";"CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3ccn(CCN(C)C)c3n2)cc1";"IC50";"'='";"33.0";"nM";"7.48";"";"";"UO_0000065";"17.67";"0.33";"5.23";"8.55";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1090573";"";"0";"526.65";"1";"4.46";"36";"O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)c3ccn(CCN4CCCCC4)c3n2)cc1";"IC50";"'='";"52.0";"nM";"7.28";"";"";"UO_0000065";"13.83";"0.26";"2.82";"7.25";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1092404";"";"0";"554.65";"1";"3.64";"52";"CCn1ccc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)N5CCNCC5)cc4)cc3)nc21";"IC50";"'='";"0.9";"nM";"9.05";"";"";"UO_0000065";"16.31";"0.30";"5.41";"7.75";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL3646536";"";"0";"382.43";"0";"1.05";"BDBM125387";"COc1ccc(Nc2ncc(CNCCO)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255116";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646546";"";"0";"511.64";"2";"2.25";"BDBM125398";"Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2ccc3scnc3c2)n1";"IC50";"'='";"849.0";"nM";"6.07";"";"255130";"UO_0000065";"11.87";"0.24";"3.82";"4.24";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646549";"";"0";"444.53";"0";"0.37";"BDBM125401";"Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2cc[nH]n2)n1";"IC50";"'='";"389.0";"nM";"6.41";"";"255134";"UO_0000065";"14.42";"0.28";"6.04";"4.03";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3357863";"";"0";"327.32";"0";"2.11";"BDBM125403";"COc1ncc(Nc2ncccc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255136";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165033";"";"0";"389.42";"0";"2.37";"BDBM50394857";"COc1ccc(Nc2ncc(-c3cnn(C)c3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255137";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646557";"";"0";"404.41";"0";"3.17";"BDBM125410";"COc1ncc(Nc2nc(-c3cccnc3)ccc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255145";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646558";"";"0";"331.74";"0";"2.76";"BDBM125411";"Cc1nc(N)nc(-c2cc(Cl)cnc2Nc2cncc(F)c2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255147";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646560";"";"0";"401.40";"0";"2.14";"BDBM125413";"COCCOc1ccc(-c2nc(C)nc(N)n2)c(Nc2cnc(OC)c(F)c2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255149";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2206912";"";"0";"486.92";"0";"3.56";"BDBM50401270";"Cc1nc(N)nc(-c2cccnc2Nc2cnc(Cl)c(NS(=O)(=O)c3ccc(F)cc3)c2)n1";"IC50";"'='";"389.0";"nM";"6.41";"";"255154";"UO_0000065";"13.16";"0.27";"2.85";"4.31";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646566";"";"0";"529.60";"1";"1.74";"BDBM125419";"CC(=O)Nc1ccc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'='";"623.0";"nM";"6.21";"";"255157";"UO_0000065";"11.72";"0.23";"4.47";"3.89";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646574";"";"0";"511.61";"2";"1.54";"BDBM125428";"COc1ccc(Nc2ncc(C3(N4CCN(S(C)(=O)=O)CC4)CC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255171";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646580";"";"0";"448.56";"0";"3.57";"BDBM125434";"Cc1nc(N)nc(-c2cc(C(C)N3CCOCC3)cnc2Nc2ccc3scnc3c2)n1";"IC50";"'='";"239.0";"nM";"6.62";"";"255177";"UO_0000065";"14.76";"0.28";"3.05";"5.76";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646601";"";"0";"385.40";"0";"2.21";"BDBM125457";"COc1ncc(Nc2ncc(C(C)CO)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255202";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2170082";"";"0";"517.59";"2";"1.58";"BDBM50396807";"COc1ncc(Nc2ncc(CN3CCN(S(C)(=O)=O)C[C@H]3C)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255207";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646606";"";"0";"504.02";"1";"2.08";"BDBM125463";"Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)C[C@@H]3C)cnc2Nc2ccc(Cl)nc2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255209";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2206904";"";"0";"465.93";"0";"1.84";"BDBM50401256";"COc1cnc(Nc2cnc(Cl)c(NS(=O)(=O)N(C)C)c2)c(-c2nc(C)nc(N)n2)c1";"IC50";"'='";"64.0";"nM";"7.19";"";"255222";"UO_0000065";"15.44";"0.32";"5.35";"4.46";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646622";"";"0";"409.43";"0";"2.91";"BDBM125479";"COc1ncc(Nc2ncc(C3=CCOCC3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255234";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646629";"";"0";"524.61";"1";"2.69";"BDBM125493";"COc1ncc(Nc2ncc(CN3CCN(C(=O)N(C)C(C)C)CC3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255248";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646632";"";"0";"514.62";"2";"1.39";"BDBM125496";"COc1ncc(Nc2ncc([C@@H](C)N3CCN(S(C)(=O)=O)C[C@@H]3C)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"1209.0";"nM";"5.92";"";"255253";"UO_0000065";"11.50";"0.22";"4.53";"3.58";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646634";"";"0";"517.59";"2";"1.58";"BDBM125498";"COc1ncc(Nc2ncc(CN3CCN(S(C)(=O)=O)[C@H](C)C3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255255";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646635";"";"0";"358.79";"0";"2.21";"BDBM125499";"COc1cnc(Nc2cnc(Cl)c(N)c2)c(-c2nc(C)nc(N)n2)c1";"IC50";"'='";"262.0";"nM";"6.58";"";"255259";"UO_0000065";"18.34";"0.36";"4.37";"4.78";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649465";"";"0";"549.06";"2";"2.23";"BDBM125504";"Cc1nc(N)nc(-c2cc([C@@H](C)N3CCOCC3)cnc2Nc2cnc(Cl)c(NS(=O)(=O)N(C)C)c2)n1";"IC50";"'='";"315.0";"nM";"6.50";"";"255264";"UO_0000065";"11.84";"0.24";"4.27";"3.96";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649472";"";"0";"548.07";"1";"2.83";"BDBM125511";"Cc1nc(N)cc(-c2cc([C@@H](C)N3CCOCC3)cnc2Nc2cnc(Cl)c(NS(=O)(=O)N(C)C)c2)n1";"IC50";"'='";"5394.0";"nM";"5.27";"";"255272";"UO_0000065";"9.61";"0.19";"2.44";"3.48";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643255";"";"0";"486.58";"0";"2.15";"BDBM115920";"CCc1ncnc(-c2ccc(C(=O)NCCN3CCOCC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"21.85";"nM";"7.66";"";"240532";"UO_0000065";"15.74";"0.29";"5.51";"6.63";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645782";"";"0";"401.47";"0";"3.02";"BDBM115960";"CCc1ncnc(-c2ccc(C(=O)N(C)OC)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.87";"nM";"8.54";"";"240572";"UO_0000065";"21.28";"0.39";"5.52";"9.07";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645785";"";"0";"498.59";"0";"3.31";"BDBM115963";"CCOC(=O)N1CCN(C(=O)c2ccc(-c3ncnc(CC)c3C#Cc3ccc(N)nc3)cc2C)CC1";"IC50";"'='";"2.68";"nM";"8.57";"";"240575";"UO_0000065";"17.19";"0.32";"5.26";"7.48";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645786";"";"0";"468.56";"0";"2.70";"BDBM115964";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C(C)=O)CC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"9.66";"nM";"8.02";"";"240576";"UO_0000065";"17.11";"0.31";"5.32";"7.61";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645789";"";"0";"482.59";"0";"3.09";"BDBM115967";"CCc1ncnc(-c2ccc(C(=O)N(C)CCN3CCCC3=O)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"15.32";"nM";"7.82";"";"240579";"UO_0000065";"16.19";"0.30";"4.72";"7.42";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645802";"";"0";"427.51";"0";"2.60";"BDBM115980";"CCc1ncnc(-c2ccc(C(=O)N3CC[C@@H](O)C3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"28.7";"nM";"7.54";"";"240592";"UO_0000065";"17.64";"0.32";"4.94";"7.17";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645820";"";"0";"484.58";"0";"3.53";"BDBM115998";"CCc1ncnc(-c2ccc(C(=O)N3CCN4CCCC[C@@H]4C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.73";"nM";"9.14";"";"240610";"UO_0000065";"18.85";"0.35";"5.61";"10.35";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645828";"";"0";"585.11";"1";"3.07";"BDBM116006";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(CCCS(C)(=O)=O)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.71";"nM";"9.15";"";"240618";"UO_0000065";"15.64";"0.31";"6.08";"7.48";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645851";"";"0";"528.63";"1";"3.62";"BDBM116030";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCOCC4)CC3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"3.11";"nM";"8.51";"";"240642";"UO_0000065";"16.09";"0.30";"4.89";"10.19";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645852";"";"0";"528.63";"1";"3.62";"BDBM116031";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C4CCOCC4)CC3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"5.43";"nM";"8.27";"";"240643";"UO_0000065";"15.64";"0.29";"4.65";"9.90";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645974";"";"0";"549.05";"1";"3.55";"BDBM116154";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(C4CCCC4O)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.32";"nM";"9.49";"";"240766";"UO_0000065";"17.29";"0.33";"5.94";"8.75";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL188678";"";"0";"413.50";"1";"5.66";"2, NU7441";"O=c1cc(N2CCOCC2)oc2c(-c3cccc4c3sc3ccccc34)cccc12";"IC50";"'='";"2400.0";"nM";"5.62";"";"";"UO_0000065";"13.59";"0.26";"-0.04";"13.17";"False";"CHEMBL2423428";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2417539";"1";"Scientific Literature";"J. Med. Chem.";"2013";""
"CHEMBL3645816";"";"0";"487.01";"0";"3.66";"BDBM115994";"CCc1ncnc(-c2ccc(C(=O)N3CCN4CCC[C@H]4C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.5";"nM";"8.82";"";"240606";"UO_0000065";"18.12";"0.34";"5.16";"10.00";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645822";"";"0";"485.50";"0";"3.21";"BDBM116000";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCn4ccnc4C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.36";"nM";"8.87";"";"240612";"UO_0000065";"18.26";"0.34";"5.66";"8.62";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL1945958";"";"0";"375.44";"0";"2.95";"48";"O=c1[nH]c2ncc(-c3ccc(-n4ccnn4)cc3)nc2n1CC1CCCCC1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1946268";"";"0";"347.42";"0";"3.85";"62";"O=c1[nH]c2ncc(-c3ccc4cc[nH]c4c3)nc2n1CC1CCCCC1";"IC50";"'='";"3500.0";"nM";"5.46";"";"";"UO_0000065";"15.70";"0.29";"1.61";"6.87";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1945794";"";"0";"353.38";"0";"1.71";"23";"NC(=O)[C@H]1CC[C@H](n2c(=O)[nH]c3ncc(-c4ccc(O)cc4)nc32)CC1";"IC50";"'>'";"5000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1949072";"Inhibition of mTOR-mediated S6 phosphorylation in human PC3 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";"CHEMBL3307570"
"CHEMBL3918830";"";"0";"535.61";"1";"3.94";"BDBM178241";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccon4)c(C)c3)c2C1=O";"IC50";"'='";"112.0";"nM";"6.95";"";"324261";"UO_0000065";"12.98";"0.24";"3.01";"5.15";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3944386";"";"0";"455.52";"0";"2.79";"BDBM178318";"CCN1CC(C)(C)Oc2nc(N3CCOCC3)nc(-c3ccc(NC(=O)OC)cc3)c2C1=O";"IC50";"'='";"194.0";"nM";"6.71";"";"324338";"UO_0000065";"14.74";"0.28";"3.92";"6.33";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3897742";"";"0";"481.55";"0";"3.32";"BDBM178320";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)OC)cc3)c2C1=O";"IC50";"'='";"180.0";"nM";"6.75";"";"324340";"UO_0000065";"14.01";"0.26";"3.42";"6.36";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3986566";"";"0";"546.63";"1";"3.52";"BDBM178341";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4cnn(C)c4)cc3)c2C1=O";"IC50";"'='";"13.0";"nM";"7.89";"";"324361";"UO_0000065";"14.43";"0.27";"4.37";"6.22";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3981392";"";"0";"563.70";"1";"3.36";"BDBM178347";"CCNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)nc3c2C(=O)N(C2CCN(C)CC2)CC(C)(C)O3)cc1";"IC50";"'='";"245.0";"nM";"6.61";"";"324367";"UO_0000065";"11.73";"0.22";"3.25";"5.89";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3986092";"";"0";"592.63";"1";"3.73";"BDBM178355";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(OC)nn4)c(F)c3)c2C1=O";"IC50";"'='";"45.0";"nM";"7.35";"";"324375";"UO_0000065";"12.40";"0.23";"3.62";"5.10";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3903818";"";"0";"579.63";"1";"4.19";"BDBM178356";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccc(OC)nc4)c(F)c3)c2C1=O";"IC50";"'='";"34.0";"nM";"7.47";"";"324376";"UO_0000065";"12.88";"0.24";"3.28";"5.70";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3929323";"";"0";"607.64";"1";"4.07";"BDBM178368";"CC1(C)CN(C2CCOCC2)C(=O)c2c(nc(N3CC4CCC(C3)O4)nc2-c2ccc(NC(=O)Nc3ccon3)c(F)c2)O1";"IC50";"'='";"31.0";"nM";"7.51";"";"324388";"UO_0000065";"12.36";"0.23";"3.44";"5.21";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3976928";"";"0";"608.65";"2";"5.08";"BDBM178370";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4cc(OC)c(F)cc4F)cc3)c2C1=O";"IC50";"'='";"79.0";"nM";"7.10";"";"324390";"UO_0000065";"11.67";"0.22";"2.02";"6.01";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3984997";"";"0";"589.65";"1";"3.94";"BDBM178372";"CC1(C)CN(C2CCOCC2)C(=O)c2c(nc(N3CC4CCC(C3)O4)nc2-c2ccc(NC(=O)Nc3ccon3)cc2)O1";"IC50";"'='";"27.0";"nM";"7.57";"";"324392";"UO_0000065";"12.84";"0.24";"3.63";"5.25";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3892705";"";"0";"539.57";"1";"3.77";"BDBM178374";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccon4)c(F)c3)c2C1=O";"IC50";"'='";"18.0";"nM";"7.75";"";"324394";"UO_0000065";"14.35";"0.27";"3.97";"5.74";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3983827";"";"0";"579.63";"1";"4.19";"BDBM178378";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccc(OC)cn4)c(F)c3)c2C1=O";"IC50";"'='";"55.0";"nM";"7.26";"";"324398";"UO_0000065";"12.52";"0.24";"3.07";"5.54";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3977525";"";"0";"615.67";"2";"4.22";"BDBM178398";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(Nc4nnc(-c5ccc(OC)nc5)[nH]4)c(F)c3)c2C1=O";"IC50";"'='";"128.0";"nM";"6.89";"";"324418";"UO_0000065";"11.20";"0.21";"2.67";"4.80";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3899512";"";"0";"575.65";"1";"4.63";"BDBM178400";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(C)nc4)c(F)c3)c2C1=O";"IC50";"'='";"24.0";"nM";"7.62";"";"324420";"UO_0000065";"13.24";"0.25";"2.99";"6.26";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3952837";"";"0";"645.76";"1";"4.15";"BDBM178434";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)NCC(C)(C)O)cc4)cc3)c2C1=O";"IC50";"'='";"38.0";"nM";"7.42";"";"324454";"UO_0000065";"11.49";"0.22";"3.27";"4.69";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3910206";"";"0";"605.68";"1";"3.78";"BDBM178449";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4cnc(N(C)C)cn4)c(F)c3)c2C1=O";"IC50";"'='";"67.0";"nM";"7.17";"";"324469";"UO_0000065";"11.84";"0.22";"3.39";"5.20";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL4115580";"";"0";"543.60";"1";"3.21";"BDBM178454";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)OC[C@@H](C)O)c(F)c3)c2C1=O";"IC50";"'='";"1070.0";"nM";"5.97";"";"324474";"UO_0000065";"10.98";"0.21";"2.76";"4.73";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3218578";"BGT-226";"2";"534.54";"1";"4.38";"BDBM185147";"COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cn1";"IC50";"'='";"1.99";"nM";"8.70";"";"375937";"UO_0000065";"16.28";"0.30";"4.32";"11.27";"False";"CHEMBL3888153";"mTOR Activity Assay: 1. Preparation of test reagents {circle around (1)} 1x kinase buffer (50 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 3 mM MnCl, 0.01% Tween-20, 2 mM DTT); {circle around (2)} 4x kinase solution (added mTOR kinase to 1x kinase buffer to provide 4x kinase solution with a final concentration of 2.5 nM); {circle around (3)} 2x substrate solution (added the substrates of 4EBP1 and ATP into 1x kinase buffer to provide 2x substrate solution with 4EBP1 final concentration of 50 nM and ATP final concentration of 10.8 uM); {circle around (4)} 4x test substance solutions (100x test substance solutions with different concentration gradients were prepared using 100% DMSO, and diluted 25-fold with 1x kinase buffer to give 4x test substance solutions with different concentration gradients) {circle around (5)} preparation of test solution (test solution containing EDTA and 4EBP1 phosphorylated antibody was prepared using activity test kit with assay buffer, the final concentration of EDTA was 8 mM, and the final concentration of 4EBP1 phosphorylated antibody was 2 nM) 2. 2.5 uL of 4x test solution was added to a 384-well plate in parallel; 3. added 2.54 uL of 4x kinase solution and incubated for 10 min; 4. then added 5 uL of 2x solutions of 4EBP1 and ATP substrates and incubated for 1 h at room temperature; 5. finally, added 10 uL of test solution to quench the reaction, and read after 60 min; 6. IC50 value was obtained via curve fitting.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886601";"37";"BindingDB Database";"";"2016";""
"CHEMBL4112318";"";"0";"476.54";"0";"2.44";"BDBM213787";"COc1ccc(-c2ccc3ncc4c(c3n2)N(C2CCN(C(=O)[C@@H](C)O)CC2)C(=O)N(C)C4)cn1";"IC50";"'='";"257.2";"nM";"6.59";"";"375951";"UO_0000065";"13.83";"0.26";"4.15";"5.88";"False";"CHEMBL3888153";"mTOR Activity Assay: 1. Preparation of test reagents {circle around (1)} 1x kinase buffer (50 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 3 mM MnCl, 0.01% Tween-20, 2 mM DTT); {circle around (2)} 4x kinase solution (added mTOR kinase to 1x kinase buffer to provide 4x kinase solution with a final concentration of 2.5 nM); {circle around (3)} 2x substrate solution (added the substrates of 4EBP1 and ATP into 1x kinase buffer to provide 2x substrate solution with 4EBP1 final concentration of 50 nM and ATP final concentration of 10.8 uM); {circle around (4)} 4x test substance solutions (100x test substance solutions with different concentration gradients were prepared using 100% DMSO, and diluted 25-fold with 1x kinase buffer to give 4x test substance solutions with different concentration gradients) {circle around (5)} preparation of test solution (test solution containing EDTA and 4EBP1 phosphorylated antibody was prepared using activity test kit with assay buffer, the final concentration of EDTA was 8 mM, and the final concentration of 4EBP1 phosphorylated antibody was 2 nM) 2. 2.5 uL of 4x test solution was added to a 384-well plate in parallel; 3. added 2.54 uL of 4x kinase solution and incubated for 10 min; 4. then added 5 uL of 2x solutions of 4EBP1 and ATP substrates and incubated for 1 h at room temperature; 5. finally, added 10 uL of test solution to quench the reaction, and read after 60 min; 6. IC50 value was obtained via curve fitting.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886601";"37";"BindingDB Database";"";"2016";""
"CHEMBL1258067";"";"0";"547.62";"1";"3.40";"8e";"COc1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4C5CCC4COC5)n3)cc2)cc1OC";"IC50";"'='";"93.5";"nM";"7.03";"";"";"UO_0000065";"12.84";"0.24";"3.63";"5.71";"False";"CHEMBL1259905";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255533";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1097898";"";"0";"583.74";"1";"3.85";"16k";"CN(C)CCNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)cc1";"IC50";"'='";"65.0";"nM";"7.19";"";"";"UO_0000065";"12.31";"0.23";"3.34";"6.93";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1092841";"";"0";"486.58";"0";"3.54";"25";"CN(C)CCn1ccc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccncc4)cc3)nc21";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"17.88";"0.33";"5.16";"8.66";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1090780";"";"0";"497.48";"0";"4.54";"32";"O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)c3ccn(CC(F)(F)F)c3n2)cc1";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"18.09";"0.34";"4.46";"9.26";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1092071";"";"0";"459.51";"0";"2.97";"40";"O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)c3ccn(CCO)c3n2)cc1";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"18.93";"0.35";"5.73";"7.41";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1089443";"";"0";"367.45";"0";"2.20";"21";"CN(C)CCn1ccc2c(N3CCOCC3)nc(-c3cccc(O)c3)nc21";"IC50";"'>'";"800.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL562999";"";"0";"520.59";"1";"3.02";"25c";"COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)NC5CC5)cc4)nc32)CC1";"IC50";"'='";"0.5";"nM";"9.30";"";"";"UO_0000065";"17.87";"0.33";"6.28";"7.34";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1095933";"";"0";"536.64";"1";"3.65";"27a";"CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)OC(C)(C)C)CC4)c3n2)cc1";"IC50";"'='";"0.7";"nM";"9.15";"";"";"UO_0000065";"17.06";"0.32";"5.50";"7.22";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1097263";"";"0";"372.43";"0";"2.90";"6c";"Nc1ccc(-c2nc(N3CCOCC3)c3cnn(-c4ccccc4)c3n2)cc1";"IC50";"'='";"73.0";"nM";"7.14";"";"";"UO_0000065";"19.16";"0.35";"4.24";"8.69";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1090574";"";"0";"529.65";"1";"3.13";"37";"CN(C)CCNCCn1ccc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccncc4)cc3)nc21";"IC50";"'='";"11.0";"nM";"7.96";"";"";"UO_0000065";"15.03";"0.28";"4.83";"7.08";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1258517";"PKI-179";"1";"488.55";"0";"2.78";"8m";"O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1";"IC50";"'='";"0.42";"nM";"9.38";"";"";"UO_0000065";"19.19";"0.36";"6.60";"7.97";"False";"CHEMBL1259905";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255533";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL3653543";"";"0";"503.59";"1";"3.49";"BDBM136399";"CC(C)[C@H]1CN(CCN2CC[C@@H](F)C2)C(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"9.8";"nM";"8.01";"";"270273";"UO_0000065";"15.90";"0.30";"4.52";"8.13";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653545";"";"0";"501.60";"1";"2.51";"BDBM136401";"CC(C)[C@H]1CN(CCN2CC[C@@H](O)C2)C(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"26.8";"nM";"7.57";"";"270275";"UO_0000065";"15.10";"0.28";"5.06";"6.37";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653546";"";"0";"515.62";"1";"3.17";"BDBM136402";"CO[C@@H]1CCN(CCN2C[C@H](C(C)C)N(c3ccn4ncc(-c5ccc(-c6nc[nH]n6)cc5)c4n3)C2=O)C1";"IC50";"'='";"20.7";"nM";"7.68";"";"270276";"UO_0000065";"14.90";"0.28";"4.51";"7.13";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL2058170";"";"0";"424.47";"0";"0.51";"9";"Nc1ncc(-c2cn3cc(C(=O)NC4CCOCC4)nc3c(N3CCOCC3)n2)cn1";"IC50";"'='";"751.0";"nM";"6.12";"";"";"UO_0000065";"14.43";"0.27";"5.61";"4.61";"False";"CHEMBL2060320";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2057167";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2064408";"";"0";"326.36";"0";"1.65";"36";"Cc1ccc2nc(Cc3nc(N4CCOCC4)cc(=O)[nH]3)oc2c1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064354";"";"0";"330.32";"0";"1.48";"32";"O=c1cc(N2CCOCC2)nc(Cc2nc3cccc(F)c3o2)[nH]1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064353";"";"0";"330.32";"0";"1.48";"31";"O=c1cc(N2CCOCC2)nc(Cc2nc3ccc(F)cc3o2)[nH]1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064351";"";"0";"330.32";"0";"1.48";"29";"O=c1cc(N2CCOCC2)nc(Cc2nc3c(F)cccc3o2)[nH]1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064347";"";"0";"401.47";"0";"2.75";"25";"Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2c(-c3ccccc3)cccc21";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064341";"";"0";"369.40";"0";"2.02";"19";"O=c1cc(N2CCOCC2)nc(Cc2nc3cc(F)ccc3n2C2CC2)[nH]1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064337";"";"0";"325.37";"0";"1.38";"15";"Cc1ccc2[nH]c(Cc3nc(N4CCOCC4)cc(=O)[nH]3)nc2c1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL4109093";"";"0";"459.55";"0";"3.22";"BDBM227492";"C[C@@H]1COCCN1c1nc(N2C3CCC2CC(O)C3)nc2[nH]c(-c3cccc4[nH]ccc34)nc12";"IC50";"'='";"143.0";"nM";"6.84";"";"397251";"UO_0000065";"14.89";"0.27";"3.62";"6.45";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL4112338";"";"0";"459.55";"0";"3.34";"BDBM227496";"C[C@@H]1COCCN1c1nc(N2CC3(CCCOC3)C2)nc2[nH]c(-c3cccc4[nH]ccc34)nc12";"IC50";"'='";"112.0";"nM";"6.95";"";"397255";"UO_0000065";"15.13";"0.28";"3.61";"7.30";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL1760156";"";"0";"374.41";"0";"2.80";"29";"CC(=O)Nc1cccc(Nc2nc3ccccc3n2-c2nc(C)nc(N)n2)c1";"IC50";"'='";"1500.0";"nM";"5.82";"";"";"UO_0000065";"15.55";"0.28";"3.02";"4.71";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760165";"";"0";"364.37";"0";"1.80";"39";"CNC(=O)c1ccc(Nc2nc3ccccc3n2-c2nc(C)nc(N)n2)o1";"IC50";"'='";"680.0";"nM";"6.17";"";"";"UO_0000065";"16.93";"0.31";"4.37";"4.51";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762775";"";"0";"333.36";"0";"2.70";"3";"CNc1ncnc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"2900.0";"nM";"5.54";"";"";"UO_0000065";"16.61";"0.30";"2.84";"5.49";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762779";"";"0";"304.31";"0";"2.66";"7";"Oc1cccc(Nc2nc3ccccc3n2-c2ncncn2)c1";"IC50";"'>'";"25000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762782";"";"0";"372.39";"0";"2.90";"10";"Cc1nc(NCC#N)nc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"17.0";"nM";"7.77";"";"";"UO_0000065";"20.86";"0.38";"4.87";"6.24";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL4110496";"";"0";"384.44";"0";"1.19";"BDBM227481";"C[C@H]1COCCN1c1nc(N2CCOC[C@H]2C)c2nc(-c3cc[nH]n3)[nH]c2n1";"IC50";"'='";"104.0";"nM";"6.98";"";"397240";"UO_0000065";"18.16";"0.34";"5.79";"6.46";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL1089784";"";"0";"419.44";"1";"6.02";"18";"O=C1/C(=C/c2c(-c3ccc4ccccc4c3)[nH]c3ccccc23)Oc2cc(O)cc(O)c21";"IC50";"'='";"280.0";"nM";"6.55";"";"";"UO_0000065";"15.62";"0.28";"0.53";"7.94";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1095281";"";"0";"428.50";"0";"3.30";"7";"CC(=O)N(C)c1ccc(-c2nc(N3CCOCC3)c3cnn(-c4ccccc4)c3n2)cc1";"IC50";"'='";"480.0";"nM";"6.32";"";"";"UO_0000065";"14.75";"0.27";"3.02";"8.27";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1093449";"";"0";"507.59";"1";"2.99";"38";"COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)c(C)n2CCCN1CCN(CCO)CC1";"IC50";"'='";"108.0";"nM";"6.97";"";"";"UO_0000065";"13.72";"0.26";"3.98";"6.47";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1090506";"";"0";"408.45";"0";"3.63";"32";"COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)cn2CCCN(C)C";"IC50";"'='";"2125.0";"nM";"5.67";"";"";"UO_0000065";"13.89";"0.26";"2.04";"6.74";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1090478";"";"0";"408.45";"0";"3.55";"28";"COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)c(C)n2CCN(C)C";"IC50";"'='";"18.0";"nM";"7.75";"";"";"UO_0000065";"18.96";"0.35";"4.19";"9.20";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1097896";"";"0";"556.67";"1";"3.28";"16i";"O=C(NCCO)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)cc1";"IC50";"'='";"0.3";"nM";"9.52";"";"";"UO_0000065";"17.11";"0.32";"6.24";"7.89";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1822052";"";"0";"434.91";"0";"4.53";"2";"Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)cc2s1";"IC50";"'='";"24.0";"nM";"7.62";"";"";"UO_0000065";"17.52";"0.37";"3.09";"7.78";"False";"CHEMBL1828260";"Inhibition of recombinant N-terminal GST-tagged mTOR-mediated 4E-BP1 phosphorylation after 60 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1821651";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1822210";"";"0";"460.87";"0";"4.44";"24";"CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)cc2o1";"IC50";"'='";"146.0";"nM";"6.84";"";"";"UO_0000065";"14.83";"0.30";"2.40";"5.99";"False";"CHEMBL1828260";"Inhibition of recombinant N-terminal GST-tagged mTOR-mediated 4E-BP1 phosphorylation after 60 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1821651";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL3585359";"";"0";"397.48";"0";"2.34";"12";"CC(C)(O)c1ccc(-c2cnc3c(n2)N(CCC2CCOCC2)C(=O)CN3)cn1";"IC50";"'='";"33.0";"nM";"7.48";"";"";"UO_0000065";"18.82";"0.35";"5.14";"7.45";"False";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3586571";"";"0";"366.39";"0";"1.04";"24";"COCCN1C(=O)CNc2ncc(-c3ccc(-c4nc[nH]n4)nc3C)nc21";"IC50";"'='";"19.0";"nM";"7.72";"";"";"UO_0000065";"21.07";"0.39";"6.68";"6.34";"False";"CHEMBL3587521";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585264";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL521851";"PICTILISIB";"2";"513.65";"1";"2.15";"GDC-0941";"CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1";"IC50";"'='";"410.0";"nM";"6.39";"";"";"UO_0000065";"12.43";"0.25";"4.24";"5.94";"False";"CHEMBL3861255";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3860068";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL3937989";"";"0";"486.55";"0";"2.89";"BDBM178226";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)NC)cc3F)c2C1=O";"IC50";"'='";"13.0";"nM";"7.89";"";"324246";"UO_0000065";"16.21";"0.31";"5.00";"7.24";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3932069";"";"0";"603.68";"1";"4.24";"BDBM178230";"Cc1cc(NC(=O)Nc2ccc(-c3nc(N4CC5CCC(C4)O5)nc4c3C(=O)N(C3CCOCC3)CC(C)(C)O4)cc2)no1";"IC50";"'='";"12.0";"nM";"7.92";"";"324250";"UO_0000065";"13.12";"0.25";"3.68";"5.49";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3901218";"";"0";"561.62";"1";"4.24";"BDBM178281";"Cc1ccc(NC(=O)Nc2ccc(-c3nc(N4CC5CCC(C4)O5)nc4c3C(=O)N(C)CC(C)(C)O4)cc2F)cn1";"IC50";"'='";"16.0";"nM";"7.80";"";"324301";"UO_0000065";"13.88";"0.26";"3.56";"6.40";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3909036";"";"0";"646.72";"1";"4.16";"BDBM178289";"C[C@H]1COCCN1c1ccc(NC(=O)Nc2ccc(-c3nc(N4C5CCC4COC5)nc4c3C(=O)N(C)CC(C)(C)O4)cc2F)cn1";"IC50";"'='";"64.0";"nM";"7.19";"";"324309";"UO_0000065";"11.12";"0.21";"3.03";"5.36";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3978467";"";"0";"370.41";"0";"0.86";"BDBM178310";"CC1(C)CNC(=O)c2c(nc(N3CCOCC3)nc2-c2ccc(N)nc2)O1";"IC50";"'='";"624.0";"nM";"6.21";"";"324330";"UO_0000065";"16.75";"0.31";"5.34";"5.37";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3899666";"";"0";"482.59";"0";"3.14";"BDBM178313";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)nc3c2C(=O)N(CC)CC(C)(C)O3)cc1";"IC50";"'='";"26.0";"nM";"7.58";"";"324333";"UO_0000065";"15.72";"0.30";"4.45";"6.96";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3959841";"";"0";"610.66";"2";"5.48";"BDBM178427";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4cccc(OC(C)F)c4)c(F)c3)c2C1=O";"IC50";"'='";"141.0";"nM";"6.85";"";"324447";"UO_0000065";"11.22";"0.21";"1.37";"5.80";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3969319";"";"0";"672.76";"1";"4.69";"BDBM178474";"CCN1CC(C)(C)Oc2nc(N3C4CCC3COC4)nc(-c3ccc(NC(=O)Nc4ccc(N5CC6CCC(C5)O6)nc4)c(F)c3)c2C1=O";"IC50";"'='";"87.0";"nM";"7.06";"";"324494";"UO_0000065";"10.49";"0.20";"2.37";"5.26";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3954867";"";"0";"680.73";"2";"5.56";"BDBM178476";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccnc(N5CCC(F)(F)CC5)c4)c(F)c3)c2C1=O";"IC50";"'='";"387.0";"nM";"6.41";"";"324496";"UO_0000065";"9.42";"0.18";"0.85";"5.13";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3327006";"";"0";"447.48";"0";"2.66";"2o";"COc1ncc(-c2cnc3nc(N)nc(C)c3c2)cc1NS(=O)(=O)c1ccc(C#N)cc1";"IC50";"'='";"45.8";"nM";"7.34";"";"";"UO_0000065";"16.40";"0.31";"4.68";"4.68";"False";"CHEMBL3380578";"Inhibition of mTOR (unknown origin) assessed as inhibition of 4EBP-1 phosphorylation preincubated for 15 mins before substrate addition by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3351642";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL1945949";"";"0";"393.49";"0";"3.51";"38";"CC(C)NC(=O)c1ccc(-c2cnc3[nH]c(=O)n(CC4CCCCC4)c3n2)cc1";"IC50";"'='";"8900.0";"nM";"5.05";"";"";"UO_0000065";"12.84";"0.24";"1.54";"5.45";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL3326099";"";"0";"509.08";"2";"6.80";"29a";"CCN(CC)CCCNc1nc(-c2ccc(NC(=O)Nc3ccc(Cl)cc3)cc2)nc2ccsc12";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3371129";"Inhibition of mTOR (unknown origin) using poly (Glu, Tyr) 4:1 substrate incubated for 30 mins by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352345";"1";"Scientific Literature";"Eur. J. Med. Chem.";"2014";""
"CHEMBL1801204";"AZD-8055";"1";"465.55";"0";"2.64";"10, AZD-8055";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO";"IC50";"'='";"0.8";"nM";"9.10";"";"";"UO_0000065";"19.54";"0.37";"6.46";"9.77";"False";"CHEMBL1804915";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1800032";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1760162";"";"0";"357.38";"0";"2.72";"36";"Cc1nc(N)nc(-n2c(Nc3n[nH]c4ccccc34)nc3ccccc32)n1";"IC50";"'='";"250.0";"nM";"6.60";"";"";"UO_0000065";"18.47";"0.33";"3.88";"5.36";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760171";"";"0";"345.37";"0";"2.03";"45";"C#CCNc1nc(C)nc(-n2c(Nc3cc[nH]n3)nc3ccccc32)n1";"IC50";"'='";"1400.0";"nM";"5.85";"";"";"UO_0000065";"16.95";"0.31";"3.82";"5.36";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760164";"";"0";"321.35";"0";"1.58";"38";"Cc1nc(N)nc(-n2c(Nc3ccnn3C)nc3ccccc32)n1";"IC50";"'='";"540.0";"nM";"6.27";"";"";"UO_0000065";"19.50";"0.36";"4.69";"5.58";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760160";"";"0";"357.33";"0";"2.44";"34";"Cc1nc(N)nc(-n2c(Nc3ccn(C(F)F)n3)nc3ccccc32)n1";"IC50";"'='";"6500.0";"nM";"5.19";"";"";"UO_0000065";"14.52";"0.27";"2.75";"4.62";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760164";"";"0";"321.35";"0";"1.58";"38";"Cc1nc(N)nc(-n2c(Nc3ccnn3C)nc3ccccc32)n1";"IC50";"'>'";"25000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760165";"";"0";"364.37";"0";"1.80";"39";"CNC(=O)c1ccc(Nc2nc3ccccc3n2-c2nc(C)nc(N)n2)o1";"IC50";"'>'";"25000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL3962490";"";"0";"488.55";"0";"2.02";"BDBM251649";"CNc1nc2cc(F)ccc2n1-c1nc2c(c(C3(S(C)(=O)=O)CCC3)n1)OC[C@@H]1COCCN21";"IC50";"'='";"6080.0";"nM";"5.22";"";"438549";"UO_0000065";"10.68";"0.21";"3.20";"4.68";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3898993";"";"0";"488.55";"0";"2.02";"BDBM251664";"CNc1nc2ccc(F)cc2n1-c1nc2c(c(C3(S(C)(=O)=O)CCC3)n1)OC[C@@H]1COCCN21";"IC50";"'='";"6800.0";"nM";"5.17";"";"438550";"UO_0000065";"10.58";"0.21";"3.15";"4.64";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL565849";"";"0";"422.49";"0";"2.57";"19";"OCc1cccc(-c2ccc(-c3cc(N4CCOCC4)nc(N4CCOCC4)n3)o2)c1";"IC50";"'='";"510.0";"nM";"6.29";"";"";"UO_0000065";"14.89";"0.28";"3.72";"7.48";"False";"CHEMBL1049650";"Inhibition of mTOR kinase in human HeLa cells by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HeLa";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156040";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3308376"
"CHEMBL585699";"";"0";"445.48";"1";"0.71";"1";"COc1cc(/C=N/Nc2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc(OC)c1O";"IC50";"'='";"270.0";"nM";"6.57";"";"";"UO_0000065";"14.75";"0.28";"5.86";"5.18";"False";"CHEMBL1049650";"Inhibition of mTOR kinase in human HeLa cells by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HeLa";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156040";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3308376"
"CHEMBL1986603";"";"0";"451.51";"0";"3.75";"24, NVS-P13-3";"Cc1cc(NC(=O)CCNC(=O)Nc2nc(C)c(-c3ccc(-n4cccn4)cc3)s2)no1";"IC50";"'>'";"9100.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2073006";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2069199";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL3903443";"";"0";"520.62";"1";"3.71";"BDBM222572";"CSc1cnc(-c2ccc(NC(=O)Nc3ccc(N4CCOCC4=O)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"18.8";"nM";"7.73";"";"389361";"UO_0000065";"14.84";"0.29";"4.02";"7.09";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3984561";"";"0";"592.72";"1";"4.75";"BDBM222576";"CCOC(=O)c1nc(-c2ccc(NC(=O)Nc3ccc(N4CCSCC4)cc3)cc2)nc(N2CCOCC2)c1OCC";"IC50";"'='";"184.7";"nM";"6.73";"";"389365";"UO_0000065";"11.36";"0.22";"1.98";"5.70";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3937371";"";"0";"570.63";"1";"2.85";"BDBM222597";"CCOC(=O)c1nc(-c2ccc(NC(=O)Nc3ccc(S(N)(=O)=O)cc3)cc2)nc(N2CCOCC2)c1OCC";"IC50";"'='";"81.1";"nM";"7.09";"";"389386";"UO_0000065";"12.43";"0.24";"4.24";"4.05";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3922384";"";"0";"484.54";"0";"2.28";"BDBM222602";"COc1cnc(-c2ccc(NC(=O)Nc3ccc(S(N)(=O)=O)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"30.5";"nM";"7.52";"";"389391";"UO_0000065";"15.51";"0.30";"5.24";"5.05";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3975208";"";"0";"549.08";"1";"4.37";"BDBM222615";"CSc1c(Cl)nc(-c2ccc(NC(=O)Nc3ccc(NS(C)(=O)=O)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"174.5";"nM";"6.76";"";"389404";"UO_0000065";"12.31";"0.26";"2.39";"5.38";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3646496";"";"0";"326.34";"0";"2.72";"BDBM125338";"COc1ccc(Nc2ncccc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255066";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646513";"";"0";"315.29";"0";"2.24";"BDBM125356";"Cc1nc(N)nc(-c2cc(F)cnc2Nc2cncc(F)c2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255085";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646519";"";"0";"379.43";"0";"2.49";"BDBM125362";"Cc1nc(N)nc(-c2cccnc2Nc2ccc(NC(=O)NC(C)C)nc2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255091";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646531";"";"0";"432.49";"0";"2.69";"BDBM125374";"COc1ccc(Nc2ncc(N3CC[C@H](CO)C3)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255103";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165022";"";"0";"343.78";"0";"2.62";"BDBM50394868";"COc1ccc(Nc2ncc(Cl)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255083";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL1940140";"";"0";"375.44";"0";"2.60";"5";"CCc1nccn1-c1nc(-c2cccc3[nH]ccc23)nc(N2CCOCC2)n1";"IC50";"'='";"26.0";"nM";"7.58";"";"";"UO_0000065";"20.20";"0.37";"4.99";"8.95";"False";"CHEMBL1942431";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1938252";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1940137";"";"0";"357.81";"0";"2.29";"2";"Clc1cccc(Nc2nc(N3CCOCC3)nc(-n3cccn3)n2)c1";"IC50";"'='";"570.0";"nM";"6.24";"";"";"UO_0000065";"17.45";"0.34";"3.95";"7.71";"False";"CHEMBL1942431";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1938252";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1762784";"";"0";"361.41";"0";"3.19";"13";"CCCc1nc(N)nc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'>'";"25000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762779";"";"0";"304.31";"0";"2.66";"7";"Oc1cccc(Nc2nc3ccccc3n2-c2ncncn2)c1";"IC50";"'='";"1600.0";"nM";"5.80";"";"";"UO_0000065";"19.05";"0.34";"3.14";"6.53";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762784";"";"0";"361.41";"0";"3.19";"13";"CCCc1nc(N)nc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"2640.0";"nM";"5.58";"";"";"UO_0000065";"15.44";"0.28";"2.39";"4.86";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762783";"";"0";"347.38";"0";"2.80";"12";"CCc1nc(N)nc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"410.0";"nM";"6.39";"";"";"UO_0000065";"18.39";"0.34";"3.59";"5.57";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL577743";"";"0";"581.73";"1";"4.27";"33";"CCn1ncc2c(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(CN5CCN(C)CC5)cc4)cc3)nc21";"IC50";"'='";"0.7";"nM";"9.15";"";"";"UO_0000065";"15.74";"0.29";"4.88";"8.83";"False";"CHEMBL1039195";"Inhibition of human FLAG-tagged mTOR expressed in HEK293 cells after 2 hrs by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156748";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307715"
"CHEMBL566087";"";"0";"447.42";"0";"2.78";"42";"CNC(=O)Nc1ccc(-c2nc(N3C[C@@H]4C[C@H]3CO4)c3cnn(CC(F)(F)F)c3n2)cc1";"IC50";"'='";"5.5";"nM";"8.26";"";"";"UO_0000065";"18.46";"0.35";"5.48";"8.50";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL576937";"";"0";"522.61";"1";"3.26";"17";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC(C)C3)c3cnn(C4CCN(C(=O)OC)CC4)c3n2)cc1";"IC50";"'='";"1.9";"nM";"8.72";"";"";"UO_0000065";"16.69";"0.31";"5.46";"6.88";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL575130";"";"0";"510.48";"1";"4.07";"46";"O=C(Nc1ccc(-c2nc(N3C[C@H]4C[C@@H]3CO4)c3cnn(CC(F)(F)F)c3n2)cc1)Nc1cccnc1";"IC50";"'='";"17.0";"nM";"7.77";"";"";"UO_0000065";"15.22";"0.29";"3.70";"7.06";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL3939926";"";"0";"466.47";"0";"2.87";"BDBM222639";"COc1cnc(-c2ccc(NC(=O)Nc3ccc(C(N)=O)cc3)cc2F)nc1N1CCOCC1";"IC50";"'='";"219.5";"nM";"6.66";"";"389428";"UO_0000065";"14.27";"0.27";"3.79";"5.06";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL2063760";"";"0";"443.53";"0";"2.08";"10";"CCNC(=O)Nc1ccc(-c2nc3c(c(N4C[C@@H]5CC[C@H](C4)O5)n2)CS(=O)(=O)C3)cc1";"IC50";"'='";"84.0";"nM";"7.08";"";"";"UO_0000065";"15.95";"0.31";"5.00";"6.23";"False";"CHEMBL2065058";"Inhibition of mTOR-mediated AKT phosphorylation at Ser473 by cell based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062409";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1241269";"";"0";"268.32";"0";"2.97";"PP208";"CC(C)n1cc(-c2cccc(O)c2)c2c(N)ncnc21";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242199";"";"0";"313.34";"0";"3.04";"PP79";"Nc1ncnc2c1c(-c1cc(O)cc(F)c1)nn2C1CCCC1";"IC50";"'='";"10000.0";"nM";"5.00";"";"";"UO_0000065";"15.96";"0.30";"1.96";"5.56";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242846";"";"0";"315.34";"0";"1.46";"PP66";"COc1ncc(-c2nn(C(C)C)c3ncnc(N)c23)c(OC)n1";"IC50";"'='";"635.0";"nM";"6.20";"";"";"UO_0000065";"19.65";"0.37";"4.74";"5.44";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1240545";"";"0";"292.35";"0";"2.72";"PP45";"CC(C)n1nc(-c2ccc(CC#N)cc2)c2c(N)ncnc21";"IC50";"'='";"3500.0";"nM";"5.46";"";"";"UO_0000065";"18.66";"0.34";"2.74";"5.84";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1240554";"";"0";"353.43";"0";"3.60";"PP359";"CCOc1ccc(-c2nn(C3CCCC3)c3ncnc(N)c23)cc1OC";"IC50";"'='";"6500.0";"nM";"5.19";"";"";"UO_0000065";"14.68";"0.27";"1.59";"5.89";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242659";"";"0";"367.45";"0";"3.99";"PP362";"CCOc1ccc(-c2nn(C3CCCCC3)c3ncnc(N)c23)cc1OC";"IC50";"'='";"616.0";"nM";"6.21";"";"";"UO_0000065";"16.90";"0.31";"2.22";"7.05";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242109";"";"0";"297.36";"0";"3.06";"PP327";"CCC(C)n1nc(-c2ccc(C)c(O)c2)c2c(N)ncnc21";"IC50";"'='";"16.0";"nM";"7.80";"";"";"UO_0000065";"26.22";"0.48";"4.74";"8.68";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241390";"";"0";"254.30";"0";"2.05";"PP52";"CC(C)n1nc(-c2cccnc2)c2c(N)ncnc21";"IC50";"'='";"5500.0";"nM";"5.26";"";"";"UO_0000065";"20.68";"0.38";"3.21";"6.37";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241482";"";"0";"402.39";"0";"3.62";"PP401";"Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2Cc1ocnc1-c1ccccc1";"IC50";"'='";"100000.0";"nM";"4.00";"";"";"UO_0000065";"9.94";"0.18";"0.38";"3.45";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1240544";"";"0";"318.77";"0";"1.95";"PP456";"C[C@@H](CN)n1nc(-c2ccc(Cl)c(O)c2)c2c(N)ncnc21";"IC50";"'='";"880.0";"nM";"6.06";"";"";"UO_0000065";"19.00";"0.38";"4.11";"5.23";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242031";"";"0";"332.39";"0";"1.30";"PP41";"CC(C)n1nc(-c2cccc(S(N)(=O)=O)c2)c2c(N)ncnc21";"IC50";"'='";"4300.0";"nM";"5.37";"";"";"UO_0000065";"16.15";"0.32";"4.07";"4.14";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242032";"";"0";"332.39";"0";"1.30";"PP14";"CC(C)n1nc(-c2ccc(S(N)(=O)=O)cc2)c2c(N)ncnc21";"IC50";"'='";"5000.0";"nM";"5.30";"";"";"UO_0000065";"15.95";"0.31";"4.00";"4.08";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242473";"";"0";"315.38";"0";"3.64";"PP165";"Nc1ncnc2c1c(-c1ccc3ccccc3c1)nn2CC1CC1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242113";"";"0";"285.31";"0";"1.81";"PP347";"CCn1nc(-c2ccc(OC)c(O)c2)c2c(N)ncnc21";"IC50";"'='";"20.0";"nM";"7.70";"";"";"UO_0000065";"26.98";"0.50";"5.89";"7.77";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242201";"";"0";"325.37";"0";"2.90";"PP349";"COc1ccc(-c2nn(C3CCCC3)c3ncnc(N)c23)cc1O";"IC50";"'='";"40.0";"nM";"7.40";"";"";"UO_0000065";"22.74";"0.42";"4.50";"7.47";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL2030441";"";"0";"386.48";"0";"2.02";"20";"Cn1ccc2cc(-c3nc(CS(C)(=O)=O)cc(N4CCOCC4)n3)ccc21";"IC50";"'>'";"100000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2033327";"Inhibition of recombinant FLAG-tagged mTOR kinase expressed in HEK293 cells using Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2 as substrate after 90 mins";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2029234";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";"CHEMBL3307715"
"CHEMBL1914727";"";"0";"490.95";"1";"5.95";"16l";"O=S(=O)(Nc1cc(-c2ccc3nccc(-c4ccncc4)c3c2)cnc1Cl)c1ccc(F)cc1";"IC50";"'='";"0.41";"nM";"9.39";"";"";"UO_0000065";"19.12";"0.38";"3.44";"11.06";"False";"CHEMBL1919685";"Inhibition of mTOR using GFP-tagged 4E-BP1 after 1 hr by spectrophotometric analysis";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1914426";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL2030450";"";"0";"367.39";"0";"0.10";"31";"CS(=O)(=O)Cc1cc(N2CCOCC2)nc(NC(=O)c2ccno2)n1";"IC50";"'='";"37.0";"nM";"7.43";"";"";"UO_0000065";"20.23";"0.41";"7.33";"5.83";"False";"CHEMBL2033327";"Inhibition of recombinant FLAG-tagged mTOR kinase expressed in HEK293 cells using Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2 as substrate after 90 mins";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2029234";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";"CHEMBL3307715"
"CHEMBL3358288";"";"0";"367.41";"0";"2.20";"21";"COc1cncc(Nc2ncc(C(C)(C)O)cc2-c2nc(C)nc(N)n2)c1";"IC50";"'='";"2100.0";"nM";"5.68";"";"";"UO_0000065";"15.45";"0.29";"3.48";"4.30";"False";"CHEMBL3379685";"Inhibition of recombinant N-terminally GST-tagged mTOR (1360 to 2549 aa) (unknown origin) assessed as inhibition of 27BP1 phosphorylation after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352452";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3358287";"";"0";"397.44";"0";"2.21";"20";"COc1cc(Nc2ncc(C(C)(C)O)cc2-c2nc(C)nc(N)n2)cnc1OC";"IC50";"'='";"10600.0";"nM";"4.97";"";"";"UO_0000065";"12.52";"0.23";"2.76";"3.52";"False";"CHEMBL3379685";"Inhibition of recombinant N-terminally GST-tagged mTOR (1360 to 2549 aa) (unknown origin) assessed as inhibition of 27BP1 phosphorylation after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352452";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL573339";"PI-103";"0";"348.36";"0";"2.98";"PI-103";"Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1";"IC50";"'='";"14.0";"nM";"7.85";"";"";"UO_0000065";"22.55";"0.41";"4.87";"9.29";"False";"CHEMBL3784491";"Inhibition of human mTOR using ULight-4E-BP1 peptide as substrate after 1 hr by Lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3779897";"1";"Scientific Literature";"MedChemComm";"2016";""
"CHEMBL3963018";"";"0";"560.63";"2";"6.11";"13b; NSC765844";"COc1ncc(-c2ccc3nccc(-c4ccc(CN(C)C)cc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"3.8";"nM";"8.42";"";"";"UO_0000065";"15.02";"0.29";"2.31";"9.97";"False";"CHEMBL3867034";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide as substrate after 1 hr in presence of ATP by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3865829";"1";"Scientific Literature";"Eur J Med Chem";"2016";""
"CHEMBL1234815";"";"0";"275.31";"0";"2.77";"76, S2";"Cn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21";"IC50";"'='";"100000.0";"nM";"4.00";"";"";"UO_0000065";"14.53";"0.26";"1.23";"5.75";"False";"CHEMBL3223610";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3217752";"1";"Scientific Literature";"MedChemComm";"2012";""
"CHEMBL1945495";"";"0";"324.38";"0";"3.07";"14";"O=c1[nH]c2ncc(-c3ccc(O)cc3)nc2n1CC1CCCCC1";"IC50";"'='";"780.0";"nM";"6.11";"";"";"UO_0000065";"18.83";"0.35";"3.04";"7.29";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1241773";"";"0";"295.35";"0";"2.86";"PP31";"CC(=O)c1ccc(-c2nn(C(C)C)c3ncnc(N)c23)cc1";"IC50";"'='";"100000.0";"nM";"4.00";"";"";"UO_0000065";"13.54";"0.25";"1.14";"4.61";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1085178";"";"0";"386.48";"0";"2.10";"21, GNE-490";"Cc1nc(N)ncc1-c1nc(N2CCOCC2)c2sc(C(C)(C)O)cc2n1";"IC50";"'='";"750.0";"nM";"6.12";"";"";"UO_0000065";"15.85";"0.31";"4.02";"5.55";"False";"CHEMBL1103322";"Inhibition of human recombinant mTOR by FRET";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154879";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL3907354";"";"0";"323.36";"0";"2.84";"13";"CNc1noc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc12";"IC50";"'<'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3882339";"Inhibition of recombinant human GST-tagged mTOR (1360 to 2549 residues) catalytic domain assessed as inhibition of GFP labeled 4EBP1 phosphorylation measured after 1 hr by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3882246";"38";"Patent Bioactivity Data";"";"2010";""
"CHEMBL3799221";"";"0";"367.41";"0";"2.35";"8d";"CCOC(Cn1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc21)OCC";"IC50";"'='";"328.0";"nM";"6.48";"";"";"UO_0000065";"17.65";"0.33";"4.13";"5.55";"True";"CHEMBL3826741";"Inhibition of human mTOR using poly[Glu,Tyr]4:1 as substrate in presence of [gamma-33P]ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3822371";"1";"Scientific Literature";"J. Med. Chem.";"2016";""
"CHEMBL3824089";"";"0";"510.64";"1";"3.46";"11a";"COc1cc(-c2nn(CCN3CCC(N(C)C)CC3)c3ncnc(N)c23)ccc1NC(=O)OC(C)(C)C";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3826741";"Inhibition of human mTOR using poly[Glu,Tyr]4:1 as substrate in presence of [gamma-33P]ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3822371";"1";"Scientific Literature";"J. Med. Chem.";"2016";""
"CHEMBL3945869";"";"0";"325.33";"0";"1.35";"23";"CC(CO)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21";"IC50";"'<'";"100.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3882339";"Inhibition of recombinant human GST-tagged mTOR (1360 to 2549 residues) catalytic domain assessed as inhibition of GFP labeled 4EBP1 phosphorylation measured after 1 hr by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3882246";"38";"Patent Bioactivity Data";"";"2010";""
"CHEMBL1945955";"";"0";"376.42";"0";"2.60";"45";"O=c1[nH]c2ncc(-c3ccc(-c4ncc[nH]4)cc3)nc2n1CC1CCOCC1";"IC50";"'='";"273.0";"nM";"6.56";"";"";"UO_0000065";"17.44";"0.32";"3.96";"6.47";"False";"CHEMBL1949072";"Inhibition of mTOR-mediated S6 phosphorylation in human PC3 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";"CHEMBL3307570"
"CHEMBL1946133";"";"0";"351.37";"0";"1.48";"54";"O=c1[nH]c2ncc(-c3cnc4[nH]cnc4c3)nc2n1CC1CCOCC1";"IC50";"'='";"390.0";"nM";"6.41";"";"";"UO_0000065";"18.24";"0.34";"4.93";"5.60";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL3360068";"";"0";"431.52";"0";"2.27";"II";"COc1cc(/C=N/Nc2nc3c(c(N4CCOCC4)n2)CSCC3)cc(OC)c1O";"IC50";"'='";"800.0";"nM";"6.10";"";"";"UO_0000065";"14.13";"0.28";"3.83";"6.02";"False";"CHEMBL3815304";"Inhibition of mTOR (unknown origin) using ULight4E-BP1 peptide as substrate incubated for 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3813678";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2016";""
"CHEMBL1945491";"";"0";"348.36";"0";"2.55";"1";"COc1cccc(Cn2c(=O)[nH]c3ncc(-c4ccc(O)cc4)nc32)c1";"IC50";"'='";"1270.0";"nM";"5.90";"";"";"UO_0000065";"16.93";"0.31";"3.35";"6.34";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1945797";"";"0";"352.39";"0";"3.07";"33";"O=C(O)c1ccc(-c2cnc3[nH]c(=O)n(CC4CCCCC4)c3n2)cc1";"IC50";"'='";"130.0";"nM";"6.89";"";"";"UO_0000065";"19.54";"0.36";"3.82";"6.83";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1946132";"";"0";"348.41";"0";"3.24";"53";"O=c1[nH]c2ncc(-c3ccc4[nH]ncc4c3)nc2n1CC1CCCCC1";"IC50";"'='";"190.0";"nM";"6.72";"";"";"UO_0000065";"19.29";"0.35";"3.48";"7.29";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1945496";"";"0";"270.29";"0";"2.07";"15";"CC(C)n1c(=O)[nH]c2ncc(-c3ccc(O)cc3)nc21";"IC50";"'='";"1040.0";"nM";"5.98";"";"";"UO_0000065";"22.14";"0.41";"3.91";"7.14";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1945953";"";"0";"377.41";"0";"2.00";"2";"O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CC1CCOCC1";"IC50";"'='";"273.0";"nM";"6.56";"";"";"UO_0000065";"17.39";"0.32";"4.56";"5.74";"False";"CHEMBL1949072";"Inhibition of mTOR-mediated S6 phosphorylation in human PC3 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";"CHEMBL3307570"
"CHEMBL1631894";"";"0";"219.25";"0";"2.36";"12";"C(#Cc1n[nH]c2ccccc12)c1ccccn1";"IC50";"'>'";"100000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1633333";"Inhibition of mTOR by LanthaScreen Eu kinase binding assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL596533";"";"0";"470.58";"0";"3.87";"16";"Oc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccccc5)CC4)c3n2)c1";"IC50";"'='";"140.0";"nM";"6.85";"";"";"UO_0000065";"14.56";"0.27";"2.98";"8.62";"True";"CHEMBL1068429";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153170";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL572932";"";"0";"435.41";"0";"2.64";"8";"CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(CC(F)(F)F)c3n2)cc1";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"20.67";"0.40";"6.36";"9.26";"False";"CHEMBL1074679";"Inhibition of mTOR in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153200";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL601054";"";"0";"370.41";"0";"3.99";"18";"Oc1cccc(-c2nc(C3=CCOCC3)c3cnn(-c4ccccc4)c3n2)c1";"IC50";"'='";"18.0";"nM";"7.75";"";"";"UO_0000065";"20.91";"0.38";"3.75";"10.60";"False";"CHEMBL1074679";"Inhibition of mTOR in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153200";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL3765587";"";"0";"621.67";"1";"4.51";"7j";"CCOC(=O)N1CCN(CC#Cc2ccnc3ccc(-c4cnc(OC)c(NS(=O)(=O)c5ccc(F)cc5F)c4)cc23)CC1";"IC50";"'='";"9.9";"nM";"8.00";"";"";"UO_0000065";"12.88";"0.25";"3.49";"7.02";"False";"CHEMBL3766570";"Inhibition of mTOR kinase (unknown origin) assessed as suppression of ULight-4E-BP1 substrate phosphorylation incubated for 1 hr by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3763019";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2016";""
"CHEMBL1822058";"";"0";"417.85";"0";"3.57";"14";"Nc1cn2cc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1";"IC50";"'='";"20.0";"nM";"7.70";"";"";"UO_0000065";"18.43";"0.38";"4.13";"7.52";"False";"CHEMBL1828260";"Inhibition of recombinant N-terminal GST-tagged mTOR-mediated 4E-BP1 phosphorylation after 60 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1821651";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1092555";"";"0";"296.33";"0";"2.17";"6";"Oc1cccc(-c2nc(N3CCOCC3)c3[nH]ccc3n2)c1";"IC50";"'='";"355.0";"nM";"6.45";"";"";"UO_0000065";"21.77";"0.40";"4.28";"8.68";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1090115";"";"0";"399.40";"0";"4.87";"19";"COc1ccc2[nH]c(-c3ccccc3)c(/C=C3\Oc4cc(O)cc(O)c4C3=O)c2c1";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"20.03";"0.36";"3.13";"8.72";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091351";"";"0";"570.70";"1";"3.85";"22";"O=C(Nc1ccc(-c2nc(C3CCOCC3)nc(N3C4CCC3COC4)n2)cc1)Nc1ccc(N2CCNCC2)cc1";"IC50";"'='";"0.535";"nM";"9.27";"";"";"UO_0000065";"16.25";"0.30";"5.42";"7.94";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL566679";"";"0";"444.49";"1";"1.32";"4";"COc1cc(/C=N/Nc2cc(N3CCOCC3)nc(N3CCOCC3)n2)cc(OC)c1O";"IC50";"'='";"660.0";"nM";"6.18";"";"";"UO_0000065";"13.90";"0.26";"4.86";"5.43";"False";"CHEMBL1049650";"Inhibition of mTOR kinase in human HeLa cells by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HeLa";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156040";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3308376"
"CHEMBL567293";"";"0";"383.40";"0";"2.96";"12";"COc1cc(-c2ccc(-c3ccnc(N4CCOCC4)n3)o2)cc(OC)c1O";"IC50";"'='";"52.0";"nM";"7.28";"";"";"UO_0000065";"19.00";"0.36";"4.32";"8.09";"False";"CHEMBL1049650";"Inhibition of mTOR kinase in human HeLa cells by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HeLa";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156040";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3308376"
"CHEMBL3601925";"";"0";"556.62";"1";"3.20";"1e";"CCN(CC)CCNC(=O)Nc1nc2ccc(-c3cnc(OC)c(NS(=O)(=O)c4ccc(F)cc4)c3)cn2n1";"IC50";"'='";"123.0";"nM";"6.91";"";"";"UO_0000065";"12.41";"0.24";"3.71";"4.84";"False";"CHEMBL3602347";"Inhibition of mTOR (unknown origin) assessed as reduction of ATP level after 40 mins by luciferase based luminescence assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3600364";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2015";""
"CHEMBL1879463";"DACTOLISIB";"2";"469.55";"1";"5.89";"BEZ235";"Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21";"IC50";"'='";"89.0";"nM";"7.05";"";"";"UO_0000065";"15.02";"0.27";"1.16";"9.22";"False";"CHEMBL3602347";"Inhibition of mTOR (unknown origin) assessed as reduction of ATP level after 40 mins by luciferase based luminescence assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3600364";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2015";""
"CHEMBL1241357";"";"0";"226.24";"0";"1.18";"PP212";"Nc1cccc(-c2n[nH]c3ncnc(N)c23)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241242";"";"0";"227.23";"0";"1.31";"PP207";"Nc1ncnc2[nH]nc(-c3cccc(O)c3)c12";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL3327008";"";"0";"452.50";"0";"2.80";"2q";"COc1ccc(S(=O)(=O)Nc2cc(-c3cnc4nc(N)nc(C)c4c3)cnc2OC)cc1";"IC50";"'='";"180.0";"nM";"6.75";"";"";"UO_0000065";"14.91";"0.29";"3.94";"4.74";"False";"CHEMBL3380578";"Inhibition of mTOR (unknown origin) assessed as inhibition of 4EBP-1 phosphorylation preincubated for 15 mins before substrate addition by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3351642";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL1242752";"";"0";"327.39";"0";"3.06";"PP305";"CCOc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1OC";"IC50";"'='";"2400.0";"nM";"5.62";"";"";"UO_0000065";"17.17";"0.32";"2.56";"6.38";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL2348865";"";"0";"391.44";"0";"2.39";"9a, CC214-1";"O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CCC1CCOCC1";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"22.22";"0.41";"6.31";"7.61";"False";"CHEMBL2352069";"Inhibition of recombinant mTOR (unknown origin) using GST-p70S6 as substrate after 60 mins by TR-FRET analysis";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346597";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";""
"CHEMBL1762789";"";"0";"317.36";"0";"2.84";"24";"Cc1nc(N)nc(-n2c(Nc3ccccc3)nc3ccccc32)n1";"IC50";"'='";"420.0";"nM";"6.38";"";"";"UO_0000065";"20.09";"0.36";"3.54";"6.75";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1241582";"";"0";"283.34";"0";"2.15";"PP26";"CC(C)n1nc(-c2cccc(CO)c2)c2c(N)ncnc21";"IC50";"'='";"5400.0";"nM";"5.27";"";"";"UO_0000065";"18.59";"0.34";"3.12";"5.86";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242377";"";"0";"287.30";"0";"2.50";"PP262";"CC(C)n1nc(-c2ccc(F)c(O)c2)c2c(N)ncnc21";"IC50";"'='";"37.0";"nM";"7.43";"";"";"UO_0000065";"25.87";"0.48";"4.93";"8.27";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL3112718";"";"0";"458.45";"0";"3.07";"12";"COc1ncc(-c2cnc3nc(N)nc(C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"35.27";"nM";"7.45";"";"";"UO_0000065";"16.26";"0.32";"4.38";"5.60";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3112732";"";"0";"469.57";"0";"3.38";"9m";"COc1ncc(-c2cc3c(C)nc(N)cc3n(C3CCCC3)c2=O)cc1NS(=O)(=O)C1CC1";"IC50";"'='";"140.9";"nM";"6.85";"";"";"UO_0000065";"14.59";"0.28";"3.47";"5.30";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL1822056";"";"0";"403.83";"0";"3.38";"12";"O=S(=O)(Nc1cc(-c2ccc3nccn3n2)cnc1Cl)c1ccc(F)cc1";"IC50";"'='";"49.0";"nM";"7.31";"";"";"UO_0000065";"18.10";"0.37";"3.93";"8.19";"False";"CHEMBL1828260";"Inhibition of recombinant N-terminal GST-tagged mTOR-mediated 4E-BP1 phosphorylation after 60 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1821651";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1822214";"";"0";"419.89";"0";"4.95";"27";"O=S(=O)(Nc1cc(-c2ccc3sncc3c2)cnc1Cl)c1ccc(F)cc1";"IC50";"'='";"292.0";"nM";"6.54";"";"";"UO_0000065";"15.56";"0.33";"1.58";"9.08";"False";"CHEMBL1828260";"Inhibition of recombinant N-terminal GST-tagged mTOR-mediated 4E-BP1 phosphorylation after 60 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1821651";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL3798574";"";"0";"294.32";"0";"2.80";"INK128";"CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2cncnc21";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"30.58";"0.56";"6.20";"9.41";"False";"CHEMBL3802992";"Inhibition of recombinant human mTOR by LanthaScreen Kinase assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3797068";"1";"Scientific Literature";"MedChemComm";"2016";""
"CHEMBL1242751";"";"0";"313.36";"0";"2.67";"PP65";"COc1cccc(-c2nn(C(C)C)c3ncnc(N)c23)c1OC";"IC50";"'='";"5500.0";"nM";"5.26";"";"";"UO_0000065";"16.78";"0.31";"2.59";"5.97";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242469";"";"0";"312.31";"0";"2.22";"PP469";"N#CCCCn1nc(-c2ccc(F)c(O)c2)c2c(N)ncnc21";"IC50";"'='";"2200.0";"nM";"5.66";"";"";"UO_0000065";"18.12";"0.34";"3.44";"4.98";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1957857";"";"0";"406.41";"0";"3.02";"1";"Cc1c(Cn2c(C)cn3c(=O)cc(N4CCOCC4)nc23)cccc1C(F)(F)F";"IC50";"'='";"32000.0";"nM";"4.50";"";"";"UO_0000065";"11.06";"0.21";"1.47";"8.68";"False";"CHEMBL2019379";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2016550";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1312643";"";"0";"396.47";"0";"2.35";"1";"O=S(=O)(Cc1cc(N2CCOCC2)nc(-c2ccccn2)n1)c1ccccc1";"IC50";"'='";"1412.54";"nM";"5.85";"";"";"UO_0000065";"14.76";"0.29";"3.50";"6.86";"False";"CHEMBL3413521";"Inhibition of recombinant truncated FLAG-tagged mTOR (1362 to 2549 aa) (unknown origin) expressed in HEK293 cells using biotinylated p70 peptide as substrate";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407414";"1";"Scientific Literature";"J. Med. Chem.";"2015";"CHEMBL3307715"
"CHEMBL1241862";"";"0";"330.78";"0";"2.41";"PP32";"CC(C)n1nc(-c2ccc(C(N)=O)c(Cl)c2)c2c(N)ncnc21";"IC50";"'='";"10000.0";"nM";"5.00";"";"";"UO_0000065";"15.12";"0.30";"2.59";"4.44";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241675";"";"0";"319.37";"0";"2.84";"PP162";"Nc1ncnc2c1c(-c1ccn3ccnc3c1)nn2C1CCCC1";"IC50";"'='";"4800.0";"nM";"5.32";"";"";"UO_0000065";"16.65";"0.30";"2.48";"6.12";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1234815";"";"0";"275.31";"0";"2.77";"S2";"Cn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21";"IC50";"'='";"100000.0";"nM";"4.00";"";"";"UO_0000065";"14.53";"0.26";"1.23";"5.75";"True";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1762789";"";"0";"317.36";"0";"2.84";"24";"Cc1nc(N)nc(-n2c(Nc3ccccc3)nc3ccccc32)n1";"IC50";"'>'";"25000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760165";"";"0";"364.37";"0";"1.80";"39";"CNC(=O)c1ccc(Nc2nc3ccccc3n2-c2nc(C)nc(N)n2)o1";"IC50";"'='";"150.0";"nM";"6.82";"";"";"UO_0000065";"18.73";"0.35";"5.02";"4.99";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL3327147";"";"0";"423.46";"0";"2.18";"2t";"COc1ncc(-c2cnc3nc(N)nc(C)c3c2)cc1NS(=O)(=O)c1cccnc1";"IC50";"'='";"111.0";"nM";"6.96";"";"";"UO_0000065";"16.42";"0.32";"4.77";"4.77";"False";"CHEMBL3380578";"Inhibition of mTOR (unknown origin) assessed as inhibition of 4EBP-1 phosphorylation preincubated for 15 mins before substrate addition by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3351642";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL1760169";"";"0";"346.36";"0";"1.92";"43";"Cc1nc(NCC#N)nc(-n2c(Nc3cc[nH]n3)nc3ccccc32)n1";"IC50";"'='";"31.0";"nM";"7.51";"";"";"UO_0000065";"21.68";"0.39";"5.59";"5.64";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762780";"";"0";"334.34";"0";"2.67";"8";"COc1ncnc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'>'";"50000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762781";"";"0";"318.34";"0";"2.85";"9";"Nc1cc(-n2c(Nc3cccc(O)c3)nc3ccccc32)ncn1";"IC50";"'='";"3500.0";"nM";"5.46";"";"";"UO_0000065";"17.14";"0.31";"2.61";"5.36";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760163";"";"0";"307.32";"0";"1.57";"37";"Cc1nc(N)nc(-n2c(Nc3cn[nH]c3)nc3ccccc32)n1";"IC50";"'='";"5300.0";"nM";"5.28";"";"";"UO_0000065";"17.17";"0.31";"3.71";"4.28";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760172";"";"0";"343.30";"0";"1.85";"46";"Cc1nc(N)nc(-n2c(Nc3cc[nH]n3)nc3cc(F)c(F)cc32)n1";"IC50";"'='";"340.0";"nM";"6.47";"";"";"UO_0000065";"18.84";"0.35";"4.62";"5.25";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760159";"";"0";"321.35";"0";"1.58";"33";"Cc1nc(N)nc(-n2c(Nc3ccn(C)n3)nc3ccccc32)n1";"IC50";"'='";"580.0";"nM";"6.24";"";"";"UO_0000065";"19.41";"0.35";"4.66";"5.55";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760161";"";"0";"308.31";"0";"1.83";"35";"Cc1nc(N)nc(-n2c(Nc3ccon3)nc3ccccc32)n1";"IC50";"'='";"260.0";"nM";"6.58";"";"";"UO_0000065";"21.36";"0.39";"4.76";"5.46";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760169";"";"0";"346.36";"0";"1.92";"43";"Cc1nc(NCC#N)nc(-n2c(Nc3cc[nH]n3)nc3ccccc32)n1";"IC50";"'='";"73.0";"nM";"7.14";"";"";"UO_0000065";"20.60";"0.37";"5.22";"5.37";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760171";"";"0";"345.37";"0";"2.03";"45";"C#CCNc1nc(C)nc(-n2c(Nc3cc[nH]n3)nc3ccccc32)n1";"IC50";"'='";"80.0";"nM";"7.10";"";"";"UO_0000065";"20.55";"0.37";"5.07";"6.50";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1774367";"";"0";"427.51";"0";"2.25";"22e";"CCNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3c(n2)[C@@](C)(CCO)OC3)cc1";"IC50";"'='";"23.0";"nM";"7.64";"";"";"UO_0000065";"17.87";"0.34";"5.39";"7.02";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774372";"";"0";"468.60";"0";"3.21";"23d";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)[C@@](C)(CCN(C)C)OC3)cc1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774376";"";"0";"413.48";"0";"1.86";"29d";"CCNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3c(n2)[C@](C)(CO)OC3)cc1";"IC50";"'='";"32.0";"nM";"7.50";"";"";"UO_0000065";"18.13";"0.34";"5.63";"6.89";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774353";"";"0";"411.51";"0";"3.28";"13a";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)C(C)(C)OC3)cc1";"IC50";"'='";"13.0";"nM";"7.89";"";"";"UO_0000065";"19.16";"0.36";"4.61";"8.90";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774356";"";"0";"436.52";"0";"3.17";"13e";"C[C@H]1COCCN1c1nc(-c2ccc(NC(=O)NCCC#N)cc2)nc2c1COC2(C)C";"IC50";"'='";"30.0";"nM";"7.52";"";"";"UO_0000065";"17.23";"0.32";"4.35";"6.69";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774362";"";"0";"451.57";"0";"4.06";"21b";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)[C@](C)(CC2CC2)OC3)cc1";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"17.72";"0.33";"3.94";"9.03";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774367";"";"0";"427.51";"0";"2.25";"22e";"CCNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3c(n2)[C@@](C)(CCO)OC3)cc1";"IC50";"'='";"47.0";"nM";"7.33";"";"";"UO_0000065";"17.14";"0.32";"5.08";"6.73";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774369";"";"0";"450.54";"0";"3.56";"23a";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)[C@@](C)(CCC#N)OC3)cc1";"IC50";"'='";"14.0";"nM";"7.85";"";"";"UO_0000065";"17.43";"0.33";"4.29";"6.99";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774371";"";"0";"468.60";"0";"3.21";"23c";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)[C@](C)(CCN(C)C)OC3)cc1";"IC50";"'='";"42.0";"nM";"7.38";"";"";"UO_0000065";"15.74";"0.30";"4.17";"8.03";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774380";"";"0";"455.56";"0";"3.03";"29h";"CCNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3c(n2)[C@](C)(CC(C)(C)O)OC3)cc1";"IC50";"'='";"7.2";"nM";"8.14";"";"";"UO_0000065";"17.87";"0.34";"5.11";"7.48";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774382";"";"0";"455.56";"0";"3.03";"29j";"CCNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3c(n2)[C@@](C)(CC(C)(C)O)OC3)cc1";"IC50";"'='";"41.0";"nM";"7.39";"";"";"UO_0000065";"16.22";"0.31";"4.36";"6.79";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773735";"";"0";"476.94";"0";"4.91";"80";"CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccccc4F)c3)cc2s1";"IC50";"'='";"1.1";"nM";"8.96";"";"";"UO_0000065";"18.78";"0.39";"4.05";"8.87";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1762775";"";"0";"333.36";"0";"2.70";"3";"CNc1ncnc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"180.0";"nM";"6.75";"";"";"UO_0000065";"20.23";"0.37";"4.04";"6.69";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760153";"";"0";"360.38";"0";"1.94";"26";"Cc1nc(N)nc(-n2c(Nc3cccc(C(N)=O)c3)nc3ccccc32)n1";"IC50";"'='";"3900.0";"nM";"5.41";"";"";"UO_0000065";"15.01";"0.27";"3.47";"3.93";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760161";"";"0";"308.31";"0";"1.83";"35";"Cc1nc(N)nc(-n2c(Nc3ccon3)nc3ccccc32)n1";"IC50";"'='";"3300.0";"nM";"5.48";"";"";"UO_0000065";"17.78";"0.33";"3.65";"4.55";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760153";"";"0";"360.38";"0";"1.94";"26";"Cc1nc(N)nc(-n2c(Nc3cccc(C(N)=O)c3)nc3ccccc32)n1";"IC50";"'='";"190.0";"nM";"6.72";"";"";"UO_0000065";"18.65";"0.34";"4.78";"4.88";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760154";"";"0";"389.42";"0";"2.60";"27";"CNC(=O)Nc1ccc(Nc2nc3ccccc3n2-c2nc(C)nc(N)n2)cc1";"IC50";"'='";"11.0";"nM";"7.96";"";"";"UO_0000065";"20.44";"0.37";"5.36";"5.87";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760156";"";"0";"374.41";"0";"2.80";"29";"CC(=O)Nc1cccc(Nc2nc3ccccc3n2-c2nc(C)nc(N)n2)c1";"IC50";"'='";"120.0";"nM";"6.92";"";"";"UO_0000065";"18.48";"0.34";"4.12";"5.60";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760158";"";"0";"357.38";"0";"2.72";"31";"Cc1nc(N)nc(-n2c(Nc3ccc4cn[nH]c4c3)nc3ccccc32)n1";"IC50";"'='";"120.0";"nM";"6.92";"";"";"UO_0000065";"19.37";"0.35";"4.20";"5.62";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760170";"";"0";"360.39";"0";"2.31";"44";"Cc1nc(NCCC#N)nc(-n2c(Nc3cc[nH]n3)nc3ccccc32)n1";"IC50";"'='";"82.0";"nM";"7.09";"";"";"UO_0000065";"19.66";"0.36";"4.78";"5.33";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL3357868";"";"0";"385.40";"0";"2.34";"7";"COc1ncc(Nc2ncc(C(C)(C)O)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'='";"7800.0";"nM";"5.11";"";"";"UO_0000065";"13.25";"0.25";"2.77";"3.87";"False";"CHEMBL3379685";"Inhibition of recombinant N-terminally GST-tagged mTOR (1360 to 2549 aa) (unknown origin) assessed as inhibition of 27BP1 phosphorylation after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352452";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3907190";"";"0";"447.54";"0";"3.62";"BDBM245486";"CN(C)CCCOc1ccc(-c2ccc3ncc4[nH]c(=O)n(C5CCOCC5)c4c3c2)cn1";"IC50";"'='";"248.0";"nM";"6.61";"";"427896";"UO_0000065";"14.76";"0.27";"2.99";"7.75";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3898165";"";"0";"473.58";"0";"3.51";"BDBM245488";"Cn1c(=O)n([C@H]2C[C@@H](O)C2)c2c3cc(-c4ccc(OCCCN5CCCC5)nc4)ccc3ncc21";"IC50";"'='";"2580.0";"nM";"5.59";"";"427898";"UO_0000065";"11.80";"0.22";"2.08";"6.54";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3958682";"";"0";"479.56";"0";"3.77";"BDBM245491";"CO[C@H]1C[C@@H](n2c(=O)n(C)c3cnc4ccc(-c5ccc(OCCCN(C)C)nc5F)cc4c32)C1";"IC50";"'='";"3780.0";"nM";"5.42";"";"427901";"UO_0000065";"11.31";"0.21";"1.65";"7.29";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL4114060";"";"0";"505.59";"1";"4.31";"BDBM245497";"Cn1c(=O)n([C@@H]2CCCOC2)c2c3cc(-c4ccc(OCCCN5CCCC5)nc4)c(F)cc3ncc21";"IC50";"'>'";"9430.0";"nM";"";"";"427907";"UO_0000065";"";"";"";"";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3908403";"";"0";"549.59";"1";"3.55";"BDBM222649";"CCOC(=O)c1nc(-c2ccc(NC(=O)Nc3ccc(NC(C)=O)nc3)cc2)nc(N2CCOCC2)c1OCC";"IC50";"'='";"76.8";"nM";"7.12";"";"389438";"UO_0000065";"12.95";"0.24";"3.56";"4.53";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3979099";"";"0";"499.62";"0";"3.75";"BDBM222636";"CSc1cnc(-c2ccc(NC(=O)Nc3ccc(S(C)(=O)=O)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"148.5";"nM";"6.83";"";"389425";"UO_0000065";"13.67";"0.27";"3.08";"6.02";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3946937";"";"0";"423.45";"0";"3.77";"BDBM222552";"COc1cnc(-c2ccc(NC(=O)Nc3ccc(F)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"206.8";"nM";"6.68";"";"389341";"UO_0000065";"15.79";"0.29";"2.91";"7.54";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3952301";"";"0";"568.66";"1";"3.04";"BDBM222652";"CCOc1cnc(-c2ccc(NC(=O)Nc3ccc(S(=O)(=O)N4CCOCC4)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"155.1";"nM";"6.81";"";"389441";"UO_0000065";"11.97";"0.23";"3.77";"5.04";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3901120";"";"0";"581.70";"1";"3.10";"BDBM222641";"CCOc1cnc(-c2ccc(NC(=O)Nc3ccc(N4CCN(S(C)(=O)=O)CC4)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"65.7";"nM";"7.18";"";"389430";"UO_0000065";"12.35";"0.24";"4.08";"5.56";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3957931";"";"0";"449.47";"0";"3.33";"BDBM222616";"COc1cnc(-c2ccc(NC(=O)Nc3ccc(C(=O)O)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"65.7";"nM";"7.18";"";"389405";"UO_0000065";"15.98";"0.30";"3.85";"5.70";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL1879463";"DACTOLISIB";"2";"469.55";"1";"5.89";"BEZ-235";"Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21";"IC50";"'='";"11.5";"nM";"7.94";"";"";"UO_0000065";"16.91";"0.30";"2.05";"10.38";"False";"CHEMBL3579762";"Inhibition of mTOR (unknown origin) using GFP-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3576869";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL3639877";"";"0";"460.54";"0";"3.02";"BDBM174374";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1C#N";"IC50";"'='";"310.0";"nM";"6.51";"";"319691";"UO_0000065";"14.13";"0.26";"3.49";"6.74";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL1760172";"";"0";"343.30";"0";"1.85";"46";"Cc1nc(N)nc(-n2c(Nc3cc[nH]n3)nc3cc(F)c(F)cc32)n1";"IC50";"'='";"24.0";"nM";"7.62";"";"";"UO_0000065";"22.20";"0.42";"5.77";"6.18";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762777";"";"0";"410.44";"0";"3.67";"5";"Oc1cccc(Nc2nc3ccccc3n2-c2ncnc(NCc3ccccn3)n2)c1";"IC50";"'='";"21000.0";"nM";"4.68";"";"";"UO_0000065";"11.40";"0.21";"1.01";"4.12";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1336";"SORAFENIB";"4";"464.83";"1";"5.55";"5";"CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL3371129";"Inhibition of mTOR (unknown origin) using poly (Glu, Tyr) 4:1 substrate incubated for 30 mins by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352345";"1";"Scientific Literature";"Eur. J. Med. Chem.";"2014";""
"CHEMBL1762775";"";"0";"333.36";"0";"2.70";"3";"CNc1ncnc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"250.0";"nM";"6.60";"";"";"UO_0000065";"19.80";"0.36";"3.90";"6.55";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL3643163";"";"0";"474.57";"0";"3.79";"BDBM115804";"Cc1ncnc(-c2ccc(C(=O)N3CCN(c4ccccc4)CC3)cc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.0";"nM";"8.40";"";"240416";"UO_0000065";"17.70";"0.32";"4.61";"9.52";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643168";"";"0";"482.59";"0";"2.77";"BDBM115809";"Cc1ncnc(-c2ccc(C(=O)N3CCN(C4CCOCC4)CC3)cc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"240421";"UO_0000065";"17.66";"0.32";"5.75";"8.74";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643189";"";"0";"493.56";"0";"2.48";"BDBM115832";"CCc1ncnc(-c2ccc(C(=O)N(C)C3CCS(=O)(=O)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.0";"nM";"9.00";"";"240444";"UO_0000065";"18.23";"0.35";"6.52";"7.55";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643192";"";"0";"431.47";"0";"3.39";"BDBM115835";"CCc1ncnc(-c2ccc(C(=O)N3CCCCO3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"11.0";"nM";"7.96";"";"240447";"UO_0000065";"18.45";"0.34";"4.57";"8.45";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643141";"";"0";"501.03";"1";"3.90";"BDBM115757";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CC4CC4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.41";"nM";"8.27";"";"240486";"UO_0000065";"16.50";"0.31";"4.37";"9.37";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643149";"";"0";"447.93";"0";"2.94";"BDBM115765";"CCc1ncnc(-c2ccc(C(=O)N3CC[C@@H](O)C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.94";"nM";"8.40";"";"240496";"UO_0000065";"18.76";"0.36";"5.46";"7.99";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3670174";"";"0";"364.49";"0";"3.13";"BDBM111648";"CCc1ncnc(N2CCC(O)(C(C)C)CC2)c1C#Cc1ccc(C)nc1";"IC50";"'='";"23.0";"nM";"7.64";"";"232471";"UO_0000065";"20.96";"0.39";"4.51";"12.29";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670185";"";"0";"351.45";"0";"2.42";"BDBM111659";"CCOC1CCN(c2ncnc(CC)c2C#Cc2ccc(N)nc2)CC1";"IC50";"'='";"16.0";"nM";"7.80";"";"232482";"UO_0000065";"22.18";"0.41";"5.38";"10.10";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670190";"";"0";"341.44";"0";"0.98";"BDBM111665";"CCc1ncnc(N2CC[S+]([O-])CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"28.0";"nM";"7.55";"";"232488";"UO_0000065";"22.12";"0.43";"6.57";"8.89";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670213";"";"0";"345.41";"0";"1.69";"BDBM111689";"Cc1ncnc(N2CCn3c(C)cnc3C2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"97.0";"nM";"7.01";"";"232512";"UO_0000065";"20.30";"0.37";"5.32";"8.18";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670222";"";"0";"376.46";"0";"1.52";"BDBM111698";"CCc1ncnc(N2CCC3(CCNC3=O)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"30.0";"nM";"7.52";"";"232521";"UO_0000065";"19.98";"0.37";"6.00";"7.75";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670230";"";"0";"420.52";"0";"1.63";"BDBM111706";"Cc1ncnc(N2CCC(CC(=O)N3CCOCC3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"59.0";"nM";"7.23";"";"232529";"UO_0000065";"17.19";"0.32";"5.60";"7.42";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3643173";"";"0";"444.51";"0";"2.66";"BDBM115815";"CCc1ncnc(-c2ccc(C(=O)NC3CCN(C)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"15.0";"nM";"7.82";"";"240427";"UO_0000065";"17.60";"0.32";"5.16";"8.06";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643195";"";"0";"399.45";"0";"2.86";"BDBM115838";"CCc1ncnc(-c2ccc(C(=O)N3CCCO3)cc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"10.0";"nM";"8.00";"";"240450";"UO_0000065";"20.03";"0.36";"5.14";"8.49";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643200";"";"0";"417.44";"0";"3.14";"BDBM115843";"Cc1ncnc(-c2ccc(C(=O)N3CCCCO3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"17.0";"nM";"7.77";"";"240455";"UO_0000065";"18.61";"0.34";"4.63";"8.25";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643258";"";"0";"538.70";"1";"4.43";"BDBM115923";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CC4CCCCC4)CC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"15.89";"nM";"7.80";"";"240535";"UO_0000065";"14.48";"0.27";"3.37";"8.00";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643157";"";"0";"475.00";"0";"3.51";"BDBM115773";"CCc1ncnc(-c2ccc(C(=O)N3CCCN(C)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"22.0";"nM";"7.66";"";"240410";"UO_0000065";"16.12";"0.31";"4.15";"8.68";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643172";"";"0";"513.62";"1";"2.73";"BDBM115814";"CCc1ncnc(-c2ccc(C(=O)NC3CC(N4CCN(C)CC4)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"240426";"UO_0000065";"16.59";"0.31";"5.79";"8.50";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643140";"";"0";"445.50";"0";"2.82";"BDBM115756";"CCc1ncnc(-c2ccc(C(=O)N3CCC[C@H]3CO)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.4";"nM";"8.47";"";"240485";"UO_0000065";"19.01";"0.35";"5.65";"8.05";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643146";"";"0";"475.98";"0";"3.99";"BDBM115762";"CCc1ncnc(-c2ccc(C(=O)N3CCC(OC)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"6.2";"nM";"8.21";"";"240492";"UO_0000065";"17.24";"0.33";"4.22";"8.71";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3670159";"";"0";"364.45";"0";"1.52";"BDBM111633";"CCc1ncnc(N2CCCC(NC(C)=O)C2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"16.0";"nM";"7.80";"";"232456";"UO_0000065";"21.39";"0.39";"6.28";"8.03";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3643174";"";"0";"472.57";"0";"3.44";"BDBM115816";"CCc1ncnc(-c2ccc(C(=O)NC[C@H]3CCCN3CC)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"46.0";"nM";"7.34";"";"240428";"UO_0000065";"15.53";"0.29";"3.90";"7.56";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643211";"";"0";"486.60";"0";"3.78";"BDBM115854";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N(CC)CC)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"25.0";"nM";"7.60";"";"240466";"UO_0000065";"15.62";"0.29";"3.82";"8.62";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643230";"";"0";"504.03";"1";"4.36";"BDBM115876";"CCc1ncnc(-c2ccc(C(=O)N3CCC(C(C)(C)O)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.5";"nM";"8.35";"";"240488";"UO_0000065";"16.56";"0.32";"3.99";"7.93";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645780";"";"0";"522.70";"1";"4.87";"BDBM115958";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCCCCC4)CC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"11.54";"nM";"7.94";"";"240570";"UO_0000065";"15.19";"0.28";"3.07";"9.00";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3670165";"";"0";"351.41";"0";"1.51";"BDBM111639";"Cc1ncnc(N2CCC3(CC2)OCCO3)c1C#Cc1ccc(N)nc1";"IC50";"'='";"10.0";"nM";"8.00";"";"232462";"UO_0000065";"22.77";"0.42";"6.49";"9.26";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL1940142";"";"0";"375.44";"0";"2.66";"7";"Cc1ccc(-c2nc(N3CCOCC3)nc(-n3ccnc3C)n2)c2cc[nH]c12";"IC50";"'='";"84.0";"nM";"7.08";"";"";"UO_0000065";"18.85";"0.35";"4.42";"8.35";"False";"CHEMBL1942434";"Inhibition of mTOR-mediated p70S6K phosphorylation at Thr389 in human PC3 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1938252";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";"CHEMBL3307570"
"CHEMBL1082616";"";"0";"552.57";"2";"5.99";"18d";"COc1cc(F)c2[nH]c(-c3c(C)nn(C)c3C)c(/C=C3/Oc4ccc(NC(=O)Nc5cccnc5)cc4C3=O)c2c1";"IC50";"'='";"1.5";"nM";"8.82";"";"";"UO_0000065";"15.97";"0.29";"2.83";"7.16";"False";"CHEMBL1119658";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1158598";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL3407717";"";"0";"452.45";"1";"2.99";"10h";"O=c1c(/C=N/Nc2nc(N3CCOCC3)c3sccc3n2)coc2ccc([N+](=O)[O-])cc12";"IC50";"'='";"4620.0";"nM";"5.33";"";"";"UO_0000065";"11.79";"0.23";"2.35";"3.92";"False";"CHEMBL3414045";"Inhibition of mTOR kinase (unknown origin) using ULight-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407441";"1";"Scientific Literature";"Eur. J. Med. Chem.";"2015";""
"CHEMBL2088442";"";"0";"486.58";"1";"5.12";"III";"Fc1cccc(Cn2cc(/C=N/Nc3nc(N4CCOCC4)c4sccc4n3)c3ccccc32)c1";"IC50";"'>'";"30000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3414045";"Inhibition of mTOR kinase (unknown origin) using ULight-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407441";"1";"Scientific Literature";"Eur. J. Med. Chem.";"2015";""
"CHEMBL594431";"";"0";"634.79";"1";"3.84";"16d";"CS(=O)(=O)N1CCN(Cc2cc3nc(-c4ccc(NC(=O)Nc5ccncc5)cc4)nc(N4CC5CCC(C4)O5)c3s2)CC1";"IC50";"'='";"0.45";"nM";"9.35";"";"";"UO_0000065";"14.72";"0.29";"5.51";"7.03";"False";"CHEMBL1067293";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153098";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL603848";"";"0";"484.60";"0";"3.66";"33";"OCc1cccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)c1";"IC50";"'='";"90.0";"nM";"7.05";"";"";"UO_0000065";"14.54";"0.27";"3.39";"8.86";"False";"CHEMBL1074731";"Inhibition of human TOR in HEK293 cells by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153204";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL584362";"";"0";"380.45";"0";"1.96";"36";"Oc1cccc(-c2nc(N3CCOCC3)c3cnn(C4CCNCC4)c3n2)c1";"IC50";"'='";"215.0";"nM";"6.67";"";"";"UO_0000065";"17.53";"0.33";"4.71";"7.55";"False";"CHEMBL1074731";"Inhibition of human TOR in HEK293 cells by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153204";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL1879463";"DACTOLISIB";"2";"469.55";"1";"5.89";"NVP-BEZ235";"Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21";"IC50";"'='";"21.0";"nM";"7.68";"";"";"UO_0000065";"16.35";"0.29";"1.79";"10.04";"True";"CHEMBL3223610";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3217752";"1";"Scientific Literature";"MedChemComm";"2012";""
"CHEMBL2165016";"";"0";"478.56";"0";"1.77";"53";"COc1ccc(Nc2ncc(CN3CCN(C(=O)N(C)C)CC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"1400.0";"nM";"5.85";"";"";"UO_0000065";"12.23";"0.23";"4.08";"4.23";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165027";"";"0";"353.39";"0";"2.12";"37";"COCc1cnc(Nc2ccc(OC)nc2)c(-c2nc(C)nc(N)n2)c1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165023";"";"0";"388.23";"0";"2.73";"33";"COc1ccc(Nc2ncc(Br)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2158858";"";"0";"475.53";"0";"3.35";"11a";"CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccn2)cc1";"IC50";"'='";"18.0";"nM";"7.75";"";"";"UO_0000065";"16.29";"0.31";"4.39";"5.10";"False";"CHEMBL2161544";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2157945";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1091316";"";"0";"607.67";"1";"4.43";"6f";"Cn1cc(/C=C2\Oc3ccc(NC(=O)Nc4ccc(N5CCOCC5)nc4)cc3C2=O)c2c(N3CC4CCC(C3)O4)ccnc21";"IC50";"'='";"29.0";"nM";"7.54";"";"";"UO_0000065";"12.40";"0.23";"3.11";"6.12";"False";"CHEMBL1107893";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156282";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1093685";"";"0";"522.57";"1";"4.60";"6e";"Cn1cc(/C=C2\Oc3ccc(NC(=O)Nc4cccnc4)cc3C2=O)c2c(N3CC4CCC(C3)O4)ccnc21";"IC50";"'='";"14.3";"nM";"7.84";"";"";"UO_0000065";"15.01";"0.27";"3.24";"7.09";"False";"CHEMBL1107893";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156282";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1090434";"";"0";"424.46";"0";"4.61";"3a";"CNC(=O)Nc1ccc2c(c1)C(=O)/C(=C/c1cn(C)c3nccc(-c4ccccc4)c13)O2";"IC50";"'='";"37.0";"nM";"7.43";"";"";"UO_0000065";"17.51";"0.32";"2.82";"8.72";"False";"CHEMBL1107893";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156282";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL98350";"LY-294002";"0";"307.35";"0";"3.30";"LY-294002";"O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12";"IC50";"'='";"6796.0";"nM";"5.17";"";"";"UO_0000065";"16.81";"0.31";"1.87";"12.11";"False";"CHEMBL1919765";"Inhibition of MTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1914457";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2011";""
"CHEMBL590325";"";"0";"457.50";"0";"3.10";"16";"O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)c3nnn(C4CC4)c3n2)cc1";"IC50";"'='";"0.84";"nM";"9.08";"";"";"UO_0000065";"19.84";"0.36";"5.98";"7.38";"False";"CHEMBL1068073";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157707";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1091159";"";"0";"437.55";"0";"2.64";"27";"CCNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3ccn(CCN(C)C)c3n2)cc1";"IC50";"'='";"30.0";"nM";"7.52";"";"";"UO_0000065";"17.19";"0.32";"4.88";"8.59";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL601462";"";"0";"457.50";"0";"3.10";"20";"O=C(Nc1ccc(-c2nc(N3CCOCC3)c3nnn(C4CC4)c3n2)cc1)Nc1cccnc1";"IC50";"'='";"0.57";"nM";"9.24";"";"";"UO_0000065";"20.21";"0.37";"6.14";"7.52";"False";"CHEMBL1068073";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157707";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL595746";"";"0";"393.49";"0";"2.35";"35";"OCc1cccc(-c2nc(N3CCOCC3)c3ccn(C4CCNCC4)c3n2)c1";"IC50";"'='";"290.0";"nM";"6.54";"";"";"UO_0000065";"16.61";"0.31";"4.19";"8.67";"False";"CHEMBL1074731";"Inhibition of human TOR in HEK293 cells by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153204";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL2325703";"";"0";"400.50";"0";"2.74";"11";"CC(C)(c1cc(N2CCOCC2)nc(-c2cccc3[nH]ccc23)n1)S(C)(=O)=O";"IC50";"'='";"2700.0";"nM";"5.57";"";"";"UO_0000065";"13.90";"0.27";"2.83";"6.32";"False";"CHEMBL2330630";"Inhibition of mTOR-mediated AKT phosphorylation at serine 473 in human MDA-MB-468 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MDA-MB-468";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2321758";"1";"Scientific Literature";"J. Med. Chem.";"2013";"CHEMBL3308424"
"CHEMBL601689";"";"0";"429.51";"1";"5.20";"29";"O=C(Nc1ccncc1)Nc1ccc(-c2nc(C3=CCOCC3)c3sccc3n2)cc1";"IC50";"'='";"1.8";"nM";"8.74";"";"";"UO_0000065";"20.36";"0.39";"3.54";"9.82";"False";"CHEMBL1074679";"Inhibition of mTOR in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153200";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL2165025";"";"0";"339.36";"0";"1.98";"35";"COc1cnc(Nc2ccc(OC)nc2)c(-c2nc(C)nc(N)n2)c1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2336325";"VISTUSERTIB";"2";"462.55";"0";"2.50";"21, AZD2014";"CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"2.8";"nM";"8.55";"";"";"UO_0000065";"18.49";"0.34";"6.05";"9.23";"True";"CHEMBL2338832";"Inhibition of recombinant FLAG-tagged mTOR (1362 to 2549) (unknown origin) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331448";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";"CHEMBL3307715"
"CHEMBL2158862";"";"0";"503.59";"1";"3.92";"11f";"CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(C)c(S(=O)(=O)NC)c4)n3)ccn2)cc1";"IC50";"'='";"18.0";"nM";"7.75";"";"";"UO_0000065";"15.38";"0.29";"3.82";"5.61";"False";"CHEMBL2161544";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2157945";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL300389";"";"0";"355.83";"0";"3.73";"1";"OCCCNc1cc(-c2ccnc(Nc3cccc(Cl)c3)n2)ccn1";"IC50";"'='";"800.0";"nM";"6.10";"";"";"UO_0000065";"17.13";"0.33";"2.37";"7.35";"False";"CHEMBL2161544";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2157945";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2158859";"";"0";"489.56";"0";"3.61";"11b";"CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4cccc(S(=O)(=O)NC)c4)n3)ccn2)cc1";"IC50";"'='";"15.0";"nM";"7.82";"";"";"UO_0000065";"15.98";"0.31";"4.21";"5.67";"False";"CHEMBL2161544";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2157945";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL219410";"ZOTAROLIMUS";"3";"966.23";"3";"6.05";"3";"CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@H](n3cnnn3)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C";"IC50";"'='";"3.3";"nM";"8.48";"";"";"UO_0000065";"8.78";"0.17";"2.43";"3.88";"False";"CHEMBL871328";"Inhibitory activity against FKBP12";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1141950";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2005";""
"CHEMBL3800138";"";"0";"355.36";"0";"1.42";"14";"COC(Cn1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21)OC";"IC50";"'='";"25.0";"nM";"7.60";"";"";"UO_0000065";"21.39";"0.40";"6.18";"5.43";"False";"CHEMBL3802995";"Inhibition of human mTOR using (poly [Glu, Tyr] 4:1) as substrate assessed as incorporation of 33P in substrate by [gamma33P] ATP-based kinase assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3797068";"1";"Scientific Literature";"MedChemComm";"2016";""
"CHEMBL1808986";"";"0";"562.68";"1";"3.44";"17";"CC(C)Oc1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)N(C)CCN(C)C)cc3)cc2)nc(N2CCOCC2)n1";"IC50";"'='";"0.3";"nM";"9.52";"";"";"UO_0000065";"16.92";"0.32";"6.08";"7.62";"False";"CHEMBL1810297";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1806467";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL98350";"LY-294002";"0";"307.35";"0";"3.30";"K00235";"O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12";"IC50";"'='";"5000.0";"nM";"5.30";"";"";"UO_0000065";"17.25";"0.31";"2.00";"12.42";"False";"CHEMBL941421";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156476";"1";"Scientific Literature";"J. Biol. Chem.";"2007";""
"CHEMBL1945960";"";"0";"374.45";"0";"3.76";"50";"O=c1[nH]c2ncc(-c3ccc(-c4ccn[nH]4)cc3)nc2n1CC1CCCCC1";"IC50";"'='";"1690.0";"nM";"5.77";"";"";"UO_0000065";"15.41";"0.28";"2.01";"6.26";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762780";"";"0";"334.34";"0";"2.67";"8";"COc1ncnc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"1900.0";"nM";"5.72";"";"";"UO_0000065";"17.11";"0.31";"3.05";"5.84";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762785";"";"0";"332.37";"0";"3.16";"14";"Cc1nc(N)cc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"43.0";"nM";"7.37";"";"";"UO_0000065";"22.16";"0.40";"4.21";"7.23";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762787";"";"0";"388.39";"0";"2.60";"16";"COc1nc(NCC#N)nc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"2100.0";"nM";"5.68";"";"";"UO_0000065";"14.62";"0.27";"3.08";"4.24";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762776";"";"0";"401.35";"0";"3.63";"4";"Oc1cccc(Nc2nc3ccccc3n2-c2ncnc(NCC(F)(F)F)n2)c1";"IC50";"'>'";"25000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1945793";"";"0";"353.38";"0";"1.71";"22";"NC(=O)[C@H]1CC[C@@H](n2c(=O)[nH]c3ncc(-c4ccc(O)cc4)nc32)CC1";"IC50";"'='";"179.0";"nM";"6.75";"";"";"UO_0000065";"19.09";"0.35";"5.04";"5.32";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL413";"SIROLIMUS";"4";"914.19";"3";"6.18";"RAPAMYCIN";"CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1949073";"Inhibition of mTOR-mediated Akt phosphorylation in human PC3 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";"CHEMBL3307570"
"CHEMBL594217";"";"0";"359.41";"0";"1.26";"9";"CS(=O)(=O)c1ccc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)cc1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1074731";"Inhibition of human TOR in HEK293 cells by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153204";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL590112";"";"0";"484.60";"0";"3.95";"23";"Oc1cccc(-c2nc(N3CCOCC3)c3ncn(CC4CCN(Cc5ccccc5)CC4)c3n2)c1";"IC50";"'='";"600.0";"nM";"6.22";"";"";"UO_0000065";"12.84";"0.24";"2.27";"7.82";"False";"CHEMBL1074731";"Inhibition of human TOR in HEK293 cells by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153204";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL3822591";"";"0";"407.57";"0";"3.05";"7k";"Cc1ccc(-c2nn(CCN3CCC(CCN(C)C)CC3)c3ncnc(N)c23)cc1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3826741";"Inhibition of human mTOR using poly[Glu,Tyr]4:1 as substrate in presence of [gamma-33P]ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3822371";"1";"Scientific Literature";"J. Med. Chem.";"2016";""
"CHEMBL611630";"";"0";"320.36";"0";"2.34";"10";"c1cc2ccc(-c3nc(N4CCOCC4)c4nc[nH]c4n3)cc2[nH]1";"IC50";"'='";"150.0";"nM";"6.82";"";"";"UO_0000065";"21.30";"0.39";"4.48";"8.25";"False";"CHEMBL1074731";"Inhibition of human TOR in HEK293 cells by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153204";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL1945793";"";"0";"353.38";"0";"1.71";"22";"NC(=O)[C@H]1CC[C@@H](n2c(=O)[nH]c3ncc(-c4ccc(O)cc4)nc32)CC1";"IC50";"'>'";"5000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1949072";"Inhibition of mTOR-mediated S6 phosphorylation in human PC3 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";"CHEMBL3307570"
"CHEMBL3109138";"";"0";"322.37";"0";"2.02";"12b";"OCc1cccc(-c2nc(N3CCOCC3)c3cccnc3n2)c1";"IC50";"'='";"127.0";"nM";"6.90";"";"";"UO_0000065";"21.39";"0.39";"4.88";"9.66";"False";"CHEMBL3112126";"Inhibition of mTOR (unknown origin) after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3108735";"1";"Scientific Literature";"J. Med. Chem.";"2014";""
"CHEMBL3109126";"";"0";"322.37";"0";"2.02";"4e";"OCc1cccc(-c2nc(N3CCOCC3)c3ncccc3n2)c1";"IC50";"'='";"336.0";"nM";"6.47";"";"";"UO_0000065";"20.08";"0.37";"4.45";"9.07";"False";"CHEMBL3112126";"Inhibition of mTOR (unknown origin) after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3108735";"1";"Scientific Literature";"J. Med. Chem.";"2014";""
"CHEMBL1957504";"";"0";"476.54";"0";"1.17";"25d";"O=C(NCCN1CCOCC1)c1cn2cc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)c2n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1959594";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1955823";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1945787";"";"0";"286.29";"0";"1.14";"16";"COCCn1c(=O)[nH]c2ncc(-c3ccc(O)cc3)nc21";"IC50";"'='";"2380.0";"nM";"5.62";"";"";"UO_0000065";"19.64";"0.37";"4.48";"6.04";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1945798";"";"0";"337.43";"0";"2.83";"34";"NCc1ccc(-c2cnc3[nH]c(=O)n(CC4CCCCC4)c3n2)cc1";"IC50";"'='";"8300.0";"nM";"5.08";"";"";"UO_0000065";"15.06";"0.28";"2.25";"5.67";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1945959";"";"0";"375.43";"0";"4.02";"49";"O=c1[nH]c2ncc(-c3ccc(-c4cnco4)cc3)nc2n1CC1CCCCC1";"IC50";"'='";"1360.0";"nM";"5.87";"";"";"UO_0000065";"15.63";"0.29";"1.85";"6.55";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL406237";"";"0";"606.72";"1";"3.07";"Table S1, S18";"COC[C@H]1OC(=O)/C(=C/N2CCN(Cc3ccccc3)CC2)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"890.0";"nM";"6.05";"";"";"UO_0000065";"9.97";"0.19";"2.98";"4.81";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL272593";"";"0";"547.60";"1";"2.05";"Table S1, S12";"COC[C@H]1OC(=O)/C(=C/N(C)CCCC(=O)O)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"12600.0";"nM";"4.90";"";"";"UO_0000065";"8.95";"0.17";"2.85";"3.06";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL407215";"";"0";"588.70";"2";"1.91";"Table S1, S8";"COC[C@H]1OC(=O)/C(=C/N(C)CCCN2CCOCC2)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"2290.0";"nM";"5.64";"";"";"UO_0000065";"9.58";"0.18";"3.73";"4.18";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL405258";"";"0";"693.84";"2";"3.41";"Table S1, S9";"COC[C@H]1OC(=O)/C(=C/N(C)CCCN2CCN(c3ccc(OC)cc3)CC2)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"1350.0";"nM";"5.87";"";"";"UO_0000065";"8.46";"0.16";"2.46";"4.24";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL428873";"";"0";"501.58";"1";"2.35";"12";"COC[C@H]1OC(=O)/C(=C/N2CCCC2)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'>'";"20000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL408074";"";"0";"643.78";"2";"1.59";"Table S1, S23";"COC[C@H]1OC(=O)/C(=C/N2CCN(CCCN3CCOCC3)CC2)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"1200.0";"nM";"5.92";"";"";"UO_0000065";"9.20";"0.18";"4.33";"4.28";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL411907";"SONOLISIB";"2";"525.60";"1";"3.13";"4, PX-866";"C=CCN(/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)C(=O)CC[C@@H]12)CC=C";"IC50";"'='";"3100.0";"nM";"5.51";"";"";"UO_0000065";"10.48";"0.20";"2.38";"4.61";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL1945788";"";"0";"284.32";"0";"2.15";"17";"CC(C)Cn1c(=O)[nH]c2ncc(-c3ccc(O)cc3)nc21";"IC50";"'='";"1020.0";"nM";"5.99";"";"";"UO_0000065";"21.07";"0.39";"3.84";"7.15";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1256451";"";"0";"551.57";"2";"6.18";"23";"O=c1ccc2cnc3ccc(-c4cncc5ccccc45)cc3c2n1-c1ccc(N2CCNCC2)c(C(F)(F)F)c1";"IC50";"'='";"33.2";"nM";"7.48";"";"";"UO_0000065";"13.56";"0.25";"1.30";"11.86";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1256464";"";"0";"621.66";"2";"7.14";"43";"CCC(=O)N1CCN(c2ccc(-n3c(=O)cc(C)c4cnc5ccc(-c6cnc7ccccc7c6)cc5c43)cc2C(F)(F)F)CC1";"IC50";"'='";"51.9";"nM";"7.29";"";"";"UO_0000065";"11.72";"0.22";"0.14";"10.21";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1258516";"";"0";"488.55";"0";"2.78";"8l";"O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1)Nc1cccnc1";"IC50";"'='";"0.5";"nM";"9.30";"";"";"UO_0000065";"19.04";"0.35";"6.52";"7.91";"False";"CHEMBL1259905";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255533";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1241584";"";"0";"329.41";"0";"4.34";"PP228";"Nc1ncnc2c1c(-c1ccc3ccccc3c1)nn2C1CCCC1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1256459";"TORIN1";"0";"607.64";"2";"6.83";"37";"CCC(=O)N1CCN(c2ccc(-n3c(=O)ccc4cnc5ccc(-c6cnc7ccccc7c6)cc5c43)cc2C(F)(F)F)CC1";"IC50";"'='";"4.32";"nM";"8.37";"";"";"UO_0000065";"13.77";"0.25";"1.53";"11.73";"False";"CHEMBL1261705";"Inhibition of human mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1242206";"";"0";"331.38";"0";"3.19";"PP216";"Cn1nc(-c2ccc(OCc3ccccc3)cc2)c2c(N)ncnc21";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242382";"";"0";"365.44";"0";"4.47";"PP230";"Nc1ncnc2c1c(-c1ccc3ccccc3c1)nn2CCc1ccccc1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241680";"";"0";"296.31";"0";"2.67";"PP150";"CC(C)n1nc(-c2ccc(F)c(C#N)c2)c2c(N)ncnc21";"IC50";"'='";"100000.0";"nM";"4.00";"";"";"UO_0000065";"13.50";"0.25";"1.33";"4.28";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL535";"SUNITINIB";"4";"398.48";"0";"3.33";"Sunitinib";"CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C";"IC50";"'>'";"50000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242289";"";"0";"339.40";"0";"3.29";"PP98";"CCOc1ccc(-c2nn(C3CCCC3)c3ncnc(N)c23)cc1O";"IC50";"'='";"110.0";"nM";"6.96";"";"";"UO_0000065";"20.50";"0.38";"3.67";"7.02";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1240566";"";"0";"264.29";"0";"2.09";"PP119";"Cn1nc(-c2ccc3cc[nH]c3c2)c2c(N)ncnc21";"IC50";"'='";"8300.0";"nM";"5.08";"";"";"UO_0000065";"19.22";"0.35";"2.99";"5.95";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242666";"";"0";"320.36";"0";"2.95";"PP43";"CC(C)n1nc(-c2ccc3c(C=O)c[nH]c3c2)c2c(N)ncnc21";"IC50";"'='";"220.0";"nM";"6.66";"";"";"UO_0000065";"20.78";"0.38";"3.71";"6.50";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242381";"";"0";"343.39";"0";"1.72";"PP496";"COc1ccc(-c2nn(C[C@@H](C)CO)c3ncnc(N)c23)cc1OC";"IC50";"'='";"1200.0";"nM";"5.92";"";"";"UO_0000065";"17.24";"0.32";"4.20";"5.47";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1258183";"";"0";"517.59";"1";"2.88";"8f";"O=C(Nc1ccc(CO)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3C4CCC3COC4)n2)cc1";"IC50";"'='";"0.43";"nM";"9.37";"";"";"UO_0000065";"18.10";"0.34";"6.49";"7.50";"False";"CHEMBL1259905";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255533";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1258995";"";"0";"543.55";"2";"7.01";"15";"O=C(O)N1CCN(c2ccc(Nc3ccnc4ccc(-c5cnc6ccccc6c5)cc34)cc2C(F)(F)F)CC1";"IC50";"'='";"1700.0";"nM";"5.77";"";"";"UO_0000065";"10.61";"0.20";"-1.24";"7.07";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1259031";"";"0";"556.61";"2";"6.85";"21";"O=c1ccc2cnc3ccc(-c4csc5ccccc45)cc3c2n1-c1ccc(N2CCNCC2)c(C(F)(F)F)c1";"IC50";"'='";"93.8";"nM";"7.03";"";"";"UO_0000065";"12.63";"0.24";"0.18";"14.01";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1957508";"";"0";"435.49";"0";"1.88";"25h";"COCCCNC(=O)c1cn2cc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)c2n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1959594";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1955823";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL371029";"";"0";"672.78";"1";"0.48";"268";"CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)N[C@H](CCc2ccccc2)C(=O)NCC(=O)N(C)CC(=O)O[C@H]1C";"IC50";"'='";"9.6";"nM";"8.02";"";"";"UO_0000065";"11.92";"0.23";"7.54";"4.43";"False";"CHEMBL881403";"Inhibitory concentration against FKBP12 receptor";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143652";"1";"Scientific Literature";"J. Med. Chem.";"2005";""
"CHEMBL600447";"";"0";"380.47";"0";"4.30";"25";"CCNC(=O)Nc1ccc(-c2nc(C3=CCOCC3)c3sccc3n2)cc1";"IC50";"'='";"3.3";"nM";"8.48";"";"";"UO_0000065";"22.29";"0.43";"4.18";"11.14";"False";"CHEMBL1074679";"Inhibition of mTOR in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153200";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL593283";"";"0";"325.33";"0";"1.59";"12";"c1nc2c(N3CCOCC3)nc(-c3ccc4c(c3)OCO4)nc2[nH]1";"IC50";"'='";"8900.0";"nM";"5.05";"";"";"UO_0000065";"15.52";"0.29";"3.46";"5.91";"False";"CHEMBL1074731";"Inhibition of human TOR in HEK293 cells by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153204";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL604876";"";"0";"287.35";"0";"1.92";"21";"c1csc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)c1";"IC50";"'='";"2800.0";"nM";"5.55";"";"";"UO_0000065";"19.32";"0.38";"3.63";"8.30";"False";"CHEMBL1074731";"Inhibition of human TOR in HEK293 cells by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153204";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL1762776";"";"0";"401.35";"0";"3.63";"4";"Oc1cccc(Nc2nc3ccccc3n2-c2ncnc(NCC(F)(F)F)n2)c1";"IC50";"'='";"3200.0";"nM";"5.50";"";"";"UO_0000065";"13.69";"0.26";"1.86";"5.45";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL2165037";"";"0";"342.37";"0";"3.34";"17";"Cc1nc(-c2cccnc2Nc2cccc3n[nH]cc23)c2[nH]cnc2n1";"IC50";"'='";"530.0";"nM";"6.28";"";"";"UO_0000065";"18.33";"0.33";"2.94";"5.81";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL3360068";"";"0";"431.52";"0";"2.27";"7e";"COc1cc(/C=N/Nc2nc3c(c(N4CCOCC4)n2)CSCC3)cc(OC)c1O";"IC50";"'='";"800.0";"nM";"6.10";"";"";"UO_0000065";"14.13";"0.28";"3.83";"6.02";"True";"CHEMBL3371734";"Inhibition of mTOR kinase (unknown origin) after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352220";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2014";""
"CHEMBL3355072";"";"0";"407.50";"0";"3.24";"5";"C[C@@H]1Cn2ncc(-c3ccc(S(C)(=O)=O)cc3)c2CN1c1ccnc2[nH]ccc12";"IC50";"'='";"1100.0";"nM";"5.96";"";"";"UO_0000065";"14.62";"0.28";"2.72";"7.10";"False";"CHEMBL3379631";"Inhibition of mTOR (unknown origin) by alphascreen SureFire p70 S6K (p-Thr389) assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3351372";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL3355074";"";"0";"448.98";"0";"2.96";"7";"C[C@@H]1Cn2ncc(C3CCN(S(C)(=O)=O)CC3)c2CN1c1cc(Cl)nc2[nH]ccc12";"IC50";"'='";"4400.0";"nM";"5.36";"";"";"UO_0000065";"11.93";"0.24";"2.40";"6.15";"False";"CHEMBL3379631";"Inhibition of mTOR (unknown origin) by alphascreen SureFire p70 S6K (p-Thr389) assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3351372";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL3823212";"";"0";"379.51";"0";"2.41";"7i";"Cc1ccc(-c2nn(CCN3CCC(N(C)C)CC3)c3ncnc(N)c23)cc1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3826741";"Inhibition of human mTOR using poly[Glu,Tyr]4:1 as substrate in presence of [gamma-33P]ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3822371";"1";"Scientific Literature";"J. Med. Chem.";"2016";""
"CHEMBL2165045";"";"0";"293.33";"0";"2.88";"25";"Cc1cc(-c2cccnc2Nc2cccc(O)c2)nc(N)n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2172486";"";"0";"399.42";"0";"2.31";"13";"Cc1nc(N)nc(-c2c(Nc3cc[nH]n3)nc3ccc(-c4cncnc4C)cn23)n1";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"21.34";"0.39";"6.21";"5.74";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2165020";"";"0";"484.59";"0";"2.19";"57";"COc1ccc(Nc2ncc(CC3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165042";"";"0";"342.37";"0";"3.34";"22";"Cc1nc(-c2cccnc2Nc2cccc3n[nH]cc23)c2c[nH]nc2n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064405";"";"0";"326.36";"0";"1.35";"33";"Cn1c(Cc2nc3ccccc3o2)nc(N2CCOCC2)cc1=O";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2030447";"";"0";"386.48";"0";"2.39";"27";"C[C@@H]1COCCN1c1cc(CS(C)(=O)=O)nc(-c2ccc3[nH]ccc3c2)n1";"IC50";"'='";"385.0";"nM";"6.42";"";"";"UO_0000065";"16.60";"0.32";"4.02";"7.27";"False";"CHEMBL2033327";"Inhibition of recombinant FLAG-tagged mTOR kinase expressed in HEK293 cells using Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2 as substrate after 90 mins";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2029234";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";"CHEMBL3307715"
"CHEMBL2030451";"";"0";"485.54";"0";"3.31";"32";"CS(=O)(=O)Cc1cc(N2CCOCC2)nc(-c2ccc(NC(=O)Nc3ccc(F)cc3)cc2)n1";"IC50";"'='";"28.0";"nM";"7.55";"";"";"UO_0000065";"15.56";"0.30";"4.24";"6.65";"True";"CHEMBL2033327";"Inhibition of recombinant FLAG-tagged mTOR kinase expressed in HEK293 cells using Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2 as substrate after 90 mins";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2029234";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";"CHEMBL3307715"
"CHEMBL1928561";"";"0";"428.43";"0";"1.44";"5";"Cc1ccc([N+](=O)[O-])cc1S(=O)(=O)N(CCO)/N=C/c1cnn2ccc(C#N)cc12";"IC50";"'='";"234.0";"nM";"6.63";"";"";"UO_0000065";"15.48";"0.30";"5.19";"4.30";"False";"CHEMBL1932645";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1926530";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2012";""
"CHEMBL2158865";"";"0";"538.03";"1";"4.60";"11i";"CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(Cl)c(S(=O)(=O)N(C)C)c4)n3)ccn2)cc1";"IC50";"'='";"12.0";"nM";"7.92";"";"";"UO_0000065";"14.72";"0.29";"3.32";"6.13";"False";"CHEMBL2161544";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2157945";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2158864";"";"0";"524.01";"1";"4.26";"11h";"CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(Cl)c(S(=O)(=O)NC)c4)n3)ccn2)cc1";"IC50";"'='";"7.7";"nM";"8.11";"";"";"UO_0000065";"15.48";"0.31";"3.85";"5.88";"False";"CHEMBL2161544";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2157945";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1940141";"";"0";"443.43";"0";"3.62";"6";"CCc1cc(C(F)(F)F)nn1-c1nc(-c2cccc3[nH]ccc23)nc(N2CCOCC2)n1";"IC50";"'='";"71.0";"nM";"7.15";"";"";"UO_0000065";"16.12";"0.31";"3.53";"8.44";"False";"CHEMBL1942431";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1938252";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1241948";"";"0";"346.42";"0";"2.03";"PP38";"CC(C)n1nc(-c2cccc(NS(C)(=O)=O)c2)c2c(N)ncnc21";"IC50";"'='";"5000.0";"nM";"5.30";"";"";"UO_0000065";"15.30";"0.30";"3.27";"4.58";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242111";"";"0";"313.34";"0";"3.04";"PP78";"Nc1ncnc2c1c(-c1cccc(O)c1F)nn2C1CCCC1";"IC50";"'='";"692.0";"nM";"6.16";"";"";"UO_0000065";"19.66";"0.37";"3.12";"6.86";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241949";"";"0";"319.37";"0";"2.79";"PP146";"CC(C)n1nc(-c2ccc3nc(N)ccc3c2)c2c(N)ncnc21";"IC50";"'='";"33.0";"nM";"7.48";"";"";"UO_0000065";"23.43";"0.43";"4.69";"6.89";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL606423";"";"0";"548.65";"1";"3.79";"4b";"CNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(C4CCN(C(=O)OC(C)C)CC4)c3n2)cc1";"IC50";"'='";"0.19";"nM";"9.72";"";"";"UO_0000065";"17.72";"0.33";"5.93";"7.67";"False";"CHEMBL1068272";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156873";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL600084";"";"0";"562.68";"1";"4.18";"4c";"CNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(C4CCN(C(=O)OC(C)(C)C)CC4)c3n2)cc1";"IC50";"'='";"0.26";"nM";"9.59";"";"";"UO_0000065";"17.03";"0.32";"5.41";"7.56";"False";"CHEMBL1068272";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156873";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL600811";"";"0";"407.48";"0";"2.63";"3b";"CCn1ncc2c(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)NC)cc3)nc21";"IC50";"'='";"0.74";"nM";"9.13";"";"";"UO_0000065";"22.41";"0.42";"6.50";"9.39";"False";"CHEMBL1068272";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156873";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1914724";"";"0";"589.10";"2";"5.61";"16e";"O=S(=O)(Nc1cc(-c2ccc3nccc(N4CCN(Cc5ccncc5)CC4)c3c2)cnc1Cl)c1ccc(F)cc1";"IC50";"'='";"3.9";"nM";"8.41";"";"";"UO_0000065";"14.27";"0.28";"2.80";"9.21";"False";"CHEMBL1919685";"Inhibition of mTOR using GFP-tagged 4E-BP1 after 1 hr by spectrophotometric analysis";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1914426";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1914726";"";"0";"490.95";"1";"5.95";"16k";"O=S(=O)(Nc1cc(-c2ccc3nccc(-c4cccnc4)c3c2)cnc1Cl)c1ccc(F)cc1";"IC50";"'='";"1.6";"nM";"8.80";"";"";"UO_0000065";"17.92";"0.35";"2.85";"10.37";"False";"CHEMBL1919685";"Inhibition of mTOR using GFP-tagged 4E-BP1 after 1 hr by spectrophotometric analysis";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1914426";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1672328";"";"0";"380.41";"0";"1.50";"17";"COc1ccc(Nc2cc(-c3cnc(N)nc3)nc(N3CCOCC3)n2)cn1";"IC50";"'='";"4000.0";"nM";"5.40";"";"";"UO_0000065";"14.19";"0.26";"3.90";"4.35";"False";"CHEMBL1680120";"Inhibition of mTOR after 15 mins";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1671825";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2011";""
"CHEMBL1945559";"";"0";"363.25";"0";"2.96";"20";"Cn1c2c(c3ccc(Cl)c(Cl)c31)C(C#N)C1(CCNCC1)NC2=O";"IC50";"'>'";"9100.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1948134";"Inhibition of mTOR using ATP as substrate";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944596";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL602841";"";"0";"394.48";"0";"1.75";"26";"OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCNCC4)c3n2)c1";"IC50";"'='";"7200.0";"nM";"5.14";"";"";"UO_0000065";"13.04";"0.24";"3.39";"5.82";"False";"CHEMBL1074731";"Inhibition of human TOR in HEK293 cells by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153204";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL611021";"";"0";"295.35";"0";"2.72";"16";"Oc1cccc(-c2nc(N3CCCCC3)c3nc[nH]c3n2)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1074731";"Inhibition of human TOR in HEK293 cells by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153204";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL593514";"";"0";"271.28";"0";"1.45";"14";"c1nc2c(N3CCOCC3)nc(-c3ccoc3)nc2[nH]1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1074731";"Inhibition of human TOR in HEK293 cells by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153204";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL592917";"";"0";"458.55";"0";"4.76";"9h";"O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3sccc3n2)cc1";"IC50";"'='";"0.44";"nM";"9.36";"";"";"UO_0000065";"20.40";"0.39";"4.60";"10.14";"False";"CHEMBL1067293";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153098";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL596426";"";"0";"533.70";"1";"3.76";"13b";"CN1CCN(Cc2cc3nc(-c4ccc(NC(=O)NC5CC5)cc4)nc(N4CC5CCC(C4)O5)c3s2)CC1";"IC50";"'='";"16.0";"nM";"7.80";"";"";"UO_0000065";"14.61";"0.28";"4.04";"9.08";"False";"CHEMBL1067293";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153098";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL583228";"";"0";"561.69";"1";"4.72";"27";"OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccc(-c6ccncc6)cc5)CC4)c3n2)c1";"IC50";"'='";"720.0";"nM";"6.14";"";"";"UO_0000065";"10.94";"0.20";"1.42";"6.65";"False";"CHEMBL1068429";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153170";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL504547";"";"0";"486.26";"0";"3.66";"89d";"O=C1NC(=O)c2ccc(I)cc2/C1=C/NCc1ccc(-c2ccoc2)c(O)c1";"IC50";"'='";"18000.0";"nM";"4.75";"";"";"UO_0000065";"9.76";"0.23";"1.08";"5.18";"False";"CHEMBL1011859";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153424";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL599258";"";"0";"463.50";"0";"1.65";"20";"O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1)Nc1ccnnc1";"IC50";"'='";"2.3";"nM";"8.64";"";"";"UO_0000065";"18.64";"0.35";"6.99";"6.62";"False";"CHEMBL1065057";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157610";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1822053";"";"0";"419.89";"0";"4.95";"9";"O=S(=O)(Nc1cc(-c2ccc3ncsc3c2)cnc1Cl)c1ccc(F)cc1";"IC50";"'='";"33.0";"nM";"7.48";"";"";"UO_0000065";"17.82";"0.38";"2.53";"10.40";"False";"CHEMBL1828260";"Inhibition of recombinant N-terminal GST-tagged mTOR-mediated 4E-BP1 phosphorylation after 60 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1821651";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL2158843";"";"0";"400.46";"0";"1.72";"9a";"NS(=O)(=O)c1cccc(Nc2nccc(-c3ccnc(NCCCO)c3)n2)c1";"IC50";"'='";"320.0";"nM";"6.50";"";"";"UO_0000065";"16.22";"0.32";"4.77";"4.54";"False";"CHEMBL2161544";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2157945";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL590355";"";"0";"372.43";"0";"4.08";"19";"Oc1cccc(-c2nc(C3CCOCC3)c3cnn(-c4ccccc4)c3n2)c1";"IC50";"'='";"500.0";"nM";"6.30";"";"";"UO_0000065";"16.92";"0.31";"2.22";"8.62";"False";"CHEMBL1074679";"Inhibition of mTOR in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153200";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL600366";"";"0";"581.68";"2";"5.36";"8e";"O=C(Nc1ccccc1)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(C4CCC5(CC4)OCCO5)c3n2)cc1";"IC50";"'='";"0.16";"nM";"9.80";"";"";"UO_0000065";"16.84";"0.31";"4.44";"8.47";"False";"CHEMBL1068272";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156873";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL565428";"";"0";"394.43";"0";"2.77";"9";"COc1cc(-c2cccc(-c3ccnc(N4CCOCC4)n3)n2)cc(OC)c1O";"IC50";"'='";"550.0";"nM";"6.26";"";"";"UO_0000065";"15.87";"0.29";"3.49";"6.97";"False";"CHEMBL1049650";"Inhibition of mTOR kinase in human HeLa cells by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HeLa";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156040";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3308376"
"CHEMBL567095";"";"0";"408.46";"0";"2.78";"17";"Oc1cccc(-c2ccc(-c3cc(N4CCOCC4)nc(N4CCOCC4)n3)o2)c1";"IC50";"'='";"1500.0";"nM";"5.82";"";"";"UO_0000065";"14.26";"0.27";"3.04";"6.93";"False";"CHEMBL1049650";"Inhibition of mTOR kinase in human HeLa cells by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HeLa";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156040";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3308376"
"CHEMBL599668";"";"0";"462.51";"0";"2.25";"18";"O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1)Nc1cccnc1";"IC50";"'='";"1.2";"nM";"8.92";"";"";"UO_0000065";"19.29";"0.36";"6.67";"7.58";"False";"CHEMBL1065057";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157610";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL566004";"";"0";"470.54";"0";"3.92";"17";"CCn1ncc2c(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4cccnc4)cc3)nc21";"IC50";"'='";"0.1";"nM";"10.00";"";"";"UO_0000065";"21.25";"0.39";"6.08";"9.08";"False";"CHEMBL1039195";"Inhibition of human FLAG-tagged mTOR expressed in HEK293 cells after 2 hrs by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156748";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307715"
"CHEMBL2158856";"";"0";"425.52";"0";"1.68";"9n";"CN1CCN(c2cc(-c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccn2)CC1";"IC50";"'='";"3300.0";"nM";"5.48";"";"";"UO_0000065";"12.88";"0.25";"3.80";"4.67";"False";"CHEMBL2161544";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2157945";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL603212";"";"0";"340.41";"0";"2.10";"8b";"Nc1ncc(-c2nc(N3CC4CCC(C3)O4)c3sccc3n2)cn1";"IC50";"'='";"57.0";"nM";"7.24";"";"";"UO_0000065";"21.28";"0.41";"5.14";"8.04";"False";"CHEMBL1067293";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153098";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL600258";"";"0";"488.55";"0";"3.44";"26";"CC(C)n1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(CO)cc4)cc3)nc21";"IC50";"'='";"0.32";"nM";"9.49";"";"";"UO_0000065";"19.43";"0.36";"6.05";"7.29";"False";"CHEMBL1068073";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157707";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL590357";"";"0";"592.66";"1";"3.76";"36";"CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)NCCc5ccccn5)cc4)cc3)nc21";"IC50";"'='";"1.21";"nM";"8.92";"";"";"UO_0000065";"15.05";"0.28";"5.16";"5.86";"False";"CHEMBL1068073";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157707";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1762778";"";"0";"319.33";"0";"2.24";"6";"Nc1ncnc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"21.0";"nM";"7.68";"";"";"UO_0000065";"24.04";"0.44";"5.44";"6.69";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762781";"";"0";"318.34";"0";"2.85";"9";"Nc1cc(-n2c(Nc3cccc(O)c3)nc3ccccc32)ncn1";"IC50";"'='";"110.0";"nM";"6.96";"";"";"UO_0000065";"21.86";"0.40";"4.11";"6.83";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762786";"";"0";"317.35";"0";"3.57";"15";"Cc1nccc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"370.0";"nM";"6.43";"";"";"UO_0000065";"20.27";"0.37";"2.86";"8.48";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1615189";"";"0";"476.94";"0";"4.91";"1";"CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)cc2s1";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"18.24";"0.38";"3.79";"8.61";"True";"CHEMBL1828260";"Inhibition of recombinant N-terminal GST-tagged mTOR-mediated 4E-BP1 phosphorylation after 60 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1821651";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL566882";"";"0";"441.54";"0";"3.02";"3";"COc1cc(/C=N/Nc2nc(N3CCCCC3)nc(N3CCCCC3)n2)cc(OC)c1O";"IC50";"'='";"5900.0";"nM";"5.23";"";"";"UO_0000065";"11.84";"0.22";"2.21";"4.83";"False";"CHEMBL1049650";"Inhibition of mTOR kinase in human HeLa cells by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HeLa";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156040";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3308376"
"CHEMBL566247";"";"0";"431.50";"0";"3.56";"21";"c1cc2cc(-c3ccc(-c4cc(N5CCOCC5)nc(N5CCOCC5)n4)o3)ccc2[nH]1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1049650";"Inhibition of mTOR kinase in human HeLa cells by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HeLa";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156040";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3308376"
"CHEMBL2418349";"";"0";"409.49";"0";"2.79";"21b";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3CC)c3c(cnn3C)n2)cc1";"IC50";"'='";"15.0";"nM";"7.82";"";"";"UO_0000065";"19.11";"0.36";"5.03";"8.05";"False";"CHEMBL2421122";"Inhibition of mTOR in PTEN deficient human PC3 cells assessed as inhibition of p70S6K phosphorylation";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2417437";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";"CHEMBL3307570"
"CHEMBL1242204";"";"0";"303.32";"0";"3.39";"PP126";"Nc1ncnc2[nH]nc(-c3ccc(Oc4ccccc4)cc3)c12";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241860";"";"0";"299.31";"0";"2.61";"PP152";"CC(C)n1nc(-c2ccc(C=O)c(F)c2)c2c(N)ncnc21";"IC50";"'='";"2400.0";"nM";"5.62";"";"";"UO_0000065";"18.78";"0.35";"3.01";"6.48";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241240";"";"0";"267.34";"0";"2.90";"PP125";"CC(C)(C)c1ccc(-c2n[nH]c3ncnc(N)c23)cc1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242664";"";"0";"318.38";"0";"3.67";"PP124";"Nc1ncnc2c1c(-c1ccc3cc[nH]c3c1)nn2C1CCCC1";"IC50";"'='";"493.0";"nM";"6.31";"";"";"UO_0000065";"19.81";"0.36";"2.64";"7.38";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241440";"";"0";"265.32";"0";"2.21";"PP221";"Nc1ncnc2[nH]nc(C3CCc4ccccc4C3)c12";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241441";"";"0";"261.29";"0";"2.76";"PP222";"Nc1ncnc2[nH]nc(-c3ccc4ccccc4c3)c12";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241299";"";"0";"320.15";"0";"2.08";"PP489";"Cn1nc(-c2ccc(Br)c(O)c2)c2c(N)ncnc21";"IC50";"'='";"548.0";"nM";"6.26";"";"";"UO_0000065";"19.56";"0.45";"4.18";"6.97";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1762781";"";"0";"318.34";"0";"2.85";"9";"Nc1cc(-n2c(Nc3cccc(O)c3)nc3ccccc32)ncn1";"IC50";"'='";"420.0";"nM";"6.38";"";"";"UO_0000065";"20.03";"0.36";"3.53";"6.26";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1242288";"";"0";"326.36";"0";"1.32";"PP407";"COc1ccc(-c2nn([C@@H]3CCNC3)c3ncnc(N)c23)cc1O";"IC50";"'='";"3900.0";"nM";"5.41";"";"";"UO_0000065";"16.57";"0.31";"4.09";"4.87";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242118";"";"0";"321.34";"0";"2.76";"PP143";"CC(C)n1nc(-c2ccc3occc(=O)c3c2)c2c(N)ncnc21";"IC50";"'='";"1300.0";"nM";"5.89";"";"";"UO_0000065";"18.32";"0.33";"3.13";"5.90";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241681";"";"0";"330.40";"0";"3.74";"PP112";"Nc1ncnc2c1c(-c1ccc3ncccc3c1)nn2C1CCCC1";"IC50";"'='";"550.0";"nM";"6.26";"";"";"UO_0000065";"18.95";"0.34";"2.52";"7.59";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242286";"";"0";"392.26";"0";"3.40";"PP502";"COCOc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1Br";"IC50";"'='";"1100.0";"nM";"5.96";"";"";"UO_0000065";"15.19";"0.34";"2.56";"6.76";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1095618";"";"0";"373.42";"0";"2.30";"6d";"Nc1ccc(-c2nc(N3CCOCC3)c3cnn(-c4ccccc4)c3n2)cn1";"IC50";"'='";"9.6";"nM";"8.02";"";"";"UO_0000065";"21.47";"0.39";"5.72";"8.44";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1089819";"";"0";"381.48";"0";"1.99";"20";"CN(C)CCn1ccc2c(N3CCOCC3)nc(-c3cccc(CO)c3)nc21";"IC50";"'>'";"800.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1095932";"";"0";"522.61";"1";"3.26";"26a";"CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)OC(C)C)CC4)c3n2)cc1";"IC50";"'='";"0.2";"nM";"9.70";"";"";"UO_0000065";"18.56";"0.35";"6.44";"7.65";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1091348";"";"0";"599.74";"1";"3.53";"19";"C[C@@H]1COCCN1c1nc(-c2ccc(NC(=O)Nc3ccc(N4CCN(C)CC4)cc3)cc2)nc(N2C3CCC2COC3)n1";"IC50";"'='";"1.2";"nM";"8.92";"";"";"UO_0000065";"14.87";"0.28";"5.39";"8.02";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1092391";"";"0";"597.72";"1";"3.33";"2";"O=C(Nc1ccc(-c2nc(N3C4CCC3COC4)nc(N3C4CCC3COC4)n2)cc1)Nc1ccc(N2CCNCC2)cc1";"IC50";"'='";"0.57";"nM";"9.24";"";"";"UO_0000065";"15.47";"0.29";"5.91";"7.70";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL525042";"";"0";"1017.36";"";"";"AP21967";"CO[C@H]1[C@@H](O)[C@H](C)C[C@H](C)/C=C/C=C/C=C(\C)[C@@H](c2c[nH]c3c(C)cccc23)C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)C[C@H](O)[C@H](C)/C=C(\C)[C@H]1O";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"7.86";"";"";"";"False";"CHEMBL997061";"Inhibition of mTOR kinase expressed in human HEK293 cells by Western blot analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156445";"1";"Scientific Literature";"J. Biol. Chem.";"2007";"CHEMBL3307715"
"CHEMBL1615188";"";"0";"316.41";"0";"3.43";"1";"CSc1nccc(-c2ccc3nc(NC(C)=O)sc3c2)n1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773588";"";"0";"375.46";"0";"4.32";"11";"CC(=O)Nc1nc2ccc(-c3ccnc(NCc4ccccc4)n3)cc2s1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1078983";"AZD-2014";"0";"465.55";"0";"2.64";"31";"COc1ccc(-c2ccc3c(N4CCOCC4)nc(N4C[C@H](C)O[C@H](C)C4)nc3n2)cc1CO";"IC50";"'='";"100.0";"nM";"7.00";"";"";"UO_0000065";"15.04";"0.28";"4.36";"7.52";"False";"CHEMBL1107750";"Inhibition of mTORC1 in human U87MG cells assessed as phosphorylated S6 ribosomal protein (Ser235/236) level after 2 hrs by Western blotting";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87 MG";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154286";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307575"
"CHEMBL1091706";"";"0";"642.72";"2";"5.50";"6w";"CN(Cc1ccccn1)C(=O)C1CCN(c2ccnc3c2c(/C=C2\Oc4ccc(NC(=O)Nc5cccnc5)cc4C2=O)cn3C)CC1";"IC50";"'='";"8.4";"nM";"8.08";"";"";"UO_0000065";"12.56";"0.23";"2.58";"6.00";"False";"CHEMBL1107893";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156282";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1774369";"";"0";"450.54";"0";"3.56";"23a";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)[C@@](C)(CCC#N)OC3)cc1";"IC50";"'='";"8.3";"nM";"8.08";"";"";"UO_0000065";"17.94";"0.33";"4.52";"7.19";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774380";"";"0";"455.56";"0";"3.03";"29h";"CCNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3c(n2)[C@](C)(CC(C)(C)O)OC3)cc1";"IC50";"'='";"11.0";"nM";"7.96";"";"";"UO_0000065";"17.47";"0.33";"4.93";"7.31";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774381";"";"0";"469.59";"0";"3.42";"29i";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)[C@@](C)(CC(C)(C)O)OC3)cc1";"IC50";"'='";"19.0";"nM";"7.72";"";"";"UO_0000065";"16.44";"0.31";"4.30";"7.09";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774372";"";"0";"468.60";"0";"3.21";"23d";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)[C@@](C)(CCN(C)C)OC3)cc1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1091707";"";"0";"641.73";"2";"6.10";"6x";"CN(Cc1ccccc1)C(=O)C1CCN(c2ccnc3c2c(/C=C2\Oc4ccc(NC(=O)Nc5cccnc5)cc4C2=O)cn3C)CC1";"IC50";"'='";"102.5";"nM";"6.99";"";"";"UO_0000065";"10.89";"0.20";"0.89";"5.74";"False";"CHEMBL1107893";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156282";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091704";"";"0";"642.72";"2";"5.50";"6u";"CN(Cc1cccnc1)C(=O)C1CCN(c2ccnc3c2c(/C=C2\Oc4ccc(NC(=O)Nc5cccnc5)cc4C2=O)cn3C)CC1";"IC50";"'='";"10.9";"nM";"7.96";"";"";"UO_0000065";"12.39";"0.23";"2.46";"5.92";"False";"CHEMBL1107893";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156282";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091884";"";"0";"307.31";"0";"3.50";"11";"Cc1[nH]c2ccccc2c1/C=C1\Oc2cc(O)cc(O)c2C1=O";"IC50";"'='";"500.0";"nM";"6.30";"";"";"UO_0000065";"20.50";"0.37";"2.80";"7.63";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1093930";"";"0";"372.17";"0";"3.96";"8";"O=C1/C(=C/c2c[nH]c3ccc(Br)cc23)Oc2cc(O)cc(O)c21";"IC50";"'='";"3700.0";"nM";"5.43";"";"";"UO_0000065";"14.59";"0.32";"1.47";"6.58";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1090153";"";"0";"463.53";"0";"3.23";"30";"COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)c(C)n2CCN1CCN(C)CC1";"IC50";"'='";"11.0";"nM";"7.96";"";"";"UO_0000065";"17.17";"0.32";"4.73";"9.11";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1089823";"";"0";"450.49";"0";"3.32";"29";"COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)c(C)n2CCN1CCOCC1";"IC50";"'='";"9.0";"nM";"8.05";"";"";"UO_0000065";"17.86";"0.33";"4.73";"8.62";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1090131";"";"0";"493.56";"0";"2.68";"27";"COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)cn2CCN1CCN(CCCO)CC1";"IC50";"'='";"215.0";"nM";"6.67";"";"";"UO_0000065";"13.51";"0.25";"3.99";"6.19";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1090130";"";"0";"383.40";"0";"4.87";"24";"Cn1c(-c2ccccc2)c(/C=C2\Oc3cc(O)cc(O)c3C2=O)c2ccccc21";"IC50";"'='";"96.0";"nM";"7.02";"";"";"UO_0000065";"18.30";"0.33";"2.15";"9.79";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091864";"";"0";"403.82";"1";"5.52";"17";"O=C1/C(=C/c2c(-c3ccc(Cl)cc3)[nH]c3ccccc23)Oc2cc(O)cc(O)c21";"IC50";"'='";"190.0";"nM";"6.72";"";"";"UO_0000065";"16.64";"0.32";"1.20";"8.14";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1089424";"";"0";"387.37";"1";"5.00";"16";"O=C1/C(=C/c2c(-c3ccc(F)cc3)[nH]c3ccccc23)Oc2cc(O)cc(O)c21";"IC50";"'='";"123.0";"nM";"6.91";"";"";"UO_0000065";"17.84";"0.33";"1.91";"8.37";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1822055";"";"0";"418.84";"0";"2.97";"11";"Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1";"IC50";"'='";"35.0";"nM";"7.46";"";"";"UO_0000065";"17.80";"0.36";"4.49";"6.47";"False";"CHEMBL1828260";"Inhibition of recombinant N-terminal GST-tagged mTOR-mediated 4E-BP1 phosphorylation after 60 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1821651";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1241859";"";"0";"358.83";"0";"2.43";"PP385";"Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2CC1CCNCC1";"IC50";"'='";"3000.0";"nM";"5.52";"";"";"UO_0000065";"15.39";"0.30";"3.09";"5.42";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241944";"";"0";"294.32";"0";"2.23";"PP155";"CC(C)n1nc(-c2ccc(C#N)c(O)c2)c2c(N)ncnc21";"IC50";"'='";"596.0";"nM";"6.22";"";"";"UO_0000065";"21.15";"0.39";"3.99";"5.48";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242291";"";"0";"317.35";"0";"3.18";"PP217";"Nc1ncnc2[nH]nc(-c3cccc(OCc4ccccc4)c3)c12";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241488";"";"0";"301.35";"0";"3.41";"PP225";"C=CCn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242474";"";"0";"331.42";"0";"4.27";"PP232";"CC(C)CCn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1098311";"";"0";"373.42";"0";"2.30";"6f";"Nc1ccc(-c2nc(N3CCOCC3)c3cnn(-c4ccccc4)c3n2)nc1";"IC50";"'='";"145.0";"nM";"6.84";"";"";"UO_0000065";"18.31";"0.33";"4.54";"7.20";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1093629";"";"0";"293.28";"0";"3.20";"6";"O=C1/C(=C/c2c[nH]c3ccccc23)Oc2cc(O)cc(O)c21";"IC50";"'='";"9200.0";"nM";"5.04";"";"";"UO_0000065";"17.17";"0.31";"1.84";"6.10";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL2017974";"BUPARLISIB";"3";"410.40";"0";"1.81";"15, NVP-BKM120";"Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1";"IC50";"'='";"4600.0";"nM";"5.34";"";"";"UO_0000065";"13.00";"0.25";"3.53";"5.95";"False";"CHEMBL2020176";"Inhibition of mTOR after 15 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2016472";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2011";""
"CHEMBL1879463";"DACTOLISIB";"2";"469.55";"1";"5.89";"SID103905146";"Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21";"IC50";"'<'";"10.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2173150";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169756";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2165011";"";"0";"422.49";"0";"1.93";"48";"COc1ccc(Nc2ncc(CN3CCC(O)CC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165033";"";"0";"389.42";"0";"2.37";"43";"COc1ccc(Nc2ncc(-c3cnn(C)c3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL1762782";"";"0";"372.39";"0";"2.90";"7";"Cc1nc(NCC#N)nc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"8.0";"nM";"8.10";"";"";"UO_0000065";"21.74";"0.39";"5.20";"6.50";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL1940138";"";"0";"338.37";"0";"1.57";"3";"Cc1nccn1-c1nc(-c2cccc(O)c2)nc(N2CCOCC2)n1";"IC50";"'='";"95.0";"nM";"7.02";"";"";"UO_0000065";"20.75";"0.38";"5.45";"7.87";"False";"CHEMBL1942431";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1938252";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1940139";"";"0";"339.36";"0";"0.24";"4";"Cc1nccn1-c1nc(-c2cnc(N)nc2)nc(N2CCOCC2)n1";"IC50";"'='";"420.0";"nM";"6.38";"";"";"UO_0000065";"18.79";"0.35";"6.14";"5.28";"False";"CHEMBL1942431";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1938252";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2165014";"";"0";"421.51";"0";"1.72";"51";"COc1ccc(Nc2ncc(CN3CCN(C)CC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165047";"";"0";"309.33";"0";"1.97";"27";"COc1ccc(Nc2cnccc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165041";"";"0";"319.33";"0";"2.56";"21";"COc1ccc(Nc2ncccc2-c2ncnc3nc[nH]c23)cn1";"IC50";"'='";"5100.0";"nM";"5.29";"";"";"UO_0000065";"16.57";"0.30";"2.73";"5.21";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL1774355";"";"0";"427.51";"0";"2.25";"13d";"C[C@H]1COCCN1c1nc(-c2ccc(NC(=O)NCCO)cc2)nc2c1COC2(C)C";"IC50";"'='";"4.8";"nM";"8.32";"";"";"UO_0000065";"19.46";"0.37";"6.07";"7.64";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1945953";"";"0";"377.41";"0";"2.00";"2";"O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CC1CCOCC1";"IC50";"'='";"150.0";"nM";"6.82";"";"";"UO_0000065";"18.08";"0.33";"4.82";"5.97";"False";"CHEMBL1949073";"Inhibition of mTOR-mediated Akt phosphorylation in human PC3 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";"CHEMBL3307570"
"CHEMBL113";"CAFFEINE";"4";"194.19";"0";"-1.03";"4";"Cn1c(=O)c2c(ncn2C)n(C)c1=O";"IC50";"'='";"400000.0";"nM";"";"Outside typical range";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1767684";"Inhibition of mTOR by radiometric phosphate incorporation assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1765064";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1796761";"";"0";"498.00";"0";"4.34";"15, GNE-614";"CNC(=O)c1ccc2c(c1)OCCc1cc(C(=O)N(C)c3ccc(C(=O)N(C)C)cc3Cl)sc1-2";"IC50";"'='";"530.0";"nM";"6.28";"";"";"UO_0000065";"12.60";"0.25";"1.94";"7.95";"False";"CHEMBL1798658";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1795251";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1773731";"";"0";"493.40";"1";"5.42";"76";"CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4cccc(Cl)c4)c3)cc2s1";"IC50";"'<'";"1.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1256450";"";"0";"638.74";"2";"8.25";"22";"O=c1ccc2cnc3ccc(-c4cccc5c4Sc4ccccc4S5)cc3c2n1-c1ccc(N2CCNCC2)c(C(F)(F)F)c1";"IC50";"'='";"3440.0";"nM";"5.46";"";"";"UO_0000065";"8.55";"0.17";"-2.79";"10.89";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1256455";"";"0";"552.56";"2";"6.61";"30";"O=c1ccc2cnc3ccc(-c4cnc5ccccc5c4)cc3c2n1-c1ccc(N2CCOCC2)c(C(F)(F)F)c1";"IC50";"'='";"25.8";"nM";"7.59";"";"";"UO_0000065";"13.73";"0.25";"0.98";"12.59";"False";"CHEMBL1261684";"Inhibition of human mTOR complex 1 after 30 mins by FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255226";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL265123";"";"0";"1007.32";"";"";"2";"C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)C2C[C@@](O)(C(=O)C(=O)N3CCCCC3C(=O)O[C@H](C(C)C[C@@H]3CC[C@@H](CC(=O)Nc4ccc(CCCC(=O)O)cc4)C(OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC";"IC50";"'='";"1.88";"nM";"8.73";"";"";"UO_0000065";"8.66";"";"";"";"False";"CHEMBL829473";"Inhibitory activity against macrophilin (FKBP-12)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1138768";"1";"Scientific Literature";"J. Med. Chem.";"2004";""
"CHEMBL1241586";"";"0";"309.33";"0";"1.83";"PP156";"CC(C)n1nc(-c2ccc3[nH]c(=O)[nH]c3c2)c2c(N)ncnc21";"IC50";"'='";"3600.0";"nM";"5.44";"";"";"UO_0000065";"17.60";"0.32";"3.61";"4.60";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241775";"";"0";"306.33";"0";"1.99";"PP139";"CC(C)n1nc(-c2cnc3nccnc3c2)c2c(N)ncnc21";"IC50";"'='";"6800.0";"nM";"5.17";"";"";"UO_0000065";"16.87";"0.31";"3.18";"4.77";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241769";"";"0";"344.81";"0";"2.19";"PP387";"Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2CC1CCCN1";"IC50";"'='";"15000.0";"nM";"4.82";"";"";"UO_0000065";"13.99";"0.27";"2.63";"4.73";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL2030436";"";"0";"372.45";"0";"2.01";"2";"CS(=O)(=O)Cc1cc(N2CCOCC2)nc(-c2ccc3[nH]ccc3c2)n1";"IC50";"'='";"288.4";"nM";"6.54";"";"";"UO_0000065";"17.56";"0.34";"4.53";"7.42";"False";"CHEMBL3413521";"Inhibition of recombinant truncated FLAG-tagged mTOR (1362 to 2549 aa) (unknown origin) expressed in HEK293 cells using biotinylated p70 peptide as substrate";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407414";"1";"Scientific Literature";"J. Med. Chem.";"2015";"CHEMBL3307715"
"CHEMBL3357863";"";"0";"327.32";"0";"2.11";"2";"COc1ncc(Nc2ncccc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"22000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3379685";"Inhibition of recombinant N-terminally GST-tagged mTOR (1360 to 2549 aa) (unknown origin) assessed as inhibition of 27BP1 phosphorylation after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352452";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3357876";"";"0";"435.41";"0";"3.22";"15";"COc1ncc(Nc2ncc(C(C)(C)O)cc2-c2nc(C)nc(N)n2)cc1C(F)(F)F";"IC50";"'>'";"25000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3379685";"Inhibition of recombinant N-terminally GST-tagged mTOR (1360 to 2549 aa) (unknown origin) assessed as inhibition of 27BP1 phosphorylation after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352452";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3357872";"";"0";"399.43";"0";"2.38";"11";"COc1ncc(Nc2ncc(C(C)(C)CO)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"17000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3379685";"Inhibition of recombinant N-terminally GST-tagged mTOR (1360 to 2549 aa) (unknown origin) assessed as inhibition of 27BP1 phosphorylation after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352452";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3357865";"";"0";"371.38";"0";"2.16";"4";"COc1ncc(Nc2ncc([C@@H](C)O)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"25000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3379685";"Inhibition of recombinant N-terminally GST-tagged mTOR (1360 to 2549 aa) (unknown origin) assessed as inhibition of 27BP1 phosphorylation after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352452";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL2170081";"";"0";"517.59";"2";"1.75";"1, AMG 511";"COc1ncc(Nc2ncc([C@@H](C)N3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'='";"14800.0";"nM";"4.83";"";"";"UO_0000065";"9.33";"0.18";"3.08";"3.17";"False";"CHEMBL3379685";"Inhibition of recombinant N-terminally GST-tagged mTOR (1360 to 2549 aa) (unknown origin) assessed as inhibition of 27BP1 phosphorylation after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352452";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3618238";"";"0";"450.48";"1";"1.77";"11";"COc1ncc(Nc2nc3ccc(N4CCNCC4)cn3c2-c2nc(C)nc(N)n2)cc1F";"IC50";"'='";"62.0";"nM";"7.21";"";"";"UO_0000065";"16.00";"0.30";"5.44";"5.48";"False";"CHEMBL3620381";"Inhibition of GST-tagged mTOR (1360 to 2549 residues) (unknown origin) using Ulight 4eBP1 peptide incubated for 90 mins by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3616407";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2015";""
"CHEMBL3735090";"";"0";"584.60";"2";"5.98";"16b";"CC(=O)N1CCN(c2ccc(Nc3c(C(N)=O)cnc4ccc(-c5cnc6ccccc6c5)cc34)cc2C(F)(F)F)CC1";"IC50";"'='";"31.0";"nM";"7.51";"";"";"UO_0000065";"12.84";"0.24";"1.53";"7.19";"False";"CHEMBL3738862";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide as substrate after 1 hr by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3734757";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2015";""
"CHEMBL3735667";"";"0";"620.66";"2";"5.39";"16c";"CS(=O)(=O)N1CCN(c2ccc(Nc3c(C(N)=O)cnc4ccc(-c5cnc6ccccc6c5)cc34)cc2C(F)(F)F)CC1";"IC50";"'='";"73.0";"nM";"7.14";"";"";"UO_0000065";"11.50";"0.22";"1.75";"5.87";"False";"CHEMBL3738862";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide as substrate after 1 hr by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3734757";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2015";""
"CHEMBL3735716";"";"0";"593.05";"2";"5.98";"15b";"CNC(=O)c1cnc2ccc(-c3cnc4ccccc4c3)cc2c1Nc1ccc(N2CCNCC2)c(C(F)(F)F)c1.Cl";"IC50";"'='";"806.0";"nM";"6.09";"";"";"UO_0000065";"10.95";"0.20";"0.11";"7.42";"False";"CHEMBL3738862";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide as substrate after 1 hr by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3734757";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2015";""
"CHEMBL3618232";"";"0";"362.40";"0";"2.61";"5";"CCOc1ccc(Nc2nc3ccccn3c2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"57.0";"nM";"7.24";"";"";"UO_0000065";"19.99";"0.37";"4.63";"6.24";"False";"CHEMBL3620381";"Inhibition of GST-tagged mTOR (1360 to 2549 residues) (unknown origin) using Ulight 4eBP1 peptide incubated for 90 mins by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3616407";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2015";""
"CHEMBL574234";"";"0";"467.43";"0";"2.98";"9";"O=C(NCCF)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(CC(F)(F)F)c3n2)cc1";"IC50";"'='";"0.6";"nM";"9.22";"";"";"UO_0000065";"19.73";"0.38";"6.24";"9.49";"False";"CHEMBL1074679";"Inhibition of mTOR in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153200";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL3618245";"";"0";"424.44";"0";"2.59";"18";"COc1ncc(Nc2nc3ccc(C(C)(C)O)cn3c2-c2nc(C)nc(N)n2)cc1F";"IC50";"'='";"206.0";"nM";"6.69";"";"";"UO_0000065";"15.75";"0.29";"4.10";"4.90";"False";"CHEMBL3620381";"Inhibition of GST-tagged mTOR (1360 to 2549 residues) (unknown origin) using Ulight 4eBP1 peptide incubated for 90 mins by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3616407";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2015";""
"CHEMBL590105";"";"0";"495.47";"0";"4.90";"13";"O=C(Nc1ccc(-c2nc(C3=CCOCC3)c3cnn(CC(F)(F)F)c3n2)cc1)Nc1cccnc1";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"18.16";"0.34";"4.10";"8.42";"False";"CHEMBL1074679";"Inhibition of mTOR in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153200";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL594793";"";"0";"421.53";"0";"4.01";"9e";"O=C(Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3sccc3n2)cc1)NC1CC1";"IC50";"'='";"0.68";"nM";"9.17";"";"";"UO_0000065";"21.75";"0.42";"5.16";"11.55";"False";"CHEMBL1067293";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153098";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL104468";"";"0";"281.31";"0";"2.78";"3";"O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12";"IC50";"'='";"6400.0";"nM";"5.19";"";"";"UO_0000065";"18.46";"0.34";"2.41";"12.17";"True";"CHEMBL830918";"Inhibition of mTOR protein isolated from HeLa cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HeLa";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1141182";"1";"Scientific Literature";"J. Med. Chem.";"2005";"CHEMBL3308376"
"CHEMBL2325703";"";"0";"400.50";"0";"2.74";"11";"CC(C)(c1cc(N2CCOCC2)nc(-c2cccc3[nH]ccc23)n1)S(C)(=O)=O";"IC50";"'='";"190.0";"nM";"6.72";"";"";"UO_0000065";"16.78";"0.33";"3.98";"7.62";"False";"CHEMBL2330634";"Inhibition of recombinant mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2321758";"1";"Scientific Literature";"J. Med. Chem.";"2013";""
"CHEMBL1773559";"";"0";"408.51";"0";"4.87";"22";"COc1ccc(Sc2nccc(-c3ccc4nc(NC(C)=O)sc4c3)n2)cc1";"IC50";"'='";"3010.0";"nM";"5.52";"";"";"UO_0000065";"13.52";"0.27";"0.65";"7.17";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773564";"";"0";"406.47";"0";"4.30";"28";"COc1ccc(COc2nccc(-c3ccc4nc(NC(C)=O)sc4c3)n2)cc1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773569";"";"0";"413.50";"0";"2.81";"33";"CC(=O)Nc1nc2ccc(-c3ccnc(OCCCN4CCOCC4)n3)cc2s1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773558";"";"0";"454.53";"0";"4.13";"51";"COc1ccc(S(=O)(=O)Nc2cc(-c3ccc4nc(NC(C)=O)sc4c3)ccn2)cc1";"IC50";"'='";"29.0";"nM";"7.54";"";"";"UO_0000065";"16.58";"0.33";"3.41";"6.83";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773563";"";"0";"390.47";"0";"4.60";"27";"CC(=O)Nc1nc2ccc(-c3ccnc(OCc4ccc(C)cc4)n3)cc2s1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773581";"";"0";"439.52";"0";"3.82";"44";"CC(=O)Nc1nc2ccc(-c3ccnc(NS(=O)(=O)c4ccc(C)cc4)n3)cc2s1";"IC50";"'='";"65.0";"nM";"7.19";"";"";"UO_0000065";"16.35";"0.33";"3.37";"6.31";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773600";"";"0";"455.52";"0";"3.52";"57";"COc1ccc(S(=O)(=O)Nc2cncc(-c3ccc4nc(NC(C)=O)sc4c3)n2)cc1";"IC50";"'='";"15.0";"nM";"7.82";"";"";"UO_0000065";"17.18";"0.34";"4.30";"6.35";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774370";"";"0";"450.54";"0";"3.56";"23b";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)[C@](C)(CCC#N)OC3)cc1";"IC50";"'='";"11.0";"nM";"7.96";"";"";"UO_0000065";"17.66";"0.33";"4.40";"7.08";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774375";"";"0";"427.51";"0";"2.25";"29c";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)[C@](C)(CO)OC3)cc1";"IC50";"'='";"11.0";"nM";"7.96";"";"";"UO_0000065";"18.62";"0.35";"5.71";"7.31";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774357";"";"0";"439.52";"0";"2.65";"13f";"C[C@H]1COCCN1c1nc(-c2ccc(NC(=O)NC3COC3)cc2)nc2c1COC2(C)C";"IC50";"'='";"30.0";"nM";"7.52";"";"";"UO_0000065";"17.12";"0.32";"4.87";"7.69";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1738719";"";"0";"498.97";"0";"4.73";"16d";"O=S(=O)(Nc1cc(-c2ccc3nccc(N4CCOCC4)c3c2)cnc1Cl)c1ccc(F)cc1";"IC50";"'='";"3.9";"nM";"8.41";"";"";"UO_0000065";"16.85";"0.34";"3.68";"9.96";"False";"CHEMBL1919685";"Inhibition of mTOR using GFP-tagged 4E-BP1 after 1 hr by spectrophotometric analysis";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1914426";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1092072";"";"0";"624.67";"1";"4.77";"46";"CN(C)CCN(C)C(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)c4ccn(CC(F)(F)F)c4n3)cc2)cc1";"IC50";"'='";"0.6";"nM";"9.22";"";"";"UO_0000065";"14.76";"0.28";"4.45";"8.55";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1092401";"";"0";"650.71";"2";"5.31";"49";"CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)c5ccn(CC(F)(F)F)c5n4)cc3)cc2)CC1";"IC50";"'='";"1.7";"nM";"8.77";"";"";"UO_0000065";"13.48";"0.25";"3.46";"8.13";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1091699";"";"0";"591.67";"2";"5.07";"6p";"Cn1cc(/C=C2\Oc3ccc(NC(=O)Nc4cccnc4)cc3C2=O)c2c(N3CCC(C(=O)N4CCCC4)CC3)ccnc21";"IC50";"'='";"8.2";"nM";"8.09";"";"";"UO_0000065";"13.67";"0.25";"3.02";"6.64";"False";"CHEMBL1107893";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156282";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1090043";"";"0";"368.39";"0";"4.56";"9b";"Cn1cc(/C=C2\Oc3cccc(O)c3C2=O)c2c(-c3ccccc3)ccnc21";"IC50";"'='";"3.45";"nM";"8.46";"";"";"UO_0000065";"22.97";"0.41";"3.90";"13.15";"False";"CHEMBL1107897";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156283";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1093334";"";"0";"521.58";"2";"5.20";"6d";"Cn1cc(/C=C2\Oc3ccc(NC(=O)Nc4ccccc4)cc3C2=O)c2c(N3CC4CCC(C3)O4)ccnc21";"IC50";"'='";"145.0";"nM";"6.84";"";"";"UO_0000065";"13.11";"0.24";"1.64";"7.00";"False";"CHEMBL1107893";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156282";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1093368";"";"0";"424.46";"0";"4.61";"3b";"CNC(=O)Nc1cccc2c1C(=O)/C(=C/c1cn(C)c3nccc(-c4ccccc4)c13)O2";"IC50";"'='";"3500.0";"nM";"5.46";"";"";"UO_0000065";"12.85";"0.23";"0.85";"6.40";"False";"CHEMBL1107893";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156282";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1092393";"";"0";"570.70";"1";"3.98";"4";"CN(C)Cc1ccc(NC(=O)Nc2ccc(-c3nc(N4C5CCC4COC5)nc(N4C5CCC4COC5)n3)cc2)cc1";"IC50";"'='";"1.1";"nM";"8.96";"";"";"UO_0000065";"15.70";"0.29";"4.98";"8.30";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1773589";"";"0";"360.44";"0";"4.30";"12";"CC(=O)Nc1nc2ccc(-c3ccnc(Cc4ccccc4)n3)cc2s1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773592";"";"0";"396.47";"1";"5.00";"15";"CC(=O)Nc1nc2ccc(-c3ccnc(Sc4cccc(F)c4)n3)cc2s1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773594";"";"0";"392.51";"1";"5.17";"17";"CC(=O)Nc1nc2ccc(-c3ccnc(Sc4ccccc4C)n3)cc2s1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773567";"";"0";"405.48";"0";"4.12";"31";"CC(=O)Nc1nc2ccc(-c3ccnc(OCCCc4cccnc4)n3)cc2s1";"IC50";"'='";"913.0";"nM";"6.04";"";"";"UO_0000065";"14.89";"0.28";"1.92";"6.72";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773604";"";"0";"488.98";"0";"4.78";"70";"COc1ccc(S(=O)(=O)Nc2cc(-c3ccc4nc(NC(C)=O)sc4c3)cnc2Cl)cc1";"IC50";"'='";"2.1";"nM";"8.68";"";"";"UO_0000065";"17.75";"0.37";"3.90";"7.87";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1088746";"";"0";"439.47";"0";"4.26";"9i";"CN(C)C(=O)c1cccc(-c2ccnc3c2c(/C=C2\Oc4cccc(O)c4C2=O)cn3C)c1";"IC50";"'='";"18.0";"nM";"7.75";"";"";"UO_0000065";"17.62";"0.32";"3.48";"9.15";"False";"CHEMBL1107897";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156283";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1092768";"";"0";"377.40";"0";"2.73";"10j";"Cn1cc(/C=C2\Oc3cccc(O)c3C2=O)c2c(N3CCOCC3)ccnc21";"IC50";"'='";"2.2";"nM";"8.66";"";"";"UO_0000065";"22.94";"0.42";"5.93";"11.27";"False";"CHEMBL1107897";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156283";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1092818";"";"0";"439.47";"0";"4.26";"9j";"CN(C)C(=O)c1ccccc1-c1ccnc2c1c(/C=C1\Oc3cccc(O)c3C1=O)cn2C";"IC50";"'='";"180.0";"nM";"6.75";"";"";"UO_0000065";"15.35";"0.28";"2.48";"7.97";"False";"CHEMBL1107897";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156283";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1092554";"";"0";"294.36";"0";"2.77";"5";"Cc1cccc(-c2nc(N3CCOCC3)c3[nH]ccc3n2)c1";"IC50";"'='";"5000.0";"nM";"5.30";"";"";"UO_0000065";"18.01";"0.33";"2.53";"9.81";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1092568";"";"0";"407.52";"0";"2.56";"11";"Cn1cc(CN2CCCC2)c2nc(-c3cccc(CO)c3)nc(N3CCOCC3)c21";"IC50";"'>'";"4000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1091962";"";"0";"541.66";"1";"3.22";"38";"CN1CCN(CCn2ccc3c(N4CCOCC4)nc(-c4ccc(NC(=O)Nc5ccncc5)cc4)nc32)CC1";"IC50";"'='";"24.0";"nM";"7.62";"";"";"UO_0000065";"14.07";"0.26";"4.40";"7.35";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1094016";"";"0";"404.47";"0";"3.07";"17a";"Cn1cc(/C=C2\Oc3cccc(O)c3C2=O)c2c(N3CCC(CN)CC3)ccnc21";"IC50";"'='";"17.0";"nM";"7.77";"";"";"UO_0000065";"19.21";"0.35";"4.70";"8.30";"False";"CHEMBL1107897";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156283";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL306380";"";"0";"281.36";"0";"3.14";"PP1";"Cc1ccc(-c2nn(C(C)(C)C)c3ncnc(N)c23)cc1";"IC50";"'='";"9318.0";"nM";"5.03";"";"";"UO_0000065";"17.88";"0.33";"1.89";"7.23";"False";"CHEMBL3826741";"Inhibition of human mTOR using poly[Glu,Tyr]4:1 as substrate in presence of [gamma-33P]ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3822371";"1";"Scientific Literature";"J. Med. Chem.";"2016";""
"CHEMBL561103";"";"0";"528.62";"1";"3.74";"9";"COC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5cccnc5)CC4)c3n2)cc1";"IC50";"'='";"4.6";"nM";"8.34";"";"";"UO_0000065";"15.77";"0.29";"4.60";"7.54";"True";"CHEMBL1058638";"Inhibition of flag-tagged truncated human mTOR (1360-2549) expressed in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1151963";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL562439";"";"0";"507.60";"1";"2.40";"17";"CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)N(C)C)CC4)c3n2)cc1";"IC50";"'='";"1.1";"nM";"8.96";"";"";"UO_0000065";"17.65";"0.33";"6.56";"7.42";"False";"CHEMBL1058638";"Inhibition of flag-tagged truncated human mTOR (1360-2549) expressed in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1151963";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL589142";"";"0";"484.60";"0";"3.66";"21";"OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccccc5)CC4)c3n2)c1";"IC50";"'='";"1000.0";"nM";"6.00";"";"";"UO_0000065";"12.38";"0.23";"2.34";"7.54";"False";"CHEMBL1068429";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153170";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1760155";"";"0";"374.41";"0";"2.80";"28";"CC(=O)Nc1ccc(Nc2nc3ccccc3n2-c2nc(C)nc(N)n2)cc1";"IC50";"'='";"13.0";"nM";"7.89";"";"";"UO_0000065";"21.06";"0.38";"5.09";"6.38";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760154";"";"0";"389.42";"0";"2.60";"27";"CNC(=O)Nc1ccc(Nc2nc3ccccc3n2-c2nc(C)nc(N)n2)cc1";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"22.34";"0.41";"6.10";"6.41";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1808977";"";"0";"590.69";"1";"2.82";"3";"CN(C)CCN(C)C(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(O[C@H]4CCOC4)nc(N4CCOCC4)n3)cc2)cc1";"IC50";"'='";"0.7";"nM";"9.15";"";"";"UO_0000065";"15.50";"0.29";"6.33";"6.82";"False";"CHEMBL1810297";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1806467";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL595287";"";"0";"427.51";"0";"3.82";"9c";"O=C(NCCF)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3sccc3n2)cc1";"IC50";"'='";"0.7";"nM";"9.15";"";"";"UO_0000065";"21.41";"0.42";"5.33";"11.53";"False";"CHEMBL1067293";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153098";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL595288";"";"0";"339.42";"0";"3.43";"8c";"Oc1ccc(-c2nc(N3CC4CCC(C3)O4)c3sccc3n2)cc1";"IC50";"'='";"32.0";"nM";"7.50";"";"";"UO_0000065";"22.08";"0.43";"4.06";"12.82";"False";"CHEMBL1067293";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153098";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL2087482";"";"0";"501.62";"2";"0.46";"22";"C[C@H]1CN(S(C)(=O)=O)C[C@@H](C)N1Cc1cn2cc(-c3cnc(N)nc3)nc(N3CCOCC3)c2n1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL2092092";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2086238";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL591337";"";"0";"485.59";"0";"3.05";"24";"OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccccn5)CC4)c3n2)c1";"IC50";"'='";"310.0";"nM";"6.51";"";"";"UO_0000065";"13.40";"0.25";"3.46";"7.04";"False";"CHEMBL1068429";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153170";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1631895";"";"0";"233.27";"0";"2.54";"13";"Nc1cccc(C#Cc2n[nH]c3ccccc23)c1";"IC50";"'='";"5100.0";"nM";"5.29";"";"";"UO_0000065";"22.69";"0.40";"2.75";"9.68";"False";"CHEMBL1633336";"Inhibition of mTORC1 expressed in HEK293 cells assessed as PRAS40 Ser183 phosphorylation level by LanthaScreen cellular assay";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";"CHEMBL3307715"
"CHEMBL2087474";"";"0";"473.56";"1";"-0.32";"14, ETP-46321";"CS(=O)(=O)N1CCN(Cc2cn3cc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1";"IC50";"'='";"4880.0";"nM";"5.31";"";"";"UO_0000065";"11.22";"0.22";"5.63";"3.93";"False";"CHEMBL2092092";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2086238";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2087488";"";"0";"480.58";"1";"-0.19";"28";"CN(C)CC(=O)N1CCN(Cc2cn3cc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL2092092";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2086238";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1808984";"";"0";"574.64";"1";"2.18";"14";"CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(OC5COC5)nc(N5CCOCC5)n4)cc3)cc2)CC1";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"14.83";"0.28";"6.34";"6.35";"False";"CHEMBL1810297";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1806467";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL2071338";"";"0";"396.48";"0";"2.79";"21, NVS-P13-1";"Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccc(-n2cccn2)cc1";"IC50";"'>'";"9100.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2073006";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2069199";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1760166";"";"0";"308.31";"0";"0.96";"40";"Cc1nc(N)nc(-n2c(Nc3nc[nH]n3)nc3ccccc32)n1";"IC50";"'>'";"25000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760155";"";"0";"374.41";"0";"2.80";"28";"CC(=O)Nc1ccc(Nc2nc3ccccc3n2-c2nc(C)nc(N)n2)cc1";"IC50";"'='";"180.0";"nM";"6.75";"";"";"UO_0000065";"18.01";"0.33";"3.94";"5.46";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762785";"";"0";"332.37";"0";"3.16";"14";"Cc1nc(N)cc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"1200.0";"nM";"5.92";"";"";"UO_0000065";"17.81";"0.32";"2.76";"5.81";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762780";"";"0";"334.34";"0";"2.67";"8";"COc1ncnc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'>'";"25000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1808978";"";"0";"560.66";"1";"3.24";"8";"COc1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)NCCN4CCCCC4)cc3)cc2)nc(N2CCOCC2)n1";"IC50";"'='";"8.2";"nM";"8.09";"";"";"UO_0000065";"14.42";"0.27";"4.85";"6.04";"False";"CHEMBL1810297";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1806467";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762782";"";"0";"372.39";"0";"2.90";"10";"Cc1nc(NCC#N)nc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"380.0";"nM";"6.42";"";"";"UO_0000065";"17.24";"0.31";"3.52";"5.15";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL600825";"";"0";"533.63";"1";"3.86";"8b";"CCNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(C4CCC5(CC4)OCCO5)c3n2)cc1";"IC50";"'='";"0.26";"nM";"9.59";"";"";"UO_0000065";"17.96";"0.34";"5.73";"8.29";"False";"CHEMBL1068272";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156873";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL596790";"";"0";"413.48";"0";"1.35";"9";"CCNC(=O)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"19.35";"0.36";"6.65";"7.64";"False";"CHEMBL1065057";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157610";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL589345";"";"0";"459.51";"0";"3.34";"18";"CC(C)n1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4cccnc4)cc3)nc21";"IC50";"'='";"0.57";"nM";"9.24";"";"";"UO_0000065";"20.12";"0.37";"5.90";"7.52";"False";"CHEMBL1068073";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157707";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL589599";"";"0";"431.46";"0";"2.30";"19";"Cn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4cccnc4)cc3)nc21";"IC50";"'='";"2.95";"nM";"8.53";"";"";"UO_0000065";"19.77";"0.36";"6.23";"6.94";"False";"CHEMBL1068073";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157707";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1241674";"";"0";"308.35";"0";"2.84";"7, PP242";"CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21";"IC50";"'='";"8.0";"nM";"8.10";"";"";"UO_0000065";"26.26";"0.48";"5.26";"7.66";"True";"CHEMBL1804917";"Inhibition of mTOR assessed as inhibition of gamma32ATP incorporation to histone H1 by phosphor imaging";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1800032";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL566895";"";"0";"459.51";"1";"1.02";"14";"COc1cc(/C=N/Nc2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc(OC)c1OC";"IC50";"'='";"30000.0";"nM";"4.52";"";"";"UO_0000065";"9.84";"0.19";"3.50";"3.91";"False";"CHEMBL1049650";"Inhibition of mTOR kinase in human HeLa cells by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HeLa";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156040";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3308376"
"CHEMBL1760168";"";"0";"321.35";"0";"2.03";"42";"CNc1nc(C)nc(-n2c(Nc3cc[nH]n3)nc3ccccc32)n1";"IC50";"'='";"600.0";"nM";"6.22";"";"";"UO_0000065";"19.36";"0.35";"4.19";"5.70";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760157";"";"0";"356.39";"0";"3.33";"30";"Cc1nc(N)nc(-n2c(Nc3ccc4cc[nH]c4c3)nc3ccccc32)n1";"IC50";"'='";"140.0";"nM";"6.85";"";"";"UO_0000065";"19.23";"0.35";"3.52";"6.21";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762777";"";"0";"410.44";"0";"3.67";"5";"Oc1cccc(Nc2nc3ccccc3n2-c2ncnc(NCc3ccccn3)n2)c1";"IC50";"'>'";"25000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762787";"";"0";"388.39";"0";"2.60";"16";"COc1nc(NCC#N)nc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"21500.0";"nM";"4.67";"";"";"UO_0000065";"12.02";"0.22";"2.07";"3.49";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762777";"";"0";"410.44";"0";"3.67";"5";"Oc1cccc(Nc2nc3ccccc3n2-c2ncnc(NCc3ccccn3)n2)c1";"IC50";"'='";"2400.0";"nM";"5.62";"";"";"UO_0000065";"13.69";"0.25";"1.95";"4.94";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760158";"";"0";"357.38";"0";"2.72";"31";"Cc1nc(N)nc(-n2c(Nc3ccc4cn[nH]c4c3)nc3ccccc32)n1";"IC50";"'='";"1500.0";"nM";"5.82";"";"";"UO_0000065";"16.30";"0.29";"3.10";"4.73";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1760170";"";"0";"360.39";"0";"2.31";"44";"Cc1nc(NCCC#N)nc(-n2c(Nc3cc[nH]n3)nc3ccccc32)n1";"IC50";"'='";"1300.0";"nM";"5.89";"";"";"UO_0000065";"16.33";"0.30";"3.58";"4.42";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL2030448";"";"0";"398.49";"0";"2.54";"28";"CS(=O)(=O)Cc1cc(N2CC3CCC(C2)O3)nc(-c2ccc3[nH]ccc3c2)n1";"IC50";"'='";"252.0";"nM";"6.60";"";"";"UO_0000065";"16.56";"0.32";"4.06";"7.48";"False";"CHEMBL2033327";"Inhibition of recombinant FLAG-tagged mTOR kinase expressed in HEK293 cells using Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2 as substrate after 90 mins";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2029234";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";"CHEMBL3307715"
"CHEMBL2030444";"";"0";"377.47";"0";"1.67";"23";"COCc1cccc(-c2nc(CS(C)(=O)=O)cc(N3CCOCC3)n2)c1";"IC50";"'='";"22500.0";"nM";"4.65";"";"";"UO_0000065";"12.31";"0.24";"2.98";"5.69";"False";"CHEMBL2033327";"Inhibition of recombinant FLAG-tagged mTOR kinase expressed in HEK293 cells using Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2 as substrate after 90 mins";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2029234";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";"CHEMBL3307715"
"CHEMBL565389";"";"0";"464.57";"0";"2.56";"16";"CCn1ncc2c(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)NCCN(C)C)cc3)nc21";"IC50";"'='";"51.0";"nM";"7.29";"";"";"UO_0000065";"15.70";"0.29";"4.73";"7.26";"False";"CHEMBL1039195";"Inhibition of human FLAG-tagged mTOR expressed in HEK293 cells after 2 hrs by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156748";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307715"
"CHEMBL98350";"LY-294002";"0";"307.35";"0";"3.30";"1";"O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12";"IC50";"'='";"2500.0";"nM";"5.60";"";"";"UO_0000065";"18.23";"0.33";"2.30";"13.13";"True";"CHEMBL830270";"Inhibition of Mammalian target of Rapamycin mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1138727";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2004";""
"CHEMBL550286";"";"0";"471.57";"0";"3.27";"1";"Oc1cccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5cccnc5)CC4)c3n2)c1";"IC50";"'='";"9.6";"nM";"8.02";"";"";"UO_0000065";"17.00";"0.31";"4.75";"8.67";"False";"CHEMBL1058638";"Inhibition of flag-tagged truncated human mTOR (1360-2549) expressed in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1151963";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL595256";"";"0";"458.55";"0";"4.76";"9g";"O=C(Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3sccc3n2)cc1)Nc1cccnc1";"IC50";"'='";"0.29";"nM";"9.54";"";"";"UO_0000065";"20.80";"0.39";"4.78";"10.34";"False";"CHEMBL1067293";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153098";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1204015";"";"0";"626.16";"1";"2.49";"30";"CN(C)CCN(C)C(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4CCOCC4)n3)cc2)cc1.Cl";"IC50";"'='";"0.6";"nM";"9.22";"";"";"UO_0000065";"15.64";"0.29";"6.73";"7.19";"False";"CHEMBL1065057";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157610";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL571318";"";"0";"393.45";"0";"2.47";"20";"c1cc(-c2ccc(-c3cc(N4CCOCC4)nc(N4CCOCC4)n3)o2)ccn1";"IC50";"'='";"520.0";"nM";"6.28";"";"";"UO_0000065";"15.97";"0.30";"3.81";"8.19";"False";"CHEMBL1049650";"Inhibition of mTOR kinase in human HeLa cells by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HeLa";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156040";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3308376"
"CHEMBL558955";"";"0";"586.65";"1";"3.87";"28";"COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)Nc5ccc(CO)cc5)cc4)nc32)CC1";"IC50";"'='";"0.08";"nM";"10.10";"";"";"UO_0000065";"17.21";"0.32";"6.23";"6.87";"False";"CHEMBL1058638";"Inhibition of flag-tagged truncated human mTOR (1360-2549) expressed in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1151963";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1088835";"";"0";"337.33";"0";"3.51";"13";"COc1ccc2[nH]c(C)c(/C=C3\Oc4cc(O)cc(O)c4C3=O)c2c1";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"25.27";"0.47";"5.01";"9.29";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1957499";"";"0";"521.61";"1";"1.06";"21";"CS(=O)(=O)N1CCN(Cc2cn3c(C#N)c(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3n2)CC1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1959594";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1955823";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL561907";"";"0";"526.57";"1";"2.82";"22";"COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)NCCF)cc4)nc32)CC1";"IC50";"'='";"0.61";"nM";"9.21";"";"";"UO_0000065";"17.50";"0.33";"6.39";"7.27";"True";"CHEMBL1058638";"Inhibition of flag-tagged truncated human mTOR (1360-2549) expressed in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1151963";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1631903";"";"0";"220.24";"0";"1.75";"21";"C(#Cc1n[nH]c2ncccc12)c1cccnc1";"IC50";"'='";"5000.0";"nM";"5.30";"";"";"UO_0000065";"24.07";"0.43";"3.55";"9.73";"False";"CHEMBL1633333";"Inhibition of mTOR by LanthaScreen Eu kinase binding assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL413";"SIROLIMUS";"4";"914.19";"3";"6.18";"Rapamycin";"CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C";"IC50";"'<'";"10.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1949072";"Inhibition of mTOR-mediated S6 phosphorylation in human PC3 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";"CHEMBL3307570"
"CHEMBL1095945";"";"0";"542.64";"1";"3.85";"16c";"CONC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)cc1";"IC50";"'='";"16.0";"nM";"7.80";"";"";"UO_0000065";"14.37";"0.27";"3.95";"7.11";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1093445";"";"0";"400.39";"0";"4.27";"20";"COc1ccc2[nH]c(-c3cccnc3)c(/C=C3\Oc4cc(O)cc(O)c4C3=O)c2c1";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"22.48";"0.41";"4.73";"8.60";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1089423";"";"0";"370.36";"0";"4.26";"15";"O=C1/C(=C/c2c(-c3ccccn3)[nH]c3ccccc23)Oc2cc(O)cc(O)c21";"IC50";"'='";"22.0";"nM";"7.66";"";"";"UO_0000065";"20.68";"0.37";"3.40";"8.02";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1098248";"";"0";"669.79";"2";"4.25";"25i";"COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)Nc5ccc(CCN6CCOCC6)cc5)cc4)nc32)CC1";"IC50";"'='";"0.6";"nM";"9.22";"";"";"UO_0000065";"13.77";"0.26";"4.97";"6.62";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL552532";"";"0";"558.64";"2";"3.10";"22b";"O=C(Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5cccnc5)CC4)c3n2)cc1)OCCO";"IC50";"'='";"1.5";"nM";"8.82";"";"";"UO_0000065";"15.80";"0.29";"5.72";"6.75";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1773733";"";"0";"515.06";"2";"6.07";"78";"CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4cccc(C(C)(C)C)c4)c3)cc2s1";"IC50";"'='";"2.1";"nM";"8.68";"";"";"UO_0000065";"16.85";"0.35";"2.61";"8.59";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1822211";"";"0";"418.84";"0";"4.07";"19";"Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)cc2o1";"IC50";"'='";"70.0";"nM";"7.16";"";"";"UO_0000065";"17.08";"0.35";"3.08";"6.44";"False";"CHEMBL1828260";"Inhibition of recombinant N-terminal GST-tagged mTOR-mediated 4E-BP1 phosphorylation after 60 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1821651";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL565987";"";"0";"513.61";"1";"3.99";"21";"CCn1ncc2c(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(N(C)C)nc4)cc3)nc21";"IC50";"'='";"1.5";"nM";"8.82";"";"";"UO_0000065";"17.18";"0.32";"4.83";"7.79";"False";"CHEMBL1039195";"Inhibition of human FLAG-tagged mTOR expressed in HEK293 cells after 2 hrs by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156748";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307715"
"CHEMBL606131";"";"0";"395.49";"0";"3.48";"9a";"CNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3sccc3n2)cc1";"IC50";"'='";"0.9";"nM";"9.05";"";"";"UO_0000065";"22.87";"0.44";"5.57";"11.40";"False";"CHEMBL1067293";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153098";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL591338";"";"0";"502.59";"1";"3.80";"26";"OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccc(F)cc5)CC4)c3n2)c1";"IC50";"'='";"1700.0";"nM";"5.77";"";"";"UO_0000065";"11.48";"0.21";"1.97";"7.25";"False";"CHEMBL1068429";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153170";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL602184";"";"0";"585.75";"1";"3.99";"29";"CN(C)CCCOc1ccc(CN2CCC(n3cnc4c(N5CCOCC5)nc(-c5cccc(CO)c5)nc43)CC2)cc1";"IC50";"'>'";"4000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1068429";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153170";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1090709";"";"0";"522.57";"1";"4.60";"6h";"Cn1cc(/C=C2\Oc3ccc(NC(=O)Nc4cccnc4)cc3C2=O)c2c(N3CC4CCC3CO4)ccnc21";"IC50";"'='";"7.5";"nM";"8.12";"";"";"UO_0000065";"15.55";"0.28";"3.52";"7.35";"False";"CHEMBL1107893";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156282";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091703";"";"0";"628.69";"2";"5.16";"6t";"Cn1cc(/C=C2\Oc3ccc(NC(=O)Nc4cccnc4)cc3C2=O)c2c(N3CCC(C(=O)NCc4cccnc4)CC3)ccnc21";"IC50";"'='";"9.0";"nM";"8.05";"";"";"UO_0000065";"12.80";"0.23";"2.89";"5.61";"False";"CHEMBL1107893";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156282";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL593515";"";"0";"297.32";"0";"1.56";"14";"Oc1cccc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)c1";"IC50";"'='";"1650.0";"nM";"5.78";"";"";"UO_0000065";"19.45";"0.36";"4.22";"6.63";"False";"CHEMBL1068429";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153170";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL591807";"";"0";"501.59";"1";"3.28";"20";"COc1ccc(CN2CCC(n3cnc4c(N5CCOCC5)nc(-c5cccc(O)c5)nc43)CC2)cn1";"IC50";"'='";"51.0";"nM";"7.29";"";"";"UO_0000065";"14.54";"0.27";"4.01";"7.17";"False";"CHEMBL1068429";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153170";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL602841";"";"0";"394.48";"0";"1.75";"22";"OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCNCC4)c3n2)c1";"IC50";"'='";"7200.0";"nM";"5.14";"";"";"UO_0000065";"13.04";"0.24";"3.39";"5.82";"True";"CHEMBL1068429";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153170";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL594844";"";"0";"314.37";"0";"1.57";"2";"Nc1ncc(-c2nc(N3CCOCC3)c3sccc3n2)cn1";"IC50";"'='";"61.0";"nM";"7.21";"";"";"UO_0000065";"22.95";"0.45";"5.64";"8.01";"False";"CHEMBL1067293";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153098";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL605529";"";"0";"507.66";"1";"3.22";"13a";"CNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3sc(CN4CCN(C)CC4)cc3n2)cc1";"IC50";"'='";"20.0";"nM";"7.70";"";"";"UO_0000065";"15.17";"0.29";"4.48";"8.97";"False";"CHEMBL1067293";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153098";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL556947";"";"0";"654.78";"2";"4.13";"27";"COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)Nc5ccc(N6CCN(C)CC6)cc5)cc4)nc32)CC1";"IC50";"'='";"0.34";"nM";"9.47";"";"";"UO_0000065";"14.46";"0.27";"5.34";"7.11";"False";"CHEMBL1058638";"Inhibition of flag-tagged truncated human mTOR (1360-2549) expressed in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1151963";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL2172629";"";"0";"349.36";"0";"1.92";"19d, 21a";"CC(=O)Nc1cc(-c2c(Nc3cc[nH]n3)nc3cccnn23)nc(C)n1";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"24.40";"0.45";"6.60";"6.78";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2172633";"";"0";"470.50";"1";"2.33";"19h";"Cc1nc(Nc2ccc(N3CCOCC3)nn2)cc(-c2c(Nc3cc[nH]n3)nc3cccnn23)n1";"IC50";"'='";"35.0";"nM";"7.46";"";"";"UO_0000065";"15.85";"0.29";"5.13";"5.07";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL551442";"";"0";"436.52";"0";"2.01";"6";"CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCNCC4)c3n2)cc1";"IC50";"'='";"1.4";"nM";"8.85";"";"";"UO_0000065";"20.28";"0.38";"6.84";"8.11";"False";"CHEMBL1058638";"Inhibition of flag-tagged truncated human mTOR (1360-2549) expressed in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1151963";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL562365";"";"0";"478.56";"0";"2.26";"15";"CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(C)=O)CC4)c3n2)cc1";"IC50";"'='";"2.1";"nM";"8.68";"";"";"UO_0000065";"18.13";"0.34";"6.42";"7.38";"False";"CHEMBL1058638";"Inhibition of flag-tagged truncated human mTOR (1360-2549) expressed in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1151963";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL558288";"";"0";"493.57";"0";"2.06";"16";"CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)NC)CC4)c3n2)cc1";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"17.62";"0.33";"6.64";"6.72";"False";"CHEMBL1058638";"Inhibition of flag-tagged truncated human mTOR (1360-2549) expressed in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1151963";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL563985";"";"0";"494.56";"0";"2.48";"18";"CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)OC)CC4)c3n2)cc1";"IC50";"'='";"0.46";"nM";"9.34";"";"";"UO_0000065";"18.88";"0.35";"6.86";"7.37";"True";"CHEMBL1058638";"Inhibition of flag-tagged truncated human mTOR (1360-2549) expressed in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1151963";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1774366";"";"0";"441.53";"0";"2.64";"22d";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)[C@@](C)(CCO)OC3)cc1";"IC50";"'='";"19.0";"nM";"7.72";"";"";"UO_0000065";"17.49";"0.33";"5.08";"7.09";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774359";"";"0";"457.53";"0";"1.61";"13h";"C[C@H]1COCCN1c1nc(-c2ccc(NC(=O)NC[C@@H](O)CO)cc2)nc2c1COC2(C)C";"IC50";"'='";"47.0";"nM";"7.33";"";"";"UO_0000065";"16.02";"0.30";"5.72";"5.68";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774376";"";"0";"413.48";"0";"1.86";"29d";"CCNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3c(n2)[C@](C)(CO)OC3)cc1";"IC50";"'='";"30.0";"nM";"7.52";"";"";"UO_0000065";"18.19";"0.34";"5.66";"6.91";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773603";"";"0";"468.56";"0";"4.43";"68";"COc1ccc(S(=O)(=O)Nc2cc(-c3ccc4nc(NC(C)=O)sc4c3)cnc2C)cc1";"IC50";"'='";"6.0";"nM";"8.22";"";"";"UO_0000065";"17.55";"0.35";"3.79";"7.46";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773730";"";"0";"493.40";"1";"5.42";"75";"CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccccc4Cl)c3)cc2s1";"IC50";"'<'";"1.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773584";"";"0";"392.51";"1";"5.00";"7";"CC(=O)Nc1nc2ccc(-c3ccnc(SCc4ccccc4)n3)cc2s1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773586";"";"0";"376.44";"0";"4.29";"9";"CC(=O)Nc1nc2ccc(-c3ccnc(OCc4ccccc4)n3)cc2s1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773566";"";"0";"405.48";"0";"4.12";"30";"CC(=O)Nc1nc2ccc(-c3ccnc(OCCCc4ccncc4)n3)cc2s1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773576";"";"0";"483.58";"0";"3.94";"39";"CCN(c1nccc(-c2ccc3nc(NC(C)=O)sc3c2)n1)S(=O)(=O)c1ccc(OC)cc1";"IC50";"'='";"262.0";"nM";"6.58";"";"";"UO_0000065";"13.61";"0.27";"2.64";"5.75";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL552532";"";"0";"558.64";"2";"3.10";"12";"O=C(Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5cccnc5)CC4)c3n2)cc1)OCCO";"IC50";"'='";"1.5";"nM";"8.82";"";"";"UO_0000065";"15.80";"0.29";"5.72";"6.75";"True";"CHEMBL1058638";"Inhibition of flag-tagged truncated human mTOR (1360-2549) expressed in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1151963";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL538378";"";"0";"557.62";"1";"3.77";"24";"COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)Nc5cccnc5)cc4)nc32)CC1";"IC50";"'='";"0.2";"nM";"9.70";"";"";"UO_0000065";"17.39";"0.32";"5.93";"6.95";"True";"CHEMBL1058638";"Inhibition of flag-tagged truncated human mTOR (1360-2549) expressed in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1151963";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL586702";"";"0";"417.42";"0";"1.82";"1, ZSTK-474";"FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1";"IC50";"'='";"350.0";"nM";"6.46";"";"";"UO_0000065";"15.47";"0.29";"4.64";"7.93";"False";"CHEMBL1942431";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1938252";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1940141";"";"0";"443.43";"0";"3.62";"6";"CCc1cc(C(F)(F)F)nn1-c1nc(-c2cccc3[nH]ccc23)nc(N2CCOCC2)n1";"IC50";"'='";"490.0";"nM";"6.31";"";"";"UO_0000065";"14.23";"0.27";"2.69";"7.45";"False";"CHEMBL1942434";"Inhibition of mTOR-mediated p70S6K phosphorylation at Thr389 in human PC3 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1938252";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";"CHEMBL3307570"
"CHEMBL2165007";"";"0";"477.55";"0";"2.97";"62";"COc1ccc(Nc2ncc(Cc3ccc(S(C)(=O)=O)cc3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165013";"";"0";"407.48";"0";"1.38";"50";"COc1ccc(Nc2ncc(CN3CCNCC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165031";"";"0";"407.48";"0";"1.72";"41";"COc1ccc(Nc2ncc(N3CCN(C)CC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"1400.0";"nM";"5.85";"";"";"UO_0000065";"14.37";"0.27";"4.13";"4.95";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165050";"";"0";"310.32";"0";"1.37";"30";"COc1ccc(Nc2nccnc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165051";"";"0";"318.34";"0";"2.97";"8";"Cc1ncnc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"7.0";"nM";"8.15";"";"";"UO_0000065";"25.62";"0.46";"5.18";"9.19";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2172488";"";"0";"387.41";"0";"1.94";"15";"Cc1nc(N)nc(-c2c(Nc3cc[nH]n3)nc3ccc(-c4cncn4C)cn23)n1";"IC50";"'='";"5.0";"nM";"8.30";"";"";"UO_0000065";"21.43";"0.39";"6.36";"5.91";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2172632";"";"0";"385.40";"0";"2.50";"19g";"Cc1nc(Nc2cccnn2)cc(-c2c(Nc3cc[nH]n3)nc3cccnn23)n1";"IC50";"'='";"24.0";"nM";"7.62";"";"";"UO_0000065";"19.77";"0.36";"5.12";"5.67";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2172640";"";"0";"384.41";"0";"2.61";"5";"Cc1nc(N)nc(-c2c(Nc3cc[nH]n3)nc3ccc(-c4ccncc4)cn23)n1";"IC50";"'='";"6.0";"nM";"8.22";"";"";"UO_0000065";"21.39";"0.39";"5.61";"6.06";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1615183";"";"0";"307.32";"0";"1.57";"1";"Cc1nc(N)nc(-n2c(Nc3cc[nH]n3)nc3ccccc32)n1";"IC50";"'='";"23.0";"nM";"7.64";"";"";"UO_0000065";"24.85";"0.45";"6.07";"6.20";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2165018";"";"0";"514.62";"2";"0.90";"55";"COc1ccc(Nc2ncc(CN3CCN(S(=O)(=O)N(C)C)CC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL577966";"";"0";"568.69";"1";"3.67";"19";"CCn1ncc2c(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(N5CCN(C)CC5)nc4)cc3)nc21";"IC50";"'='";"0.7";"nM";"9.15";"";"";"UO_0000065";"16.10";"0.30";"5.48";"7.85";"False";"CHEMBL1039195";"Inhibition of human FLAG-tagged mTOR expressed in HEK293 cells after 2 hrs by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156748";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307715"
"CHEMBL1774368";"";"0";"453.54";"0";"2.78";"22f";"CCNC(=O)Nc1ccc(-c2nc(N3C[C@@H]4CC[C@H](C3)O4)c3c(n2)[C@@](C)(CCO)OC3)cc1";"IC50";"'='";"28.0";"nM";"7.55";"";"";"UO_0000065";"16.65";"0.31";"4.77";"6.94";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774353";"";"0";"411.51";"0";"3.28";"13a";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)C(C)(C)OC3)cc1";"IC50";"'='";"4.6";"nM";"8.34";"";"";"UO_0000065";"20.26";"0.38";"5.06";"9.41";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774363";"";"0";"441.53";"0";"2.64";"22a";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)[C@](C)(CCO)OC3)cc1";"IC50";"'='";"1.7";"nM";"8.77";"";"";"UO_0000065";"19.86";"0.37";"6.13";"8.06";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774371";"";"0";"468.60";"0";"3.21";"23c";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)[C@](C)(CCN(C)C)OC3)cc1";"IC50";"'='";"51.0";"nM";"7.29";"";"";"UO_0000065";"15.56";"0.29";"4.08";"7.94";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774373";"";"0";"455.56";"0";"3.29";"29a";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)[C@](C)(CCOC)OC3)cc1";"IC50";"'='";"12.0";"nM";"7.92";"";"";"UO_0000065";"17.39";"0.33";"4.63";"8.10";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773583";"";"0";"378.48";"0";"4.86";"6";"CC(=O)Nc1nc2ccc(-c3ccnc(Sc4ccccc4)n3)cc2s1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773562";"";"0";"394.43";"0";"4.43";"26";"CC(=O)Nc1nc2ccc(-c3ccnc(OCc4ccc(F)cc4)n3)cc2s1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL565808";"";"0";"513.61";"1";"3.46";"18";"CN(C)CCn1ncc2c(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4cccnc4)cc3)nc21";"IC50";"'='";"2.7";"nM";"8.57";"";"";"UO_0000065";"16.68";"0.31";"5.11";"7.56";"False";"CHEMBL1039195";"Inhibition of human FLAG-tagged mTOR expressed in HEK293 cells after 2 hrs by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156748";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307715"
"CHEMBL1631899";"";"0";"354.25";"1";"5.00";"17";"FC(F)(F)c1cc(C#Cc2n[nH]c3ccccc23)cc(C(F)(F)F)c1";"IC50";"'>'";"100000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1633333";"Inhibition of mTOR by LanthaScreen Eu kinase binding assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1940140";"";"0";"375.44";"0";"2.60";"5";"CCc1nccn1-c1nc(-c2cccc3[nH]ccc23)nc(N2CCOCC2)n1";"IC50";"'='";"96.0";"nM";"7.02";"";"";"UO_0000065";"18.69";"0.34";"4.42";"8.28";"False";"CHEMBL1942434";"Inhibition of mTOR-mediated p70S6K phosphorylation at Thr389 in human PC3 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1938252";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";"CHEMBL3307570"
"CHEMBL1093448";"";"0";"477.56";"0";"3.62";"37";"COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)c(C)n2CCCN1CCN(C)CC1";"IC50";"'='";"153.0";"nM";"6.82";"";"";"UO_0000065";"14.27";"0.27";"3.20";"7.80";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091534";"";"0";"327.72";"0";"3.85";"7";"O=C1/C(=C/c2c[nH]c3ccc(Cl)cc23)Oc2cc(O)cc(O)c21";"IC50";"'='";"11000.0";"nM";"4.96";"";"";"UO_0000065";"15.13";"0.29";"1.11";"6.01";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1092546";"";"0";"486.58";"0";"3.54";"23";"CN(C)CCn1ccc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccccn4)cc3)nc21";"IC50";"'='";"7.0";"nM";"8.15";"";"";"UO_0000065";"16.76";"0.31";"4.61";"8.12";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1089428";"";"0";"512.62";"1";"4.07";"35";"O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)c3ccn(CCN4CCCC4)c3n2)cc1";"IC50";"'='";"7.0";"nM";"8.15";"";"";"UO_0000065";"15.91";"0.29";"4.08";"8.12";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1258408";"";"0";"530.63";"1";"3.45";"8h";"CN(C)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4C5CCC4COC5)n3)cc2)cc1";"IC50";"'='";"13.5";"nM";"7.87";"";"";"UO_0000065";"14.83";"0.28";"4.42";"7.29";"False";"CHEMBL1259905";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1255533";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1822057";"";"0";"459.89";"0";"3.95";"13";"CC(=O)Nc1cn2cc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1";"IC50";"'='";"6.6";"nM";"8.18";"";"";"UO_0000065";"17.79";"0.36";"4.23";"7.76";"False";"CHEMBL1828260";"Inhibition of recombinant N-terminal GST-tagged mTOR-mediated 4E-BP1 phosphorylation after 60 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1821651";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1822208";"";"0";"417.85";"0";"3.80";"17";"Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)cc2[nH]1";"IC50";"'='";"430.0";"nM";"6.37";"";"";"UO_0000065";"15.24";"0.31";"2.57";"5.60";"False";"CHEMBL1828260";"Inhibition of recombinant N-terminal GST-tagged mTOR-mediated 4E-BP1 phosphorylation after 60 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1821651";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1822209";"";"0";"402.84";"0";"4.22";"18";"O=S(=O)(Nc1cc(-c2ccc3nc[nH]c3c2)cnc1Cl)c1ccc(F)cc1";"IC50";"'='";"446.0";"nM";"6.35";"";"";"UO_0000065";"15.76";"0.32";"2.13";"7.24";"False";"CHEMBL1828260";"Inhibition of recombinant N-terminal GST-tagged mTOR-mediated 4E-BP1 phosphorylation after 60 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1821651";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1082622";"";"0";"551.60";"1";"4.82";"19";"COc1ccc2[nH]cc(/C=C3/Oc4ccc(NC(=O)Nc5ccc(C(=O)N6CCN(C)CC6)cc5)cc4C3=O)c2c1";"IC50";"'>'";"4000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1119658";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1158598";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL98350";"LY-294002";"0";"307.35";"0";"3.30";"1, LY294002";"O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12";"IC50";"'='";"1060.0";"nM";"5.97";"";"";"UO_0000065";"19.44";"0.35";"2.67";"14.00";"False";"CHEMBL2330617";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2321770";"1";"Scientific Literature";"J. Med. Chem.";"2013";""
"CHEMBL1241578";"";"0";"348.20";"0";"3.12";"PP487";"CC(C)n1nc(-c2ccc(Br)c(O)c2)c2c(N)ncnc21";"IC50";"'='";"72.0";"nM";"7.14";"";"";"UO_0000065";"20.51";"0.46";"4.02";"7.95";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1945953";"";"0";"377.41";"0";"2.00";"2";"O=c1[nH]c2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2n1CC1CCOCC1";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"23.05";"0.42";"6.70";"7.61";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1945493";"";"0";"334.33";"0";"2.25";"12";"O=c1[nH]c2ncc(-c3ccc(O)cc3)nc2n1Cc1cccc(O)c1";"IC50";"'='";"1050.0";"nM";"5.98";"";"";"UO_0000065";"17.88";"0.33";"3.73";"5.75";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1945494";"";"0";"318.34";"0";"2.54";"13";"O=c1[nH]c2ncc(-c3ccc(O)cc3)nc2n1Cc1ccccc1";"IC50";"'='";"1930.0";"nM";"5.71";"";"";"UO_0000065";"17.95";"0.33";"3.17";"6.82";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1945789";"";"0";"326.36";"0";"1.92";"18";"O=c1[nH]c2ncc(-c3ccc(O)cc3)nc2n1CC1CCOCC1";"IC50";"'='";"340.0";"nM";"6.47";"";"";"UO_0000065";"19.82";"0.37";"4.55";"6.95";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1945791";"";"0";"310.36";"0";"3.00";"20";"O=c1[nH]c2ncc(-c3ccc(O)cc3)nc2n1C1CCCCC1";"IC50";"'='";"2880.0";"nM";"5.54";"";"";"UO_0000065";"17.85";"0.33";"2.54";"6.61";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1945799";"";"0";"351.41";"0";"2.47";"35";"NC(=O)c1ccc(-c2cnc3[nH]c(=O)n(CC4CCCCC4)c3n2)cc1";"IC50";"'='";"70.0";"nM";"7.16";"";"";"UO_0000065";"20.36";"0.38";"4.68";"6.71";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1945948";"";"0";"366.42";"0";"3.15";"37";"COC(=O)c1ccc(-c2cnc3[nH]c(=O)n(CC4CCCCC4)c3n2)cc1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1945951";"";"0";"376.42";"0";"2.55";"42";"O=c1[nH]c2ncc(-c3ccc(-c4nn[nH]n4)cc3)nc2n1CC1CCCCC1";"IC50";"'='";"1590.0";"nM";"5.80";"";"";"UO_0000065";"15.40";"0.28";"3.25";"4.91";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1242285";"";"0";"348.20";"0";"3.12";"PP87";"CC(C)n1nc(-c2cc(O)cc(Br)c2)c2c(N)ncnc21";"IC50";"'='";"30000.0";"nM";"4.52";"";"";"UO_0000065";"12.99";"0.29";"1.40";"5.03";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242748";"";"0";"315.31";"0";"1.88";"PP432";"Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2[C@H]1CCOC1";"IC50";"'='";"9200.0";"nM";"5.04";"";"";"UO_0000065";"15.97";"0.30";"3.16";"5.08";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241483";"";"0";"301.33";"0";"2.80";"PP62";"COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1F";"IC50";"'='";"8200.0";"nM";"5.09";"";"";"UO_0000065";"16.88";"0.32";"2.29";"6.45";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242567";"";"0";"300.30";"0";"1.06";"PP413";"Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2C1CNC1";"IC50";"'='";"30000.0";"nM";"4.52";"";"";"UO_0000065";"15.06";"0.28";"3.46";"4.44";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241484";"";"0";"303.75";"0";"3.02";"PP358";"CC(C)n1nc(-c2ccc(Cl)c(O)c2)c2c(N)ncnc21";"IC50";"'='";"130.0";"nM";"6.89";"";"";"UO_0000065";"22.67";"0.45";"3.87";"7.66";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL413";"SIROLIMUS";"4";"914.19";"3";"6.18";"1";"CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C";"IC50";"'='";"1.6";"nM";"8.80";"";"";"UO_0000065";"9.62";"0.18";"2.62";"4.50";"False";"CHEMBL871328";"Inhibitory activity against FKBP12";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1141950";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2005";""
"CHEMBL179242";"";"0";"281.31";"0";"1.68";"13";"O=c1cc(N2CCOCC2)nc2c3ccccc3ccn12";"IC50";"'='";"5300.0";"nM";"5.28";"";"";"UO_0000065";"18.75";"0.34";"3.60";"11.26";"True";"CHEMBL830918";"Inhibition of mTOR protein isolated from HeLa cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HeLa";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1141182";"1";"Scientific Literature";"J. Med. Chem.";"2005";"CHEMBL3308376"
"CHEMBL593063";"";"0";"471.57";"0";"3.27";"17";"Oc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5cccnc5)CC4)c3n2)c1";"IC50";"'='";"170.0";"nM";"6.77";"";"";"UO_0000065";"14.36";"0.26";"3.50";"7.32";"False";"CHEMBL1068429";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153170";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL593768";"";"0";"380.45";"0";"1.96";"27";"Oc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCNCC4)c3n2)c1";"IC50";"'='";"870.0";"nM";"6.06";"";"";"UO_0000065";"15.93";"0.30";"4.10";"6.86";"False";"CHEMBL1074731";"Inhibition of human TOR in HEK293 cells by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153204";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL1090382";"";"0";"403.44";"0";"3.26";"10l";"Cn1cc(/C=C2\Oc3cccc(O)c3C2=O)c2c(N3C4CCC3COC4)ccnc21";"IC50";"'='";"2.1";"nM";"8.68";"";"";"UO_0000065";"21.51";"0.40";"5.42";"11.30";"False";"CHEMBL1107897";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156283";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL565637";"";"0";"469.50";"1";"1.12";"5";"COc1cc(-c2cn(-c3nc(N4CCOCC4)nc(N4CCOCC4)n3)cn2)cc(OC)c1O";"IC50";"'='";"21.0";"nM";"7.68";"";"";"UO_0000065";"16.35";"0.31";"6.56";"6.39";"False";"CHEMBL1049650";"Inhibition of mTOR kinase in human HeLa cells by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HeLa";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156040";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3308376"
"CHEMBL1242383";"";"0";"318.34";"0";"1.71";"PP231";"NC(=O)Cn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241676";"";"0";"329.79";"0";"3.55";"PP371";"Nc1ncnc2c1c(-c1ccc(Cl)c(O)c1)nn2C1CCCC1";"IC50";"'='";"439.0";"nM";"6.36";"";"";"UO_0000065";"19.28";"0.38";"2.81";"7.08";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242852";"";"0";"392.46";"0";"4.39";"PP86";"CC(C)n1nc(-c2ccc3c(ccn3C(=O)OC(C)(C)C)c2)c2c(N)ncnc21";"IC50";"'='";"300.0";"nM";"6.52";"";"";"UO_0000065";"16.62";"0.31";"2.13";"6.47";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241490";"";"0";"293.33";"0";"3.40";"PP96";"CC(C)n1nc(-c2ccc3occc3c2)c2c(N)ncnc21";"IC50";"'='";"3400.0";"nM";"5.47";"";"";"UO_0000065";"18.64";"0.34";"2.07";"6.61";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL269553";"";"0";"1001.26";"";"";"6";"CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)OC([C@H](C)C[C@@H]2CC[C@@H](OC(=O)N(C)OC)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C";"IC50";"'='";"5.8";"nM";"8.24";"";"";"UO_0000065";"8.23";"";"";"";"False";"CHEMBL871328";"Inhibitory activity against FKBP12";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1141950";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2005";""
"CHEMBL1242471";"";"0";"285.31";"0";"2.01";"PP341";"CCOc1ccc(-c2n[nH]c3ncnc(N)c23)cc1OC";"IC50";"'='";"100000.0";"nM";"4.00";"";"";"UO_0000065";"14.02";"0.26";"1.99";"4.04";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL104468";"";"0";"281.31";"0";"2.78";"4";"O=c1cc(N2CCOCC2)oc2c1ccc1ccccc12";"IC50";"'='";"6400.0";"nM";"5.19";"";"";"UO_0000065";"18.46";"0.34";"2.41";"12.17";"True";"CHEMBL830270";"Inhibition of Mammalian target of Rapamycin mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1138727";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2004";""
"CHEMBL2165039";"";"0";"333.36";"0";"2.87";"19";"COc1ccc(Nc2ncccc2-c2nc(C)nc3nc[nH]c23)cn1";"IC50";"'='";"290.0";"nM";"6.54";"";"";"UO_0000065";"19.61";"0.36";"3.67";"6.44";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165271";"";"0";"317.36";"0";"3.05";"14";"Cc1nc(N)cc(-c2cccnc2Nc2cccc3[nH]ncc23)n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165005";"";"0";"456.53";"1";"1.20";"60";"COc1ccc(Nc2ncc(CN3CCS(=O)(=O)CC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165029";"";"0";"394.44";"0";"1.81";"39";"COc1ccc(Nc2ncc(N3CCOCC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL3112725";"";"0";"359.43";"0";"3.95";"9f";"Cc1nc(N)cc2c1cc(-c1cnc3[nH]ccc3c1)c(=O)n2C1CCCC1";"IC50";"'='";"12.25";"nM";"7.91";"";"";"UO_0000065";"22.01";"0.40";"3.96";"8.83";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL2170090";"";"0";"531.62";"2";"1.92";"69";"COc1ncc(Nc2ncc(C(C)(C)N3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2173749";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169865";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL1631903";"";"0";"220.24";"0";"1.75";"21";"C(#Cc1n[nH]c2ncccc12)c1cccnc1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1633336";"Inhibition of mTORC1 expressed in HEK293 cells assessed as PRAS40 Ser183 phosphorylation level by LanthaScreen cellular assay";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";"CHEMBL3307715"
"CHEMBL1631902";"";"0";"220.24";"0";"1.75";"20";"C(#Cc1n[nH]c2ncccc12)c1ccncc1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1633333";"Inhibition of mTOR by LanthaScreen Eu kinase binding assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1631901";"";"0";"243.27";"0";"2.83";"19";"N#Cc1ccc(C#Cc2n[nH]c3ccccc23)cc1";"IC50";"'>'";"100000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1633333";"Inhibition of mTOR by LanthaScreen Eu kinase binding assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1631891";"";"0";"219.25";"0";"2.36";"9";"C(#Cc1n[nH]c2ccccc12)c1cccnc1";"IC50";"'>'";"50000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1633336";"Inhibition of mTORC1 expressed in HEK293 cells assessed as PRAS40 Ser183 phosphorylation level by LanthaScreen cellular assay";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";"CHEMBL3307715"
"CHEMBL2170084";"";"0";"571.56";"2";"2.29";"32";"COc1ncc(Nc2ncc([C@@H](N3CCN(S(C)(=O)=O)CC3)C(F)(F)F)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2173749";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169865";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2172484";"";"0";"398.43";"0";"2.91";"11";"Cc1cc(-c2ccc3nc(Nc4cc[nH]n4)c(-c4nc(C)nc(N)n4)n3c2)ccn1";"IC50";"'='";"4.0";"nM";"8.40";"";"";"UO_0000065";"21.08";"0.38";"5.49";"6.19";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2170098";"";"0";"485.57";"1";"1.05";"21";"COc1cncc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)c1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2173749";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169865";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165032";"";"0";"400.45";"0";"3.34";"42";"COc1ccc(Nc2ncc(-c3ccc(C)nc3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165040";"";"0";"328.34";"0";"3.03";"20";"c1cnc(Nc2cccc3n[nH]cc23)c(-c2ncnc3nc[nH]c23)c1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2172474";"";"0";"363.39";"0";"1.93";"21b";"CC(=O)Nc1cc(-c2c(Nc3ccn(C)n3)nc3cccnn23)nc(C)n1";"IC50";"'='";"55.0";"nM";"7.26";"";"";"UO_0000065";"19.98";"0.37";"5.33";"6.32";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL273832";"";"0";"430.45";"0";"2.33";"2, 17-hydroxywortmannin";"COC[C@H]1OC(=O)c2coc3c2[C@@]1(C)C1=C(C3=O)[C@@H]2CC[C@H](O)[C@@]2(C)C[C@H]1OC(C)=O";"IC50";"'='";"193.0";"nM";"6.71";"";"";"UO_0000065";"15.60";"0.30";"4.38";"5.98";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL1083305";"";"0";"489.51";"0";"4.70";"18c";"CNC(=O)Nc1ccc2c(c1)C(=O)/C(=C\c1c(-c3c(C)nn(C)c3C)[nH]c3c(F)cc(OC)cc13)O2";"IC50";"'='";"2.4";"nM";"8.62";"";"";"UO_0000065";"17.61";"0.33";"3.92";"7.82";"False";"CHEMBL1119658";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1158598";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL272190";"";"0";"503.59";"1";"2.64";"10";"COC[C@H]1OC(=O)/C(=C/NC(C)(C)C)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'>'";"20000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL590084";"";"0";"450.53";"0";"3.45";"22";"CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4cccs4)cc3)nc21";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"18.92";"0.36";"5.07";"7.74";"False";"CHEMBL1068073";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157707";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL591760";"";"0";"501.55";"1";"3.05";"28";"CC(C)n1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(N)=O)cc4)cc3)nc21";"IC50";"'='";"0.31";"nM";"9.51";"";"";"UO_0000065";"18.96";"0.35";"6.46";"6.21";"False";"CHEMBL1068073";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157707";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL591761";"";"0";"543.63";"1";"3.79";"30";"CC(C)n1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(N5CCOCC5)cc4)cc3)nc21";"IC50";"'='";"0.35";"nM";"9.46";"";"";"UO_0000065";"17.39";"0.32";"5.67";"7.72";"False";"CHEMBL1068073";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157707";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL589612";"";"0";"613.73";"2";"2.37";"37";"CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)NCCN5CCN(C)CC5)cc4)cc3)nc21";"IC50";"'='";"1.1";"nM";"8.96";"";"";"UO_0000065";"14.60";"0.27";"6.59";"6.15";"False";"CHEMBL1068073";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157707";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1092110";"";"0";"516.60";"1";"3.24";"6c";"CN(C)CCNC(=O)Nc1ccc2c(c1)C(=O)/C(=C/c1cn(C)c3nccc(N4CC5CCC(C4)O5)c13)O2";"IC50";"'='";"5.6";"nM";"8.25";"";"";"UO_0000065";"15.97";"0.30";"5.01";"8.17";"False";"CHEMBL1107893";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156282";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1093068";"";"0";"473.53";"0";"3.70";"6b";"CCNC(=O)Nc1ccc2c(c1)C(=O)/C(=C/c1cn(C)c3nccc(N4CC5CCC(C4)O5)c13)O2";"IC50";"'='";"57.0";"nM";"7.24";"";"";"UO_0000065";"15.30";"0.28";"3.54";"7.41";"False";"CHEMBL1107893";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156282";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1090043";"";"0";"368.39";"0";"4.56";"9b";"Cn1cc(/C=C2\Oc3cccc(O)c3C2=O)c2c(-c3ccccc3)ccnc21";"IC50";"'='";"3.5";"nM";"8.46";"";"";"UO_0000065";"22.95";"0.41";"3.90";"13.14";"True";"CHEMBL1107893";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156282";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091071";"";"0";"383.40";"0";"4.87";"2";"Cn1cc(/C=C2\Oc3cc(O)cc(O)c3C2=O)c2c(-c3ccccc3)cccc21";"IC50";"'='";"33.0";"nM";"7.48";"";"";"UO_0000065";"19.51";"0.35";"2.61";"10.44";"False";"CHEMBL1107897";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156283";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1090381";"";"0";"403.44";"0";"3.26";"10k";"Cn1cc(/C=C2\Oc3cccc(O)c3C2=O)c2c(N3CC4CCC(C3)O4)ccnc21";"IC50";"'='";"0.38";"nM";"9.42";"";"";"UO_0000065";"23.35";"0.43";"6.16";"12.26";"False";"CHEMBL1107897";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156283";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091491";"";"0";"446.51";"0";"3.20";"10d";"CN(C)C(=O)C1CCN(c2ccnc3c2c(/C=C2\Oc4cccc(O)c4C2=O)cn3C)CC1";"IC50";"'='";"0.67";"nM";"9.17";"";"";"UO_0000065";"20.55";"0.38";"5.97";"10.44";"False";"CHEMBL1107897";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156283";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1090388";"";"0";"514.58";"1";"3.50";"10f";"Cn1cc(/C=C2\Oc3cccc(O)c3C2=O)c2c(N3CCC(C(=O)N4CC5CCC(C4)O5)CC3)ccnc21";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"16.90";"0.31";"5.20";"8.96";"False";"CHEMBL1107897";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156283";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091697";"";"0";"633.71";"1";"4.83";"6n";"Cn1cc(/C=C2\Oc3ccc(NC(=O)Nc4cccnc4)cc3C2=O)c2c(N3CCC(C(=O)N4C5CCC4COC5)CC3)ccnc21";"IC50";"'='";"5.4";"nM";"8.27";"";"";"UO_0000065";"13.05";"0.24";"3.44";"6.32";"False";"CHEMBL1107893";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156282";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091701";"";"0";"634.74";"1";"4.61";"6r";"CN(C)C1CCN(C(=O)C2CCN(c3ccnc4c3c(/C=C3\Oc5ccc(NC(=O)Nc6cccnc6)cc5C3=O)cn4C)CC2)C1";"IC50";"'='";"11.0";"nM";"7.96";"";"";"UO_0000065";"12.54";"0.23";"3.35";"6.37";"False";"CHEMBL1107893";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156282";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091700";"";"0";"605.70";"2";"5.46";"6q";"Cn1cc(/C=C2\Oc3ccc(NC(=O)Nc4cccnc4)cc3C2=O)c2c(N3CCC(C(=O)N4CCCCC4)CC3)ccnc21";"IC50";"'='";"47.5";"nM";"7.32";"";"";"UO_0000065";"12.09";"0.22";"1.86";"6.02";"False";"CHEMBL1107893";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156282";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1092815";"";"0";"439.47";"0";"4.26";"9d";"CN(C)C(=O)c1ccc(-c2ccnc3c2c(/C=C2\Oc4cccc(O)c4C2=O)cn3C)cc1";"IC50";"'='";"0.55";"nM";"9.26";"";"";"UO_0000065";"21.07";"0.38";"5.00";"10.94";"False";"CHEMBL1107897";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156283";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1631898";"";"0";"233.27";"0";"2.54";"16";"Nc1ccccc1C#Cc1n[nH]c2ccccc12";"IC50";"'>'";"50000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1633336";"Inhibition of mTORC1 expressed in HEK293 cells assessed as PRAS40 Ser183 phosphorylation level by LanthaScreen cellular assay";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";"CHEMBL3307715"
"CHEMBL564099";"";"0";"450.55";"0";"2.35";"14";"CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C)CC4)c3n2)cc1";"IC50";"'='";"22.0";"nM";"7.66";"";"";"UO_0000065";"17.00";"0.32";"5.31";"7.62";"False";"CHEMBL1058638";"Inhibition of flag-tagged truncated human mTOR (1360-2549) expressed in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1151963";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1088789";"";"0";"367.45";"0";"2.02";"8";"CN(C)Cc1c[nH]c2c(N3CCOCC3)nc(-c3cccc(CO)c3)nc12";"IC50";"'='";"108.0";"nM";"6.97";"";"";"UO_0000065";"18.96";"0.35";"4.95";"8.99";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL596597";"";"0";"462.51";"0";"2.25";"19";"O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1";"IC50";"'='";"1.2";"nM";"8.92";"";"";"UO_0000065";"19.29";"0.36";"6.67";"7.58";"False";"CHEMBL1065057";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157610";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1097561";"";"0";"555.69";"1";"3.77";"16d";"CN(C)NC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)cc1";"IC50";"'='";"84.0";"nM";"7.08";"";"";"UO_0000065";"12.73";"0.24";"3.31";"6.82";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1091855";"";"0";"422.48";"0";"3.94";"35";"COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)c(C)n2CCCN(C)C";"IC50";"'='";"118.0";"nM";"6.93";"";"";"UO_0000065";"16.40";"0.31";"2.99";"8.23";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1093437";"";"0";"450.49";"0";"3.40";"33";"COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)cn2CCCN1CCOCC1";"IC50";"'='";"430.0";"nM";"6.37";"";"";"UO_0000065";"14.13";"0.26";"2.97";"6.82";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1631892";"";"0";"219.25";"0";"2.36";"10";"C(#Cc1n[nH]c2ccccc12)c1ccncc1";"IC50";"'='";"10700.0";"nM";"4.97";"";"";"UO_0000065";"22.67";"0.40";"2.61";"11.96";"False";"CHEMBL1633333";"Inhibition of mTOR by LanthaScreen Eu kinase binding assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1098310";"";"0";"373.42";"0";"2.30";"6e";"Nc1cccc(-c2nc(N3CCOCC3)c3cnn(-c4ccccc4)c3n2)n1";"IC50";"'='";"113.0";"nM";"6.95";"";"";"UO_0000065";"18.60";"0.34";"4.65";"7.31";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1091158";"";"0";"503.58";"1";"4.28";"26";"CN(C)CCn1ccc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(F)cc4)cc3)nc21";"IC50";"'='";"8.0";"nM";"8.10";"";"";"UO_0000065";"16.08";"0.30";"3.82";"9.25";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1089141";"";"0";"415.46";"0";"3.50";"29";"O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)c3cc[nH]c3n2)cc1";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"21.66";"0.40";"5.50";"8.33";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL596994";"";"0";"399.46";"0";"0.96";"10";"CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1";"IC50";"'='";"11.3";"nM";"7.95";"";"";"UO_0000065";"19.89";"0.37";"6.99";"7.59";"False";"CHEMBL1065057";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157610";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1092556";"";"0";"295.35";"0";"2.04";"7";"Nc1cccc(-c2nc(N3CCOCC3)c3[nH]ccc3n2)c1";"IC50";"'='";"430.0";"nM";"6.37";"";"";"UO_0000065";"21.56";"0.40";"4.33";"7.95";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL551440";"";"0";"527.63";"1";"3.31";"22c";"CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5cccnc5)CC4)c3n2)cc1";"IC50";"'='";"0.4";"nM";"9.40";"";"";"UO_0000065";"17.81";"0.33";"6.09";"8.29";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL610630";"";"0";"477.57";"0";"3.09";"15";"CNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn([C@H]4CC[C@H](O)CC4)c3n2)cc1";"IC50";"'='";"0.24";"nM";"9.62";"";"";"UO_0000065";"20.14";"0.38";"6.53";"8.19";"False";"CHEMBL1068272";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156873";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL601023";"";"0";"551.62";"1";"3.81";"8c";"O=C(NCCF)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(C4CCC5(CC4)OCCO5)c3n2)cc1";"IC50";"'='";"0.22";"nM";"9.66";"";"";"UO_0000065";"17.51";"0.33";"5.85";"8.35";"False";"CHEMBL1068272";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156873";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL2170093";"";"0";"469.58";"0";"1.35";"18";"Cc1ccc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2173749";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169865";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165019";"";"0";"484.59";"1";"1.98";"56";"COc1ccc(Nc2ncc(CN3CCC(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165009";"";"0";"406.49";"0";"2.96";"46";"COc1ccc(Nc2ncc(CN3CCCCC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165034";"";"0";"378.44";"0";"2.18";"44";"COc1ccc(Nc2ncc(CN3CCC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165024";"";"0";"323.36";"0";"2.28";"34";"COc1ccc(Nc2ncc(C)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165021";"";"0";"309.33";"0";"1.97";"31";"COc1ccc(Nc2nccnc2-c2cc(N)nc(C)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165046";"";"0";"308.35";"0";"2.58";"26";"COc1ccc(Nc2ccccc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165044";"";"0";"323.36";"0";"2.00";"24";"COc1ccc(N(C)c2ncccc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165052";"";"0";"294.32";"0";"2.27";"9";"Cc1nc(N)nc(-c2cccnc2Nc2cccc(O)c2)n1";"IC50";"'='";"200.0";"nM";"6.70";"";"";"UO_0000065";"22.76";"0.42";"4.43";"6.10";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL1092392";"";"0";"625.78";"1";"3.67";"3";"CN1CCN(Cc2ccc(NC(=O)Nc3ccc(-c4nc(N5C6CCC5COC6)nc(N5C6CCC5COC6)n4)cc3)cc2)CC1";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"14.38";"0.27";"5.33";"8.09";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091346";"";"0";"571.73";"1";"4.15";"17";"CC(C)N(C)c1nc(-c2ccc(NC(=O)Nc3ccc(N4CCN(C)CC4)cc3)cc2)nc(N2C3CCC2COC3)n1";"IC50";"'='";"6.6";"nM";"8.18";"";"";"UO_0000065";"14.31";"0.27";"4.03";"8.02";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL601690";"";"0";"359.41";"0";"1.26";"18";"CS(=O)(=O)c1cccc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)c1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1074731";"Inhibition of human TOR in HEK293 cells by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153204";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL589142";"";"0";"484.60";"0";"3.66";"24";"OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccccc5)CC4)c3n2)c1";"IC50";"'='";"691.0";"nM";"6.16";"";"";"UO_0000065";"12.71";"0.23";"2.50";"7.75";"False";"CHEMBL1074731";"Inhibition of human TOR in HEK293 cells by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153204";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL2063759";"";"0";"457.56";"0";"2.12";"9";"CCNC(=O)Nc1ccc(-c2nc3c(c(N4C[C@@H]5CC[C@H](C4)O5)n2)CS(=O)(=O)CC3)cc1";"IC50";"'='";"55.0";"nM";"7.26";"";"";"UO_0000065";"15.87";"0.31";"5.14";"6.40";"False";"CHEMBL2065058";"Inhibition of mTOR-mediated AKT phosphorylation at Ser473 by cell based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062409";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL590577";"";"0";"459.51";"0";"3.09";"24";"CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccnc(C)c4)cc3)nc21";"IC50";"'='";"21.0";"nM";"7.68";"";"";"UO_0000065";"16.71";"0.31";"4.59";"6.24";"False";"CHEMBL1068073";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157707";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL589412";"";"0";"543.63";"1";"3.92";"34";"CCCCNC(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)c4nnn(CC)c4n3)cc2)cc1";"IC50";"'='";"2.7";"nM";"8.57";"";"";"UO_0000065";"15.76";"0.29";"4.65";"6.16";"False";"CHEMBL1068073";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157707";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL2064419";"";"0";"314.35";"0";"0.79";"1";"O=C(Cc1nc(N2CCOCC2)cc(=O)[nH]1)Nc1ccccc1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2156799";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2150988";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2158850";"";"0";"363.42";"0";"3.13";"9h";"COc1cccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)c1";"IC50";"'='";"4600.0";"nM";"5.34";"";"";"UO_0000065";"14.69";"0.27";"2.21";"7.37";"False";"CHEMBL2161544";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2157945";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1091693";"";"0";"565.63";"1";"4.53";"6j";"CN(C)C(=O)C1CCN(c2ccnc3c2c(/C=C2\Oc4ccc(NC(=O)Nc5cccnc5)cc4C2=O)cn3C)CC1";"IC50";"'='";"10.5";"nM";"7.98";"";"";"UO_0000065";"14.11";"0.26";"3.45";"6.56";"False";"CHEMBL1107893";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156282";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091347";"";"0";"601.78";"1";"3.86";"18";"CN1CCN(c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCSCC5)nc(N5C6CCC5COC6)n4)cc3)cc2)CC1";"IC50";"'='";"8.8";"nM";"8.06";"";"";"UO_0000065";"13.39";"0.26";"4.20";"7.90";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1092569";"";"0";"379.46";"0";"2.63";"12";"Oc1cccc(-c2nc(N3CCOCC3)c3[nH]cc(C4CCNCC4)c3n2)c1";"IC50";"'='";"5900.0";"nM";"5.23";"";"";"UO_0000065";"13.78";"0.26";"2.60";"6.06";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1088832";"";"0";"487.58";"0";"4.69";"14";"Oc1cccc(-c2nc(N3CCOCC3)c3[nH]cc(C4CCN(Cc5ccc(F)cc5)CC4)c3n2)c1";"IC50";"'='";"3650.0";"nM";"5.44";"";"";"UO_0000065";"11.15";"0.21";"0.75";"7.02";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1092403";"";"0";"568.68";"1";"3.99";"51";"CCn1ccc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)N5CCN(C)CC5)cc4)cc3)nc21";"IC50";"'='";"1.4";"nM";"8.85";"";"";"UO_0000065";"15.57";"0.29";"4.86";"8.21";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL590074";"";"0";"459.51";"0";"3.34";"15";"CC(C)n1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccncc4)cc3)nc21";"IC50";"'='";"0.51";"nM";"9.29";"";"";"UO_0000065";"20.22";"0.37";"5.95";"7.56";"False";"CHEMBL1068073";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157707";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1091705";"";"0";"642.72";"2";"5.50";"6v";"CN(Cc1ccncc1)C(=O)C1CCN(c2ccnc3c2c(/C=C2\Oc4ccc(NC(=O)Nc5cccnc5)cc4C2=O)cn3C)CC1";"IC50";"'='";"9.3";"nM";"8.03";"";"";"UO_0000065";"12.50";"0.23";"2.53";"5.97";"False";"CHEMBL1107893";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156282";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1090710";"";"0";"522.57";"1";"4.60";"6i";"Cn1cc(/C=C2\Oc3ccc(NC(=O)Nc4cccnc4)cc3C2=O)c2c(N3C4CCC3COC4)ccnc21";"IC50";"'='";"42.0";"nM";"7.38";"";"";"UO_0000065";"14.12";"0.26";"2.78";"6.67";"False";"CHEMBL1107893";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156282";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1090387";"";"0";"496.53";"0";"4.07";"6g";"Cn1cc(/C=C2\Oc3ccc(NC(=O)Nc4cccnc4)cc3C2=O)c2c(N3CCOCC3)ccnc21";"IC50";"'='";"71.0";"nM";"7.15";"";"";"UO_0000065";"14.40";"0.26";"3.08";"6.46";"False";"CHEMBL1107893";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156282";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1092814";"";"0";"368.39";"0";"4.56";"9c";"Cn1cc(/C=C2\Oc3cc(O)ccc3C2=O)c2c(-c3ccccc3)ccnc21";"IC50";"'='";"19.0";"nM";"7.72";"";"";"UO_0000065";"20.96";"0.38";"3.16";"12.00";"False";"CHEMBL1107897";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156283";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091492";"";"0";"481.51";"0";"4.03";"9e";"Cn1cc(/C=C2\Oc3cccc(O)c3C2=O)c2c(-c3ccc(C(=O)N4CCOCC4)cc3)ccnc21";"IC50";"'='";"0.5";"nM";"9.30";"";"";"UO_0000065";"19.32";"0.35";"5.27";"9.91";"False";"CHEMBL1107897";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156283";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1092485";"";"0";"494.55";"0";"3.95";"9g";"CN1CCN(C(=O)c2ccc(-c3ccnc4c3c(/C=C3\Oc5cccc(O)c5C3=O)cn4C)cc2)CC1";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"18.20";"0.33";"5.05";"10.24";"False";"CHEMBL1107897";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156283";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1092486";"";"0";"501.59";"1";"2.89";"10g";"CN1CCN(C(=O)C2CCN(c3ccnc4c3c(/C=C3\Oc5cccc(O)c5C3=O)cn4C)CC2)CC1";"IC50";"'='";"3.1";"nM";"8.51";"";"";"UO_0000065";"16.96";"0.31";"5.62";"9.34";"False";"CHEMBL1107897";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156283";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL567304";"";"0";"468.51";"0";"2.80";"15";"COc1cc(-c2ccc(-c3cc(N4CCOCC4)nc(N4CCOCC4)n3)o2)cc(OC)c1O";"IC50";"'='";"23.0";"nM";"7.64";"";"";"UO_0000065";"16.30";"0.31";"4.84";"7.45";"False";"CHEMBL1049650";"Inhibition of mTOR kinase in human HeLa cells by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HeLa";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156040";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3308376"
"CHEMBL1940142";"";"0";"375.44";"0";"2.66";"7";"Cc1ccc(-c2nc(N3CCOCC3)nc(-n3ccnc3C)n2)c2cc[nH]c12";"IC50";"'='";"18.0";"nM";"7.75";"";"";"UO_0000065";"20.63";"0.38";"5.08";"9.14";"False";"CHEMBL1942431";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1938252";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2030442";"";"0";"372.45";"0";"2.01";"5";"CS(=O)(=O)Cc1cc(N2CCOCC2)nc(-c2cccc3[nH]ccc23)n1";"IC50";"'='";"330.0";"nM";"6.48";"";"";"UO_0000065";"17.40";"0.34";"4.47";"7.35";"False";"CHEMBL2330634";"Inhibition of recombinant mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2321758";"1";"Scientific Literature";"J. Med. Chem.";"2013";""
"CHEMBL2325705";"";"0";"442.54";"0";"2.51";"13";"CS(=O)(=O)C1(c2cc(N3CCOCC3)nc(-c3cccc4[nH]ccc34)n2)CCOCC1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL2330634";"Inhibition of recombinant mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2321758";"1";"Scientific Literature";"J. Med. Chem.";"2013";""
"CHEMBL1615183";"";"0";"307.32";"0";"1.57";"32";"Cc1nc(N)nc(-n2c(Nc3cc[nH]n3)nc3ccccc32)n1";"IC50";"'='";"55.0";"nM";"7.26";"";"";"UO_0000065";"23.62";"0.43";"5.69";"5.89";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762787";"";"0";"388.39";"0";"2.60";"16";"COc1nc(NCC#N)nc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'>'";"50000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL573202";"";"0";"583.65";"1";"4.30";"30";"COC(=O)N1CCC(n2ncc3c(N4C5CCC4COC5)nc(-c4ccc(NC(=O)Nc5cccnc5)cc4)nc32)CC1";"IC50";"'='";"0.16";"nM";"9.80";"";"";"UO_0000065";"16.78";"0.31";"5.50";"7.02";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL572956";"";"0";"422.49";"0";"2.22";"5b";"CC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4cccc(O)c4)nc32)CC1";"IC50";"'='";"49.0";"nM";"7.31";"";"";"UO_0000065";"17.30";"0.32";"5.09";"7.57";"False";"CHEMBL1063861";"Inhibition of human mTOR by DELFIA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154644";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL1773582";"";"0";"453.55";"0";"3.85";"45";"CC(=O)Nc1nc2ccc(-c3ccnc(N(C)S(=O)(=O)c4ccc(C)cc4)n3)cc2s1";"IC50";"'='";"269.0";"nM";"6.57";"";"";"UO_0000065";"14.49";"0.29";"2.72";"6.25";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774363";"";"0";"441.53";"0";"2.64";"22a";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)[C@](C)(CCO)OC3)cc1";"IC50";"'='";"1.6";"nM";"8.80";"";"";"UO_0000065";"19.92";"0.38";"6.16";"8.08";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL574193";"";"0";"470.58";"0";"3.87";"5h";"Oc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)cc1";"IC50";"'='";"170.0";"nM";"6.77";"";"";"UO_0000065";"14.39";"0.26";"2.90";"8.51";"False";"CHEMBL1063861";"Inhibition of human mTOR by DELFIA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154644";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL558486";"";"0";"508.58";"1";"2.87";"19";"CCNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)OC)CC4)c3n2)cc1";"IC50";"'='";"0.32";"nM";"9.49";"";"";"UO_0000065";"18.67";"0.35";"6.62";"7.49";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL1773598";"";"0";"408.51";"0";"4.87";"21";"COc1cccc(Sc2nccc(-c3ccc4nc(NC(C)=O)sc4c3)n2)c1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773575";"";"0";"469.55";"0";"3.55";"38";"COc1ccc(S(=O)(=O)N(C)c2nccc(-c3ccc4nc(NC(C)=O)sc4c3)n2)cc1";"IC50";"'='";"285.0";"nM";"6.54";"";"";"UO_0000065";"13.94";"0.28";"3.00";"5.72";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1774359";"";"0";"457.53";"0";"1.61";"13h";"C[C@H]1COCCN1c1nc(-c2ccc(NC(=O)NC[C@@H](O)CO)cc2)nc2c1COC2(C)C";"IC50";"'='";"37.0";"nM";"7.43";"";"";"UO_0000065";"16.24";"0.31";"5.82";"5.76";"False";"CHEMBL1777165";"Inhibition of mTor in human NCI-PC3 cells assessed as inhibition of Akt phosphorylation at serine473 by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773565";"";"0";"377.43";"0";"3.69";"29";"CC(=O)Nc1nc2ccc(-c3ccnc(OCc4ccncc4)n3)cc2s1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1773605";"";"0";"458.95";"0";"4.77";"71";"CC(=O)Nc1nc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccccc4)c3)cc2s1";"IC50";"'<'";"1.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL578453";"";"0";"493.62";"0";"4.65";"5o";"c1ccc(CN2CCC(n3ncc4c(N5CCOCC5)nc(-c5cccc6[nH]ccc56)nc43)CC2)cc1";"IC50";"'='";"145.0";"nM";"6.84";"";"";"UO_0000065";"13.85";"0.25";"2.19";"9.11";"False";"CHEMBL1063861";"Inhibition of human mTOR by DELFIA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154644";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL1808983";"";"0";"546.63";"1";"2.85";"13";"COc1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)N4CCNC(C)(C)C4)cc3)cc2)nc(N2CCOCC2)n1";"IC50";"'='";"18.5";"nM";"7.73";"";"";"UO_0000065";"14.15";"0.26";"4.88";"5.78";"False";"CHEMBL1810297";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1806467";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1808993";"";"0";"518.58";"1";"1.70";"27";"CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(=O)nc(N5CCOCC5)[nH]4)cc3)cc2)CC1";"IC50";"'='";"1200.0";"nM";"5.92";"";"";"UO_0000065";"11.42";"0.21";"4.22";"4.36";"False";"CHEMBL1810297";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1806467";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1774941";"HOMOTEMSIROLIMUS B";"0";"1044.33";"";"";"2b";"CC[C@@H]1/C=C/C=C/C=C(\C)[C@@H](OC)C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C1";"IC50";"'='";"2500.0";"nM";"5.60";"";"";"UO_0000065";"5.36";"";"";"";"False";"CHEMBL1777505";"Inhibition of FKBP12-independent human recombinant mTOR expressed in HEK293 cells using His6-S6K1 as a substrate by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1772963";"1";"Scientific Literature";"J. Nat. Prod.";"2011";"CHEMBL3307715"
"CHEMBL592263";"";"0";"297.32";"0";"1.56";"6";"Oc1ccc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)cc1";"IC50";"'='";"450.0";"nM";"6.35";"";"";"UO_0000065";"21.35";"0.39";"4.79";"7.28";"False";"CHEMBL1074731";"Inhibition of human TOR in HEK293 cells by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153204";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL594669";"";"0";"311.35";"0";"1.35";"7";"OCc1ccc(-c2nc(N3CCOCC3)c3nc[nH]c3n2)cc1";"IC50";"'='";"4500.0";"nM";"5.35";"";"";"UO_0000065";"17.17";"0.32";"4.00";"6.13";"False";"CHEMBL1074731";"Inhibition of human TOR in HEK293 cells by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153204";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL596533";"";"0";"470.58";"0";"3.87";"25";"Oc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccccc5)CC4)c3n2)c1";"IC50";"'='";"140.0";"nM";"6.85";"";"";"UO_0000065";"14.56";"0.27";"2.98";"8.62";"False";"CHEMBL1074731";"Inhibition of human TOR in HEK293 cells by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153204";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL1808987";"";"0";"548.65";"1";"3.10";"18";"CC(C)Oc1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)NCCN(C)C)cc3)cc2)nc(N2CCOCC2)n1";"IC50";"'='";"0.4";"nM";"9.40";"";"";"UO_0000065";"17.13";"0.32";"6.30";"7.02";"False";"CHEMBL1810297";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1806467";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1808981";"";"0";"520.59";"1";"2.32";"11";"CNCCN(C)C(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(OC)nc(N4CCOCC4)n3)cc2)cc1";"IC50";"'='";"14.5";"nM";"7.84";"";"";"UO_0000065";"15.06";"0.28";"5.52";"5.86";"False";"CHEMBL1810297";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1806467";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1089082";"";"0";"459.43";"1";"5.73";"9";"O=C(Nc1cccc(-c2ccnc3cc(-c4ccncc4)nn23)c1)c1cccc(C(F)(F)F)c1";"IC50";"'>'";"50000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1110880";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156255";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";""
"CHEMBL550972";"";"0";"526.65";"1";"3.92";"16a";"CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)cc1";"IC50";"'='";"0.5";"nM";"9.30";"";"";"UO_0000065";"17.66";"0.33";"5.38";"9.26";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1097901";"";"0";"589.70";"2";"5.21";"16n";"O=C(Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)cc1)Nc1cccnc1";"IC50";"'='";"0.8";"nM";"9.10";"";"";"UO_0000065";"15.43";"0.28";"3.89";"8.03";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1097893";"";"0";"558.66";"1";"4.26";"16g";"O=C(NCCF)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)cc1";"IC50";"'='";"1.4";"nM";"8.85";"";"";"UO_0000065";"15.85";"0.29";"4.59";"8.82";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1098619";"";"0";"414.47";"0";"3.28";"6g";"CC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(-c4ccccc4)c3n2)cc1";"IC50";"'='";"16.0";"nM";"7.80";"";"";"UO_0000065";"18.81";"0.34";"4.52";"9.15";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1090505";"";"0";"507.59";"1";"2.99";"31";"COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)c(C)n2CCN1CCN(CCCO)CC1";"IC50";"'='";"7.0";"nM";"8.15";"";"";"UO_0000065";"16.07";"0.30";"5.16";"7.58";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1089653";"";"0";"351.36";"0";"3.52";"23";"COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)c(C)n2C";"IC50";"'='";"4.0";"nM";"8.40";"";"";"UO_0000065";"23.90";"0.44";"4.88";"10.38";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1088834";"";"0";"386.20";"0";"4.27";"12";"Cc1[nH]c2ccc(Br)cc2c1/C=C1\Oc2cc(O)cc(O)c2C1=O";"IC50";"'='";"190.0";"nM";"6.72";"";"";"UO_0000065";"17.40";"0.38";"2.45";"8.14";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091883";"";"0";"385.38";"0";"4.99";"10";"O=C1/C(=C/c2c[nH]c3ccc(Oc4ccccc4)cc23)Oc2cc(O)cc(O)c21";"IC50";"'='";"5000.0";"nM";"5.30";"";"";"UO_0000065";"13.76";"0.25";"0.31";"5.78";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091882";"";"0";"323.30";"0";"3.20";"9";"COc1ccc2[nH]cc(/C=C3\Oc4cc(O)cc(O)c4C3=O)c2c1";"IC50";"'='";"265.0";"nM";"6.58";"";"";"UO_0000065";"20.34";"0.37";"3.38";"7.17";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL2170087";"";"0";"531.62";"2";"2.14";"57";"COc1ncc(Nc2ncc([C@H](C)N3CCN(S(C)(=O)=O)C[C@H]3C)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2173749";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169865";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2170083";"";"0";"517.59";"2";"1.58";"43";"COc1ncc(Nc2ncc(CN3CCN(S(C)(=O)=O)C[C@@H]3C)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2173749";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169865";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2170082";"";"0";"517.59";"2";"1.58";"42";"COc1ncc(Nc2ncc(CN3CCN(S(C)(=O)=O)C[C@H]3C)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2173749";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169865";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2170097";"";"0";"473.54";"0";"1.18";"19";"Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2cncc(F)c2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2173749";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169865";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2170096";"";"0";"503.56";"2";"1.19";"16";"COc1ncc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2173749";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169865";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2158845";"";"0";"412.48";"0";"1.77";"9c";"NS(=O)(=O)c1cccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)c1";"IC50";"'='";"610.0";"nM";"6.21";"";"";"UO_0000065";"15.07";"0.29";"4.44";"5.04";"False";"CHEMBL2161544";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2157945";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL413";"SIROLIMUS";"4";"914.19";"3";"6.18";"rapamycin";"CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C";"IC50";"'='";"0.1";"nM";"10.00";"";"";"UO_0000065";"10.94";"0.21";"3.82";"5.12";"False";"CHEMBL997061";"Inhibition of mTOR kinase expressed in human HEK293 cells by Western blot analysis";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156445";"1";"Scientific Literature";"J. Biol. Chem.";"2007";"CHEMBL3307715"
"CHEMBL2158853";"";"0";"398.49";"0";"2.78";"9k";"CCN(CC)c1cc(-c2ccnc(Nc3cccc(S(N)(=O)=O)c3)n2)ccn1";"IC50";"'='";"110.0";"nM";"6.96";"";"";"UO_0000065";"17.46";"0.34";"4.18";"6.10";"False";"CHEMBL2161544";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2157945";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1082619";"";"0";"661.76";"2";"6.09";"18g";"COc1ccc2[nH]c(-c3c(C)nn(C)c3C)c(/C=C3/Oc4ccc(NC(=O)Nc5ccc(C(=O)N(C)CCN(C)C)cc5)cc4C3=O)c2c1";"IC50";"'='";"1.1";"nM";"8.96";"";"";"UO_0000065";"13.54";"0.25";"2.87";"6.69";"False";"CHEMBL1119658";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1158598";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL577967";"";"0";"555.64";"1";"3.73";"37";"CCn1ncc2c(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)NN(C)C)cc4)cc3)nc21";"IC50";"'='";"0.3";"nM";"9.52";"";"";"UO_0000065";"17.14";"0.32";"5.79";"7.35";"False";"CHEMBL1039195";"Inhibition of human FLAG-tagged mTOR expressed in HEK293 cells after 2 hrs by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156748";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307715"
"CHEMBL570870";"";"0";"569.71";"1";"4.52";"30";"CCn1ncc2c(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(N(C)CCN(C)C)cc4)cc3)nc21";"IC50";"'='";"0.9";"nM";"9.05";"";"";"UO_0000065";"15.88";"0.29";"4.53";"8.72";"False";"CHEMBL1039195";"Inhibition of human FLAG-tagged mTOR expressed in HEK293 cells after 2 hrs by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156748";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307715"
"CHEMBL585206";"";"0";"526.65";"1";"4.59";"31";"CCn1ncc2c(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(CN(C)C)cc4)cc3)nc21";"IC50";"'='";"1.1";"nM";"8.96";"";"";"UO_0000065";"17.01";"0.31";"4.37";"8.92";"False";"CHEMBL1039195";"Inhibition of human FLAG-tagged mTOR expressed in HEK293 cells after 2 hrs by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156748";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307715"
"CHEMBL3112715";"";"0";"515.54";"1";"4.02";"9y";"COc1ncc(-c2cc3c(C)nc(N)cc3n(C(C)C)c2=O)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"125.93";"nM";"6.90";"";"";"UO_0000065";"13.38";"0.26";"2.88";"5.34";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3112707";"";"0";"573.60";"2";"5.29";"9q";"COc1ncc(-c2cc3c(C)nc(N)cc3n(C3CCCC3)c2=O)cc1NS(=O)(=O)c1ccc(C(F)(F)F)cc1";"IC50";"'='";"78.2";"nM";"7.11";"";"";"UO_0000065";"12.39";"0.24";"1.82";"5.50";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL1774940";"HOMOTEMSIROLIMUS A";"0";"1044.33";"";"";"2a";"CC[C@@H]1CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C[C@@H]([C@H](C)C[C@@H]3CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C3)OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@]1(O)O2";"IC50";"'='";"1800.0";"nM";"5.75";"";"";"UO_0000065";"5.50";"";"";"";"False";"CHEMBL1777505";"Inhibition of FKBP12-independent human recombinant mTOR expressed in HEK293 cells using His6-S6K1 as a substrate by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1772963";"1";"Scientific Literature";"J. Nat. Prod.";"2011";"CHEMBL3307715"
"CHEMBL1631900";"";"0";"224.29";"0";"3.02";"18";"C(#Cc1n[nH]c2ccccc12)c1ccsc1";"IC50";"'>'";"100000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1633333";"Inhibition of mTOR by LanthaScreen Eu kinase binding assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1631897";"";"0";"182.23";"0";"2.32";"15";"C(#CC1CC1)c1n[nH]c2ccccc12";"IC50";"'>'";"100000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1633333";"Inhibition of mTOR by LanthaScreen Eu kinase binding assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1773596";"";"0";"392.51";"1";"5.17";"19";"CC(=O)Nc1nc2ccc(-c3ccnc(Sc4ccc(C)cc4)n3)cc2s1";"IC50";"'>'";"6000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1775866";"Inhibition of mTOR assessed as inhibition of 4EBP1 phosphorylation by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773016";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL1088745";"";"0";"538.60";"1";"3.80";"13";"CCn1cc(/C=C2\Oc3cccc(O)c3C2=O)c2c(-c3ccc(C(=O)N4CCN(CCO)CC4)cc3)ccnc21";"IC50";"'='";"4.55";"nM";"8.34";"";"";"UO_0000065";"15.49";"0.28";"4.54";"7.71";"False";"CHEMBL1107897";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156283";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1093754";"";"0";"531.61";"1";"2.25";"10h";"Cn1cc(/C=C2\Oc3cccc(O)c3C2=O)c2c(N3CCC(C(=O)N4CCN(CCO)CC4)CC3)ccnc21";"IC50";"'='";"1.85";"nM";"8.73";"";"";"UO_0000065";"16.43";"0.31";"6.48";"7.84";"False";"CHEMBL1107897";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156283";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091702";"";"0";"621.70";"1";"4.69";"6s";"COC1CCN(C(=O)C2CCN(c3ccnc4c3c(/C=C3\Oc5ccc(NC(=O)Nc6cccnc6)cc5C3=O)cn4C)CC2)C1";"IC50";"'='";"8.2";"nM";"8.09";"";"";"UO_0000065";"13.01";"0.24";"3.40";"6.18";"False";"CHEMBL1107893";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156282";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091694";"";"0";"593.69";"2";"5.31";"6k";"CCN(CC)C(=O)C1CCN(c2ccnc3c2c(/C=C2\Oc4ccc(NC(=O)Nc5cccnc5)cc4C2=O)cn3C)CC1";"IC50";"'='";"115.0";"nM";"6.94";"";"";"UO_0000065";"11.69";"0.22";"1.63";"5.70";"False";"CHEMBL1107893";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156282";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1093069";"";"0";"459.51";"0";"3.31";"6a";"CNC(=O)Nc1ccc2c(c1)C(=O)/C(=C/c1cn(C)c3nccc(N4CC5CCC(C4)O5)c13)O2";"IC50";"'='";"9.5";"nM";"8.02";"";"";"UO_0000065";"17.46";"0.32";"4.71";"8.21";"False";"CHEMBL1107893";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156282";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1078983";"AZD-2014";"0";"465.55";"0";"2.64";"31";"COc1ccc(-c2ccc3c(N4CCOCC4)nc(N4C[C@H](C)O[C@H](C)C4)nc3n2)cc1CO";"IC50";"'='";"150.0";"nM";"6.82";"";"";"UO_0000065";"14.66";"0.27";"4.18";"7.33";"False";"CHEMBL1107751";"Inhibition of mTORC2 in human U87MG cells assessed as phosphorylated AKT (Ser473) level after 2 hrs by Western blotting";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87 MG";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154286";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307575"
"CHEMBL1078983";"AZD-2014";"0";"465.55";"0";"2.64";"31";"COc1ccc(-c2ccc3c(N4CCOCC4)nc(N4C[C@H](C)O[C@H](C)C4)nc3n2)cc1CO";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"18.31";"0.34";"5.88";"9.16";"False";"CHEMBL1100402";"Inhibition of recombinant FLAG-tagged mTOR expressed in HEK293 cells using biotinylated p70S6K substrate after 2 hrs by alphascreen competition assay";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154286";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307715"
"CHEMBL570833";"";"0";"621.67";"1";"4.82";"27";"CN1CCN(c2ccc(NC(=O)Nc3ccc(-c4nc(N5CC6CCC(C5)O6)c5cnn(CC(F)(F)F)c5n4)cc3)cc2)CC1";"IC50";"'='";"0.6";"nM";"9.22";"";"";"UO_0000065";"14.83";"0.28";"4.40";"8.89";"False";"CHEMBL1039195";"Inhibition of human FLAG-tagged mTOR expressed in HEK293 cells after 2 hrs by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156748";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307715"
"CHEMBL1082618";"";"0";"659.75";"2";"5.84";"18f";"COc1ccc2[nH]c(-c3c(C)nn(C)c3C)c(/C=C3/Oc4ccc(NC(=O)Nc5ccc(C(=O)N6CCN(C)CC6)cc5)cc4C3=O)c2c1";"IC50";"'='";"3.8";"nM";"8.42";"";"";"UO_0000065";"12.76";"0.23";"2.58";"6.29";"False";"CHEMBL1119658";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1158598";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1774377";"";"0";"427.51";"0";"2.25";"29e";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(n2)[C@@](C)(CO)OC3)cc1";"IC50";"'='";"77.0";"nM";"7.11";"";"";"UO_0000065";"16.64";"0.31";"4.86";"6.54";"False";"CHEMBL1777163";"Inhibition of mTOR in human NCI-PC3 cells assessed as inhibition of p70S6k phosphorylation by electrochemiluminescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"NCI-PC3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1773044";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL3653624";"";"0";"510.41";"1";"4.43";"BDBM136481";"O=C1OC[C@H](c2ccc(C(F)(F)F)cn2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"2.6";"nM";"8.59";"";"270355";"UO_0000065";"16.82";"0.32";"4.16";"7.52";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653638";"";"0";"454.45";"0";"3.28";"BDBM136495";"COc1cccc([C@H]2COC(=O)N2c2ccn3ncc(-c4ccc(-c5nc[nH]n5)cc4)c3n2)n1";"IC50";"'='";"7.5";"nM";"8.12";"";"270369";"UO_0000065";"17.88";"0.33";"4.84";"6.58";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653594";"";"0";"449.45";"0";"3.07";"BDBM136451";"O=C1OC[C@H](C2CCOCC2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"4.4";"nM";"8.36";"";"270325";"UO_0000065";"18.59";"0.35";"5.29";"7.56";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653595";"";"0";"448.46";"0";"2.65";"BDBM136452";"O=C1OCC(C2CCNCC2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"257.0";"nM";"6.59";"";"270326";"UO_0000065";"14.69";"0.27";"3.94";"5.81";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL1082617";"";"0";"646.70";"2";"5.93";"18e";"COc1ccc2[nH]c(-c3c(C)nn(C)c3C)c(/C=C3/Oc4ccc(NC(=O)Nc5ccc(C(=O)N6CCOCC6)cc5)cc4C3=O)c2c1";"IC50";"'='";"4.2";"nM";"8.38";"";"";"UO_0000065";"12.95";"0.24";"2.45";"5.99";"False";"CHEMBL1119658";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1158598";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1092119";"";"0";"488.54";"0";"2.97";"10e";"Cn1cc(/C=C2\Oc3cccc(O)c3C2=O)c2c(N3CCC(C(=O)N4CCOCC4)CC3)ccnc21";"IC50";"'='";"1.4";"nM";"8.85";"";"";"UO_0000065";"18.12";"0.34";"5.88";"9.12";"False";"CHEMBL1107897";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156283";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091360";"";"0";"585.71";"1";"3.18";"31";"C[C@@H]1COCCN1c1nc(-c2ccc(NC(=O)Nc3ccc(N4CCNCC4)cc3)cc2)nc(N2C3CCC2COC3)n1";"IC50";"'='";"0.4";"nM";"9.40";"";"";"UO_0000065";"16.05";"0.30";"6.22";"7.83";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1076864";"";"0";"613.77";"1";"3.92";"32";"CCN1CCN(c2ccc(NC(=O)Nc3ccc(-c4nc(N5C6CCC5COC6)nc(N5CCOC[C@H]5C)n4)cc3)cc2)CC1";"IC50";"'='";"1.2";"nM";"8.92";"";"";"UO_0000065";"14.53";"0.27";"5.00";"8.02";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091713";"";"0";"655.80";"1";"3.94";"36";"CC(C)N1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5C6CCC5COC6)nc(N5CCOC[C@H]5C)n4)cc3)cc2)CC1";"IC50";"'='";"0.42";"nM";"9.38";"";"";"UO_0000065";"14.30";"0.27";"5.44";"7.31";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1092389";"";"0";"655.80";"1";"3.94";"37";"C[C@@H]1COCCN1c1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)N4CCC(N(C)C)CC4)cc3)cc2)nc(N2C3CCC2COC3)n1";"IC50";"'='";"0.25";"nM";"9.60";"";"";"UO_0000065";"14.64";"0.27";"5.66";"7.48";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1093446";"";"0";"337.33";"0";"3.21";"22";"COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)cn2C";"IC50";"'='";"62.0";"nM";"7.21";"";"";"UO_0000065";"21.37";"0.39";"4.00";"8.91";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091070";"";"0";"307.31";"0";"3.21";"21";"Cn1cc(/C=C2\Oc3cc(O)cc(O)c3C2=O)c2ccccc21";"IC50";"'='";"800.0";"nM";"6.10";"";"";"UO_0000065";"19.84";"0.36";"2.89";"8.50";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1092189";"";"0";"464.52";"0";"3.71";"36";"COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)c(C)n2CCCN1CCOCC1";"IC50";"'='";"18.0";"nM";"7.75";"";"";"UO_0000065";"16.67";"0.31";"4.03";"8.29";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091854";"";"0";"493.56";"0";"2.68";"34";"COc1ccc2c(c1)c(/C=C1\Oc3cc(O)cc(O)c3C1=O)cn2CCCN1CCN(CCO)CC1";"IC50";"'='";"1650.0";"nM";"5.78";"";"";"UO_0000065";"11.72";"0.22";"3.10";"5.37";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1097262";"";"0";"372.43";"0";"2.90";"6b";"Nc1cccc(-c2nc(N3CCOCC3)c3cnn(-c4ccccc4)c3n2)c1";"IC50";"'='";"111.0";"nM";"6.96";"";"";"UO_0000065";"18.67";"0.34";"4.05";"8.47";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1097899";"";"0";"609.78";"1";"4.38";"16l";"CN1CCC(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)c4cnn(C5CCN(Cc6ccccc6)CC5)c4n3)cc2)CC1";"IC50";"'='";"125.0";"nM";"6.90";"";"";"UO_0000065";"11.32";"0.21";"2.52";"6.66";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL595507";"";"0";"556.67";"2";"3.10";"18";"Oc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccc(N6CCOCC6)nc5)CC4)c3n2)c1";"IC50";"'='";"152.0";"nM";"6.82";"";"";"UO_0000065";"12.25";"0.23";"3.72";"6.50";"False";"CHEMBL1068429";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153170";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL595743";"";"0";"339.42";"0";"2.70";"8d";"Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3sccc3n2)cn1";"IC50";"'='";"35.0";"nM";"7.46";"";"";"UO_0000065";"21.97";"0.42";"4.76";"9.66";"False";"CHEMBL1067293";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153098";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1082986";"";"0";"534.58";"2";"5.85";"18b";"COc1ccc2[nH]c(-c3c(C)nn(C)c3C)c(/C=C3/Oc4ccc(NC(=O)Nc5cccnc5)cc4C3=O)c2c1";"IC50";"'='";"5.2";"nM";"8.28";"";"";"UO_0000065";"15.50";"0.28";"2.43";"6.73";"False";"CHEMBL1119658";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1158598";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1822213";"";"0";"403.83";"0";"3.38";"21";"O=S(=O)(Nc1cc(-c2ccc3nncn3c2)cnc1Cl)c1ccc(F)cc1";"IC50";"'>'";"25000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1828260";"Inhibition of recombinant N-terminal GST-tagged mTOR-mediated 4E-BP1 phosphorylation after 60 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1821651";"1";"Scientific Literature";"J. Med. Chem.";"2011";""
"CHEMBL3586389";"";"0";"377.45";"0";"3.20";"21";"O=C1CNc2ncc(-c3ccc4[nH]ccc4c3)nc2N1CCC1CCOCC1";"IC50";"'='";"72.0";"nM";"7.14";"";"";"UO_0000065";"18.92";"0.35";"3.94";"8.59";"False";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL601445";"";"0";"491.60";"0";"3.74";"13";"CNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn([C@H]4CC[C@@H](OC)CC4)c3n2)cc1";"IC50";"'='";"0.33";"nM";"9.48";"";"";"UO_0000065";"19.29";"0.36";"5.74";"8.91";"False";"CHEMBL1068272";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156873";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL3586564";"";"0";"420.48";"0";"2.35";"17";"CO[C@H]1CC[C@H](N2CC(=O)Nc3ncc(-c4ccc(-c5nc[nH]n5)nc4C)nc32)CC1";"IC50";"'='";"41.0";"nM";"7.39";"";"";"UO_0000065";"17.57";"0.33";"5.04";"6.06";"False";"CHEMBL3587521";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585264";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL602682";"";"0";"423.48";"0";"1.60";"3e";"CNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(CCO)c3n2)cc1";"IC50";"'='";"2.85";"nM";"8.54";"";"";"UO_0000065";"20.18";"0.38";"6.95";"7.28";"False";"CHEMBL1068272";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156873";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL597825";"";"0";"518.58";"1";"2.22";"23";"CNC(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)nc(N4CCOCC4)n3)cc2)cc1";"IC50";"'='";"0.7";"nM";"9.15";"";"";"UO_0000065";"17.65";"0.33";"6.93";"6.84";"False";"CHEMBL1065057";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157610";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL3109134";"";"0";"309.33";"0";"0.90";"4m";"Nc1ncc(-c2nc(N3CCOCC3)c3ncccc3n2)cn1";"IC50";"'='";"59.0";"nM";"7.23";"";"";"UO_0000065";"23.37";"0.43";"6.33";"7.02";"False";"CHEMBL3112126";"Inhibition of mTOR (unknown origin) after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3108735";"1";"Scientific Literature";"J. Med. Chem.";"2014";""
"CHEMBL2158852";"";"0";"333.40";"0";"3.12";"9j";"c1ccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)cc1";"IC50";"'>'";"4000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2161544";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2157945";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2158844";"";"0";"367.84";"0";"3.77";"9b";"Clc1cccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)c1";"IC50";"'>'";"20000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2161544";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2157945";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2158842";"";"0";"437.53";"0";"3.16";"2";"NS(=O)(=O)c1ccc(Nc2nccc(-c3cccc(C(=O)N4CCCCC4)c3)n2)cc1";"IC50";"'='";"890.0";"nM";"6.05";"";"";"UO_0000065";"13.83";"0.27";"2.89";"5.12";"False";"CHEMBL2161544";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2157945";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2158846";"";"0";"367.84";"0";"3.77";"9d";"Clc1ccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)cc1";"IC50";"'>'";"20000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2161544";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2157945";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL592063";"";"0";"502.54";"1";"3.18";"29";"CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)OC)cc4)cc3)nc21";"IC50";"'='";"2.55";"nM";"8.59";"";"";"UO_0000065";"17.10";"0.32";"5.41";"6.30";"False";"CHEMBL1068073";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157707";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL590594";"";"0";"572.67";"1";"3.07";"38";"CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)NCCCN(C)C)cc4)cc3)nc21";"IC50";"'='";"2.2";"nM";"8.66";"";"";"UO_0000065";"15.12";"0.28";"5.59";"6.08";"False";"CHEMBL1068073";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157707";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL605121";"";"0";"505.58";"1";"2.39";"16";"O=C(Nc1ccc(CCO)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1";"IC50";"'='";"1.8";"nM";"8.74";"";"";"UO_0000065";"17.30";"0.32";"6.35";"7.00";"False";"CHEMBL1065057";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157610";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1242755";"";"0";"330.40";"0";"3.74";"PP122";"Nc1ncnc2c1c(-c1cnc3ccccc3c1)nn2C1CCCC1";"IC50";"'='";"243.0";"nM";"6.61";"";"";"UO_0000065";"20.02";"0.36";"2.87";"8.02";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242477";"";"0";"293.33";"0";"2.53";"PP110";"CC(C)n1nc(-c2ccc3cn[nH]c3c2)c2c(N)ncnc21";"IC50";"'='";"1200.0";"nM";"5.92";"";"";"UO_0000065";"20.18";"0.37";"3.39";"6.02";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL599246";"";"0";"479.52";"0";"2.99";"11";"O=C(Nc1ccc(F)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1";"IC50";"'='";"3.9";"nM";"8.41";"";"";"UO_0000065";"17.54";"0.33";"5.42";"8.03";"False";"CHEMBL1065057";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157610";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL98350";"LY-294002";"0";"307.35";"0";"3.30";"1, LY294002";"O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12";"IC50";"'='";"3018.0";"nM";"5.52";"";"";"UO_0000065";"17.96";"0.33";"2.22";"12.93";"False";"CHEMBL1687369";"inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1681781";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2011";""
"CHEMBL1083192";"";"0";"490.62";"1";"0.64";"4";"CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cnc(N)nc4)nc(N4CCOCC4)c3s2)CC1";"IC50";"'='";"29.0";"nM";"7.54";"";"";"UO_0000065";"15.36";"0.31";"6.90";"5.77";"False";"CHEMBL1103322";"Inhibition of human recombinant mTOR by FRET";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154879";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL2064348";"";"0";"401.47";"0";"2.75";"26";"Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2cccc(-c3ccccc3)c21";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064346";"";"0";"387.44";"0";"2.74";"24";"O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4ccccc4)cccc3[nH]2)[nH]1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064339";"";"0";"379.34";"0";"2.09";"17";"O=c1cc(N2CCOCC2)nc(Cc2nc3cc(C(F)(F)F)ccc3[nH]2)[nH]1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL411735";"";"0";"1021.34";"";"";"1";"C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)C2C[C@@](O)(C(=O)C(=O)N3CCCCC3C(=O)O[C@H](C(C)C[C@@H]3CC[C@@H](CC(=O)Nc4ccc(CCCC(=O)OC)cc4)C(OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC";"IC50";"'='";"1.45";"nM";"8.84";"";"";"UO_0000065";"8.65";"";"";"";"False";"CHEMBL829473";"Inhibitory activity against macrophilin (FKBP-12)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1138768";"1";"Scientific Literature";"J. Med. Chem.";"2004";""
"CHEMBL589142";"";"0";"484.60";"0";"3.66";"4";"OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccccc5)CC4)c3n2)c1";"IC50";"'='";"634.0";"nM";"6.20";"";"";"UO_0000065";"12.79";"0.24";"2.54";"7.79";"True";"CHEMBL1068073";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157707";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL590578";"";"0";"501.60";"1";"4.02";"25";"CC(C)n1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(N(C)C)cc4)cc3)nc21";"IC50";"'='";"1.6";"nM";"8.80";"";"";"UO_0000065";"17.54";"0.32";"4.78";"7.76";"False";"CHEMBL1068073";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157707";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1241863";"";"0";"320.36";"0";"2.50";"PP140";"CC(C)n1nc(-c2ccc3[nH]c(=O)ccc3c2)c2c(N)ncnc21";"IC50";"'='";"8700.0";"nM";"5.06";"";"";"UO_0000065";"15.80";"0.29";"2.56";"4.94";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241486";"";"0";"356.43";"0";"2.46";"PP99";"COc1cc(-c2nn(C(C)C)c3ncnc(N)c23)ccc1NC(C)CO";"IC50";"'='";"18000.0";"nM";"4.75";"";"";"UO_0000065";"13.31";"0.25";"2.28";"4.27";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1083508";"";"0";"395.49";"0";"3.30";"3";"CC(C)(O)c1cc2nc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)c2s1";"IC50";"'='";"130.0";"nM";"6.89";"";"";"UO_0000065";"17.41";"0.34";"3.59";"7.90";"False";"CHEMBL1103322";"Inhibition of human recombinant mTOR by FRET";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154879";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL602884";"";"0";"450.55";"0";"2.17";"3f";"CNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(CCN(C)C)c3n2)cc1";"IC50";"'='";"14.5";"nM";"7.84";"";"";"UO_0000065";"17.40";"0.32";"5.67";"7.80";"False";"CHEMBL1068272";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156873";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL521851";"PICTILISIB";"2";"513.65";"1";"2.15";"2, GDC-0941";"CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1";"IC50";"'='";"310.0";"nM";"6.51";"";"";"UO_0000065";"12.67";"0.25";"4.36";"6.05";"False";"CHEMBL1103322";"Inhibition of human recombinant mTOR by FRET";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154879";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL2064412";"";"0";"388.43";"0";"3.01";"40";"O=c1cc(N2CCOCC2)nc(Cc2nc3cccc(-c4ccccc4)c3o2)[nH]1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064345";"";"0";"401.47";"0";"2.60";"23";"O=c1cc(N2CCOCC2)nc(Cc2nc3ccccc3n2Cc2ccccc2)[nH]1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064416";"";"0";"389.42";"0";"2.40";"44";"O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4ccncc4)cccc3o2)[nH]1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2058168";"";"0";"438.49";"0";"0.64";"7";"Nc1ncc(-c2cn3cc(C(=O)N[C@H]4CC[C@H](O)CC4)nc3c(N3CCOCC3)n2)cn1";"IC50";"'='";"989.0";"nM";"6.00";"";"";"UO_0000065";"13.69";"0.26";"5.36";"4.18";"False";"CHEMBL2060320";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2057167";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2418343";"";"0";"395.47";"0";"2.40";"11d";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@H]3C)c3c(ncn3C)n2)cc1";"IC50";"'='";"730.0";"nM";"6.14";"";"";"UO_0000065";"15.52";"0.29";"3.74";"6.31";"False";"CHEMBL2421122";"Inhibition of mTOR in PTEN deficient human PC3 cells assessed as inhibition of p70S6K phosphorylation";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2417437";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";"CHEMBL3307570"
"CHEMBL272281";"";"0";"575.66";"2";"2.53";"Table S1, S11";"COC[C@H]1OC(=O)/C(=C/N(C)CC(=O)OC(C)(C)C)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"13900.0";"nM";"4.86";"";"";"UO_0000065";"8.44";"0.16";"2.33";"3.26";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL272897";"";"0";"560.69";"1";"2.53";"Table S1, S3";"CCN(/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)[C@@H](O)CC[C@@H]12)CCCN(C)C";"IC50";"'='";"3570.0";"nM";"5.45";"";"";"UO_0000065";"9.72";"0.19";"2.92";"4.33";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL409251";"";"0";"517.62";"1";"2.98";"11";"CCCCN(C)/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](OC(C)=O)C[C@]2(C)[C@@H](O)CC[C@@H]12";"IC50";"'='";"8700.0";"nM";"5.06";"";"";"UO_0000065";"9.78";"0.19";"2.08";"4.13";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL406655";"";"0";"461.56";"0";"2.02";"6";"CCN(/C=C1/C(=O)O[C@H](COC)[C@@]2(C)C1=C(O)C(=O)C1=C2[C@H](O)C[C@]2(C)[C@@H](O)CC[C@@H]12)CC";"IC50";"'>'";"20000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL271257";"";"0";"608.73";"1";"3.32";"17";"COC[C@H]1OC(=O)/C(=C/N(CCN(C)C)Cc2ccccc2)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"5600.0";"nM";"5.25";"";"";"UO_0000065";"8.63";"0.16";"1.93";"4.17";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL1082620";"";"0";"664.69";"2";"6.07";"18h";"COc1cc(F)c2[nH]c(-c3c(C)nn(C)c3C)c(/C=C3/Oc4ccc(NC(=O)Nc5ccc(C(=O)N6CCOCC6)cc5)cc4C3=O)c2c1";"IC50";"'='";"2.5";"nM";"8.60";"";"";"UO_0000065";"12.94";"0.24";"2.53";"6.15";"False";"CHEMBL1119658";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1158598";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL3109146";"";"0";"427.47";"0";"3.57";"13g";"O=C(Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1)Nc1cccnc1";"IC50";"'='";"35.0";"nM";"7.46";"";"";"UO_0000065";"17.44";"0.32";"3.89";"7.09";"False";"CHEMBL3112126";"Inhibition of mTOR (unknown origin) after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3108735";"1";"Scientific Literature";"J. Med. Chem.";"2014";""
"CHEMBL3109139";"";"0";"309.33";"0";"0.90";"12c";"Nc1ncc(-c2nc(N3CCOCC3)c3cccnc3n2)cn1";"IC50";"'='";"400.0";"nM";"6.40";"";"";"UO_0000065";"20.68";"0.38";"5.50";"6.22";"False";"CHEMBL3112126";"Inhibition of mTOR (unknown origin) after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3108735";"1";"Scientific Literature";"J. Med. Chem.";"2014";""
"CHEMBL3109142";"";"0";"456.51";"0";"3.66";"13c";"O=C(Nc1ccc(CO)cc1)Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1";"IC50";"'='";"5.0";"nM";"8.30";"";"";"UO_0000065";"18.18";"0.33";"4.64";"7.38";"True";"CHEMBL3112126";"Inhibition of mTOR (unknown origin) after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3108735";"1";"Scientific Literature";"J. Med. Chem.";"2014";""
"CHEMBL2172483";"";"0";"414.43";"0";"2.61";"10";"COc1ncccc1-c1ccc2nc(Nc3cc[nH]n3)c(-c3nc(C)nc(N)n3)n2c1";"IC50";"'='";"39.0";"nM";"7.41";"";"";"UO_0000065";"17.88";"0.33";"4.80";"5.12";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL3349370";"";"0";"599.67";"2";"5.76";"52, XL765, SAR245409";"COc1cc(Nc2nc3ccccc3nc2NS(=O)(=O)c2ccc(NC(=O)c3ccc(C)c(OC)c3)cc2)cc(OC)c1";"IC50";"'='";"190.0";"nM";"6.72";"";"";"UO_0000065";"11.21";"0.21";"0.96";"4.77";"False";"CHEMBL3223610";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3217752";"1";"Scientific Literature";"MedChemComm";"2012";""
"CHEMBL6449";"";"0";"346.43";"0";"2.16";"S1M1M'3";"CC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(=O)OCCCc1cccnc1";"IC50";"'<'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL682171";"The inhibitory activity by using FK506 binding protein 12 SPA binding assay.";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1132865";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2000";""
"CHEMBL6833";"";"0";"352.48";"0";"2.01";"S1M3M'2";"CC(C)CC(=O)C(=O)N1CCC[C@H]1C(=O)OC(C)CN1CCCCC1";"IC50";"'<'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL682171";"The inhibitory activity by using FK506 binding protein 12 SPA binding assay.";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1132865";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2000";""
"CHEMBL3923749";"";"0";"535.05";"1";"3.65";"BDBM222618";"CSc1c(Cl)nc(-c2ccc(NC(=O)Nc3ccc(S(N)(=O)=O)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"26.8";"nM";"7.57";"";"389407";"UO_0000065";"14.15";"0.30";"3.92";"5.43";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL1089422";"";"0";"369.38";"0";"4.86";"14";"O=C1/C(=C/c2c(-c3ccccc3)[nH]c3ccccc23)Oc2cc(O)cc(O)c21";"IC50";"'='";"130.0";"nM";"6.89";"";"";"UO_0000065";"18.64";"0.34";"2.03";"8.34";"False";"CHEMBL1109869";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156153";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1095946";"";"0";"543.63";"1";"3.24";"22d";"CONC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5cccnc5)CC4)c3n2)cc1";"IC50";"'='";"23.0";"nM";"7.64";"";"";"UO_0000065";"14.05";"0.26";"4.40";"6.23";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL556947";"";"0";"654.78";"2";"4.13";"25e";"COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)Nc5ccc(N6CCN(C)CC6)cc5)cc4)nc32)CC1";"IC50";"'='";"0.3";"nM";"9.52";"";"";"UO_0000065";"14.54";"0.27";"5.39";"7.15";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1098244";"";"0";"556.63";"1";"4.38";"25d";"COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)Nc5ccccc5)cc4)nc32)CC1";"IC50";"'='";"0.3";"nM";"9.52";"";"";"UO_0000065";"17.11";"0.32";"5.14";"7.51";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL563985";"";"0";"494.56";"0";"2.48";"25a";"CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)OC)CC4)c3n2)cc1";"IC50";"'='";"0.5";"nM";"9.30";"";"";"UO_0000065";"18.81";"0.35";"6.82";"7.34";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1098243";"";"0";"562.68";"1";"4.19";"27c";"CC(C)(C)OC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)NC5CC5)cc4)nc32)CC1";"IC50";"'='";"0.6";"nM";"9.22";"";"";"UO_0000065";"16.39";"0.31";"5.03";"7.28";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL3112718";"";"0";"458.45";"0";"3.07";"2g";"COc1ncc(-c2cnc3nc(N)nc(C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"35.3";"nM";"7.45";"";"";"UO_0000065";"16.26";"0.32";"4.38";"5.60";"True";"CHEMBL3380578";"Inhibition of mTOR (unknown origin) assessed as inhibition of 4EBP-1 phosphorylation preincubated for 15 mins before substrate addition by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3351642";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL2158857";"";"0";"410.50";"0";"2.92";"9o";"NS(=O)(=O)c1cccc(Nc2nccc(-c3ccnc(N4CCCCC4)c3)n2)c1";"IC50";"'='";"140.0";"nM";"6.85";"";"";"UO_0000065";"16.70";"0.32";"3.93";"6.01";"False";"CHEMBL2161544";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2157945";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL411950";"";"0";"517.58";"1";"1.58";"Table S1, S28";"COC[C@H]1OC(=O)/C(=C/N2CCOCC2)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"831.0";"nM";"6.08";"";"";"UO_0000065";"11.75";"0.22";"4.50";"4.61";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL270746";"";"0";"517.62";"1";"2.98";"9";"COC[C@H]1OC(=O)/C(=C/N(C)C(C)(C)C)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"6500.0";"nM";"5.19";"";"";"UO_0000065";"10.02";"0.19";"2.21";"4.23";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL271780";"";"0";"601.74";"2";"1.82";"Table S1, S21";"COC[C@H]1OC(=O)/C(=C/N2CCN(CCCN(C)C)CC2)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"249.0";"nM";"6.60";"";"";"UO_0000065";"10.97";"0.21";"4.78";"5.12";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL270039";"";"0";"515.60";"1";"2.74";"Table S1, S30";"COC[C@H]1OC(=O)/C(=C/N2CCCCC2)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"1800.0";"nM";"5.75";"";"";"UO_0000065";"11.14";"0.21";"3.00";"4.69";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL405230";"";"0";"598.74";"1";"3.20";"Table S1, S27";"COC[C@H]1OC(=O)/C(=C/N2CCC(N3CCCCC3)CC2)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'='";"568.0";"nM";"6.25";"";"";"UO_0000065";"10.43";"0.20";"3.05";"4.96";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL412076";"";"0";"535.59";"2";"0.54";"Table S1, S13";"COC[C@H]1OC(=O)/C(=C/N(CCO)CCO)C2=C(O)C(=O)C3=C([C@H](OC(C)=O)C[C@]4(C)[C@@H](O)CC[C@@H]34)[C@]21C";"IC50";"'>'";"18700.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL934449";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1143164";"1";"Scientific Literature";"J. Med. Chem.";"2008";""
"CHEMBL1615183";"";"0";"307.32";"0";"1.57";"32";"Cc1nc(N)nc(-n2c(Nc3cc[nH]n3)nc3ccccc32)n1";"IC50";"'='";"390.0";"nM";"6.41";"";"";"UO_0000065";"20.85";"0.38";"4.84";"5.20";"False";"CHEMBL1763481";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of 4EBP1 at T37/46";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762776";"";"0";"401.35";"0";"3.63";"4";"Oc1cccc(Nc2nc3ccccc3n2-c2ncnc(NCC(F)(F)F)n2)c1";"IC50";"'>'";"50000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1763480";"Inhibition of mTOR assessed as inhibition of phosphorylation of 4EBP1 by Lantha-Screen enzyme assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1762786";"";"0";"317.35";"0";"3.57";"15";"Cc1nccc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"600.0";"nM";"6.22";"";"";"UO_0000065";"19.61";"0.35";"2.65";"8.20";"False";"CHEMBL1763561";"Inhibition of mTOR in human U-87 cells assessed as inhibition of phosphorylation of AKT at S473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"U-87";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1759974";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL3109143";"";"0";"442.48";"0";"3.88";"13d";"O=C(Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1)Nc1cccc(O)c1";"IC50";"'='";"36.0";"nM";"7.44";"";"";"UO_0000065";"16.82";"0.31";"3.56";"6.62";"False";"CHEMBL3112126";"Inhibition of mTOR (unknown origin) after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3108735";"1";"Scientific Literature";"J. Med. Chem.";"2014";""
"CHEMBL3112723";"";"0";"351.41";"0";"2.87";"9d";"COc1ncc(-c2cc3c(C)nc(N)cc3n(C3CCCC3)c2=O)cn1";"IC50";"'='";"36.54";"nM";"7.44";"";"";"UO_0000065";"21.16";"0.39";"4.57";"7.75";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3112711";"";"0";"546.07";"1";"4.99";"9u";"COc1ncc(-c2cc3c(C)nc(N)cc3n(C3CCCC3)c2=O)cc1NS(=O)(=O)c1ccc(Cl)s1";"IC50";"'='";"8.49";"nM";"8.07";"";"";"UO_0000065";"14.78";"0.31";"3.08";"6.25";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3109115";"";"0";"308.34";"0";"2.23";"9";"Oc1cccc(-c2nc(N3CCOCC3)nc3cccnc23)c1";"IC50";"'='";"453.0";"nM";"6.34";"";"";"UO_0000065";"20.57";"0.38";"4.11";"8.89";"False";"CHEMBL3112126";"Inhibition of mTOR (unknown origin) after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3108735";"1";"Scientific Literature";"J. Med. Chem.";"2014";""
"CHEMBL1092781";"";"0";"524.58";"1";"3.31";"9h";"Cn1cc(/C=C2\Oc3cccc(O)c3C2=O)c2c(-c3ccc(C(=O)N4CCN(CCO)CC4)cc3)ccnc21";"IC50";"'='";"0.39";"nM";"9.41";"";"";"UO_0000065";"17.94";"0.33";"6.10";"8.70";"False";"CHEMBL1107897";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156283";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1094015";"";"0";"418.45";"0";"2.60";"10i";"Cn1cc(/C=C2\Oc3cccc(O)c3C2=O)c2c(N3CCC(C(N)=O)CC3)ccnc21";"IC50";"'='";"0.72";"nM";"9.14";"";"";"UO_0000065";"21.85";"0.40";"6.54";"8.26";"False";"CHEMBL1107897";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156283";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL2172482";"";"0";"398.43";"0";"2.91";"9";"Cc1nc(N)nc(-c2c(Nc3cc[nH]n3)nc3ccc(-c4cnccc4C)cn23)n1";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"21.83";"0.40";"5.79";"6.42";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1615182";"";"0";"358.36";"0";"2.60";"5";"N#CCNc1ncnc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1";"IC50";"'='";"93.0";"nM";"7.03";"";"";"UO_0000065";"19.62";"0.36";"4.43";"5.64";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165036";"";"0";"371.33";"0";"3.76";"16";"Nc1cc(-c2cccnc2Nc2cccc3[nH]ncc23)nc(C(F)(F)F)n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL596430";"";"0";"380.47";"0";"3.68";"8g";"CC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3sccc3n2)cc1";"IC50";"'='";"26.5";"nM";"7.58";"";"";"UO_0000065";"19.91";"0.38";"3.90";"11.25";"False";"CHEMBL1067293";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153098";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL572932";"";"0";"435.41";"0";"2.64";"39";"CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(CC(F)(F)F)c3n2)cc1";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"20.67";"0.40";"6.36";"9.26";"True";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL573663";"";"0";"585.67";"1";"4.55";"50";"CCOC(=O)N1CCC(n2ncc3c(N4CCOC[C@H]4C)nc(-c4ccc(NC(=O)Nc5ccncc5)cc4)nc32)CC1";"IC50";"'='";"0.28";"nM";"9.55";"";"";"UO_0000065";"16.31";"0.30";"5.00";"6.84";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL1088973";"";"0";"611.75";"1";"3.67";"1";"CN1CCN(c2ccc(NC(=O)Nc3ccc(-c4nc(N5C6CCC5COC6)nc(N5C6CCC5COC6)n4)cc3)cc2)CC1";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"14.71";"0.27";"5.33";"8.09";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1092397";"";"0";"626.76";"1";"4.39";"8";"O=C(Nc1ccc(OCCN2CCCC2)cc1)Nc1ccc(-c2nc(N3C4CCC3COC4)nc(N3C4CCC3COC4)n2)cc1";"IC50";"'='";"0.8";"nM";"9.10";"";"";"UO_0000065";"14.51";"0.27";"4.71";"7.76";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1092398";"";"0";"573.65";"1";"3.29";"9";"O=C(Nc1ccc(OCCO)cc1)Nc1ccc(-c2nc(N3C4CCC3COC4)nc(N3C4CCC3COC4)n2)cc1";"IC50";"'='";"0.26";"nM";"9.59";"";"";"UO_0000065";"16.71";"0.31";"6.30";"7.14";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091349";"";"0";"582.71";"1";"4.11";"20";"CN1CCN(c2ccc(NC(=O)Nc3ccc(-c4nc(C5=CCOCC5)nc(N5C6CCC5COC6)n4)cc3)cc2)CC1";"IC50";"'='";"0.7";"nM";"9.15";"";"";"UO_0000065";"15.71";"0.29";"5.04";"8.48";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1092390";"";"0";"627.75";"1";"3.16";"35";"C[C@@H]1COCCN1c1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)N4CCN(C)CC4)cc3)cc2)nc(N2C3CCC2COC3)n1";"IC50";"'='";"0.57";"nM";"9.24";"";"";"UO_0000065";"14.73";"0.27";"6.08";"7.21";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL567607";"";"0";"536.64";"1";"3.65";"21";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@H]3C)c3cnn(C4CCN(C(=O)OCC)CC4)c3n2)cc1";"IC50";"'='";"0.87";"nM";"9.06";"";"";"UO_0000065";"16.88";"0.32";"5.41";"7.15";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL574012";"";"0";"520.59";"1";"3.02";"28";"CNC(=O)Nc1ccc(-c2nc(N3C4CCC3COC4)c3cnn(C4CCN(C(=O)OC)CC4)c3n2)cc1";"IC50";"'='";"0.22";"nM";"9.66";"";"";"UO_0000065";"18.55";"0.35";"6.64";"7.62";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL583194";"";"0";"494.60";"0";"4.04";"5u";"c1cncc(CN2CCC(n3ncc4c(N5CCOCC5)nc(-c5ccc6[nH]ccc6c5)nc43)CC2)c1";"IC50";"'='";"9.0";"nM";"8.05";"";"";"UO_0000065";"16.27";"0.30";"4.01";"9.14";"True";"CHEMBL1063861";"Inhibition of human mTOR by DELFIA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154644";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL572679";"";"0";"554.63";"1";"3.60";"49";"CCOC(=O)N1CCC(n2ncc3c(N4CCOC[C@H]4C)nc(-c4ccc(NC(=O)NCCF)cc4)nc32)CC1";"IC50";"'='";"1.2";"nM";"8.92";"";"";"UO_0000065";"16.08";"0.30";"5.32";"7.04";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL575345";"";"0";"473.46";"0";"3.32";"45";"O=C(Nc1ccc(-c2nc(N3C[C@H]4C[C@@H]3CO4)c3cnn(CC(F)(F)F)c3n2)cc1)NC1CC1";"IC50";"'='";"53.0";"nM";"7.28";"";"";"UO_0000065";"15.37";"0.29";"3.96";"7.49";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL2064331";"";"0";"329.33";"0";"1.21";"9";"O=c1cc(N2CCOCC2)nc(Cc2nc3cc(F)ccc3[nH]2)[nH]1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064329";"";"0";"311.35";"0";"1.07";"6";"O=c1cc(N2CCOCC2)nc(Cc2nc3ccccc3[nH]2)[nH]1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064417";"";"0";"406.42";"0";"3.14";"45";"O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4ccccc4)c(F)ccc3o2)[nH]1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2158863";"";"0";"545.67";"2";"5.04";"11g";"CCN(CC)S(=O)(=O)c1cc(Nc2nccc(-c3ccnc(-c4ccc(NC(=O)NC)cc4)c3)n2)ccc1C";"IC50";"'='";"88.0";"nM";"7.06";"";"";"UO_0000065";"12.93";"0.25";"2.02";"5.46";"False";"CHEMBL2161544";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2157945";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL3577908";"";"0";"504.52";"2";"5.45";"5a";"COc1ncc(-c2ccc3nccc(-c4ccncc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"0.75";"nM";"9.12";"";"";"UO_0000065";"18.09";"0.35";"3.67";"9.70";"False";"CHEMBL3579762";"Inhibition of mTOR (unknown origin) using GFP-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3576869";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL3577915";"";"0";"320.38";"0";"3.82";"6a";"COc1ccc(-c2cc3c(-c4ccncc4)ncnc3s2)cn1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL3579762";"Inhibition of mTOR (unknown origin) using GFP-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3576869";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL3577917";"";"0";"338.37";"0";"3.96";"6c";"COc1ncc(-c2cc3c(-c4ccncc4)ncnc3s2)cc1F";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL3579762";"Inhibition of mTOR (unknown origin) using GFP-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3576869";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL3577919";"";"0";"525.56";"2";"5.21";"6e";"COc1ncc(-c2sc3ncnc(-c4ccncc4)c3c2C)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL3579762";"Inhibition of mTOR (unknown origin) using GFP-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3576869";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL3407729";"";"0";"452.45";"1";"2.99";"16h";"O=c1c(/C=N/Nc2nc(N3CCOCC3)c3ccsc3n2)coc2ccc([N+](=O)[O-])cc12";"IC50";"'='";"920.0";"nM";"6.04";"";"";"UO_0000065";"13.34";"0.26";"3.05";"4.44";"False";"CHEMBL3414045";"Inhibition of mTOR kinase (unknown origin) using ULight-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407441";"1";"Scientific Literature";"Eur. J. Med. Chem.";"2015";""
"CHEMBL2071342";"";"0";"453.53";"0";"2.03";"27, NVS-P13-5";"CCn1nnc(CCNC(=O)Nc2nc(C)c(-c3ccc(S(C)(=O)=O)c(F)c3)s2)n1";"IC50";"'>'";"9100.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2073006";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2069199";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1631889";"";"0";"218.26";"0";"2.96";"7";"C(#Cc1n[nH]c2ccccc12)c1ccccc1";"IC50";"'>'";"100000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1633333";"Inhibition of mTOR by LanthaScreen Eu kinase binding assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1631898";"";"0";"233.27";"0";"2.54";"16";"Nc1ccccc1C#Cc1n[nH]c2ccccc12";"IC50";"'>'";"100000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1633333";"Inhibition of mTOR by LanthaScreen Eu kinase binding assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1631890";"";"0";"254.24";"0";"3.24";"8";"Fc1cc(F)cc(C#Cc2n[nH]c3ccccc23)c1";"IC50";"'>'";"100000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1633333";"Inhibition of mTOR by LanthaScreen Eu kinase binding assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1631896";"";"0";"210.28";"0";"3.10";"14";"C(#CC1CCCC1)c1n[nH]c2ccccc12";"IC50";"'>'";"50000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1633336";"Inhibition of mTORC1 expressed in HEK293 cells assessed as PRAS40 Ser183 phosphorylation level by LanthaScreen cellular assay";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";"CHEMBL3307715"
"CHEMBL1631891";"";"0";"219.25";"0";"2.36";"9";"C(#Cc1n[nH]c2ccccc12)c1cccnc1";"IC50";"'>'";"100000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1633333";"Inhibition of mTOR by LanthaScreen Eu kinase binding assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL576505";"";"0";"567.70";"1";"4.28";"25";"CCn1ncc2c(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(N5CCN(C)CC5)cc4)cc3)nc21";"IC50";"'='";"0.3";"nM";"9.52";"";"";"UO_0000065";"16.77";"0.31";"5.24";"9.18";"False";"CHEMBL1039195";"Inhibition of human FLAG-tagged mTOR expressed in HEK293 cells after 2 hrs by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156748";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307715"
"CHEMBL576506";"";"0";"607.64";"1";"4.48";"28";"O=C(Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(CC(F)(F)F)c3n2)cc1)Nc1ccc(N2CCNCC2)cc1";"IC50";"'='";"0.2";"nM";"9.70";"";"";"UO_0000065";"15.96";"0.30";"5.22";"8.62";"False";"CHEMBL1039195";"Inhibition of human FLAG-tagged mTOR expressed in HEK293 cells after 2 hrs by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156748";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307715"
"CHEMBL597824";"";"0";"505.54";"1";"2.55";"22";"O=C(Nc1ccc(C(=O)O)cc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1";"IC50";"'='";"1.5";"nM";"8.82";"";"";"UO_0000065";"17.45";"0.33";"6.27";"6.21";"False";"CHEMBL1065057";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157610";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL590073";"";"0";"445.49";"0";"2.78";"14";"CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccncc4)cc3)nc21";"IC50";"'='";"0.63";"nM";"9.20";"";"";"UO_0000065";"20.65";"0.38";"6.42";"7.48";"False";"CHEMBL1068073";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157707";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL604908";"";"0";"461.53";"0";"2.86";"8";"O=C(Nc1ccccc1)Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1";"IC50";"'='";"3.9";"nM";"8.41";"";"";"UO_0000065";"18.22";"0.34";"5.55";"8.03";"False";"CHEMBL1065057";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157610";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL561844";"";"0";"512.62";"1";"3.52";"7";"CC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5cccnc5)CC4)c3n2)cc1";"IC50";"'='";"7.0";"nM";"8.15";"";"";"UO_0000065";"15.91";"0.29";"4.63";"8.05";"False";"CHEMBL1058638";"Inhibition of flag-tagged truncated human mTOR (1360-2549) expressed in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1151963";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL562165";"";"0";"541.66";"1";"4.74";"11";"CCOC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)cc1";"IC50";"'='";"46.0";"nM";"7.34";"";"";"UO_0000065";"13.55";"0.25";"2.60";"7.51";"False";"CHEMBL1058638";"Inhibition of flag-tagged truncated human mTOR (1360-2549) expressed in HEK293 cells by DELFIA assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1151963";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL561708";"";"0";"495.54";"0";"2.91";"12, WYE-354";"COC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(C(=O)OC)CC4)c3n2)cc1";"IC50";"'='";"5.0";"nM";"8.30";"";"";"UO_0000065";"16.75";"0.31";"5.39";"6.70";"False";"CHEMBL1804918";"Inhibition of recombinant mTOR assessed as inhibition of S6K T389 phosphorylation by DELFIA assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1800032";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL3357869";"";"0";"383.39";"0";"2.09";"8";"COc1ncc(Nc2ncc(C3(O)CC3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'='";"3700.0";"nM";"5.43";"";"";"UO_0000065";"14.17";"0.26";"3.34";"4.12";"False";"CHEMBL3379685";"Inhibition of recombinant N-terminally GST-tagged mTOR (1360 to 2549 aa) (unknown origin) assessed as inhibition of 27BP1 phosphorylation after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352452";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL1684984";"PA-799";"1";"377.43";"0";"-0.33";"1, CH5132799";"CS(=O)(=O)N1CCc2c(-c3cnc(N)nc3)nc(N3CCOCC3)nc21";"IC50";"'='";"1600.0";"nM";"5.80";"";"";"UO_0000065";"15.36";"0.30";"6.13";"4.55";"False";"CHEMBL1686451";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1681712";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1097895";"";"0";"552.68";"1";"4.45";"17a";"O=C(Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)cc1)NC1CC1";"IC50";"'='";"2.6";"nM";"8.59";"";"";"UO_0000065";"15.53";"0.29";"4.14";"8.55";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1098305";"";"0";"512.62";"1";"3.66";"16e";"NC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)cc1";"IC50";"'='";"2.7";"nM";"8.57";"";"";"UO_0000065";"16.72";"0.31";"4.91";"7.49";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL2087492";"";"0";"487.59";"1";"-0.01";"32";"Cc1c(CN2CCN(S(C)(=O)=O)CC2)nc2c(N3CCOCC3)nc(-c3cnc(N)nc3)cn12";"IC50";"'='";"1260.0";"nM";"5.90";"";"";"UO_0000065";"12.10";"0.24";"5.91";"4.37";"False";"CHEMBL2092092";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2086238";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1092395";"";"0";"600.72";"1";"3.86";"6";"CN(C)CCOc1ccc(NC(=O)Nc2ccc(-c3nc(N4C5CCC4COC5)nc(N4C5CCC4COC5)n3)cc2)cc1";"IC50";"'='";"1.6";"nM";"8.80";"";"";"UO_0000065";"14.64";"0.27";"4.94";"7.50";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091345";"";"0";"557.70";"1";"4.12";"16";"CC(C)Nc1nc(-c2ccc(NC(=O)Nc3ccc(N4CCN(C)CC4)cc3)cc2)nc(N2C3CCC2COC3)n1";"IC50";"'='";"5.4";"nM";"8.27";"";"";"UO_0000065";"14.82";"0.28";"4.15";"7.46";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091714";"";"0";"615.74";"1";"3.07";"38";"C[C@@H]1COCCN1c1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)NCCN(C)C)cc3)cc2)nc(N2C3CCC2COC3)n1";"IC50";"'='";"0.1";"nM";"10.00";"";"";"UO_0000065";"16.24";"0.30";"6.93";"7.30";"False";"CHEMBL1108787";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156955";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL3601923";"";"0";"497.51";"0";"3.02";"1c";"COc1ncc(-c2ccc3nc(NC(=O)NC4CC4)nn3c2)cc1NS(=O)(=O)c1ccc(F)cc1";"IC50";"'='";"275.0";"nM";"6.56";"";"";"UO_0000065";"13.19";"0.26";"3.54";"4.70";"False";"CHEMBL3602347";"Inhibition of mTOR (unknown origin) assessed as reduction of ATP level after 40 mins by luciferase based luminescence assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3600364";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2015";""
"CHEMBL1095623";"";"0";"525.66";"1";"3.46";"18";"CNC(=O)Cc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)cc1";"IC50";"'='";"170.0";"nM";"6.77";"";"";"UO_0000065";"12.88";"0.24";"3.31";"7.66";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL2418346";"";"0";"394.48";"0";"3.00";"15";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(ccn3C)n2)cc1";"IC50";"'='";"77.0";"nM";"7.11";"";"";"UO_0000065";"18.03";"0.34";"4.11";"8.44";"False";"CHEMBL2421123";"Inhibition of mTOR in PTEN deficient human PC3 cells assessed as inhibition of Akt phosphorylation at Ser473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2417437";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";"CHEMBL3307570"
"CHEMBL2418347";"";"0";"408.51";"0";"3.39";"16";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3CC)c3c(ccn3C)n2)cc1";"IC50";"'='";"40.0";"nM";"7.40";"";"";"UO_0000065";"18.11";"0.34";"4.01";"8.77";"False";"CHEMBL2421122";"Inhibition of mTOR in PTEN deficient human PC3 cells assessed as inhibition of p70S6K phosphorylation";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2417437";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";"CHEMBL3307570"
"CHEMBL2165022";"";"0";"343.78";"0";"2.62";"32";"COc1ccc(Nc2ncc(Cl)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165035";"";"0";"335.35";"0";"3.19";"15";"Cc1nc(N)c(F)c(-c2cccnc2Nc2cccc3[nH]ncc23)n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165269";"";"0";"309.33";"0";"1.97";"12";"COc1ccc(Nc2ncccc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"7800.0";"nM";"5.11";"";"";"UO_0000065";"16.51";"0.30";"3.14";"4.57";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165053";"";"0";"318.34";"0";"2.44";"10";"Cc1nc(N)nc(-c2cccnc2Nc2cccc3[nH]ncc23)n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL1631899";"";"0";"354.25";"1";"5.00";"17";"FC(F)(F)c1cc(C#Cc2n[nH]c3ccccc23)cc(C(F)(F)F)c1";"IC50";"'>'";"100000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1633336";"Inhibition of mTORC1 expressed in HEK293 cells assessed as PRAS40 Ser183 phosphorylation level by LanthaScreen cellular assay";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1629532";"1";"Scientific Literature";"J. Med. Chem.";"2010";"CHEMBL3307715"
"CHEMBL3358284";"";"0";"409.49";"0";"3.32";"17";"COc1ncc(Nc2ncc(C(C)(C)O)cc2-c2nc(C)nc(N)n2)cc1C(C)C";"IC50";"'>'";"25000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3379685";"Inhibition of recombinant N-terminally GST-tagged mTOR (1360 to 2549 aa) (unknown origin) assessed as inhibition of 27BP1 phosphorylation after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352452";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL98350";"LY-294002";"0";"307.35";"0";"3.30";"2 (LY-294002)";"O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12";"IC50";"'='";"2500.0";"nM";"5.60";"";"";"UO_0000065";"18.23";"0.33";"2.30";"13.13";"False";"CHEMBL830918";"Inhibition of mTOR protein isolated from HeLa cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HeLa";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1141182";"1";"Scientific Literature";"J. Med. Chem.";"2005";"CHEMBL3308376"
"CHEMBL3701156";"";"0";"444.51";"0";"3.61";"BDBM172291";"CCc1nc(N)ccc1C#Cc1c(-c2ccc(C(=O)N3CCOCC3)c(F)c2)ccnc1C";"IC50";"'='";"44.0";"nM";"7.36";"";"317215";"UO_0000065";"16.55";"0.30";"3.75";"9.04";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701164";"";"0";"487.58";"0";"3.29";"BDBM172299";"COCCN1CCN(C(=O)c2ccc(-c3ccnc(C)c3C#Cc3ccc(N)nc3C)cc2F)CC1";"IC50";"'='";"5.0";"nM";"8.30";"";"317223";"UO_0000065";"17.02";"0.31";"5.01";"9.81";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701168";"";"0";"497.62";"0";"4.45";"BDBM172303";"CCc1nccc(-c2ccc(C(=O)N3CCN(CC4CC4)CC3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"14.0";"nM";"7.85";"";"317227";"UO_0000065";"15.78";"0.29";"3.40";"12.80";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701173";"";"0";"497.62";"0";"4.31";"BDBM172308";"CCc1nc(N)ccc1C#Cc1c(-c2ccc(C(=O)N3CCN(C4CC4)CC3)c(F)c2)ccnc1CC";"IC50";"'='";"96.0";"nM";"7.02";"";"317232";"UO_0000065";"14.10";"0.26";"2.71";"9.31";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693495";"";"0";"464.57";"0";"2.35";"BDBM174657";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCCC(N)C4)nc3n2)cc1CO";"IC50";"'='";"110.0";"nM";"6.96";"";"319935";"UO_0000065";"14.98";"0.28";"4.61";"6.33";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693503";"";"0";"525.65";"1";"4.80";"BDBM174665";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCC(c5ccccc5)CC4)nc3n2)cc1CO";"IC50";"'='";"790.0";"nM";"6.10";"";"319945";"UO_0000065";"11.61";"0.21";"1.30";"7.28";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693505";"";"0";"463.58";"0";"3.80";"BDBM174667";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4C(C)CCC4C)nc3n2)cc1CO";"IC50";"'='";"47.0";"nM";"7.33";"";"319947";"UO_0000065";"15.81";"0.29";"3.53";"8.74";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693521";"";"0";"439.52";"0";"2.48";"BDBM174684";"COCCNc1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(OC)c(CO)c3)nc2n1";"IC50";"'='";"39.0";"nM";"7.41";"";"319965";"UO_0000065";"16.86";"0.32";"4.93";"7.27";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693523";"";"0";"450.54";"0";"1.83";"BDBM174686";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCNCC4)nc3n2)cc1CO";"IC50";"'='";"2.6";"nM";"8.59";"";"319967";"UO_0000065";"19.05";"0.36";"6.76";"8.95";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693525";"";"0";"453.54";"0";"2.60";"BDBM174688";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(NC(C)(C)CO)nc3n2)cc1CO";"IC50";"'='";"18.0";"nM";"7.75";"";"319969";"UO_0000065";"17.08";"0.32";"5.14";"6.86";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693530";"";"0";"494.60";"0";"1.53";"BDBM174693";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCN(CCO)CC4)nc3n2)cc1CO";"IC50";"'='";"68.0";"nM";"7.17";"";"319975";"UO_0000065";"14.49";"0.27";"5.64";"6.68";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693537";"";"0";"452.52";"0";"1.70";"BDBM174700";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N[C@H](C)C(N)=O)nc3n2)cc1CO";"IC50";"'='";"5.7";"nM";"8.24";"";"319982";"UO_0000065";"18.22";"0.34";"6.54";"6.07";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693562";"";"0";"465.55";"0";"2.64";"BDBM174725";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@H]4C)nc3n2)cc1CO";"IC50";"'='";"26.0";"nM";"7.58";"";"320005";"UO_0000065";"16.29";"0.30";"4.95";"8.15";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693563";"";"0";"432.48";"0";"3.68";"BDBM174727";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(-c4ccco4)nc3n2)cc1CO";"IC50";"'='";"48.0";"nM";"7.32";"";"320006";"UO_0000065";"16.92";"0.31";"3.64";"7.81";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL4083504";"";"0";"599.62";"1";"3.66";"17e";"COc1ncc(-c2ccc3ncc(NC(=O)CN4CCOCC4)c(OC)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"13.34";"0.26";"4.34";"6.06";"False";"CHEMBL3993907";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362-end residues) using ULight-4E-BP1 peptide substrate after 1 hr in presence of ATP by Lance Ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3992539";"1";"Scientific Literature";"Eur J Med Chem";"2017";""
"CHEMBL1957505";"";"0";"448.53";"0";"1.79";"25e";"CN(C)CCCNC(=O)c1cn2cc(-c3cccc4[nH]ncc34)nc(N3CCOCC3)c2n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1959594";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1955823";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1945790";"";"0";"339.40";"0";"1.83";"19";"CN1CCC(Cn2c(=O)[nH]c3ncc(-c4ccc(O)cc4)nc32)CC1";"IC50";"'='";"14100.0";"nM";"4.85";"";"";"UO_0000065";"14.29";"0.26";"3.02";"5.57";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL98350";"LY-294002";"0";"307.35";"0";"3.30";"1, LY294002";"O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12";"IC50";"'='";"2800.0";"nM";"5.55";"";"";"UO_0000065";"18.07";"0.33";"2.25";"13.01";"False";"CHEMBL2423428";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2417539";"1";"Scientific Literature";"J. Med. Chem.";"2013";""
"CHEMBL1086377";"";"0";"582.73";"2";"5.24";"39";"CCN1CCN(CC(=O)Nc2ccc(-c3cccc4c(=O)cc(N5CCOCC5)oc34)c3sc4ccccc4c23)CC1";"IC50";"'='";"10000.0";"nM";"5.00";"";"";"UO_0000065";"8.58";"0.16";"-0.24";"6.39";"False";"CHEMBL2423428";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2417539";"1";"Scientific Literature";"J. Med. Chem.";"2013";""
"CHEMBL2158860";"";"0";"489.56";"0";"3.66";"11d";"CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(C)c(S(N)(=O)=O)c4)n3)ccn2)cc1";"IC50";"'='";"16.0";"nM";"7.80";"";"";"UO_0000065";"15.92";"0.30";"4.14";"5.13";"False";"CHEMBL2161544";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2157945";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL3693399";"";"0";"518.66";"1";"3.76";"BDBM174540";"CC(C)C(=O)N(C)Cc1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"890.0";"nM";"6.05";"";"319836";"UO_0000065";"11.67";"0.22";"2.29";"7.21";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693403";"";"0";"526.66";"1";"2.53";"BDBM174544";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(CN(C)S(C)(=O)=O)c3)nc2n1";"IC50";"'='";"120.0";"nM";"6.92";"";"319840";"UO_0000065";"13.14";"0.26";"4.39";"6.85";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693409";"";"0";"524.60";"1";"2.54";"BDBM174550";"COCC(=O)NCc1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccc1F";"IC50";"'='";"160.0";"nM";"6.80";"";"319846";"UO_0000065";"12.95";"0.24";"4.26";"6.67";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693462";"";"0";"457.53";"0";"4.16";"BDBM174623";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(Nc4ccccc4)nc3n2)cc1CO";"IC50";"'='";"42.0";"nM";"7.38";"";"319901";"UO_0000065";"16.12";"0.30";"3.22";"7.96";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693476";"";"0";"451.53";"0";"1.99";"BDBM174638";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CC[C@H](O)C4)nc3n2)cc1CO";"IC50";"'='";"12.0";"nM";"7.92";"";"319916";"UO_0000065";"17.54";"0.33";"5.93";"7.61";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701140";"";"0";"317.37";"0";"3.88";"BDBM172275";"Cc1nc(N)ccc1C#Cc1c(-c2cccc(F)c2)ccnc1C";"IC50";"'='";"113.0";"nM";"6.95";"";"317199";"UO_0000065";"21.89";"0.40";"3.07";"13.41";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701148";"";"0";"455.54";"0";"3.36";"BDBM172283";"CCc1nccc(-c2ccc(C(=O)N3C[C@@H]4CC3CN4C)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"9.0";"nM";"8.05";"";"317207";"UO_0000065";"17.66";"0.32";"4.69";"10.68";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701150";"";"0";"446.53";"0";"3.94";"BDBM172285";"CCc1nccc(-c2ccc(F)c(C(=O)N(C)CCCOC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"28.0";"nM";"7.55";"";"317209";"UO_0000065";"16.91";"0.31";"3.61";"9.29";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688869";"";"0";"448.53";"0";"2.24";"BDBM174328";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(C(N)=O)c3)nc2n1";"IC50";"'='";"13.0";"nM";"7.89";"";"319645";"UO_0000065";"17.58";"0.33";"5.65";"7.39";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688891";"";"0";"419.53";"0";"3.45";"BDBM174352";"Cc1ccccc1-c1ccc2c(N3CCOC[C@@H]3C)nc(N3CCOC[C@@H]3C)nc2n1";"IC50";"'='";"140.0";"nM";"6.85";"";"319668";"UO_0000065";"16.34";"0.30";"3.40";"10.77";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688956";"";"0";"447.54";"0";"1.94";"BDBM174433";"C[C@H]1COCCN1c1nc(N2CCC(N)CC2)nc2nc(-c3cccc(C(N)=O)c3)ccc12";"IC50";"'='";"640.0";"nM";"6.19";"";"319737";"UO_0000065";"13.84";"0.26";"4.25";"5.02";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689007";"";"0";"492.60";"0";"3.53";"BDBM174488";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(F)c(CNC4CC4)c3)nc2n1";"IC50";"'='";"140.0";"nM";"6.85";"";"319789";"UO_0000065";"13.91";"0.26";"3.32";"9.06";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689031";"";"0";"548.73";"1";"4.67";"BDBM174513";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CNC(C)CC(C)C";"IC50";"'='";"96.0";"nM";"7.02";"";"319814";"UO_0000065";"12.79";"0.24";"2.35";"8.27";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689032";"";"0";"577.77";"1";"3.97";"BDBM174514";"CCN(CC)CCCNCc1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccc1OC";"IC50";"'='";"3.8";"nM";"8.42";"";"319815";"UO_0000065";"14.57";"0.27";"4.45";"9.56";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693382";"";"0";"520.68";"1";"3.90";"BDBM174518";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CNCC(C)C";"IC50";"'='";"38.0";"nM";"7.42";"";"319819";"UO_0000065";"14.25";"0.27";"3.52";"8.74";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693390";"";"0";"506.61";"1";"2.40";"BDBM174531";"COCC(=O)NCc1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"54.0";"nM";"7.27";"";"319827";"UO_0000065";"14.35";"0.27";"4.87";"7.13";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693393";"";"0";"516.65";"1";"3.56";"BDBM174534";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(CNC(=O)C4CCC4)c3)nc2n1";"IC50";"'='";"120.0";"nM";"6.92";"";"319830";"UO_0000065";"13.40";"0.25";"3.36";"7.47";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3667420";"";"0";"454.49";"0";"3.36";"BDBM150992";"C[C@H]1COCCN1c1nc(N2CCC(F)(F)CC2)nc2[nH]c(-c3ccnc4[nH]ccc34)nc12";"IC50";"'='";"150.0";"nM";"6.82";"";"290539";"UO_0000065";"15.01";"0.28";"3.46";"6.90";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL3667427";"";"0";"425.49";"0";"1.53";"BDBM150999";"CC(O)c1cc(-c2nc3c(N4CCOC[C@@H]4C)nc(N4CCOCC4)nc3[nH]2)ccn1";"IC50";"'='";"2023.0";"nM";"5.69";"";"290545";"UO_0000065";"13.38";"0.25";"4.16";"5.06";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL3639662";"";"0";"433.52";"0";"2.95";"BDBM151002";"C[C@@H]1COCCN1c1nc(N2CCOC[C@H]2C)c2nc(-c3cccc4[nH]ccc34)[nH]c2n1";"IC50";"'='";"9.0";"nM";"8.05";"";"290548";"UO_0000065";"18.56";"0.34";"5.10";"8.45";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL3667444";"";"0";"423.48";"0";"1.65";"BDBM151017";"CC(=O)Nc1cccc(-c2nc3c(N4CCOCC4)nc(N4CCOCC4)nc3[nH]2)c1";"IC50";"'='";"1447.0";"nM";"5.84";"";"290563";"UO_0000065";"13.79";"0.26";"4.19";"5.38";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL3667447";"";"0";"459.53";"0";"1.06";"BDBM151020";"CS(=O)(=O)Nc1cccc(-c2nc3c(N4CCOCC4)nc(N4CCOCC4)nc3[nH]2)c1";"IC50";"'='";"380.0";"nM";"6.42";"";"290565";"UO_0000065";"13.97";"0.27";"5.36";"5.11";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL3618241";"";"0";"508.56";"2";"2.13";"14";"COCCN1CCN(c2ccc3nc(Nc4cnc(OC)c(F)c4)c(-c4nc(C)nc(N)n4)n3c2)CC1";"IC50";"'='";"121.0";"nM";"6.92";"";"";"UO_0000065";"13.60";"0.26";"4.79";"5.25";"False";"CHEMBL3620381";"Inhibition of GST-tagged mTOR (1360 to 2549 residues) (unknown origin) using Ulight 4eBP1 peptide incubated for 90 mins by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3616407";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2015";""
"CHEMBL578661";"";"0";"510.60";"1";"3.34";"5m";"O=c1[nH]c2ccc(-c3nc(N4CCOCC4)c4cnn(C5CCN(Cc6ccccc6)CC5)c4n3)cc2[nH]1";"IC50";"'='";"190.0";"nM";"6.72";"";"";"UO_0000065";"13.16";"0.24";"3.38";"6.23";"False";"CHEMBL1063861";"Inhibition of human mTOR by DELFIA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154644";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL572830";"";"0";"493.62";"0";"4.65";"5p";"c1ccc(CN2CCC(n3ncc4c(N5CCOCC5)nc(-c5ccc6[nH]ccc6c5)nc43)CC2)cc1";"IC50";"'='";"88.0";"nM";"7.06";"";"";"UO_0000065";"14.29";"0.26";"2.41";"9.39";"False";"CHEMBL1063861";"Inhibition of human mTOR by DELFIA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154644";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL574641";"";"0";"493.62";"0";"4.65";"5q";"c1ccc(CN2CCC(n3ncc4c(N5CCOCC5)nc(-c5ccc6cc[nH]c6c5)nc43)CC2)cc1";"IC50";"'='";"230.0";"nM";"6.64";"";"";"UO_0000065";"13.45";"0.25";"1.99";"8.84";"False";"CHEMBL1063861";"Inhibition of human mTOR by DELFIA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154644";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL582922";"";"0";"493.62";"0";"4.65";"5r";"c1ccc(CN2CCC(n3ncc4c(N5CCOCC5)nc(-c5cccc6cc[nH]c56)nc43)CC2)cc1";"IC50";"'='";"380.0";"nM";"6.42";"";"";"UO_0000065";"13.01";"0.24";"1.77";"8.55";"False";"CHEMBL1063861";"Inhibition of human mTOR by DELFIA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154644";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL576543";"";"0";"507.64";"1";"4.66";"5s";"Cn1ccc2cccc(-c3nc(N4CCOCC4)c4cnn(C5CCN(Cc6ccccc6)CC5)c4n3)c21";"IC50";"'='";"575.0";"nM";"6.24";"";"";"UO_0000065";"12.29";"0.22";"1.58";"9.71";"False";"CHEMBL1063861";"Inhibition of human mTOR by DELFIA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154644";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL574234";"";"0";"467.43";"0";"2.98";"31";"O=C(NCCF)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(CC(F)(F)F)c3n2)cc1";"IC50";"'='";"0.6";"nM";"9.22";"";"";"UO_0000065";"19.73";"0.38";"6.24";"9.49";"True";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL2325697";"";"0";"412.52";"0";"2.88";"6, AZ20";"C[C@@H]1COCCN1c1cc(C2(S(C)(=O)=O)CC2)nc(-c2cccc3[nH]ccc23)n1";"IC50";"'='";"2400.0";"nM";"5.62";"";"";"UO_0000065";"13.62";"0.26";"2.74";"6.37";"True";"CHEMBL2330630";"Inhibition of mTOR-mediated AKT phosphorylation at serine 473 in human MDA-MB-468 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MDA-MB-468";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2321758";"1";"Scientific Literature";"J. Med. Chem.";"2013";"CHEMBL3308424"
"CHEMBL2325705";"";"0";"442.54";"0";"2.51";"13";"CS(=O)(=O)C1(c2cc(N3CCOCC3)nc(-c3cccc4[nH]ccc34)n2)CCOCC1";"IC50";"'='";"3300.0";"nM";"5.48";"";"";"UO_0000065";"12.39";"0.24";"2.97";"5.63";"False";"CHEMBL2330630";"Inhibition of mTOR-mediated AKT phosphorylation at serine 473 in human MDA-MB-468 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MDA-MB-468";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2321758";"1";"Scientific Literature";"J. Med. Chem.";"2013";"CHEMBL3308424"
"CHEMBL1242376";"";"0";"374.24";"0";"3.66";"PP493";"Nc1ncnc2c1c(-c1ccc(Br)c(O)c1)nn2C1CCCC1";"IC50";"'='";"156.0";"nM";"6.81";"";"";"UO_0000065";"18.19";"0.40";"3.15";"7.58";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242470";"";"0";"326.34";"0";"2.61";"PP471";"N#CCCCCn1nc(-c2ccc(F)c(O)c2)c2c(N)ncnc21";"IC50";"'='";"833.0";"nM";"6.08";"";"";"UO_0000065";"18.63";"0.35";"3.47";"5.35";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242658";"";"0";"314.32";"0";"1.45";"PP405";"Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2[C@@H]1CCNC1";"IC50";"'='";"5000.0";"nM";"5.30";"";"";"UO_0000065";"16.87";"0.31";"3.85";"5.20";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242749";"";"0";"315.31";"0";"1.88";"PP434";"Nc1ncnc2c1c(-c1ccc(F)c(O)c1)nn2[C@@H]1CCOC1";"IC50";"'='";"1000.0";"nM";"6.00";"";"";"UO_0000065";"19.03";"0.36";"4.12";"6.06";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241772";"";"0";"279.31";"0";"1.92";"PP21";"CC(C)n1nc(-c2ccc(C#N)nc2)c2c(N)ncnc21";"IC50";"'='";"5800.0";"nM";"5.24";"";"";"UO_0000065";"18.75";"0.34";"3.32";"4.93";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241771";"";"0";"296.31";"0";"2.67";"PP151";"CC(C)n1nc(-c2ccc(C#N)c(F)c2)c2c(N)ncnc21";"IC50";"'='";"100000.0";"nM";"4.00";"";"";"UO_0000065";"13.50";"0.25";"1.33";"4.28";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242848";"";"0";"284.32";"0";"1.94";"PP203";"CC(C)n1nc(-c2ccc(N)c(O)c2)c2c(N)ncnc21";"IC50";"'='";"3600.0";"nM";"5.44";"";"";"UO_0000065";"19.15";"0.35";"3.50";"4.70";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL575501";"";"0";"485.55";"0";"2.91";"5d";"O=C(c1cccnc1)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4cccc(O)c4)nc32)CC1";"IC50";"'='";"6.0";"nM";"8.22";"";"";"UO_0000065";"16.93";"0.31";"5.31";"7.51";"False";"CHEMBL1063861";"Inhibition of human mTOR by DELFIA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154644";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL1945794";"";"0";"353.38";"0";"1.71";"23";"NC(=O)[C@H]1CC[C@H](n2c(=O)[nH]c3ncc(-c4ccc(O)cc4)nc32)CC1";"IC50";"'>'";"5000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1949073";"Inhibition of mTOR-mediated Akt phosphorylation in human PC3 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";"CHEMBL3307570"
"CHEMBL1945955";"";"0";"376.42";"0";"2.60";"45";"O=c1[nH]c2ncc(-c3ccc(-c4ncc[nH]4)cc3)nc2n1CC1CCOCC1";"IC50";"'='";"55.0";"nM";"7.26";"";"";"UO_0000065";"19.29";"0.35";"4.66";"7.15";"False";"CHEMBL1949073";"Inhibition of mTOR-mediated Akt phosphorylation in human PC3 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";"CHEMBL3307570"
"CHEMBL1945793";"";"0";"353.38";"0";"1.71";"22";"NC(=O)[C@H]1CC[C@@H](n2c(=O)[nH]c3ncc(-c4ccc(O)cc4)nc32)CC1";"IC50";"'>'";"5000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1949073";"Inhibition of mTOR-mediated Akt phosphorylation in human PC3 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";"CHEMBL3307570"
"CHEMBL574672";"";"0";"470.58";"0";"3.87";"5g";"Oc1ccccc1-c1nc(N2CCOCC2)c2cnn(C3CCN(Cc4ccccc4)CC3)c2n1";"IC50";"'='";"1265.0";"nM";"5.90";"";"";"UO_0000065";"12.53";"0.23";"2.03";"7.42";"False";"CHEMBL1063861";"Inhibition of human mTOR by DELFIA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154644";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL574405";"";"0";"455.57";"0";"3.56";"5j";"c1ccc(CN2CCC(n3ncc4c(N5CCOCC5)nc(-c5ccncc5)nc43)CC2)cc1";"IC50";"'='";"7300.0";"nM";"5.14";"";"";"UO_0000065";"11.28";"0.21";"1.58";"7.11";"False";"CHEMBL1063861";"Inhibition of human mTOR by DELFIA assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154644";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL1233881";"";"0";"325.37";"0";"2.82";"79, PP494";"COc1ccc(-c2nn(C3CCC3)c3ncnc(N)c23)cc1OC";"IC50";"'='";"1700.0";"nM";"5.77";"";"";"UO_0000065";"17.73";"0.33";"2.95";"6.55";"False";"CHEMBL3223610";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3217752";"1";"Scientific Literature";"MedChemComm";"2012";""
"CHEMBL1241945";"";"0";"287.30";"0";"2.50";"PP59";"CC(C)n1nc(-c2ccc(O)c(F)c2)c2c(N)ncnc21";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"29.67";"0.55";"6.02";"9.49";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1240565";"";"0";"265.28";"0";"1.49";"PP120";"Cn1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc21";"IC50";"'='";"412.0";"nM";"6.38";"";"";"UO_0000065";"24.07";"0.44";"4.90";"6.50";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242203";"";"0";"312.33";"0";"0.93";"PP411";"COc1ccc(-c2nn(C3CNC3)c3ncnc(N)c23)cc1O";"IC50";"'='";"5100.0";"nM";"5.29";"";"";"UO_0000065";"16.94";"0.31";"4.36";"4.76";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1240567";"";"0";"255.24";"0";"1.33";"PP233";"Nc1ncnc2[nH]nc(-c3ccc4c(c3)OCO4)c12";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242386";"";"0";"293.33";"0";"2.53";"PP137";"CC(C)n1nc(-c2ccc3[nH]ncc3c2)c2c(N)ncnc21";"IC50";"'='";"657.0";"nM";"6.18";"";"";"UO_0000065";"21.08";"0.38";"3.65";"6.29";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL939";"GEFITINIB";"4";"446.91";"0";"4.28";"Gefitinib";"COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1";"IC50";"'>'";"50000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242572";"";"0";"319.37";"0";"3.07";"PP115";"Nc1ncnc2c1c(-c1ccc3cn[nH]c3c1)nn2C1CCCC1";"IC50";"'='";"596.0";"nM";"6.22";"";"";"UO_0000065";"19.49";"0.35";"3.15";"6.33";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241491";"";"0";"319.37";"0";"3.94";"PP97";"Nc1ncnc2c1c(-c1ccc3occc3c1)nn2C1CCCC1";"IC50";"'='";"1600.0";"nM";"5.80";"";"";"UO_0000065";"18.15";"0.33";"1.86";"7.00";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242574";"";"0";"292.35";"0";"3.14";"PP107";"CC(C)n1nc(-c2ccc3cc[nH]c3c2)c2c(N)ncnc21";"IC50";"'='";"467.0";"nM";"6.33";"";"";"UO_0000065";"21.65";"0.39";"3.19";"7.41";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241588";"";"0";"311.35";"0";"2.43";"PP54";"CC(C)n1nc(-c2ccc3c(c2)OCCO3)c2c(N)ncnc21";"IC50";"'='";"1900.0";"nM";"5.72";"";"";"UO_0000065";"18.38";"0.34";"3.29";"6.50";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242757";"";"0";"292.35";"0";"3.14";"PP91";"CC(C)n1nc(-c2cccc3[nH]ccc23)c2c(N)ncnc21";"IC50";"'='";"8000.0";"nM";"5.10";"";"";"UO_0000065";"17.43";"0.32";"1.96";"5.97";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242294";"";"0";"292.35";"0";"3.14";"PP89";"CC(C)n1nc(-c2ccc3[nH]ccc3c2)c2c(N)ncnc21";"IC50";"'='";"364.0";"nM";"6.44";"";"";"UO_0000065";"22.02";"0.40";"3.30";"7.54";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL4069279";"";"0";"441.56";"0";"3.21";"14f";"COc1ccc(-c2cc3nc(N4C[C@H](C)O[C@H](C)C4)nc(N4CCOCC4)c3s2)cn1";"IC50";"'>'";"2000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL4084746";"";"0";"413.53";"0";"0.10";"6d";"CS(=O)(=O)N1CCN(c2nc(N3CCOCC3)c3sc(CO)cc3n2)CC1";"IC50";"'>'";"2000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL2170095";"";"0";"486.56";"1";"0.44";"15";"COc1ncc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2173749";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169865";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2170086";"";"0";"531.62";"2";"2.14";"56";"COc1ncc(Nc2ncc([C@@H](C)N3CCN(S(C)(=O)=O)C[C@H]3C)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2173749";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169865";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2170085";"";"0";"571.56";"2";"2.29";"33";"COc1ncc(Nc2ncc([C@H](N3CCN(S(C)(=O)=O)CC3)C(F)(F)F)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2173749";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169865";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165017";"";"0";"485.57";"1";"1.05";"1";"COc1ccc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2173749";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169865";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL1082621";"";"0";"679.75";"2";"6.23";"18i";"COc1cc(F)c2[nH]c(-c3c(C)nn(C)c3C)c(/C=C3/Oc4ccc(NC(=O)Nc5ccc(C(=O)N(C)CCN(C)C)cc5)cc4C3=O)c2c1";"IC50";"'='";"0.3";"nM";"9.52";"";"";"UO_0000065";"14.01";"0.26";"3.29";"7.12";"False";"CHEMBL1119658";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1158598";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL2170081";"";"0";"517.59";"2";"1.75";"31";"COc1ncc(Nc2ncc([C@@H](C)N3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2173749";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169865";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL4078390";"";"0";"364.47";"0";"1.63";"6g";"C[C@H]1CN(c2nc(N3CCOCC3)c3sc(CO)cc3n2)C[C@@H](C)O1";"IC50";"'='";"463.0";"nM";"6.33";"";"";"UO_0000065";"17.38";"0.35";"4.70";"8.93";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL1098246";"";"0";"653.79";"2";"5.02";"25g";"COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)Nc5ccc(CCN6CCCC6)cc5)cc4)nc32)CC1";"IC50";"'='";"0.7";"nM";"9.15";"";"";"UO_0000065";"14.00";"0.26";"4.13";"7.04";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1098247";"";"0";"682.83";"2";"4.17";"25h";"COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)Nc5ccc(CCN6CCN(C)CC6)cc5)cc4)nc32)CC1";"IC50";"'='";"0.8";"nM";"9.10";"";"";"UO_0000065";"13.32";"0.25";"4.93";"6.83";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1097894";"";"0";"554.70";"1";"4.70";"16h";"CC(C)NC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)cc1";"IC50";"'='";"4.8";"nM";"8.32";"";"";"UO_0000065";"15.00";"0.28";"3.62";"8.28";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1097897";"";"0";"570.70";"1";"3.93";"16j";"COCCNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)cc1";"IC50";"'='";"23.0";"nM";"7.64";"";"";"UO_0000065";"13.38";"0.25";"3.71";"6.96";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1097261";"";"0";"396.45";"0";"3.80";"6a";"c1ccc(-n2ncc3c(N4CCOCC4)nc(-c4ccc5[nH]ccc5c4)nc32)cc1";"IC50";"'='";"27.0";"nM";"7.57";"";"";"UO_0000065";"19.09";"0.34";"3.77";"10.53";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL2172637";"";"0";"307.32";"0";"1.54";"2";"Cc1nc(N)nc(-c2c(Nc3cc[nH]n3)nc3ccccn23)n1";"IC50";"'='";"12.0";"nM";"7.92";"";"";"UO_0000065";"25.77";"0.47";"6.38";"6.46";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1083912";"";"0";"471.52";"0";"4.56";"18a";"CNC(=O)Nc1ccc2c(c1)C(=O)/C(=C\c1c(-c3c(C)nn(C)c3C)[nH]c3ccc(OC)cc13)O2";"IC50";"'='";"1.3";"nM";"8.89";"";"";"UO_0000065";"18.85";"0.35";"4.33";"8.06";"False";"CHEMBL1119658";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1158598";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL2172479";"";"0";"429.44";"0";"3.19";"21g";"CC(=O)Nc1cc(-c2c(Nc3ccn(C)n3)nc3ccc(-c4cnco4)cn23)nc(C)n1";"IC50";"'='";"20.0";"nM";"7.70";"";"";"UO_0000065";"17.93";"0.33";"4.51";"6.01";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1097902";"";"0";"578.68";"1";"4.53";"17b";"O=C(Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)cc1)Nc1ncc[nH]1";"IC50";"'='";"0.7";"nM";"9.15";"";"";"UO_0000065";"15.82";"0.29";"4.62";"7.09";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1097942";"";"0";"548.65";"1";"3.80";"26c";"CC(C)OC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(NC(=O)NC5CC5)cc4)nc32)CC1";"IC50";"'='";"0.5";"nM";"9.30";"";"";"UO_0000065";"16.95";"0.32";"5.50";"7.34";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1088833";"";"0";"310.36";"0";"1.95";"17";"OCc1cccc(-c2nc(N3CCOCC3)c3cc[nH]c3n2)c1";"IC50";"'='";"205.0";"nM";"6.69";"";"";"UO_0000065";"21.55";"0.40";"4.74";"9.01";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL2172627";"";"0";"321.35";"0";"2.00";"19b";"CNc1cc(-c2c(Nc3cc[nH]n3)nc3cccnn23)nc(C)n1";"IC50";"'='";"63.0";"nM";"7.20";"";"";"UO_0000065";"22.41";"0.41";"5.20";"6.62";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2170092";"";"0";"489.99";"0";"1.69";"17";"Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2ccc(Cl)nc2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2173749";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169865";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064411";"";"0";"388.43";"0";"3.01";"39";"O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4ccccc4)cccc3o2)[nH]1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064409";"";"0";"326.36";"0";"1.65";"37";"Cc1cccc2nc(Cc3nc(N4CCOCC4)cc(=O)[nH]3)oc12";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2063756";"";"0";"445.55";"0";"1.98";"6S, PF-05139962";"CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CS(=O)(=O)CC3)cc1";"IC50";"'='";"48.0";"nM";"7.32";"";"";"UO_0000065";"16.43";"0.32";"5.34";"6.45";"False";"CHEMBL2065058";"Inhibition of mTOR-mediated AKT phosphorylation at Ser473 by cell based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062409";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL585400";"";"0";"297.32";"0";"1.56";"20";"Oc1ccccc1-c1nc(N2CCOCC2)c2nc[nH]c2n1";"IC50";"'='";"2500.0";"nM";"5.60";"";"";"UO_0000065";"18.84";"0.35";"4.04";"6.43";"False";"CHEMBL1074731";"Inhibition of human TOR in HEK293 cells by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1153204";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";"CHEMBL3307715"
"CHEMBL3355474";"";"0";"440.53";"0";"2.76";"7";"C[C@@H]1COCCN1c1nc(-c2cncc3[nH]ccc23)cc2c1ncn2[C@@H](C)S(C)(=O)=O";"IC50";"'>'";"4600.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3372424";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352352";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL572500";"";"0";"536.64";"1";"3.65";"47";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3cnn(C4CCN(C(=O)OCC)CC4)c3n2)cc1";"IC50";"'='";"1.8";"nM";"8.74";"";"";"UO_0000065";"16.30";"0.31";"5.09";"6.90";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL1233882";"";"0";"304.36";"0";"3.20";"77, PP102";"CC(C)n1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21";"IC50";"'='";"140.0";"nM";"6.85";"";"";"UO_0000065";"22.52";"0.41";"3.65";"8.31";"False";"CHEMBL3223610";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3217752";"1";"Scientific Literature";"MedChemComm";"2012";""
"CHEMBL576304";"";"0";"555.64";"1";"3.76";"22";"CCn1ncc2c(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(N5CCOCC5)nc4)cc3)nc21";"IC50";"'='";"0.3";"nM";"9.52";"";"";"UO_0000065";"17.14";"0.32";"5.76";"7.77";"False";"CHEMBL1039195";"Inhibition of human FLAG-tagged mTOR expressed in HEK293 cells after 2 hrs by DELFIA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156748";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3307715"
"CHEMBL574680";"";"0";"498.47";"0";"3.93";"33";"O=C(Nc1ccc(-c2nc(N3CCOCC3)c3cnn(CC(F)(F)F)c3n2)cc1)Nc1cccnc1";"IC50";"'='";"0.23";"nM";"9.64";"";"";"UO_0000065";"19.34";"0.37";"5.71";"8.75";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL576143";"";"0";"508.58";"1";"2.87";"16";"CNC(=O)Nc1ccc(-c2nc(N3CCOC(C)C3)c3cnn(C4CCN(C(=O)OC)CC4)c3n2)cc1";"IC50";"'='";"2.3";"nM";"8.64";"";"";"UO_0000065";"16.99";"0.32";"5.77";"6.82";"False";"CHEMBL1047613";"Inhibition of FLAG-tagged human mTOR by DELFIA method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1154707";"1";"Scientific Literature";"J. Med. Chem.";"2009";""
"CHEMBL568550";"";"0";"400.46";"0";"2.83";"11";"COc1cc(-c2csc(-c3ccnc(N4CCOCC4)n3)n2)cc(OC)c1O";"IC50";"'='";"180.0";"nM";"6.75";"";"";"UO_0000065";"16.84";"0.33";"3.91";"7.51";"False";"CHEMBL1049650";"Inhibition of mTOR kinase in human HeLa cells by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HeLa";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156040";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3308376"
"CHEMBL566033";"";"0";"443.51";"1";"1.87";"2";"COc1cc(/C=N/Nc2nc(N3CCCCC3)nc(N3CCOCC3)n2)cc(OC)c1O";"IC50";"'='";"750.0";"nM";"6.12";"";"";"UO_0000065";"13.81";"0.26";"4.25";"5.21";"False";"CHEMBL1049650";"Inhibition of mTOR kinase in human HeLa cells by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HeLa";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156040";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3308376"
"CHEMBL585292";"";"0";"408.46";"0";"2.78";"16";"Oc1ccc(-c2ccc(-c3cc(N4CCOCC4)nc(N4CCOCC4)n3)o2)cc1";"IC50";"'='";"550.0";"nM";"6.26";"";"";"UO_0000065";"15.32";"0.28";"3.48";"7.44";"False";"CHEMBL1049650";"Inhibition of mTOR kinase in human HeLa cells by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HeLa";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156040";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3308376"
"CHEMBL1241581";"";"0";"324.39";"0";"2.78";"PP81";"COc1cc(-c2nn(C3CCCC3)c3ncnc(N)c23)ccc1N";"IC50";"'='";"1900.0";"nM";"5.72";"";"";"UO_0000065";"17.64";"0.33";"2.94";"5.46";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1081312";"";"0";"319.37";"0";"3.07";"PP121";"Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1";"IC50";"'<'";"10.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1233881";"";"0";"325.37";"0";"2.82";"PP494";"COc1ccc(-c2nn(C3CCC3)c3ncnc(N)c23)cc1OC";"IC50";"'='";"1700.0";"nM";"5.77";"";"";"UO_0000065";"17.73";"0.33";"2.95";"6.55";"True";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242198";"";"0";"287.30";"0";"2.50";"PP22";"CC(C)n1nc(-c2cc(O)cc(F)c2)c2c(N)ncnc21";"IC50";"'='";"14000.0";"nM";"4.85";"";"";"UO_0000065";"16.89";"0.32";"2.35";"5.40";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL3290307";"";"0";"382.42";"0";"3.95";"16g";"COc1ccc(-n2c(=O)n(C)c3cnc4ccc(-c5ccncc5)cc4c32)cc1";"IC50";"'='";"380.0";"nM";"6.42";"";"";"UO_0000065";"16.79";"0.30";"2.47";"10.37";"False";"CHEMBL3291527";"Inhibition of human recombinant mTOR assessed as inhibition of 4EBP1 phosphorylation after 30 mins by TR-FRET analysis";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3286093";"1";"Scientific Literature";"J. Med. Chem.";"2014";""
"CHEMBL1241389";"";"0";"256.23";"0";"1.51";"PP128";"Nc1ncnc2[nH]nc(-c3cccc([N+](=O)[O-])c3)c12";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241767";"";"0";"489.54";"0";"4.15";"PIK-294";"Cc1ccccc1-n1c(Cn2nc(-c3cccc(O)c3)c3c(N)ncnc32)nc2cccc(C)c2c1=O";"IC50";"'='";"50000.0";"nM";"4.30";"";"";"UO_0000065";"8.79";"0.16";"0.15";"3.45";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241144";"";"0";"225.25";"0";"1.91";"PP205";"Cc1ccccc1-c1n[nH]c2ncnc(N)c12";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1241145";"";"0";"239.28";"0";"2.22";"PP206";"Cc1cccc(-c2n[nH]c3ncnc(N)c23)c1C";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL1242845";"";"0";"416.42";"0";"2.86";"PP399";"Cc1nn(-c2ccccc2)nc1Cn1nc(-c2ccc(F)c(O)c2)c2c(N)ncnc21";"IC50";"'='";"50000.0";"nM";"4.30";"";"";"UO_0000065";"10.33";"0.19";"1.44";"3.57";"False";"CHEMBL1243969";"Inhibition of recombinant mTOR by radioactive phosphotransfer assay in presence of 10 uM ATP";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1240340";"1";"Scientific Literature";"Nat. Chem. Biol.";"2008";""
"CHEMBL3590219";"";"0";"446.52";"0";"1.38";"1";"CN(C)CC(=O)N1CCC(n2cc(-c3cnc(N)c(-n4nnc5ccccc54)n3)cn2)CC1";"IC50";"'='";"15000.0";"nM";"4.82";"";"";"UO_0000065";"10.80";"0.20";"3.44";"3.89";"False";"CHEMBL3591971";"Inhibition of m-TOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3588784";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2015";""
"CHEMBL3688849";"";"0";"438.51";"0";"2.98";"BDBM174308";"Cc1nc(F)ccc1-c1ccc2c(N3CCOC[C@@H]3C)nc(N3CCOC[C@@H]3C)nc2n1";"IC50";"'='";"530.0";"nM";"6.28";"";"319624";"UO_0000065";"14.31";"0.27";"3.30";"8.20";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL2336325";"VISTUSERTIB";"2";"462.55";"0";"2.50";"BDBM50429701";"CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"20.0";"nM";"7.70";"";"319642";"UO_0000065";"16.64";"0.31";"5.20";"8.30";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688890";"";"0";"439.95";"0";"3.80";"BDBM174351";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(Cl)cc3)nc2n1";"IC50";"'='";"140.0";"nM";"6.85";"";"319667";"UO_0000065";"15.58";"0.30";"3.05";"10.77";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688895";"";"0";"406.49";"0";"2.54";"BDBM174356";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccnc3)nc2n1";"IC50";"'='";"16.0";"nM";"7.80";"";"319672";"UO_0000065";"19.18";"0.35";"5.26";"10.19";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688897";"";"0";"444.54";"0";"3.40";"BDBM174358";"C[C@H]1CN(c2nc(N3CCOC[C@@H]3C)c3ccc(-c4ccc(C#N)cc4)nc3n2)C[C@@H](C)O1";"IC50";"'='";"36.0";"nM";"7.44";"";"319674";"UO_0000065";"16.74";"0.31";"4.04";"8.52";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688900";"";"0";"435.53";"0";"3.24";"BDBM174361";"C[C@H]1CN(c2nc(N3CCOC[C@@H]3C)c3ccc(-c4cccc(O)c4)nc3n2)C[C@@H](C)O1";"IC50";"'='";"18.0";"nM";"7.75";"";"319677";"UO_0000065";"17.78";"0.33";"4.50";"9.24";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701139";"";"0";"404.90";"0";"4.01";"BDBM172274";"CCc1nccc(-c2ccc(C(=O)NC)c(Cl)c2)c1C#Cc1ccc(N)nc1C";"IC50";"'='";"4.0";"nM";"8.40";"";"317198";"UO_0000065";"20.74";"0.40";"4.39";"10.38";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688962";"";"0";"494.57";"0";"2.84";"BDBM174439";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(C(=O)NCCF)c3)nc2n1";"IC50";"'='";"4.7";"nM";"8.33";"";"319743";"UO_0000065";"16.84";"0.32";"5.49";"8.98";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688967";"";"0";"504.64";"1";"3.62";"BDBM174444";"CC(C)N(C)C(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"170.0";"nM";"6.77";"";"319748";"UO_0000065";"13.41";"0.25";"3.15";"8.07";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688968";"";"0";"520.63";"1";"2.86";"BDBM174445";"COCCN(C)C(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"230.0";"nM";"6.64";"";"319749";"UO_0000065";"12.75";"0.24";"3.78";"7.13";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688977";"";"0";"520.63";"1";"3.24";"BDBM174454";"CCN(C)C(=O)c1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccc1OC";"IC50";"'='";"130.0";"nM";"6.89";"";"319759";"UO_0000065";"13.23";"0.25";"3.65";"7.39";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688986";"";"0";"448.57";"0";"2.86";"BDBM174467";"CNCc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1";"IC50";"'='";"1.6";"nM";"8.80";"";"319769";"UO_0000065";"19.61";"0.36";"5.94";"11.63";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689001";"";"0";"500.61";"1";"3.48";"BDBM174482";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(CNc4cc[nH]n4)c3)nc2n1";"IC50";"'='";"170.0";"nM";"6.77";"";"319783";"UO_0000065";"13.52";"0.25";"3.29";"6.49";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689008";"";"0";"494.62";"0";"3.78";"BDBM174489";"CC(C)NCc1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccc1F";"IC50";"'='";"28.0";"nM";"7.55";"";"319790";"UO_0000065";"15.27";"0.29";"3.77";"9.99";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689011";"";"0";"506.63";"1";"3.78";"BDBM174492";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(F)c(CNCC4CC4)c3)nc2n1";"IC50";"'='";"130.0";"nM";"6.89";"";"319793";"UO_0000065";"13.59";"0.25";"3.11";"9.10";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689022";"";"0";"504.64";"1";"3.40";"BDBM174504";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CNC1CC1";"IC50";"'='";"64.0";"nM";"7.19";"";"319805";"UO_0000065";"14.26";"0.27";"3.79";"8.48";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689028";"";"0";"570.74";"1";"4.58";"BDBM174510";"C#CC1(NCc2cc(-c3ccc4c(N5CCOC[C@@H]5C)nc(N5CCOC[C@@H]5C)nc4n3)ccc2OC)CCCCC1";"IC50";"'='";"60.0";"nM";"7.22";"";"319811";"UO_0000065";"12.65";"0.23";"2.64";"8.51";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693428";"";"0";"463.54";"0";"1.90";"BDBM174574";"CNC(=O)c1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cn1";"IC50";"'='";"130.0";"nM";"6.89";"";"319866";"UO_0000065";"14.86";"0.28";"4.99";"6.52";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693435";"";"0";"406.49";"0";"2.54";"BDBM174584";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ncc(-c3ccccc3)nc2n1";"IC50";"'='";"26.3";"nM";"7.58";"";"319874";"UO_0000065";"18.65";"0.35";"5.04";"9.91";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693450";"";"0";"463.58";"0";"3.80";"BDBM174611";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCCC[C@H]4C)nc3n2)cc1CO";"IC50";"'='";"30.0";"nM";"7.52";"";"319889";"UO_0000065";"16.23";"0.30";"3.72";"8.97";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693458";"";"0";"463.58";"0";"3.65";"BDBM174619";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCCC(C)C4)nc3n2)cc1CO";"IC50";"'='";"30.0";"nM";"7.52";"";"319897";"UO_0000065";"16.23";"0.30";"3.87";"8.97";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693459";"";"0";"525.65";"1";"4.80";"BDBM174620";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCCC(c5ccccc5)C4)nc3n2)cc1CO";"IC50";"'='";"88.0";"nM";"7.06";"";"319898";"UO_0000065";"13.42";"0.25";"2.26";"8.42";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693467";"";"0";"478.60";"0";"2.59";"BDBM174629";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCC(CN)CC4)nc3n2)cc1CO";"IC50";"'='";"37.0";"nM";"7.43";"";"319907";"UO_0000065";"15.53";"0.29";"4.84";"6.76";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688896";"";"0";"395.46";"0";"2.74";"BDBM174357";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccoc3)nc2n1";"IC50";"'='";"5.0";"nM";"8.30";"";"319673";"UO_0000065";"20.99";"0.39";"5.56";"10.82";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688903";"";"0";"467.55";"0";"3.68";"BDBM174364";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4C[C@H](C)O[C@H](C)C4)nc3n2)cc1F";"IC50";"'='";"6.4";"nM";"8.19";"";"319680";"UO_0000065";"17.53";"0.33";"4.51";"11.25";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3653561";"";"0";"462.51";"0";"1.80";"BDBM136417";"CC(C)[C@H]1CN(C[C@H](O)CO)C(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"7.6";"nM";"8.12";"";"270291";"UO_0000065";"17.55";"0.33";"6.32";"5.98";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653572";"";"0";"489.56";"0";"3.29";"BDBM136429";"CCN1CC(N2CC(C(C)C)N(c3ccn4ncc(-c5ccc(-c6nc[nH]n6)c(F)c5)c4n3)C2=O)C1";"IC50";"'='";"21.7";"nM";"7.66";"";"270303";"UO_0000065";"15.65";"0.29";"4.37";"7.78";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653590";"";"0";"393.38";"0";"3.06";"BDBM136447";"CC[C@H]1COC(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"31.7";"nM";"7.50";"";"270321";"UO_0000065";"19.06";"0.35";"4.44";"7.40";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653593";"";"0";"405.39";"0";"3.06";"BDBM136450";"O=C1OC[C@H](C2CC2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"4.5";"nM";"8.35";"";"270324";"UO_0000065";"20.59";"0.38";"5.29";"8.24";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653606";"";"0";"425.40";"0";"3.44";"BDBM136463";"CC(C)[C@H]1COC(=O)N1c1ccn2ncc(-c3cc(F)c(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"14.2";"nM";"7.85";"";"270337";"UO_0000065";"18.45";"0.35";"4.41";"7.75";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653617";"";"0";"460.40";"0";"3.55";"BDBM136474";"O=C1OC[C@H](c2ccc(F)cn2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"0.51";"nM";"9.29";"";"270348";"UO_0000065";"20.18";"0.37";"5.74";"8.14";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653621";"";"0";"459.42";"0";"4.16";"BDBM136478";"O=C1OC[C@H](c2ccc(F)cc2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"0.51";"nM";"9.29";"";"270352";"UO_0000065";"20.23";"0.37";"5.13";"9.17";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3113388";"";"0";"509.63";"2";"6.20";"6";"COc1ccc(CCNC(=O)c2sc3nc(-c4ccccc4)cc(-c4ccccc4)c3c2N)cc1OC";"IC50";"'='";"57600.0";"nM";"4.24";"";"";"UO_0000065";"8.32";"0.16";"-1.96";"4.90";"False";"CHEMBL3116603";"Inhibition of mTOR (unknown origin) by KINOMEscan assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112406";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3622372";"";"0";"443.86";"0";"2.86";"47, SAR405";"C[C@@H]1COCCN1c1cc(=O)n2c(n1)N(Cc1cncc(Cl)c1)[C@H](C(F)(F)F)CC2";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3626592";"Inhibition of recombinant human mTOR by TR-FRET analysis";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3621113";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL2165008";"";"0";"392.47";"0";"2.57";"45";"COc1ccc(Nc2ncc(CN3CCCC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165004";"";"0";"470.56";"1";"1.59";"59";"COc1ccc(Nc2ncc(CN3CCC(S(C)(=O)=O)C3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"3600.0";"nM";"5.44";"";"";"UO_0000065";"11.57";"0.23";"3.85";"3.65";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165026";"";"0";"339.36";"0";"1.46";"36";"COc1ccc(Nc2ncc(CO)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"2500.0";"nM";"5.60";"";"";"UO_0000065";"16.51";"0.31";"4.14";"4.25";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2170088";"";"0";"531.62";"2";"2.14";"58";"COc1ncc(Nc2ncc([C@@H](C)N3CCN(S(C)(=O)=O)C[C@@H]3C)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2173749";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169865";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL585130";"";"0";"383.41";"0";"1.89";"6";"COc1cc(-c2cn(-c3ccnc(N4CCOCC4)n3)cn2)cc(OC)c1O";"IC50";"'='";"460.0";"nM";"6.34";"";"";"UO_0000065";"16.53";"0.31";"4.45";"6.69";"False";"CHEMBL1049650";"Inhibition of mTOR kinase in human HeLa cells by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HeLa";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156040";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3308376"
"CHEMBL566044";"";"0";"422.49";"0";"2.57";"18";"OCc1ccc(-c2ccc(-c3cc(N4CCOCC4)nc(N4CCOCC4)n3)o2)cc1";"IC50";"'='";"5500.0";"nM";"5.26";"";"";"UO_0000065";"12.45";"0.23";"2.69";"6.25";"False";"CHEMBL1049650";"Inhibition of mTOR kinase in human HeLa cells by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HeLa";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156040";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3308376"
"CHEMBL3112714";"";"0";"513.53";"1";"3.77";"9x";"COc1ncc(-c2cc3c(C)nc(N)cc3n(C3CC3)c2=O)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3112733";"";"0";"505.60";"1";"4.27";"9n";"COc1ncc(-c2cc3c(C)nc(N)cc3n(C3CCCC3)c2=O)cc1NS(=O)(=O)c1ccccc1";"IC50";"'='";"19.2";"nM";"7.72";"";"";"UO_0000065";"15.26";"0.29";"3.45";"5.97";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3112728";"";"0";"360.42";"0";"3.34";"9i";"Cc1nc(N)cc2c1cc(-c1cnc3[nH]ncc3c1)c(=O)n2C1CCCC1";"IC50";"'='";"171.72";"nM";"6.76";"";"";"UO_0000065";"18.77";"0.34";"3.43";"6.60";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3112720";"";"0";"457.46";"0";"3.67";"14";"COc1ncc(-c2ccc3nc(N)nc(C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"2.32";"nM";"8.63";"";"";"UO_0000065";"18.87";"0.37";"4.96";"7.19";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3112719";"";"0";"521.51";"1";"3.82";"13";"COc1ncc(-c2cnc3nc(N)nc(-c4ccncc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"18.39";"nM";"7.74";"";"";"UO_0000065";"14.83";"0.29";"3.92";"5.30";"True";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL584929";"";"0";"400.46";"0";"2.83";"10";"COc1cc(-c2nc(-c3ccnc(N4CCOCC4)n3)cs2)cc(OC)c1O";"IC50";"'='";"560.0";"nM";"6.25";"";"";"UO_0000065";"15.61";"0.30";"3.42";"6.96";"False";"CHEMBL1049650";"Inhibition of mTOR kinase in human HeLa cells by ELISA";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HeLa";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156040";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2009";"CHEMBL3308376"
"CHEMBL1879463";"DACTOLISIB";"2";"469.55";"1";"5.89";"NVP-BEZ235";"Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"18.53";"0.33";"2.81";"11.37";"False";"CHEMBL3861272";"Inhibition of human recombinant mTOR using substrate PI incubated for 1 hr by Adapta kinase assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3860068";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL3735194";"";"0";"579.03";"2";"5.72";"15a";"Cl.NC(=O)c1cnc2ccc(-c3cnc4ccccc4c3)cc2c1Nc1ccc(N2CCNCC2)c(C(F)(F)F)c1";"IC50";"'='";"14.0";"nM";"7.85";"";"";"UO_0000065";"14.48";"0.27";"2.13";"8.17";"False";"CHEMBL3738862";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide as substrate after 1 hr by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3734757";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2015";""
"CHEMBL2418345";"";"0";"395.47";"0";"2.40";"11f";"CCNC(=O)Nc1ccc(-c2nc(N3CCCOCC3)c3c(ncn3C)n2)cc1";"IC50";"'='";"8900.0";"nM";"5.05";"";"";"UO_0000065";"12.77";"0.24";"2.65";"5.20";"False";"CHEMBL2421122";"Inhibition of mTOR in PTEN deficient human PC3 cells assessed as inhibition of p70S6K phosphorylation";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2417437";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";"CHEMBL3307570"
"CHEMBL2418349";"";"0";"409.49";"0";"2.79";"21b";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3CC)c3c(cnn3C)n2)cc1";"IC50";"'='";"8.0";"nM";"8.10";"";"";"UO_0000065";"19.77";"0.37";"5.31";"8.33";"False";"CHEMBL2421123";"Inhibition of mTOR in PTEN deficient human PC3 cells assessed as inhibition of Akt phosphorylation at Ser473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2417437";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";"CHEMBL3307570"
"CHEMBL589258";"";"0";"570.66";"1";"2.78";"77";"CCn1nnc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)N5CCN(C)CC5)cc4)cc3)nc21";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"14.94";"0.28";"5.74";"6.38";"False";"CHEMBL3395890";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3392967";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3965413";"";"0";"351.37";"0";"2.15";"5; 9";"Nc1nc2cc(-c3nn(C4CCOCC4)c4ncnc(N)c34)ccc2o1";"IC50";"'<'";"100.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3882339";"Inhibition of recombinant human GST-tagged mTOR (1360 to 2549 residues) catalytic domain assessed as inhibition of GFP labeled 4EBP1 phosphorylation measured after 1 hr by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3882246";"38";"Patent Bioactivity Data";"";"2010";""
"CHEMBL3650231";"";"0";"389.42";"0";"3.16";"BDBM136374";"CC(C)[C@H]1COC(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"4.8";"nM";"8.32";"";"270248";"UO_0000065";"21.36";"0.39";"5.16";"8.21";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653536";"";"0";"423.86";"0";"3.82";"BDBM136392";"CC(C)[C@H]1COC(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3Cl)c2n1";"IC50";"'='";"48.2";"nM";"7.32";"";"270266";"UO_0000065";"17.26";"0.33";"3.50";"7.22";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL1312643";"";"0";"396.47";"0";"2.35";"1";"O=S(=O)(Cc1cc(N2CCOCC2)nc(-c2ccccn2)n1)c1ccccc1";"IC50";"'='";"1410.0";"nM";"5.85";"";"";"UO_0000065";"14.76";"0.29";"3.50";"6.86";"True";"CHEMBL2033327";"Inhibition of recombinant FLAG-tagged mTOR kinase expressed in HEK293 cells using Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2 as substrate after 90 mins";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2029234";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";"CHEMBL3307715"
"CHEMBL2418339";"";"0";"395.47";"0";"2.40";"11a";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(ncn3C)n2)cc1";"IC50";"'='";"630.0";"nM";"6.20";"";"";"UO_0000065";"15.68";"0.29";"3.80";"6.38";"False";"CHEMBL2421123";"Inhibition of mTOR in PTEN deficient human PC3 cells assessed as inhibition of Akt phosphorylation at Ser473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2417437";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";"CHEMBL3307570"
"CHEMBL3646446";"";"0";"432.49";"0";"2.83";"BDBM125288";"COc1ccc(Nc2ncc(N3CCC[C@H]3CO)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'='";"1149.0";"nM";"5.94";"";"255000";"UO_0000065";"13.73";"0.25";"3.11";"4.75";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2063756";"";"0";"445.55";"0";"1.98";"6S, PF-05139962";"CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CS(=O)(=O)CC3)cc1";"IC50";"'='";"6.0";"nM";"8.22";"";"";"UO_0000065";"18.45";"0.36";"6.24";"7.24";"False";"CHEMBL2065059";"Inhibition of mTOR-mediated ribosomal protein S6 kinase phosphorylation by cell based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062409";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL4065928";"";"0";"601.71";"1";"2.68";"3; PKI-587";"CNC1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1";"IC50";"'='";"1.6";"nM";"8.80";"";"";"UO_0000065";"14.62";"0.27";"6.12";"6.42";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL4092587";"";"0";"426.48";"0";"4.17";"4a";"O=C(Nc1ccccc1)Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1";"IC50";"'='";"201.0";"nM";"6.70";"";"";"UO_0000065";"15.70";"0.29";"2.53";"7.26";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL3735478";"";"0";"423.40";"0";"4.74";"9g";"NC(=O)c1cnc2ccc(-c3ccc(N)nc3)cc2c1Nc1cccc(C(F)(F)F)c1";"IC50";"'='";"51.0";"nM";"7.29";"";"";"UO_0000065";"17.22";"0.32";"2.55";"6.82";"False";"CHEMBL3738862";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide as substrate after 1 hr by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3734757";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2015";""
"CHEMBL3736442";"";"0";"682.75";"2";"5.21";"20";"CN1CCN(CC(=O)N2CCN(c3ccc(Nc4c(C(N)=O)cnc5ccc(-c6cnc7ccccc7c6)cc45)cc3C(F)(F)F)CC2)CC1";"IC50";"'='";"24.0";"nM";"7.62";"";"";"UO_0000065";"11.16";"0.21";"2.41";"6.87";"False";"CHEMBL3738862";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide as substrate after 1 hr by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3734757";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2015";""
"CHEMBL3736372";"";"0";"558.99";"1";"4.58";"15d";"COc1ccc(-c2ccc3ncc(C(N)=O)c(Nc4ccc(N5CCNCC5)c(C(F)(F)F)c4)c3c2)cn1.Cl";"IC50";"'='";"284.0";"nM";"6.55";"";"";"UO_0000065";"12.53";"0.24";"1.97";"6.21";"False";"CHEMBL3738862";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide as substrate after 1 hr by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3734757";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2015";""
"CHEMBL3734962";"";"0";"437.50";"0";"4.95";"9f";"COc1ccc(-c2ccc3ncc(C(N)=O)c(Nc4ccc(C(C)(C)C#N)cc4)c3c2)cn1";"IC50";"'='";"674.0";"nM";"6.17";"";"";"UO_0000065";"14.11";"0.26";"1.22";"5.42";"False";"CHEMBL3738862";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide as substrate after 1 hr by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3734757";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2015";""
"CHEMBL3736038";"";"0";"422.49";"0";"4.52";"9d";"CC(C)(C#N)c1ccc(Nc2c(C(N)=O)cnc3ccc(-c4ccc(N)nc4)cc23)cc1";"IC50";"'='";"30.0";"nM";"7.52";"";"";"UO_0000065";"17.81";"0.32";"3.00";"5.76";"False";"CHEMBL3738862";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide as substrate after 1 hr by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3734757";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2015";""
"CHEMBL1946132";"";"0";"348.41";"0";"3.24";"53";"O=c1[nH]c2ncc(-c3ccc4[nH]ncc4c3)nc2n1CC1CCCCC1";"IC50";"'='";"633.0";"nM";"6.20";"";"";"UO_0000065";"17.79";"0.33";"2.96";"6.72";"False";"CHEMBL1949072";"Inhibition of mTOR-mediated S6 phosphorylation in human PC3 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";"CHEMBL3307570"
"CHEMBL1946264";"";"0";"363.43";"0";"2.83";"58";"Nc1nc2cc(-c3cnc4[nH]c(=O)n(CC5CCCCC5)c4n3)ccc2[nH]1";"IC50";"'='";"201.0";"nM";"6.70";"";"";"UO_0000065";"18.43";"0.34";"3.87";"5.66";"False";"CHEMBL1949072";"Inhibition of mTOR-mediated S6 phosphorylation in human PC3 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";"CHEMBL3307570"
"CHEMBL3112713";"";"0";"557.58";"1";"3.79";"9w";"COc1ncc(-c2cc3c(C)nc(N)cc3n(C3CCOCC3)c2=O)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"13.36";"nM";"7.87";"";"";"UO_0000065";"14.12";"0.28";"4.08";"5.69";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3112722";"";"0";"350.42";"0";"3.47";"9c";"COc1ccc(-c2cc3c(C)nc(N)cc3n(C3CCCC3)c2=O)cn1";"IC50";"'='";"39.04";"nM";"7.41";"";"";"UO_0000065";"21.14";"0.39";"3.94";"8.92";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL2057725";"";"0";"351.41";"0";"2.87";"9b";"COc1ccc(-c2cc3c(C)nc(N)nc3n(C3CCCC3)c2=O)cn1";"IC50";"'='";"30.09";"nM";"7.52";"";"";"UO_0000065";"21.40";"0.40";"4.65";"7.84";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3112721";"";"0";"424.50";"0";"2.85";"9a";"COc1ccc(-c2cc3c(C)nc(N)cc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1";"IC50";"'='";"11.19";"nM";"7.95";"";"";"UO_0000065";"18.73";"0.35";"5.10";"7.07";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL2030439";"";"0";"414.46";"0";"2.49";"16";"O=S(=O)(Cc1cc(N2CCOCC2)nc(-c2ccccn2)n1)c1ccc(F)cc1";"IC50";"'='";"1380.0";"nM";"5.86";"";"";"UO_0000065";"14.14";"0.28";"3.37";"6.87";"False";"CHEMBL2033327";"Inhibition of recombinant FLAG-tagged mTOR kinase expressed in HEK293 cells using Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2 as substrate after 90 mins";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2029234";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";"CHEMBL3307715"
"CHEMBL3736052";"";"0";"573.60";"1";"3.58";"16a";"Cn1nccc1-c1ccc2ncc(C(N)=O)c(Nc3ccc(N4CCN(S(C)(=O)=O)CC4)c(C(F)(F)F)c3)c2c1";"IC50";"'='";"1225.0";"nM";"5.91";"";"";"UO_0000065";"10.31";"0.20";"2.33";"4.68";"False";"CHEMBL3738862";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide as substrate after 1 hr by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3734757";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2015";""
"CHEMBL3113389";"";"0";"477.55";"0";"3.12";"4";"CNS(=O)(=O)c1cc(-c2nnc(Nc3ccc(OCC(N)=O)cc3)c3ccccc23)ccc1C";"IC50";"'='";"52200.0";"nM";"4.28";"";"";"UO_0000065";"8.97";"0.17";"1.16";"3.14";"False";"CHEMBL3116603";"Inhibition of mTOR (unknown origin) by KINOMEscan assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112406";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL1088240";"";"0";"526.47";"2";"5.82";"20";"COc1cc(Nc2c(C#N)cnc3cc(/C=C/CCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1117428";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157919";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091696";"";"0";"633.71";"1";"4.83";"6m";"Cn1cc(/C=C2\Oc3ccc(NC(=O)Nc4cccnc4)cc3C2=O)c2c(N3CCC(C(=O)N4CC5CCC(C4)O5)CC3)ccnc21";"IC50";"'='";"17.0";"nM";"7.77";"";"";"UO_0000065";"12.26";"0.23";"2.94";"5.93";"False";"CHEMBL1107893";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156282";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091455";"";"0";"308.29";"0";"2.60";"3";"Cn1cc(/C=C2\Oc3cc(O)cc(O)c3C2=O)c2cccnc21";"IC50";"'='";"42.0";"nM";"7.38";"";"";"UO_0000065";"23.93";"0.44";"4.78";"8.72";"False";"CHEMBL1107897";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156283";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1091456";"";"0";"384.39";"0";"4.27";"9a";"Cn1cc(/C=C2\Oc3cc(O)cc(O)c3C2=O)c2c(-c3ccccc3)ccnc21";"IC50";"'='";"0.46";"nM";"9.34";"";"";"UO_0000065";"24.29";"0.44";"5.07";"11.04";"False";"CHEMBL1107897";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156283";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL1090383";"";"0";"390.44";"0";"2.65";"10m";"CN1CCN(c2ccnc3c2c(/C=C2\Oc4cccc(O)c4C2=O)cn3C)CC1";"IC50";"'='";"2.75";"nM";"8.56";"";"";"UO_0000065";"21.93";"0.40";"5.91";"12.09";"False";"CHEMBL1107897";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156283";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL3736298";"";"0";"457.54";"1";"6.09";"9b";"CC(C)(C#N)c1ccc(Nc2c(C(N)=O)cnc3ccc(-c4cnc5ccccc5c4)cc23)cc1";"IC50";"'='";"33.0";"nM";"7.48";"";"";"UO_0000065";"16.35";"0.29";"1.39";"7.15";"True";"CHEMBL3738862";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide as substrate after 1 hr by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3734757";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2015";""
"CHEMBL1879463";"DACTOLISIB";"2";"469.55";"1";"5.89";"BEZ-235";"Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21";"IC50";"'='";"21.0";"nM";"7.68";"";"";"UO_0000065";"16.35";"0.29";"1.79";"10.04";"True";"CHEMBL3738862";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide as substrate after 1 hr by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3734757";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2015";""
"CHEMBL3736495";"";"0";"563.58";"1";"4.80";"19";"CCC(=O)N1CCN(c2ccc(Nc3c(C(N)=O)cnc4ccc(-c5ccc(N)nc5)cc34)cc2C(F)(F)F)CC1";"IC50";"'='";"21.0";"nM";"7.68";"";"";"UO_0000065";"13.62";"0.26";"2.88";"5.88";"False";"CHEMBL3738862";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide as substrate after 1 hr by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3734757";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2015";""
"CHEMBL3735181";"";"0";"471.56";"1";"6.35";"9c";"CNC(=O)c1cnc2ccc(-c3cnc4ccccc4c3)cc2c1Nc1ccc(C(C)(C)C#N)cc1";"IC50";"'='";"514.0";"nM";"6.29";"";"";"UO_0000065";"13.34";"0.24";"-0.06";"6.93";"False";"CHEMBL3738862";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide as substrate after 1 hr by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3734757";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2015";""
"CHEMBL3735791";"";"0";"458.44";"1";"6.31";"9h";"NC(=O)c1cnc2ccc(-c3cnc4ccccc4c3)cc2c1Nc1cccc(C(F)(F)F)c1";"IC50";"'='";"361.0";"nM";"6.44";"";"";"UO_0000065";"14.05";"0.26";"0.13";"7.96";"False";"CHEMBL3738862";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide as substrate after 1 hr by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3734757";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2015";""
"CHEMBL1092474";"";"0";"390.44";"0";"2.82";"17b";"Cn1cc(/C=C2\Oc3cccc(O)c3C2=O)c2c(N3CCC(N)CC3)ccnc21";"IC50";"'='";"19.0";"nM";"7.72";"";"";"UO_0000065";"19.78";"0.36";"4.90";"8.25";"False";"CHEMBL1107897";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156283";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL4239569";"";"0";"377.40";"0";"1.90";"3a";"COc1ccc(-c2ccc3c(N4CCOCC4)nc(C#N)nc3n2)cc1CO";"IC50";"'='";"32.0";"nM";"7.50";"";"";"UO_0000065";"19.86";"0.37";"5.59";"7.18";"False";"CHEMBL4233142";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide substrate measured after 1 hr by Lance Ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4229417";"1";"Scientific Literature";"Bioorg Med Chem";"2018";""
"CHEMBL4239712";"";"0";"419.53";"0";"3.57";"3k";"CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(C(C)(C)C)nc3n2)c1";"IC50";"'='";"72.0";"nM";"7.14";"";"";"UO_0000065";"17.03";"0.31";"3.57";"8.90";"False";"CHEMBL4233142";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide substrate measured after 1 hr by Lance Ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4229417";"1";"Scientific Literature";"Bioorg Med Chem";"2018";""
"CHEMBL3109116";"";"0";"308.34";"0";"2.23";"3a";"Oc1cccc(-c2nc(N3CCOCC3)c3ncccc3n2)c1";"IC50";"'='";"37.0";"nM";"7.43";"";"";"UO_0000065";"24.10";"0.44";"5.20";"10.41";"False";"CHEMBL3112126";"Inhibition of mTOR (unknown origin) after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3108735";"1";"Scientific Literature";"J. Med. Chem.";"2014";""
"CHEMBL3586404";"";"0";"397.48";"0";"2.48";"37, CC-223";"CO[C@H]1CC[C@H](N2C(=O)CNc3ncc(-c4ccc(C(C)(C)O)nc4)nc32)CC1";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"20.13";"0.38";"5.52";"7.96";"False";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3586380";"";"0";"396.49";"0";"2.95";"10";"CC(C)(O)c1ccc(-c2cnc3c(n2)N(CCC2CCOCC2)C(=O)CN3)cc1";"IC50";"'='";"25.0";"nM";"7.60";"";"";"UO_0000065";"19.17";"0.36";"4.65";"8.68";"False";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3586400";"";"0";"383.45";"0";"1.83";"33";"CC(C)(O)c1ccc(-c2cnc3c(n2)N([C@H]2CC[C@@H](O)CC2)C(=O)CN3)cn1";"IC50";"'='";"203.0";"nM";"6.69";"";"";"UO_0000065";"17.45";"0.33";"4.86";"6.00";"False";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3586395";"";"0";"381.48";"0";"3.10";"28";"CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCCCC2)CC(=O)N3)cn1";"IC50";"'='";"108.0";"nM";"6.97";"";"";"UO_0000065";"18.26";"0.34";"3.87";"7.64";"False";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL4100237";"";"0";"350.44";"0";"1.25";"6h";"C[C@@H]1COCCN1c1nc(N2CCOCC2)c2sc(CO)cc2n1";"IC50";"'='";"335.0";"nM";"6.47";"";"";"UO_0000065";"18.48";"0.37";"5.22";"9.13";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL4095594";"";"0";"412.52";"0";"2.60";"14h";"C[C@H]1CN(c2nc(N3CCOCC3)c3sc(-c4cncnc4)cc3n2)C[C@@H](C)O1";"IC50";"'>'";"2000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL2064332";"";"0";"343.36";"0";"1.22";"10";"Cn1c(Cc2nc3cc(F)ccc3[nH]2)nc(N2CCOCC2)cc1=O";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2030443";"";"0";"363.44";"0";"1.02";"22";"CS(=O)(=O)Cc1cc(N2CCOCC2)nc(-c2cccc(CO)c2)n1";"IC50";"'='";"601.0";"nM";"6.22";"";"";"UO_0000065";"17.12";"0.34";"5.20";"6.72";"False";"CHEMBL2033327";"Inhibition of recombinant FLAG-tagged mTOR kinase expressed in HEK293 cells using Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2 as substrate after 90 mins";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2029234";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";"CHEMBL3307715"
"CHEMBL4089567";"";"0";"342.40";"0";"0.79";"9";"Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1";"IC50";"'='";"1282.0";"nM";"5.89";"";"";"UO_0000065";"17.21";"0.32";"5.10";"6.57";"False";"CHEMBL4019299";"Inhibition of mTOR in human A2058 cells assessed as reduction in phosphorylation of S6 at ser235/236 residues after 1 hr by in-cell Western method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017506";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL4083691";"";"0";"415.46";"0";"2.30";"9ag";"NC(=O)N1CCC(n2c(=O)cnc3cnc4ccc(-c5ccc(N)nc5)cc4c32)CC1";"IC50";"'='";"4.0";"nM";"8.40";"";"";"UO_0000065";"20.21";"0.37";"6.10";"6.31";"False";"CHEMBL4023016";"Inhibition of N-terminal FLAG-tagged recombinant human mTOR (1362 to end residues)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020823";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL4075931";"";"0";"429.48";"0";"1.71";"12c";"NC(=O)CN1CCC(n2c(=O)cnc3cnc4ccc(-c5ccc(N)nc5)cc4c32)CC1";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"19.84";"0.36";"6.81";"6.41";"False";"CHEMBL4023016";"Inhibition of N-terminal FLAG-tagged recombinant human mTOR (1362 to end residues)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020823";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL4077990";"";"0";"443.48";"0";"3.92";"9ab";"COc1ccc(-c2cc3c(cc2F)ncc2ncc(=O)n(C4CCN(CC#N)CC4)c23)cc1";"IC50";"'='";"60.0";"nM";"7.22";"";"";"UO_0000065";"16.28";"0.30";"3.30";"8.59";"False";"CHEMBL4023016";"Inhibition of N-terminal FLAG-tagged recombinant human mTOR (1362 to end residues)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020823";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL4076699";"";"0";"414.54";"0";"2.84";"14q";"Cc1c(-c2ccn[nH]2)sc2c(N3CCOCC3)nc(N3C[C@H](C)O[C@H](C)C3)nc12";"IC50";"'='";"73.0";"nM";"7.14";"";"";"UO_0000065";"17.22";"0.34";"4.30";"8.99";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL4063840";"";"0";"468.56";"0";"3.09";"10i";"CCNC(=O)Nc1ccc(-c2cc(N3CCOC[C@@H]3C)c3ncn(COCCOC)c3n2)cc1";"IC50";"'='";"410.0";"nM";"6.39";"";"";"UO_0000065";"13.63";"0.26";"3.30";"6.22";"False";"CHEMBL4056088";"Inhibition of mTOR (unknown origin) by Kinase-Glo plus luminescence kinase assay or and ADP-Glo Plus luminescence kinase assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052688";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL4095949";"";"0";"436.56";"0";"4.18";"10o";"CCCn1c(C)nc2c(N3CCOC[C@@H]3C)cc(-c3ccc(NC(=O)NCC)cc3)nc21";"IC50";"'='";"423.0";"nM";"6.37";"";"";"UO_0000065";"14.60";"0.27";"2.19";"7.56";"False";"CHEMBL4056088";"Inhibition of mTOR (unknown origin) by Kinase-Glo plus luminescence kinase assay or and ADP-Glo Plus luminescence kinase assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052688";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL1421";"DASATINIB";"4";"488.02";"0";"3.31";"Dasatinib";"Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3826741";"Inhibition of human mTOR using poly[Glu,Tyr]4:1 as substrate in presence of [gamma-33P]ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3822371";"1";"Scientific Literature";"J. Med. Chem.";"2016";""
"CHEMBL3797590";"";"0";"353.34";"0";"1.17";"13";"Nc1nc2cc(-c3nn(CC4OCCO4)c4ncnc(N)c34)ccc2o1";"IC50";"'='";"59.0";"nM";"7.23";"";"";"UO_0000065";"20.46";"0.38";"6.06";"5.16";"False";"CHEMBL3802995";"Inhibition of human mTOR using (poly [Glu, Tyr] 4:1) as substrate assessed as incorporation of 33P in substrate by [gamma33P] ATP-based kinase assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3797068";"1";"Scientific Literature";"MedChemComm";"2016";""
"CHEMBL3797834";"";"0";"351.37";"0";"1.98";"18";"Nc1nc2cc(-c3nn(CC4CCCO4)c4ncnc(N)c34)ccc2o1";"IC50";"'='";"5.0";"nM";"8.30";"";"";"UO_0000065";"23.62";"0.44";"6.32";"6.34";"False";"CHEMBL3802992";"Inhibition of recombinant human mTOR by LanthaScreen Kinase assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3797068";"1";"Scientific Literature";"MedChemComm";"2016";""
"CHEMBL3799221";"";"0";"367.41";"0";"2.35";"5";"CCOC(Cn1nc(-c2cnc3[nH]ccc3c2)c2c(N)ncnc21)OCC";"IC50";"'='";"328.0";"nM";"6.48";"";"";"UO_0000065";"17.65";"0.33";"4.13";"5.55";"False";"CHEMBL3802995";"Inhibition of human mTOR using (poly [Glu, Tyr] 4:1) as substrate assessed as incorporation of 33P in substrate by [gamma33P] ATP-based kinase assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3797068";"1";"Scientific Literature";"MedChemComm";"2016";""
"CHEMBL3650229";"";"0";"360.38";"0";"3.13";"BDBM136372";"CC1CN(c2ccn3ncc(-c4ccc(-c5ncc[nH]5)cc4)c3n2)C(=O)O1";"IC50";"'='";"58.1";"nM";"7.24";"";"270246";"UO_0000065";"20.08";"0.37";"4.11";"8.18";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3650238";"";"0";"449.47";"0";"2.83";"BDBM136381";"CC(C)[C@H]1COC(=O)N1c1ccn2ncc(-c3ccc(-c4nnc(NCCO)o4)cc3)c2n1";"IC50";"'='";"18.9";"nM";"7.72";"";"270255";"UO_0000065";"17.18";"0.32";"4.89";"5.90";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3701087";"";"0";"513.62";"1";"3.76";"BDBM172221";"CCc1nccc(-c2ccc(C(=O)N3CCN(C4CCOCC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.0";"nM";"9.00";"";"317145";"UO_0000065";"17.52";"0.32";"5.24";"10.64";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688971";"";"0";"504.64";"1";"3.62";"BDBM174448";"CCN(CC)C(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"230.0";"nM";"6.64";"";"319752";"UO_0000065";"13.15";"0.25";"3.02";"7.91";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701162";"";"0";"443.53";"0";"3.27";"BDBM172297";"Cc1nc(N)ccc1C#Cc1c(-c2ccc(C(=O)N3CCN(C)CC3)c(F)c2)ccnc1C";"IC50";"'='";"3.0";"nM";"8.52";"";"317221";"UO_0000065";"19.22";"0.35";"5.25";"11.31";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701163";"";"0";"513.62";"1";"3.82";"BDBM172298";"Cc1nc(N)ccc1C#Cc1c(-c2ccc(C(=O)N3CCN(C4CCOCC4)CC3)c(F)c2)ccnc1C";"IC50";"'='";"4.0";"nM";"8.40";"";"317222";"UO_0000065";"16.35";"0.30";"4.58";"9.93";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL2206917";"";"0";"477.94";"0";"1.61";"BDBM50401265";"Cc1nc(N)nc(-c2cccnc2Nc2cnc(Cl)c(NS(=O)(=O)N3CCOCC3)c2)n1";"IC50";"'='";"416.0";"nM";"6.38";"";"255257";"UO_0000065";"13.35";"0.27";"4.77";"3.96";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649439";"";"0";"428.91";"0";"3.33";"BDBM122462";"CN(C)S(=O)(=O)Nc1cc(-c2cnc3cc(-c4cccnc4)ccn23)cnc1Cl";"IC50";"'='";"157.0";"nM";"6.80";"";"251069";"UO_0000065";"15.86";"0.32";"3.47";"7.36";"False";"CHEMBL3705287";"In Vitro mTOR Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP 1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639163";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646518";"";"0";"431.44";"0";"3.75";"BDBM125361";"Cc1nc(N)nc(-c2cccnc2Nc2ccc(NC(=O)Nc3cccc(F)c3)nc2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255090";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646609";"";"0";"553.57";"2";"2.15";"BDBM125466";"COc1ccc(Nc2ncc(C(N3CCN(S(C)(=O)=O)CC3)C(F)(F)F)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"3093.0";"nM";"5.51";"";"255212";"UO_0000065";"9.95";"0.20";"3.36";"3.62";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646610";"";"0";"407.36";"0";"2.57";"BDBM125467";"COc1ccc(Nc2ncc([C@@H](O)C(F)(F)F)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"599.0";"nM";"6.22";"";"255213";"UO_0000065";"15.28";"0.29";"3.65";"4.72";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646624";"";"0";"384.42";"0";"2.94";"BDBM125481";"COc1ncc(Nc2ncc(C(C)(C)O)cc2-c2cc(N)nc(C)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255236";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3688972";"";"0";"492.58";"0";"2.78";"BDBM174449";"CON(C)C(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"370.0";"nM";"6.43";"";"319753";"UO_0000065";"13.06";"0.24";"3.65";"6.90";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688974";"";"0";"500.60";"1";"2.85";"BDBM174451";"C#CCN(C)C(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"120.0";"nM";"6.92";"";"319755";"UO_0000065";"13.83";"0.26";"4.07";"8.25";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688979";"";"0";"522.63";"1";"3.76";"BDBM174456";"CCN(CC)C(=O)c1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccc1F";"IC50";"'='";"500.0";"nM";"6.30";"";"319761";"UO_0000065";"12.06";"0.23";"2.54";"7.51";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3646565";"";"0";"387.81";"0";"3.32";"BDBM125418";"CC(=O)Nc1ccc(Nc2ncc(Cl)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'='";"463.0";"nM";"6.33";"";"255156";"UO_0000065";"16.33";"0.32";"3.01";"5.34";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646567";"";"0";"511.61";"1";"1.60";"BDBM125420";"CC(=O)Nc1ccc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cc1";"IC50";"'='";"161.0";"nM";"6.79";"";"255158";"UO_0000065";"13.28";"0.26";"5.19";"4.26";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646579";"";"0";"537.63";"1";"2.89";"BDBM125433";"Cc1nc(N)nc(-c2cc([C@@H](C)N3CCN(S(C)(=O)=O)CC3)cnc2Nc2cc(F)c3cccnc3c2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255176";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646593";"";"0";"419.44";"0";"1.90";"BDBM125448";"CCS(=O)(=O)c1cnc(Nc2cnc(OC)c(F)c2)c(-c2nc(C)nc(N)n2)c1";"IC50";"'>'";"10000.0";"nM";"";"";"255192";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646623";"";"0";"411.44";"0";"3.00";"BDBM125480";"COc1ncc(Nc2ncc(C3CCOCC3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255235";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646626";"";"0";"415.43";"0";"1.91";"BDBM125483";"COc1ncc(Nc2ncc(C(O)C(C)(C)O)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255238";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3928767";"";"0";"380.41";"0";"1.13";"18";"Nc1noc2ccc(-c3nn(CCN4CCOCC4)c4ncnc(N)c34)cc12";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3882339";"Inhibition of recombinant human GST-tagged mTOR (1360 to 2549 residues) catalytic domain assessed as inhibition of GFP labeled 4EBP1 phosphorylation measured after 1 hr by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3882246";"38";"Patent Bioactivity Data";"";"2010";""
"CHEMBL3701119";"";"0";"387.44";"0";"2.21";"BDBM172254";"COCCNC(=O)c1ccc(-c2ccnc(C)c2C#Cc2ccc(N)nc2)cn1";"IC50";"'='";"88.0";"nM";"7.06";"";"317178";"UO_0000065";"18.21";"0.33";"4.85";"6.85";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3640957";"";"0";"386.46";"0";"2.31";"BDBM115607";"CCc1ncnc(-c2ccc(N3CCOCC3)nc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"41.0";"nM";"7.39";"";"240244";"UO_0000065";"19.12";"0.35";"5.08";"8.20";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3693448";"";"0";"463.54";"0";"2.50";"BDBM174606";"CC(=O)Nc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cn1";"IC50";"'='";"34.0";"nM";"7.47";"";"319887";"UO_0000065";"16.11";"0.30";"4.97";"7.07";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693471";"";"0";"583.69";"1";"4.53";"BDBM174633";"COc1ccc(C(=O)C2CCN(c3nc(N4CCOC[C@@H]4C)c4ccc(-c5ccc(OC)c(CO)c5)nc4n3)CC2)cc1";"IC50";"'='";"250.0";"nM";"6.60";"";"319911";"UO_0000065";"11.31";"0.21";"2.07";"5.99";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693477";"";"0";"534.66";"1";"2.72";"BDBM174639";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCC(N5CCOCC5)CC4)nc3n2)cc1CO";"IC50";"'='";"14.0";"nM";"7.85";"";"319917";"UO_0000065";"14.69";"0.28";"5.13";"8.15";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701127";"";"0";"444.51";"0";"3.69";"BDBM172262";"CCc1nccc(-c2ccc(C(=O)N3CCCOCC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"317186";"UO_0000065";"19.57";"0.36";"5.01";"10.69";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701145";"";"0";"471.58";"0";"3.99";"BDBM172280";"CCc1nccc(-c2ccc(C(=O)N3CCN(CC)C(C)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"9.0";"nM";"8.05";"";"317204";"UO_0000065";"17.06";"0.31";"4.06";"10.68";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL4097194";"";"0";"505.56";"1";"2.82";"4k";"NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)c4ncccc4n3)cc2)cc1";"IC50";"'='";"23.4";"nM";"7.63";"";"";"UO_0000065";"15.09";"0.29";"4.81";"5.01";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL4065878";"";"0";"426.48";"0";"4.17";"5a";"O=C(Nc1ccccc1)Nc1ccc(-c2nc(N3CCOCC3)c3cccnc3n2)cc1";"IC50";"'='";"75.8";"nM";"7.12";"";"";"UO_0000065";"16.70";"0.30";"2.95";"7.72";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL4173671";"";"0";"572.07";"2";"5.18";"9j";"O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1)Nc1ccc(Cl)c(-c2ccccc2)c1";"IC50";"'='";"3450.0";"nM";"5.46";"";"";"UO_0000065";"9.55";"0.18";"0.28";"5.21";"False";"CHEMBL4141549";"Inhibition of mTOR (unknown origin) using Ulight-4EBP1 peptide as substrate measured after 1 hr by Lance Ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4138149";"1";"Scientific Literature";"Eur J Med Chem";"2017";""
"CHEMBL4162272";"";"0";"572.07";"2";"5.18";"9c";"O=C(Nc1ccc(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cc1)Nc1ccc(Cl)c(-c2ccncc2)c1";"IC50";"'='";"260.0";"nM";"6.58";"";"";"UO_0000065";"11.51";"0.22";"1.41";"6.29";"False";"CHEMBL4141549";"Inhibition of mTOR (unknown origin) using Ulight-4EBP1 peptide as substrate measured after 1 hr by Lance Ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4138149";"1";"Scientific Literature";"Eur J Med Chem";"2017";""
"CHEMBL3577916";"";"0";"321.37";"0";"3.22";"6b";"COc1ncc(-c2cc3c(-c4ccncc4)ncnc3s2)cn1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL3579762";"Inhibition of mTOR (unknown origin) using GFP-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3576869";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL3577920";"";"0";"543.55";"2";"5.64";"6f";"COc1ncc(-c2cc3c(-c4ccncc4)ncnc3s2)cc1NS(=O)(=O)c1ccc(C(F)(F)F)cc1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL3579762";"Inhibition of mTOR (unknown origin) using GFP-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3576869";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL3577922";"";"0";"500.57";"1";"4.50";"6h";"COc1ncc(-c2cc3c(-c4ccncc4)ncnc3s2)cc1NS(=O)(=O)c1ccc(C#N)cc1";"IC50";"'='";"363.0";"nM";"6.44";"";"";"UO_0000065";"12.87";"0.25";"1.94";"4.93";"False";"CHEMBL3579762";"Inhibition of mTOR (unknown origin) using GFP-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3576869";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL3969807";"";"0";"323.36";"0";"2.84";"15";"CNc1noc2ccc(-c3nn(C(C)C)c4ncnc(N)c34)cc12";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3882339";"Inhibition of recombinant human GST-tagged mTOR (1360 to 2549 residues) catalytic domain assessed as inhibition of GFP labeled 4EBP1 phosphorylation measured after 1 hr by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3882246";"38";"Patent Bioactivity Data";"";"2010";""
"CHEMBL3923400";"";"0";"309.33";"0";"2.38";"12";"CC(C)n1nc(-c2ccc3c(N)noc3c2)c2c(N)ncnc21";"IC50";"'<'";"1000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3882339";"Inhibition of recombinant human GST-tagged mTOR (1360 to 2549 residues) catalytic domain assessed as inhibition of GFP labeled 4EBP1 phosphorylation measured after 1 hr by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3882246";"38";"Patent Bioactivity Data";"";"2010";""
"CHEMBL3975796";"";"0";"367.37";"0";"2.98";"20";"COC(=O)Nc1noc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc12";"IC50";"'<'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3882339";"Inhibition of recombinant human GST-tagged mTOR (1360 to 2549 residues) catalytic domain assessed as inhibition of GFP labeled 4EBP1 phosphorylation measured after 1 hr by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3882246";"38";"Patent Bioactivity Data";"";"2010";""
"CHEMBL3943182";"";"0";"316.38";"0";"2.38";"22";"[2H]C([2H])([2H])C([2H])(n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21)C([2H])([2H])[2H]";"IC50";"'<'";"100.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3882339";"Inhibition of recombinant human GST-tagged mTOR (1360 to 2549 residues) catalytic domain assessed as inhibition of GFP labeled 4EBP1 phosphorylation measured after 1 hr by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3882246";"38";"Patent Bioactivity Data";"";"2010";""
"CHEMBL3781488";"";"0";"472.47";"1";"7.17";"22";"CC(=O)Nc1cnc2ccc(-c3cnc4ccccc4c3)cc2c1Nc1ccc(C(F)(F)F)cc1";"IC50";"'>'";"3000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3784491";"Inhibition of human mTOR using ULight-4E-BP1 peptide as substrate after 1 hr by Lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3779897";"1";"Scientific Literature";"MedChemComm";"2016";""
"CHEMBL4074098";"";"0";"441.41";"0";"1.60";"20";"CONc1cc(C(F)(F)F)c(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cn1";"IC50";"'='";"5588.0";"nM";"5.25";"";"";"UO_0000065";"11.90";"0.23";"3.65";"5.37";"False";"CHEMBL4019299";"Inhibition of mTOR in human A2058 cells assessed as reduction in phosphorylation of S6 at ser235/236 residues after 1 hr by in-cell Western method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017506";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL4226082";"";"0";"463.49";"0";"3.73";"8a";"COc1ncc(-c2cc3c(C)nc(N)nc3s2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"17.26";"0.35";"4.27";"6.66";"False";"CHEMBL4220376";"Inhibition of recombinant N-terminal FLAG-tagged human mTOR (1362 to end residues) using ULight-4E-BP1 peptide as substrate measured after 1 hr by LANCE assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4219058";"1";"Scientific Literature";"Bioorg Med Chem";"2018";""
"CHEMBL3693398";"";"0";"516.65";"1";"3.51";"BDBM174539";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(CN(C)C(=O)C4CC4)c3)nc2n1";"IC50";"'='";"310.0";"nM";"6.51";"";"319835";"UO_0000065";"12.60";"0.23";"3.00";"7.76";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688842";"";"0";"424.48";"0";"2.68";"BDBM174300";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccnc3F)nc2n1";"IC50";"'='";"38.0";"nM";"7.42";"";"319616";"UO_0000065";"17.48";"0.33";"4.74";"9.70";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL4100335";"";"0";"426.54";"0";"3.51";"14b";"C[C@H]1CN(c2nc(N3CCOCC3)c3sc(-c4ccccc4O)cc3n2)C[C@@H](C)O1";"IC50";"'='";"225.0";"nM";"6.65";"";"";"UO_0000065";"15.59";"0.30";"3.14";"9.37";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL585699";"";"0";"445.48";"1";"0.71";"BMCL-200908069-1";"COc1cc(/C=N/Nc2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc(OC)c1O";"IC50";"'='";"1370.0";"nM";"5.86";"";"";"UO_0000065";"13.16";"0.25";"5.15";"4.63";"True";"CHEMBL3371734";"Inhibition of mTOR kinase (unknown origin) after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352220";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2014";""
"CHEMBL3813704";"";"0";"465.58";"0";"3.78";"10c";"CC(C)c1ccc2occ(/C=N/Nc3nc4c(c(N5CCOCC5)n3)CSCC4)c(=O)c2c1";"IC50";"";"";"";"";"";"Not Active";"";"";"";"";"";"False";"CHEMBL3815304";"Inhibition of mTOR (unknown origin) using ULight4E-BP1 peptide as substrate incubated for 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3813678";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2016";""
"CHEMBL3577913";"";"0";"505.51";"1";"4.84";"5f";"COc1ncc(-c2ccc3nncc(-c4ccncc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"21.6";"nM";"7.67";"";"";"UO_0000065";"15.16";"0.29";"2.83";"7.17";"False";"CHEMBL3579762";"Inhibition of mTOR (unknown origin) using GFP-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3576869";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL2064413";"";"0";"394.46";"0";"3.07";"41";"O=c1cc(N2CCOCC2)nc(Cc2nc3c(-c4cccs4)cccc3o2)[nH]1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2058163";"";"0";"340.35";"0";"-0.30";"2";"NC(=O)c1cn2cc(-c3cnc(N)nc3)nc(N3CCOCC3)c2n1";"IC50";"'='";"237.0";"nM";"6.62";"";"";"UO_0000065";"19.47";"0.36";"6.93";"4.82";"False";"CHEMBL2060320";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2057167";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1808988";"";"0";"616.72";"1";"3.35";"19, 23";"CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(O[C@H]5CCOC5)nc(N5CCOCC5)n4)cc3)cc2)CC1";"IC50";"'='";"1.1";"nM";"8.96";"";"";"UO_0000065";"14.53";"0.27";"5.61";"6.67";"False";"CHEMBL1810297";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1806467";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL2087493";"";"0";"508.01";"2";"0.34";"38";"CS(=O)(=O)N1CCN(Cc2cn3c(Cl)c(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1";"IC50";"'='";"5710.0";"nM";"5.24";"";"";"UO_0000065";"10.32";"0.21";"4.90";"3.88";"False";"CHEMBL2092092";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2086238";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL4169844";"";"0";"573.06";"1";"4.57";"9g";"O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1)Nc1ccc(Cl)c(-c2ccccn2)c1";"IC50";"'='";"90.0";"nM";"7.05";"";"";"UO_0000065";"12.29";"0.23";"2.48";"5.99";"False";"CHEMBL4141549";"Inhibition of mTOR (unknown origin) using Ulight-4EBP1 peptide as substrate measured after 1 hr by Lance Ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4138149";"1";"Scientific Literature";"Eur J Med Chem";"2017";""
"CHEMBL3640954";"";"0";"351.41";"0";"3.63";"BDBM115604";"CCc1ncnc(-c2cnc3ccccc3c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"34.0";"nM";"7.47";"";"240241";"UO_0000065";"21.25";"0.38";"3.84";"9.63";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3688984";"";"0";"518.59";"1";"2.99";"BDBM174461";"C#CCN(C)C(=O)c1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccc1F";"IC50";"'='";"140.0";"nM";"6.85";"";"319766";"UO_0000065";"13.22";"0.25";"3.86";"8.17";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688993";"";"0";"478.60";"0";"2.22";"BDBM174474";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(CNCCO)c3)nc2n1";"IC50";"'='";"31.0";"nM";"7.51";"";"319775";"UO_0000065";"15.69";"0.29";"5.29";"7.83";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689013";"";"0";"496.59";"0";"2.36";"BDBM174495";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(F)c(CNCCO)c3)nc2n1";"IC50";"'='";"87.0";"nM";"7.06";"";"319796";"UO_0000065";"14.22";"0.27";"4.70";"7.36";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693380";"";"0";"518.66";"1";"3.65";"BDBM174516";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CNCC1CC1";"IC50";"'='";"100.0";"nM";"7.00";"";"319817";"UO_0000065";"13.50";"0.25";"3.35";"8.25";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693389";"";"0";"476.58";"0";"2.78";"BDBM174530";"CC(=O)NCc1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"23.0";"nM";"7.64";"";"319826";"UO_0000065";"16.03";"0.30";"4.86";"8.24";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693395";"";"0";"530.55";"1";"3.32";"BDBM174536";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(CNC(=O)C(F)(F)F)c3)nc2n1";"IC50";"'='";"120.0";"nM";"6.92";"";"319832";"UO_0000065";"13.04";"0.25";"3.60";"7.47";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693420";"";"0";"464.57";"0";"2.99";"BDBM174566";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(CNC4CC4)o3)nc2n1";"IC50";"'='";"150.0";"nM";"6.82";"";"319857";"UO_0000065";"14.69";"0.27";"3.83";"7.69";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693429";"";"0";"477.57";"0";"2.24";"BDBM174575";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(C(=O)N(C)C)nc3)nc2n1";"IC50";"'='";"2000.0";"nM";"5.70";"";"319867";"UO_0000065";"11.93";"0.22";"3.46";"5.89";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693437";"";"0";"436.52";"0";"2.55";"BDBM174587";"COc1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccn1";"IC50";"'='";"240.0";"nM";"6.62";"";"319876";"UO_0000065";"15.16";"0.28";"4.07";"7.72";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3112734";"";"0";"535.63";"1";"4.28";"9o";"COc1ccc(S(=O)(=O)Nc2cc(-c3cc4c(C)nc(N)cc4n(C4CCCC4)c3=O)cnc2OC)cc1";"IC50";"'='";"65.64";"nM";"7.18";"";"";"UO_0000065";"13.41";"0.26";"2.90";"5.19";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3112731";"";"0";"443.53";"0";"2.84";"9l";"COc1ncc(-c2cc3c(C)nc(N)cc3n(C3CCCC3)c2=O)cc1NS(C)(=O)=O";"IC50";"'='";"62.64";"nM";"7.20";"";"";"UO_0000065";"16.24";"0.32";"4.36";"5.58";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3937461";"";"0";"422.49";"0";"1.73";"BDBM60568";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(C3C=CC(=O)N=C3)nc2n1";"IC50";"'='";"31.0";"nM";"7.51";"";"319705";"UO_0000065";"17.77";"0.33";"5.78";"8.07";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3639878";"";"0";"510.61";"1";"3.02";"BDBM174493";"COCCNCc1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccc1F";"IC50";"'='";"210.0";"nM";"6.68";"";"319794";"UO_0000065";"13.08";"0.25";"3.66";"7.87";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693407";"";"0";"520.63";"1";"2.75";"BDBM174548";"COCC(=O)N(C)Cc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1";"IC50";"'='";"670.0";"nM";"6.17";"";"319844";"UO_0000065";"11.86";"0.22";"3.42";"6.63";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693431";"";"0";"436.52";"0";"1.84";"BDBM174579";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccn(C)c(=O)c3)nc2n1";"IC50";"'='";"110.0";"nM";"6.96";"";"319869";"UO_0000065";"15.94";"0.30";"5.12";"8.13";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701056";"";"0";"429.50";"0";"2.96";"BDBM172190";"Cc1nccc(-c2ccc(C(=O)N3CCN(C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"7.0";"nM";"8.15";"";"317114";"UO_0000065";"18.99";"0.35";"5.19";"10.82";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701060";"";"0";"445.95";"0";"3.48";"BDBM172194";"Cc1nccc(-c2ccc(C(=O)N3CCN(C)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"317118";"UO_0000065";"19.51";"0.37";"5.22";"11.54";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701157";"";"0";"457.55";"0";"3.52";"BDBM172292";"CCc1nc(N)ccc1C#Cc1c(-c2ccc(C(=O)N3CCN(C)CC3)c(F)c2)ccnc1C";"IC50";"'='";"17.0";"nM";"7.77";"";"317216";"UO_0000065";"16.98";"0.31";"4.25";"10.31";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL589142";"";"0";"484.60";"0";"3.66";"1f";"OCc1cccc(-c2nc(N3CCOCC3)c3ncn(C4CCN(Cc5ccccc5)CC4)c3n2)c1";"IC50";"'='";"634.0";"nM";"6.20";"";"";"UO_0000065";"12.79";"0.24";"2.54";"7.79";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1088790";"";"0";"393.49";"0";"2.55";"9";"OCc1cccc(-c2nc(N3CCOCC3)c3[nH]cc(CN4CCCC4)c3n2)c1";"IC50";"'='";"3600.0";"nM";"5.44";"";"";"UO_0000065";"13.83";"0.26";"2.89";"7.02";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1088831";"";"0";"469.59";"0";"4.55";"13";"Oc1cccc(-c2nc(N3CCOCC3)c3[nH]cc(C4CCN(Cc5ccccc5)CC4)c3n2)c1";"IC50";"'='";"2000.0";"nM";"5.70";"";"";"UO_0000065";"12.14";"0.22";"1.15";"7.35";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1092280";"";"0";"527.63";"1";"2.88";"39";"O=C(Nc1ccncc1)Nc1ccc(-c2nc(N3CCOCC3)c3ccn(CCN4CCNCC4)c3n2)cc1";"IC50";"'='";"14.0";"nM";"7.85";"";"";"UO_0000065";"14.89";"0.28";"4.97";"6.98";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1092074";"";"0";"622.65";"1";"4.53";"48";"CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)c5ccn(CC(F)(F)F)c5n4)cc3)cc2)CC1";"IC50";"'='";"1.7";"nM";"8.77";"";"";"UO_0000065";"14.08";"0.27";"4.24";"8.13";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL1091130";"";"0";"457.49";"0";"3.17";"34";"O=CCn1ccc2c(N3CCOCC3)nc(-c3ccc(NC(=O)Nc4ccncc4)cc3)nc21";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"18.63";"0.34";"5.35";"7.46";"False";"CHEMBL1106091";"Inhibition of mTOR by DELFIA";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1156188";"1";"Scientific Literature";"J. Med. Chem.";"2010";""
"CHEMBL3327009";"";"0";"428.50";"0";"2.85";"2r";"COc1ncc(-c2cnc3nc(N)nc(C)c3c2)cc1NS(=O)(=O)c1cccs1";"IC50";"'='";"245.0";"nM";"6.61";"";"";"UO_0000065";"15.43";"0.31";"3.76";"4.97";"False";"CHEMBL3380578";"Inhibition of mTOR (unknown origin) assessed as inhibition of 4EBP-1 phosphorylation preincubated for 15 mins before substrate addition by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3351642";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3735998";"";"0";"619.09";"2";"6.51";"15c";"Cl.O=C(NC1CC1)c1cnc2ccc(-c3cnc4ccccc4c3)cc2c1Nc1ccc(N2CCNCC2)c(C(F)(F)F)c1";"IC50";"'>'";"3000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3738862";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide as substrate after 1 hr by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3734757";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2015";""
"CHEMBL413";"SIROLIMUS";"4";"914.19";"3";"6.18";"Rapamycin";"CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C";"IC50";"'='";"430.0";"nM";"6.37";"";"";"UO_0000065";"6.96";"0.13";"0.19";"3.26";"False";"CHEMBL4272807";"Inhibition of mTOR (unknown origin) incubated for 1 hr by ELISA";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4270553";"1";"Scientific Literature";"Eur J Med Chem";"2018";""
"CHEMBL2029359";"";"0";"373.44";"0";"1.40";"25";"CS(=O)(=O)Cc1cc(N2CCOCC2)nc(-c2cnc3[nH]ccc3c2)n1";"IC50";"'='";"262.0";"nM";"6.58";"";"";"UO_0000065";"17.62";"0.35";"5.18";"6.51";"False";"CHEMBL2033327";"Inhibition of recombinant FLAG-tagged mTOR kinase expressed in HEK293 cells using Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2 as substrate after 90 mins";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2029234";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";"CHEMBL3307715"
"CHEMBL2030438";"";"0";"362.45";"0";"1.70";"17";"CC(C)S(=O)(=O)Cc1cc(N2CCOCC2)nc(-c2ccccn2)n1";"IC50";"'='";"1540.0";"nM";"5.81";"";"";"UO_0000065";"16.04";"0.32";"4.11";"6.82";"False";"CHEMBL2033327";"Inhibition of recombinant FLAG-tagged mTOR kinase expressed in HEK293 cells using Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2 as substrate after 90 mins";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2029234";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";"CHEMBL3307715"
"CHEMBL2030440";"";"0";"333.41";"0";"1.52";"2";"CS(=O)(=O)Cc1cc(N2CCOCC2)nc(-c2ccccc2)n1";"IC50";"'='";"5000.0";"nM";"5.30";"";"";"UO_0000065";"15.90";"0.31";"3.78";"7.32";"False";"CHEMBL2033327";"Inhibition of recombinant FLAG-tagged mTOR kinase expressed in HEK293 cells using Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2 as substrate after 90 mins";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2029234";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";"CHEMBL3307715"
"CHEMBL3701155";"";"0";"485.56";"0";"2.98";"BDBM172290";"CCc1nccc(-c2ccc(C(=O)N3CCN(C4COC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.0";"nM";"8.40";"";"317214";"UO_0000065";"17.30";"0.32";"5.42";"9.93";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701104";"";"0";"485.61";"0";"4.38";"BDBM172239";"CCc1nccc(-c2ccc(C(=O)N3CCN(C(C)(C)C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.0";"nM";"8.30";"";"317163";"UO_0000065";"17.09";"0.31";"3.92";"11.02";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701121";"";"0";"401.47";"0";"2.55";"BDBM172256";"COCCN(C)C(=O)c1ccc(-c2ccnc(C)c2C#Cc2ccc(N)nc2)cn1";"IC50";"'='";"20.0";"nM";"7.70";"";"317180";"UO_0000065";"19.18";"0.35";"5.15";"8.17";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701123";"";"0";"397.48";"0";"3.46";"BDBM172258";"Cc1nccc(-c2ccc(C(=O)N3CCCCC3)nc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"21.0";"nM";"7.68";"";"317182";"UO_0000065";"19.32";"0.35";"4.22";"9.03";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701141";"";"0";"483.59";"0";"4.14";"BDBM172276";"CCc1nccc(-c2ccc(C(=O)N3CCN4CCCCC4C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.0";"nM";"8.40";"";"317200";"UO_0000065";"17.37";"0.32";"4.26";"11.15";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL2158847";"";"0";"412.48";"0";"1.77";"9e";"NS(=O)(=O)c1ccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)cc1";"IC50";"'>'";"20000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2161544";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2157945";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL3109133";"";"0";"308.35";"0";"1.51";"4l";"Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cn1";"IC50";"'='";"266.0";"nM";"6.58";"";"";"UO_0000065";"21.32";"0.39";"5.07";"7.30";"False";"CHEMBL3112126";"Inhibition of mTOR (unknown origin) after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3108735";"1";"Scientific Literature";"J. Med. Chem.";"2014";""
"CHEMBL1921986";"";"0";"498.61";"1";"0.90";"69";"Cc1c(CN2CCN(C(=O)[C@@H](C)O)CC2)sc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12";"IC50";"'='";"17.0";"nM";"7.77";"";"";"UO_0000065";"15.58";"0.30";"6.87";"5.81";"False";"CHEMBL3395890";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3392967";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL2381373";"";"0";"422.51";"0";"3.44";"27";"CC(C)n1ncnc1-c1nc2c(s1)CCOc1cc(-c3cnn(CCO)c3)ccc1-2";"IC50";"'>'";"4300.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2383006";"Inhibition of mTOR (unknown origin) assessed as inhibition of GFP-4E-BP1 phosphorylation after 30 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2380305";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";""
"CHEMBL3688911";"";"0";"465.51";"0";"2.55";"BDBM174372";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(O)c(C(=O)O)c3)nc2n1";"IC50";"'='";"65.0";"nM";"7.19";"";"319688";"UO_0000065";"15.44";"0.29";"4.64";"5.93";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3646542";"";"0";"601.49";"2";"3.07";"BDBM125394";"COc1ccc(Nc2ncc(C(O)c3cc(Br)ccc3S(=O)(=O)N(C)C)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"726.0";"nM";"6.14";"";"255125";"UO_0000065";"10.21";"0.22";"3.07";"3.63";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646553";"";"0";"375.40";"0";"2.36";"BDBM125406";"COc1ccc(Nc2ncc(-c3cn[nH]c3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255140";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646564";"";"0";"295.31";"0";"1.26";"BDBM125417";"Cc1nc(N)nc(-c2cccnc2Nc2cc[nH]c(=O)c2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255153";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646568";"";"0";"814.71";"";"";"BDBM125421";"COc1ccc(Nc2ncc([C@@H](O)C(F)(F)F)cc2-c2nc(C)nc(N)n2)cn1.COc1ccc(Nc2ncc([C@H](O)C(F)(F)F)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"581.0";"nM";"6.24";"";"255159";"UO_0000065";"7.65";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646573";"";"0";"454.51";"0";"2.68";"BDBM125427";"COc1ncc(Nc2ncc(C(C)(C)N3CCOCC3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255170";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646577";"";"0";"351.37";"0";"2.17";"BDBM125431";"COc1ccc(Nc2ncc(C(C)=O)nc2-c2cc(N)nc(C)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255174";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646601";"";"0";"385.40";"0";"2.21";"BDBM125457";"COc1ncc(Nc2ncc(C(C)CO)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255201";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3577921";"";"0";"511.54";"1";"4.90";"6g";"COc1ncc(-c2cc3c(-c4ccncc4)ncnc3s2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"218.0";"nM";"6.66";"";"";"UO_0000065";"13.02";"0.26";"1.76";"6.23";"False";"CHEMBL3579762";"Inhibition of mTOR (unknown origin) using GFP-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3576869";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL3577924";"";"0";"495.54";"1";"5.20";"6j";"Cc1ncc(-c2cc3c(-c4ccncc4)ncnc3s2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"345.0";"nM";"6.46";"";"";"UO_0000065";"13.04";"0.26";"1.26";"6.61";"False";"CHEMBL3579762";"Inhibition of mTOR (unknown origin) using GFP-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3576869";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL3688943";"";"0";"450.54";"0";"2.73";"BDBM174420";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1N";"IC50";"'='";"57.0";"nM";"7.24";"";"319724";"UO_0000065";"16.08";"0.30";"4.51";"7.33";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688944";"";"0";"445.53";"0";"3.02";"BDBM174421";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cnc4[nH]ccc4c3)nc2n1";"IC50";"'='";"170.0";"nM";"6.77";"";"319725";"UO_0000065";"15.19";"0.28";"3.75";"7.34";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688946";"";"0";"460.54";"0";"2.39";"BDBM174423";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc4c(c3)CNC4=O)nc2n1";"IC50";"'='";"16.0";"nM";"7.80";"";"319727";"UO_0000065";"16.93";"0.31";"5.41";"8.41";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688948";"";"0";"447.54";"0";"1.77";"BDBM174425";"C[C@H]1COCCN1c1nc(N2CCN(C)CC2)nc2nc(-c3cccc(C(N)=O)c3)ccc12";"IC50";"'='";"700.0";"nM";"6.16";"";"319729";"UO_0000065";"13.75";"0.25";"4.38";"6.11";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688992";"";"0";"463.58";"0";"3.68";"BDBM174473";"CCOCc1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"130.0";"nM";"6.89";"";"319774";"UO_0000065";"14.85";"0.28";"3.21";"9.45";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3646563";"";"0";"375.34";"0";"2.57";"BDBM125416";"COc1ccc(Nc2ncc(OC(F)F)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255152";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646621";"";"0";"401.86";"0";"2.85";"BDBM125478";"COc1cc(Nc2ncc(C(C)(C)O)cc2-c2nc(C)nc(N)n2)cnc1Cl";"IC50";"'='";"474.0";"nM";"6.32";"";"255233";"UO_0000065";"15.74";"0.31";"3.47";"4.79";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3357876";"";"0";"435.41";"0";"3.22";"BDBM125484";"COc1ncc(Nc2ncc(C(C)(C)O)cc2-c2nc(C)nc(N)n2)cc1C(F)(F)F";"IC50";"'>'";"10000.0";"nM";"";"";"255239";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3358288";"";"0";"367.41";"0";"2.20";"BDBM125489";"COc1cncc(Nc2ncc(C(C)(C)O)cc2-c2nc(C)nc(N)n2)c1";"IC50";"'='";"2125.0";"nM";"5.67";"";"255244";"UO_0000065";"15.44";"0.29";"3.47";"4.30";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3334621";"";"0";"470.53";"1";"7.04";"15, ETP-46464";"CC(C)(C#N)c1ccc(N2C(=O)OCc3cnc4ccc(-c5cnc6ccccc6c5)cc4c32)cc1";"IC50";"'='";"0.6";"nM";"9.22";"";"";"UO_0000065";"19.60";"0.35";"2.18";"11.66";"False";"CHEMBL3374527";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352686";"1";"Scientific Literature";"J. Med. Chem.";"2014";""
"CHEMBL2064349";"";"0";"401.47";"0";"2.75";"27";"Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2cc(-c3ccccc3)ccc21";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL3357864";"";"0";"357.35";"0";"1.60";"3";"COc1ncc(Nc2ncc(CO)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"15000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3379685";"Inhibition of recombinant N-terminally GST-tagged mTOR (1360 to 2549 aa) (unknown origin) assessed as inhibition of 27BP1 phosphorylation after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352452";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3688969";"";"0";"512.56";"1";"3.14";"BDBM174446";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(C(=O)NCC(F)F)c3)nc2n1";"IC50";"'='";"44.0";"nM";"7.36";"";"319750";"UO_0000065";"14.35";"0.27";"4.22";"7.94";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688989";"";"0";"504.64";"1";"2.71";"BDBM174470";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(CN4CC[C@H](O)C4)cc3)nc2n1";"IC50";"'='";"13.0";"nM";"7.89";"";"319772";"UO_0000065";"15.63";"0.29";"5.18";"9.06";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689000";"";"0";"492.62";"0";"2.88";"BDBM174481";"COCCNCc1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"21.0";"nM";"7.68";"";"319782";"UO_0000065";"15.59";"0.29";"4.80";"9.05";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701061";"";"0";"500.05";"1";"4.79";"BDBM172195";"Cc1nccc(-c2ccc(C(=O)N3CCN(C4CCCC4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.0";"nM";"8.40";"";"317119";"UO_0000065";"16.79";"0.32";"3.61";"11.15";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701076";"";"0";"430.48";"0";"3.30";"BDBM172210";"CCc1nccc(-c2ccc(C(=O)N3CCOCC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"317134";"UO_0000065";"19.80";"0.36";"5.22";"10.48";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701080";"";"0";"457.55";"0";"3.67";"BDBM172214";"CCc1nccc(-c2ccc(C(=O)N3CCN(C)CC3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"11.0";"nM";"7.96";"";"317138";"UO_0000065";"17.39";"0.32";"4.29";"12.97";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701166";"";"0";"457.55";"0";"3.66";"BDBM172301";"CCN1CCN(C(=O)c2ccc(-c3ccnc(C)c3C#Cc3ccc(N)nc3C)cc2F)CC1";"IC50";"'='";"19.0";"nM";"7.72";"";"317225";"UO_0000065";"16.88";"0.31";"4.06";"10.25";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701082";"";"0";"457.55";"0";"3.60";"BDBM172216";"CCc1nccc(-c2ccc(C(=O)N3CCN(CC)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"317140";"UO_0000065";"19.01";"0.35";"5.10";"11.54";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3357873";"";"0";"367.41";"0";"2.20";"12";"COc1ccc(Nc2ncc(C(C)(C)O)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"790.0";"nM";"6.10";"";"";"UO_0000065";"16.61";"0.31";"3.90";"4.62";"False";"CHEMBL3379685";"Inhibition of recombinant N-terminally GST-tagged mTOR (1360 to 2549 aa) (unknown origin) assessed as inhibition of 27BP1 phosphorylation after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352452";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL2336331";"";"0";"419.53";"0";"3.53";"BDBM50429717";"C[C@H]1CN(c2nc(N3CCOC[C@@H]3C)c3ccc(-c4ccccc4)nc3n2)C[C@@H](C)O1";"IC50";"'='";"35.0";"nM";"7.46";"";"319610";"UO_0000065";"17.77";"0.33";"3.93";"11.72";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688846";"";"0";"467.53";"1";"1.95";"BDBM174304";"COc1ncc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c(OC)n1";"IC50";"'='";"340.0";"nM";"6.47";"";"319620";"UO_0000065";"13.84";"0.26";"4.52";"6.00";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688850";"";"0";"440.94";"0";"3.19";"BDBM174309";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cncc(Cl)c3)nc2n1";"IC50";"'='";"330.0";"nM";"6.48";"";"319625";"UO_0000065";"14.70";"0.29";"3.29";"8.47";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688902";"";"0";"433.56";"0";"3.84";"BDBM174363";"Cc1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4C[C@H](C)O[C@H](C)C4)nc3n2)c1";"IC50";"'='";"500.0";"nM";"6.30";"";"319679";"UO_0000065";"14.53";"0.27";"2.46";"9.91";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688996";"";"0";"476.63";"0";"3.64";"BDBM174477";"CC(C)NCc1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"16.0";"nM";"7.80";"";"319778";"UO_0000065";"16.36";"0.30";"4.16";"10.31";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3327007";"";"0";"490.47";"0";"3.81";"2p";"COc1ncc(-c2cnc3nc(N)nc(C)c3c2)cc1NS(=O)(=O)c1ccc(C(F)(F)F)cc1";"IC50";"'='";"67.0";"nM";"7.17";"";"";"UO_0000065";"14.63";"0.29";"3.36";"5.39";"False";"CHEMBL3380578";"Inhibition of mTOR (unknown origin) assessed as inhibition of 4EBP-1 phosphorylation preincubated for 15 mins before substrate addition by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3351642";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3693515";"";"0";"425.49";"0";"1.82";"BDBM174678";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(NCCO)nc3n2)cc1CO";"IC50";"'='";"42.0";"nM";"7.38";"";"319959";"UO_0000065";"17.34";"0.32";"5.56";"6.54";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693527";"";"0";"462.51";"0";"2.10";"BDBM174690";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(-n4ccnc4CO)nc3n2)cc1CO";"IC50";"'='";"370.0";"nM";"6.43";"";"319971";"UO_0000065";"13.91";"0.26";"4.33";"5.42";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693536";"";"0";"478.55";"0";"1.74";"BDBM174699";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCNC(=O)C4C)nc3n2)cc1CO";"IC50";"'='";"5.2";"nM";"8.28";"";"319981";"UO_0000065";"17.31";"0.32";"6.54";"7.33";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3952134";"";"0";"483.55";"1";"1.61";"BDBM251659";"CNc1nc2ccc(C#N)cc2n1-c1nc2c(c(C(C)(C)S(C)(=O)=O)n1)OC[C@@H]1COCCN21";"IC50";"'='";"10000.0";"nM";"5.00";"";"438560";"UO_0000065";"10.34";"0.20";"3.39";"3.70";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3639923";"";"0";"521.62";"1";"3.20";"BDBM174628";"CCOC(=O)C1CCCN(c2nc(N3CCOC[C@@H]3C)c3ccc(-c4ccc(OC)c(CO)c4)nc3n2)C1";"IC50";"'='";"180.0";"nM";"6.75";"";"319906";"UO_0000065";"12.93";"0.24";"3.54";"6.12";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688939";"";"0";"503.56";"1";"1.82";"BDBM174416";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc4c(c3)C(=O)NCC(=O)N4)nc2n1";"IC50";"'='";"20.0";"nM";"7.70";"";"319720";"UO_0000065";"15.29";"0.28";"5.88";"6.32";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701144";"";"0";"485.61";"0";"4.38";"BDBM172279";"CCc1nccc(-c2ccc(C(=O)N3CCN(C(C)C)C(C)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"10.0";"nM";"8.00";"";"317203";"UO_0000065";"16.47";"0.30";"3.62";"10.62";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL2152252";"";"0";"453.86";"0";"2.82";"31";"CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3F)c2)cnc1N";"IC50";"'='";"623.0";"nM";"6.21";"";"";"UO_0000065";"13.67";"0.28";"3.39";"4.88";"False";"CHEMBL2156910";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2150966";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2158861";"";"0";"517.62";"1";"4.26";"11e";"CNC(=O)Nc1ccc(-c2cc(-c3ccnc(Nc4ccc(C)c(S(=O)(=O)N(C)C)c4)n3)ccn2)cc1";"IC50";"'='";"45.0";"nM";"7.35";"";"";"UO_0000065";"14.19";"0.27";"3.09";"5.69";"False";"CHEMBL2161544";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2157945";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2418348";"";"0";"395.47";"0";"2.40";"21a";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(cnn3C)n2)cc1";"IC50";"'='";"8.0";"nM";"8.10";"";"";"UO_0000065";"20.47";"0.38";"5.70";"8.33";"False";"CHEMBL2421123";"Inhibition of mTOR in PTEN deficient human PC3 cells assessed as inhibition of Akt phosphorylation at Ser473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2417437";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";"CHEMBL3307570"
"CHEMBL2418345";"";"0";"395.47";"0";"2.40";"11f";"CCNC(=O)Nc1ccc(-c2nc(N3CCCOCC3)c3c(ncn3C)n2)cc1";"IC50";"'='";"7200.0";"nM";"5.14";"";"";"UO_0000065";"13.00";"0.24";"2.74";"5.29";"False";"CHEMBL2421123";"Inhibition of mTOR in PTEN deficient human PC3 cells assessed as inhibition of Akt phosphorylation at Ser473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2417437";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";"CHEMBL3307570"
"CHEMBL585699";"";"0";"445.48";"1";"0.71";"I";"COc1cc(/C=N/Nc2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc(OC)c1O";"IC50";"'='";"1370.0";"nM";"5.86";"";"";"UO_0000065";"13.16";"0.25";"5.15";"4.63";"False";"CHEMBL3414045";"Inhibition of mTOR kinase (unknown origin) using ULight-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407441";"1";"Scientific Literature";"Eur. J. Med. Chem.";"2015";""
"CHEMBL3410642";"";"0";"476.60";"0";"1.60";"12";"C[C@H]1COCCN1c1cc(CS(C)(=O)=O)nc(-c2ccc(NC(=O)NCCN(C)C)cc2)n1";"IC50";"'='";"758.58";"nM";"6.12";"";"";"UO_0000065";"12.84";"0.25";"4.52";"5.24";"False";"CHEMBL3413521";"Inhibition of recombinant truncated FLAG-tagged mTOR (1362 to 2549 aa) (unknown origin) expressed in HEK293 cells using biotinylated p70 peptide as substrate";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407414";"1";"Scientific Literature";"J. Med. Chem.";"2015";"CHEMBL3307715"
"CHEMBL3407730";"";"0";"451.46";"0";"2.78";"16i";"O=C(O)c1ccc2occ(/C=N/Nc3nc(N4CCOCC4)c4ccsc4n3)c(=O)c2c1";"IC50";"'='";"160.0";"nM";"6.80";"";"";"UO_0000065";"15.05";"0.29";"4.02";"5.22";"True";"CHEMBL3414045";"Inhibition of mTOR kinase (unknown origin) using ULight-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407441";"1";"Scientific Literature";"Eur. J. Med. Chem.";"2015";""
"CHEMBL3653633";"";"0";"423.41";"0";"2.68";"BDBM136490";"COCC1(C)COC(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"6.6";"nM";"8.18";"";"270364";"UO_0000065";"19.32";"0.36";"5.50";"7.40";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653634";"";"0";"423.41";"0";"2.68";"BDBM136491";"CO[C@@H](C)[C@H]1COC(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"7.4";"nM";"8.13";"";"270365";"UO_0000065";"19.20";"0.36";"5.45";"7.36";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653653";"";"0";"474.43";"0";"3.56";"BDBM136511";"Cn1cnc(-c2ccc(-c3cnn4ccc(N5C(=O)OC[C@@H]5c5ccc(F)cn5)nc34)cc2F)n1";"IC50";"'='";"14.5";"nM";"7.84";"";"270385";"UO_0000065";"16.52";"0.31";"4.28";"7.59";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643111";"";"0";"473.55";"0";"3.46";"BDBM115727";"CCc1ncnc(-c2ccc(C(=O)N3CCC(CCO)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"6.0";"nM";"8.22";"";"240364";"UO_0000065";"17.36";"0.32";"4.76";"7.81";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643113";"";"0";"484.58";"0";"3.39";"BDBM115729";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CC4CC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.0";"nM";"8.30";"";"240366";"UO_0000065";"17.13";"0.31";"4.91";"9.41";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL2064350";"";"0";"401.47";"0";"2.75";"28";"Cn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2ccc(-c3ccccc3)cc21";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064344";"";"0";"387.44";"0";"2.54";"22";"O=c1cc(N2CCOCC2)nc(Cc2nc3ccccc3n2-c2ccccc2)[nH]1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064340";"";"0";"339.40";"0";"1.57";"18";"CCn1c(Cc2nc(N3CCOCC3)cc(=O)[nH]2)nc2ccccc21";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2058169";"";"0";"453.51";"1";"-0.33";"8";"Nc1ncc(-c2cn3cc(C(=O)NCCN4CCOCC4)nc3c(N3CCOCC3)n2)cn1";"IC50";"'>'";"5000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2060320";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2057167";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL3800481";"";"0";"383.41";"0";"2.20";"12";"CCOC(Cn1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21)OCC";"IC50";"'='";"15.0";"nM";"7.82";"";"";"UO_0000065";"20.41";"0.38";"5.62";"5.58";"False";"CHEMBL3802992";"Inhibition of recombinant human mTOR by LanthaScreen Kinase assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3797068";"1";"Scientific Literature";"MedChemComm";"2016";""
"CHEMBL3800481";"";"0";"383.41";"0";"2.20";"12";"CCOC(Cn1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21)OCC";"IC50";"'='";"15.0";"nM";"7.82";"";"";"UO_0000065";"20.41";"0.38";"5.62";"5.58";"False";"CHEMBL3802995";"Inhibition of human mTOR using (poly [Glu, Tyr] 4:1) as substrate assessed as incorporation of 33P in substrate by [gamma33P] ATP-based kinase assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3797068";"1";"Scientific Literature";"MedChemComm";"2016";""
"CHEMBL2087483";"";"0";"487.59";"1";"0.07";"23";"C[C@H]1CN(Cc2cn3cc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CCN1S(C)(=O)=O";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL2092092";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2086238";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL3938266";"";"0";"389.46";"0";"2.88";"BDBM245468";"COc1ccc(-c2ccc3ncc4c(c3c2)n(C2CCNCC2)c(=O)n4C)cn1";"IC50";"'='";"237.0";"nM";"6.62";"";"427979";"UO_0000065";"17.01";"0.31";"3.75";"8.96";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3641015";"";"0";"510.98";"1";"3.76";"BDBM115666";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CC(F)F)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"240303";"UO_0000065";"17.02";"0.33";"4.94";"9.86";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL2063761";"";"0";"429.50";"0";"1.69";"11";"CCNC(=O)Nc1ccc(-c2nc3c(c(N4C[C@@H]5C[C@H]4CO5)n2)CS(=O)(=O)C3)cc1";"IC50";"'='";"1290.0";"nM";"5.89";"";"";"UO_0000065";"13.71";"0.27";"4.20";"5.19";"False";"CHEMBL2065058";"Inhibition of mTOR-mediated AKT phosphorylation at Ser473 by cell based assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062409";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2170096";"";"0";"503.56";"2";"1.19";"BDBM50396812";"COc1ncc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"254954";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2064406";"";"0";"326.36";"0";"1.65";"34";"Cc1cccc2oc(Cc3nc(N4CCOCC4)cc(=O)[nH]3)nc12";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL3640975";"";"0";"357.42";"0";"2.44";"BDBM115625";"CCc1ncnc(-c2cccc(C(=O)NC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"44.0";"nM";"7.36";"";"240262";"UO_0000065";"20.58";"0.37";"4.92";"7.84";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165026";"";"0";"339.36";"0";"1.46";"BDBM50394864";"COc1ccc(Nc2ncc(CO)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"2475.0";"nM";"5.61";"";"255078";"UO_0000065";"16.52";"0.31";"4.15";"4.25";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646510";"";"0";"385.43";"0";"3.82";"BDBM125353";"Cc1nc(-c2cccnc2Nc2ccc(NC(=O)C3CC3)cc2)c2nc[nH]c2n1";"IC50";"'='";"50.0";"nM";"7.30";"";"255081";"UO_0000065";"18.94";"0.34";"3.48";"6.73";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3641017";"";"0";"503.05";"1";"4.29";"BDBM115668";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C(C)(C)C)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"240305";"UO_0000065";"17.29";"0.33";"4.41";"9.86";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3641018";"";"0";"460.93";"0";"2.31";"BDBM115669";"CCc1ncnc(-c2ccc(C(=O)N3CCNC(=O)C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.82";"nM";"9.09";"";"240306";"UO_0000065";"19.71";"0.38";"6.78";"7.96";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643071";"";"0";"494.52";"0";"3.25";"BDBM115686";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CC(F)F)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.0";"nM";"9.00";"";"240323";"UO_0000065";"18.20";"0.34";"5.75";"10.20";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643089";"";"0";"447.51";"0";"3.07";"BDBM115705";"CCc1ncnc(-c2ccc(C(=O)N(C)CC(C)(C)O)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.0";"nM";"8.40";"";"240342";"UO_0000065";"18.77";"0.35";"5.33";"7.98";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643101";"";"0";"507.57";"1";"3.58";"BDBM115717";"CCc1ncnc(-c2ccc(C(=O)N3CCN(c4ccncc4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"7.0";"nM";"8.15";"";"240354";"UO_0000065";"16.07";"0.29";"4.57";"8.06";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643110";"";"0";"502.59";"1";"2.75";"BDBM115726";"CCc1ncnc(-c2ccc(C(=O)N3CCC(O)(CN(C)C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"28.0";"nM";"7.55";"";"240363";"UO_0000065";"15.03";"0.28";"4.80";"6.96";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643139";"";"0";"428.47";"0";"2.67";"BDBM115755";"CCc1ncnc(-c2ccc(C(=O)N3[C@H]4C[C@@H]3N4C)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"21.0";"nM";"7.68";"";"240392";"UO_0000065";"17.92";"0.33";"5.01";"8.70";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643144";"";"0";"475.00";"0";"3.56";"BDBM115760";"CCc1ncnc(-c2ccc(C(=O)NC3CCCN(C)C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"57.0";"nM";"7.24";"";"240397";"UO_0000065";"15.25";"0.29";"3.68";"7.47";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646534";"";"0";"422.49";"0";"2.19";"BDBM125385";"COc1ccc(Nc2ncc(CN3CCOC[C@@H]3C)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255110";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3648868";"";"0";"484.58";"0";"3.44";"BDBM116174";"CCc1ncnc(-c2ccc(C(=O)N3CCC4(CCNCC4)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"25.52";"nM";"7.59";"";"240786";"UO_0000065";"15.67";"0.29";"4.15";"7.83";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3648870";"";"0";"456.53";"0";"2.51";"BDBM116176";"CCc1ncnc(-c2ccc(C(=O)N3C[C@@H]4CNC[C@@H]4C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"32.58";"nM";"7.49";"";"240788";"UO_0000065";"16.40";"0.30";"4.98";"7.72";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3648871";"";"0";"556.64";"1";"4.30";"BDBM116177";"CCc1ncnc(-c2ccc(C(=O)N3C[C@@H]4CCN(C(=O)OC(C)(C)C)[C@@H]4C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.0";"nM";"8.30";"";"240789";"UO_0000065";"14.91";"0.28";"4.00";"7.25";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165271";"";"0";"317.36";"0";"3.05";"BDBM50394886";"Cc1nc(N)cc(-c2cccnc2Nc2cccc3[nH]ncc23)n1";"IC50";"'>'";"50000.0";"nM";"";"";"254942";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643925";"";"0";"495.57";"1";"1.79";"BDBM125236";"Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2ccc3ncoc3c2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"254953";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649476";"";"0";"316.37";"0";"3.65";"BDBM125515";"Cc1nc(N)cc(-c2cnccc2Nc2cccc3[nH]ccc23)n1";"IC50";"'>'";"50000.0";"nM";"";"";"255009";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646458";"";"0";"325.34";"0";"0.95";"BDBM125300";"COc1ccc(Nc2nc(N)ncc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255018";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3641009";"";"0";"449.94";"0";"3.45";"BDBM115660";"CCc1ncnc(-c2ccc(C(=O)N(C)CCOC)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"240297";"UO_0000065";"19.33";"0.37";"5.25";"9.23";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646481";"";"0";"517.59";"2";"1.75";"BDBM125323";"COc1ncc(Nc2ncc(C(C)N3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255043";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646532";"";"0";"418.46";"0";"2.44";"BDBM125375";"COc1ccc(Nc2ncc(N3CC[C@H](O)C3)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'='";"839.0";"nM";"6.08";"";"255104";"UO_0000065";"14.52";"0.27";"3.64";"4.86";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3641019";"";"0";"475.00";"0";"3.51";"BDBM115670";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CC)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"240307";"UO_0000065";"18.31";"0.35";"5.19";"9.86";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3641020";"";"0";"488.98";"0";"3.04";"BDBM115671";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C(C)=O)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"240308";"UO_0000065";"17.79";"0.34";"5.66";"8.26";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3641024";"";"0";"484.60";"0";"3.26";"BDBM115675";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C(C)C)CC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"240312";"UO_0000065";"17.95";"0.33";"5.44";"8.92";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643066";"";"0";"484.56";"0";"2.40";"BDBM115681";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C(C)=O)CC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"240318";"UO_0000065";"17.95";"0.33";"6.30";"7.59";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643068";"";"0";"456.55";"0";"2.48";"BDBM115683";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C)CC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"240320";"UO_0000065";"19.05";"0.35";"6.22";"8.92";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643124";"";"0";"486.55";"0";"2.92";"BDBM115740";"CCc1ncnc(-c2ccc(C(=O)N(C)CCN3CCCC3=O)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"14.0";"nM";"7.85";"";"240377";"UO_0000065";"16.14";"0.30";"4.93";"7.46";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643150";"";"0";"461.95";"0";"3.33";"BDBM115766";"CCc1ncnc(-c2ccc(C(=O)N3CCCC(O)C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"240403";"UO_0000065";"18.45";"0.35";"5.19";"8.10";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3813725";"";"0";"467.51";"0";"2.35";"10j";"O=C(O)c1ccc2occ(/C=N/Nc3nc4c(c(N5CCOCC5)n3)CSCC4)c(=O)c2c1";"IC50";"'='";"1100.0";"nM";"5.96";"";"";"UO_0000065";"12.75";"0.25";"3.61";"4.58";"False";"CHEMBL3815304";"Inhibition of mTOR (unknown origin) using ULight4E-BP1 peptide as substrate incubated for 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3813678";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2016";""
"CHEMBL3823861";"";"0";"419.54";"0";"2.23";"9d";"CN(C)CC1CCN(CCn2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)CC1";"IC50";"'='";"8565.0";"nM";"5.07";"";"";"UO_0000065";"12.08";"0.22";"2.84";"4.84";"False";"CHEMBL3826741";"Inhibition of human mTOR using poly[Glu,Tyr]4:1 as substrate in presence of [gamma-33P]ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3822371";"1";"Scientific Literature";"J. Med. Chem.";"2016";""
"CHEMBL4060857";"";"0";"414.54";"0";"2.54";"14s";"C[C@H]1CN(c2nc(N3CCOCC3)c3sc(-c4cnn(C)c4)cc3n2)C[C@@H](C)O1";"IC50";"'>'";"2000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL4080009";"";"0";"411.53";"0";"3.20";"14d";"C[C@H]1CN(c2nc(N3CCOCC3)c3sc(-c4cccnc4)cc3n2)C[C@@H](C)O1";"IC50";"'='";"612.0";"nM";"6.21";"";"";"UO_0000065";"15.10";"0.29";"3.01";"9.77";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL521851";"PICTILISIB";"2";"513.65";"1";"2.15";"1; GDC-0941";"CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1";"IC50";"'='";"134.0";"nM";"6.87";"";"";"UO_0000065";"13.38";"0.27";"4.72";"6.39";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL4092492";"";"0";"392.53";"0";"2.58";"12a";"CCC(O)c1cc2nc(N3C[C@H](C)O[C@H](C)C3)nc(N3CCOCC3)c2s1";"IC50";"'>'";"2000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL4077217";"";"0";"399.52";"0";"3.14";"14n";"C[C@H]1CN(c2nc(N3CCOCC3)c3sc(-c4ccc[nH]4)cc3n2)C[C@@H](C)O1";"IC50";"'='";"172.0";"nM";"6.76";"";"";"UO_0000065";"16.93";"0.33";"3.62";"10.17";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL3981745";"";"0";"349.40";"0";"3.37";"16";"CC(C)n1nc(-c2ccc3onc(NC4CC4)c3c2)c2c(N)ncnc21";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3882339";"Inhibition of recombinant human GST-tagged mTOR (1360 to 2549 residues) catalytic domain assessed as inhibition of GFP labeled 4EBP1 phosphorylation measured after 1 hr by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3882246";"38";"Patent Bioactivity Data";"";"2010";""
"CHEMBL3946594";"";"0";"367.37";"0";"2.98";"19";"COC(=O)Nc1noc2ccc(-c3nn(C(C)C)c4ncnc(N)c34)cc12";"IC50";"'<'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3882339";"Inhibition of recombinant human GST-tagged mTOR (1360 to 2549 residues) catalytic domain assessed as inhibition of GFP labeled 4EBP1 phosphorylation measured after 1 hr by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3882246";"38";"Patent Bioactivity Data";"";"2010";""
"CHEMBL592445";"GEDATOLISIB";"2";"615.74";"1";"3.02";"54, PKI587";"CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1";"IC50";"'='";"1.6";"nM";"8.80";"";"";"UO_0000065";"14.29";"0.27";"5.78";"6.86";"False";"CHEMBL3223610";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3217752";"1";"Scientific Literature";"MedChemComm";"2012";""
"CHEMBL2348862";"";"0";"383.45";"0";"1.95";"10b, CC214-2";"CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1";"IC50";"'='";"106.0";"nM";"6.97";"";"";"UO_0000065";"18.19";"0.34";"5.02";"6.94";"True";"CHEMBL2352069";"Inhibition of recombinant mTOR (unknown origin) using GST-p70S6 as substrate after 60 mins by TR-FRET analysis";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346597";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";""
"CHEMBL2418346";"";"0";"394.48";"0";"3.00";"15";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(ccn3C)n2)cc1";"IC50";"'='";"110.0";"nM";"6.96";"";"";"UO_0000065";"17.64";"0.33";"3.96";"8.25";"False";"CHEMBL2421122";"Inhibition of mTOR in PTEN deficient human PC3 cells assessed as inhibition of p70S6K phosphorylation";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2417437";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";"CHEMBL3307570"
"CHEMBL2418344";"";"0";"409.49";"0";"2.79";"11e";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3CC)c3c(ncn3C)n2)cc1";"IC50";"'='";"69.0";"nM";"7.16";"";"";"UO_0000065";"17.49";"0.33";"4.37";"7.37";"False";"CHEMBL2421123";"Inhibition of mTOR in PTEN deficient human PC3 cells assessed as inhibition of Akt phosphorylation at Ser473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2417437";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";"CHEMBL3307570"
"CHEMBL573339";"PI-103";"0";"348.36";"0";"2.98";"PI-103";"Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1";"IC50";"'='";"19.0";"nM";"7.72";"";"";"UO_0000065";"22.16";"0.41";"4.74";"9.14";"False";"CHEMBL3815304";"Inhibition of mTOR (unknown origin) using ULight4E-BP1 peptide as substrate incubated for 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3813678";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2016";""
"CHEMBL580212";"";"0";"553.67";"1";"3.84";"13";"CNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)c3cnn(C4CCN(Cc5cccnc5)CC4)c3n2)cc1";"IC50";"'='";"0.48";"nM";"9.32";"";"";"UO_0000065";"16.83";"0.31";"5.48";"8.22";"False";"CHEMBL1804915";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1800032";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2010";""
"CHEMBL3944878";"";"0";"428.51";"0";"2.50";"BDBM251578";"CC(C)(c1nc(-c2cccc3[nH]ccc23)nc2c1OCC1COCCN21)S(C)(=O)=O";"IC50";"'='";"146.0";"nM";"6.84";"";"438474";"UO_0000065";"15.95";"0.31";"4.34";"7.02";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3907457";"";"0";"484.58";"0";"2.58";"BDBM251597";"Cc1cc2c(-c3nc4c(c(C5(S(C)(=O)=O)CCOCC5)n3)OCC3COCCN43)cccc2[nH]1";"IC50";"'='";"1820.0";"nM";"5.74";"";"438493";"UO_0000065";"11.85";"0.23";"3.16";"5.38";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3912026";"";"0";"446.50";"0";"2.64";"BDBM251634";"CC(C)(c1nc(-c2cc(F)cc3[nH]ccc23)nc2c1OC[C@@H]1COCCN21)S(C)(=O)=O";"IC50";"'='";"99.3";"nM";"7.00";"";"438530";"UO_0000065";"15.68";"0.31";"4.36";"7.19";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3973389";"";"0";"476.53";"0";"1.87";"BDBM251644";"CNc1nc2cc(F)ccc2n1-c1nc2c(c(C(C)(C)S(C)(=O)=O)n1)OC[C@@H]1COCCN21";"IC50";"'='";"1590.0";"nM";"5.80";"";"438541";"UO_0000065";"12.17";"0.24";"3.93";"5.20";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3693391";"";"0";"502.62";"1";"3.17";"BDBM174532";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(CNC(=O)C4CC4)c3)nc2n1";"IC50";"'='";"120.0";"nM";"6.92";"";"319828";"UO_0000065";"13.77";"0.26";"3.75";"7.47";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3909202";"";"0";"454.43";"0";"2.66";"BDBM251582";"O=S(=O)(Cc1nc(-c2cccc3[nH]ccc23)nc2c1OCC1COCCN21)C(F)(F)F";"IC50";"'='";"194.0";"nM";"6.71";"";"438478";"UO_0000065";"14.77";"0.30";"4.05";"6.89";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3914324";"";"0";"396.45";"0";"1.68";"BDBM251616";"CNc1nc2ccccc2n1-c1nc2c(c(C(C)(C)O)n1)OCC1COCCN21";"IC50";"'='";"1240.0";"nM";"5.91";"";"438512";"UO_0000065";"14.90";"0.28";"4.23";"6.05";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL2205766";"";"0";"346.42";"0";"1.45";"14, CZC24758";"CC(C)(C)NS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2211545";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2203257";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL3923162";"";"0";"493.58";"0";"4.16";"BDBM245546";"CO[C@@H]1CC[C@H](n2c(=O)n(C)c3cnc4cc(F)c(-c5ccc(OCCCN(C)C)nc5)cc4c32)C1";"IC50";"'='";"15200.0";"nM";"4.82";"";"427951";"UO_0000065";"9.76";"0.18";"0.66";"6.48";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3218580";"";"0";"852.86";"3";"-2.87";"56";"N=C(N)NCCCC(NC(=O)CCC(=O)OC[N+]1(c2cc(=O)c3cccc(-c4ccccc4)c3o2)CCOCC1)C(=O)NCC(=O)NC(CC(=O)O)C(=O)NC(CO)C(=O)[O-]";"IC50";"'='";"1060.0";"nM";"5.97";"";"";"UO_0000065";"7.01";"0.13";"8.84";"1.75";"False";"CHEMBL3223610";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3217752";"1";"Scientific Literature";"MedChemComm";"2012";""
"CHEMBL3688847";"";"0";"421.51";"0";"2.12";"BDBM174305";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(N)nc3)nc2n1";"IC50";"'='";"15.0";"nM";"7.82";"";"319621";"UO_0000065";"18.56";"0.34";"5.70";"7.63";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688857";"";"0";"494.57";"0";"3.03";"BDBM174316";"CCNC(=O)c1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccc1F";"IC50";"'='";"54.0";"nM";"7.27";"";"319632";"UO_0000065";"14.69";"0.28";"4.24";"7.84";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL2442291";"";"0";"335.37";"0";"2.13";"11j";"Cc1nnc(-c2cccc(-c3cnn4ccc(NCCN)nc34)c2)o1";"IC50";"'>'";"3000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2446205";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2440090";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";""
"CHEMBL3688872";"";"0";"430.51";"0";"3.01";"BDBM174332";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(C#N)c3)nc2n1";"IC50";"'='";"62.0";"nM";"7.21";"";"319649";"UO_0000065";"16.74";"0.31";"4.20";"8.25";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688887";"";"0";"444.54";"0";"3.62";"BDBM174348";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc4[nH]ccc4c3)nc2n1";"IC50";"'='";"55.0";"nM";"7.26";"";"319664";"UO_0000065";"16.33";"0.30";"3.64";"9.14";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688899";"";"0";"449.56";"0";"3.02";"BDBM174360";"C[C@H]1CN(c2nc(N3CCOC[C@@H]3C)c3ccc(-c4ccc(CO)cc4)nc3n2)C[C@@H](C)O1";"IC50";"'='";"4.6";"nM";"8.34";"";"319676";"UO_0000065";"18.55";"0.35";"5.32";"9.94";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL2018222";"";"0";"421.42";"0";"2.80";"14, enantiomer2";"Cc1c(Cn2c(C)nn3c(=O)cc(N4CCOC(C)C4)nc23)cccc1C(F)(F)F";"IC50";"'='";"6300.0";"nM";"5.20";"";"";"UO_0000065";"12.34";"0.24";"2.40";"8.04";"False";"CHEMBL2019379";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2016550";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL1945794";"";"0";"353.38";"0";"1.71";"23";"NC(=O)[C@H]1CC[C@H](n2c(=O)[nH]c3ncc(-c4ccc(O)cc4)nc32)CC1";"IC50";"'='";"178.0";"nM";"6.75";"";"";"UO_0000065";"19.10";"0.35";"5.04";"5.32";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1946264";"";"0";"363.43";"0";"2.83";"58";"Nc1nc2cc(-c3cnc4[nH]c(=O)n(CC5CCCCC5)c4n3)ccc2[nH]1";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"23.94";"0.44";"5.87";"7.36";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL3358286";"";"0";"477.55";"0";"3.02";"BDBM125492";"Cc1nc(N)nc(-c2cc(C(C)(C)O)cnc2Nc2cncc(S(=O)(=O)c3ccccc3)c2)n1";"IC50";"'='";"7120.0";"nM";"5.15";"";"255247";"UO_0000065";"10.78";"0.21";"2.13";"3.28";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649470";"";"0";"548.07";"1";"2.83";"BDBM125509";"Cc1nc(N)cc(-c2cc(C(C)N3CCOCC3)cnc2Nc2cnc(Cl)c(NS(=O)(=O)N(C)C)c2)n1";"IC50";"'='";"3847.0";"nM";"5.42";"";"255270";"UO_0000065";"9.88";"0.20";"2.58";"3.57";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649441";"";"0";"402.84";"0";"3.99";"BDBM122464";"O=S(=O)(Nc1cc(-c2cnc3ccccn23)cnc1Cl)c1ccc(F)cc1";"IC50";"'='";"155.0";"nM";"6.81";"";"251051";"UO_0000065";"16.90";"0.34";"2.82";"8.92";"False";"CHEMBL3705287";"In Vitro mTOR Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP 1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639163";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649431";"";"0";"332.36";"0";"3.48";"BDBM122454";"COc1cc(-c2cnc3ccc(-c4ccncc4)cn23)cnc1OC";"IC50";"'='";"3748.0";"nM";"5.43";"";"251059";"UO_0000065";"16.33";"0.30";"1.95";"8.82";"False";"CHEMBL3705287";"In Vitro mTOR Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP 1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639163";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646512";"";"0";"345.31";"0";"2.25";"BDBM125355";"COc1ncc(Nc2ncc(F)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255084";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649433";"";"0";"430.46";"0";"3.98";"BDBM122456";"COc1cc(-c2cnc3ccc(N4C(=O)OC[C@H]4Cc4ccccc4)cn23)cnc1OC";"IC50";"'='";"5101.0";"nM";"5.29";"";"251061";"UO_0000065";"12.29";"0.23";"1.31";"6.77";"False";"CHEMBL3705287";"In Vitro mTOR Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP 1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639163";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649445";"";"0";"428.91";"0";"3.33";"BDBM122468";"CN(C)S(=O)(=O)Nc1cc(-c2cnc3ccc(-c4ccncc4)cn23)cnc1Cl";"IC50";"'='";"15.0";"nM";"7.82";"";"251065";"UO_0000065";"18.24";"0.37";"4.49";"8.46";"False";"CHEMBL3705287";"In Vitro mTOR Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP 1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639163";"37";"BindingDB Database";"";"2014";""
"CHEMBL3618237";"";"0";"357.38";"0";"2.70";"10";"Cc1nc(N)nc(-c2c(Nc3cccc4[nH]ncc34)nc3ccccn23)n1";"IC50";"'='";"16.0";"nM";"7.80";"";"";"UO_0000065";"21.81";"0.39";"5.10";"6.35";"False";"CHEMBL3620381";"Inhibition of GST-tagged mTOR (1360 to 2549 residues) (unknown origin) using Ulight 4eBP1 peptide incubated for 90 mins by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3616407";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2015";""
"CHEMBL3688915";"";"0";"445.53";"0";"3.02";"BDBM174377";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc4[nH]ncc4c3)nc2n1";"IC50";"'='";"250.0";"nM";"6.60";"";"319694";"UO_0000065";"14.82";"0.27";"3.58";"7.15";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688940";"";"0";"473.54";"0";"2.38";"BDBM174417";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc4c(=O)[nH]cnc4c3)nc2n1";"IC50";"'='";"35.0";"nM";"7.46";"";"319721";"UO_0000065";"15.75";"0.29";"5.08";"6.82";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688980";"";"0";"522.63";"1";"3.76";"BDBM174457";"CC(C)N(C)C(=O)c1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccc1F";"IC50";"'='";"240.0";"nM";"6.62";"";"319762";"UO_0000065";"12.67";"0.24";"2.86";"7.89";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688988";"";"0";"504.64";"1";"2.71";"BDBM174469";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(CN4CC[C@@H](O)C4)cc3)nc2n1";"IC50";"'='";"93.0";"nM";"7.03";"";"319771";"UO_0000065";"13.93";"0.26";"4.32";"8.07";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689009";"";"0";"466.56";"0";"3.00";"BDBM174490";"CNCc1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccc1F";"IC50";"'='";"120.0";"nM";"6.92";"";"319791";"UO_0000065";"14.83";"0.28";"3.92";"9.15";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693384";"";"0";"522.65";"1";"2.89";"BDBM174520";"COCCNCc1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccc1OC";"IC50";"'='";"32.0";"nM";"7.50";"";"319821";"UO_0000065";"14.34";"0.27";"4.60";"7.96";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693480";"";"0";"517.55";"1";"4.20";"BDBM174642";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCC(C(F)(F)F)CC4)nc3n2)cc1CO";"IC50";"'='";"230.0";"nM";"6.64";"";"319920";"UO_0000065";"12.83";"0.25";"2.44";"7.92";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693500";"";"0";"511.38";"1";"3.37";"BDBM174662";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(-n4cnc(Br)c4)nc3n2)cc1CO";"IC50";"'='";"650.0";"nM";"6.19";"";"319942";"UO_0000065";"12.10";"0.26";"2.82";"6.29";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693502";"";"0";"491.64";"0";"4.43";"BDBM174664";"CCC1CCC(C)N(c2nc(N3CCOC[C@@H]3C)c3ccc(-c4ccc(OC)c(CO)c4)nc3n2)C1";"IC50";"'='";"190.0";"nM";"6.72";"";"319944";"UO_0000065";"13.67";"0.25";"2.29";"8.02";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693504";"";"0";"527.63";"1";"4.00";"BDBM174666";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC(c5ccccc5)C4)nc3n2)cc1CO";"IC50";"'='";"77.0";"nM";"7.11";"";"319946";"UO_0000065";"13.48";"0.25";"3.11";"7.64";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693519";"";"0";"439.52";"0";"2.21";"BDBM174682";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N[C@H](C)CO)nc3n2)cc1CO";"IC50";"'='";"31.0";"nM";"7.51";"";"319963";"UO_0000065";"17.08";"0.32";"5.30";"6.65";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3639924";"";"0";"518.62";"2";"5.75";"BDBM174730";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(-c4cccc(-c5ccccc5)c4)nc3n2)cc1CO";"IC50";"'='";"250.0";"nM";"6.60";"";"320009";"UO_0000065";"12.73";"0.23";"0.85";"8.19";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693566";"";"0";"471.56";"0";"3.54";"BDBM174731";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(-c4cccc(CN)c4)nc3n2)cc1CO";"IC50";"'='";"110.0";"nM";"6.96";"";"320010";"UO_0000065";"14.76";"0.27";"3.42";"6.53";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693569";"";"0";"487.52";"0";"3.99";"BDBM174735";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(-c4cccc([N+](=O)[O-])c4)nc3n2)cc1CO";"IC50";"'='";"280.0";"nM";"6.55";"";"320014";"UO_0000065";"13.44";"0.25";"2.56";"5.30";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693531";"";"0";"497.60";"0";"2.52";"BDBM174694";"COCCN(CCOC)c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(OC)c(CO)c3)nc2n1";"IC50";"'='";"55.0";"nM";"7.26";"";"319976";"UO_0000065";"14.59";"0.28";"4.74";"7.10";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693564";"";"0";"470.53";"0";"3.90";"BDBM174728";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(-c4cccc(C=O)c4)nc3n2)cc1CO";"IC50";"'='";"18.0";"nM";"7.75";"";"320007";"UO_0000065";"16.46";"0.30";"3.84";"7.93";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701053";"";"0";"471.99";"0";"4.01";"BDBM172187";"Cc1nccc(-c2ccc(C(=O)N3CCN(C4CC4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.66";"nM";"9.18";"";"317111";"UO_0000065";"19.45";"0.37";"5.17";"12.18";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701068";"";"0";"411.51";"0";"2.82";"BDBM172202";"Cc1nccc(-c2ccc(C(=O)N3CCN(C)CC3)cc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"7.0";"nM";"8.15";"";"317126";"UO_0000065";"19.82";"0.36";"5.33";"10.82";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701074";"";"0";"340.43";"0";"3.96";"BDBM172208";"CCc1nccc(-c2ccc(C3CC3)nc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"47.0";"nM";"7.33";"";"317132";"UO_0000065";"21.53";"0.38";"3.37";"11.33";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701091";"";"0";"355.44";"0";"3.86";"BDBM172226";"Cc1ccc(C#Cc2c(-c3cccc(C(=O)N(C)C)c3)ccnc2C)cn1";"IC50";"'='";"207.0";"nM";"6.68";"";"317150";"UO_0000065";"18.80";"0.34";"2.82";"14.50";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701093";"";"0";"431.92";"0";"4.29";"BDBM172228";"Cc1ccc(C#Cc2c(-c3ccc(Cl)c(C(=O)N4CCOCC4)c3)ccnc2C)cn1";"IC50";"'='";"4.0";"nM";"8.40";"";"317152";"UO_0000065";"19.44";"0.37";"4.11";"15.18";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701100";"";"0";"462.00";"0";"4.11";"BDBM172235";"Cc1nccc(-c2ccc(Cl)c(C(=O)N(C)CCCN(C)C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"19.0";"nM";"7.72";"";"317159";"UO_0000065";"16.71";"0.32";"3.61";"10.25";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701103";"";"0";"416.46";"0";"3.05";"BDBM172238";"Cc1nccc(-c2ccc(F)c(C(=O)N3CCOCC3)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"26.0";"nM";"7.58";"";"317162";"UO_0000065";"18.21";"0.33";"4.54";"9.33";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701108";"";"0";"357.42";"0";"2.53";"BDBM172243";"Cc1nccc(-c2ccc(C(=O)N(C)C)nc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"9.0";"nM";"8.05";"";"317167";"UO_0000065";"22.51";"0.41";"5.52";"9.47";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701111";"";"0";"404.45";"0";"2.64";"BDBM172246";"Cc1nccc(-c2ccc(F)c(C(=O)N(C)CCO)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"317170";"UO_0000065";"21.07";"0.39";"5.88";"9.23";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701135";"";"0";"390.87";"0";"3.76";"BDBM172270";"CNC(=O)c1cc(-c2ccnc(C)c2C#Cc2ccc(N)nc2C)ccc1Cl";"IC50";"'='";"85.0";"nM";"7.07";"";"317194";"UO_0000065";"18.09";"0.34";"3.31";"8.74";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701174";"";"0";"342.45";"0";"3.95";"BDBM172309";"CCc1cc(-c2ccnc(CC)c2C#Cc2ccc(N)nc2C)ccn1";"IC50";"'='";"44.0";"nM";"7.36";"";"317233";"UO_0000065";"21.48";"0.39";"3.41";"11.37";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701176";"";"0";"446.48";"0";"3.17";"BDBM172311";"COC(=O)CCNC(=O)c1ccc(-c2ccnc(C)c2C#Cc2ccc(N)nc2C)cc1F";"IC50";"'='";"24.0";"nM";"7.62";"";"317235";"UO_0000065";"17.07";"0.32";"4.45";"7.11";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701179";"";"0";"356.47";"0";"4.38";"BDBM172314";"CCc1nccc(-c2ccnc(C(C)(C)C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"56.0";"nM";"7.25";"";"317238";"UO_0000065";"20.34";"0.37";"2.87";"11.21";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL2058165";"";"0";"425.50";"0";"0.29";"4";"CN(C)CCCNC(=O)c1cn2cc(-c3cnc(N)nc3)nc(N3CCOCC3)c2n1";"IC50";"'>'";"5000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2060320";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2057167";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL3693508";"";"0";"465.55";"0";"2.38";"BDBM174671";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCC[C@@H](O)C4)nc3n2)cc1CO";"IC50";"'='";"22.0";"nM";"7.66";"";"319951";"UO_0000065";"16.45";"0.31";"5.28";"7.36";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL2336332";"";"0";"451.53";"0";"1.99";"BDBM50429716";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CC[C@@H](O)C4)nc3n2)cc1CO";"IC50";"'='";"10.0";"nM";"8.00";"";"319954";"UO_0000065";"17.72";"0.33";"6.01";"7.69";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL2064336";"";"0";"345.79";"0";"1.73";"14";"O=c1cc(N2CCOCC2)nc(Cc2nc3cc(Cl)ccc3[nH]2)[nH]1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2064343";"";"0";"393.49";"0";"3.05";"21";"O=c1cc(N2CCOCC2)nc(Cc2nc3ccccc3n2C2CCCCC2)[nH]1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2067906";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2062364";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL3586392";"";"0";"369.43";"0";"1.70";"24";"CC(C)(O)c1ccc(-c2cnc3c(n2)N(C2CCOCC2)CC(=O)N3)cn1";"IC50";"'='";"185.0";"nM";"6.73";"";"";"UO_0000065";"18.22";"0.34";"5.03";"6.70";"False";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL2348864";"";"0";"405.46";"0";"2.50";"13";"O=C1CN(CCC2CCOCC2)c2nc(-c3ccc(-c4nc[nH]n4)cc3)cnc2N1";"IC50";"'='";"8.0";"nM";"8.10";"";"";"UO_0000065";"19.97";"0.37";"5.60";"7.43";"False";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3586570";"";"0";"366.39";"0";"1.04";"23";"COCCN1CC(=O)Nc2ncc(-c3ccc(-c4nc[nH]n4)nc3C)nc21";"IC50";"'='";"68.0";"nM";"7.17";"";"";"UO_0000065";"19.56";"0.36";"6.13";"5.88";"False";"CHEMBL3587521";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585264";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL573339";"PI-103";"0";"348.36";"0";"2.98";"PI-103";"Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1";"IC50";"'='";"5.3";"nM";"8.28";"";"";"UO_0000065";"23.76";"0.43";"5.30";"9.79";"False";"CHEMBL3766570";"Inhibition of mTOR kinase (unknown origin) assessed as suppression of ULight-4E-BP1 substrate phosphorylation incubated for 1 hr by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3763019";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2016";""
"CHEMBL4112039";"";"0";"501.63";"1";"4.56";"BDBM245504";"Cn1c(=O)n([C@@H]2CCCOC2)c2c3cc(-c4ccc(OCCCN5CCCCC5)nc4)ccc3ncc21";"IC50";"'='";"6100.0";"nM";"5.21";"";"427915";"UO_0000065";"10.40";"0.19";"0.65";"7.01";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3670259";"";"0";"390.45";"0";"1.17";"BDBM111735";"CCc1ncnc(N2CCn3c(COC)nnc3C2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"138.0";"nM";"6.86";"";"232558";"UO_0000065";"17.57";"0.32";"5.69";"6.36";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3946340";"";"0";"501.63";"1";"4.56";"BDBM245509";"Cn1c(=O)n(C2CCOCC2)c2c3cc(-c4ccc(OCCCN5CCCCC5)nc4)ccc3ncc21";"IC50";"'='";"12400.0";"nM";"4.91";"";"427920";"UO_0000065";"9.78";"0.18";"0.35";"6.59";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3940070";"";"0";"484.56";"1";"6.35";"BDBM213785";"CN1Cc2cnc3ccc(-c4cnc5ccccc5c4)nc3c2N(c2ccc(C(C)(C)C#N)cc2)C1=O";"IC50";"'='";"66.5";"nM";"7.18";"";"375949";"UO_0000065";"14.81";"0.26";"0.83";"8.34";"False";"CHEMBL3888153";"mTOR Activity Assay: 1. Preparation of test reagents {circle around (1)} 1x kinase buffer (50 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 3 mM MnCl, 0.01% Tween-20, 2 mM DTT); {circle around (2)} 4x kinase solution (added mTOR kinase to 1x kinase buffer to provide 4x kinase solution with a final concentration of 2.5 nM); {circle around (3)} 2x substrate solution (added the substrates of 4EBP1 and ATP into 1x kinase buffer to provide 2x substrate solution with 4EBP1 final concentration of 50 nM and ATP final concentration of 10.8 uM); {circle around (4)} 4x test substance solutions (100x test substance solutions with different concentration gradients were prepared using 100% DMSO, and diluted 25-fold with 1x kinase buffer to give 4x test substance solutions with different concentration gradients) {circle around (5)} preparation of test solution (test solution containing EDTA and 4EBP1 phosphorylated antibody was prepared using activity test kit with assay buffer, the final concentration of EDTA was 8 mM, and the final concentration of 4EBP1 phosphorylated antibody was 2 nM) 2. 2.5 uL of 4x test solution was added to a 384-well plate in parallel; 3. added 2.54 uL of 4x kinase solution and incubated for 10 min; 4. then added 5 uL of 2x solutions of 4EBP1 and ATP substrates and incubated for 1 h at room temperature; 5. finally, added 10 uL of test solution to quench the reaction, and read after 60 min; 6. IC50 value was obtained via curve fitting.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886601";"37";"BindingDB Database";"";"2016";""
"CHEMBL3670144";"";"0";"334.43";"0";"1.45";"BDBM111618";"Cc1ncnc(N2CCN(C3CC3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"10.0";"nM";"8.00";"";"232441";"UO_0000065";"23.92";"0.44";"6.55";"11.24";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670184";"";"0";"337.43";"0";"1.62";"BDBM111658";"CCc1ncnc(N2CCC(CO)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"10.0";"nM";"8.00";"";"232481";"UO_0000065";"23.71";"0.44";"6.38";"9.07";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL2348862";"";"0";"383.45";"0";"1.95";"26, CC214-2";"CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)CC(=O)N3)cn1";"IC50";"'='";"106.0";"nM";"6.97";"";"";"UO_0000065";"18.19";"0.34";"5.02";"6.94";"False";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL2396661";"ALPELISIB";"4";"441.48";"0";"3.84";"8, NVP-BYL719";"Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(C(C)(C)C(F)(F)F)c1";"IC50";"'>'";"9100.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2400708";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2396607";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";""
"CHEMBL2418351";"";"0";"393.45";"0";"2.15";"21d";"CCNC(=O)Nc1ccc(-c2nc(N3C[C@@H]4C[C@H]3CO4)c3c(cnn3C)n2)cc1";"IC50";"'='";"270.0";"nM";"6.57";"";"";"UO_0000065";"16.69";"0.31";"4.42";"6.76";"False";"CHEMBL2421122";"Inhibition of mTOR in PTEN deficient human PC3 cells assessed as inhibition of p70S6K phosphorylation";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2417437";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";"CHEMBL3307570"
"CHEMBL2418348";"";"0";"395.47";"0";"2.40";"21a";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(cnn3C)n2)cc1";"IC50";"'='";"47.0";"nM";"7.33";"";"";"UO_0000065";"18.53";"0.35";"4.93";"7.54";"False";"CHEMBL2421122";"Inhibition of mTOR in PTEN deficient human PC3 cells assessed as inhibition of p70S6K phosphorylation";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2417437";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";"CHEMBL3307570"
"CHEMBL2418344";"";"0";"409.49";"0";"2.79";"11e";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3CC)c3c(ncn3C)n2)cc1";"IC50";"'='";"153.0";"nM";"6.82";"";"";"UO_0000065";"16.64";"0.31";"4.03";"7.01";"False";"CHEMBL2421122";"Inhibition of mTOR in PTEN deficient human PC3 cells assessed as inhibition of p70S6K phosphorylation";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2417437";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";"CHEMBL3307570"
"CHEMBL3688852";"";"0";"423.49";"0";"3.28";"BDBM174311";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(F)cc3)nc2n1";"IC50";"'='";"25.0";"nM";"7.60";"";"319627";"UO_0000065";"17.95";"0.33";"4.32";"11.95";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688864";"";"0";"483.59";"0";"2.55";"BDBM174323";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(S(C)(=O)=O)cc3)nc2n1";"IC50";"'='";"210.0";"nM";"6.68";"";"319639";"UO_0000065";"13.81";"0.27";"4.13";"6.83";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688874";"";"0";"442.47";"0";"2.82";"BDBM174334";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cc(F)nc(F)c3)nc2n1";"IC50";"'='";"290.0";"nM";"6.54";"";"319648";"UO_0000065";"14.78";"0.28";"3.72";"8.55";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688881";"";"0";"493.56";"0";"2.94";"BDBM174342";"COC(=O)c1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccc1OC";"IC50";"'='";"170.0";"nM";"6.77";"";"319658";"UO_0000065";"13.72";"0.26";"3.83";"6.83";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688894";"";"0";"435.53";"0";"3.15";"BDBM174355";"COc1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"140.0";"nM";"6.85";"";"319671";"UO_0000065";"15.74";"0.29";"3.70";"9.41";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688901";"";"0";"433.56";"0";"3.84";"BDBM174362";"Cc1ccccc1-c1ccc2c(N3CCOC[C@@H]3C)nc(N3C[C@H](C)O[C@H](C)C3)nc2n1";"IC50";"'='";"350.0";"nM";"6.46";"";"319678";"UO_0000065";"14.89";"0.28";"2.62";"10.15";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688906";"";"0";"409.49";"0";"3.12";"BDBM174367";"C[C@H]1CN(c2nc(N3CCOC[C@@H]3C)c3ccc(-c4ccoc4)nc3n2)C[C@@H](C)O1";"IC50";"'='";"73.0";"nM";"7.14";"";"319683";"UO_0000065";"17.43";"0.32";"4.02";"9.30";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL2165269";"";"0";"309.33";"0";"1.97";"BDBM50394888";"COc1ccc(Nc2ncccc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"7734.0";"nM";"5.11";"";"254940";"UO_0000065";"16.52";"0.30";"3.14";"4.57";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3667425";"";"0";"444.92";"0";"2.23";"BDBM150997";"C[C@H]1COCCN1c1nc(N2CCOCC2)nc2[nH]c(-c3cc(CO)ccc3Cl)nc12";"IC50";"'='";"1836.0";"nM";"5.74";"";"290543";"UO_0000065";"12.89";"0.25";"3.51";"5.76";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL4100862";"";"0";"430.82";"0";"2.28";"19";"FC(F)(F)c1cc(Cl)ncc1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1";"IC50";"'='";"1100000.0";"nM";"";"Outside typical range";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4019299";"Inhibition of mTOR in human A2058 cells assessed as reduction in phosphorylation of S6 at ser235/236 residues after 1 hr by in-cell Western method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017506";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL3912605";"";"0";"500.58";"2";"1.51";"BDBM251589";"CNc1nc2ccccc2n1-c1nc2c(c(C3(S(C)(=O)=O)CCOCC3)n1)OCC1COCCN21";"IC50";"'='";"10000.0";"nM";"5.00";"";"438485";"UO_0000065";"9.99";"0.20";"3.49";"4.14";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3972495";"";"0";"349.40";"0";"3.37";"14";"CC(C)n1nc(-c2ccc3c(NC4CC4)noc3c2)c2c(N)ncnc21";"IC50";"'<'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3882339";"Inhibition of recombinant human GST-tagged mTOR (1360 to 2549 residues) catalytic domain assessed as inhibition of GFP labeled 4EBP1 phosphorylation measured after 1 hr by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3882246";"38";"Patent Bioactivity Data";"";"2010";""
"CHEMBL4080467";"";"0";"422.53";"0";"3.79";"10k";"CCCn1c(C)nc2c(N3CCOCC3)cc(-c3ccc(NC(=O)NCC)cc3)nc21";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL4056088";"Inhibition of mTOR (unknown origin) by Kinase-Glo plus luminescence kinase assay or and ADP-Glo Plus luminescence kinase assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052688";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL2348864";"";"0";"405.46";"0";"2.50";"10a";"O=C1CN(CCC2CCOCC2)c2nc(-c3ccc(-c4nc[nH]n4)cc3)cnc2N1";"IC50";"'='";"8.0";"nM";"8.10";"";"";"UO_0000065";"19.97";"0.37";"5.60";"7.43";"True";"CHEMBL2352069";"Inhibition of recombinant mTOR (unknown origin) using GST-p70S6 as substrate after 60 mins by TR-FRET analysis";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346597";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";""
"CHEMBL2172624";"";"0";"399.42";"1";"2.01";"18";"Cc1nc(N)nc(-c2c(Nc3ccn(C)n3)nc3ccc(-c4cncnc4)cn23)n1";"IC50";"'='";"76.0";"nM";"7.12";"";"";"UO_0000065";"17.82";"0.32";"5.11";"5.17";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2172625";"";"0";"307.32";"0";"1.54";"19a";"Cc1nc(N)cc(-c2c(Nc3cc[nH]n3)nc3cccnn23)n1";"IC50";"'='";"13.0";"nM";"7.89";"";"";"UO_0000065";"25.66";"0.47";"6.35";"6.43";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2152253";"";"0";"449.90";"0";"2.99";"32";"CNC(=O)c1nc(-c2ccc(Cl)c(S(=O)(=O)Nc3cccc(F)c3C)c2)cnc1N";"IC50";"'='";"1781.0";"nM";"5.75";"";"";"UO_0000065";"12.78";"0.26";"2.76";"4.52";"False";"CHEMBL2156910";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2150966";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL3577910";"";"0";"505.51";"1";"4.84";"5c";"COc1ncc(-c2cc3c(-c4ccncc4)ccnc3cn2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"3.04";"nM";"8.52";"";"";"UO_0000065";"16.85";"0.32";"3.68";"7.96";"False";"CHEMBL3579762";"Inhibition of mTOR (unknown origin) using GFP-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3576869";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL3577927";"";"0";"520.45";"2";"5.98";"6m";"O=S(=O)(Nc1cc(-c2cc3c(-c4ccncc4)ncnc3s2)cnc1Cl)c1ccc(Cl)s1";"IC50";"'='";"25.8";"nM";"7.59";"";"";"UO_0000065";"14.58";"0.32";"1.61";"7.76";"False";"CHEMBL3579762";"Inhibition of mTOR (unknown origin) using GFP-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3576869";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL2158011";"";"0";"531.64";"1";"4.73";"11c";"CCN(CC)S(=O)(=O)c1cccc(Nc2nccc(-c3ccnc(-c4ccc(NC(=O)NC)cc4)c3)n2)c1";"IC50";"'='";"25.0";"nM";"7.60";"";"";"UO_0000065";"14.30";"0.27";"2.87";"5.88";"False";"CHEMBL2161544";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2157945";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2158849";"";"0";"401.39";"0";"4.14";"9g";"FC(F)(F)c1cccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)c1";"IC50";"'='";"1700.0";"nM";"5.77";"";"";"UO_0000065";"14.37";"0.27";"1.63";"9.13";"False";"CHEMBL2161544";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2157945";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL3693453";"";"0";"463.58";"0";"3.80";"BDBM174614";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCCCCC4)nc3n2)cc1CO";"IC50";"'='";"150.0";"nM";"6.82";"";"319892";"UO_0000065";"14.72";"0.27";"3.02";"8.14";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689025";"";"0";"546.72";"1";"4.57";"BDBM174507";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CNC1CCCCC1";"IC50";"'='";"64.0";"nM";"7.19";"";"319808";"UO_0000065";"13.16";"0.25";"2.62";"8.48";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693581";"";"0";"431.47";"0";"3.61";"BDBM174747";"C[C@H]1COCCN1c1nc(-c2cccnc2F)nc2nc(-c3cccc(CO)c3)ccc12";"IC50";"'='";"55.0";"nM";"7.26";"";"320026";"UO_0000065";"16.83";"0.31";"3.65";"8.62";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL2335862";"";"0";"479.58";"0";"3.03";"BDBM174287";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4C[C@H](C)O[C@H](C)C4)nc3n2)cc1CO";"IC50";"'='";"1.85";"nM";"8.73";"";"320034";"UO_0000065";"18.21";"0.34";"5.70";"9.38";"False";"CHEMBL3705656";"Biological Assay: For mTOR enzyme activity assays, mTOR protein was isolated from HeLa cell cytoplasmic extract by immunoprecipitation, and activity determined essentially as described previously using recombinant PHAS-1as a substrate (ref 21).";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"HeLa";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";"CHEMBL3308376"
"CHEMBL3693449";"";"0";"435.53";"0";"3.66";"BDBM174607";"C[C@H]1CN(c2nc(N3CCOC[C@@H]3C)c3ccc(Oc4ccccc4)nc3n2)C[C@@H](C)O1";"IC50";"'='";"520.0";"nM";"6.28";"";"319888";"UO_0000065";"14.43";"0.27";"2.62";"8.63";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693464";"";"0";"458.52";"0";"3.56";"BDBM174625";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(Nc4cccnc4)nc3n2)cc1CO";"IC50";"'='";"510.0";"nM";"6.29";"";"319903";"UO_0000065";"13.72";"0.25";"2.73";"5.96";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693466";"";"0";"435.53";"0";"3.02";"BDBM174627";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCCC4)nc3n2)cc1CO";"IC50";"'='";"110.0";"nM";"6.96";"";"319905";"UO_0000065";"15.98";"0.30";"3.94";"8.30";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693473";"";"0";"479.58";"0";"2.63";"BDBM174635";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCCC(CO)C4)nc3n2)cc1CO";"IC50";"'='";"23.0";"nM";"7.64";"";"319913";"UO_0000065";"15.93";"0.30";"5.01";"7.34";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL2030449";"";"0";"426.52";"0";"0.90";"30";"CS(=O)(=O)Cc1cc(N2CCOCC2)nc(-c2ccc(NS(C)(=O)=O)cc2)n1";"IC50";"'='";"2600.0";"nM";"5.58";"";"";"UO_0000065";"13.09";"0.27";"4.69";"4.71";"False";"CHEMBL2033327";"Inhibition of recombinant FLAG-tagged mTOR kinase expressed in HEK293 cells using Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2 as substrate after 90 mins";"B";"BAO_0000219";"cell-based format";"";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2029234";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";"CHEMBL3307715"
"CHEMBL3930790";"";"0";"440.53";"0";"2.56";"BDBM251656";"Cc1cc2c(-c3nc4c(c(C5(S(C)(=O)=O)CC5)n3)OC[C@@H]3COCCN43)cccc2[nH]1";"IC50";"'='";"224.0";"nM";"6.65";"";"438557";"UO_0000065";"15.09";"0.29";"4.09";"6.83";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3971270";"";"0";"508.52";"1";"3.67";"BDBM251658";"CS(=O)(=O)C1(c2nc(-c3cc(C(F)(F)F)cc4[nH]ccc34)nc3c2OC[C@@H]2COCCN32)CCC1";"IC50";"'='";"235.0";"nM";"6.63";"";"438559";"UO_0000065";"13.04";"0.26";"2.96";"6.81";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3932194";"";"0";"423.48";"0";"4.37";"BDBM251619";"c1cc(-c2nc(-c3cccc4[nH]ccc34)c3c(n2)N2CCOCC2CO3)c2cc[nH]c2c1";"IC50";"'='";"412.0";"nM";"6.38";"";"438515";"UO_0000065";"15.08";"0.27";"2.02";"8.08";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3925064";"";"0";"384.41";"0";"2.59";"BDBM251622";"CC(C)(O)c1nc(-c2cc(F)cc3[nH]ccc23)nc2c1OC[C@@H]1COCCN21";"IC50";"'='";"53.0";"nM";"7.28";"";"438518";"UO_0000065";"18.93";"0.35";"4.69";"8.71";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3958563";"";"0";"458.52";"0";"2.79";"BDBM251639";"CS(=O)(=O)C1(c2nc(-c3ccc(F)c4[nH]ccc34)nc3c2OC[C@@H]2COCCN32)CCC1";"IC50";"'='";"10000.0";"nM";"5.00";"";"438535";"UO_0000065";"10.90";"0.21";"2.21";"5.13";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3918930";"";"0";"446.50";"0";"2.64";"BDBM251651";"CC(C)(c1nc(-c2ccc(F)c3[nH]ccc23)nc2c1OC[C@@H]1COCCN21)S(C)(=O)=O";"IC50";"'='";"1820.0";"nM";"5.74";"";"438552";"UO_0000065";"12.86";"0.25";"3.10";"5.89";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3901984";"";"0";"471.54";"0";"1.67";"BDBM251595";"CS(=O)(=O)C1(c2nc(-c3ccnc4[nH]ccc34)nc3c2OCC2COCCN32)CCOCC1";"IC50";"'='";"10000.0";"nM";"5.00";"";"438491";"UO_0000065";"10.60";"0.21";"3.33";"4.18";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3938953";"";"0";"500.58";"1";"2.28";"BDBM251596";"COc1cc(-c2nc3c(c(C4(S(C)(=O)=O)CCOCC4)n2)OCC2COCCN32)c2cc[nH]c2c1";"IC50";"'='";"1760.0";"nM";"5.75";"";"438492";"UO_0000065";"11.50";"0.22";"3.47";"4.97";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3978765";"";"0";"514.61";"2";"1.90";"BDBM251609";"CNc1nc2ccccc2n1-c1nc2c(c(C3(S(C)(=O)=O)CCOCC3)n1)OCCC1COCCN21";"IC50";"'='";"3090.0";"nM";"5.51";"";"438505";"UO_0000065";"10.71";"0.21";"3.61";"4.57";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3919855";"";"0";"500.58";"1";"2.28";"BDBM251614";"COc1ccc(-c2nc3c(c(C4(S(C)(=O)=O)CCOCC4)n2)OCC2COCCN32)c2cc[nH]c12";"IC50";"'='";"4400.0";"nM";"5.36";"";"438510";"UO_0000065";"10.70";"0.21";"3.08";"4.62";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL4088235";"";"0";"468.52";"0";"4.38";"4e";"CC(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)c4ncccc4n3)cc2)cc1";"IC50";"'='";"167.0";"nM";"6.78";"";"";"UO_0000065";"14.47";"0.26";"2.40";"6.20";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL4059989";"";"0";"482.54";"0";"4.77";"4f";"CCC(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)c4ncccc4n3)cc2)cc1";"IC50";"'='";"301.0";"nM";"6.52";"";"";"UO_0000065";"13.51";"0.25";"1.75";"5.96";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL4079178";"";"0";"519.59";"1";"3.54";"4l";"CS(=O)(=O)Nc1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)c4ncccc4n3)cc2)cc1";"IC50";"'='";"72.3";"nM";"7.14";"";"";"UO_0000065";"13.74";"0.26";"3.60";"5.16";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL4092544";"";"0";"456.51";"0";"3.66";"5c";"O=C(Nc1ccc(-c2nc(N3CCOCC3)c3cccnc3n2)cc1)Nc1cccc(CO)c1";"IC50";"'='";"82.9";"nM";"7.08";"";"";"UO_0000065";"15.51";"0.28";"3.42";"6.29";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL4088056";"";"0";"519.59";"1";"3.54";"5l";"CS(=O)(=O)Nc1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)c4cccnc4n3)cc2)cc1";"IC50";"'='";"18.8";"nM";"7.73";"";"";"UO_0000065";"14.87";"0.29";"4.19";"5.58";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL4059778";"";"0";"547.60";"1";"2.34";"5m";"N=C(N)NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)c4cccnc4n3)cc2)cc1";"IC50";"'='";"15.8";"nM";"7.80";"";"";"UO_0000065";"14.25";"0.27";"5.46";"4.14";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL3646492";"";"0";"489.54";"1";"0.88";"BDBM125334";"Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2cnc(O)c(F)c2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255061";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646500";"";"0";"338.37";"0";"2.59";"BDBM125342";"COc1ccc(Nc2ncccc2-c2nc(C)nc(N)n2)cc1OC";"IC50";"'>'";"10000.0";"nM";"";"";"255070";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL4108514";"";"0";"501.63";"1";"4.55";"BDBM245537";"CO[C@@H]1CC[C@@H](n2c(=O)n(C)c3cnc4ccc(-c5ccc(OCCCN6CCCC6)nc5)cc4c32)C1";"IC50";"'='";"996.0";"nM";"6.00";"";"427948";"UO_0000065";"11.96";"0.22";"1.45";"8.07";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL4109764";"";"0";"479.56";"0";"3.77";"BDBM245495";"CN(C)CCCOc1ccc(-c2ccc3ncc4c(c3c2)n([C@@H]2CCCOC2)c(=O)n4C)c(F)n1";"IC50";"'='";"1370.0";"nM";"5.86";"";"427905";"UO_0000065";"12.23";"0.23";"2.09";"7.88";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL2325704";"";"0";"398.49";"0";"2.50";"12";"CS(=O)(=O)C1(c2cc(N3CCOCC3)nc(-c3cccc4[nH]ccc34)n2)CC1";"IC50";"'='";"3200.0";"nM";"5.50";"";"";"UO_0000065";"13.79";"0.27";"2.99";"6.23";"False";"CHEMBL2330630";"Inhibition of mTOR-mediated AKT phosphorylation at serine 473 in human MDA-MB-468 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MDA-MB-468";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2321758";"1";"Scientific Literature";"J. Med. Chem.";"2013";"CHEMBL3308424"
"CHEMBL3946647";"";"0";"395.47";"0";"1.87";"BDBM227487";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2nc(-c3ccccn3)[nH]c2n1";"IC50";"'='";"1027.0";"nM";"5.99";"";"397246";"UO_0000065";"15.14";"0.28";"4.12";"6.49";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL4113218";"";"0";"474.57";"0";"2.25";"BDBM227497";"C[C@@H]1COCCN1c1nc(N2CCN(C3COC3)CC2)nc2[nH]c(-c3cccc4[nH]ccc34)nc12";"IC50";"'='";"91.0";"nM";"7.04";"";"397256";"UO_0000065";"14.84";"0.27";"4.79";"7.15";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL4114224";"";"0";"449.52";"0";"1.92";"BDBM227505";"C[C@@H]1COCCN1c1nc(N2CCO[C@@H](CO)C2)nc2[nH]c(-c3cccc4[nH]ccc34)nc12";"IC50";"'='";"67.0";"nM";"7.17";"";"397264";"UO_0000065";"15.96";"0.30";"5.25";"6.22";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL4112516";"";"0";"411.47";"0";"0.84";"BDBM227508";"C[C@@H]1COCCN1c1nc(N2CCOC[C@H]2C)c2nc(-c3cnc(N)nc3)[nH]c2n1";"IC50";"'='";"1314.0";"nM";"5.88";"";"397267";"UO_0000065";"14.29";"0.27";"5.04";"4.48";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL4110445";"";"0";"491.55";"0";"2.74";"BDBM227511";"COC(=O)c1cc(-c2nc3c(N4CCOC[C@H]4C)nc(N4CCOC[C@H]4C)nc3[nH]2)c2cc[nH]c2c1";"IC50";"'='";"533.0";"nM";"6.27";"";"397270";"UO_0000065";"12.76";"0.24";"3.53";"5.16";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL3586379";"";"0";"396.49";"0";"2.95";"9";"CC(C)(O)c1ccc(-c2cnc3c(n2)N(CCC2CCOCC2)CC(=O)N3)cc1";"IC50";"'='";"66.0";"nM";"7.18";"";"";"UO_0000065";"18.11";"0.34";"4.23";"8.20";"False";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL4065513";"";"0";"400.50";"0";"3.40";"14l";"C[C@H]1CN(c2nc(N3CCOCC3)c3sc(-c4ccoc4)cc3n2)C[C@@H](C)O1";"IC50";"'='";"222.0";"nM";"6.65";"";"";"UO_0000065";"16.61";"0.32";"3.25";"10.42";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL2172634";"";"0";"443.48";"1";"2.86";"19i";"Cc1nc(Nc2cnn(C3CCOC3)c2)cc(-c2c(Nc3cc[nH]n3)nc3cccnn23)n1";"IC50";"'='";"36.0";"nM";"7.44";"";"";"UO_0000065";"16.78";"0.31";"4.58";"5.48";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL3670258";"";"0";"349.44";"0";"2.03";"BDBM111734";"CCc1ncnc(N2CCC3(CC2)COC3)c1C#Cc1ccc(N)nc1";"IC50";"'='";"15.0";"nM";"7.82";"";"232557";"UO_0000065";"22.39";"0.41";"5.79";"10.14";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670277";"";"0";"364.45";"0";"0.94";"BDBM111753";"CCc1ncnc(N2CCN(C3COC3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"47.0";"nM";"7.33";"";"232576";"UO_0000065";"20.11";"0.37";"6.39";"9.11";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670214";"";"0";"390.49";"0";"1.86";"BDBM111690";"CCc1ncnc(N2CCC3(CCN(C)C3=O)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"8.0";"nM";"8.10";"";"232513";"UO_0000065";"20.74";"0.38";"6.24";"9.18";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670219";"";"0";"404.47";"0";"1.44";"BDBM111695";"CCc1ncnc(N2CCC3(CC2)CC(=O)NC(=O)C3)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.0";"nM";"8.30";"";"232518";"UO_0000065";"20.52";"0.38";"6.86";"7.28";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670227";"";"0";"435.58";"0";"1.79";"BDBM111703";"Cc1ncnc(N2CCC(CC(=O)N(C)CCN(C)C)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"457.0";"nM";"6.34";"";"232526";"UO_0000065";"14.56";"0.27";"4.55";"6.93";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670239";"";"0";"406.53";"0";"2.54";"BDBM111715";"Cc1ncnc(N2CCC(CNC(=O)CC(C)C)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"237.0";"nM";"6.62";"";"232538";"UO_0000065";"16.30";"0.30";"4.09";"6.83";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670244";"";"0";"412.50";"0";"2.38";"BDBM111720";"CCc1ncnc(N2CCN(C(=O)c3ccccc3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"157.0";"nM";"6.80";"";"232543";"UO_0000065";"16.49";"0.30";"4.42";"7.71";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670150";"";"0";"365.48";"0";"2.40";"BDBM111624";"CCc1ncnc(N2CCC(C(C)(C)O)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"7.0";"nM";"8.15";"";"232447";"UO_0000065";"22.31";"0.41";"5.75";"9.25";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670166";"";"0";"385.47";"0";"2.65";"BDBM111640";"Cc1ncnc(N2CCC(O)(c3ccccc3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"23.0";"nM";"7.64";"";"232463";"UO_0000065";"19.82";"0.36";"4.99";"8.66";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670181";"";"0";"343.38";"0";"2.65";"BDBM111655";"CCc1ncnc(N2CCC(F)(F)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"31.0";"nM";"7.51";"";"232478";"UO_0000065";"21.87";"0.41";"4.86";"11.05";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670186";"";"0";"323.40";"0";"1.38";"BDBM111661";"CCc1ncnc(N2CCC(O)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"14.0";"nM";"7.85";"";"232484";"UO_0000065";"24.29";"0.45";"6.47";"8.91";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670194";"";"0";"322.42";"0";"1.17";"BDBM111669";"CCc1ncnc(N2CCN(C)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"57.0";"nM";"7.24";"";"232492";"UO_0000065";"22.47";"0.41";"6.07";"10.18";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670202";"";"0";"307.36";"0";"1.33";"BDBM111678";"Cc1ncnc(N2CCC(=O)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"60.0";"nM";"7.22";"";"232501";"UO_0000065";"23.50";"0.43";"5.89";"8.50";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL2172475";"";"0";"348.37";"0";"2.52";"21c";"CC(=O)Nc1cc(-c2c(Nc3cc[nH]n3)nc3ccccn23)nc(C)n1";"IC50";"'='";"9.0";"nM";"8.05";"";"";"UO_0000065";"23.10";"0.42";"5.53";"7.13";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2172487";"";"0";"440.47";"0";"3.17";"14";"CC(=O)Nc1cccc(-c2ccc3nc(Nc4cc[nH]n4)c(-c4nc(C)nc(N)n4)n3c2)c1";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"18.16";"0.33";"4.83";"5.27";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2170094";"";"0";"523.55";"1";"2.06";"BDBM50396814";"Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2ccc(C(F)(F)F)nc2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"254951";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646586";"";"0";"555.64";"1";"3.04";"BDBM125440";"COc1ncc(Nc2ncc([C@@H](C)N3CCN(S(C)(=O)=O)C[C@@H]3C)cc2-c2nc(C)nc3[nH]cnc23)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255184";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646607";"";"0";"500.59";"2";"0.83";"BDBM125464";"COc1ncc(Nc2ncc(CN3CCN(S(C)(=O)=O)C[C@@H]3C)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"1579.0";"nM";"5.80";"";"255210";"UO_0000065";"11.59";"0.23";"4.97";"3.51";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2206920";"";"0";"436.89";"0";"2.00";"BDBM50401262";"COc1ncc(Nc2ncc(Cl)cc2-c2nc(C)nc(N)n2)cc1NS(C)(=O)=O";"IC50";"'>'";"10000.0";"nM";"";"";"255220";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646620";"";"0";"534.05";"2";"2.26";"BDBM125477";"COc1cc(Nc2ncc([C@@H](C)N3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cnc1Cl";"IC50";"'>'";"10000.0";"nM";"";"";"255232";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646625";"";"0";"413.41";"0";"2.47";"BDBM125482";"COc1ncc(Nc2ncc(C(C)(C)C(=O)O)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255237";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646628";"";"0";"553.98";"2";"4.43";"BDBM125487";"COc1ncc(Nc2ncc(C(OC(=O)c3cccc(Cl)c3)C(C)(C)O)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255242";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649462";"";"0";"549.06";"2";"2.23";"BDBM125501";"Cc1nc(N)nc(-c2cc(C(C)N3CCOCC3)cnc2Nc2cnc(Cl)c(NS(=O)(=O)N(C)C)c2)n1";"IC50";"'='";"700.0";"nM";"6.16";"";"255261";"UO_0000065";"11.21";"0.23";"3.92";"3.74";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649463";"";"0";"520.02";"2";"2.38";"BDBM125502";"Cc1nc(N)nc(-c2cc([C@@H](C)N3CCOCC3)cnc2Nc2cnc(Cl)c(NS(C)(=O)=O)c2)n1";"IC50";"'='";"322.0";"nM";"6.49";"";"255262";"UO_0000065";"12.48";"0.25";"4.11";"4.03";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646441";"";"0";"376.42";"0";"3.30";"BDBM125282";"CCNc1cnc(Nc2ccc(OC)nc2)c(-c2nc(C)nc3[nH]cnc23)c1";"IC50";"'='";"4138.0";"nM";"5.38";"";"254994";"UO_0000065";"14.30";"0.26";"2.08";"4.74";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165019";"";"0";"484.59";"1";"1.98";"BDBM50394844";"COc1ccc(Nc2ncc(CN3CCC(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255115";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165028";"";"0";"396.46";"0";"1.71";"BDBM50394862";"COCCNCc1cnc(Nc2ccc(OC)nc2)c(-c2nc(C)nc(N)n2)c1";"IC50";"'>'";"10000.0";"nM";"";"";"255118";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646545";"";"0";"359.39";"0";"3.12";"BDBM125397";"COc1ccc(Nc2nc3ccccc3cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255128";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2170097";"";"0";"473.54";"0";"1.18";"BDBM50396811";"Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2cncc(F)c2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255132";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646548";"";"0";"444.53";"0";"0.37";"BDBM125400";"Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2cn[nH]c2)n1";"IC50";"'='";"1749.0";"nM";"5.76";"";"255133";"UO_0000065";"12.95";"0.25";"5.39";"3.62";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646555";"";"0";"404.41";"0";"3.17";"BDBM125408";"COc1ccc(Nc2ncc(-c3cncc(F)c3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255143";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2170083";"";"0";"517.59";"2";"1.58";"BDBM50396806";"COc1ncc(Nc2ncc(CN3CCN(S(C)(=O)=O)C[C@@H]3C)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255160";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646587";"";"0";"555.64";"1";"3.04";"BDBM125441";"COc1ncc(Nc2ncc([C@H](C)N3CCN(S(C)(=O)=O)C[C@@H]3C)cc2-c2nc(C)nc3[nH]cnc23)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255185";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646594";"";"0";"405.87";"0";"2.59";"BDBM125449";"Cc1nc(N)cc(-c2cccnc2Nc2cnc(Cl)c(NS(C)(=O)=O)c2)n1";"IC50";"'='";"444.0";"nM";"6.35";"";"255193";"UO_0000065";"15.65";"0.32";"3.76";"4.68";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646451";"";"0";"528.60";"1";"3.81";"BDBM125293";"CC(=O)Nc1ccc(Nc2ncc(Cc3ccc(S(C)(=O)=O)cc3)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'='";"270.0";"nM";"6.57";"";"255005";"UO_0000065";"12.43";"0.24";"2.76";"4.22";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643937";"";"0";"372.39";"0";"2.84";"BDBM125260";"Cc1nc(-c2cc(CO)cnc2Nc2cccc3[nH]ncc23)c2nc[nH]c2n1";"IC50";"'='";"2752.0";"nM";"5.56";"";"254972";"UO_0000065";"14.93";"0.27";"2.72";"4.33";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643942";"";"0";"468.52";"0";"4.49";"BDBM125265";"COc1ccc(NCc2cnc(Nc3ccc(OC)nc3)c(-c3nc(C)nc4[nH]cnc34)c2)cc1";"IC50";"'='";"353.0";"nM";"6.45";"";"254977";"UO_0000065";"13.77";"0.25";"1.96";"5.26";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165047";"";"0";"309.33";"0";"1.97";"BDBM50394873";"COc1ccc(Nc2cnccc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255015";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646459";"";"0";"340.35";"0";"1.38";"BDBM125301";"COc1ccc(Nc2nc(OC)ncc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255019";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649479";"";"0";"482.52";"0";"1.61";"BDBM125518";"Cc1nc(N)nc(-c2cc(CN3CCN(C(=O)N(C)C)CC3)cnc2Nc2cnc(O)c(F)c2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255060";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646501";"";"0";"343.39";"0";"3.42";"BDBM125343";"Cc1ccc2cc(Nc3ncccc3-c3nc(C)nc(N)n3)ccc2n1";"IC50";"'>'";"10000.0";"nM";"";"";"255071";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646515";"";"0";"320.78";"0";"2.07";"BDBM125358";"Cc1nc(N)nc(-c2cc(Cl)cnc2NC2CCOCC2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255087";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649430";"";"0";"334.17";"0";"3.18";"BDBM122453";"COc1cc(-c2cnc3ccc(Br)cn23)cnc1OC";"IC50";"'='";"2169.0";"nM";"5.66";"";"251058";"UO_0000065";"16.95";"0.39";"2.48";"11.64";"False";"CHEMBL3705287";"In Vitro mTOR Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP 1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639163";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649434";"";"0";"430.46";"0";"3.98";"BDBM122457";"COc1cc(-c2cnc3ccc(N4C(=O)OC[C@@H]4Cc4ccccc4)cn23)cnc1OC";"IC50";"'='";"2038.0";"nM";"5.69";"";"251062";"UO_0000065";"13.22";"0.24";"1.71";"7.28";"False";"CHEMBL3705287";"In Vitro mTOR Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP 1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639163";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649440";"";"0";"438.27";"0";"4.04";"BDBM122463";"O=S(=O)(Nc1cc(-c2cnc3ccc(Cl)nn23)cnc1Cl)c1ccc(F)cc1";"IC50";"'='";"102.0";"nM";"6.99";"";"251072";"UO_0000065";"15.95";"0.34";"2.95";"7.83";"False";"CHEMBL3705287";"In Vitro mTOR Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP 1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639163";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165052";"";"0";"294.32";"0";"2.27";"BDBM50394891";"Cc1nc(N)nc(-c2cccnc2Nc2cccc(O)c2)n1";"IC50";"'='";"201.0";"nM";"6.70";"";"254938";"UO_0000065";"22.75";"0.42";"4.43";"6.10";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643921";"";"0";"293.33";"0";"2.27";"BDBM125232";"Cc1cnc(Nc2cccnc2)c(-c2nc(C)nc(N)n2)c1";"IC50";"'>'";"50000.0";"nM";"";"";"254946";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646431";"";"0";"431.50";"0";"2.28";"BDBM125272";"COc1ccc(Nc2ncc(CN3CCNCC3)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"254984";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646435";"";"0";"538.64";"1";"1.79";"BDBM125276";"COc1ccc(Nc2ncc(CN3CCN(S(=O)(=O)N(C)C)CC3)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"254988";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646438";"";"0";"438.50";"0";"4.48";"BDBM125279";"COc1ccc(Nc2ncc(NCc3ccccc3)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"254991";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646537";"";"0";"396.46";"0";"1.44";"BDBM125388";"COc1ccc(Nc2ncc(CN[C@H](C)CO)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255117";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646551";"";"0";"314.30";"0";"2.85";"BDBM125404";"Cc1nc(N)nc(-c2cccnc2Nc2ccc(F)c(F)c2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255138";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL1241674";"";"0";"308.35";"0";"2.84";"PP-242";"CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21";"IC50";"'='";"8.0";"nM";"8.10";"";"";"UO_0000065";"26.26";"0.48";"5.26";"7.66";"False";"CHEMBL3877201";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3875233";"1";"Scientific Literature";"Nat Rev Drug Discov";"2017";""
"CHEMBL3618231";"";"0";"348.37";"0";"2.22";"4";"COc1ccc(Nc2nc3ccccn3c2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"37.0";"nM";"7.43";"";"";"UO_0000065";"21.33";"0.39";"5.21";"6.40";"False";"CHEMBL3620381";"Inhibition of GST-tagged mTOR (1360 to 2549 residues) (unknown origin) using Ulight 4eBP1 peptide incubated for 90 mins by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3616407";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2015";""
"CHEMBL3980955";"";"0";"670.82";"1";"4.42";"BDBM178391";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)N(C)CCN(C)C)cc4)cc3)c2C1=O";"IC50";"'='";"69.0";"nM";"7.16";"";"324411";"UO_0000065";"10.68";"0.20";"2.74";"5.41";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693450";"";"0";"463.58";"0";"3.80";"BDBM174611";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCCC[C@H]4C)nc3n2)cc1CO";"IC50";"'='";"40.0";"nM";"7.40";"";"319948";"UO_0000065";"15.96";"0.30";"3.60";"8.82";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3893108";"";"0";"609.70";"1";"3.42";"BDBM178221";"CCNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)nc3c2C(=O)N(C[C@@H]2CCCN2C(C)=O)CC(C)(C)O3)cc1F";"IC50";"'='";"1070.0";"nM";"5.97";"";"324241";"UO_0000065";"9.79";"0.19";"2.55";"4.62";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3915652";"";"0";"538.61";"1";"2.74";"BDBM178222";"CCNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)nc3c2C(=O)N(CCC(=O)O)CC(C)(C)O3)cc1";"IC50";"'='";"17.0";"nM";"7.77";"";"324242";"UO_0000065";"14.43";"0.27";"5.03";"5.31";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3985385";"";"0";"565.68";"1";"2.74";"BDBM178223";"CCNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)nc3c2C(=O)N(CCC(=O)N(C)C)CC(C)(C)O3)cc1";"IC50";"'='";"44.0";"nM";"7.36";"";"324243";"UO_0000065";"13.00";"0.25";"4.62";"5.69";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3941317";"";"0";"644.75";"2";"5.31";"BDBM178246";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(N5CCCCC5)nc4)c(F)c3)c2C1=O";"IC50";"'='";"65.0";"nM";"7.19";"";"324266";"UO_0000065";"11.15";"0.21";"1.88";"5.75";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3915101";"";"0";"466.54";"0";"2.51";"BDBM178253";"CNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)nc3c2C(=O)N(C)CC(C)(C)O3)cc1";"IC50";"'='";"22.0";"nM";"7.66";"";"324273";"UO_0000065";"16.41";"0.31";"5.15";"7.03";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3927107";"";"0";"560.66";"1";"4.05";"BDBM178306";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4cc(C)nc(C)n4)cc3)c2C1=O";"IC50";"'='";"53.0";"nM";"7.28";"";"324326";"UO_0000065";"12.98";"0.24";"3.23";"5.40";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3921660";"";"0";"605.67";"1";"4.01";"BDBM178360";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)NCc4ccc(OC)nc4)c(F)c3)c2C1=O";"IC50";"'='";"2977.0";"nM";"5.53";"";"324380";"UO_0000065";"9.12";"0.17";"1.52";"4.22";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3947641";"";"0";"595.63";"1";"3.93";"BDBM178371";"C[C@H]1COCCN1c1nc2c(c(-c3ccc(NC(=O)Nc4ccon4)c(F)c3)n1)C(=O)N(C1CCOCC1)CC(C)(C)O2";"IC50";"'='";"27.0";"nM";"7.57";"";"324391";"UO_0000065";"12.71";"0.24";"3.64";"5.25";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3653528";"";"0";"431.50";"0";"3.05";"BDBM136384";"CC(C)[C@H]1CN(CCO)C(=O)N1c1ccn2ncc(-c3ccc(-c4ncc[nH]4)cc3)c2n1";"IC50";"'='";"1.7";"nM";"8.77";"";"270258";"UO_0000065";"20.32";"0.37";"5.72";"8.54";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653607";"";"0";"475.87";"0";"4.67";"BDBM136464";"O=C1OC[C@H](c2ccc(F)c(Cl)c2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"1.2";"nM";"8.92";"";"270338";"UO_0000065";"18.75";"0.36";"4.25";"8.81";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3974020";"";"0";"499.57";"0";"2.54";"BDBM178401";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)OCCO)cc3)c2C1=O";"IC50";"'='";"25.0";"nM";"7.60";"";"324421";"UO_0000065";"15.22";"0.29";"5.06";"6.02";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3653637";"";"0";"472.44";"0";"3.42";"BDBM136494";"COc1cccc([C@H]2COC(=O)N2c2ccn3ncc(-c4ccc(-c5nc[nH]n5)c(F)c4)c3n2)n1";"IC50";"'='";"2.7";"nM";"8.57";"";"270368";"UO_0000065";"18.14";"0.33";"5.15";"6.94";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653639";"";"0";"474.43";"0";"3.86";"BDBM136496";"Cc1nc([C@H]2COC(=O)N2c2ccn3ncc(-c4ccc(-c5nc[nH]n5)c(F)c4)c3n2)ccc1F";"IC50";"'='";"0.79";"nM";"9.10";"";"270370";"UO_0000065";"19.19";"0.36";"5.24";"7.97";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3961744";"";"0";"517.56";"1";"2.68";"BDBM178424";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)OCCO)c(F)c3)c2C1=O";"IC50";"'='";"155.0";"nM";"6.81";"";"324444";"UO_0000065";"13.16";"0.25";"4.13";"5.39";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3984640";"";"0";"693.80";"1";"4.16";"BDBM178452";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(N5CCS(=O)(=O)CC5)cc4)c(F)c3)c2C1=O";"IC50";"'='";"39.0";"nM";"7.41";"";"324472";"UO_0000065";"10.68";"0.21";"3.25";"5.06";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3977285";"";"0";"529.57";"1";"2.82";"BDBM178461";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)OCCO)cc3F)c2C1=O";"IC50";"'='";"82.0";"nM";"7.09";"";"324481";"UO_0000065";"13.38";"0.25";"4.27";"5.61";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3978660";"";"0";"662.77";"1";"4.80";"BDBM178471";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccc(N5CCOCC5(C)C)nc4)c(F)c3)c2C1=O";"IC50";"'='";"196.0";"nM";"6.71";"";"324491";"UO_0000065";"10.12";"0.19";"1.91";"5.00";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3646472";"";"0";"419.49";"0";"3.95";"BDBM125314";"COc1ccc(Nc2ncc([C@@H](O)C(C)(C)C)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'='";"129.0";"nM";"6.89";"";"255032";"UO_0000065";"16.42";"0.30";"2.94";"5.66";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3650232";"";"0";"407.41";"0";"3.30";"BDBM136375";"CC(C)[C@H]1COC(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"2.0";"nM";"8.70";"";"270249";"UO_0000065";"21.35";"0.40";"5.40";"8.59";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653579";"";"0";"514.64";"1";"2.70";"BDBM136436";"CC(C)[C@H]1CN(CCN2CCN(C)CC2)C(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"21.9";"nM";"7.66";"";"270310";"UO_0000065";"14.88";"0.28";"4.96";"7.52";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653604";"";"0";"401.43";"0";"3.45";"BDBM136461";"O=C1O[C@@H]2CCCC[C@@H]2N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"16.4";"nM";"7.79";"";"270335";"UO_0000065";"19.39";"0.35";"4.34";"7.69";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653608";"";"0";"493.86";"0";"4.81";"BDBM136465";"O=C1OC[C@H](c2ccc(F)c(Cl)c2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"0.51";"nM";"9.29";"";"270339";"UO_0000065";"18.82";"0.36";"4.48";"9.17";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653618";"";"0";"424.42";"0";"3.27";"BDBM136475";"O=C1OC[C@H](c2ccccn2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"12.0";"nM";"7.92";"";"270349";"UO_0000065";"18.66";"0.34";"4.65";"6.94";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653631";"";"0";"471.45";"0";"4.03";"BDBM136488";"COc1ccc([C@H]2COC(=O)N2c2ccn3ncc(-c4ccc(-c5nc[nH]n5)c(F)c4)c3n2)cc1";"IC50";"'='";"20.4";"nM";"7.69";"";"270362";"UO_0000065";"16.31";"0.30";"3.66";"6.96";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3975008";"";"0";"566.61";"1";"4.92";"BDBM178406";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccc(F)cc4F)cc3)c2C1=O";"IC50";"'='";"24.0";"nM";"7.62";"";"324426";"UO_0000065";"13.45";"0.25";"2.70";"7.00";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3653640";"";"0";"456.44";"0";"3.72";"BDBM136497";"Cc1nc([C@H]2COC(=O)N2c2ccn3ncc(-c4ccc(-c5nc[nH]n5)cc4)c3n2)ccc1F";"IC50";"'='";"2.0";"nM";"8.70";"";"270371";"UO_0000065";"19.06";"0.35";"4.98";"7.62";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653643";"";"0";"475.87";"0";"4.67";"BDBM136500";"O=C1OC[C@H](c2ccccc2Cl)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"25.3";"nM";"7.60";"";"270374";"UO_0000065";"15.96";"0.31";"2.93";"7.50";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653646";"";"0";"440.44";"0";"4.62";"BDBM136503";"O=C1OC[C@H](c2ccc(F)cc2)N1c1ccn2ncc(-c3ccc(-c4cc[nH]n4)cc3)c2n1";"IC50";"'='";"4.9";"nM";"8.31";"";"270377";"UO_0000065";"18.87";"0.34";"3.69";"9.40";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653654";"";"0";"476.40";"0";"3.40";"BDBM136512";"Nc1nnc(-c2ccc(-c3cnn4ccc(N5C(=O)OC[C@@H]5c5ccc(F)cn5)nc34)cc2F)o1";"IC50";"'='";"6.3";"nM";"8.20";"";"270386";"UO_0000065";"17.21";"0.32";"4.80";"5.96";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165024";"";"0";"323.36";"0";"2.28";"BDBM50394866";"COc1ccc(Nc2ncc(C)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"50000.0";"nM";"";"";"254945";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643920";"";"0";"470.56";"0";"1.35";"BDBM125231";"Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2cccc(O)c2)n1";"IC50";"'='";"178.0";"nM";"6.75";"";"254944";"UO_0000065";"14.34";"0.28";"5.40";"4.49";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646497";"";"0";"326.34";"0";"2.72";"BDBM125339";"COc1cc(Nc2ncccc2-c2nc(C)nc(N)n2)ccc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255067";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3809489";"BEMCENTINIB";"2";"506.66";"1";"4.88";"BGB324";"Nc1nc(Nc2ccc3c(c2)CC[C@@H](N2CCCC2)CC3)nn1-c1cc2c(nn1)-c1ccccc1CCC2";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4188979";"Inhibition of wild-type human partial length MTOR (L1382 to W2549 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4184298";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL4207004";"";"0";"565.69";"2";"3.31";"12d";"CNc1ncc2c(-c3ccc(N4CCN(C(=O)C(C)(C)C)CC4)nc3)nn(Cc3cn(Cc4ccccc4)nn3)c2n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4188979";"Inhibition of wild-type human partial length MTOR (L1382 to W2549 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4184298";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL3112735";"";"0";"530.61";"1";"4.15";"9p";"COc1ncc(-c2cc3c(C)nc(N)cc3n(C3CCCC3)c2=O)cc1NS(=O)(=O)c1ccc(C#N)cc1";"IC50";"'='";"24.69";"nM";"7.61";"";"";"UO_0000065";"14.34";"0.27";"3.46";"4.97";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3640927";"";"0";"329.41";"0";"3.04";"BDBM115577";"CCc1cc(-c2ncnc(CC)c2C#Cc2ccc(N)nc2)ccn1";"IC50";"'='";"11.0";"nM";"7.96";"";"240214";"UO_0000065";"24.16";"0.43";"4.92";"10.26";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640930";"";"0";"357.42";"0";"2.53";"BDBM115580";"Cc1ncnc(-c2ccc(C(=O)N(C)C)cc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.0";"nM";"8.30";"";"240217";"UO_0000065";"23.22";"0.42";"5.77";"9.77";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640950";"";"0";"370.46";"0";"3.21";"BDBM115600";"Cc1ncnc(-c2ccc(N3CCCCC3)nc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"163.0";"nM";"6.79";"";"240237";"UO_0000065";"18.32";"0.33";"3.58";"8.40";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640961";"";"0";"385.47";"0";"3.31";"BDBM115611";"CCN(CC)C(=O)c1cccc(-c2ncnc(C)c2C#Cc2ccc(N)nc2)c1";"IC50";"'='";"82.0";"nM";"7.09";"";"240248";"UO_0000065";"18.38";"0.33";"3.78";"8.34";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640965";"";"0";"433.90";"0";"2.95";"BDBM115615";"Cc1ncnc(-c2ccc(Cl)c(C(=O)N3CCOCC3)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.0";"nM";"8.40";"";"240252";"UO_0000065";"19.35";"0.37";"5.45";"8.91";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640966";"";"0";"415.47";"0";"3.59";"BDBM115616";"Cc1ncnc(-c2ccc(F)c(C(=O)N3CCCCC3)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"14.0";"nM";"7.85";"";"240253";"UO_0000065";"18.90";"0.35";"4.26";"9.24";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640972";"";"0";"433.94";"0";"4.22";"BDBM115622";"CCc1ncnc(-c2ccc(Cl)c(C(=O)N(CC)CC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"17.0";"nM";"7.77";"";"240259";"UO_0000065";"17.90";"0.34";"3.55";"9.14";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640989";"";"0";"511.52";"1";"4.95";"BDBM115639";"CCc1ncnc(-c2ccc(C(=O)N3CCC(C(F)(F)F)CC3)c(F)c2)c1C#Cc1ccc(N)nc1C";"IC50";"'='";"27.0";"nM";"7.57";"";"240276";"UO_0000065";"14.80";"0.28";"2.62";"8.90";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3641007";"";"0";"435.92";"0";"3.11";"BDBM115658";"CCc1ncnc(-c2ccc(C(=O)NCCOC)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"240295";"UO_0000065";"19.55";"0.38";"5.41";"8.27";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643065";"";"0";"534.64";"1";"2.20";"BDBM115680";"CCc1ncnc(-c2ccc(C(=O)N3CCN(S(=O)(=O)CC)CC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"240317";"UO_0000065";"16.27";"0.31";"6.50";"6.61";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643095";"";"0";"484.58";"0";"3.53";"BDBM115711";"CCc1ncnc(-c2ccc(C(=O)N3CCN4CCCCC4C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"7.0";"nM";"8.15";"";"240348";"UO_0000065";"16.83";"0.31";"4.62";"9.24";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643096";"";"0";"514.61";"1";"3.16";"BDBM115712";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CC4CCCO4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.0";"nM";"8.40";"";"240349";"UO_0000065";"16.32";"0.30";"5.24";"8.62";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643098";"";"0";"472.52";"0";"2.53";"BDBM115714";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C(C)=O)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"6.0";"nM";"8.22";"";"240351";"UO_0000065";"17.40";"0.32";"5.69";"7.81";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3650227";"";"0";"388.43";"0";"3.77";"BDBM136370";"CC(C)[C@H]1COC(=O)N1c1ccn2ncc(-c3ccc(-c4ncc[nH]4)cc3)c2n1";"IC50";"'='";"2.4";"nM";"8.62";"";"270244";"UO_0000065";"22.19";"0.41";"4.85";"9.75";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3650228";"";"0";"360.38";"0";"3.13";"BDBM136371";"C[C@H]1COC(=O)N1c1ccn2ncc(-c3ccc(-c4ncc[nH]4)cc3)c2n1";"IC50";"'='";"23.2";"nM";"7.63";"";"270245";"UO_0000065";"21.18";"0.39";"4.50";"8.64";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3641014";"";"0";"514.94";"1";"4.01";"BDBM115665";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C(F)(F)F)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"18.0";"nM";"7.75";"";"240302";"UO_0000065";"15.04";"0.29";"3.73";"8.78";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643067";"";"0";"486.58";"0";"1.84";"BDBM115682";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CCO)CC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"240319";"UO_0000065";"17.52";"0.32";"6.68";"7.24";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643073";"";"0";"514.61";"1";"3.16";"BDBM115688";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCOCC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"240325";"UO_0000065";"16.90";"0.31";"5.54";"8.92";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643076";"";"0";"610.78";"1";"3.54";"BDBM115692";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCN(C5CCN(C)CC5)CC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"240329";"UO_0000065";"14.24";"0.26";"5.16";"9.18";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643077";"";"0";"391.41";"0";"2.68";"BDBM115693";"CCc1ncnc(-c2ccc(C(=O)N(C)O)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.0";"nM";"8.40";"";"240330";"UO_0000065";"21.46";"0.40";"5.72";"7.98";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643129";"";"0";"487.58";"0";"3.85";"BDBM115745";"CCc1ncnc(-c2ccc(C(=O)N3CCC(O)(C(C)C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"7.0";"nM";"8.15";"";"240382";"UO_0000065";"16.73";"0.31";"4.30";"7.75";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643133";"";"0";"458.54";"0";"3.00";"BDBM115749";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C)C(C)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"8.0";"nM";"8.10";"";"240386";"UO_0000065";"17.66";"0.33";"5.10";"9.18";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643148";"";"0";"447.93";"0";"2.94";"BDBM115764";"CCc1ncnc(-c2ccc(C(=O)N3CC[C@H](O)C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"240401";"UO_0000065";"19.42";"0.37";"5.76";"8.27";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643117";"";"0";"526.66";"1";"4.70";"BDBM115733";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCCCCC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"24.0";"nM";"7.62";"";"240370";"UO_0000065";"14.47";"0.27";"2.92";"8.64";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653570";"";"0";"433.47";"0";"2.63";"BDBM136427";"CC(C)[C@H]1COC(=O)N1c1ccn2ncc(-c3ccc(-c4ncn(CCO)n4)cc3)c2n1";"IC50";"'='";"189.0";"nM";"6.72";"";"270301";"UO_0000065";"15.51";"0.29";"4.09";"6.08";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653527";"";"0";"387.45";"0";"3.34";"BDBM136383";"CC(C)[C@H]1CNC(=O)N1c1ccn2ncc(-c3ccc(-c4ncc[nH]4)cc3)c2n1";"IC50";"'='";"8.2";"nM";"8.09";"";"270257";"UO_0000065";"20.87";"0.38";"4.75";"8.87";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653529";"";"0";"445.53";"0";"3.44";"BDBM136385";"CC(C)[C@H]1CN(CCCO)C(=O)N1c1ccn2ncc(-c3ccc(-c4ncc[nH]4)cc3)c2n1";"IC50";"'='";"1.5";"nM";"8.82";"";"270259";"UO_0000065";"19.81";"0.37";"5.38";"8.60";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653535";"";"0";"498.64";"0";"4.39";"BDBM136391";"CC(C)[C@H]1CN(CC2CCN(C)CC2)C(=O)N1c1ccn2ncc(-c3ccc(-c4ncc[nH]4)cc3)c2n1";"IC50";"'='";"12.3";"nM";"7.91";"";"270265";"UO_0000065";"15.86";"0.29";"3.52";"9.23";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653605";"";"0";"419.42";"0";"3.59";"BDBM136462";"O=C1O[C@@H]2CCCC[C@@H]2N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"5.8";"nM";"8.24";"";"270336";"UO_0000065";"19.64";"0.36";"4.65";"8.13";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653610";"";"0";"475.87";"0";"4.67";"BDBM136467";"O=C1OC[C@@H](c2ccc(Cl)cc2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"916.0";"nM";"6.04";"";"270341";"UO_0000065";"12.69";"0.24";"1.37";"5.96";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653548";"";"0";"527.63";"1";"3.31";"BDBM136404";"CC(C)[C@H]1CN(CCN2CC3CCC(C2)O3)C(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"5.1";"nM";"8.29";"";"270278";"UO_0000065";"15.72";"0.29";"4.98";"7.69";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653552";"";"0";"499.62";"0";"3.84";"BDBM136408";"CC(C)[C@H]1CN(CCC2CCCNC2)C(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"27.6";"nM";"7.56";"";"270282";"UO_0000065";"15.13";"0.28";"3.72";"7.04";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653560";"";"0";"515.62";"1";"3.17";"BDBM136416";"CCN1CCO[C@@H](CN2C[C@H](C(C)C)N(c3ccn4ncc(-c5ccc(-c6nc[nH]n6)cc5)c4n3)C2=O)C1";"IC50";"'='";"29.7";"nM";"7.53";"";"270290";"UO_0000065";"14.60";"0.27";"4.36";"6.98";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653650";"";"0";"423.44";"0";"3.88";"BDBM136507";"O=C1OC[C@H](c2ccccn2)N1c1ccn2ncc(-c3ccc(-c4ncc[nH]4)cc3)c2n1";"IC50";"'='";"12.8";"nM";"7.89";"";"270381";"UO_0000065";"18.64";"0.34";"4.01";"7.79";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653569";"";"0";"423.86";"0";"3.82";"BDBM136425";"CC(C)[C@H]1COC(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(Cl)c3)c2n1";"IC50";"'='";"2.8";"nM";"8.55";"";"270299";"UO_0000065";"20.18";"0.39";"4.73";"8.44";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3940004";"";"0";"458.54";"0";"2.51";"BDBM251635";"COc1cc(-c2nc3c(c(C(C)(C)S(C)(=O)=O)n2)OC[C@@H]2COCCN32)c2cc[nH]c2c1";"IC50";"'='";"45.3";"nM";"7.34";"";"438531";"UO_0000065";"16.02";"0.31";"4.83";"6.89";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3907358";"";"0";"458.52";"0";"2.79";"BDBM251640";"CS(=O)(=O)C1(c2nc(-c3cc(F)cc4[nH]ccc34)nc3c2OC[C@@H]2COCCN32)CCC1";"IC50";"'>'";"10000.0";"nM";"";"";"438536";"UO_0000065";"";"";"";"";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3955986";"";"0";"454.55";"0";"2.95";"BDBM251647";"Cc1cc2c(-c3nc4c(c(C5(S(C)(=O)=O)CCC5)n3)OC[C@@H]3COCCN43)cccc2[nH]1";"IC50";"'='";"117.0";"nM";"6.93";"";"438546";"UO_0000065";"15.25";"0.30";"3.98";"7.12";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL1879463";"DACTOLISIB";"2";"469.55";"1";"5.89";"Dactolisib";"Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21";"IC50";"'='";"20.74";"nM";"7.68";"";"";"UO_0000065";"16.36";"0.29";"1.79";"10.04";"False";"CHEMBL3993907";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362-end residues) using ULight-4E-BP1 peptide substrate after 1 hr in presence of ATP by Lance Ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3992539";"1";"Scientific Literature";"Eur J Med Chem";"2017";""
"CHEMBL3653577";"";"0";"387.40";"0";"3.06";"BDBM136434";"O=C1O[C@@H]2CCC[C@@H]2N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"16.1";"nM";"7.79";"";"270308";"UO_0000065";"20.12";"0.37";"4.73";"7.69";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653578";"";"0";"500.61";"1";"2.35";"BDBM136435";"CC(C)[C@H]1CN(CCN2CCNCC2)C(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"31.3";"nM";"7.50";"";"270309";"UO_0000065";"14.99";"0.28";"5.15";"6.79";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653601";"";"0";"456.44";"0";"3.72";"BDBM136458";"Cc1ccc([C@@H]2COC(=O)N2c2ccn3ncc(-c4ccc(-c5nc[nH]n5)c(F)c4)c3n2)cn1";"IC50";"'='";"43.4";"nM";"7.36";"";"270332";"UO_0000065";"16.13";"0.30";"3.64";"6.45";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653537";"";"0";"407.41";"0";"3.30";"BDBM136393";"CC(C)[C@H]1COC(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3F)c2n1";"IC50";"'='";"27.7";"nM";"7.56";"";"270267";"UO_0000065";"18.55";"0.34";"4.26";"7.46";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653547";"";"0";"501.60";"1";"2.78";"BDBM136403";"CC(C)[C@H]1CN(CCN2CCOCC2)C(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"7.5";"nM";"8.12";"";"270277";"UO_0000065";"16.20";"0.30";"5.34";"7.54";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653632";"";"0";"423.41";"0";"2.68";"BDBM136489";"CCOC[C@H]1COC(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"15.3";"nM";"7.82";"";"270363";"UO_0000065";"18.46";"0.34";"5.14";"7.07";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653641";"";"0";"474.43";"0";"3.86";"BDBM136498";"Cc1cc([C@H]2COC(=O)N2c2ccn3ncc(-c4ccc(-c5nc[nH]n5)c(F)c4)c3n2)ncc1F";"IC50";"'='";"2.5";"nM";"8.60";"";"270372";"UO_0000065";"18.13";"0.34";"4.74";"7.53";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653642";"";"0";"456.44";"0";"3.72";"BDBM136499";"Cc1cc([C@H]2COC(=O)N2c2ccn3ncc(-c4ccc(-c5nc[nH]n5)cc4)c3n2)ncc1F";"IC50";"'='";"4.0";"nM";"8.40";"";"270373";"UO_0000065";"18.40";"0.34";"4.68";"7.35";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653564";"";"0";"471.57";"0";"3.15";"BDBM136420";"CCN1CC(N2C[C@H](C(C)C)N(c3ccn4ncc(-c5ccc(-c6nc[nH]n6)cc5)c4n3)C2=O)C1";"IC50";"'='";"42.7";"nM";"7.37";"";"270294";"UO_0000065";"15.63";"0.29";"4.22";"7.48";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3906660";"";"0";"529.60";"1";"3.79";"BDBM178283";"CN1CC(C)(C)Oc2nc(N3C4CCC3COC4)nc(-c3ccc(NC(=O)Nc4ccncc4)cc3)c2C1=O";"IC50";"'='";"12.0";"nM";"7.92";"";"324303";"UO_0000065";"14.96";"0.28";"4.13";"6.50";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3904948";"";"0";"547.59";"1";"3.93";"BDBM178298";"CN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccncc4)c(F)c3)c2C1=O";"IC50";"'='";"20.0";"nM";"7.70";"";"324318";"UO_0000065";"14.06";"0.26";"3.77";"6.32";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3900200";"";"0";"547.59";"1";"3.93";"BDBM178300";"CN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccncc4F)cc3)c2C1=O";"IC50";"'='";"24.0";"nM";"7.62";"";"324320";"UO_0000065";"13.92";"0.26";"3.69";"6.26";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3970745";"";"0";"574.64";"1";"3.59";"BDBM178413";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4cnc(OC)cn4)cc3)c2C1=O";"IC50";"'='";"57.0";"nM";"7.24";"";"324433";"UO_0000065";"12.61";"0.24";"3.65";"5.03";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3913253";"";"0";"543.63";"1";"4.18";"BDBM178248";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccccn4)cc3)c2C1=O";"IC50";"'='";"24.0";"nM";"7.62";"";"324268";"UO_0000065";"14.02";"0.26";"3.44";"6.26";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3969513";"";"0";"621.67";"1";"3.96";"BDBM178393";"COCCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(OC)nc4)c(F)c3)c2C1=O";"IC50";"'='";"45.0";"nM";"7.35";"";"324413";"UO_0000065";"11.82";"0.22";"3.39";"5.24";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693488";"";"0";"550.66";"1";"4.48";"BDBM174650";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCC(C#N)(c5ccccc5)CC4)nc3n2)cc1CO";"IC50";"'='";"140.0";"nM";"6.85";"";"319928";"UO_0000065";"12.45";"0.23";"2.37";"6.37";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693509";"";"0";"499.57";"0";"3.95";"BDBM174672";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOc5ccccc54)nc3n2)cc1CO";"IC50";"'='";"610.0";"nM";"6.21";"";"319952";"UO_0000065";"12.44";"0.23";"2.26";"6.68";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3914977";"";"0";"723.83";"2";"3.40";"BDBM178295";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccnc(N5CCN(S(C)(=O)=O)CC5)c4)c(F)c3)c2C1=O";"IC50";"'='";"72.0";"nM";"7.14";"";"324315";"UO_0000065";"9.87";"0.19";"3.74";"4.40";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3951327";"";"0";"544.62";"1";"3.58";"BDBM178307";"CCN1CC(C)(C)Oc2nc(N3C4CCC3COC4)nc(-c3ccc(NC(=O)Nc4ccncn4)cc3)c2C1=O";"IC50";"'='";"40.0";"nM";"7.40";"";"324327";"UO_0000065";"13.58";"0.25";"3.82";"5.49";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3912230";"";"0";"468.56";"0";"2.75";"BDBM178311";"CCNC(=O)Nc1ccc(-c2nc(N3CCOCC3)nc3c2C(=O)N(CC)CC(C)(C)O3)cc1";"IC50";"'='";"72.0";"nM";"7.14";"";"324331";"UO_0000065";"15.24";"0.29";"4.39";"6.56";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3983105";"";"0";"397.48";"0";"2.20";"BDBM178317";"CCN1CC(C)(C)Oc2nc(N3CCOCC3)nc(-c3ccc(N)cc3)c2C1=O";"IC50";"'='";"927.0";"nM";"6.03";"";"324337";"UO_0000065";"15.18";"0.28";"3.83";"6.43";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3949231";"";"0";"542.61";"1";"3.05";"BDBM178346";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)NCCOC)c(F)c3)c2C1=O";"IC50";"'='";"383.0";"nM";"6.42";"";"324366";"UO_0000065";"11.83";"0.22";"3.37";"5.43";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3896558";"";"0";"582.68";"1";"3.83";"BDBM178349";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)NCC4CCOCC4)c(F)c3)c2C1=O";"IC50";"'='";"3165.0";"nM";"5.50";"";"324369";"UO_0000065";"9.44";"0.18";"1.67";"4.65";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3918592";"";"0";"542.61";"1";"3.05";"BDBM178426";"CCNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)nc3c2C(=O)N(CCOC)CC(C)(C)O3)cc1F";"IC50";"'='";"87.0";"nM";"7.06";"";"324446";"UO_0000065";"13.01";"0.25";"4.01";"5.98";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3971848";"";"0";"529.60";"1";"3.79";"BDBM178256";"CN1CC(C)(C)Oc2nc(N3C4CCC3COC4)nc(-c3ccc(NC(=O)Nc4ccccn4)cc3)c2C1=O";"IC50";"'='";"35.0";"nM";"7.46";"";"324276";"UO_0000065";"14.08";"0.26";"3.67";"6.12";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3915048";"";"0";"542.61";"1";"2.79";"BDBM178272";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)N[C@@H](C)CO)c(F)c3)c2C1=O";"IC50";"'='";"239.0";"nM";"6.62";"";"324292";"UO_0000065";"12.20";"0.23";"3.83";"5.13";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3952358";"";"0";"561.62";"1";"4.24";"BDBM178282";"Cc1ccc(NC(=O)Nc2ccc(-c3nc(N4C5CCC4COC5)nc4c3C(=O)N(C)CC(C)(C)O4)cc2F)cn1";"IC50";"'='";"15.0";"nM";"7.82";"";"324302";"UO_0000065";"13.93";"0.26";"3.58";"6.42";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693538";"";"0";"452.52";"0";"1.70";"BDBM174701";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N[C@@H](C)C(N)=O)nc3n2)cc1CO";"IC50";"'='";"27.0";"nM";"7.57";"";"319983";"UO_0000065";"16.73";"0.31";"5.87";"5.58";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693570";"";"0";"443.51";"0";"3.48";"BDBM174736";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(-c4cccnc4)nc3n2)cc1CO";"IC50";"'='";"57.0";"nM";"7.24";"";"320015";"UO_0000065";"16.33";"0.30";"3.76";"7.75";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693571";"";"0";"485.54";"0";"3.18";"BDBM174737";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(-c4cccc(C(N)=O)c4)nc3n2)cc1CO";"IC50";"'='";"77.0";"nM";"7.11";"";"320016";"UO_0000065";"14.65";"0.27";"3.93";"5.75";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL1097603";"";"0";"540.67";"1";"4.26";"16b";"CN(C)C(=O)Nc1ccc(-c2nc(N3CCOCC3)c3cnn(C4CCN(Cc5ccccc5)CC4)c3n2)cc1";"IC50";"'='";"76.0";"nM";"7.12";"";"";"UO_0000065";"13.17";"0.24";"2.86";"7.77";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL1095626";"";"0";"437.50";"0";"2.32";"24a";"COC(=O)N1CCC(n2ncc3c(N4CCOCC4)nc(-c4ccc(N)cc4)nc32)CC1";"IC50";"'='";"4.6";"nM";"8.34";"";"";"UO_0000065";"19.06";"0.36";"6.02";"7.47";"False";"CHEMBL1104613";"Inhibition of human mTOR (1360-2549 amino acids) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1157009";"1";"Scientific Literature";"J. Med. Chem.";"2009";"CHEMBL3307715"
"CHEMBL3966011";"";"0";"529.57";"1";"2.82";"BDBM178458";"CCN1CC(C)(C)Oc2nc(N3C4CCC3COC4)nc(-c3ccc(NC(=O)OCCO)cc3F)c2C1=O";"IC50";"'='";"63.0";"nM";"7.20";"";"324478";"UO_0000065";"13.60";"0.26";"4.38";"5.70";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3918705";"";"0";"460.54";"0";"2.86";"BDBM227509";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2nc(-c3ccc(-c4ncc[nH]4)cc3)[nH]c2n1";"IC50";"'='";"364.0";"nM";"6.44";"";"397268";"UO_0000065";"13.98";"0.26";"3.58";"5.96";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL4113765";"";"0";"463.54";"0";"2.96";"BDBM227510";"COc1cc(-c2nc3c(N4CCOC[C@H]4C)nc(N4CCOC[C@@H]4C)nc3[nH]2)c2cc[nH]c2c1";"IC50";"'='";"28.0";"nM";"7.55";"";"397269";"UO_0000065";"16.29";"0.30";"4.59";"7.23";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL3941619";"";"0";"583.74";"1";"3.43";"BDBM222554";"CSc1c(N2CCOCC2)nc(-c2ccc(NC(=O)Nc3ccccc3)cc2)nc1N1CCN(S(C)(=O)=O)CC1";"IC50";"'='";"198.1";"nM";"6.70";"";"389343";"UO_0000065";"11.48";"0.23";"3.27";"5.59";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3932354";"";"0";"429.48";"0";"2.31";"BDBM222562";"CCOC(=O)c1nc(-c2ccc(NC(=O)NC)cc2)nc(N2CCOCC2)c1OCC";"IC50";"'='";"253.6";"nM";"6.60";"";"389351";"UO_0000065";"15.36";"0.29";"4.29";"5.74";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3948281";"";"0";"504.55";"1";"3.00";"BDBM222580";"COc1cnc(-c2ccc(NC(=O)Nc3ccc(N4CCOCC4=O)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"8.1";"nM";"8.09";"";"389369";"UO_0000065";"16.04";"0.30";"5.09";"6.85";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3939504";"";"0";"548.60";"1";"4.16";"BDBM222586";"CCOC(=O)c1nc(-c2ccc(NC(=O)Nc3cccc(NC(C)=O)c3)cc2)nc(N2CCOCC2)c1OCC";"IC50";"'='";"150.2";"nM";"6.82";"";"389375";"UO_0000065";"12.44";"0.23";"2.66";"4.74";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3940715";"";"0";"533.59";"1";"2.89";"BDBM222588";"CCOc1c(C(=O)N2CCOCC2)nc(-c2ccc(NC(=O)Nc3cccnc3)cc2)nc1N1CCOCC1";"IC50";"'='";"62.5";"nM";"7.20";"";"389377";"UO_0000065";"13.50";"0.25";"4.31";"5.50";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3978502";"";"0";"500.61";"1";"2.99";"BDBM222603";"CSc1cnc(-c2ccc(NC(=O)Nc3ccc(S(N)(=O)=O)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"78.9";"nM";"7.10";"";"389392";"UO_0000065";"14.19";"0.29";"4.11";"5.09";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3970194";"";"0";"473.03";"0";"4.56";"BDBM222605";"CSc1c(Cl)nc(-c2ccc(NC(=S)Nc3cccnc3)cc2)nc1N1CCOCC1";"IC50";"'='";"237.9";"nM";"6.62";"";"389394";"UO_0000065";"14.00";"0.29";"2.06";"8.81";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL1801204";"AZD-8055";"1";"465.55";"0";"2.64";"AZD8055";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO";"IC50";"'='";"4.0";"nM";"8.40";"";"";"UO_0000065";"18.04";"0.34";"5.76";"9.02";"False";"CHEMBL4009793";"Inhibition of human N-terminal FLAG-tagged mTOR (1362-end residues) in presence of [gamma33P]ATP after 40 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007445";"1";"Scientific Literature";"Eur J Med Chem";"2017";""
"CHEMBL3410672";"";"0";"517.68";"1";"2.21";"42, AZD3147";"C[C@H]1COCCN1c1cc(C2(S(=O)(=O)C3CC3)CC2)nc(-c2ccc(NC(=S)NCCO)cc2)n1";"IC50";"'='";"1.514";"nM";"8.82";"";"";"UO_0000065";"17.04";"0.34";"6.61";"7.56";"False";"CHEMBL3413521";"Inhibition of recombinant truncated FLAG-tagged mTOR (1362 to 2549 aa) (unknown origin) expressed in HEK293 cells using biotinylated p70 peptide as substrate";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407414";"1";"Scientific Literature";"J. Med. Chem.";"2015";"CHEMBL3307715"
"CHEMBL3648869";"";"0";"556.64";"1";"4.16";"BDBM116175";"CCc1ncnc(-c2ccc(C(=O)N3C[C@H]4CN(C(=O)OC(C)(C)C)C[C@H]4C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.43";"nM";"8.35";"";"240787";"UO_0000065";"15.01";"0.28";"4.19";"7.29";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3648879";"";"0";"484.58";"0";"3.39";"BDBM116185";"CCc1ncnc(-c2ccc(C(=O)N3CCC4(CC3)CN(C)C4)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"7.04";"nM";"8.15";"";"240797";"UO_0000065";"16.82";"0.31";"4.76";"9.24";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645810";"";"0";"441.54";"0";"2.99";"BDBM115988";"CCc1ncnc(-c2ccc(C(=O)N3CCC(O)CC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"6.85";"nM";"8.16";"";"240600";"UO_0000065";"18.49";"0.34";"5.17";"7.76";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645860";"";"0";"525.00";"1";"4.22";"BDBM116039";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CC(F)F)CC3)c(Cl)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"4.69";"nM";"8.33";"";"240651";"UO_0000065";"15.86";"0.31";"4.11";"11.22";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645973";"";"0";"574.06";"1";"4.44";"BDBM116153";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(Cc4nc(C)c(C)o4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.45";"nM";"9.35";"";"240765";"UO_0000065";"16.28";"0.31";"4.91";"8.18";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645979";"";"0";"519.05";"1";"3.53";"BDBM116159";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C(C)COC)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.92";"nM";"9.04";"";"240771";"UO_0000065";"17.41";"0.33";"5.51";"9.27";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3648875";"";"0";"535.48";"1";"4.56";"BDBM116181";"CCc1ncnc(-c2cc(Cl)c(C(=O)N3CCC4(CC3)CN(C)C4)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"10.6";"nM";"7.97";"";"240793";"UO_0000065";"14.89";"0.29";"3.41";"9.04";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645790";"";"0";"480.62";"0";"3.56";"BDBM115968";"CCc1ncnc(-c2ccc(C(=O)N3CCC4(CCN(C)C4)C3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.51";"nM";"8.35";"";"240580";"UO_0000065";"17.36";"0.32";"4.79";"9.46";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645793";"";"0";"516.65";"1";"4.35";"BDBM115971";"CCc1ncnc(-c2ccc(C(=O)N3CCN(Cc4ccccc4)CC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"6.82";"nM";"8.17";"";"240583";"UO_0000065";"15.81";"0.29";"3.82";"9.25";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645900";"";"0";"580.61";"1";"3.92";"BDBM116079";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCOCC4)CC3)c(OC(F)(F)F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"27.93";"nM";"7.55";"";"240691";"UO_0000065";"13.01";"0.25";"3.63";"7.08";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645945";"";"0";"503.05";"1";"4.15";"BDBM116124";"CCc1ncnc(-c2ccc(C(=O)N3CCC(CN(C)C)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"39.77";"nM";"7.40";"";"240736";"UO_0000065";"14.71";"0.28";"3.25";"8.39";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645953";"";"0";"456.53";"0";"2.61";"BDBM116133";"CCc1ncnc(-c2ccc(C(=O)N3CC4(CN(C)C4)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"9.81";"nM";"8.01";"";"240745";"UO_0000065";"17.54";"0.32";"5.40";"9.08";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645958";"";"0";"488.57";"0";"2.36";"BDBM116138";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C(C)CO)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.26";"nM";"8.90";"";"240750";"UO_0000065";"18.22";"0.34";"6.54";"8.20";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653558";"";"0";"499.62";"0";"3.93";"BDBM136414";"CCN1CCC[C@@H]1CN1C[C@H](C(C)C)N(c2ccn3ncc(-c4ccc(-c5nc[nH]n5)cc4)c3n2)C1=O";"IC50";"'='";"51.2";"nM";"7.29";"";"270288";"UO_0000065";"14.59";"0.27";"3.36";"7.40";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643102";"";"0";"526.66";"1";"4.56";"BDBM115718";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CC4CCCCC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"39.0";"nM";"7.41";"";"240355";"UO_0000065";"14.07";"0.26";"2.85";"8.40";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643104";"";"0";"498.61";"0";"3.92";"BDBM115720";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C4CCCC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"6.0";"nM";"8.22";"";"240357";"UO_0000065";"16.49";"0.30";"4.30";"9.32";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643109";"";"0";"445.50";"0";"3.08";"BDBM115725";"CCc1ncnc(-c2ccc(C(=O)N3CCCOCC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"240362";"UO_0000065";"19.53";"0.36";"5.62";"9.23";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643112";"";"0";"463.54";"0";"2.43";"BDBM115728";"CCc1ncnc(-c2ccc(C(=O)N3CC[S+]([O-])CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"240365";"UO_0000065";"18.39";"0.35";"6.09";"8.35";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643115";"";"0";"512.63";"1";"4.17";"BDBM115731";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCC(C)CC4)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"13.0";"nM";"7.89";"";"240368";"UO_0000065";"15.38";"0.28";"3.72";"8.94";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643126";"";"0";"470.55";"0";"3.14";"BDBM115742";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C4CC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"240379";"UO_0000065";"18.11";"0.33";"5.38";"9.66";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643127";"";"0";"472.57";"0";"3.39";"BDBM115743";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C(C)C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"6.0";"nM";"8.22";"";"240380";"UO_0000065";"17.40";"0.32";"4.83";"9.32";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643146";"";"0";"475.98";"0";"3.99";"BDBM115762";"CCc1ncnc(-c2ccc(C(=O)N3CCC(OC)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"6.0";"nM";"8.22";"";"240399";"UO_0000065";"17.27";"0.33";"4.23";"8.73";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643149";"";"0";"447.93";"0";"2.94";"BDBM115765";"CCc1ncnc(-c2ccc(C(=O)N3CC[C@@H](O)C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.0";"nM";"8.40";"";"240402";"UO_0000065";"18.75";"0.36";"5.46";"7.98";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645963";"";"0";"543.58";"1";"3.62";"BDBM116143";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(Cc4cc(C)no4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.21";"nM";"9.68";"";"240755";"UO_0000065";"17.80";"0.33";"6.06";"8.47";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3648881";"";"0";"492.99";"0";"3.65";"BDBM116187";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(C)C[C@@H]3C)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.36";"nM";"8.36";"";"240799";"UO_0000065";"16.96";"0.33";"4.71";"9.47";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645812";"";"0";"441.54";"0";"3.16";"BDBM115990";"CCc1ncnc(-c2ccc(C(=O)NCC3(C)COC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"16.74";"nM";"7.78";"";"240602";"UO_0000065";"17.61";"0.32";"4.62";"7.55";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645862";"";"0";"489.02";"0";"3.97";"BDBM116041";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CC)CC3)c(Cl)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"19.97";"nM";"7.70";"";"240653";"UO_0000065";"15.75";"0.30";"3.73";"10.37";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645897";"";"0";"510.52";"1";"3.37";"BDBM116076";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C)CC3)c(OC(F)(F)F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"14.07";"nM";"7.85";"";"240688";"UO_0000065";"15.38";"0.29";"4.48";"8.06";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645944";"";"0";"503.01";"1";"2.89";"BDBM116123";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C4COC4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.24";"nM";"8.37";"";"240735";"UO_0000065";"16.65";"0.32";"5.48";"8.59";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3931669";"";"0";"458.54";"0";"1.73";"BDBM251585";"CNc1nc2ccccc2n1-c1nc2c(c(C(C)(C)S(C)(=O)=O)n1)OCC1COCCN21";"IC50";"'='";"588.0";"nM";"6.23";"";"438481";"UO_0000065";"13.59";"0.27";"4.50";"5.59";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3929932";"";"0";"488.54";"0";"2.41";"BDBM251594";"CS(=O)(=O)C1(c2nc(-c3cc(F)cc4[nH]ccc34)nc3c2OCC2COCCN32)CCOCC1";"IC50";"'='";"2620.0";"nM";"5.58";"";"438490";"UO_0000065";"11.43";"0.22";"3.17";"5.23";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3941268";"";"0";"502.57";"1";"2.80";"BDBM251610";"CS(=O)(=O)C1(c2nc(-c3cc(F)cc4[nH]ccc34)nc3c2OCCC2COCCN32)CCOCC1";"IC50";"'='";"1930.0";"nM";"5.71";"";"438506";"UO_0000065";"11.37";"0.22";"2.91";"5.36";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3928755";"";"0";"401.45";"0";"1.59";"BDBM251612";"CS(=O)(=O)Nc1nc(-c2cccc3[nH]ccc23)nc2c1OCC1COCCN21";"IC50";"'='";"2350.0";"nM";"5.63";"";"438508";"UO_0000065";"14.02";"0.27";"4.04";"5.14";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3942322";"";"0";"375.43";"0";"3.02";"BDBM251617";"CC(C)(C#N)c1nc(-c2cccc3[nH]ccc23)nc2c1OCC1COCCN21";"IC50";"'='";"279.0";"nM";"6.55";"";"438513";"UO_0000065";"17.46";"0.32";"3.53";"7.53";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3907738";"";"0";"440.53";"0";"2.65";"BDBM251618";"CC1(c2nc(-c3cccc4[nH]ccc34)nc3c2OCC2COCCN32)CCCS1(=O)=O";"IC50";"'='";"381.0";"nM";"6.42";"";"438514";"UO_0000065";"14.57";"0.28";"3.77";"6.59";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL2172630";"";"0";"385.40";"0";"2.50";"19e";"Cc1nc(Nc2cnccn2)cc(-c2c(Nc3cc[nH]n3)nc3cccnn23)n1";"IC50";"'='";"6.0";"nM";"8.22";"";"";"UO_0000065";"21.33";"0.39";"5.72";"6.11";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL3645966";"";"0";"557.61";"1";"3.92";"BDBM116146";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(Cc4nc(C)c(C)o4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.49";"nM";"9.31";"";"240758";"UO_0000065";"16.70";"0.31";"5.39";"8.15";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653582";"";"0";"442.41";"0";"3.41";"BDBM136439";"O=C1OCC(c2ccccn2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"7.4";"nM";"8.13";"";"270313";"UO_0000065";"18.38";"0.34";"4.72";"7.12";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653596";"";"0";"442.41";"0";"3.41";"BDBM136453";"O=C1OC[C@H](c2cccnc2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"2.4";"nM";"8.62";"";"270327";"UO_0000065";"19.48";"0.36";"5.21";"7.55";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649446";"";"0";"442.93";"0";"3.64";"BDBM122469";"Cc1cc2ncc(-c3cnc(Cl)c(NS(=O)(=O)N(C)C)c3)n2cc1-c1ccncc1";"IC50";"'='";"18.0";"nM";"7.75";"";"251070";"UO_0000065";"17.49";"0.35";"4.10";"8.37";"False";"CHEMBL3705287";"In Vitro mTOR Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP 1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639163";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643158";"";"0";"524.03";"1";"4.09";"BDBM115774";"CCc1ncnc(-c2ccc(C(=O)N3CCN(c4ccncc4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"9.65";"nM";"8.02";"";"240505";"UO_0000065";"15.30";"0.29";"3.93";"7.93";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643243";"";"0";"524.67";"1";"4.04";"BDBM115908";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCC(C)CC4)C3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"75.07";"nM";"7.12";"";"240520";"UO_0000065";"13.58";"0.25";"3.08";"7.31";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643259";"";"0";"510.64";"1";"3.79";"BDBM115924";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C4CCCC4)CC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"6.82";"nM";"8.17";"";"240536";"UO_0000065";"15.99";"0.29";"4.38";"8.38";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645770";"";"0";"427.51";"0";"2.86";"BDBM115948";"CCc1ncnc(-c2ccc(C(=O)N3CCOCC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.79";"nM";"8.55";"";"240560";"UO_0000065";"20.01";"0.37";"5.69";"9.08";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645808";"";"0";"503.61";"1";"3.75";"BDBM115986";"CCc1ncnc(-c2ccc(C(=O)N3CCN(c4ccccn4)CC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"17.09";"nM";"7.77";"";"240598";"UO_0000065";"15.42";"0.28";"4.02";"7.68";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645849";"";"0";"490.56";"0";"3.53";"BDBM116028";"CCc1ncnc(-c2cc(F)c(C(=O)N(C)C3CCN(C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.63";"nM";"8.33";"";"240640";"UO_0000065";"16.99";"0.32";"4.80";"9.45";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645882";"";"0";"476.53";"0";"3.21";"BDBM116061";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(C)CC3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"2.84";"nM";"8.55";"";"240673";"UO_0000065";"17.94";"0.33";"5.34";"11.51";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645939";"";"0";"470.55";"0";"3.05";"BDBM116118";"CCc1ncnc(-c2ccc(C(=O)N3CCC4(CC3)CNC4)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"10.44";"nM";"7.98";"";"240730";"UO_0000065";"16.96";"0.31";"4.93";"8.23";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645965";"";"0";"506.56";"1";"2.50";"BDBM116145";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(C(C)CO)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.58";"nM";"9.24";"";"240757";"UO_0000065";"18.23";"0.34";"6.74";"8.52";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653573";"";"0";"429.48";"0";"4.09";"BDBM136430";"O=C1OC[C@H](C2CCCCC2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"3.5";"nM";"8.46";"";"270304";"UO_0000065";"19.69";"0.36";"4.37";"8.35";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653645";"";"0";"453.44";"0";"3.94";"BDBM136502";"O=C1O[C@@H]2Cc3ccccc3[C@@H]2N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"14.3";"nM";"7.84";"";"270376";"UO_0000065";"17.30";"0.32";"3.90";"7.74";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3648888";"";"0";"458.54";"0";"3.00";"BDBM116194";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C)C[C@@H]3C)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.46";"nM";"8.26";"";"240806";"UO_0000065";"18.02";"0.33";"5.26";"9.36";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643248";"";"0";"496.62";"0";"3.40";"BDBM115913";"CCc1ncnc(-c2ccc(C(=O)N3CCN4CCCCC4C3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"20.94";"nM";"7.68";"";"240525";"UO_0000065";"15.46";"0.28";"4.28";"7.88";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643254";"";"0";"524.67";"1";"4.18";"BDBM115919";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCCCC4)CC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"32.4";"nM";"7.49";"";"240531";"UO_0000065";"14.27";"0.26";"3.31";"7.68";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643274";"";"0";"491.00";"0";"2.80";"BDBM115940";"CCc1ncnc(-c2ccc(C(=O)NCCN3CCOCC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.8";"nM";"8.42";"";"240552";"UO_0000065";"17.15";"0.33";"5.62";"7.92";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643275";"";"0";"503.01";"1";"3.43";"BDBM115941";"CCc1ncnc(-c2ccc(C(=O)N(C)CCN3CCCC3=O)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.4";"nM";"8.36";"";"240553";"UO_0000065";"16.61";"0.32";"4.93";"7.94";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645776";"";"0";"544.68";"1";"2.34";"BDBM115954";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C4CCS(=O)(=O)C4)CC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.41";"nM";"8.85";"";"240566";"UO_0000065";"16.25";"0.31";"6.51";"7.23";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645788";"";"0";"470.58";"0";"2.45";"BDBM115966";"CCc1ncnc(-c2ccc(C(=O)NCCN3CCOCC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.98";"nM";"8.22";"";"240578";"UO_0000065";"17.47";"0.32";"5.77";"7.74";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645848";"";"0";"476.53";"0";"3.09";"BDBM116027";"CCc1ncnc(-c2cc(F)c(C(=O)NCC3CCNCC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"39.16";"nM";"7.41";"";"240639";"UO_0000065";"15.54";"0.29";"4.32";"7.00";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645888";"";"0";"546.62";"1";"3.76";"BDBM116067";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(C4CCOCC4)CC3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"2.14";"nM";"8.67";"";"240679";"UO_0000065";"15.86";"0.30";"4.91";"10.39";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645928";"";"0";"567.12";"1";"2.93";"BDBM116107";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CCCS(C)(=O)=O)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.7";"nM";"8.57";"";"240719";"UO_0000065";"15.11";"0.30";"5.64";"7.00";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3763244";"";"0";"627.69";"1";"3.31";"7k; NSC781406";"COc1ncc(-c2ccc3nccc(C#CCN4CCN(S(C)(=O)=O)CC4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"5.4";"nM";"8.27";"";"";"UO_0000065";"13.17";"0.26";"4.96";"6.79";"False";"CHEMBL3766570";"Inhibition of mTOR kinase (unknown origin) assessed as suppression of ULight-4E-BP1 substrate phosphorylation incubated for 1 hr by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3763019";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2016";""
"CHEMBL3586381";"";"0";"397.48";"0";"2.34";"11";"CC(C)(O)c1ccc(-c2cnc3c(n2)N(CCC2CCOCC2)CC(=O)N3)cn1";"IC50";"'='";"103.0";"nM";"6.99";"";"";"UO_0000065";"17.58";"0.33";"4.65";"6.95";"False";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3586567";"";"0";"406.45";"0";"1.69";"20";"Cc1nc(-c2nc[nH]n2)ccc1-c1cnc2c(n1)N([C@H]1CC[C@H](O)CC1)C(=O)CN2";"IC50";"'='";"19.0";"nM";"7.72";"";"";"UO_0000065";"19.00";"0.35";"6.03";"5.81";"False";"CHEMBL3587521";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585264";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL2418351";"";"0";"393.45";"0";"2.15";"21d";"CCNC(=O)Nc1ccc(-c2nc(N3C[C@@H]4C[C@H]3CO4)c3c(cnn3C)n2)cc1";"IC50";"'='";"340.0";"nM";"6.47";"";"";"UO_0000065";"16.44";"0.30";"4.32";"6.65";"False";"CHEMBL2421123";"Inhibition of mTOR in PTEN deficient human PC3 cells assessed as inhibition of Akt phosphorylation at Ser473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2417437";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";"CHEMBL3307570"
"CHEMBL3693479";"";"0";"477.61";"0";"3.90";"BDBM174641";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CC(C)CC(C)C4)nc3n2)cc1CO";"IC50";"'='";"34.0";"nM";"7.47";"";"319919";"UO_0000065";"15.64";"0.29";"3.57";"8.91";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693486";"";"0";"539.68";"1";"4.88";"BDBM174648";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCC(Cc5ccccc5)CC4)nc3n2)cc1CO";"IC50";"'='";"360.0";"nM";"6.44";"";"319926";"UO_0000065";"11.94";"0.22";"1.56";"7.69";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693490";"";"0";"449.56";"0";"3.41";"BDBM174652";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCCC4C)nc3n2)cc1CO";"IC50";"'='";"13.0";"nM";"7.89";"";"319930";"UO_0000065";"17.54";"0.33";"4.48";"9.41";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693497";"";"0";"449.56";"0";"3.77";"BDBM174659";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(NC4CCCC4)nc3n2)cc1CO";"IC50";"'='";"58.0";"nM";"7.24";"";"319937";"UO_0000065";"16.10";"0.30";"3.47";"7.81";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL2336334";"";"0";"453.54";"0";"2.86";"BDBM50429713";"COCC(C)Nc1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(OC)c(CO)c3)nc2n1";"IC50";"'='";"26.0";"nM";"7.58";"";"319938";"UO_0000065";"16.72";"0.31";"4.73";"7.45";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL2336318";"";"0";"432.48";"0";"2.60";"BDBM50429708";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(-n4ccnc4)nc3n2)cc1CO";"IC50";"'='";"87.0";"nM";"7.06";"";"319939";"UO_0000065";"16.33";"0.30";"4.46";"7.17";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693507";"";"0";"465.55";"0";"2.38";"BDBM174670";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCC[C@H](O)C4)nc3n2)cc1CO";"IC50";"'='";"24.0";"nM";"7.62";"";"319950";"UO_0000065";"16.37";"0.31";"5.24";"7.32";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693514";"";"0";"423.52";"0";"3.24";"BDBM174677";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(NC(C)C)nc3n2)cc1CO";"IC50";"'='";"30.0";"nM";"7.52";"";"319958";"UO_0000065";"17.76";"0.33";"4.28";"8.12";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL2322228";"";"0";"371.41";"0";"3.13";"43";"O=c1cc(N2CCOCC2)oc2c(-c3ccc4c(c3)OCCO4)csc12";"IC50";"'='";"289.0";"nM";"6.54";"";"";"UO_0000065";"17.61";"0.34";"3.41";"10.70";"False";"CHEMBL2330617";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2321770";"1";"Scientific Literature";"J. Med. Chem.";"2013";""
"CHEMBL3586397";"";"0";"411.51";"0";"2.73";"30";"CO[C@H]1CC[C@@H](CN2C(=O)CNc3ncc(-c4ccc(C(C)(C)O)nc4)nc32)CC1";"IC50";"'='";"12.0";"nM";"7.92";"";"";"UO_0000065";"19.25";"0.36";"5.19";"7.88";"False";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3586394";"";"0";"383.45";"0";"1.95";"27";"CC(C)(O)c1ccc(-c2cnc3c(n2)N(CC2CCOCC2)C(=O)CN3)cn1";"IC50";"'='";"46.0";"nM";"7.34";"";"";"UO_0000065";"19.13";"0.36";"5.39";"7.30";"False";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3586561";"";"0";"434.50";"0";"2.60";"14";"CO[C@H]1CC[C@@H](CN2C(=O)CNc3ncc(-c4ccc(-c5nc[nH]n5)nc4C)nc32)CC1";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"19.62";"0.36";"5.92";"7.00";"False";"CHEMBL3587521";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585264";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3586573";"";"0";"336.36";"0";"1.41";"26";"CCN1C(=O)CNc2ncc(-c3ccc(-c4nc[nH]n4)nc3C)nc21";"IC50";"'='";"21.0";"nM";"7.68";"";"";"UO_0000065";"22.83";"0.42";"6.27";"6.82";"False";"CHEMBL3587521";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585264";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3586560";"";"0";"406.45";"0";"1.82";"13";"Cc1nc(-c2nc[nH]n2)ccc1-c1cnc2c(n1)N(CC1CCOCC1)C(=O)CN2";"IC50";"'='";"12.0";"nM";"7.92";"";"";"UO_0000065";"19.49";"0.36";"6.10";"6.50";"False";"CHEMBL3587521";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585264";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3972724";"";"0";"519.62";"1";"4.70";"BDBM245519";"Cn1c(=O)n([C@H]2CCCOC2)c2c3cc(-c4ccc(OCCCN5CCCCC5)nc4)c(F)cc3ncc21";"IC50";"'>'";"30000.0";"nM";"";"";"427929";"UO_0000065";"";"";"";"";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3586562";"";"0";"434.50";"0";"2.60";"15";"CO[C@H]1CC[C@H](CN2C(=O)CNc3ncc(-c4ccc(-c5nc[nH]n5)nc4C)nc32)CC1";"IC50";"'='";"31.0";"nM";"7.51";"";"";"UO_0000065";"17.28";"0.32";"4.91";"6.16";"False";"CHEMBL3587521";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585264";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3586566";"";"0";"406.45";"0";"1.69";"19";"Cc1nc(-c2nc[nH]n2)ccc1-c1cnc2c(n1)N([C@H]1CC[C@@H](O)CC1)C(=O)CN2";"IC50";"'='";"8.0";"nM";"8.10";"";"";"UO_0000065";"19.92";"0.37";"6.41";"6.10";"False";"CHEMBL3587521";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585264";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL2172635";"";"0";"415.42";"1";"2.50";"19j";"COc1cnnc(Nc2cc(-c3c(Nc4cc[nH]n4)nc4cccnn34)nc(C)n2)c1";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"20.52";"0.38";"6.02";"5.93";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL4066277";"";"0";"482.63";"0";"0.44";"13";"CS(=O)(=O)N1CCN(Cc2cc3nc(N4CCOCC4)nc(N4CCOCC4)c3s2)CC1";"IC50";"'>'";"2000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL4063088";"";"0";"352.49";"0";"1.57";"6e";"OCc1cc2nc(N3CCSCC3)nc(N3CCOCC3)c2s1";"IC50";"'='";"603.0";"nM";"6.22";"";"";"UO_0000065";"17.64";"0.37";"4.65";"10.08";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL3693560";"";"0";"476.59";"0";"2.20";"BDBM174723";"C[C@H]1COCCN1c1nc(N2CCC(C(=O)N(C)C)CC2)nc2nc(-c3ccc(N)nc3)ccc12";"IC50";"'='";"60.0";"nM";"7.22";"";"320003";"UO_0000065";"15.15";"0.28";"5.02";"6.36";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693561";"";"0";"465.55";"0";"2.64";"BDBM174724";"COc1ccc(-c2ccc3c(N4CCOC[C@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO";"IC50";"'='";"9.4";"nM";"8.03";"";"320004";"UO_0000065";"17.24";"0.32";"5.39";"8.62";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693580";"";"0";"443.51";"0";"3.48";"BDBM174746";"COc1ncccc1-c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(CO)c3)nc2n1";"IC50";"'='";"97.0";"nM";"7.01";"";"320025";"UO_0000065";"15.81";"0.29";"3.53";"7.50";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3968925";"";"0";"584.61";"2";"5.69";"13n";"COc1ncc(-c2ccc3nccc(-c4ccc(Cn5cncn5)cc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"1.1";"nM";"8.96";"";"";"UO_0000065";"15.32";"0.29";"3.27";"8.01";"False";"CHEMBL3867034";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide as substrate after 1 hr in presence of ATP by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3865829";"1";"Scientific Literature";"Eur J Med Chem";"2016";""
"CHEMBL3646439";"";"0";"424.47";"0";"4.61";"BDBM125280";"COc1ccc(Nc2ncc(Nc3ccccc3)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'='";"714.0";"nM";"6.15";"";"254992";"UO_0000065";"14.48";"0.26";"1.54";"5.41";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646447";"";"0";"432.49";"0";"2.83";"BDBM125289";"COc1ccc(Nc2ncc(N3CCC[C@@H]3CO)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'='";"2701.0";"nM";"5.57";"";"255001";"UO_0000065";"12.88";"0.24";"2.74";"4.46";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640946";"";"0";"355.32";"0";"3.24";"BDBM115596";"Cc1ncnc(-c2ccc(C(F)(F)F)nc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"44.0";"nM";"7.36";"";"240233";"UO_0000065";"20.70";"0.39";"4.12";"9.48";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646471";"";"0";"419.49";"0";"3.95";"BDBM125313";"COc1ccc(Nc2ncc(C(O)C(C)(C)C)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'='";"268.0";"nM";"6.57";"";"255031";"UO_0000065";"15.67";"0.29";"2.62";"5.40";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640980";"";"0";"375.41";"0";"2.58";"BDBM115630";"CCc1ncnc(-c2ccc(C(=O)NC)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"8.0";"nM";"8.10";"";"240267";"UO_0000065";"21.57";"0.39";"5.52";"8.63";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640985";"";"0";"443.53";"0";"4.16";"BDBM115635";"CCc1ncnc(-c2ccc(C(=O)N3CCCCC3)c(F)c2)c1C#Cc1ccc(N)nc1C";"IC50";"'='";"4.0";"nM";"8.40";"";"240272";"UO_0000065";"18.93";"0.35";"4.24";"9.88";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646480";"";"0";"495.54";"0";"3.10";"BDBM125322";"COc1ncc(Nc2ncc(Cc3ccc(S(C)(=O)=O)cc3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255042";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3641011";"";"0";"524.03";"1";"4.09";"BDBM115662";"CCc1ncnc(-c2ccc(C(=O)N3CCN(c4ccccn4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"240299";"UO_0000065";"16.26";"0.31";"4.43";"8.43";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL4071083";"";"0";"400.51";"0";"2.53";"14o";"C[C@H]1CN(c2nc(N3CCOCC3)c3sc(-c4ccn[nH]4)cc3n2)C[C@@H](C)O1";"IC50";"'='";"16.0";"nM";"7.80";"";"";"UO_0000065";"19.46";"0.38";"5.27";"9.82";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL4097432";"";"0";"414.54";"0";"2.54";"14p";"C[C@H]1CN(c2nc(N3CCOCC3)c3sc(-c4ccnn4C)cc3n2)C[C@@H](C)O1";"IC50";"'>'";"2000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL3974856";"";"0";"449.53";"0";"4.14";"BDBM245523";"CN(C)CCCOc1ccc(-c2ccc3ncc4c(c3c2)n(C2CCC2)c(=O)n4C)c(F)n1";"IC50";"'='";"5380.0";"nM";"5.27";"";"427933";"UO_0000065";"11.72";"0.22";"1.13";"8.08";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL1801204";"AZD-8055";"1";"465.55";"0";"2.64";"AZD8055";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO";"IC50";"'='";"0.13";"nM";"9.89";"";"";"UO_0000065";"21.24";"0.40";"7.25";"10.62";"False";"CHEMBL2338832";"Inhibition of recombinant FLAG-tagged mTOR (1362 to 2549) (unknown origin) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331448";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";"CHEMBL3307715"
"CHEMBL4099904";"";"0";"412.37";"0";"1.33";"18";"Oc1cc(C(F)(F)F)c(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cn1";"IC50";"'='";"1.7";"10'7nM";"";"Non standard unit for type";"";"";"";"";"";"";"False";"CHEMBL4019299";"Inhibition of mTOR in human A2058 cells assessed as reduction in phosphorylation of S6 at ser235/236 residues after 1 hr by in-cell Western method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017506";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL3693455";"";"0";"541.65";"1";"4.51";"BDBM174616";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCC(c5cccc(O)c5)CC4)nc3n2)cc1CO";"IC50";"'='";"38.0";"nM";"7.42";"";"319894";"UO_0000065";"13.70";"0.25";"2.91";"7.13";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693491";"";"0";"560.10";"2";"5.46";"BDBM174653";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCC(c5ccc(Cl)cc5)CC4)nc3n2)cc1CO";"IC50";"'='";"190.0";"nM";"6.72";"";"319931";"UO_0000065";"12.00";"0.23";"1.26";"8.02";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693494";"";"0";"679.24";"1";"4.89";"BDBM174656";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCC(N(C5CC5)S(=O)(=O)c5ccc(Cl)cc5)CC4)nc3n2)cc1CO";"IC50";"'='";"780.0";"nM";"6.11";"";"319934";"UO_0000065";"8.99";"0.18";"1.22";"5.04";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693529";"";"0";"467.60";"0";"2.97";"BDBM174692";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCSCC4)nc3n2)cc1CO";"IC50";"'='";"78.0";"nM";"7.11";"";"319974";"UO_0000065";"15.20";"0.29";"4.14";"8.48";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693532";"";"0";"469.54";"0";"1.21";"BDBM174695";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N(CCO)CCO)nc3n2)cc1CO";"IC50";"'='";"9.5";"nM";"8.02";"";"319977";"UO_0000065";"17.09";"0.32";"6.81";"6.45";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693400";"";"0";"530.67";"1";"3.90";"BDBM174541";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(CN(C)C(=O)C4CCC4)c3)nc2n1";"IC50";"'='";"49.0";"nM";"7.31";"";"319837";"UO_0000065";"13.77";"0.26";"3.41";"8.71";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3895211";"";"0";"505.59";"1";"4.30";"BDBM245499";"CO[C@H]1C[C@@H](n2c(=O)n(C)c3cnc4cc(F)c(-c5ccc(OCCCN6CCCC6)nc5)cc4c32)C1";"IC50";"'>'";"17500.0";"nM";"";"";"427910";"UO_0000065";"";"";"";"";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3963290";"";"0";"487.60";"0";"4.17";"BDBM245502";"Cn1c(=O)n(C2CCOCC2)c2c3cc(-c4ccc(OCCCN5CCCC5)nc4)ccc3ncc21";"IC50";"'='";"1570.0";"nM";"5.80";"";"427913";"UO_0000065";"11.90";"0.22";"1.63";"7.80";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL4110808";"";"0";"493.58";"0";"4.16";"BDBM245539";"CO[C@H]1CC[C@@H](n2c(=O)n(C)c3cnc4cc(F)c(-c5ccc(OCCCN(C)C)nc5)cc4c32)C1";"IC50";"'>'";"30000.0";"nM";"";"";"427950";"UO_0000065";"";"";"";"";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3932908";"";"0";"481.50";"1";"6.14";"BDBM213779";"CSc1ccc(-c2ccc3ncc4c(c3n2)N(c2cccc(C(F)(F)F)c2)C(=O)N(C)C4)cn1";"IC50";"'='";"76.5";"nM";"7.12";"";"375945";"UO_0000065";"14.78";"0.29";"0.98";"11.44";"False";"CHEMBL3888153";"mTOR Activity Assay: 1. Preparation of test reagents {circle around (1)} 1x kinase buffer (50 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 3 mM MnCl, 0.01% Tween-20, 2 mM DTT); {circle around (2)} 4x kinase solution (added mTOR kinase to 1x kinase buffer to provide 4x kinase solution with a final concentration of 2.5 nM); {circle around (3)} 2x substrate solution (added the substrates of 4EBP1 and ATP into 1x kinase buffer to provide 2x substrate solution with 4EBP1 final concentration of 50 nM and ATP final concentration of 10.8 uM); {circle around (4)} 4x test substance solutions (100x test substance solutions with different concentration gradients were prepared using 100% DMSO, and diluted 25-fold with 1x kinase buffer to give 4x test substance solutions with different concentration gradients) {circle around (5)} preparation of test solution (test solution containing EDTA and 4EBP1 phosphorylated antibody was prepared using activity test kit with assay buffer, the final concentration of EDTA was 8 mM, and the final concentration of 4EBP1 phosphorylated antibody was 2 nM) 2. 2.5 uL of 4x test solution was added to a 384-well plate in parallel; 3. added 2.54 uL of 4x kinase solution and incubated for 10 min; 4. then added 5 uL of 2x solutions of 4EBP1 and ATP substrates and incubated for 1 h at room temperature; 5. finally, added 10 uL of test solution to quench the reaction, and read after 60 min; 6. IC50 value was obtained via curve fitting.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886601";"37";"BindingDB Database";"";"2016";""
"CHEMBL4082222";"";"0";"377.47";"0";"1.24";"10";"C[C@H]1CN(c2nc(N3CCOCC3)c3sc(C(N)=O)cc3n2)C[C@@H](C)O1";"IC50";"'='";"865.0";"nM";"6.06";"";"";"UO_0000065";"16.06";"0.32";"4.82";"6.46";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL3898577";"";"0";"497.55";"0";"3.91";"BDBM245492";"CO[C@H]1C[C@@H](n2c(=O)n(C)c3cnc4cc(F)c(-c5ccc(OCCCN(C)C)nc5F)cc4c32)C1";"IC50";"'='";"13700.0";"nM";"4.86";"";"427902";"UO_0000065";"9.77";"0.18";"0.95";"6.54";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3912416";"";"0";"473.58";"0";"3.78";"BDBM245511";"Cn1c(=O)n(C2CCOCC2)c2c3cc(-c4ccc(OCCCN5CCC5)nc4)ccc3ncc21";"IC50";"'='";"1270.0";"nM";"5.90";"";"427922";"UO_0000065";"12.45";"0.23";"2.12";"7.92";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3701136";"";"0";"377.47";"0";"3.15";"BDBM172271";"Cc1nc(N)ccc1C#Cc1c(-c2ccc(S(C)(=O)=O)cc2)ccnc1C";"IC50";"'='";"5.0";"nM";"8.30";"";"317195";"UO_0000065";"21.99";"0.42";"5.15";"9.66";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701149";"";"0";"535.60";"2";"5.07";"BDBM172284";"CCc1nccc(-c2ccc(C(=O)N3C[C@@H]4CC3CN4c3ccc(F)cc3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"42.0";"nM";"7.38";"";"317208";"UO_0000065";"13.77";"0.25";"2.31";"9.79";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701160";"";"0";"428.51";"0";"4.37";"BDBM172295";"CCc1nc(N)ccc1C#Cc1c(-c2ccc(C(=O)N3CCCC3)c(F)c2)ccnc1C";"IC50";"'='";"21.0";"nM";"7.68";"";"317219";"UO_0000065";"17.92";"0.33";"3.31";"10.65";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693410";"";"0";"520.61";"1";"3.31";"BDBM174551";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(F)c(CNC(=O)C4CC4)c3)nc2n1";"IC50";"'='";"140.0";"nM";"6.85";"";"319847";"UO_0000065";"13.17";"0.25";"3.54";"7.39";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693414";"";"0";"548.54";"1";"3.46";"BDBM174555";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(F)c(CNC(=O)C(F)(F)F)c3)nc2n1";"IC50";"'='";"1400.0";"nM";"5.85";"";"319851";"UO_0000065";"10.67";"0.20";"2.39";"6.31";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693417";"";"0";"495.63";"0";"2.39";"BDBM174563";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(CNCCN(C)C)o3)nc2n1";"IC50";"'='";"130.0";"nM";"6.89";"";"319854";"UO_0000065";"13.89";"0.26";"4.50";"7.48";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693430";"";"0";"467.55";"0";"3.43";"BDBM174577";"COCc1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccc1F";"IC50";"'='";"88.0";"nM";"7.06";"";"319868";"UO_0000065";"15.09";"0.28";"3.63";"9.69";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3667426";"";"0";"396.46";"0";"0.55";"BDBM150998";"NCc1cc(-c2nc3c(N4CCOCC4)nc(N4CCOCC4)nc3[nH]2)ccn1";"IC50";"'='";"2425.0";"nM";"5.62";"";"290544";"UO_0000065";"14.16";"0.26";"5.07";"4.75";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL3769902";"";"0";"425.46";"0";"2.52";"17f";"N#Cc1ncccc1Nc1ccc2c(N3CCOCC3)nc(-c3cnc(N)nc3)nc2c1";"IC50";"'='";"78.0";"nM";"7.11";"";"";"UO_0000065";"16.71";"0.30";"4.59";"5.12";"False";"CHEMBL3772928";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3769354";"1";"Scientific Literature";"Eur. J. Med. Chem.";"2016";""
"CHEMBL3586563";"";"0";"420.48";"0";"2.35";"16";"CO[C@H]1CC[C@@H](N2CC(=O)Nc3ncc(-c4ccc(-c5nc[nH]n5)nc4C)nc32)CC1";"IC50";"'='";"51.0";"nM";"7.29";"";"";"UO_0000065";"17.34";"0.32";"4.94";"5.99";"False";"CHEMBL3587521";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585264";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3586565";"";"0";"420.48";"0";"2.35";"18";"CO[C@H]1CC[C@H](N2C(=O)CNc3ncc(-c4ccc(-c5nc[nH]n5)nc4C)nc32)CC1";"IC50";"'='";"15.0";"nM";"7.82";"";"";"UO_0000065";"18.61";"0.34";"5.47";"6.42";"False";"CHEMBL3587521";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585264";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL2030451";"";"0";"485.54";"0";"3.31";"3";"CS(=O)(=O)Cc1cc(N2CCOCC2)nc(-c2ccc(NC(=O)Nc3ccc(F)cc3)cc2)n1";"IC50";"'='";"28.18";"nM";"7.55";"";"";"UO_0000065";"15.55";"0.30";"4.24";"6.65";"False";"CHEMBL3413521";"Inhibition of recombinant truncated FLAG-tagged mTOR (1362 to 2549 aa) (unknown origin) expressed in HEK293 cells using biotinylated p70 peptide as substrate";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407414";"1";"Scientific Literature";"J. Med. Chem.";"2015";"CHEMBL3307715"
"CHEMBL1957498";"";"0";"575.49";"1";"1.95";"20";"CS(=O)(=O)N1CCN(Cc2nc3c(N4CCOCC4)nc(-c4cccc5[nH]ncc45)cn3c2Br)CC1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL1959594";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1955823";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL3586405";"";"0";"383.45";"0";"2.23";"2";"CC(C)(O)c1ccc(-c2cnc3[nH]c(=O)n(CCC4CCOCC4)c3n2)cn1";"IC50";"'='";"64.0";"nM";"7.19";"";"";"UO_0000065";"18.76";"0.35";"4.96";"6.79";"False";"CHEMBL3587361";"Inhibition of recombinant mTOR (unknown origin) using GST-p70S6 as substrate after 60 mins by TR-FRET analysis";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3590222";"";"0";"461.53";"1";"0.86";"4";"CN(C)CC(=O)N1CCC(c2nc(-c3cnc(N)c(-n4nnc5ccccc54)n3)n(C)n2)CC1";"IC50";"'='";"21000.0";"nM";"4.68";"";"";"UO_0000065";"10.14";"0.19";"3.82";"3.42";"False";"CHEMBL3591971";"Inhibition of m-TOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3588784";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2015";""
"CHEMBL3814066";"";"0";"441.49";"0";"2.79";"10f";"O=c1c(/C=N/Nc2nc3c(c(N4CCOCC4)n2)CSCC3)coc2ccc(F)cc12";"IC50";"";"";"";"";"";"Not Active";"";"";"";"";"";"False";"CHEMBL3815304";"Inhibition of mTOR (unknown origin) using ULight4E-BP1 peptide as substrate incubated for 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3813678";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2016";""
"CHEMBL3343621";"";"0";"502.60";"1";"4.67";"36";"Cc1cc(/C=N/NC(=O)Nc2ccc(-c3nc(N4CCOCC4)c4sccc4n3)cc2)cc(C)c1O";"IC50";"'='";"770.0";"nM";"6.11";"";"";"UO_0000065";"12.16";"0.23";"1.44";"5.46";"False";"CHEMBL3387484";"Inhibition of purified mTOR (unknown origin) after 30 mins by homogeneous time-resolved fluorescence assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3351335";"1";"Scientific Literature";"Eur. J. Med. Chem.";"2014";""
"CHEMBL3393594";"";"0";"437.50";"0";"2.43";"111, X-387";"CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)nc3c2cnn3C2CCOCC2)cc1";"IC50";"'='";"23.0";"nM";"7.64";"";"";"UO_0000065";"17.46";"0.33";"5.21";"7.18";"False";"CHEMBL3395890";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3392967";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3290300";"";"0";"342.40";"0";"3.68";"9";"Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3ccccc3ncc21";"IC50";"'='";"1622.0";"nM";"5.79";"";"";"UO_0000065";"16.91";"0.30";"2.11";"9.10";"False";"CHEMBL3291527";"Inhibition of human recombinant mTOR assessed as inhibition of 4EBP1 phosphorylation after 30 mins by TR-FRET analysis";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3286093";"1";"Scientific Literature";"J. Med. Chem.";"2014";""
"CHEMBL1945490";"";"0";"348.36";"0";"2.55";"10";"COc1ccccc1Cn1c(=O)[nH]c2ncc(-c3ccc(O)cc3)nc21";"IC50";"'='";"2440.0";"nM";"5.61";"";"";"UO_0000065";"16.11";"0.29";"3.06";"6.03";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL1945950";"";"0";"366.47";"0";"3.59";"39";"CC(C)(O)c1ccc(-c2cnc3[nH]c(=O)n(CC4CCCCC4)c3n2)cc1";"IC50";"'='";"322.0";"nM";"6.49";"";"";"UO_0000065";"17.72";"0.33";"2.90";"7.75";"False";"CHEMBL1949073";"Inhibition of mTOR-mediated Akt phosphorylation in human PC3 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";"CHEMBL3307570"
"CHEMBL3112710";"";"0";"523.59";"1";"4.41";"9t";"COc1ncc(-c2cc3c(C)nc(N)cc3n(C3CCCC3)c2=O)cc1NS(=O)(=O)c1ccccc1F";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3113392";"";"0";"377.39";"0";"2.48";"3";"N=C1/C(=C\c2ccc3c(c2)OCO3)C(=O)N=C2SC(c3cccnc3)=NN12";"IC50";"'='";"32200.0";"nM";"4.49";"";"";"UO_0000065";"11.90";"0.23";"2.01";"4.48";"False";"CHEMBL3116603";"Inhibition of mTOR (unknown origin) by KINOMEscan assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112406";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3113391";"";"0";"334.34";"0";"2.95";"2";"Cn1ncc2c(Nc3ccc(NC(=O)c4ccco4)cc3)ncnc21";"IC50";"'='";"20400.0";"nM";"4.69";"";"";"UO_0000065";"14.03";"0.26";"1.74";"4.79";"False";"CHEMBL3116603";"Inhibition of mTOR (unknown origin) by KINOMEscan assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112406";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3113390";"";"0";"384.39";"1";"5.29";"1";"Cc1c(CC(=O)O)c(=O)oc2cc3occ(-c4ccc5ccccc5c4)c3cc12";"IC50";"'='";"8300.0";"nM";"5.08";"";"";"UO_0000065";"13.22";"0.24";"-0.21";"6.30";"False";"CHEMBL3116603";"Inhibition of mTOR (unknown origin) by KINOMEscan assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112406";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3112716";"";"0";"397.48";"0";"2.89";"10";"COc1ccc(-c2cn([C@H]3CC[C@H](OCCO)CC3)c3nc(N)nc(C)c23)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3112708";"";"0";"523.59";"1";"4.41";"9r";"COc1ncc(-c2cc3c(C)nc(N)cc3n(C3CCCC3)c2=O)cc1NS(=O)(=O)c1ccc(F)cc1";"IC50";"'='";"35.02";"nM";"7.46";"";"";"UO_0000065";"14.24";"0.28";"3.05";"5.77";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3112729";"";"0";"541.58";"1";"4.55";"9j";"COc1ncc(-c2cc3c(C)nc(N)cc3n(C3CCCC3)c2=O)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"33.92";"nM";"7.47";"";"";"UO_0000065";"13.79";"0.27";"2.92";"5.78";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL1234354";"PF-04691502";"2";"425.49";"0";"2.25";"PF-04691502";"COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1";"IC50";"'='";"7.9";"nM";"8.10";"";"";"UO_0000065";"19.04";"0.36";"5.85";"6.46";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3112717";"";"0";"397.48";"0";"2.89";"11";"COc1ccc(-c2cc3c(C)nc(N)nc3n2[C@H]2CC[C@H](OCCO)CC2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3263869";"";"0";"449.51";"1";"6.01";"32";"COc1ccc(Oc2cc(C)c(-c3csc(NC(=O)c4ccnc(F)c4)n3)c(C)c2)cc1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3270463";"Inhibition of mTOR (unknown origin) assessed as [33P] incorporation in substrate by TopCount microplate scintillation counting analysis";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3259640";"1";"Scientific Literature";"J. Med. Chem.";"2014";""
"CHEMBL3670140";"";"0";"323.40";"0";"1.78";"BDBM111614";"Cc1ncnc(N2CCOC(C)(C)C2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"105.0";"nM";"6.98";"";"232437";"UO_0000065";"21.58";"0.40";"5.20";"9.04";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670191";"";"0";"357.44";"0";"0.65";"BDBM111666";"CCc1ncnc(N2CCS(=O)(=O)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"12.0";"nM";"7.92";"";"232489";"UO_0000065";"22.16";"0.43";"7.27";"7.76";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL1945954";"";"0";"374.45";"0";"3.76";"44";"O=c1[nH]c2ncc(-c3ccc(-c4ncc[nH]4)cc3)nc2n1CC1CCCCC1";"IC50";"'='";"9.0";"nM";"8.05";"";"";"UO_0000065";"21.49";"0.39";"4.29";"8.72";"False";"CHEMBL1948804";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";""
"CHEMBL3670256";"";"0";"322.37";"0";"0.35";"BDBM111732";"CCc1ncnc(N2CCNC(=O)C2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"45.0";"nM";"7.35";"";"232555";"UO_0000065";"22.79";"0.42";"7.00";"7.57";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3688913";"";"0";"492.58";"0";"2.64";"BDBM174375";"CCOc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1C(N)=O";"IC50";"'='";"2500.0";"nM";"5.60";"";"319692";"UO_0000065";"11.37";"0.21";"2.96";"4.83";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688926";"";"0";"435.53";"0";"2.58";"BDBM174389";"CNc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cn1";"IC50";"'='";"20.0";"nM";"7.70";"";"319706";"UO_0000065";"17.68";"0.33";"5.12";"8.70";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693590";"";"0";"514.53";"1";"2.84";"BDBM174768";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(OC(F)F)c(C(N)=O)c3)nc2n1";"IC50";"'='";"14.0";"nM";"7.85";"";"319709";"UO_0000065";"15.26";"0.29";"5.01";"6.77";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL2336323";"";"0";"528.56";"1";"3.10";"BDBM50429711";"CNC(=O)c1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccc1OC(F)F";"IC50";"'='";"40.0";"nM";"7.40";"";"319710";"UO_0000065";"14.00";"0.27";"4.30";"7.26";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688990";"";"0";"518.66";"1";"3.41";"BDBM174471";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(CNC4CCOCC4)cc3)nc2n1";"IC50";"'='";"1.9";"nM";"8.72";"";"319773";"UO_0000065";"16.81";"0.31";"5.31";"10.28";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688998";"";"0";"518.66";"1";"3.41";"BDBM174479";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(CNC4CCOCC4)c3)nc2n1";"IC50";"'='";"15.0";"nM";"7.82";"";"319780";"UO_0000065";"15.08";"0.28";"4.41";"9.22";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689016";"";"0";"480.59";"0";"3.34";"BDBM174498";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(F)c(CN(C)C)c3)nc2n1";"IC50";"'='";"580.0";"nM";"6.24";"";"319799";"UO_0000065";"12.98";"0.24";"2.90";"9.33";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL1946262";"";"0";"348.41";"0";"3.24";"56";"O=c1[nH]c2ncc(-c3ccc4[nH]cnc4c3)nc2n1CC1CCCCC1";"IC50";"'='";"427.0";"nM";"6.37";"";"";"UO_0000065";"18.28";"0.33";"3.13";"6.90";"False";"CHEMBL1949072";"Inhibition of mTOR-mediated S6 phosphorylation in human PC3 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL1944561";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2011";"CHEMBL3307570"
"CHEMBL3670151";"";"0";"405.55";"0";"3.33";"BDBM111625";"CCc1ncnc(N2CCC(O)(C3CCCCC3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"16.0";"nM";"7.80";"";"232448";"UO_0000065";"19.22";"0.35";"4.47";"8.84";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670160";"";"0";"364.45";"0";"1.52";"BDBM111634";"CCc1ncnc(N2CCC(NC(C)=O)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"19.0";"nM";"7.72";"";"232457";"UO_0000065";"21.19";"0.39";"6.20";"7.96";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670189";"";"0";"348.45";"0";"1.70";"BDBM111664";"CCc1ncnc(N2CCN(C3CC3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"43.0";"nM";"7.37";"";"232487";"UO_0000065";"21.14";"0.39";"5.67";"10.35";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670198";"";"0";"365.44";"0";"1.90";"BDBM111673";"Cc1ncnc(N2CCC3(CC2)OCCCO3)c1C#Cc1ccc(N)nc1";"IC50";"'='";"6.0";"nM";"8.22";"";"232496";"UO_0000065";"22.50";"0.42";"6.32";"9.52";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670255";"";"0";"375.52";"0";"3.97";"BDBM111731";"CCc1ncnc(N2CCC3(CCCCC3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"333.0";"nM";"6.48";"";"232554";"UO_0000065";"17.25";"0.32";"2.51";"9.54";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3290293";"";"0";"422.49";"0";"4.08";"4e";"Cn1cc(-c2ccc3ncc4c(c3c2)n(-c2ccc(C(C)(C)C#N)cc2)c(=O)n4C)cn1";"IC50";"'='";"1175.0";"nM";"5.93";"";"";"UO_0000065";"14.04";"0.25";"1.85";"7.28";"False";"CHEMBL3291527";"Inhibition of human recombinant mTOR assessed as inhibition of 4EBP1 phosphorylation after 30 mins by TR-FRET analysis";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3286093";"1";"Scientific Literature";"J. Med. Chem.";"2014";""
"CHEMBL4066534";"";"0";"429.46";"0";"2.89";"9a";"N#CCN1CCC(n2c(=O)cnc3cnc4cc(F)c(-c5ccc(N)nc5)cc4c32)CC1";"IC50";"'='";"31.0";"nM";"7.51";"";"";"UO_0000065";"17.48";"0.32";"4.62";"6.60";"False";"CHEMBL4023016";"Inhibition of N-terminal FLAG-tagged recombinant human mTOR (1362 to end residues)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020823";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL4060744";"";"0";"411.47";"0";"2.75";"9i";"N#CCN1CCC[C@H](n2c(=O)cnc3cnc4ccc(-c5ccc(N)nc5)cc4c32)C1";"IC50";"'='";"42.0";"nM";"7.38";"";"";"UO_0000065";"17.93";"0.32";"4.63";"6.49";"False";"CHEMBL4023016";"Inhibition of N-terminal FLAG-tagged recombinant human mTOR (1362 to end residues)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020823";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL4069422";"";"0";"397.44";"0";"2.36";"9k";"N#CCN1CCC(n2c(=O)cnc3cnc4ccc(-c5ccc(N)nc5)cc4c32)C1";"IC50";"'='";"12.0";"nM";"7.92";"";"";"UO_0000065";"19.93";"0.36";"5.56";"6.97";"False";"CHEMBL4023016";"Inhibition of N-terminal FLAG-tagged recombinant human mTOR (1362 to end residues)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020823";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL4079272";"";"0";"483.53";"0";"3.53";"5i";"CNC(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)c4cccnc4n3)cc2)cc1";"IC50";"'='";"32.9";"nM";"7.48";"";"";"UO_0000065";"15.48";"0.28";"3.95";"6.17";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL3643232";"";"0";"461.95";"0";"3.33";"BDBM115894";"CCc1ncnc(-c2ccc(C(=O)N3CCC(O)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.8";"nM";"8.55";"";"240506";"UO_0000065";"18.51";"0.35";"5.22";"8.13";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643160";"";"0";"461.95";"0";"3.60";"BDBM115776";"CCc1ncnc(-c2ccc(C(=O)N3CCCOCC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.57";"nM";"8.34";"";"240507";"UO_0000065";"18.05";"0.35";"4.74";"8.85";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643239";"";"0";"443.51";"0";"2.56";"BDBM115904";"CCc1ncnc(-c2ccc(C(=O)N3CCOCC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"6.34";"nM";"8.20";"";"240516";"UO_0000065";"18.48";"0.34";"5.64";"7.92";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643252";"";"0";"505.60";"1";"2.35";"BDBM115917";"CCc1ncnc(-c2ccc(C(=O)N(C)C3CCS(=O)(=O)C3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.84";"nM";"8.31";"";"240529";"UO_0000065";"16.45";"0.32";"5.97";"6.48";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3639421";"";"0";"529.09";"1";"4.83";"BDBM115939";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCCCC4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"6.0";"nM";"8.22";"";"240551";"UO_0000065";"15.54";"0.30";"3.39";"9.32";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645772";"";"0";"413.48";"0";"3.17";"BDBM115950";"CCc1ncnc(-c2ccc(C(=O)N3CCCO3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.42";"nM";"8.62";"";"240562";"UO_0000065";"20.84";"0.38";"5.45";"9.14";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645809";"";"0";"503.61";"1";"3.75";"BDBM115987";"CCc1ncnc(-c2ccc(C(=O)N3CCN(c4ccncc4)CC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"9.55";"nM";"8.02";"";"240599";"UO_0000065";"15.93";"0.29";"4.27";"7.93";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645821";"";"0";"568.65";"1";"2.55";"BDBM115999";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(CCCS(C)(=O)=O)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.54";"nM";"9.27";"";"240611";"UO_0000065";"16.30";"0.32";"6.72";"7.57";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3670220";"";"0";"390.54";"0";"2.73";"BDBM111696";"CCc1ncnc(N2CCC3(CCN(C)CC3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"29.0";"nM";"7.54";"";"232519";"UO_0000065";"19.30";"0.35";"4.81";"10.59";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670226";"";"0";"433.56";"0";"1.54";"BDBM111702";"Cc1ncnc(N2CCC(CC(=O)N3CCN(C)CC3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"366.0";"nM";"6.44";"";"232525";"UO_0000065";"14.85";"0.27";"4.90";"7.04";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3640931";"";"0";"286.34";"0";"2.83";"BDBM115581";"Cc1ncnc(-c2ccccc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"30.0";"nM";"7.52";"";"240218";"UO_0000065";"26.27";"0.47";"4.69";"11.63";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3670197";"";"0";"351.45";"0";"2.42";"BDBM111672";"CCc1ncnc(N2CCC(C)(OC)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.0";"nM";"8.30";"";"232495";"UO_0000065";"23.62";"0.44";"5.88";"10.76";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670264";"";"0";"336.40";"0";"0.69";"BDBM111740";"CCc1ncnc(N2CCN(C)C(=O)C2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"37.0";"nM";"7.43";"";"232563";"UO_0000065";"22.09";"0.41";"6.74";"8.42";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3360082";"";"0";"561.26";"1";"2.46";"10b";"O=S1(=O)CCc2nc(N/N=C/c3cc(Br)c(O)c(Br)c3)nc(N3CCOCC3)c2C1";"IC50";"'='";"6930.0";"nM";"5.16";"";"";"UO_0000065";"9.19";"0.23";"2.70";"4.41";"False";"CHEMBL3371734";"Inhibition of mTOR kinase (unknown origin) after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352220";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2014";""
"CHEMBL3640982";"";"0";"433.49";"0";"2.94";"BDBM115632";"CCc1ncnc(-c2ccc(C(=O)N(C)CCOC)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"240269";"UO_0000065";"20.07";"0.37";"5.76";"9.23";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640994";"";"0";"536.63";"1";"2.64";"BDBM115644";"CCc1ncnc(-c2ccc(C(=O)N3CCN(S(=O)(=O)CC)CC3)c(F)c2)c1C#Cc1ccc(N)nc1C";"IC50";"'='";"9.0";"nM";"8.05";"";"240281";"UO_0000065";"14.99";"0.29";"5.41";"6.57";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640995";"";"0";"445.50";"0";"3.00";"BDBM115645";"CCc1ncnc(-c2ccc(C(=O)N3CCOCC3)c(F)c2)c1C#Cc1ccc(N)nc1C";"IC50";"'='";"8.0";"nM";"8.10";"";"240282";"UO_0000065";"18.17";"0.34";"5.10";"8.59";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3641000";"";"0";"515.64";"1";"2.85";"BDBM115651";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CCN(C)C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1C";"IC50";"'='";"7.0";"nM";"8.15";"";"240288";"UO_0000065";"15.82";"0.29";"5.30";"8.91";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3641006";"";"0";"565.10";"1";"2.68";"BDBM115657";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C4CCS(=O)(=O)C4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.74";"nM";"9.13";"";"240294";"UO_0000065";"16.16";"0.32";"6.45";"7.46";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643062";"";"0";"500.60";"1";"2.50";"BDBM115677";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CCOC)CC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.0";"nM";"9.00";"";"240314";"UO_0000065";"17.98";"0.33";"6.50";"8.43";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643072";"";"0";"527.65";"1";"3.07";"BDBM115687";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCN(C)CC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"240324";"UO_0000065";"16.15";"0.30";"5.45";"9.32";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643087";"";"0";"487.58";"0";"3.85";"BDBM115703";"CCc1ncnc(-c2ccc(C(=O)N3CCC(C(C)(C)O)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.0";"nM";"9.00";"";"240340";"UO_0000065";"18.46";"0.34";"5.15";"8.55";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643088";"";"0";"487.58";"0";"3.99";"BDBM115704";"CCc1ncnc(-c2ccc(C(=O)N(C)CCC3(O)CCCC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.0";"nM";"8.30";"";"240341";"UO_0000065";"17.02";"0.31";"4.31";"7.89";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643097";"";"0";"522.61";"1";"2.33";"BDBM115713";"CCc1ncnc(-c2ccc(C(=O)N3CCN(S(=O)(=O)CC)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.0";"nM";"8.30";"";"240350";"UO_0000065";"15.88";"0.31";"5.97";"6.78";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643128";"";"0";"513.50";"1";"3.75";"BDBM115744";"CCc1ncnc(-c2ccc(C(=O)N3CCC(O)(C(F)(F)F)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"17.0";"nM";"7.77";"";"240381";"UO_0000065";"15.13";"0.29";"4.02";"7.38";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643130";"";"0";"473.55";"0";"3.60";"BDBM115746";"CCc1ncnc(-c2ccc(C(=O)N3CCC(O)(CC)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.0";"nM";"8.40";"";"240383";"UO_0000065";"17.73";"0.33";"4.80";"7.98";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643131";"";"0";"521.60";"1";"4.35";"BDBM115747";"CCc1ncnc(-c2ccc(C(=O)N3CCC(O)(c4ccccc4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"8.0";"nM";"8.10";"";"240384";"UO_0000065";"15.52";"0.28";"3.75";"7.69";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643132";"";"0";"472.57";"0";"3.39";"BDBM115748";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C)C(C)(C)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"13.0";"nM";"7.89";"";"240385";"UO_0000065";"16.69";"0.31";"4.50";"8.94";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643135";"";"0";"500.62";"1";"4.17";"BDBM115751";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C(CC)CC)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"16.0";"nM";"7.80";"";"240388";"UO_0000065";"15.57";"0.29";"3.63";"8.83";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643136";"";"0";"445.50";"0";"2.82";"BDBM115752";"CCc1ncnc(-c2ccc(C(=O)N3CCC[C@@H]3CO)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.0";"nM";"8.30";"";"240389";"UO_0000065";"18.63";"0.34";"5.48";"7.89";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645832";"";"0";"505.98";"1";"4.13";"BDBM116010";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCC4(CC3)COC4)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.53";"nM";"9.28";"";"240622";"UO_0000065";"18.33";"0.35";"5.15";"9.84";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645836";"";"0";"505.00";"1";"3.70";"BDBM116014";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCC4(CC3)CNC4)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.71";"nM";"8.77";"";"240626";"UO_0000065";"17.36";"0.33";"5.07";"9.04";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645841";"";"0";"473.56";"0";"1.86";"BDBM116019";"CCc1ncnc(-c2ccc(C(=O)NCCN3CCNCC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"66.44";"nM";"7.18";"";"240631";"UO_0000065";"15.16";"0.28";"5.32";"6.58";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645845";"";"0";"464.52";"0";"2.99";"BDBM116023";"CCc1ncnc(-c2cc(F)c(C(=O)N(C)CCN(C)C)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.11";"nM";"8.68";"";"240635";"UO_0000065";"18.68";"0.35";"5.69";"9.83";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645861";"";"0";"489.02";"0";"3.97";"BDBM116040";"CCc1ncnc(-c2ccc(C(=O)N3CC[C@@H](N(C)C)C3)c(Cl)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"1.6";"nM";"8.80";"";"240652";"UO_0000065";"17.99";"0.34";"4.83";"11.85";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645865";"";"0";"558.13";"1";"4.05";"BDBM116044";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCN(C)CC4)CC3)c(Cl)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"276.6";"nM";"6.56";"";"240656";"UO_0000065";"11.75";"0.22";"2.51";"8.46";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645867";"";"0";"509.40";"1";"3.30";"BDBM116046";"CCc1ncnc(-c2cc(Cl)c(C(=O)N3CCN(C)C(=O)C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.99";"nM";"8.70";"";"240658";"UO_0000065";"17.08";"0.34";"5.40";"8.26";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645868";"";"0";"509.44";"1";"4.17";"BDBM116047";"CCc1ncnc(-c2cc(Cl)c(C(=O)N3CC[C@@H](N(C)C)C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.28";"nM";"8.28";"";"240659";"UO_0000065";"16.25";"0.32";"4.11";"9.38";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645869";"";"0";"495.41";"0";"3.78";"BDBM116048";"CCc1ncnc(-c2cc(Cl)c(C(=O)N3CCN(C)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.78";"nM";"8.42";"";"240660";"UO_0000065";"17.00";"0.34";"4.64";"9.55";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645875";"";"0";"510.43";"1";"4.38";"BDBM116054";"CCc1ncnc(-c2cc(Cl)c(C(=O)N3CCC(C)(O)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.29";"nM";"8.48";"";"240666";"UO_0000065";"16.62";"0.33";"4.10";"8.06";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645880";"";"0";"490.51";"0";"2.73";"BDBM116059";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(C)C(=O)C3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"2.87";"nM";"8.54";"";"240671";"UO_0000065";"17.41";"0.32";"5.81";"9.35";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645885";"";"0";"505.57";"1";"4.05";"BDBM116064";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCC(C(C)O)CC3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"1.51";"nM";"8.82";"";"240676";"UO_0000065";"17.45";"0.33";"4.77";"9.67";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645893";"";"0";"515.57";"1";"3.49";"BDBM116072";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(CCC#N)CC3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"2.21";"nM";"8.66";"";"240684";"UO_0000065";"16.79";"0.31";"5.17";"8.83";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645899";"";"0";"553.59";"1";"4.60";"BDBM116078";"CCc1ncnc(-c2ccc(C(=O)N3CCC(C(C)(C)O)CC3)c(OC(F)(F)F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"13.28";"nM";"7.88";"";"240690";"UO_0000065";"14.23";"0.27";"3.28";"6.88";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645913";"";"0";"508.00";"1";"4.11";"BDBM116092";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCC(C(C)O)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.25";"nM";"9.60";"";"240704";"UO_0000065";"18.90";"0.36";"5.49";"9.12";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645929";"";"0";"578.71";"1";"3.26";"BDBM116108";"CCNc1ccc(C#Cc2c(CC)ncnc2-c2ccc(C(=O)N3CCN(CCCS(C)(=O)=O)CC3)c(F)c2)cn1";"IC50";"'='";"1.55";"nM";"8.81";"";"240720";"UO_0000065";"15.22";"0.29";"5.55";"8.13";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645943";"";"0";"486.60";"0";"3.64";"BDBM116122";"CCc1ncnc(-c2ccc(C(=O)N3CCC(CN(C)C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"24.53";"nM";"7.61";"";"240734";"UO_0000065";"15.64";"0.29";"3.97";"8.62";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645952";"";"0";"508.00";"1";"2.59";"BDBM116132";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(CCN)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"6.76";"nM";"8.17";"";"240744";"UO_0000065";"16.08";"0.31";"5.58";"7.15";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645954";"";"0";"474.52";"0";"2.75";"BDBM116134";"CCc1ncnc(-c2cc(F)c(C(=O)N3CC4(CN(C)C4)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.8";"nM";"8.42";"";"240746";"UO_0000065";"17.74";"0.33";"5.67";"9.54";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645970";"";"0";"560.03";"1";"4.13";"BDBM116150";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(Cc4cc(C)no4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.26";"nM";"8.90";"";"240762";"UO_0000065";"15.89";"0.30";"4.77";"7.79";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645976";"";"0";"553.04";"1";"2.64";"BDBM116156";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(CCOCCO)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.76";"nM";"9.12";"";"240768";"UO_0000065";"16.49";"0.32";"6.48";"7.75";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645977";"";"0";"533.99";"1";"3.84";"BDBM116157";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCC4(CC3)CC(=O)CO4)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.52";"nM";"9.28";"";"240769";"UO_0000065";"17.39";"0.33";"5.44";"8.34";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645983";"";"0";"505.02";"1";"2.88";"BDBM116163";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CC(C)O)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.23";"nM";"8.65";"";"240775";"UO_0000065";"17.13";"0.33";"5.77";"7.98";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3648866";"";"0";"500.58";"1";"2.82";"BDBM116172";"CCc1ncnc(-c2ccc(C(=O)N3CCOC4(CCNCC4)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"11.42";"nM";"7.94";"";"240784";"UO_0000065";"15.87";"0.29";"5.12";"7.47";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3648872";"";"0";"456.53";"0";"2.66";"BDBM116178";"CCc1ncnc(-c2ccc(C(=O)N3C[C@@H]4CCN[C@@H]4C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"26.53";"nM";"7.58";"";"240790";"UO_0000065";"16.60";"0.30";"4.92";"7.81";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3648874";"";"0";"472.98";"0";"3.12";"BDBM116180";"CCc1ncnc(-c2ccc(C(=O)N3CC4(CN(C)C4)C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"6.07";"nM";"8.22";"";"240792";"UO_0000065";"17.37";"0.33";"5.10";"9.31";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3648878";"";"0";"501.03";"1";"3.90";"BDBM116184";"CCc1ncnc(-c2ccc(C(=O)N3CCC4(CC3)CN(C)C4)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.85";"nM";"8.31";"";"240796";"UO_0000065";"16.59";"0.32";"4.41";"9.42";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3648885";"";"0";"518.59";"1";"1.99";"BDBM116191";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CCOCCO)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.15";"nM";"8.94";"";"240803";"UO_0000065";"17.24";"0.32";"6.95";"7.59";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3670162";"";"0";"337.43";"0";"1.77";"BDBM111636";"CCc1ncnc(N2CCC(C)(O)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"7.0";"nM";"8.15";"";"232459";"UO_0000065";"24.17";"0.45";"6.38";"9.25";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670142";"";"0";"327.41";"0";"0.73";"BDBM111616";"Cc1ncnc(N2CC[S+]([O-])CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"83.0";"nM";"7.08";"";"232439";"UO_0000065";"21.63";"0.42";"6.35";"8.33";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670196";"";"0";"293.37";"0";"2.02";"BDBM111671";"CCc1ncnc(N2CCCC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"42.0";"nM";"7.38";"";"232494";"UO_0000065";"25.14";"0.46";"5.36";"10.86";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670215";"";"0";"359.44";"0";"1.94";"BDBM111691";"CCc1ncnc(N2CCn3c(C)cnc3C2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"31.0";"nM";"7.51";"";"232514";"UO_0000065";"20.89";"0.38";"5.57";"8.76";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670171";"";"0";"377.37";"0";"2.06";"BDBM111645";"Cc1ncnc(N2CCC(O)(C(F)(F)F)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"232468";"UO_0000065";"22.58";"0.43";"6.46";"9.67";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670193";"";"0";"366.47";"0";"1.18";"BDBM111668";"CCc1ncnc(N2CCN(CCOC)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"26.0";"nM";"7.58";"";"232491";"UO_0000065";"20.70";"0.38";"6.41";"9.43";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670199";"";"0";"379.46";"0";"2.15";"BDBM111674";"CCc1ncnc(N2CCC3(CC2)OCCCO3)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.0";"nM";"8.40";"";"232497";"UO_0000065";"22.13";"0.41";"6.25";"9.72";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3643159";"";"0";"462.94";"0";"2.88";"BDBM115775";"CCc1ncnc(-c2ccc(C(=O)N3CCN(O)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"240412";"UO_0000065";"18.41";"0.35";"5.64";"7.86";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643160";"";"0";"461.95";"0";"3.60";"BDBM115776";"CCc1ncnc(-c2ccc(C(=O)N3CCCOCC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.0";"nM";"8.30";"";"240413";"UO_0000065";"17.97";"0.34";"4.70";"8.81";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643169";"";"0";"442.52";"0";"1.58";"BDBM115810";"Cc1ncnc(-c2ccc(C(=O)N3CCN(CCO)CC3)cc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"240422";"UO_0000065";"19.26";"0.35";"6.94";"7.86";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643179";"";"0";"515.59";"1";"2.49";"BDBM115822";"CCc1ncnc(-c2ccc(C(=O)NC3CC(N4CCN(O)CC4)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"13.0";"nM";"7.89";"";"240434";"UO_0000065";"15.30";"0.28";"5.40";"6.54";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643199";"";"0";"403.42";"0";"2.75";"BDBM115842";"Cc1ncnc(-c2ccc(C(=O)N3CCCO3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"10.0";"nM";"8.00";"";"240454";"UO_0000065";"19.83";"0.36";"5.25";"8.49";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643216";"";"0";"476.53";"0";"3.14";"BDBM115859";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(CC)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.24";"nM";"8.65";"";"240471";"UO_0000065";"18.15";"0.34";"5.51";"9.80";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643217";"";"0";"490.56";"0";"3.53";"BDBM115860";"CCCN1CCN(C(=O)c2c(F)cc(-c3ncnc(CC)c3C#Cc3ccc(N)nc3)cc2F)CC1";"IC50";"'='";"2.14";"nM";"8.67";"";"240472";"UO_0000065";"17.67";"0.33";"5.14";"9.83";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643221";"";"0";"504.59";"1";"3.92";"BDBM115864";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(C(C)(C)C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"7.52";"nM";"8.12";"";"240476";"UO_0000065";"16.10";"0.30";"4.20";"9.21";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643231";"";"0";"529.09";"1";"4.68";"BDBM115882";"CCc1ncnc(-c2ccc(C(=O)N3CCC4(CCN(C)CC4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"32.11";"nM";"7.49";"";"240494";"UO_0000065";"14.16";"0.27";"2.81";"8.49";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643155";"";"0";"446.94";"0";"2.78";"BDBM115771";"CCc1ncnc(-c2ccc(C(=O)N3CCNCC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"7.85";"nM";"8.11";"";"240502";"UO_0000065";"18.13";"0.35";"5.33";"8.35";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643267";"";"0";"529.09";"1";"4.68";"BDBM115932";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCC(C)CC4)C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.78";"nM";"8.75";"";"240544";"UO_0000065";"16.54";"0.31";"4.07";"9.92";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643278";"";"0";"510.64";"1";"3.33";"BDBM115944";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C4CCOCC4)CC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.57";"nM";"8.80";"";"240556";"UO_0000065";"17.24";"0.32";"5.47";"9.03";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645801";"";"0";"427.51";"0";"2.60";"BDBM115979";"CCc1ncnc(-c2ccc(C(=O)N3CC[C@H](O)C3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"8.91";"nM";"8.05";"";"240591";"UO_0000065";"18.83";"0.34";"5.45";"7.65";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3670212";"";"0";"376.46";"0";"1.61";"BDBM111688";"Cc1ncnc(N2CCC3(CCN(C)C3=O)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"10.0";"nM";"8.00";"";"232511";"UO_0000065";"21.25";"0.39";"6.39";"9.07";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670229";"";"0";"378.48";"0";"1.90";"BDBM111705";"CCNC(=O)CC1CCN(c2ncnc(C)c2C#Cc2ccc(N)nc2)CC1";"IC50";"'='";"58.0";"nM";"7.24";"";"232528";"UO_0000065";"19.12";"0.35";"5.34";"7.46";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL2418339";"";"0";"395.47";"0";"2.40";"11a";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)c3c(ncn3C)n2)cc1";"IC50";"'='";"2200.0";"nM";"5.66";"";"";"UO_0000065";"14.31";"0.27";"3.26";"5.82";"False";"CHEMBL2421122";"Inhibition of mTOR in PTEN deficient human PC3 cells assessed as inhibition of p70S6K phosphorylation";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2417437";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";"CHEMBL3307570"
"CHEMBL2418347";"";"0";"408.51";"0";"3.39";"16";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3CC)c3c(ccn3C)n2)cc1";"IC50";"'='";"11.0";"nM";"7.96";"";"";"UO_0000065";"19.48";"0.36";"4.57";"9.44";"False";"CHEMBL2421123";"Inhibition of mTOR in PTEN deficient human PC3 cells assessed as inhibition of Akt phosphorylation at Ser473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2417437";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";"CHEMBL3307570"
"CHEMBL3701090";"";"0";"432.50";"0";"3.55";"BDBM172225";"CCc1nccc(-c2ccc(C(=O)N(C)CCOC)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"317149";"UO_0000065";"19.71";"0.36";"4.97";"10.48";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701137";"";"0";"404.90";"0";"4.01";"BDBM172272";"CCc1nccc(-c2ccc(Cl)c(C(=O)NC)c2)c1C#Cc1ccc(N)nc1C";"IC50";"'='";"77.0";"nM";"7.11";"";"317196";"UO_0000065";"17.57";"0.34";"3.10";"8.79";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701152";"";"0";"471.58";"0";"3.91";"BDBM172287";"CCc1nccc(-c2ccc(C(=O)N3CCN(CC)CC3)c(F)c2)c1C#Cc1ccc(N)nc1C";"IC50";"'='";"38.0";"nM";"7.42";"";"317211";"UO_0000065";"15.73";"0.29";"3.51";"9.85";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701065";"";"0";"437.55";"0";"3.35";"BDBM172199";"Cc1nccc(-c2ccc(C(=O)N3CCN(C4CC4)CC3)cc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"8.0";"nM";"8.10";"";"317123";"UO_0000065";"18.51";"0.34";"4.75";"10.75";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701066";"";"0";"356.43";"0";"3.14";"BDBM172200";"Cc1nccc(-c2ccc(C(=O)N(C)C)cc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"317124";"UO_0000065";"23.91";"0.43";"5.38";"11.82";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701069";"";"0";"314.39";"0";"3.39";"BDBM172203";"CCc1nccc(-c2ccnc(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"10.0";"nM";"8.00";"";"317127";"UO_0000065";"25.45";"0.46";"4.61";"12.37";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701122";"";"0";"428.54";"0";"2.85";"BDBM172257";"Cc1nccc(-c2ccc(C(=O)N(C)CCCN(C)C)nc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"105.0";"nM";"6.98";"";"317181";"UO_0000065";"16.29";"0.30";"4.13";"7.91";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701130";"";"0";"458.54";"0";"3.81";"BDBM172265";"CCc1nccc(-c2ccc(C(=O)N3CCC(C)(O)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"317189";"UO_0000065";"18.97";"0.35";"4.89";"9.42";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701057";"";"0";"300.37";"0";"3.14";"BDBM172191";"Cc1cc(-c2ccnc(C)c2C#Cc2ccc(N)nc2)ccn1";"IC50";"'='";"236.0";"nM";"6.63";"";"317115";"UO_0000065";"22.06";"0.39";"3.49";"10.24";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701067";"";"0";"398.47";"0";"2.91";"BDBM172201";"Cc1nccc(-c2ccc(C(=O)N3CCOCC3)cc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"7.0";"nM";"8.15";"";"317125";"UO_0000065";"20.47";"0.37";"5.24";"10.03";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701116";"";"0";"471.58";"0";"3.99";"BDBM172251";"Cc1nccc(-c2ccc(F)c(C(=O)N(C)CC3CCN(C)CC3)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"69.0";"nM";"7.16";"";"317175";"UO_0000065";"15.19";"0.28";"3.17";"9.50";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701126";"";"0";"418.47";"0";"3.20";"BDBM172261";"CCc1nccc(-c2ccc(C(=O)NCCOC)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"7.0";"nM";"8.15";"";"317185";"UO_0000065";"19.49";"0.36";"4.95";"9.05";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688957";"";"0";"449.56";"0";"2.49";"BDBM174434";"C[C@H]1COCCN1c1nc(N2CCC(CCO)CC2)nc2nc(-c3ccc(N)nc3)ccc12";"IC50";"'='";"200.0";"nM";"6.70";"";"319738";"UO_0000065";"14.90";"0.28";"4.21";"5.90";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693402";"";"0";"544.58";"1";"3.66";"BDBM174543";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(CN(C)C(=O)C(F)(F)F)c3)nc2n1";"IC50";"'='";"640.0";"nM";"6.19";"";"319839";"UO_0000065";"11.37";"0.22";"2.53";"7.38";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693432";"";"0";"512.64";"1";"2.54";"BDBM174581";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(N(C)S(C)(=O)=O)c3)nc2n1";"IC50";"'='";"370.0";"nM";"6.43";"";"319870";"UO_0000065";"12.55";"0.24";"3.89";"6.37";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693441";"";"0";"449.52";"0";"1.64";"BDBM174591";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccnc(C(N)=O)c3)nc2n1";"IC50";"'='";"190.0";"nM";"6.72";"";"319880";"UO_0000065";"14.95";"0.28";"5.08";"5.62";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693469";"";"0";"521.62";"1";"3.20";"BDBM174631";"CCOC(=O)C1CCN(c2nc(N3CCOC[C@@H]3C)c3ccc(-c4ccc(OC)c(CO)c4)nc3n2)CC1";"IC50";"'='";"73.0";"nM";"7.14";"";"319909";"UO_0000065";"13.68";"0.26";"3.94";"6.48";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688936";"";"0";"460.54";"0";"2.39";"BDBM174413";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc4c(c3)C(=O)NC4)nc2n1";"IC50";"'='";"2.6";"nM";"8.59";"";"319717";"UO_0000065";"18.64";"0.34";"6.20";"9.26";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688941";"";"0";"460.54";"0";"2.64";"BDBM174418";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc4c(c3)NC(=O)C4)nc2n1";"IC50";"'='";"3.5";"nM";"8.46";"";"319722";"UO_0000065";"18.36";"0.34";"5.82";"9.12";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693396";"";"0";"490.61";"0";"3.12";"BDBM174537";"CC(=O)N(C)Cc1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"190.0";"nM";"6.72";"";"319833";"UO_0000065";"13.70";"0.25";"3.60";"8.01";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693443";"";"0";"435.53";"0";"2.58";"BDBM174593";"CNc1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccn1";"IC50";"'='";"110.0";"nM";"6.96";"";"319882";"UO_0000065";"15.98";"0.30";"4.38";"7.86";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693444";"";"0";"479.54";"0";"2.85";"BDBM174595";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1C(=O)O";"IC50";"'='";"0.15";"nM";"9.82";"";"319883";"UO_0000065";"20.49";"0.38";"6.97";"8.92";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688832";"";"0";"421.50";"0";"2.85";"BDBM174290";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(O)cc3)nc2n1";"IC50";"'='";"4.4";"nM";"8.36";"";"319605";"UO_0000065";"19.83";"0.37";"5.51";"9.97";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688859";"";"0";"424.48";"0";"2.68";"BDBM174318";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(F)nc3)nc2n1";"IC50";"'='";"12.0";"nM";"7.92";"";"319634";"UO_0000065";"18.66";"0.35";"5.24";"10.35";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3793049";"";"0";"500.99";"1";"4.60";"10";"O=C(Nc1ccc(F)c(Cl)c1)Nc1ccc(-c2nc3c(c(N4CCOCC4)n2)CSCC3)cn1";"IC50";"'='";"860.0";"nM";"6.07";"";"";"UO_0000065";"12.11";"0.24";"1.47";"6.57";"False";"CHEMBL3795347";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide substrate incubated for 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3792291";"1";"Scientific Literature";"Eur. J. Med. Chem.";"2016";""
"CHEMBL3939369";"";"0";"393.90";"0";"3.11";"BDBM222559";"CNC(=O)Nc1ccc(-c2nc(Cl)c(SC)c(N3CCOCC3)n2)cc1";"IC50";"'='";"116.4";"nM";"6.93";"";"389348";"UO_0000065";"17.60";"0.36";"3.82";"8.74";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3979215";"";"0";"594.64";"1";"4.18";"BDBM222568";"CCOC(=O)c1nc(-c2ccc(NC(=O)Nc3ccc(N4CCOCC4)c(F)c3)cc2)nc(N2CCOCC2)c1OCC";"IC50";"'='";"134.6";"nM";"6.87";"";"389357";"UO_0000065";"11.55";"0.22";"2.69";"5.39";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3922962";"";"0";"520.66";"1";"3.49";"BDBM222593";"CSc1cnc(-c2ccc(NC(=O)Nc3ccc(N4CCN(C)CC4)nc3)cc2)nc1N1CCOCC1";"IC50";"'='";"256.7";"nM";"6.59";"";"389382";"UO_0000065";"12.66";"0.24";"3.10";"6.67";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3976536";"";"0";"512.98";"1";"4.43";"BDBM222624";"CSc1c(Cl)nc(-c2ccc(NC(=O)Nc3ccc4oc(=O)[nH]c4c3)cc2)nc1N1CCOCC1";"IC50";"'='";"202.4";"nM";"6.69";"";"389413";"UO_0000065";"13.05";"0.26";"2.26";"5.34";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3896258";"";"0";"379.87";"0";"2.85";"BDBM222547";"CSc1c(Cl)nc(-c2ccc(NC(N)=O)cc2)nc1N1CCOCC1";"IC50";"'='";"107.2";"nM";"6.97";"";"389336";"UO_0000065";"18.35";"0.38";"4.12";"7.46";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3985605";"";"0";"519.68";"1";"4.10";"BDBM222583";"CSc1cnc(-c2ccc(NC(=O)Nc3ccc(N4CCN(C)CC4)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"228.1";"nM";"6.64";"";"389372";"UO_0000065";"12.78";"0.25";"2.54";"7.74";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3972538";"";"0";"534.57";"1";"3.30";"BDBM222587";"CCOC(=O)c1nc(-c2ccc(NC(=O)Nc3cccc(C(N)=O)c3)cc2)nc(N2CCOCC2)c1OCC";"IC50";"'='";"146.1";"nM";"6.83";"";"389376";"UO_0000065";"12.79";"0.24";"3.54";"4.33";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3934648";"";"0";"582.13";"1";"4.39";"BDBM222596";"CSc1c(Cl)nc(-c2ccc(NC(=O)Nc3ccc(C(=O)N4CCN(C)CC4)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"89.6";"nM";"7.05";"";"389385";"UO_0000065";"12.11";"0.24";"2.66";"6.85";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3904660";"";"0";"477.40";"0";"3.91";"BDBM236556";"CC(=O)c1ccc(-c2ccc3ncc4c(=O)[nH]c(=O)n(-c5cccc(C(F)(F)F)c5)c4c3n2)cn1";"IC50";"'='";"57.0";"nM";"7.24";"";"412060";"UO_0000065";"15.17";"0.28";"3.33";"6.55";"False";"CHEMBL3888698";"mTOR Enzymatic Assay: Agents: 1-fold kinase buffer: 50 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 3 mM MnCl2, 0.01% Tween-20, 2 mM DTT. 4-fold kinase solution: mTOR kinase was added to 1-fold kinase buffer to form 4-fold kinase solution with a final concentration of 2.5 nM. 2-fold substrate and ATP solution: the substrate 4EBP1 and ATP were added to 1-fold kinase buffer to form 2-fold substrate solution with final concentration of 50 nM of 4EBP1 and 10.8 ¿M of ATP. 4-fold test substance solutions: 100-fold test substance solutions in different gradient concentrations were formulated with 100% DMSO, and diluted by 25 folds with 1-fold kinase buffer to form 4-fold test substance solutions in different gradient concentrations. Detection solution: a detection solution containing 2-fold final concentrations of EDTA and 4EBP1 phosphorylated antibody was formulated, wherein the final concentration for EDTA was 8 mM, and the final concentration for the 4EBP phosphorylated antibody was 2 nM. Procedure: To each well of a 384-well plate was added 2.5 ¿L of the 4-fold test substance solutions in gradient concentrations. The replication was made. To each well was added 2.5 ¿L of 4-fold kinase solution, and then the plate was incubated for 10 mins. Then to each well was added 5 ¿L/of 2-fold substrate and ATP solution, and then the plate was incubated at room temperature for 1 hour. Finally, 10 ¿L of the detection solution was added to terminate the reaction. After 60 mins, the data Lance signal (665 nM) was read from Envision.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886794";"37";"BindingDB Database";"";"2016";""
"CHEMBL4115047";"";"0";"493.58";"0";"4.16";"BDBM245538";"CO[C@@H]1CC[C@@H](n2c(=O)n(C)c3cnc4ccc(-c5ccc(OCCCN(C)C)nc5F)cc4c32)C1";"IC50";"'='";"3180.0";"nM";"5.50";"";"427949";"UO_0000065";"11.14";"0.21";"1.34";"7.39";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL573339";"PI-103";"0";"348.36";"0";"2.98";"PI-103";"Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1";"IC50";"'='";"19.0";"nM";"7.72";"";"";"UO_0000065";"22.16";"0.41";"4.74";"9.14";"True";"CHEMBL3414045";"Inhibition of mTOR kinase (unknown origin) using ULight-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407441";"1";"Scientific Literature";"Eur. J. Med. Chem.";"2015";""
"CHEMBL3952396";"";"0";"514.67";"1";"4.98";"BDBM245544";"CO[C@H]1CC[C@H](n2c(=O)n(C)c3cnc4ccc(-c5ccc(NCCCN6CCCCC6)nc5)cc4c32)C1";"IC50";"'='";"6340.0";"nM";"5.20";"";"427946";"UO_0000065";"10.10";"0.19";"0.22";"6.73";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3970378";"";"0";"471.61";"0";"4.93";"BDBM245529";"Cn1c(=O)n(C2CCC2)c2c3cc(-c4ccc(OCCCN5CCCCC5)nc4)ccc3ncc21";"IC50";"'='";"5770.0";"nM";"5.24";"";"427939";"UO_0000065";"11.11";"0.20";"0.31";"8.04";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL4110135";"";"0";"487.60";"0";"4.17";"BDBM245531";"Cn1c(=O)n([C@@H]2CCCOC2)c2c3cc(-c4ccc(OCCCN5CCCC5)nc4)ccc3ncc21";"IC50";"'='";"610.0";"nM";"6.21";"";"427941";"UO_0000065";"12.75";"0.24";"2.04";"8.35";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3688960";"";"0";"476.58";"0";"2.84";"BDBM174437";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(C(=O)N(C)C)c3)nc2n1";"IC50";"'='";"90.0";"nM";"7.05";"";"319741";"UO_0000065";"14.78";"0.27";"4.21";"8.40";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689002";"";"0";"485.59";"0";"3.39";"BDBM174483";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(Cn4ccnc4)c3)nc2n1";"IC50";"'='";"130.0";"nM";"6.89";"";"319784";"UO_0000065";"14.18";"0.26";"3.50";"8.46";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689003";"";"0";"504.64";"1";"2.71";"BDBM174484";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(CN4CC[C@@H](O)C4)c3)nc2n1";"IC50";"'='";"40.0";"nM";"7.40";"";"319785";"UO_0000065";"14.66";"0.27";"4.69";"8.50";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693468";"";"0";"463.58";"0";"3.65";"BDBM174630";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCC(C)CC4)nc3n2)cc1CO";"IC50";"'='";"54.0";"nM";"7.27";"";"319908";"UO_0000065";"15.68";"0.29";"3.62";"8.67";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693475";"";"0";"509.56";"2";"1.53";"BDBM174637";"COC(=O)[C@@H]1C[C@@H](O)CN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(OC)c(CO)c3)nc2n1";"IC50";"'='";"19.0";"nM";"7.72";"";"319915";"UO_0000065";"15.15";"0.29";"6.19";"5.92";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3426225";"";"0";"576.63";"1";"4.16";"1j";"CCn1nc(C#Cc2cc(C(=O)Nc3ccc(CN4CCN(C)CC4)c(C(F)(F)F)c3)ccc2C)c2c(N)ncnc21";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3430006";"Inhibition of human mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3425429";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3701142";"";"0";"469.56";"0";"3.75";"BDBM172277";"CCc1nccc(-c2ccc(C(=O)N3CCN4CCCC4C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"317201";"UO_0000065";"18.15";"0.33";"4.77";"11.31";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701143";"";"0";"515.63";"1";"4.01";"BDBM172278";"CCc1nccc(-c2ccc(C(=O)N3CC(C)N(CCOC)C(C)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"9.0";"nM";"8.05";"";"317202";"UO_0000065";"15.60";"0.29";"4.04";"9.51";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701146";"";"0";"471.58";"0";"3.99";"BDBM172281";"CCc1nccc(-c2ccc(C(=O)N3CCN(C)C(C)(C)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"9.0";"nM";"8.05";"";"317205";"UO_0000065";"17.06";"0.31";"4.06";"10.68";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701058";"";"0";"483.59";"0";"4.27";"BDBM172192";"Cc1nccc(-c2ccc(C(=O)N3CCN(C4CCCC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.0";"nM";"8.30";"";"317116";"UO_0000065";"17.17";"0.31";"4.03";"11.02";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701070";"";"0";"390.87";"0";"3.70";"BDBM172204";"CCc1nccc(-c2ccc(C(=O)NC)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.0";"nM";"8.30";"";"317128";"UO_0000065";"21.24";"0.40";"4.60";"10.26";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701075";"";"0";"368.36";"0";"4.10";"BDBM172209";"CCc1nccc(-c2ccc(C(F)(F)F)nc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"26.0";"nM";"7.58";"";"317133";"UO_0000065";"20.59";"0.38";"3.49";"11.73";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701085";"";"0";"469.59";"0";"3.47";"BDBM172219";"CCc1nccc(-c2ccc(C(=O)N3CCN(CC)CC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"32.0";"nM";"7.50";"";"317143";"UO_0000065";"15.96";"0.29";"4.02";"8.86";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693433";"";"0";"434.54";"0";"3.23";"BDBM174582";"Cc1ccc(-c2cnc3c(N4CCOC[C@@H]4C)nc(N4C[C@H](C)O[C@H](C)C4)nc3n2)cc1";"IC50";"'='";"214.7";"nM";"6.67";"";"319872";"UO_0000065";"15.35";"0.28";"3.44";"8.72";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693436";"";"0";"355.83";"0";"3.27";"BDBM174585";"Cc1ccc(-c2cnc3c(N4CCOC[C@@H]4C)nc(Cl)nc3n2)cc1";"IC50";"'='";"541.4";"nM";"6.27";"";"319875";"UO_0000065";"17.61";"0.34";"3.00";"9.79";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL573339";"PI-103";"0";"348.36";"0";"2.98";"PI-103";"Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1";"IC50";"'='";"16.0";"nM";"7.80";"";"";"UO_0000065";"22.38";"0.41";"4.82";"9.22";"False";"CHEMBL3772928";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3769354";"1";"Scientific Literature";"Eur. J. Med. Chem.";"2016";""
"CHEMBL4082858";"";"0";"452.56";"0";"3.50";"10h";"CCNC(=O)Nc1ccc(-c2cc(N3CCOC[C@@H]3C)c3ncn(CCOCC)c3n2)cc1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL4056088";"Inhibition of mTOR (unknown origin) by Kinase-Glo plus luminescence kinase assay or and ADP-Glo Plus luminescence kinase assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052688";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL4115012";"";"0";"447.54";"0";"3.34";"BDBM227502";"C[C@H]1CN(c2nc(N3CCOC[C@H]3C)c3nc(-c4cccc5[nH]ccc45)[nH]c3n2)C[C@@H](C)O1";"IC50";"'='";"78.0";"nM";"7.11";"";"397261";"UO_0000065";"15.88";"0.29";"3.77";"7.47";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL3701159";"";"0";"326.40";"0";"3.71";"BDBM172294";"Cc1nccc(-c2ccc(C3CC3)nc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"37.0";"nM";"7.43";"";"317218";"UO_0000065";"22.77";"0.41";"3.72";"11.49";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL4109093";"";"0";"459.55";"0";"3.22";"BDBM227493";"C[C@@H]1COCCN1c1nc(N2C3CCC2CC(O)C3)nc2[nH]c(-c3cccc4[nH]ccc34)nc12";"IC50";"'='";"76.0";"nM";"7.12";"";"397252";"UO_0000065";"15.49";"0.29";"3.90";"6.70";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL3646544";"";"0";"521.61";"2";"2.27";"BDBM125396";"COc1ccc(Nc2ncc(C(N)c3ccc(S(=O)(=O)N(C)C)cc3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255127";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3618233";"";"0";"366.36";"0";"2.36";"6";"COc1ncc(Nc2nc3ccccn3c2-c2nc(C)nc(N)n2)cc1F";"IC50";"'='";"198.0";"nM";"6.70";"";"";"UO_0000065";"18.30";"0.34";"4.34";"5.77";"False";"CHEMBL3620381";"Inhibition of GST-tagged mTOR (1360 to 2549 residues) (unknown origin) using Ulight 4eBP1 peptide incubated for 90 mins by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3616407";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2015";""
"CHEMBL3618239";"";"0";"432.49";"1";"1.63";"12";"COc1ccc(Nc2nc3ccc(N4CCNCC4)cn3c2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"20.0";"nM";"7.70";"";"";"UO_0000065";"17.80";"0.33";"6.07";"5.86";"False";"CHEMBL3620381";"Inhibition of GST-tagged mTOR (1360 to 2549 residues) (unknown origin) using Ulight 4eBP1 peptide incubated for 90 mins by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3616407";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2015";""
"CHEMBL3670200";"";"0";"321.38";"0";"1.59";"BDBM111675";"CCc1ncnc(N2CCC(=O)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"28.0";"nM";"7.55";"";"232498";"UO_0000065";"23.50";"0.43";"5.96";"8.89";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3645781";"";"0";"468.61";"0";"3.56";"BDBM115959";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N(C)C)CC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.23";"nM";"8.49";"";"240571";"UO_0000065";"18.12";"0.33";"4.93";"9.62";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645784";"";"0";"518.64";"1";"2.50";"BDBM115962";"CCc1ncnc(-c2ccc(C(=O)N3CCN(S(=O)(=O)CC)CC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.48";"nM";"8.61";"";"240574";"UO_0000065";"16.59";"0.32";"6.11";"7.03";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645791";"";"0";"522.70";"1";"4.73";"BDBM115969";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CC4CCCCC4)CC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.23";"nM";"8.91";"";"240581";"UO_0000065";"17.05";"0.31";"4.18";"10.10";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645817";"";"0";"470.55";"0";"3.14";"BDBM115995";"CCc1ncnc(-c2ccc(C(=O)N3CCN4CCC[C@H]4C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.15";"nM";"8.94";"";"240607";"UO_0000065";"19.00";"0.35";"5.80";"10.13";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645819";"";"0";"484.58";"0";"3.53";"BDBM115997";"CCc1ncnc(-c2ccc(C(=O)N3CCN4CCCC[C@H]4C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.45";"nM";"8.26";"";"240609";"UO_0000065";"17.05";"0.31";"4.73";"9.36";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645826";"";"0";"569.64";"1";"1.67";"BDBM116004";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(CCNS(C)(=O)=O)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.89";"nM";"9.05";"";"240616";"UO_0000065";"15.89";"0.31";"7.38";"6.73";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646543";"";"0";"522.59";"2";"2.30";"BDBM125395";"COc1ccc(Nc2ncc(C(O)c3ccc(S(=O)(=O)N(C)C)cc3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"4767.0";"nM";"5.32";"";"255126";"UO_0000065";"10.18";"0.20";"3.02";"3.14";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646554";"";"0";"387.41";"0";"2.43";"BDBM125407";"COc1ccc(Nc2ncc(-c3ccnnc3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255142";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3618244";"";"0";"406.45";"0";"2.45";"17";"COc1ccc(Nc2nc3ccc(C(C)(C)O)cn3c2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"36.0";"nM";"7.44";"";"";"UO_0000065";"18.31";"0.34";"4.99";"5.46";"False";"CHEMBL3620381";"Inhibition of GST-tagged mTOR (1360 to 2549 residues) (unknown origin) using Ulight 4eBP1 peptide incubated for 90 mins by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3616407";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2015";""
"CHEMBL2170089";"";"0";"531.62";"2";"2.14";"BDBM50396819";"COc1ncc(Nc2ncc([C@H](C)N3CCN(S(C)(=O)=O)C[C@@H]3C)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255161";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3357869";"";"0";"383.39";"0";"2.09";"BDBM125443";"COc1ncc(Nc2ncc(C3(O)CC3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'='";"242.0";"nM";"6.62";"";"255187";"UO_0000065";"17.26";"0.32";"4.53";"5.01";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646603";"";"0";"571.56";"2";"2.12";"BDBM125459";"COc1ncc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3C(F)(F)F)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255204";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3358285";"";"0";"415.48";"0";"1.59";"BDBM125491";"Cc1nc(N)nc(-c2cc(C(C)(C)O)cnc2Nc2cncc(S(C)(=O)=O)c2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255246";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646633";"";"0";"518.05";"1";"2.64";"BDBM125497";"Cc1nc(N)nc(-c2cc([C@@H](C)N3CCN(S(C)(=O)=O)C[C@@H]3C)cnc2Nc2ccc(Cl)nc2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255254";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649468";"";"0";"460.52";"1";"1.67";"BDBM125507";"COCCOc1cnc(Nc2cnc(C)c(NS(C)(=O)=O)c2)c(-c2nc(C)nc(N)n2)c1";"IC50";"'='";"1942.0";"nM";"5.71";"";"255267";"UO_0000065";"12.40";"0.24";"4.04";"3.42";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649469";"";"0";"386.44";"0";"1.64";"BDBM125508";"Cc1nc(N)nc(-c2cccnc2Nc2cnc(C)c(NS(C)(=O)=O)c2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255268";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646466";"";"0";"393.46";"0";"2.72";"BDBM125308";"COc1ccc(Nc2nc(NC3CCCC3)ncc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255026";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2170099";"";"0";"517.59";"2";"1.75";"BDBM50396809";"COc1ncc(Nc2ncc([C@H](C)N3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255047";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2170081";"";"0";"517.59";"2";"1.75";"BDBM50396808";"COc1ncc(Nc2ncc([C@@H](C)N3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255048";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3639454";"";"0";"471.55";"1";"0.70";"BDBM125392";"COc1ccc(Nc2ncc(CN3CC(NS(C)(=O)=O)C3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"3739.0";"nM";"5.43";"";"255123";"UO_0000065";"11.51";"0.22";"4.73";"3.37";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646596";"";"0";"530.63";"1";"2.74";"BDBM125451";"COc1ncc(Nc2ncc([C@@H](C)N3CCN(S(C)(=O)=O)C[C@@H]3C)cc2-c2cc(N)nc(C)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255195";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2206907";"";"0";"490.98";"0";"2.88";"BDBM50401253";"Cc1nc(N)nc(-c2cc(C3CCOCC3)cnc2Nc2cnc(Cl)c(NS(C)(=O)=O)c2)n1";"IC50";"'='";"26.0";"nM";"7.58";"";"255219";"UO_0000065";"15.45";"0.31";"4.71";"4.80";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2206906";"";"0";"480.94";"1";"2.01";"BDBM50401254";"COCCOc1cnc(Nc2cnc(Cl)c(NS(C)(=O)=O)c2)c(-c2nc(C)nc(N)n2)c1";"IC50";"'='";"51.0";"nM";"7.29";"";"255226";"UO_0000065";"15.16";"0.31";"5.28";"4.36";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646615";"";"0";"476.52";"1";"1.37";"BDBM125472";"COCCOc1cnc(Nc2cnc(OC)c(NS(C)(=O)=O)c2)c(-c2nc(C)nc(N)n2)c1";"IC50";"'='";"1416.0";"nM";"5.85";"";"255227";"UO_0000065";"12.27";"0.24";"4.48";"3.32";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2206919";"";"0";"420.89";"0";"2.30";"BDBM50401263";"Cc1nc(N)nc(-c2cc(Cl)cnc2Nc2cnc(C)c(NS(C)(=O)=O)c2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255269";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL98350";"LY-294002";"0";"307.35";"0";"3.30";"LY294002";"O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12";"IC50";"'='";"9900.0";"nM";"5.00";"";"";"UO_0000065";"16.28";"0.30";"1.70";"11.73";"False";"CHEMBL3620301";"Inhibition of mTOR (unknown origin) after 40 mins by scintillation counting analysis";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3616395";"1";"Scientific Literature";"Eur. J. Med. Chem.";"2015";""
"CHEMBL2165007";"";"0";"477.55";"0";"2.97";"BDBM50394838";"COc1ccc(Nc2ncc(Cc3ccc(S(C)(=O)=O)cc3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255041";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3357871";"";"0";"385.40";"0";"2.21";"10";"COc1ncc(Nc2ncc([C@H](C)CO)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'='";"11100.0";"nM";"4.96";"";"";"UO_0000065";"12.86";"0.24";"2.74";"3.75";"False";"CHEMBL3379685";"Inhibition of recombinant N-terminally GST-tagged mTOR (1360 to 2549 aa) (unknown origin) assessed as inhibition of 27BP1 phosphorylation after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352452";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3357877";"";"0";"395.47";"0";"2.76";"16";"CCc1cc(Nc2ncc(C(C)(C)O)cc2-c2nc(C)nc(N)n2)cnc1OC";"IC50";"'='";"15800.0";"nM";"4.80";"";"";"UO_0000065";"12.14";"0.23";"2.04";"3.64";"False";"CHEMBL3379685";"Inhibition of recombinant N-terminally GST-tagged mTOR (1360 to 2549 aa) (unknown origin) assessed as inhibition of 27BP1 phosphorylation after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352452";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3781241";"";"0";"635.13";"2";"7.61";"20";"CC(C)(C)C(=O)Nc1cnc2ccc(-c3cnc4ccccc4c3)cc2c1Nc1ccc(N2CCNCC2)c(C(F)(F)F)c1.Cl";"IC50";"'='";"17.0";"nM";"7.77";"";"";"UO_0000065";"12.98";"0.24";"0.16";"9.45";"False";"CHEMBL3784491";"Inhibition of human mTOR using ULight-4E-BP1 peptide as substrate after 1 hr by Lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3779897";"1";"Scientific Literature";"MedChemComm";"2016";""
"CHEMBL3689030";"";"0";"534.71";"1";"4.29";"BDBM174512";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CNCCC(C)C";"IC50";"'='";"120.0";"nM";"6.92";"";"319813";"UO_0000065";"12.94";"0.24";"2.63";"8.15";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701102";"";"0";"431.52";"0";"3.21";"BDBM172237";"Cc1nccc(-c2ccc(F)c(C(=O)N(C)CCN(C)C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"20.0";"nM";"7.70";"";"317161";"UO_0000065";"17.84";"0.33";"4.49";"10.22";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701113";"";"0";"471.58";"0";"3.99";"BDBM172248";"CCN1CCC(CN(C)C(=O)c2cc(-c3ccnc(C)c3C#Cc3ccc(N)nc3)ccc2F)C1";"IC50";"'='";"19.0";"nM";"7.72";"";"317172";"UO_0000065";"16.37";"0.30";"3.73";"10.25";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701118";"";"0";"399.45";"0";"2.30";"BDBM172253";"Cc1nccc(-c2ccc(C(=O)N3CCOCC3)nc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"17.0";"nM";"7.77";"";"317177";"UO_0000065";"19.45";"0.35";"5.47";"8.25";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701171";"";"0";"442.54";"0";"4.63";"BDBM172306";"CCc1nc(N)ccc1C#Cc1c(-c2ccc(C(=O)N3CCCC3)c(F)c2)ccnc1CC";"IC50";"'='";"79.0";"nM";"7.10";"";"317230";"UO_0000065";"16.05";"0.29";"2.47";"9.85";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL2165025";"";"0";"339.36";"0";"1.98";"BDBM50394865";"COc1cnc(Nc2ccc(OC)nc2)c(-c2nc(C)nc(N)n2)c1";"IC50";"'>'";"10000.0";"nM";"";"";"254947";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL388978";"STAUROSPORINE";"0";"466.54";"0";"4.35";"Staurosporine";"CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL4050194";"Inhibition of human mTOR/FRAP1 using 4EBP1 as substrate in presence of [gamma-32P]ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049399";"1";"Scientific Literature";"Bioorg Med Chem";"2017";""
"CHEMBL2017974";"BUPARLISIB";"3";"410.40";"0";"1.81";"4; BKM120";"Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1";"IC50";"'='";"94.0";"nM";"7.03";"";"";"UO_0000065";"17.12";"0.33";"5.22";"7.84";"False";"CHEMBL4019293";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017506";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL3780963";"";"0";"429.48";"1";"6.02";"21";"CC(=O)Nc1cnc2ccc(-c3cnc4ccccc4c3)cc2c1Nc1ccc(C#N)cc1";"IC50";"'>'";"3000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3784491";"Inhibition of human mTOR using ULight-4E-BP1 peptide as substrate after 1 hr by Lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3779897";"1";"Scientific Literature";"MedChemComm";"2016";""
"CHEMBL3781921";"";"0";"647.02";"2";"7.12";"19";"Cl.O=C(Nc1cnc2ccc(-c3cnc4ccccc4c3)cc2c1Nc1ccc(N2CCNCC2)c(C(F)(F)F)c1)C(F)(F)F";"IC50";"'='";"310.0";"nM";"6.51";"";"";"UO_0000065";"10.66";"0.20";"-0.61";"7.92";"False";"CHEMBL3784491";"Inhibition of human mTOR using ULight-4E-BP1 peptide as substrate after 1 hr by Lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3779897";"1";"Scientific Literature";"MedChemComm";"2016";""
"CHEMBL3736298";"";"0";"457.54";"1";"6.09";"9";"CC(C)(C#N)c1ccc(Nc2c(C(N)=O)cnc3ccc(-c4cnc5ccccc5c4)cc23)cc1";"IC50";"'='";"33.0";"nM";"7.48";"";"";"UO_0000065";"16.35";"0.29";"1.39";"7.15";"False";"CHEMBL3784491";"Inhibition of human mTOR using ULight-4E-BP1 peptide as substrate after 1 hr by Lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3779897";"1";"Scientific Literature";"MedChemComm";"2016";""
"CHEMBL3781492";"";"0";"634.68";"2";"6.25";"25";"CC(=O)Nc1cnc2ccc(-c3cnc4ccccc4c3)cc2c1Nc1ccc(N2CCN(S(C)(=O)=O)CC2)c(C(F)(F)F)c1";"IC50";"'='";"25.0";"nM";"7.60";"";"";"UO_0000065";"11.98";"0.23";"1.35";"7.07";"False";"CHEMBL3784491";"Inhibition of human mTOR using ULight-4E-BP1 peptide as substrate after 1 hr by Lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3779897";"1";"Scientific Literature";"MedChemComm";"2016";""
"CHEMBL3780492";"";"0";"464.53";"1";"6.17";"23";"COc1cc(Nc2c(NC(C)=O)cnc3ccc(-c4cnc5ccccc5c4)cc23)cc(OC)c1";"IC50";"'>'";"3000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3784491";"Inhibition of human mTOR using ULight-4E-BP1 peptide as substrate after 1 hr by Lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3779897";"1";"Scientific Literature";"MedChemComm";"2016";""
"CHEMBL3358286";"";"0";"477.55";"0";"3.02";"19";"Cc1nc(N)nc(-c2cc(C(C)(C)O)cnc2Nc2cncc(S(=O)(=O)c3ccccc3)c2)n1";"IC50";"'='";"6700.0";"nM";"5.17";"";"";"UO_0000065";"10.83";"0.21";"2.15";"3.30";"False";"CHEMBL3379685";"Inhibition of recombinant N-terminally GST-tagged mTOR (1360 to 2549 aa) (unknown origin) assessed as inhibition of 27BP1 phosphorylation after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352452";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3355475";"";"0";"348.41";"0";"2.74";"8";"C[C@@H]1COCCN1c1nc(-c2cncc3[nH]ccc23)cc2c1ncn2C";"IC50";"'='";"7500.0";"nM";"5.12";"";"";"UO_0000065";"14.71";"0.27";"2.38";"7.13";"False";"CHEMBL3372424";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352352";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL3688904";"";"0";"449.56";"0";"3.54";"BDBM174365";"COc1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4C[C@H](C)O[C@H](C)C4)nc3n2)c1";"IC50";"'='";"460.0";"nM";"6.34";"";"319681";"UO_0000065";"14.10";"0.26";"2.80";"8.70";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3643154";"";"0";"515.06";"1";"4.44";"BDBM115770";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCCC4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"18.68";"nM";"7.73";"";"240501";"UO_0000065";"15.01";"0.29";"3.29";"8.76";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643260";"";"0";"532.65";"1";"4.05";"BDBM115925";"CCc1ncnc(-c2ccc(C(=O)N3CCN(Cc4ccccc4)CC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.95";"nM";"8.30";"";"240537";"UO_0000065";"15.59";"0.28";"4.26";"8.52";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643269";"";"0";"475.00";"0";"3.51";"BDBM115934";"CCc1ncnc(-c2ccc(C(=O)N3CC[C@@H](N(C)C)C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.38";"nM";"8.47";"";"240546";"UO_0000065";"17.83";"0.34";"4.96";"9.60";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645904";"";"0";"537.59";"1";"4.72";"BDBM116083";"CCc1ncnc(-c2ccc(C(=O)N3CCC(C(C)(C)O)CC3)c(C(F)(F)F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"11.52";"nM";"7.94";"";"240695";"UO_0000065";"14.77";"0.28";"3.22";"7.54";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645918";"";"0";"481.54";"0";"3.38";"BDBM116097";"CCc1ncnc(-c2ccc(C(=O)N3CCn4c(C)cnc4C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.8";"nM";"9.10";"";"240709";"UO_0000065";"18.89";"0.35";"5.72";"8.85";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645920";"";"0";"467.51";"0";"3.07";"BDBM116099";"CCc1ncnc(-c2ccc(C(=O)N3CCn4ccnc4C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.75";"nM";"8.76";"";"240711";"UO_0000065";"18.73";"0.34";"5.69";"8.52";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646540";"";"0";"393.46";"0";"1.11";"BDBM125391";"COc1ccc(Nc2ncc(CN3CC(N)C3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255122";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646547";"";"0";"511.64";"2";"2.25";"BDBM125399";"Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2ccc3ncsc3c2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255131";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165030";"";"0";"391.44";"0";"2.78";"BDBM50394860";"COc1ccc(Nc2ncc(C3=CCOCC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255146";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646461";"";"0";"353.39";"0";"1.43";"BDBM125303";"COc1ccc(Nc2nc(N(C)C)ncc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255021";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3701169";"";"0";"485.61";"0";"4.45";"BDBM172304";"CCc1nccc(-c2ccc(C(=O)N3CCN(C(C)C)CC3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"13.0";"nM";"7.89";"";"317228";"UO_0000065";"16.24";"0.30";"3.44";"12.85";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL4213775";"";"0";"420.57";"0";"3.26";"13c";"CCN1CCN(c2ccc(-c3nn(CC4CCCC4)c4nc(NC)ncc34)cn2)CC1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4188979";"Inhibition of wild-type human partial length MTOR (L1382 to W2549 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4184298";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL3688927";"";"0";"449.56";"0";"2.60";"BDBM174390";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(N(C)C)nc3)nc2n1";"IC50";"'='";"73.0";"nM";"7.14";"";"319707";"UO_0000065";"15.87";"0.30";"4.54";"8.95";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688837";"";"0";"425.56";"0";"3.59";"BDBM174295";"C[C@H]1CN(c2nc(N3CCOC[C@@H]3C)c3ccc(-c4ccsc4)nc3n2)C[C@@H](C)O1";"IC50";"'='";"15.0";"nM";"7.82";"";"319611";"UO_0000065";"18.38";"0.36";"4.23";"12.30";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688855";"";"0";"467.50";"0";"2.98";"BDBM174314";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(F)c(C(=O)O)c3)nc2n1";"IC50";"'='";"6.9";"nM";"8.16";"";"319630";"UO_0000065";"17.46";"0.33";"5.18";"8.09";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688858";"";"0";"510.57";"1";"2.00";"BDBM174317";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(F)c(C(=O)NCCO)c3)nc2n1";"IC50";"'='";"29.0";"nM";"7.54";"";"319633";"UO_0000065";"14.76";"0.28";"5.54";"6.67";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688871";"";"0";"424.48";"0";"2.68";"BDBM174330";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccnc(F)c3)nc2n1";"IC50";"'='";"90.0";"nM";"7.05";"";"319647";"UO_0000065";"16.60";"0.31";"4.37";"9.21";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688893";"";"0";"453.52";"0";"3.29";"BDBM174354";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1F";"IC50";"'='";"39.0";"nM";"7.41";"";"319670";"UO_0000065";"16.34";"0.31";"4.12";"10.17";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688865";"";"0";"483.59";"0";"2.55";"BDBM174324";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(S(C)(=O)=O)c3)nc2n1";"IC50";"'='";"140.0";"nM";"6.85";"";"319640";"UO_0000065";"14.17";"0.28";"4.30";"7.01";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688892";"";"0";"419.53";"0";"3.45";"BDBM174353";"Cc1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"56.0";"nM";"7.25";"";"319669";"UO_0000065";"17.29";"0.32";"3.80";"11.40";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701161";"";"0";"483.59";"0";"4.06";"BDBM172296";"CCc1nc(N)ccc1C#Cc1c(-c2ccc(C(=O)N3CCN(C4CC4)CC3)c(F)c2)ccnc1C";"IC50";"'='";"11.0";"nM";"7.96";"";"317220";"UO_0000065";"16.46";"0.30";"3.90";"10.56";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3667431";"";"0";"454.53";"0";"1.97";"BDBM151004";"COc1cc(CO)cc(-c2nc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3[nH]2)c1";"IC50";"'='";"399.0";"nM";"6.40";"";"290550";"UO_0000065";"14.08";"0.26";"4.43";"5.88";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL3667436";"";"0";"433.52";"0";"2.95";"BDBM151009";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2nc(-c3cccc4[nH]ccc34)[nH]c2n1";"IC50";"'='";"5.0";"nM";"8.30";"";"290555";"UO_0000065";"19.15";"0.35";"5.35";"8.72";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL3667442";"";"0";"405.46";"0";"2.17";"BDBM151015";"c1cc2ccc(-c3nc4c(N5CCOCC5)nc(N5CCOCC5)nc4[nH]3)cc2[nH]1";"IC50";"'='";"372.0";"nM";"6.43";"";"290561";"UO_0000065";"15.86";"0.29";"4.26";"6.75";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL3643262";"";"0";"531.06";"1";"3.67";"BDBM115927";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCOCC4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.09";"nM";"8.96";"";"240539";"UO_0000065";"16.88";"0.32";"5.29";"9.20";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646576";"";"0";"385.40";"0";"2.34";"BDBM125430";"COc1ncc(Nc2ncc(C(C)(C)O)nc2-c2cc(N)nc(C)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255173";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646578";"";"0";"499.60";"1";"1.61";"BDBM125432";"COc1ccc(Nc2ncc(C(C)N3CCN(S(C)(=O)=O)CC3)nc2-c2cc(N)nc(C)n2)cn1";"IC50";"'='";"1950.0";"nM";"5.71";"";"255175";"UO_0000065";"11.43";"0.22";"4.10";"3.75";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646582";"";"0";"525.66";"2";"2.82";"BDBM125436";"Cc1nc(N)nc(-c2cc(C(C)N3CCN(S(C)(=O)=O)CC3)cnc2Nc2ccc3scnc3c2)n1";"IC50";"'='";"202.0";"nM";"6.70";"";"255179";"UO_0000065";"12.74";"0.25";"3.87";"4.68";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646588";"";"0";"541.61";"1";"2.65";"BDBM125442";"COc1ncc(Nc2ncc([C@@H](C)N3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc3[nH]cnc23)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255186";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646589";"";"0";"412.47";"0";"3.17";"BDBM125444";"COc1ncc(Nc2ncc(C(C)NC(C)C)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255188";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646598";"";"0";"470.56";"1";"1.76";"BDBM125453";"COc1ccc(Nc2ncc(C(C)N3CC(S(C)(=O)=O)C3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"1892.0";"nM";"5.72";"";"255197";"UO_0000065";"12.16";"0.24";"3.96";"3.84";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646600";"";"0";"519.64";"1";"2.75";"BDBM125455";"Cc1nc(N)nc(-c2cc([C@@H](C)N3CCN(S(C)(=O)=O)CC3)cnc2Nc2ccc3cccnc3c2)n1";"IC50";"'='";"127.0";"nM";"6.90";"";"255199";"UO_0000065";"13.27";"0.25";"4.15";"4.82";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646611";"";"0";"406.37";"0";"2.53";"BDBM125468";"COc1ccc(Nc2ncc(C(N)C(F)(F)F)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"1085.0";"nM";"5.96";"";"255215";"UO_0000065";"14.68";"0.28";"3.43";"4.33";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646612";"";"0";"571.56";"2";"2.29";"BDBM125469";"COc1ncc(Nc2ncc(C(N3CCN(S(C)(=O)=O)CC3)C(F)(F)F)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255216";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646614";"";"0";"370.39";"0";"2.13";"BDBM125471";"COc1ncc(Nc2ncc(C(C)N)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'='";"917.0";"nM";"6.04";"";"255218";"UO_0000065";"16.30";"0.31";"3.91";"4.38";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646602";"";"0";"1143.12";"";"";"BDBM125458";"COc1ncc(Nc2ncc(CN3CCN(S(C)(=O)=O)C[C@@H]3C(F)(F)F)cc2-c2nc(C)nc(N)n2)cc1F.COc1ncc(Nc2ncc(CN3CCN(S(C)(=O)=O)C[C@H]3C(F)(F)F)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'='";"523.0";"nM";"6.28";"";"255224";"UO_0000065";"5.50";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646627";"";"0";"371.38";"0";"2.16";"BDBM125485";"COc1ncc(Nc2ncc(C(C)O)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255240";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3357875";"";"0";"381.44";"0";"2.51";"BDBM125490";"COc1ncc(Nc2ncc(C(C)(C)O)cc2-c2nc(C)nc(N)n2)cc1C";"IC50";"'='";"5999.0";"nM";"5.22";"";"255245";"UO_0000065";"13.69";"0.25";"2.71";"3.96";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643178";"";"0";"541.68";"1";"3.51";"BDBM115821";"CCc1ncnc(-c2ccc(C(=O)NC3CCCN(C4CCN(C)CC4)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"28.0";"nM";"7.55";"";"240433";"UO_0000065";"13.94";"0.26";"4.04";"7.53";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643188";"";"0";"458.54";"0";"3.00";"BDBM115831";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N(C)C)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"240443";"UO_0000065";"18.97";"0.35";"5.70";"9.86";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643194";"";"0";"405.43";"0";"2.86";"BDBM115837";"CCc1ncnc(-c2ccc(C(=O)N(C)OC)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"7.0";"nM";"8.15";"";"240449";"UO_0000065";"20.11";"0.37";"5.29";"8.65";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643226";"";"0";"492.53";"0";"2.42";"BDBM115869";"CCc1ncnc(-c2cc(F)c(C(=O)NCCN3CCOCC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.79";"nM";"8.42";"";"240481";"UO_0000065";"17.10";"0.32";"6.00";"7.93";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643229";"";"0";"518.02";"1";"4.11";"BDBM115875";"CCc1ncnc(-c2ccc(C(=O)N3CCC4(CC3)OCCCO4)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"8.74";"nM";"8.06";"";"240487";"UO_0000065";"15.56";"0.30";"3.95";"7.79";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643270";"";"0";"421.89";"0";"3.37";"BDBM115935";"CCc1ncnc(-c2ccc(C(=O)N(C)OC)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.37";"nM";"8.86";"";"240547";"UO_0000065";"21.01";"0.40";"5.49";"9.41";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645807";"";"0";"454.58";"0";"3.17";"BDBM115985";"CCc1ncnc(-c2ccc(C(=O)N3CCCN(C)CC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"14.3";"nM";"7.84";"";"240597";"UO_0000065";"17.26";"0.32";"4.67";"8.89";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643153";"";"0";"475.00";"0";"3.51";"BDBM115769";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N(C)C)C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"20.0";"nM";"7.70";"";"240406";"UO_0000065";"16.21";"0.31";"4.19";"8.73";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3667438";"";"0";"419.49";"0";"2.56";"BDBM151011";"C[C@H]1COCCN1c1nc(N2CCOCC2)nc2[nH]c(-c3ccc4cc[nH]c4c3)nc12";"IC50";"'='";"85.0";"nM";"7.07";"";"290557";"UO_0000065";"16.86";"0.31";"4.51";"7.43";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL4214476";"";"0";"396.46";"0";"0.71";"7g";"CNc1ncc2c(-c3ccc(N4CCNCC4)nc3)nn(CC3OCCO3)c2n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4188979";"Inhibition of wild-type human partial length MTOR (L1382 to W2549 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4184298";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL3643203";"";"0";"419.87";"0";"3.26";"BDBM115846";"Cc1ncnc(-c2ccc(C(=O)N3CCCO3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"15.0";"nM";"7.82";"";"240458";"UO_0000065";"18.63";"0.36";"4.56";"8.30";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643205";"";"0";"435.87";"0";"2.23";"BDBM115848";"Cc1ncnc(-c2ccc(C(=O)N3CC(O)CO3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"9.0";"nM";"8.05";"";"240460";"UO_0000065";"18.46";"0.35";"5.82";"7.03";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645925";"";"0";"497.99";"0";"3.90";"BDBM116104";"CCc1ncnc(-c2ccc(C(=O)N3CCn4c(C)cnc4C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.97";"nM";"9.01";"";"240716";"UO_0000065";"18.10";"0.34";"5.11";"8.77";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645941";"";"0";"458.95";"0";"2.78";"BDBM116120";"CCc1ncnc(-c2ccc(C(=O)N3CC4(CNC4)C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"13.23";"nM";"7.88";"";"240732";"UO_0000065";"17.17";"0.33";"5.10";"8.12";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645805";"";"0";"426.52";"0";"2.44";"BDBM115983";"CCc1ncnc(-c2ccc(C(=O)N3CCNCC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"13.88";"nM";"7.86";"";"240595";"UO_0000065";"18.42";"0.34";"5.42";"8.10";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645924";"";"0";"568.10";"1";"2.04";"BDBM116103";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CCNS(C)(=O)=O)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.47";"nM";"8.83";"";"240715";"UO_0000065";"15.55";"0.31";"6.79";"6.57";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645940";"";"0";"442.50";"0";"2.27";"BDBM116119";"CCc1ncnc(-c2ccc(C(=O)N3CC4(CNC4)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"15.21";"nM";"7.82";"";"240731";"UO_0000065";"17.67";"0.32";"5.55";"8.06";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645942";"";"0";"486.55";"0";"2.38";"BDBM116121";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C4COC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.75";"nM";"8.56";"";"240733";"UO_0000065";"17.59";"0.32";"6.18";"8.78";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3688884";"";"0";"491.53";"0";"2.46";"BDBM174345";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(F)c(-c4nnn[nH]4)c3)nc2n1";"IC50";"'='";"35.0";"nM";"7.46";"";"319661";"UO_0000065";"15.17";"0.28";"5.00";"6.31";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688885";"";"0";"516.60";"1";"2.65";"BDBM174346";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(F)c(NS(C)(=O)=O)c3)nc2n1";"IC50";"'='";"39.0";"nM";"7.41";"";"319662";"UO_0000065";"14.34";"0.28";"4.76";"6.75";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL2017974";"BUPARLISIB";"3";"410.40";"0";"1.81";"NVP-BKM120; BKM";"Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1";"IC50";"'='";"1981.0";"nM";"5.70";"";"";"UO_0000065";"13.90";"0.27";"3.89";"6.36";"False";"CHEMBL4199839";"Inhibition of recombinant human GST-tagged mTOR catalytic domain (1360 to 2549 residues) expressed in baculovirus expression system using GFP-4EBP1 as substrate measured after 1 hr by Lathascreen method";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4196123";"1";"Scientific Literature";"ACS Med Chem Lett";"2018";""
"CHEMBL4084907";"BIMIRALISIB";"2";"411.39";"0";"1.21";"1; PQR309";"Nc1cc(C(F)(F)F)c(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cn1";"IC50";"'='";"89.0";"nM";"7.05";"";"";"UO_0000065";"17.14";"0.33";"5.84";"6.88";"False";"CHEMBL4019293";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017506";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL3667443";"";"0";"381.44";"0";"1.28";"BDBM151016";"Nc1cccc(-c2nc3c(N4CCOCC4)nc(N4CCOCC4)nc3[nH]2)c1";"IC50";"'='";"1208.0";"nM";"5.92";"";"290562";"UO_0000065";"15.51";"0.29";"4.64";"5.61";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL3357868";"";"0";"385.40";"0";"2.34";"BDBM125422";"COc1ncc(Nc2ncc(C(C)(C)O)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255163";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646575";"";"0";"517.59";"2";"1.75";"BDBM125429";"COc1ncc(Nc2ncc(C(C)N3CCN(S(C)(=O)=O)CC3)nc2-c2cc(N)nc(C)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255172";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3357874";"";"0";"355.38";"0";"2.33";"BDBM125488";"Cc1nc(N)nc(-c2cc(C(C)(C)O)cnc2Nc2cncc(F)c2)n1";"IC50";"'='";"2540.0";"nM";"5.59";"";"255243";"UO_0000065";"15.74";"0.29";"3.27";"4.56";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649474";"";"0";"515.58";"2";"1.33";"BDBM125513";"COc1ncc(Nc2ncc(CN3CCN4C(CCS4(=O)=O)C3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255274";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3905146";"";"0";"590.65";"2";"5.48";"13d";"COc1ncc(-c2ccc3nccc(-c4ccc(CN(C)CCO)cc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"2.2";"nM";"8.66";"";"";"UO_0000065";"14.66";"0.28";"3.18";"8.27";"False";"CHEMBL3867034";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide as substrate after 1 hr in presence of ATP by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3865829";"1";"Scientific Literature";"Eur J Med Chem";"2016";""
"CHEMBL3910225";"";"0";"518.62";"1";"3.86";"BDBM222555";"CCOc1c(CN2CCOCC2)nc(-c2ccc(NC(=O)Nc3ccccc3)cc2)nc1N1CCOCC1";"IC50";"'='";"210.1";"nM";"6.68";"";"389344";"UO_0000065";"12.88";"0.24";"2.82";"6.61";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL2165046";"";"0";"308.35";"0";"2.58";"BDBM50394874";"COc1ccc(Nc2ccccc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255129";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165032";"";"0";"400.45";"0";"3.34";"BDBM50394858";"COc1ccc(Nc2ncc(-c3ccc(C)nc3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255141";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646569";"";"0";"439.50";"0";"3.11";"BDBM125423";"COc1ncc(Nc2ncc([C@H](C)N3CCOCC3)cc2-c2cc(N)nc(C)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255164";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3701114";"";"0";"487.58";"0";"3.45";"BDBM172249";"Cc1nccc(-c2ccc(F)c(C(=O)N(C)C3CCN(C(C)O)CC3)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"23.0";"nM";"7.64";"";"317173";"UO_0000065";"15.67";"0.29";"4.19";"7.99";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701129";"";"0";"458.54";"0";"4.08";"BDBM172264";"CCc1nccc(-c2ccc(C(=O)N3CCC(OC)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"317188";"UO_0000065";"18.59";"0.34";"4.44";"10.48";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688975";"";"0";"518.66";"1";"4.01";"BDBM174452";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(C(=O)N(C)C(C)(C)C)c3)nc2n1";"IC50";"'='";"500.0";"nM";"6.30";"";"319756";"UO_0000065";"12.15";"0.23";"2.29";"7.51";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688910";"";"0";"449.56";"0";"3.54";"BDBM174371";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4C[C@H](C)O[C@H](C)C4)nc3n2)cc1";"IC50";"'='";"91.0";"nM";"7.04";"";"319687";"UO_0000065";"15.66";"0.29";"3.50";"9.67";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688950";"";"0";"461.57";"0";"2.19";"BDBM174427";"C[C@H]1COCCN1c1nc(N2CCC(CN)CC2)nc2nc(-c3cccc(C(N)=O)c3)ccc12";"IC50";"'='";"600.0";"nM";"6.22";"";"319731";"UO_0000065";"13.48";"0.25";"4.03";"5.04";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688954";"";"0";"435.53";"0";"2.25";"BDBM174431";"C[C@H]1COCCN1c1nc(N2CCCCC2CO)nc2nc(-c3ccc(N)nc3)ccc12";"IC50";"'='";"64.0";"nM";"7.19";"";"319735";"UO_0000065";"16.52";"0.31";"4.94";"6.34";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693392";"";"0";"504.64";"1";"3.41";"BDBM174533";"CC(C)C(=O)NCc1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"120.0";"nM";"6.92";"";"319829";"UO_0000065";"13.71";"0.26";"3.51";"7.47";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688959";"";"0";"517.63";"1";"2.19";"BDBM174436";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(C(=O)N4CCNCC4)c3)nc2n1";"IC50";"'='";"320.0";"nM";"6.50";"";"319740";"UO_0000065";"12.55";"0.23";"4.30";"6.77";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688999";"";"0";"488.64";"0";"3.64";"BDBM174480";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(CNCC4CC4)c3)nc2n1";"IC50";"'='";"7.1";"nM";"8.15";"";"319781";"UO_0000065";"16.68";"0.31";"4.51";"10.77";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689006";"";"0";"452.53";"0";"2.74";"BDBM174487";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(F)c(CN)c3)nc2n1";"IC50";"'='";"27.0";"nM";"7.57";"";"319788";"UO_0000065";"16.73";"0.31";"4.83";"8.44";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689012";"";"0";"498.58";"0";"3.34";"BDBM174494";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(F)c(CNCCF)c3)nc2n1";"IC50";"'='";"1100.0";"nM";"5.96";"";"319795";"UO_0000065";"11.95";"0.23";"2.62";"7.88";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689018";"";"0";"536.65";"1";"3.24";"BDBM174500";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(F)c(CN4CCC[C@@H](O)C4)c3)nc2n1";"IC50";"'='";"200.0";"nM";"6.70";"";"319801";"UO_0000065";"12.48";"0.23";"3.46";"7.69";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3646462";"";"0";"379.43";"0";"1.97";"BDBM125304";"COc1ccc(Nc2nc(N3CCCC3)ncc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255022";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653531";"";"0";"399.46";"0";"3.63";"BDBM136387";"O=C1N[C@@H]2CCCC[C@@H]2N1c1ccn2ncc(-c3ccc(-c4ncc[nH]4)cc3)c2n1";"IC50";"'='";"9.5";"nM";"8.02";"";"270261";"UO_0000065";"20.08";"0.37";"4.39";"8.80";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653542";"";"0";"485.60";"0";"3.54";"BDBM136398";"CC(C)[C@H]1CN(CCN2CCCC2)C(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"68.6";"nM";"7.16";"";"270272";"UO_0000065";"14.75";"0.27";"3.62";"7.27";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653550";"";"0";"490.57";"0";"3.11";"BDBM136406";"COCCOCCN1C[C@H](C(C)C)N(c2ccn3ncc(-c4ccc(-c5nc[nH]n5)cc4)c3n2)C1=O";"IC50";"'='";"16.3";"nM";"7.79";"";"270280";"UO_0000065";"15.88";"0.30";"4.68";"6.85";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653563";"";"0";"443.52";"0";"2.42";"BDBM136419";"CC(C)[C@H]1CN(C2CNC2)C(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"22.4";"nM";"7.65";"";"270293";"UO_0000065";"17.25";"0.32";"5.23";"7.13";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653565";"";"0";"503.59";"1";"3.59";"BDBM136421";"CC(C)[C@H]1CN(CC2CCNCC2)C(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"5.8";"nM";"8.24";"";"270295";"UO_0000065";"16.36";"0.30";"4.65";"7.67";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653566";"";"0";"517.61";"1";"3.93";"BDBM136422";"CC(C)[C@H]1CN(CC2CCN(C)CC2)C(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"19.2";"nM";"7.72";"";"270296";"UO_0000065";"14.91";"0.28";"3.79";"7.83";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653580";"";"0";"403.45";"0";"3.55";"BDBM136437";"CC(C)C[C@H]1COC(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"7.5";"nM";"8.12";"";"270311";"UO_0000065";"20.14";"0.37";"4.57";"8.02";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653597";"";"0";"462.47";"0";"3.78";"BDBM136454";"Cc1csc([C@H]2COC(=O)N2c2ccn3ncc(-c4ccc(-c5nc[nH]n5)c(F)c4)c3n2)n1";"IC50";"'='";"6.4";"nM";"8.19";"";"270328";"UO_0000065";"17.72";"0.34";"4.41";"7.18";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653598";"";"0";"462.47";"0";"3.78";"BDBM136455";"Cc1csc([C@@H]2COC(=O)N2c2ccn3ncc(-c4ccc(-c5nc[nH]n5)c(F)c4)c3n2)n1";"IC50";"'='";"29.9";"nM";"7.52";"";"270329";"UO_0000065";"16.27";"0.31";"3.74";"6.59";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653603";"";"0";"455.45";"0";"4.33";"BDBM136460";"Cc1nc(-c2ccc(-c3cnn4ccc(N5C(=O)OC[C@@H]5c5ccc(F)cc5)nc34)cc2)n[nH]1";"IC50";"'='";"4.6";"nM";"8.34";"";"270334";"UO_0000065";"18.31";"0.33";"4.01";"8.23";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653613";"";"0";"477.41";"0";"4.30";"BDBM136470";"O=C1OC[C@@H](c2ccc(F)c(F)c2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"27.2";"nM";"7.57";"";"270344";"UO_0000065";"15.85";"0.30";"3.27";"7.47";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653620";"";"0";"458.87";"0";"3.93";"BDBM136477";"O=C1OCC(c2ccccn2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(Cl)c3)c2n1";"IC50";"'='";"5.0";"nM";"8.30";"";"270351";"UO_0000065";"18.09";"0.34";"4.37";"7.27";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653627";"";"0";"476.86";"0";"4.07";"BDBM136484";"O=C1OC[C@H](c2ccc(Cl)cn2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"2.0";"nM";"8.70";"";"270358";"UO_0000065";"18.24";"0.35";"4.63";"7.62";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165268";"";"0";"317.36";"0";"3.05";"BDBM50394889";"Cc1nc(N)nc(-c2cccnc2Nc2cccc3[nH]ccc23)n1";"IC50";"'='";"7156.0";"nM";"5.14";"";"254937";"UO_0000065";"16.21";"0.29";"2.10";"4.88";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646503";"";"0";"343.78";"0";"2.62";"BDBM125345";"COc1ncc(Nc2ncccc2-c2nc(C)nc(N)n2)cc1Cl";"IC50";"'>'";"10000.0";"nM";"";"";"255073";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646522";"";"0";"521.97";"1";"4.29";"BDBM125365";"COCCOc1ccc(NC(=O)Nc2ccc(Nc3ncc(Cl)cc3-c3nc(C)nc(N)n3)cn2)cc1";"IC50";"'>'";"10000.0";"nM";"";"";"255094";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL4083349";"";"0";"417.45";"0";"2.64";"9w";"Cn1cc(-c2cc3c(cc2F)ncc2ncc(=O)n(C4CCN(CC#N)CC4)c23)cn1";"IC50";"'='";"24.0";"nM";"7.62";"";"";"UO_0000065";"18.25";"0.34";"4.98";"8.23";"False";"CHEMBL4023016";"Inhibition of N-terminal FLAG-tagged recombinant human mTOR (1362 to end residues)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020823";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL4102252";"";"0";"428.47";"0";"3.61";"9ac";"Cc1ccc(-c2cc3c(cc2F)ncc2ncc(=O)n(C4CCN(CC#N)CC4)c23)cn1";"IC50";"'='";"68.0";"nM";"7.17";"";"";"UO_0000065";"16.73";"0.31";"3.56";"8.17";"False";"CHEMBL4023016";"Inhibition of N-terminal FLAG-tagged recombinant human mTOR (1362 to end residues)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020823";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL3937117";"";"0";"426.50";"0";"2.26";"BDBM251583";"CS(=O)(=O)C1(c2nc(-c3cccc4[nH]ccc34)nc3c2OC[C@@H]2COCCN32)CC1";"IC50";"'='";"558.0";"nM";"6.25";"";"438479";"UO_0000065";"14.66";"0.28";"3.99";"6.42";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3944360";"";"0";"488.54";"0";"2.41";"BDBM251590";"CS(=O)(=O)C1(c2nc(-c3c(F)ccc4[nH]ccc34)nc3c2OCC2COCCN32)CCOCC1";"IC50";"'='";"10000.0";"nM";"5.00";"";"438486";"UO_0000065";"10.23";"0.20";"2.59";"4.69";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3928856";"";"0";"429.50";"0";"1.90";"BDBM251593";"CC(C)(c1nc(-c2ccnc3[nH]ccc23)nc2c1OCC1COCCN21)S(C)(=O)=O";"IC50";"'='";"852.0";"nM";"6.07";"";"438489";"UO_0000065";"14.13";"0.28";"4.17";"5.50";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL4111283";"";"0";"484.58";"0";"2.66";"BDBM251599";"CS(=O)(=O)C1(c2nc(-c3cccc4[nH]ccc34)nc3c2OCC[C@@H]2COCCN32)CCOCC1";"IC50";"'='";"10000.0";"nM";"5.00";"";"438495";"UO_0000065";"10.32";"0.20";"2.34";"4.69";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL4107036";"";"0";"442.54";"0";"2.89";"BDBM251602";"CC(C)(c1nc(-c2cccc3[nH]ccc23)nc2c1OCC[C@@H]1COCCN21)S(C)(=O)=O";"IC50";"'='";"582.0";"nM";"6.24";"";"438498";"UO_0000065";"14.09";"0.27";"3.35";"6.40";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3927430";"";"0";"426.50";"0";"2.26";"BDBM251604";"CS(=O)(=O)C1(c2nc(-c3cccc4[nH]ccc34)nc3c2OCC2COCCN32)CC1";"IC50";"'='";"550.0";"nM";"6.26";"";"438500";"UO_0000065";"14.68";"0.28";"4.00";"6.43";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3936379";"";"0";"500.58";"1";"2.28";"BDBM251606";"COc1cc(-c2nc3c(c(C4(S(C)(=O)=O)CCOCC4)n2)OC[C@@H]2COCCN32)c2cc[nH]c2c1";"IC50";"'='";"435.0";"nM";"6.36";"";"438502";"UO_0000065";"12.71";"0.25";"4.08";"5.49";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3904861";"";"0";"471.54";"0";"1.67";"BDBM251607";"CS(=O)(=O)C1(c2nc(-c3ccnc4[nH]ccc34)nc3c2OC[C@@H]2COCCN32)CCOCC1";"IC50";"'='";"4680.0";"nM";"5.33";"";"438503";"UO_0000065";"11.30";"0.22";"3.66";"4.46";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3951056";"";"0";"366.42";"0";"2.45";"BDBM251615";"CC(C)(O)c1nc(-c2cccc3[nH]ccc23)nc2c1OCC1COCCN21";"IC50";"'='";"275.0";"nM";"6.56";"";"438511";"UO_0000065";"17.90";"0.33";"4.11";"7.86";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3933962";"";"0";"462.53";"0";"3.29";"BDBM251620";"CS(=O)(=O)c1cccc(-c2nc(-c3cccc4[nH]ccc34)nc3c2OCC2COCCN32)c1";"IC50";"'>'";"10000.0";"nM";"";"";"438516";"UO_0000065";"";"";"";"";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3931062";"";"0";"456.52";"0";"2.26";"BDBM251638";"COc1cc(-c2nc3c(c(C4(S(C)(=O)=O)CC4)n2)OC[C@@H]2COCCN32)c2cc[nH]c2c1";"IC50";"'='";"93.0";"nM";"7.03";"";"438534";"UO_0000065";"15.40";"0.30";"4.77";"6.59";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3934434";"";"0";"470.55";"0";"2.65";"BDBM251641";"COc1cc(-c2nc3c(c(C4(S(C)(=O)=O)CCC4)n2)OC[C@@H]2COCCN32)c2cc[nH]c2c1";"IC50";"'='";"47.0";"nM";"7.33";"";"438537";"UO_0000065";"15.57";"0.30";"4.68";"6.87";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3893482";"";"0";"505.00";"1";"2.53";"BDBM251648";"CNc1nc2cc(Cl)ccc2n1-c1nc2c(c(C3(S(C)(=O)=O)CCC3)n1)OC[C@@H]1COCCN21";"IC50";"'='";"4480.0";"nM";"5.35";"";"438547";"UO_0000065";"10.59";"0.21";"2.82";"4.80";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3945123";"";"0";"505.00";"1";"2.53";"BDBM251663";"CNc1nc2ccc(Cl)cc2n1-c1nc2c(c(C3(S(C)(=O)=O)CCC3)n1)OC[C@@H]1COCCN21";"IC50";"'='";"10000.0";"nM";"5.00";"";"438548";"UO_0000065";"9.90";"0.20";"2.47";"4.49";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3985140";"";"0";"496.51";"0";"3.52";"BDBM251650";"CC(C)(c1nc(-c2cc(C(F)(F)F)cc3[nH]ccc23)nc2c1OC[C@@H]1COCCN21)S(C)(=O)=O";"IC50";"'='";"227.0";"nM";"6.64";"";"438551";"UO_0000065";"13.38";"0.27";"3.12";"6.82";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3933294";"";"0";"494.50";"0";"3.28";"BDBM251655";"CS(=O)(=O)C1(c2nc(-c3cc(C(F)(F)F)cc4[nH]ccc34)nc3c2OC[C@@H]2COCCN32)CC1";"IC50";"'='";"579.0";"nM";"6.24";"";"438556";"UO_0000065";"12.61";"0.25";"2.96";"6.40";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3979134";"";"0";"532.60";"1";"3.50";"BDBM222548";"CCOc1c(C(=O)N2CCOCC2)nc(-c2ccc(NC(=O)Nc3ccccc3)cc2)nc1N1CCOCC1";"IC50";"'='";"102.5";"nM";"6.99";"";"389337";"UO_0000065";"13.12";"0.24";"3.49";"5.92";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3112727";"";"0";"360.42";"0";"3.34";"9h";"Cc1nc(N)cc2c1cc(-c1cnc3[nH]cnc3c1)c(=O)n2C1CCCC1";"IC50";"'='";"13.91";"nM";"7.86";"";"";"UO_0000065";"21.80";"0.40";"4.52";"7.67";"False";"CHEMBL3116931";"Inhibition of mTOR (unknown origin) after 40 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112582";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3890358";"";"0";"447.54";"0";"3.29";"BDBM245513";"CNCCCOc1ccc(-c2ccc3ncc4c(c3c2)n([C@H]2CCCOC2)c(=O)n4C)cn1";"IC50";"'='";"395.0";"nM";"6.40";"";"427924";"UO_0000065";"14.31";"0.27";"3.11";"7.70";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3924639";"";"0";"639.73";"1";"4.03";"BDBM178220";"CCNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)nc3c2C(=O)N(C[C@@H]2CCCN2C(=O)OCC)CC(C)(C)O3)cc1F";"IC50";"'='";"905.0";"nM";"6.04";"";"324240";"UO_0000065";"9.45";"0.18";"2.01";"4.36";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3959575";"";"0";"602.70";"1";"3.68";"BDBM178231";"Cn1ccc(NC(=O)Nc2ccc(-c3nc(N4CC5CCC(C4)O5)nc4c3C(=O)N(C3CCOCC3)CC(C)(C)O4)cc2)n1";"IC50";"'='";"19.0";"nM";"7.72";"";"324251";"UO_0000065";"12.81";"0.24";"4.04";"5.68";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3898326";"";"0";"696.85";"1";"4.95";"BDBM178392";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)N5CCC(N(C)C)CC5)cc4)cc3)c2C1=O";"IC50";"'='";"84.0";"nM";"7.08";"";"324412";"UO_0000065";"10.15";"0.19";"2.13";"5.34";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3967159";"";"0";"543.09";"1";"4.94";"BDBM222561";"CSc1c(Cl)nc(-c2ccc(NC(=O)Nc3ccc(OCCN(C)C)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"161.8";"nM";"6.79";"";"389350";"UO_0000065";"12.50";"0.25";"1.85";"7.39";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3959860";"";"0";"492.54";"0";"3.59";"BDBM222563";"CCOC(=O)c1nc(-c2ccc(NC(=O)Nc3cccnc3)cc2)nc(N2CCOCC2)c1OCC";"IC50";"'='";"116.4";"nM";"6.93";"";"389352";"UO_0000065";"14.08";"0.26";"3.34";"5.43";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3917708";"";"0";"536.61";"1";"2.72";"BDBM222635";"C[S+]([O-])c1cnc(-c2ccc(NC(=O)Nc3ccc(N4CCOCC4=O)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"64.8";"nM";"7.19";"";"389424";"UO_0000065";"13.40";"0.26";"4.47";"5.71";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3688882";"";"0";"473.54";"0";"2.32";"BDBM174343";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(-c4nnn[nH]4)c3)nc2n1";"IC50";"'='";"14.0";"nM";"7.85";"";"319659";"UO_0000065";"16.59";"0.31";"5.53";"6.65";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688853";"";"0";"466.52";"0";"2.38";"BDBM174312";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(F)c(C(N)=O)c3)nc2n1";"IC50";"'='";"29.0";"nM";"7.54";"";"319628";"UO_0000065";"16.16";"0.30";"5.16";"7.06";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688951";"";"0";"462.55";"0";"2.22";"BDBM174428";"C[C@H]1COCCN1c1nc(N2CCCC(CO)C2)nc2nc(-c3cccc(C(N)=O)c3)ccc12";"IC50";"'='";"270.0";"nM";"6.57";"";"319732";"UO_0000065";"14.20";"0.26";"4.35";"5.58";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL4204515";"";"0";"476.63";"0";"3.81";"13d";"CNc1ncc2c(-c3ccc(N4CCN(C(=O)C(C)(C)C)CC4)nc3)nn(CC3CCCC3)c2n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4188979";"Inhibition of wild-type human partial length MTOR (L1382 to W2549 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4184298";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL4218175";"";"0";"405.55";"0";"3.48";"13a";"CNc1ncc2c(-c3ccc(N4CCN(C)CC4)cc3)nn(CC3CCCC3)c2n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4188979";"Inhibition of wild-type human partial length MTOR (L1382 to W2549 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4184298";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL3917840";"";"0";"498.57";"0";"3.66";"BDBM222567";"CCOC(=O)c1nc(-c2ccc(NC(=O)Nc3nccs3)cc2)nc(N2CCOCC2)c1OCC";"IC50";"'='";"72.2";"nM";"7.14";"";"389356";"UO_0000065";"14.32";"0.28";"3.48";"5.59";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3902582";"";"0";"548.56";"1";"3.63";"BDBM222604";"CCOC(=O)c1nc(-c2ccc(NC(=O)Nc3ccc4oc(=O)[nH]c4c3)cc2)nc(N2CCOCC2)c1OCC";"IC50";"'='";"177.0";"nM";"6.75";"";"389393";"UO_0000065";"12.31";"0.23";"3.12";"4.20";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3972288";"";"0";"584.66";"1";"3.57";"BDBM222622";"CCOC(=O)c1nc(-c2ccc(NC(=O)Nc3ccc(NS(C)(=O)=O)cc3)cc2)nc(N2CCOCC2)c1OCC";"IC50";"'='";"214.1";"nM";"6.67";"";"389411";"UO_0000065";"11.41";"0.22";"3.10";"4.14";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3955067";"";"0";"465.53";"0";"3.38";"BDBM245521";"CN(C)CCCOc1ccc(-c2ccc3ncc4c(c3c2)n([C@H]2CCOC2)c(=O)n4C)c(F)n1";"IC50";"'='";"3760.0";"nM";"5.42";"";"427931";"UO_0000065";"11.65";"0.22";"2.04";"7.29";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL4108353";"";"0";"465.53";"0";"3.38";"BDBM245522";"CN(C)CCCOc1ccc(-c2ccc3ncc4c(c3c2)n([C@@H]2CCOC2)c(=O)n4C)c(F)n1";"IC50";"'='";"4480.0";"nM";"5.35";"";"427932";"UO_0000065";"11.49";"0.21";"1.97";"7.19";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3981628";"";"0";"546.63";"1";"3.52";"BDBM178337";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccn(C)n4)cc3)c2C1=O";"IC50";"'='";"19.0";"nM";"7.72";"";"324357";"UO_0000065";"14.13";"0.26";"4.20";"6.09";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688862";"";"0";"462.55";"0";"2.50";"BDBM174321";"CNC(=O)c1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1";"IC50";"'='";"17.0";"nM";"7.77";"";"319637";"UO_0000065";"16.80";"0.31";"5.27";"8.38";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688877";"";"0";"453.52";"0";"2.77";"BDBM174338";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(F)c(CO)c3)nc2n1";"IC50";"'='";"83.0";"nM";"7.08";"";"319654";"UO_0000065";"15.61";"0.29";"4.31";"8.45";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL2336324";"";"0";"473.54";"0";"2.38";"BDBM50429703";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc4nc[nH]c(=O)c4c3)nc2n1";"IC50";"'='";"200.0";"nM";"6.70";"";"319689";"UO_0000065";"14.15";"0.26";"4.32";"6.13";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688965";"";"0";"518.62";"1";"2.35";"BDBM174442";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(C(=O)N4CC[C@H](O)C4)c3)nc2n1";"IC50";"'='";"180.0";"nM";"6.75";"";"319746";"UO_0000065";"13.01";"0.24";"4.39";"6.48";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689014";"";"0";"522.63";"1";"2.85";"BDBM174496";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(F)c(CN4CC[C@@H](O)C4)c3)nc2n1";"IC50";"'='";"81.0";"nM";"7.09";"";"319797";"UO_0000065";"13.57";"0.25";"4.24";"8.14";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693401";"";"0";"532.69";"1";"4.15";"BDBM174542";"CC(C)CC(=O)N(C)Cc1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"1400.0";"nM";"5.85";"";"319838";"UO_0000065";"10.99";"0.20";"1.70";"6.98";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701081";"";"0";"455.56";"0";"3.08";"BDBM172215";"CCc1nccc(-c2ccc(C(=O)N3CCN(C)CC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"6.0";"nM";"8.22";"";"317139";"UO_0000065";"18.05";"0.33";"5.14";"9.72";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701124";"";"0";"471.58";"0";"3.99";"BDBM172259";"CCCN1CCN(C(=O)c2ccc(-c3ccnc(CC)c3C#Cc3ccc(N)nc3)cc2F)CC1";"IC50";"'='";"2.0";"nM";"8.70";"";"317183";"UO_0000065";"18.45";"0.34";"4.71";"11.54";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701153";"";"0";"499.63";"0";"4.69";"BDBM172288";"CCc1nccc(-c2ccc(C(=O)N3CCN(C(C)(C)C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1C";"IC50";"'='";"69.0";"nM";"7.16";"";"317212";"UO_0000065";"14.33";"0.26";"2.47";"9.50";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701072";"";"0";"328.42";"0";"3.65";"BDBM172206";"CCc1cc(-c2ccnc(CC)c2C#Cc2ccc(N)nc2)ccn1";"IC50";"'='";"9.0";"nM";"8.05";"";"317130";"UO_0000065";"24.50";"0.44";"4.40";"12.44";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701138";"";"0";"391.50";"0";"3.40";"BDBM172273";"CCc1nccc(-c2ccc(S(C)(=O)=O)cc2)c1C#Cc1ccc(N)nc1C";"IC50";"'='";"5.0";"nM";"8.30";"";"317197";"UO_0000065";"21.20";"0.40";"4.90";"9.66";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693440";"";"0";"431.50";"0";"2.41";"BDBM174590";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccnc(C#N)c3)nc2n1";"IC50";"'='";"480.0";"nM";"6.32";"";"319879";"UO_0000065";"14.64";"0.27";"3.91";"6.30";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL2336320";"";"0";"478.55";"0";"2.25";"BDBM50429706";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1C(N)=O";"IC50";"'='";"3.2";"nM";"8.49";"";"319884";"UO_0000065";"17.75";"0.33";"6.24";"7.33";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693445";"";"0";"528.64";"1";"1.88";"BDBM174602";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(NS(=O)(=O)CCO)c3)nc2n1";"IC50";"'='";"4.3";"nM";"8.37";"";"319885";"UO_0000065";"15.83";"0.31";"6.49";"6.44";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL4246923";"";"0";"426.47";"0";"1.10";"3d";"COc1ccc(-c2ccc3c(N4CCOCC4)nc(C(CO)CO)nc3n2)cc1CO";"IC50";"'>'";"500.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4233142";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide substrate measured after 1 hr by Lance Ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4229417";"1";"Scientific Literature";"Bioorg Med Chem";"2018";""
"CHEMBL4250280";"";"0";"408.50";"0";"3.54";"3i";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(C(C)C)nc3n2)cc1CO";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"19.58";"0.36";"4.46";"9.93";"False";"CHEMBL4233142";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide substrate measured after 1 hr by Lance Ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4229417";"1";"Scientific Literature";"Bioorg Med Chem";"2018";""
"CHEMBL1801204";"AZD-8055";"1";"465.55";"0";"2.64";"AZD8055";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO";"IC50";"'='";"8.0";"nM";"8.10";"";"";"UO_0000065";"17.39";"0.33";"5.46";"8.70";"False";"CHEMBL4233142";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide substrate measured after 1 hr by Lance Ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4229417";"1";"Scientific Literature";"Bioorg Med Chem";"2018";""
"CHEMBL3688970";"";"0";"490.61";"0";"3.23";"BDBM174447";"CCN(C)C(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"320.0";"nM";"6.50";"";"319751";"UO_0000065";"13.24";"0.25";"3.26";"7.74";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688987";"";"0";"434.54";"0";"2.60";"BDBM174468";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(CN)cc3)nc2n1";"IC50";"'='";"25.0";"nM";"7.60";"";"319770";"UO_0000065";"17.49";"0.32";"5.00";"8.48";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693383";"";"0";"508.62";"1";"2.23";"BDBM174519";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CNCCO";"IC50";"'='";"13.0";"nM";"7.89";"";"319820";"UO_0000065";"15.50";"0.29";"5.66";"7.50";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693385";"";"0";"560.74";"1";"4.82";"BDBM174521";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CNC1CCC(C)CC1";"IC50";"'='";"76.0";"nM";"7.12";"";"319822";"UO_0000065";"12.70";"0.24";"2.30";"8.39";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693421";"";"0";"508.62";"1";"3.00";"BDBM174567";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(CNC4CCOCC4)o3)nc2n1";"IC50";"'='";"124.0";"nM";"6.91";"";"319858";"UO_0000065";"13.58";"0.25";"3.91";"7.05";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693422";"";"0";"478.60";"0";"3.23";"BDBM174568";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(CNCC4CC4)o3)nc2n1";"IC50";"'='";"170.0";"nM";"6.77";"";"319859";"UO_0000065";"14.14";"0.26";"3.54";"7.63";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693424";"";"0";"490.57";"0";"3.07";"BDBM174570";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(CNc4cc[nH]n4)o3)nc2n1";"IC50";"'='";"79.0";"nM";"7.10";"";"319861";"UO_0000065";"14.48";"0.27";"4.03";"6.05";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693425";"";"0";"481.56";"0";"1.31";"BDBM174571";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(CNCC(N)=O)o3)nc2n1";"IC50";"'='";"124.0";"nM";"6.91";"";"319862";"UO_0000065";"14.34";"0.27";"5.60";"5.24";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693426";"";"0";"466.59";"0";"3.23";"BDBM174572";"CC(C)NCc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)o1";"IC50";"'='";"140.0";"nM";"6.85";"";"319863";"UO_0000065";"14.69";"0.28";"3.62";"7.72";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL2331605";"";"0";"420.52";"0";"2.93";"BDBM50429714";"C[C@H]1CN(c2nc(N3CCOC[C@@H]3C)c3ncc(-c4ccccc4)nc3n2)C[C@@H](C)O1";"IC50";"'='";"26.69";"nM";"7.57";"";"319871";"UO_0000065";"18.01";"0.33";"4.64";"9.90";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693482";"";"0";"493.56";"0";"2.56";"BDBM174644";"COC(=O)[C@@H]1CCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(OC)c(CO)c3)nc2n1";"IC50";"'='";"30.0";"nM";"7.52";"";"319922";"UO_0000065";"15.24";"0.29";"4.96";"6.83";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693496";"";"0";"465.60";"0";"4.26";"BDBM174658";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(NC(C)CC(C)C)nc3n2)cc1CO";"IC50";"'='";"270.0";"nM";"6.57";"";"319936";"UO_0000065";"14.11";"0.26";"2.31";"7.09";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701059";"";"0";"416.91";"0";"4.32";"BDBM172193";"Cc1nccc(-c2ccc(C(=O)N3CCCC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.0";"nM";"8.40";"";"317117";"UO_0000065";"20.14";"0.38";"4.08";"11.65";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701107";"";"0";"343.39";"0";"2.19";"BDBM172242";"CNC(=O)c1ccc(-c2ccnc(C)c2C#Cc2ccc(N)nc2)cn1";"IC50";"'='";"28.0";"nM";"7.55";"";"317166";"UO_0000065";"21.99";"0.40";"5.36";"8.05";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701109";"";"0";"289.34";"0";"2.17";"BDBM172244";"Cc1nccc(-c2cnn(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"95.0";"nM";"7.02";"";"317168";"UO_0000065";"24.27";"0.44";"4.85";"10.09";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701062";"";"0";"432.91";"0";"3.56";"BDBM172196";"Cc1nccc(-c2ccc(C(=O)N3CCOCC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"317120";"UO_0000065";"19.69";"0.38";"4.96";"10.48";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL4248529";"";"0";"391.43";"0";"2.10";"3f";"COc1ccc(-c2ccc3c(N4CCOCC4)nc(CC#N)nc3n2)cc1CO";"IC50";"'='";"88.0";"nM";"7.06";"";"";"UO_0000065";"18.02";"0.33";"4.96";"6.76";"False";"CHEMBL4233142";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide substrate measured after 1 hr by Lance Ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4229417";"1";"Scientific Literature";"Bioorg Med Chem";"2018";""
"CHEMBL3646514";"";"0";"355.33";"0";"1.92";"BDBM125357";"COc1ncc(Nc2ncc(C=O)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255086";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646475";"";"0";"453.51";"0";"3.56";"BDBM125317";"COc1ccc(Nc2ncc(CNCc3ccccn3)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'='";"556.0";"nM";"6.25";"";"255036";"UO_0000065";"13.79";"0.25";"2.69";"4.95";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646483";"";"0";"499.60";"1";"1.61";"BDBM125325";"COc1ccc(Nc2ncc([C@H](C)N3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"1719.0";"nM";"5.76";"";"255045";"UO_0000065";"11.54";"0.22";"4.15";"3.78";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646517";"";"0";"413.45";"0";"3.61";"BDBM125360";"Cc1nc(N)nc(-c2cccnc2Nc2ccc(NC(=O)Nc3ccccc3)nc2)n1";"IC50";"'='";"5320.0";"nM";"5.27";"";"255089";"UO_0000065";"12.76";"0.23";"1.66";"3.67";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640925";"";"0";"367.46";"0";"3.88";"BDBM115575";"CCc1ncnc(-c2ccc(C(C)(C)C#N)cc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"24.0";"nM";"7.62";"";"240212";"UO_0000065";"20.74";"0.37";"3.74";"8.61";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640928";"";"0";"329.41";"0";"3.09";"BDBM115578";"CCc1ncnc(-c2cc(C)nc(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"8.0";"nM";"8.10";"";"240215";"UO_0000065";"24.58";"0.44";"5.01";"10.44";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640939";"";"0";"389.43";"0";"2.92";"BDBM115589";"CCc1ncnc(-c2ccc(F)c(C(=O)N(C)C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"20.0";"nM";"7.70";"";"240226";"UO_0000065";"19.77";"0.36";"4.78";"9.06";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640941";"";"0";"390.87";"0";"3.82";"BDBM115591";"CCc1ncnc(-c2ccc(C(=O)NC)c(Cl)c2)c1C#Cc1ccc(C)nc1";"IC50";"'='";"18.0";"nM";"7.75";"";"240228";"UO_0000065";"19.81";"0.38";"3.92";"11.43";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640947";"";"0";"337.39";"0";"3.38";"BDBM115597";"Cc1ncnc(-c2cnc3ccccc3c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"76.0";"nM";"7.12";"";"240234";"UO_0000065";"21.10";"0.37";"3.74";"9.18";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640958";"";"0";"331.38";"0";"2.49";"BDBM115608";"CCc1ncnc(-c2ccnc(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"34.0";"nM";"7.47";"";"240245";"UO_0000065";"22.54";"0.41";"4.98";"8.60";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640960";"";"0";"341.42";"0";"3.36";"BDBM115610";"CCc1ncnc(-c2ccc(C3CC3)nc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"32.0";"nM";"7.50";"";"240247";"UO_0000065";"21.95";"0.39";"4.13";"9.66";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640979";"";"0";"433.49";"0";"2.68";"BDBM115629";"CCc1ncnc(-c2ccc(C(=O)N(C)CCCO)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.0";"nM";"9.00";"";"240266";"UO_0000065";"20.76";"0.38";"6.32";"8.55";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643103";"";"0";"488.57";"0";"2.63";"BDBM115719";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CCOC)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"6.0";"nM";"8.22";"";"240356";"UO_0000065";"16.83";"0.31";"5.59";"8.44";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643141";"";"0";"501.03";"1";"3.90";"BDBM115757";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CC4CC4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.0";"nM";"8.30";"";"240394";"UO_0000065";"16.57";"0.31";"4.40";"9.41";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643064";"";"0";"524.55";"1";"3.41";"BDBM115679";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CC(F)(F)F)CC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.0";"nM";"8.40";"";"240316";"UO_0000065";"16.01";"0.30";"4.99";"8.62";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3639419";"";"0";"458.54";"0";"4.35";"BDBM115691";"CCc1ncnc(-c2ccc(C(=O)C3CCC(C)(O)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"240328";"UO_0000065";"18.97";"0.35";"4.35";"8.53";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643078";"";"0";"512.51";"1";"3.54";"BDBM115694";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CC(F)(F)F)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"240331";"UO_0000065";"16.63";"0.31";"4.98";"9.66";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640952";"";"0";"315.38";"0";"2.79";"BDBM115602";"CCc1ncnc(-c2ccnc(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"20.0";"nM";"7.70";"";"240239";"UO_0000065";"24.41";"0.44";"4.91";"9.92";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640993";"";"0";"498.61";"0";"3.84";"BDBM115643";"CCc1ncnc(-c2ccc(C(=O)N3CCN4CCCCC4C3)c(F)c2)c1C#Cc1ccc(N)nc1C";"IC50";"'='";"8.0";"nM";"8.10";"";"240280";"UO_0000065";"16.24";"0.30";"4.26";"9.18";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643070";"";"0";"513.65";"1";"2.41";"BDBM115685";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CCN(C)C)CC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"8.0";"nM";"8.10";"";"240322";"UO_0000065";"15.76";"0.29";"5.69";"8.04";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643100";"";"0";"507.57";"1";"3.58";"BDBM115716";"CCc1ncnc(-c2ccc(C(=O)N3CCN(c4ccccn4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"7.0";"nM";"8.15";"";"240353";"UO_0000065";"16.07";"0.29";"4.57";"8.06";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3545097";"SAPANISERTIB";"2";"309.33";"0";"2.38";"1; 8";"CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21";"IC50";"'<'";"100.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3882339";"Inhibition of recombinant human GST-tagged mTOR (1360 to 2549 residues) catalytic domain assessed as inhibition of GFP labeled 4EBP1 phosphorylation measured after 1 hr by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3882246";"38";"Patent Bioactivity Data";"";"2010";""
"CHEMBL3893037";"";"0";"351.37";"0";"2.76";"2";"CC(=O)Nc1nc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc2o1";"IC50";"'<'";"100.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3882339";"Inhibition of recombinant human GST-tagged mTOR (1360 to 2549 residues) catalytic domain assessed as inhibition of GFP labeled 4EBP1 phosphorylation measured after 1 hr by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3882246";"38";"Patent Bioactivity Data";"";"2010";""
"CHEMBL3921512";"";"0";"589.70";"1";"3.95";"BDBM222575";"CCOC(=O)c1nc(-c2ccc(NC(=O)Nc3ccc(N4CCN(C)CC4)cc3)cc2)nc(N2CCOCC2)c1OCC";"IC50";"'='";"105.2";"nM";"6.98";"";"389364";"UO_0000065";"11.83";"0.22";"3.03";"5.75";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3926940";"";"0";"576.65";"1";"4.04";"BDBM222577";"CCOC(=O)c1nc(-c2ccc(NC(=O)Nc3ccc(N4CCOCC4)cc3)cc2)nc(N2CCOCC2)c1OCC";"IC50";"'='";"80.1";"nM";"7.10";"";"389366";"UO_0000065";"12.31";"0.23";"3.06";"5.57";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3930553";"";"0";"309.33";"0";"2.38";"10";"CC(C)n1nc(-c2ccc3onc(N)c3c2)c2c(N)ncnc21";"IC50";"'<'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3882339";"Inhibition of recombinant human GST-tagged mTOR (1360 to 2549 residues) catalytic domain assessed as inhibition of GFP labeled 4EBP1 phosphorylation measured after 1 hr by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3882246";"38";"Patent Bioactivity Data";"";"2010";""
"CHEMBL4062346";"";"0";"429.48";"0";"3.66";"A17";"C[C@H]1COCCN1c1cc(-c2ccc(NC(=O)Nc3cccnc3)cc2)nn2ccnc12";"IC50";"'='";"67.0";"nM";"7.17";"";"";"UO_0000065";"16.70";"0.31";"3.51";"7.42";"False";"CHEMBL4009793";"Inhibition of human N-terminal FLAG-tagged mTOR (1362-end residues) in presence of [gamma33P]ATP after 40 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007445";"1";"Scientific Literature";"Eur J Med Chem";"2017";""
"CHEMBL3890780";"";"0";"308.35";"0";"2.98";"8";"CC(C)n1cc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc21";"IC50";"'<'";"100.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3882339";"Inhibition of recombinant human GST-tagged mTOR (1360 to 2549 residues) catalytic domain assessed as inhibition of GFP labeled 4EBP1 phosphorylation measured after 1 hr by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3882246";"38";"Patent Bioactivity Data";"";"2010";""
"CHEMBL3978294";"";"0";"323.36";"0";"2.69";"21";"Cc1nc(N)c2c(-c3ccc4oc(N)nc4c3)nn(C(C)C)c2n1";"IC50";"'<'";"1000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3882339";"Inhibition of recombinant human GST-tagged mTOR (1360 to 2549 residues) catalytic domain assessed as inhibition of GFP labeled 4EBP1 phosphorylation measured after 1 hr by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3882246";"38";"Patent Bioactivity Data";"";"2010";""
"CHEMBL3927986";"";"0";"555.11";"1";"4.15";"BDBM222578";"CSc1c(Cl)nc(-c2ccc(NC(=O)Nc3ccc(N4CCN(C)CC4)nc3)cc2)nc1N1CCOCC1";"IC50";"'='";"80.7";"nM";"7.09";"";"389367";"UO_0000065";"12.78";"0.25";"2.94";"7.18";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3900001";"";"0";"520.66";"1";"3.49";"BDBM222579";"CSc1c(N2CCOCC2)nc(-c2ccc(NC(=O)Nc3cccnc3)cc2)nc1N1CCN(C)CC1";"IC50";"'='";"225.2";"nM";"6.65";"";"389368";"UO_0000065";"12.77";"0.25";"3.16";"6.73";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3893611";"";"0";"569.09";"1";"4.47";"BDBM222606";"CSc1c(Cl)nc(-c2ccc(NC(=O)Nc3ccc(C(=O)N4CCOCC4)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"48.6";"nM";"7.31";"";"389395";"UO_0000065";"12.85";"0.26";"2.84";"6.71";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3970067";"";"0";"498.57";"0";"2.67";"BDBM222613";"CCOc1cnc(-c2ccc(NC(=O)Nc3ccc(S(N)(=O)=O)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"40.9";"nM";"7.39";"";"389402";"UO_0000065";"14.82";"0.29";"4.72";"4.97";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3961477";"";"0";"350.38";"0";"2.76";"9";"Nc1nc2cc(-c3cn(C4CCOCC4)c4ncnc(N)c34)ccc2o1";"IC50";"'<'";"100.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3882339";"Inhibition of recombinant human GST-tagged mTOR (1360 to 2549 residues) catalytic domain assessed as inhibition of GFP labeled 4EBP1 phosphorylation measured after 1 hr by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3882246";"38";"Patent Bioactivity Data";"";"2010";""
"CHEMBL3978493";"";"0";"498.61";"1";"5.41";"BDBM222662";"CSc1c(-c2ccncc2)nc(-c2ccc(NC(=O)Nc3ccccc3)cc2)nc1N1CCOCC1";"IC50";"'='";"124.1";"nM";"6.91";"";"389451";"UO_0000065";"13.85";"0.26";"1.50";"7.48";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3645969";"";"0";"517.54";"1";"3.33";"BDBM116149";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCC4(CC3)CC(=O)CO4)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.11";"nM";"8.68";"";"240761";"UO_0000065";"16.76";"0.31";"5.35";"7.79";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645982";"";"0";"531.06";"1";"3.41";"BDBM116162";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C4CCCC4O)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.29";"nM";"8.89";"";"240774";"UO_0000065";"16.74";"0.32";"5.48";"8.20";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643251";"";"0";"417.47";"0";"2.73";"BDBM115916";"CCc1ncnc(-c2ccc(C(=O)N(C)OC)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"6.43";"nM";"8.19";"";"240528";"UO_0000065";"19.62";"0.36";"5.46";"7.92";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643264";"";"0";"449.90";"0";"2.48";"BDBM115929";"CCc1ncnc(-c2ccc(C(=O)N3CC(O)CO3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.8";"nM";"9.10";"";"240541";"UO_0000065";"20.22";"0.39";"6.62";"7.95";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL2325704";"";"0";"398.49";"0";"2.50";"12";"CS(=O)(=O)C1(c2cc(N3CCOCC3)nc(-c3cccc4[nH]ccc34)n2)CC1";"IC50";"'='";"180.0";"nM";"6.75";"";"";"UO_0000065";"16.93";"0.33";"4.24";"7.65";"False";"CHEMBL2330634";"Inhibition of recombinant mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2321758";"1";"Scientific Literature";"J. Med. Chem.";"2013";""
"CHEMBL3645824";"";"0";"499.53";"0";"3.52";"BDBM116002";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCn4c(C)cnc4C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.75";"nM";"8.76";"";"240614";"UO_0000065";"17.53";"0.32";"5.24";"8.52";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645833";"";"0";"586.09";"1";"2.18";"BDBM116011";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(CCNS(C)(=O)=O)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.88";"nM";"8.73";"";"240623";"UO_0000065";"14.89";"0.30";"6.55";"6.49";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645968";"";"0";"536.58";"1";"2.13";"BDBM116148";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(CCOCCO)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.66";"nM";"8.78";"";"240760";"UO_0000065";"16.36";"0.31";"6.65";"7.46";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL2325706";"";"0";"441.56";"0";"2.08";"14";"CS(=O)(=O)C1(c2cc(N3CCOCC3)nc(-c3cccc4[nH]ccc34)n2)CCNCC1";"IC50";"'='";"1500.0";"nM";"5.82";"";"";"UO_0000065";"13.19";"0.26";"3.74";"5.81";"False";"CHEMBL2330630";"Inhibition of mTOR-mediated AKT phosphorylation at serine 473 in human MDA-MB-468 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MDA-MB-468";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2321758";"1";"Scientific Literature";"J. Med. Chem.";"2013";"CHEMBL3308424"
"CHEMBL3643242";"";"0";"484.60";"0";"3.26";"BDBM115907";"CCc1ncnc(-c2ccc(C(=O)N3CCCC(N(C)C)C3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"88.48";"nM";"7.05";"";"240519";"UO_0000065";"14.55";"0.27";"3.79";"7.24";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643273";"";"0";"519.01";"1";"3.65";"BDBM115938";"CCOC(=O)N1CCN(C(=O)c2ccc(-c3ncnc(CC)c3C#Cc3ccc(N)nc3)cc2Cl)CC1";"IC50";"'='";"3.59";"nM";"8.45";"";"240550";"UO_0000065";"16.27";"0.31";"4.79";"7.37";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643279";"";"0";"523.69";"1";"3.24";"BDBM115945";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCN(C)CC4)CC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.84";"nM";"8.31";"";"240557";"UO_0000065";"15.88";"0.29";"5.08";"9.09";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643237";"";"0";"457.53";"0";"2.69";"BDBM115902";"CCc1ncnc(-c2ccc(C(=O)N3CCCC(O)C3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"11.86";"nM";"7.93";"";"240514";"UO_0000065";"17.32";"0.32";"5.24";"6.92";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL2325697";"";"0";"412.52";"0";"2.88";"6, AZ20";"C[C@@H]1COCCN1c1cc(C2(S(C)(=O)=O)CC2)nc(-c2cccc3[nH]ccc23)n1";"IC50";"'='";"38.0";"nM";"7.42";"";"";"UO_0000065";"17.99";"0.35";"4.54";"8.41";"True";"CHEMBL2330634";"Inhibition of recombinant mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2321758";"1";"Scientific Literature";"J. Med. Chem.";"2013";""
"CHEMBL3670276";"";"0";"386.46";"0";"1.53";"BDBM111752";"CCc1ncnc(N2CCN(c3ncccn3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"14.0";"nM";"7.85";"";"232575";"UO_0000065";"20.32";"0.37";"6.32";"8.10";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3781571";"";"0";"551.02";"2";"6.20";"16";"Cl.Nc1cnc2ccc(-c3cnc4ccccc4c3)cc2c1Nc1ccc(N2CCNCC2)c(C(F)(F)F)c1";"IC50";"'='";"46.0";"nM";"7.34";"";"";"UO_0000065";"14.26";"0.26";"1.14";"9.28";"False";"CHEMBL3784491";"Inhibition of human mTOR using ULight-4E-BP1 peptide as substrate after 1 hr by Lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3779897";"1";"Scientific Literature";"MedChemComm";"2016";""
"CHEMBL3823849";"";"0";"393.54";"0";"2.66";"7j";"Cc1ccc(-c2nn(CCN3CCC(CN(C)C)CC3)c3ncnc(N)c23)cc1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3826741";"Inhibition of human mTOR using poly[Glu,Tyr]4:1 as substrate in presence of [gamma-33P]ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3822371";"1";"Scientific Literature";"J. Med. Chem.";"2016";""
"CHEMBL3618243";"";"0";"521.56";"2";"2.17";"16";"COc1ncc(Nc2nc3ccc(N4CCN(C(=O)N(C)C)CC4)cn3c2-c2nc(C)nc(N)n2)cc1F";"IC50";"'='";"157.0";"nM";"6.80";"";"";"UO_0000065";"13.05";"0.24";"4.63";"4.76";"False";"CHEMBL3620381";"Inhibition of GST-tagged mTOR (1360 to 2549 residues) (unknown origin) using Ulight 4eBP1 peptide incubated for 90 mins by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3616407";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2015";""
"CHEMBL3618240";"";"0";"492.56";"1";"2.89";"13";"COc1ncc(Nc2nc3ccc(N4CCN(C(C)C)CC4)cn3c2-c2nc(C)nc(N)n2)cc1F";"IC50";"'='";"412.0";"nM";"6.38";"";"";"UO_0000065";"12.96";"0.24";"3.50";"5.21";"False";"CHEMBL3620381";"Inhibition of GST-tagged mTOR (1360 to 2549 residues) (unknown origin) using Ulight 4eBP1 peptide incubated for 90 mins by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3616407";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2015";""
"CHEMBL3618234";"";"0";"368.40";"0";"3.37";"7";"Cc1nc(N)nc(-c2c(Nc3ccc4ncccc4c3)nc3ccccn23)n1";"IC50";"'='";"277.0";"nM";"6.56";"";"";"UO_0000065";"17.80";"0.32";"3.19";"6.13";"False";"CHEMBL3620381";"Inhibition of GST-tagged mTOR (1360 to 2549 residues) (unknown origin) using Ulight 4eBP1 peptide incubated for 90 mins by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3616407";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2015";""
"CHEMBL3618235";"";"0";"368.40";"0";"3.37";"8";"Cc1nc(N)nc(-c2c(Nc3ccc4ccncc4c3)nc3ccccn23)n1";"IC50";"'='";"12.0";"nM";"7.92";"";"";"UO_0000065";"21.50";"0.39";"4.55";"7.41";"False";"CHEMBL3620381";"Inhibition of GST-tagged mTOR (1360 to 2549 residues) (unknown origin) using Ulight 4eBP1 peptide incubated for 90 mins by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3616407";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2015";""
"CHEMBL3618236";"";"0";"368.40";"0";"3.37";"9";"Cc1nc(N)nc(-c2c(Nc3ccc4cccnc4c3)nc3ccccn23)n1";"IC50";"'='";"1.7";"nM";"8.77";"";"";"UO_0000065";"23.80";"0.43";"5.40";"8.20";"False";"CHEMBL3620381";"Inhibition of GST-tagged mTOR (1360 to 2549 residues) (unknown origin) using Ulight 4eBP1 peptide incubated for 90 mins by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3616407";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2015";""
"CHEMBL3618242";"";"0";"503.57";"2";"2.03";"15";"COc1ccc(Nc2nc3ccc(N4CCN(C(=O)N(C)C)CC4)cn3c2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"34.0";"nM";"7.47";"";"";"UO_0000065";"14.83";"0.28";"5.44";"5.23";"False";"CHEMBL3620381";"Inhibition of GST-tagged mTOR (1360 to 2549 residues) (unknown origin) using Ulight 4eBP1 peptide incubated for 90 mins by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3616407";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2015";""
"CHEMBL1081312";"";"0";"319.37";"0";"3.07";"78, PP121";"Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"25.05";"0.46";"4.93";"8.14";"False";"CHEMBL3223610";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3217752";"1";"Scientific Literature";"MedChemComm";"2012";""
"CHEMBL1230790";"";"0";"269.31";"0";"2.36";"75, S1";"CC(C)n1nc(-c2cccc(O)c2)c2c(N)ncnc21";"IC50";"'='";"2100.0";"nM";"5.68";"";"";"UO_0000065";"21.08";"0.39";"3.32";"6.32";"False";"CHEMBL3223610";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3217752";"1";"Scientific Literature";"MedChemComm";"2012";""
"CHEMBL583194";"";"0";"494.60";"0";"4.04";"WAY-600";"c1cncc(CN2CCC(n3ncc4c(N5CCOCC5)nc(-c5ccc6[nH]ccc6c5)nc43)CC2)c1";"IC50";"'='";"9.0";"nM";"8.05";"";"";"UO_0000065";"16.27";"0.30";"4.01";"9.14";"False";"CHEMBL4009807";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007445";"1";"Scientific Literature";"Eur J Med Chem";"2017";""
"CHEMBL3667424";"";"0";"454.49";"0";"1.79";"BDBM150996";"COc1ccc(-c2nc3c(N4CCOC[C@@H]4C)nc(N4CCOCC4)nc3[nH]2)cc1C(=O)O";"IC50";"'='";"3204.0";"nM";"5.49";"";"290542";"UO_0000065";"12.09";"0.23";"3.70";"4.36";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL4064087";"";"0";"378.50";"0";"2.19";"6a";"CC(O)c1cc2nc(N3C[C@H](C)O[C@H](C)C3)nc(N3CCOCC3)c2s1";"IC50";"'='";"632.0";"nM";"6.20";"";"";"UO_0000065";"16.38";"0.33";"4.01";"8.74";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL4166823";"";"0";"486.96";"1";"5.34";"9n";"O=C(Nc1ccc(-c2ccnc(N3CCOCC3)n2)cc1)Nc1ccc(Cl)c(-c2cccnc2)c1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4141549";"Inhibition of mTOR (unknown origin) using Ulight-4EBP1 peptide as substrate measured after 1 hr by Lance Ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4138149";"1";"Scientific Literature";"Eur J Med Chem";"2017";""
"CHEMBL3667441";"";"0";"406.45";"0";"1.57";"BDBM151014";"c1cc(-c2nc3c(N4CCOCC4)nc(N4CCOCC4)nc3[nH]2)c2cn[nH]c2c1";"IC50";"'='";"340.0";"nM";"6.47";"";"290560";"UO_0000065";"15.91";"0.29";"4.90";"5.98";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL4063987";"";"0";"394.48";"0";"3.10";"10b";"CCNC(=O)Nc1ccc(-c2cc(N3CCOCC3)c3ncn(CC)c3n2)cc1";"IC50";"'='";"422.0";"nM";"6.38";"";"";"UO_0000065";"16.16";"0.30";"3.27";"7.56";"False";"CHEMBL4056088";"Inhibition of mTOR (unknown origin) by Kinase-Glo plus luminescence kinase assay or and ADP-Glo Plus luminescence kinase assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052688";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL4068631";"";"0";"450.59";"0";"4.43";"10p";"CCNC(=O)Nc1ccc(-c2cc(N3CCOC[C@@H]3C)c3nc(C)n(CC(C)C)c3n2)cc1";"IC50";"'='";"430.0";"nM";"6.37";"";"";"UO_0000065";"14.13";"0.26";"1.94";"7.55";"False";"CHEMBL4056088";"Inhibition of mTOR (unknown origin) by Kinase-Glo plus luminescence kinase assay or and ADP-Glo Plus luminescence kinase assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052688";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL3667433";"";"0";"442.50";"0";"2.10";"BDBM151006";"C[C@@H]1COCCN1c1nc(N2CCOC[C@H]2C)c2nc(-c3cc(CO)ccc3F)[nH]c2n1";"IC50";"'='";"134.0";"nM";"6.87";"";"290552";"UO_0000065";"15.53";"0.29";"4.77";"6.90";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL3667439";"";"0";"433.52";"0";"2.95";"BDBM151012";"COC1CCN(c2nc(N3CCOCC3)c3nc(-c4cccc5[nH]ccc45)[nH]c3n2)CC1";"IC50";"'='";"172.0";"nM";"6.76";"";"290558";"UO_0000065";"15.60";"0.29";"3.81";"7.11";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL3667421";"";"0";"450.50";"0";"1.64";"BDBM150993";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2nc(-c3ccc4[nH]c(=O)[nH]c4c3)[nH]c2n1";"IC50";"'='";"30.0";"nM";"7.52";"";"290540";"UO_0000065";"16.70";"0.31";"5.88";"5.87";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL3667440";"";"0";"405.46";"0";"2.17";"BDBM151013";"c1cc(-c2nc3c(N4CCOCC4)nc(N4CCOCC4)nc3[nH]2)c2cc[nH]c2c1";"IC50";"'='";"8.0";"nM";"8.10";"";"290559";"UO_0000065";"19.97";"0.37";"5.93";"8.51";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL3670203";"";"0";"351.45";"0";"2.15";"BDBM111679";"Cc1ncnc(N2CCC(O)(C(C)C)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.0";"nM";"8.30";"";"232502";"UO_0000065";"23.62";"0.44";"6.15";"9.42";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670205";"";"0";"336.44";"0";"2.76";"BDBM111681";"CCc1ncnc(N2CCC(OC)CC2)c1C#Cc1ccc(C)nc1";"IC50";"'='";"122.0";"nM";"6.91";"";"232504";"UO_0000065";"20.55";"0.38";"4.15";"13.52";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670223";"";"0";"351.45";"0";"2.49";"BDBM111699";"CCc1ncnc(N2CCC(OC)CC2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"9.0";"nM";"8.05";"";"232522";"UO_0000065";"22.89";"0.42";"5.56";"12.74";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670224";"";"0";"337.43";"0";"1.84";"BDBM111700";"CCc1ncnc(N2CCC(O)CC2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"20.0";"nM";"7.70";"";"232523";"UO_0000065";"22.82";"0.42";"5.86";"10.38";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670145";"";"0";"309.37";"0";"1.39";"BDBM111619";"Cc1ncnc(N2CCCOCC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"72.0";"nM";"7.14";"";"232442";"UO_0000065";"23.09";"0.42";"5.75";"9.26";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670163";"";"0";"350.43";"0";"1.27";"BDBM111637";"CC(=O)NC1CCCN(c2ncnc(C)c2C#Cc2ccc(N)nc2)C1";"IC50";"'='";"46.0";"nM";"7.34";"";"232460";"UO_0000065";"20.94";"0.39";"6.07";"7.56";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670149";"";"0";"322.37";"0";"0.49";"BDBM111623";"Cc1ncnc(N2CCNC(=O)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"41.0";"nM";"7.39";"";"232446";"UO_0000065";"22.92";"0.42";"6.90";"7.61";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670152";"";"0";"365.48";"0";"2.54";"BDBM111626";"Cc1ncnc(N2CCC(CC(C)(C)O)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"18.0";"nM";"7.75";"";"232449";"UO_0000065";"21.19";"0.39";"5.20";"8.78";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL2418350";"";"0";"423.52";"0";"3.10";"21c";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3CC)c3c(n2)c(C)nn3C)cc1";"IC50";"'='";"4.0";"nM";"8.40";"";"";"UO_0000065";"19.83";"0.37";"5.30";"8.64";"False";"CHEMBL2421123";"Inhibition of mTOR in PTEN deficient human PC3 cells assessed as inhibition of Akt phosphorylation at Ser473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2417437";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";"CHEMBL3307570"
"CHEMBL2418343";"";"0";"395.47";"0";"2.40";"11d";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@H]3C)c3c(ncn3C)n2)cc1";"IC50";"'='";"650.0";"nM";"6.19";"";"";"UO_0000065";"15.64";"0.29";"3.79";"6.37";"False";"CHEMBL2421123";"Inhibition of mTOR in PTEN deficient human PC3 cells assessed as inhibition of Akt phosphorylation at Ser473";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2417437";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";"CHEMBL3307570"
"CHEMBL2418350";"";"0";"423.52";"0";"3.10";"21c";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3CC)c3c(n2)c(C)nn3C)cc1";"IC50";"'='";"8.0";"nM";"8.10";"";"";"UO_0000065";"19.12";"0.36";"5.00";"8.33";"False";"CHEMBL2421122";"Inhibition of mTOR in PTEN deficient human PC3 cells assessed as inhibition of p70S6K phosphorylation";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"PC-3";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2417437";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";"CHEMBL3307570"
"CHEMBL3898563";"";"0";"447.54";"0";"3.62";"BDBM245485";"CO[C@H]1C[C@@H](n2c(=O)[nH]c3cnc4ccc(-c5ccc(OCCCN(C)C)nc5)cc4c32)C1";"IC50";"'='";"540.0";"nM";"6.27";"";"427895";"UO_0000065";"14.00";"0.26";"2.65";"7.35";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL4095781";"";"0";"588.68";"1";"4.43";"5n";"O=C(Nc1ccc(-c2nc(N3CCOCC3)c3cccnc3n2)cc1)Nc1ccc(S(=O)(=O)Nc2nccs2)cc1";"IC50";"'='";"8.8";"nM";"8.06";"";"";"UO_0000065";"13.68";"0.27";"3.63";"5.32";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL4102783";"";"0";"470.53";"0";"3.71";"4d";"O=C(Nc1ccc(CCO)cc1)Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1";"IC50";"'='";"40.6";"nM";"7.39";"";"";"UO_0000065";"15.71";"0.29";"3.68";"6.57";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL4087043";"";"0";"588.68";"1";"4.43";"4n";"O=C(Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1)Nc1ccc(S(=O)(=O)Nc2nccs2)cc1";"IC50";"'='";"54.9";"nM";"7.26";"";"";"UO_0000065";"12.33";"0.24";"2.83";"4.80";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL4072084";"";"0";"583.63";"1";"3.76";"4p";"O=C(Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1)Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1";"IC50";"'='";"26.2";"nM";"7.58";"";"";"UO_0000065";"12.99";"0.25";"3.82";"4.62";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL4097282";"";"0";"344.38";"0";"-0.42";"11";"Nc1ncc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cn1";"IC50";"'='";"415.0";"nM";"6.38";"";"";"UO_0000065";"18.53";"0.35";"6.80";"5.53";"False";"CHEMBL4019299";"Inhibition of mTOR in human A2058 cells assessed as reduction in phosphorylation of S6 at ser235/236 residues after 1 hr by in-cell Western method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017506";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL4081904";"";"0";"453.43";"0";"1.58";"17";"CC(=O)Nc1cc(C(F)(F)F)c(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cn1";"IC50";"'='";"729.0";"nM";"6.14";"";"";"UO_0000065";"13.54";"0.26";"4.56";"5.81";"False";"CHEMBL4019299";"Inhibition of mTOR in human A2058 cells assessed as reduction in phosphorylation of S6 at ser235/236 residues after 1 hr by in-cell Western method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017506";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL4098203";"";"0";"357.42";"0";"0.50";"14";"Cc1cc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cnc1N";"IC50";"'='";"1105.0";"nM";"5.96";"";"";"UO_0000065";"16.67";"0.31";"5.46";"5.81";"False";"CHEMBL4019299";"Inhibition of mTOR in human A2058 cells assessed as reduction in phosphorylation of S6 at ser235/236 residues after 1 hr by in-cell Western method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017506";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL4068426";"";"0";"343.39";"0";"0.19";"10";"Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cn1";"IC50";"'='";"415.0";"nM";"6.38";"";"";"UO_0000065";"18.59";"0.35";"6.19";"6.23";"False";"CHEMBL4019299";"Inhibition of mTOR in human A2058 cells assessed as reduction in phosphorylation of S6 at ser235/236 residues after 1 hr by in-cell Western method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017506";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL3693526";"";"0";"455.52";"0";"1.18";"BDBM174689";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(NC(CO)CO)nc3n2)cc1CO";"IC50";"'='";"25.0";"nM";"7.60";"";"319970";"UO_0000065";"16.69";"0.31";"6.42";"5.71";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693545";"";"0";"440.50";"0";"2.44";"BDBM174708";"COCCOc1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(OC)c(CO)c3)nc2n1";"IC50";"'='";"24.0";"nM";"7.62";"";"319990";"UO_0000065";"17.30";"0.33";"5.18";"7.69";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693550";"";"0";"435.48";"0";"2.71";"BDBM174713";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(OCCC#N)nc3n2)cc1CO";"IC50";"'='";"210.0";"nM";"6.68";"";"319995";"UO_0000065";"15.33";"0.29";"3.97";"5.88";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL4072637";"";"0";"363.39";"0";"0.84";"5";"CNC(=O)c1nc(-c2nc(-c3cnc4ccccn34)c(C)nc2N)n(C)n1";"IC50";"'='";"29000.0";"nM";"4.54";"";"";"UO_0000065";"12.49";"0.23";"3.70";"3.52";"False";"CHEMBL4035997";"Inhibition of m-TOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4033707";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL3797933";"";"0";"349.40";"0";"2.99";"17";"Nc1nc2cc(-c3nn(CC4CCCC4)c4ncnc(N)c34)ccc2o1";"IC50";"'='";"1.8";"nM";"8.74";"";"";"UO_0000065";"25.03";"0.46";"5.75";"7.19";"False";"CHEMBL3802992";"Inhibition of recombinant human mTOR by LanthaScreen Kinase assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3797068";"1";"Scientific Literature";"MedChemComm";"2016";""
"CHEMBL4087157";"";"0";"505.56";"1";"2.82";"5k";"NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)c4cccnc4n3)cc2)cc1";"IC50";"'='";"176.0";"nM";"6.75";"";"";"UO_0000065";"13.36";"0.26";"3.93";"4.43";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL3667446";"";"0";"409.49";"0";"2.05";"BDBM151019";"C[C@H]1CN(c2nc(N3CCOCC3)c3nc(-c4cccc(N)c4)[nH]c3n2)C[C@@H](C)O1";"IC50";"'='";"1044.0";"nM";"5.98";"";"290564";"UO_0000065";"14.61";"0.27";"3.93";"5.67";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688928";"";"0";"493.56";"0";"2.94";"BDBM174393";"COC(=O)c1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1OC";"IC50";"'='";"230.0";"nM";"6.64";"";"319711";"UO_0000065";"13.45";"0.25";"3.70";"6.70";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688930";"";"0";"478.55";"0";"2.12";"BDBM174395";"CNC(=O)c1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOCC4)nc3n2)ccc1OC";"IC50";"'='";"20.0";"nM";"7.70";"";"319713";"UO_0000065";"16.09";"0.30";"5.58";"7.55";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688937";"";"0";"512.64";"1";"2.19";"BDBM174414";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(CNS(C)(=O)=O)cc3)nc2n1";"IC50";"'='";"0.39";"nM";"9.41";"";"319718";"UO_0000065";"18.35";"0.36";"7.22";"8.57";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688947";"";"0";"484.58";"0";"2.12";"BDBM174424";"C[C@H]1COCCN1c1nc(N2CCOCC2)nc2nc(-c3cccc(NS(C)(=O)=O)c3)ccc12";"IC50";"'='";"4.8";"nM";"8.32";"";"319728";"UO_0000065";"17.17";"0.33";"6.20";"7.58";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL4092165";"";"0";"358.41";"0";"-0.11";"16";"Cc1nc(N)ncc1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1";"IC50";"'='";"831.0";"nM";"6.08";"";"";"UO_0000065";"16.96";"0.32";"6.19";"5.27";"False";"CHEMBL4019299";"Inhibition of mTOR in human A2058 cells assessed as reduction in phosphorylation of S6 at ser235/236 residues after 1 hr by in-cell Western method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017506";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL3693404";"";"0";"540.69";"1";"2.92";"BDBM174545";"CCS(=O)(=O)N(C)Cc1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"500.0";"nM";"6.30";"";"319841";"UO_0000065";"11.65";"0.23";"3.38";"6.24";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693408";"";"0";"494.57";"0";"2.92";"BDBM174549";"CC(=O)NCc1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccc1F";"IC50";"'='";"57.0";"nM";"7.24";"";"319845";"UO_0000065";"14.65";"0.27";"4.32";"7.81";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL2336326";"";"0";"492.58";"0";"1.86";"BDBM50429702";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(C(=O)NCCO)c3)nc2n1";"IC50";"'='";"28.0";"nM";"7.55";"";"319864";"UO_0000065";"15.33";"0.29";"5.69";"6.69";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693439";"";"0";"422.49";"0";"1.83";"BDBM174589";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cc[nH]c(=O)c3)nc2n1";"IC50";"'='";"140.0";"nM";"6.85";"";"319878";"UO_0000065";"16.22";"0.30";"5.02";"7.10";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693460";"";"0";"465.55";"0";"2.38";"BDBM174621";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCCC(O)C4)nc3n2)cc1CO";"IC50";"'='";"19.0";"nM";"7.72";"";"319899";"UO_0000065";"16.59";"0.31";"5.34";"7.42";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693474";"";"0";"532.69";"1";"3.87";"BDBM174636";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCC(N5CCCCC5)CC4)nc3n2)cc1CO";"IC50";"'='";"88.0";"nM";"7.06";"";"319914";"UO_0000065";"13.25";"0.25";"3.19";"8.10";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3410548";"";"0";"449.53";"0";"1.03";"11";"C[C@H]1COCCN1c1cc(CS(C)(=O)=O)nc(-c2ccc(NC(=O)NCCO)cc2)n1";"IC50";"'='";"5.754";"nM";"8.24";"";"";"UO_0000065";"18.33";"0.36";"7.21";"6.16";"False";"CHEMBL3413521";"Inhibition of recombinant truncated FLAG-tagged mTOR (1362 to 2549 aa) (unknown origin) expressed in HEK293 cells using biotinylated p70 peptide as substrate";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407414";"1";"Scientific Literature";"J. Med. Chem.";"2015";"CHEMBL3307715"
"CHEMBL2165039";"";"0";"333.36";"0";"2.87";"BDBM50394881";"COc1ccc(Nc2ncccc2-c2nc(C)nc3nc[nH]c23)cn1";"IC50";"'='";"292.0";"nM";"6.54";"";"254966";"UO_0000065";"19.60";"0.36";"3.66";"6.44";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3639453";"";"0";"468.52";"0";"4.49";"BDBM125283";"COc1ccc(CNc2cnc(Nc3ccc(OC)nc3)c(-c3nc(C)nc4[nH]cnc34)c2)cc1";"IC50";"'>'";"10000.0";"nM";"";"";"254995";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL4088526";"";"0";"414.44";"0";"3.31";"9p";"N#CCN1CCC(n2c(=O)cnc3cnc4cc(F)c(-c5cccnc5)cc4c32)CC1";"IC50";"'='";"80.0";"nM";"7.10";"";"";"UO_0000065";"17.12";"0.31";"3.79";"8.09";"False";"CHEMBL4023016";"Inhibition of N-terminal FLAG-tagged recombinant human mTOR (1362 to end residues)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020823";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL2165270";"";"0";"293.33";"0";"2.88";"BDBM50394887";"Cc1nc(N)cc(-c2cccnc2Nc2cccc(O)c2)n1";"IC50";"'='";"535.0";"nM";"6.27";"";"254941";"UO_0000065";"21.38";"0.39";"3.39";"6.47";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165013";"";"0";"407.48";"0";"1.38";"BDBM50394850";"COc1ccc(Nc2ncc(CN3CCNCC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"254955";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646454";"";"0";"342.37";"0";"3.34";"BDBM125296";"Cc1nc(-c2cnccc2Nc2cccc3[nH]ncc23)c2nc[nH]c2n1";"IC50";"'>'";"10000.0";"nM";"";"";"255010";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646455";"";"0";"333.36";"0";"2.87";"BDBM125297";"COc1ccc(Nc2ccncc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255011";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646457";"";"0";"383.42";"0";"4.02";"BDBM125299";"COc1ccc(Nc2nc3ccccc3cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255013";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646516";"";"0";"419.85";"0";"3.24";"BDBM125359";"COCCNc1nc(C)nc(-c2cc(Cl)cnc2Nc2cnc(OC)c(F)c2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255088";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL4209569";"";"0";"341.37";"0";"1.92";"7h";"CNc1ncc2c(-c3ccc(OC)cc3)nn(CC3OCCO3)c2n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4188979";"Inhibition of wild-type human partial length MTOR (L1382 to W2549 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4184298";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL4165357";"";"0";"573.06";"1";"4.57";"9h";"O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1)Nc1ccc(Cl)c(-c2cccnc2)c1";"IC50";"'='";"200.0";"nM";"6.70";"";"";"UO_0000065";"11.69";"0.22";"2.13";"5.69";"False";"CHEMBL4141549";"Inhibition of mTOR (unknown origin) using Ulight-4EBP1 peptide as substrate measured after 1 hr by Lance Ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4138149";"1";"Scientific Literature";"Eur J Med Chem";"2017";""
"CHEMBL3693528";"";"0";"464.53";"0";"1.35";"BDBM174691";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCNC(=O)C4)nc3n2)cc1CO";"IC50";"'='";"13.0";"nM";"7.89";"";"319972";"UO_0000065";"16.98";"0.32";"6.54";"6.98";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693544";"";"0";"426.47";"0";"1.79";"BDBM174707";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(OCCO)nc3n2)cc1CO";"IC50";"'='";"34.0";"nM";"7.47";"";"319989";"UO_0000065";"17.51";"0.33";"5.68";"6.79";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693547";"";"0";"467.57";"0";"2.75";"BDBM174710";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(OC(C)CN(C)C)nc3n2)cc1CO";"IC50";"'='";"79.0";"nM";"7.10";"";"319992";"UO_0000065";"15.19";"0.29";"4.35";"7.63";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693553";"";"0";"452.00";"1";"5.34";"BDBM174716";"CCC1CCCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(Cl)cc3)nc2n1";"IC50";"'='";"400.0";"nM";"6.40";"";"319998";"UO_0000065";"14.15";"0.27";"1.06";"11.77";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL586702";"";"0";"417.42";"0";"1.82";"21; ZSTK474";"FC(F)c1nc2ccccc2n1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1";"IC50";"'='";"370.0";"nM";"6.43";"";"";"UO_0000065";"15.41";"0.29";"4.61";"7.90";"False";"CHEMBL3861272";"Inhibition of human recombinant mTOR using substrate PI incubated for 1 hr by Adapta kinase assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3860068";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL3924247";"";"0";"433.51";"0";"2.85";"BDBM245477";"CN(C)CCCOc1ccc(-c2ccc3ncc4c(c3c2)n(C2COC2)c(=O)n4C)cn1";"IC50";"'='";"3460.0";"nM";"5.46";"";"427887";"UO_0000065";"12.60";"0.23";"2.61";"7.34";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3935033";"";"0";"479.56";"0";"3.77";"BDBM245493";"CN(C)CCCOc1ccc(-c2ccc3ncc4c(c3c2)n([C@H]2CCCOC2)c(=O)n4C)c(F)n1";"IC50";"'='";"529.0";"nM";"6.28";"";"427903";"UO_0000065";"13.09";"0.24";"2.51";"8.44";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3984782";"";"0";"447.54";"0";"3.29";"BDBM245512";"CNCCCOc1ccc(-c2ccc3ncc4c(c3c2)n(C2CCOCC2)c(=O)n4C)cn1";"IC50";"'='";"191.0";"nM";"6.72";"";"427923";"UO_0000065";"15.01";"0.28";"3.43";"8.08";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL4091820";"";"0";"429.48";"0";"3.66";"A18";"C[C@H]1COCCN1c1cc(-c2ccc(NC(=O)Nc3ccncc3)cc2)nn2ccnc12";"IC50";"'='";"62.0";"nM";"7.21";"";"";"UO_0000065";"16.78";"0.31";"3.55";"7.46";"False";"CHEMBL4009793";"Inhibition of human N-terminal FLAG-tagged mTOR (1362-end residues) in presence of [gamma33P]ATP after 40 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007445";"1";"Scientific Literature";"Eur J Med Chem";"2017";""
"CHEMBL3693587";"";"0";"435.48";"0";"2.81";"BDBM174753";"CC(=O)OC(C)C(=O)Nc1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccccc3)nc2n1";"IC50";"'='";"24.0";"nM";"7.62";"";"320032";"UO_0000065";"17.50";"0.33";"4.81";"7.15";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693576";"";"0";"443.51";"0";"3.48";"BDBM174742";"COc1ccc(-c2nc(N3CCOC[C@@H]3C)c3ccc(-c4cccc(CO)c4)nc3n2)cn1";"IC50";"'='";"240.0";"nM";"6.62";"";"320021";"UO_0000065";"14.93";"0.27";"3.14";"7.08";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3927903";"";"0";"407.93";"0";"3.50";"BDBM222550";"CCNC(=O)Nc1ccc(-c2nc(Cl)c(SC)c(N3CCOCC3)n2)cc1";"IC50";"'='";"116.3";"nM";"6.93";"";"389339";"UO_0000065";"17.00";"0.35";"3.43";"8.74";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3407718";"";"0";"451.46";"0";"2.78";"10i";"O=C(O)c1ccc2occ(/C=N/Nc3nc(N4CCOCC4)c4sccc4n3)c(=O)c2c1";"IC50";"'='";"3310.0";"nM";"5.48";"";"";"UO_0000065";"12.14";"0.23";"2.70";"4.21";"False";"CHEMBL3414045";"Inhibition of mTOR kinase (unknown origin) using ULight-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3407441";"1";"Scientific Literature";"Eur. J. Med. Chem.";"2015";""
"CHEMBL3357872";"";"0";"399.43";"0";"2.38";"BDBM125456";"COc1ncc(Nc2ncc(C(C)(C)CO)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255200";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3357867";"";"0";"425.35";"0";"2.71";"BDBM125460";"COc1ncc(Nc2ncc(C(O)C(F)(F)F)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'='";"2231.0";"nM";"5.65";"";"255205";"UO_0000065";"13.29";"0.26";"2.94";"4.28";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646616";"";"0";"501.57";"2";"1.18";"BDBM125473";"COc1ncc(Nc2ncc(CN3CCOCC3)cc2-c2nc(C)nc(N)n2)cc1NS(C)(=O)=O";"IC50";"'>'";"10000.0";"nM";"";"";"255228";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2206914";"";"0";"432.90";"0";"2.52";"BDBM50401268";"Cc1nc(N)nc(-c2cccnc2Nc2cnc(Cl)c(NS(=O)(=O)C3CC3)c2)n1";"IC50";"'='";"345.0";"nM";"6.46";"";"255256";"UO_0000065";"14.93";"0.30";"3.94";"4.35";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649464";"";"0";"520.02";"2";"2.38";"BDBM125503";"Cc1nc(N)nc(-c2cc([C@H](C)N3CCOCC3)cnc2Nc2cnc(Cl)c(NS(C)(=O)=O)c2)n1";"IC50";"'='";"339.0";"nM";"6.47";"";"255263";"UO_0000065";"12.44";"0.25";"4.09";"4.02";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649467";"";"0";"434.91";"0";"2.44";"BDBM125506";"Cc1nc(N)cc(-c2cccnc2Nc2cnc(Cl)c(NS(=O)(=O)N(C)C)c2)n1";"IC50";"'='";"3298.0";"nM";"5.48";"";"255266";"UO_0000065";"12.60";"0.26";"3.04";"3.94";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649471";"";"0";"431.91";"0";"3.24";"BDBM125510";"C=Cc1cnc(Nc2cnc(Cl)c(NS(C)(=O)=O)c2)c(-c2cc(N)nc(C)n2)c1";"IC50";"'='";"264.0";"nM";"6.58";"";"255271";"UO_0000065";"15.23";"0.31";"3.34";"4.84";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646430";"";"0";"438.50";"0";"4.48";"BDBM125271";"COc1ccc(Nc2ncc(CNc3ccccc3)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"254983";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646434";"";"0";"502.58";"1";"2.67";"BDBM125275";"COc1ccc(Nc2ncc(CN3CCN(C(=O)N(C)C)CC3)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'='";"1874.0";"nM";"5.73";"";"254987";"UO_0000065";"11.40";"0.21";"3.06";"4.46";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649477";"";"0";"419.49";"0";"3.95";"BDBM125516";"COc1ccc(Nc2ncc([C@H](O)C(C)(C)C)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'='";"251.0";"nM";"6.60";"";"255033";"UO_0000065";"15.73";"0.29";"2.65";"5.42";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646473";"";"0";"418.51";"0";"3.76";"BDBM125315";"COc1ccc(Nc2ncc(CNC(C)(C)C)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255034";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165020";"";"0";"484.59";"0";"2.19";"BDBM50394843";"COc1ccc(Nc2ncc(CC3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255055";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646491";"";"0";"496.55";"0";"1.91";"BDBM125333";"COc1ncc(Nc2ncc(CN3CCN(C(=O)N(C)C)CC3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255059";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646523";"";"0";"512.60";"2";"1.00";"BDBM125366";"CC(=O)Nc1ccc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"1115.0";"nM";"5.95";"";"255095";"UO_0000065";"11.61";"0.23";"4.95";"3.46";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3586399";"";"0";"411.51";"0";"2.73";"32";"CO[C@H]1CC[C@H](CN2C(=O)CNc3ncc(-c4ccc(C(C)(C)O)nc4)nc32)CC1";"IC50";"'='";"97.0";"nM";"7.01";"";"";"UO_0000065";"17.04";"0.32";"4.28";"6.98";"False";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3735771";"";"0";"410.48";"0";"4.28";"9a";"Cn1nccc1-c1ccc2ncc(C(N)=O)c(Nc3ccc(C(C)(C)C#N)cc3)c2c1";"IC50";"'='";"1105.0";"nM";"5.96";"";"";"UO_0000065";"14.51";"0.26";"1.68";"5.43";"False";"CHEMBL3738862";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide as substrate after 1 hr by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3734757";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2015";""
"CHEMBL3360065";"";"0";"529.26";"1";"3.78";"7b";"Oc1c(Br)cc(/C=N/Nc2nc3c(c(N4CCOCC4)n2)CSCC3)cc1Br";"IC50";"'='";"2670.0";"nM";"5.57";"";"";"UO_0000065";"10.53";"0.27";"1.79";"6.73";"False";"CHEMBL3371734";"Inhibition of mTOR kinase (unknown origin) after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352220";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2014";""
"CHEMBL573339";"PI-103";"0";"348.36";"0";"2.98";"PI-103";"Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1";"IC50";"'='";"19.0";"nM";"7.72";"";"";"UO_0000065";"22.16";"0.41";"4.74";"9.14";"True";"CHEMBL3371734";"Inhibition of mTOR kinase (unknown origin) after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352220";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2014";""
"CHEMBL3354566";"";"0";"467.53";"1";"5.65";"NVP-BEZ235";"Cn1c(=O)n(-c2ccc(C3(C#N)CC3)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"18.61";"0.33";"3.05";"11.37";"False";"CHEMBL3377242";"Inhibition of human mTOR by non-radiometric ADP-Glo assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352433";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL3360085";"";"0";"463.52";"1";"0.95";"10e";"COc1cc(/C=N/Nc2nc3c(c(N4CCOCC4)n2)CS(=O)(=O)CC3)cc(OC)c1O";"IC50";"'='";"2200.0";"nM";"5.66";"";"";"UO_0000065";"12.21";"0.24";"4.71";"4.18";"False";"CHEMBL3371734";"Inhibition of mTOR kinase (unknown origin) after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352220";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2014";""
"CHEMBL3360071";"";"0";"450.36";"0";"3.02";"7h";"Oc1ccc(/C=N/Nc2nc3c(c(N4CCOCC4)n2)CSCC3)cc1Br";"IC50";"'='";"1940.0";"nM";"5.71";"";"";"UO_0000065";"12.68";"0.29";"2.69";"6.89";"False";"CHEMBL3371734";"Inhibition of mTOR kinase (unknown origin) after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352220";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2014";""
"CHEMBL3955062";"";"0";"556.64";"1";"3.18";"BDBM178439";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)NC(C)(C)CO)c(F)c3)c2C1=O";"IC50";"'='";"1120.0";"nM";"5.95";"";"324459";"UO_0000065";"10.69";"0.20";"2.77";"4.61";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3963825";"";"0";"654.77";"1";"4.55";"BDBM178466";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(N5CC6CCC(C5)O6)cn4)cc3)c2C1=O";"IC50";"'='";"64.0";"nM";"7.19";"";"324486";"UO_0000065";"10.99";"0.20";"2.64";"5.36";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL2325706";"";"0";"441.56";"0";"2.08";"14";"CS(=O)(=O)C1(c2cc(N3CCOCC3)nc(-c3cccc4[nH]ccc34)n2)CCNCC1";"IC50";"'='";"230.0";"nM";"6.64";"";"";"UO_0000065";"15.03";"0.29";"4.56";"6.62";"False";"CHEMBL2330634";"Inhibition of recombinant mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2321758";"1";"Scientific Literature";"J. Med. Chem.";"2013";""
"CHEMBL3693493";"";"0";"506.65";"1";"3.20";"BDBM174655";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCCC(CN(C)C)C4)nc3n2)cc1CO";"IC50";"'='";"80.0";"nM";"7.10";"";"319933";"UO_0000065";"14.01";"0.26";"3.90";"8.15";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693552";"";"0";"437.98";"0";"4.95";"BDBM174715";"C[C@H]1CCCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(Cl)cc3)nc2n1";"IC50";"'='";"260.0";"nM";"6.58";"";"319997";"UO_0000065";"15.03";"0.29";"1.64";"12.11";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3916654";"";"0";"451.41";"0";"4.39";"BDBM213783";"CN1Cc2cnc3ccc(-c4cnc(N)nc4)nc3c2N(c2cccc(C(F)(F)F)c2)C1=O";"IC50";"'='";"8.5";"nM";"8.07";"";"375939";"UO_0000065";"17.88";"0.33";"3.68";"7.98";"False";"CHEMBL3888153";"mTOR Activity Assay: 1. Preparation of test reagents {circle around (1)} 1x kinase buffer (50 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 3 mM MnCl, 0.01% Tween-20, 2 mM DTT); {circle around (2)} 4x kinase solution (added mTOR kinase to 1x kinase buffer to provide 4x kinase solution with a final concentration of 2.5 nM); {circle around (3)} 2x substrate solution (added the substrates of 4EBP1 and ATP into 1x kinase buffer to provide 2x substrate solution with 4EBP1 final concentration of 50 nM and ATP final concentration of 10.8 uM); {circle around (4)} 4x test substance solutions (100x test substance solutions with different concentration gradients were prepared using 100% DMSO, and diluted 25-fold with 1x kinase buffer to give 4x test substance solutions with different concentration gradients) {circle around (5)} preparation of test solution (test solution containing EDTA and 4EBP1 phosphorylated antibody was prepared using activity test kit with assay buffer, the final concentration of EDTA was 8 mM, and the final concentration of 4EBP1 phosphorylated antibody was 2 nM) 2. 2.5 uL of 4x test solution was added to a 384-well plate in parallel; 3. added 2.54 uL of 4x kinase solution and incubated for 10 min; 4. then added 5 uL of 2x solutions of 4EBP1 and ATP substrates and incubated for 1 h at room temperature; 5. finally, added 10 uL of test solution to quench the reaction, and read after 60 min; 6. IC50 value was obtained via curve fitting.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886601";"37";"BindingDB Database";"";"2016";""
"CHEMBL3982245";"";"0";"450.42";"0";"5.00";"BDBM213776";"CN1Cc2cnc3ccc(-c4ccc(N)nc4)nc3c2N(c2cccc(C(F)(F)F)c2)C1=O";"IC50";"'='";"8.86";"nM";"8.05";"";"375943";"UO_0000065";"17.88";"0.33";"3.05";"9.13";"False";"CHEMBL3888153";"mTOR Activity Assay: 1. Preparation of test reagents {circle around (1)} 1x kinase buffer (50 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 3 mM MnCl, 0.01% Tween-20, 2 mM DTT); {circle around (2)} 4x kinase solution (added mTOR kinase to 1x kinase buffer to provide 4x kinase solution with a final concentration of 2.5 nM); {circle around (3)} 2x substrate solution (added the substrates of 4EBP1 and ATP into 1x kinase buffer to provide 2x substrate solution with 4EBP1 final concentration of 50 nM and ATP final concentration of 10.8 uM); {circle around (4)} 4x test substance solutions (100x test substance solutions with different concentration gradients were prepared using 100% DMSO, and diluted 25-fold with 1x kinase buffer to give 4x test substance solutions with different concentration gradients) {circle around (5)} preparation of test solution (test solution containing EDTA and 4EBP1 phosphorylated antibody was prepared using activity test kit with assay buffer, the final concentration of EDTA was 8 mM, and the final concentration of 4EBP1 phosphorylated antibody was 2 nM) 2. 2.5 uL of 4x test solution was added to a 384-well plate in parallel; 3. added 2.54 uL of 4x kinase solution and incubated for 10 min; 4. then added 5 uL of 2x solutions of 4EBP1 and ATP substrates and incubated for 1 h at room temperature; 5. finally, added 10 uL of test solution to quench the reaction, and read after 60 min; 6. IC50 value was obtained via curve fitting.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886601";"37";"BindingDB Database";"";"2016";""
"CHEMBL3925661";"";"0";"533.56";"2";"5.17";"BDBM213781";"CN1CCN(c2ccc(-c3ccc4ncc5c(c4n3)N(c3cccc(C(F)(F)F)c3)C(=O)N(C)C5)cn2)CC1";"IC50";"'='";"31.2";"nM";"7.51";"";"375947";"UO_0000065";"14.07";"0.26";"2.34";"10.93";"False";"CHEMBL3888153";"mTOR Activity Assay: 1. Preparation of test reagents {circle around (1)} 1x kinase buffer (50 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 3 mM MnCl, 0.01% Tween-20, 2 mM DTT); {circle around (2)} 4x kinase solution (added mTOR kinase to 1x kinase buffer to provide 4x kinase solution with a final concentration of 2.5 nM); {circle around (3)} 2x substrate solution (added the substrates of 4EBP1 and ATP into 1x kinase buffer to provide 2x substrate solution with 4EBP1 final concentration of 50 nM and ATP final concentration of 10.8 uM); {circle around (4)} 4x test substance solutions (100x test substance solutions with different concentration gradients were prepared using 100% DMSO, and diluted 25-fold with 1x kinase buffer to give 4x test substance solutions with different concentration gradients) {circle around (5)} preparation of test solution (test solution containing EDTA and 4EBP1 phosphorylated antibody was prepared using activity test kit with assay buffer, the final concentration of EDTA was 8 mM, and the final concentration of 4EBP1 phosphorylated antibody was 2 nM) 2. 2.5 uL of 4x test solution was added to a 384-well plate in parallel; 3. added 2.54 uL of 4x kinase solution and incubated for 10 min; 4. then added 5 uL of 2x solutions of 4EBP1 and ATP substrates and incubated for 1 h at room temperature; 5. finally, added 10 uL of test solution to quench the reaction, and read after 60 min; 6. IC50 value was obtained via curve fitting.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886601";"37";"BindingDB Database";"";"2016";""
"CHEMBL3903068";"";"0";"549.56";"1";"4.83";"BDBM213786";"COc1ccc(-c2ccc3ncc4c(c3n2)N(c2ccc(N3CCNCC3)c(C(F)(F)F)c2)C(=O)N(C)C4)cn1";"IC50";"'='";"91.94";"nM";"7.04";"";"375950";"UO_0000065";"12.80";"0.24";"2.21";"8.11";"False";"CHEMBL3888153";"mTOR Activity Assay: 1. Preparation of test reagents {circle around (1)} 1x kinase buffer (50 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 3 mM MnCl, 0.01% Tween-20, 2 mM DTT); {circle around (2)} 4x kinase solution (added mTOR kinase to 1x kinase buffer to provide 4x kinase solution with a final concentration of 2.5 nM); {circle around (3)} 2x substrate solution (added the substrates of 4EBP1 and ATP into 1x kinase buffer to provide 2x substrate solution with 4EBP1 final concentration of 50 nM and ATP final concentration of 10.8 uM); {circle around (4)} 4x test substance solutions (100x test substance solutions with different concentration gradients were prepared using 100% DMSO, and diluted 25-fold with 1x kinase buffer to give 4x test substance solutions with different concentration gradients) {circle around (5)} preparation of test solution (test solution containing EDTA and 4EBP1 phosphorylated antibody was prepared using activity test kit with assay buffer, the final concentration of EDTA was 8 mM, and the final concentration of 4EBP1 phosphorylated antibody was 2 nM) 2. 2.5 uL of 4x test solution was added to a 384-well plate in parallel; 3. added 2.54 uL of 4x kinase solution and incubated for 10 min; 4. then added 5 uL of 2x solutions of 4EBP1 and ATP substrates and incubated for 1 h at room temperature; 5. finally, added 10 uL of test solution to quench the reaction, and read after 60 min; 6. IC50 value was obtained via curve fitting.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886601";"37";"BindingDB Database";"";"2016";""
"CHEMBL4217649";"";"0";"509.62";"2";"2.76";"12c";"CCN1CCN(c2ccc(-c3nn(Cc4cn(Cc5ccccc5)nn4)c4nc(NC)ncc34)cn2)CC1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4188979";"Inhibition of wild-type human partial length MTOR (L1382 to W2549 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4184298";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL3701086";"";"0";"469.56";"0";"3.75";"BDBM172220";"CCc1nccc(-c2ccc(C(=O)N3CCN(C4CC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.0";"nM";"8.40";"";"317144";"UO_0000065";"17.88";"0.33";"4.65";"11.15";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701094";"";"0";"374.42";"0";"3.27";"BDBM172229";"Cc1nccc(-c2ccc(F)c(C(=O)N(C)C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"12.0";"nM";"7.92";"";"317153";"UO_0000065";"21.15";"0.39";"4.65";"10.98";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701101";"";"0";"418.47";"0";"3.29";"BDBM172236";"COCCN(C)C(=O)c1cc(-c2ccnc(C)c2C#Cc2ccc(N)nc2)ccc1F";"IC50";"'='";"6.0";"nM";"8.22";"";"317160";"UO_0000065";"19.65";"0.36";"4.93";"10.11";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701110";"";"0";"443.53";"0";"3.35";"BDBM172245";"Cc1nccc(-c2ccc(F)c(C(=O)N(C)C3CCN(C)C3)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"37.0";"nM";"7.43";"";"317169";"UO_0000065";"16.76";"0.31";"4.08";"9.86";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3109137";"";"0";"308.34";"0";"2.23";"12a";"Oc1cccc(-c2nc(N3CCOCC3)c3cccnc3n2)c1";"IC50";"'='";"100.0";"nM";"7.00";"";"";"UO_0000065";"22.70";"0.42";"4.77";"9.81";"False";"CHEMBL3112126";"Inhibition of mTOR (unknown origin) after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3108735";"1";"Scientific Literature";"J. Med. Chem.";"2014";""
"CHEMBL3688876";"";"0";"449.56";"0";"3.29";"BDBM174337";"COCc1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"140.0";"nM";"6.85";"";"319653";"UO_0000065";"15.25";"0.28";"3.56";"9.41";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688878";"";"0";"484.58";"0";"1.79";"BDBM174339";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(S(N)(=O)=O)c3)nc2n1";"IC50";"'='";"14.0";"nM";"7.85";"";"319655";"UO_0000065";"16.21";"0.32";"6.06";"6.35";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688886";"";"0";"430.51";"0";"3.01";"BDBM174347";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(C#N)cc3)nc2n1";"IC50";"'='";"2.7";"nM";"8.57";"";"319663";"UO_0000065";"19.90";"0.37";"5.56";"9.80";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688889";"";"0";"435.53";"0";"3.15";"BDBM174350";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1";"IC50";"'='";"18.0";"nM";"7.75";"";"319666";"UO_0000065";"17.78";"0.33";"4.59";"10.63";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693551";"";"0";"451.53";"0";"2.95";"BDBM174714";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCCCO4)nc3n2)cc1CO";"IC50";"'='";"28.0";"nM";"7.55";"";"319996";"UO_0000065";"16.73";"0.31";"4.60";"8.12";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693579";"";"0";"443.51";"0";"3.48";"BDBM174745";"COc1cncc(-c2nc(N3CCOC[C@@H]3C)c3ccc(-c4cccc(CO)c4)nc3n2)c1";"IC50";"'='";"2000.0";"nM";"5.70";"";"320024";"UO_0000065";"12.85";"0.24";"2.22";"6.10";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693582";"";"0";"416.49";"0";"2.81";"BDBM174748";"C[C@H]1COCCN1c1nc(-c2cnn(C)c2)nc2nc(-c3cccc(CO)c3)ccc12";"IC50";"'='";"70.0";"nM";"7.16";"";"320027";"UO_0000065";"17.18";"0.32";"4.34";"8.02";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693586";"";"0";"485.54";"0";"3.67";"BDBM174752";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(NC(=O)c4ccccc4)nc3n2)cc1CO";"IC50";"'='";"670.0";"nM";"6.17";"";"320031";"UO_0000065";"12.72";"0.23";"2.50";"5.63";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688834";"";"0";"435.53";"0";"2.63";"BDBM174292";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(CO)cc3)nc2n1";"IC50";"'='";"11.0";"nM";"7.96";"";"319607";"UO_0000065";"18.27";"0.34";"5.33";"9.49";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688835";"";"0";"421.50";"0";"2.85";"BDBM174293";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(O)c3)nc2n1";"IC50";"'='";"2.1";"nM";"8.68";"";"319608";"UO_0000065";"20.59";"0.38";"5.83";"10.35";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688836";"";"0";"435.53";"0";"2.63";"BDBM174294";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(CO)c3)nc2n1";"IC50";"'='";"5.6";"nM";"8.25";"";"319609";"UO_0000065";"18.95";"0.35";"5.62";"9.84";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688844";"";"0";"437.50";"0";"1.94";"BDBM174302";"COc1ncc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cn1";"IC50";"'='";"230.0";"nM";"6.64";"";"319618";"UO_0000065";"15.17";"0.28";"4.70";"6.73";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688848";"";"0";"440.94";"0";"3.19";"BDBM174307";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccnc(Cl)c3)nc2n1";"IC50";"'='";"260.0";"nM";"6.58";"";"319623";"UO_0000065";"14.93";"0.29";"3.40";"8.61";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701112";"";"0";"418.47";"0";"3.03";"BDBM172247";"Cc1nccc(-c2ccc(F)c(C(=O)N(C)CCCO)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"317171";"UO_0000065";"20.37";"0.38";"5.49";"9.23";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701170";"";"0";"501.61";"1";"3.69";"BDBM172305";"CCc1nccc(-c2ccc(C(=O)N3CCN(CCOC)CC3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"13.0";"nM";"7.89";"";"317229";"UO_0000065";"15.72";"0.29";"4.20";"11.17";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701172";"";"0";"458.54";"0";"3.86";"BDBM172307";"CCc1nc(N)ccc1C#Cc1c(-c2ccc(C(=O)N3CCOCC3)c(F)c2)ccnc1CC";"IC50";"'='";"41.0";"nM";"7.39";"";"317231";"UO_0000065";"16.11";"0.30";"3.53";"9.08";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701181";"";"0";"455.52";"0";"2.27";"BDBM172316";"CCc1nccc(-c2ccc(C(=O)N3CCNC(=O)C3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"317240";"UO_0000065";"18.71";"0.34";"6.25";"7.72";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3586387";"";"0";"420.48";"0";"2.21";"19";"Cc1nc(-c2nc[nH]n2)ccc1-c1cnc2c(n1)N(CCC1CCOCC1)C(=O)CN2";"IC50";"'='";"14.0";"nM";"7.85";"";"";"UO_0000065";"18.68";"0.35";"5.64";"6.45";"True";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3688961";"";"0";"532.65";"1";"2.74";"BDBM174438";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(C(=O)N4CCC[C@@H](O)C4)c3)nc2n1";"IC50";"'='";"280.0";"nM";"6.55";"";"319742";"UO_0000065";"12.30";"0.23";"3.81";"6.29";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688963";"";"0";"530.55";"1";"3.43";"BDBM174440";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(C(=O)NCC(F)(F)F)c3)nc2n1";"IC50";"'='";"280.0";"nM";"6.55";"";"319744";"UO_0000065";"12.35";"0.24";"3.12";"7.07";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693447";"";"0";"518.62";"1";"3.26";"BDBM174604";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(NC(=O)C4CCCO4)c3)nc2n1";"IC50";"'='";"330.0";"nM";"6.48";"";"319886";"UO_0000065";"12.50";"0.23";"3.22";"6.36";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL2348863";"";"0";"369.43";"0";"1.84";"9b";"CC(C)(O)c1ccc(-c2cnc3[nH]c(=O)n(CC4CCOCC4)c3n2)cn1";"IC50";"'='";"176.0";"nM";"6.75";"";"";"UO_0000065";"18.28";"0.34";"4.91";"6.38";"False";"CHEMBL2352069";"Inhibition of recombinant mTOR (unknown origin) using GST-p70S6 as substrate after 60 mins by TR-FRET analysis";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2346597";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";""
"CHEMBL3693451";"";"0";"381.44";"0";"2.00";"BDBM174612";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N)nc3n2)cc1CO";"IC50";"'='";"100.0";"nM";"7.00";"";"319890";"UO_0000065";"18.35";"0.34";"5.00";"6.57";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693386";"";"0";"598.75";"1";"4.49";"BDBM174522";"COc1ccc(CCNCc2cc(-c3ccc4c(N5CCOC[C@@H]5C)nc(N5CCOC[C@@H]5C)nc4n3)ccc2OC)cc1";"IC50";"'='";"120.0";"nM";"6.92";"";"319823";"UO_0000065";"11.56";"0.21";"2.43";"7.35";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693465";"";"0";"458.52";"0";"3.56";"BDBM174626";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(Nc4ccccn4)nc3n2)cc1CO";"IC50";"'='";"250.0";"nM";"6.60";"";"319904";"UO_0000065";"14.40";"0.27";"3.04";"6.26";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693381";"";"0";"520.68";"1";"4.04";"BDBM174517";"CCCCNCc1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccc1OC";"IC50";"'='";"140.0";"nM";"6.85";"";"319818";"UO_0000065";"13.16";"0.25";"2.81";"8.08";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701064";"";"0";"377.47";"0";"3.09";"BDBM172198";"CCc1nccc(-c2ccc(S(C)(=O)=O)cc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"17.0";"nM";"7.77";"";"317122";"UO_0000065";"20.58";"0.39";"4.68";"9.04";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701073";"";"0";"328.42";"0";"3.70";"BDBM172207";"CCc1nccc(-c2cc(C)nc(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"78.0";"nM";"7.11";"";"317131";"UO_0000065";"21.64";"0.39";"3.41";"10.99";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3947476";"";"0";"531.62";"1";"4.04";"BDBM178436";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccccn4)cc3)c2C1=O";"IC50";"'='";"13.0";"nM";"7.89";"";"324456";"UO_0000065";"14.83";"0.28";"3.85";"6.47";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688863";"";"0";"490.61";"0";"3.28";"BDBM174322";"CC(C)NC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"230.0";"nM";"6.64";"";"319638";"UO_0000065";"13.53";"0.25";"3.36";"7.16";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688874";"";"0";"442.47";"0";"2.82";"BDBM174334";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cc(F)nc(F)c3)nc2n1";"IC50";"'='";"150.0";"nM";"6.82";"";"319651";"UO_0000065";"15.42";"0.29";"4.00";"8.92";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3905018";"";"0";"582.67";"1";"4.66";"BDBM178333";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4nc5ccccc5[nH]4)cc3)c2C1=O";"IC50";"'='";"58.0";"nM";"7.24";"";"324353";"UO_0000065";"12.42";"0.23";"2.58";"5.26";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3961707";"";"0";"550.60";"1";"3.57";"BDBM178375";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4cnccn4)c(F)c3)c2C1=O";"IC50";"'='";"41.0";"nM";"7.39";"";"324395";"UO_0000065";"13.42";"0.25";"3.82";"5.48";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701125";"";"0";"483.59";"0";"3.99";"BDBM172260";"CCc1nccc(-c2ccc(C(=O)N3CCN(CC4CC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"317184";"UO_0000065";"17.99";"0.33";"4.71";"11.54";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701128";"";"0";"457.55";"0";"3.60";"BDBM172263";"CCc1nccc(-c2ccc(C(=O)N3CCCN(C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"10.0";"nM";"8.00";"";"317187";"UO_0000065";"17.48";"0.32";"4.40";"10.62";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701132";"";"0";"471.58";"0";"3.99";"BDBM172267";"CCc1nccc(-c2ccc(C(=O)N3CCN(C(C)C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"317191";"UO_0000065";"18.45";"0.34";"4.71";"11.54";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701147";"";"0";"457.55";"0";"3.60";"BDBM172282";"CCc1nccc(-c2ccc(C(=O)N3CCN(C)C(C)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"6.0";"nM";"8.22";"";"317206";"UO_0000065";"17.97";"0.33";"4.62";"10.91";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688966";"";"0";"532.65";"1";"3.05";"BDBM174443";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(C(=O)NC4CCOCC4)c3)nc2n1";"IC50";"'='";"140.0";"nM";"6.85";"";"319747";"UO_0000065";"12.87";"0.24";"3.80";"6.72";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688982";"";"0";"520.61";"1";"3.54";"BDBM174459";"C=CCN(C)C(=O)c1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccc1F";"IC50";"'='";"340.0";"nM";"6.47";"";"319764";"UO_0000065";"12.42";"0.23";"2.93";"7.71";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688983";"";"0";"508.60";"1";"3.37";"BDBM174460";"CCN(C)C(=O)c1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccc1F";"IC50";"'='";"26.0";"nM";"7.58";"";"319765";"UO_0000065";"14.91";"0.28";"4.22";"9.04";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689024";"";"0";"532.69";"1";"4.18";"BDBM174506";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CNC1CCCC1";"IC50";"'='";"95.0";"nM";"7.02";"";"319807";"UO_0000065";"13.18";"0.25";"2.84";"8.27";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3357875";"";"0";"381.44";"0";"2.51";"14";"COc1ncc(Nc2ncc(C(C)(C)O)cc2-c2nc(C)nc(N)n2)cc1C";"IC50";"'='";"7800.0";"nM";"5.11";"";"";"UO_0000065";"13.39";"0.25";"2.60";"3.87";"False";"CHEMBL3379685";"Inhibition of recombinant N-terminally GST-tagged mTOR (1360 to 2549 aa) (unknown origin) assessed as inhibition of 27BP1 phosphorylation after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352452";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL98350";"LY-294002";"0";"307.35";"0";"3.30";"22; LY294002";"O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12";"IC50";"'='";"3900.0";"nM";"5.41";"";"";"UO_0000065";"17.60";"0.32";"2.11";"12.67";"False";"CHEMBL3377242";"Inhibition of human mTOR by non-radiometric ADP-Glo assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352433";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL3643151";"";"0";"543.12";"2";"5.22";"BDBM115767";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCCCCC4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"43.0";"nM";"7.37";"";"240404";"UO_0000065";"13.56";"0.26";"2.15";"8.35";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643938";"";"0";"359.39";"0";"3.51";"BDBM125261";"C=Cc1cnc(Nc2ccc(OC)nc2)c(-c2nc(C)nc3[nH]cnc23)c1";"IC50";"'>'";"10000.0";"nM";"";"";"254973";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643939";"";"0";"361.41";"0";"3.43";"BDBM125262";"CCc1cnc(Nc2ccc(OC)nc2)c(-c2nc(C)nc3[nH]cnc23)c1";"IC50";"'>'";"10000.0";"nM";"";"";"254974";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643940";"";"0";"377.41";"0";"2.41";"BDBM125263";"COc1ccc(Nc2ncc(CCO)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'='";"248.0";"nM";"6.61";"";"254975";"UO_0000065";"17.50";"0.32";"4.20";"5.43";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646427";"";"0";"440.47";"0";"3.27";"BDBM125268";"COc1ccc(Nc2ncc(CNc3cccnn3)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"254980";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646428";"";"0";"439.48";"0";"3.88";"BDBM125269";"COc1ccc(Nc2ncc(CNc3ccncc3)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"254981";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643182";"";"0";"484.58";"0";"3.58";"BDBM115825";"CCc1ncnc(-c2ccc(C(=O)NC3CC(N4CCCC4)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"11.0";"nM";"7.96";"";"240437";"UO_0000065";"16.42";"0.30";"4.38";"8.20";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643204";"";"0";"433.90";"0";"3.65";"BDBM115847";"Cc1ncnc(-c2ccc(C(=O)N3CCCCO3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"22.0";"nM";"7.66";"";"240459";"UO_0000065";"17.65";"0.34";"4.01";"8.13";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643210";"";"0";"458.54";"0";"3.00";"BDBM115853";"CCc1ncnc(-c2ccc(C(=O)N3CC[C@H](N(C)C)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"18.0";"nM";"7.75";"";"240465";"UO_0000065";"16.89";"0.31";"4.74";"8.78";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643145";"";"0";"479.99";"0";"2.94";"BDBM115761";"CCc1ncnc(-c2ccc(C(=O)N3CC[S+]([O-])CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.5";"nM";"8.60";"";"240491";"UO_0000065";"17.92";"0.36";"5.66";"8.43";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643147";"";"0";"475.98";"0";"3.72";"BDBM115763";"CCc1ncnc(-c2ccc(C(=O)N3CCC(C)(O)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.9";"nM";"8.23";"";"240493";"UO_0000065";"17.29";"0.33";"4.51";"7.82";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643250";"";"0";"484.60";"0";"3.26";"BDBM115915";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N(C)C)CC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"33.19";"nM";"7.48";"";"240527";"UO_0000065";"15.43";"0.28";"4.22";"7.67";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643261";"";"0";"544.10";"1";"3.59";"BDBM115926";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCN(C)CC4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.18";"nM";"8.93";"";"240538";"UO_0000065";"16.41";"0.31";"5.34";"9.76";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643268";"";"0";"475.00";"0";"3.51";"BDBM115933";"CCc1ncnc(-c2ccc(C(=O)N3CC[C@H](N(C)C)C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.87";"nM";"8.54";"";"240545";"UO_0000065";"17.98";"0.34";"5.03";"9.68";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645773";"";"0";"468.61";"0";"3.56";"BDBM115951";"CCc1ncnc(-c2ccc(C(=O)N3CCCC(N(C)C)C3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"12.84";"nM";"7.89";"";"240563";"UO_0000065";"16.84";"0.31";"4.33";"8.94";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645775";"";"0";"508.67";"1";"4.34";"BDBM115953";"CCc1ncnc(-c2ccc(C(=O)N3CCC4(CCN(C)CC4)CC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"14.54";"nM";"7.84";"";"240565";"UO_0000065";"15.41";"0.28";"3.50";"8.88";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645792";"";"0";"494.64";"0";"4.09";"BDBM115970";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C4CCCC4)CC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.83";"nM";"8.74";"";"240582";"UO_0000065";"17.66";"0.32";"4.65";"9.90";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645795";"";"0";"497.60";"0";"3.76";"BDBM115973";"CCc1ncnc(-c2ccc(C(=O)N3CCC4(CC3)OCCCO4)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.09";"nM";"8.29";"";"240585";"UO_0000065";"16.67";"0.31";"4.53";"8.02";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645815";"";"0";"470.55";"0";"3.14";"BDBM115993";"CCc1ncnc(-c2ccc(C(=O)N3CCN4CCC[C@@H]4C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.69";"nM";"8.77";"";"240605";"UO_0000065";"18.64";"0.34";"5.63";"9.94";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645835";"";"0";"488.54";"0";"3.19";"BDBM116013";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCC4(CC3)CNC4)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"10.4";"nM";"7.98";"";"240625";"UO_0000065";"16.34";"0.30";"4.79";"8.23";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645877";"";"0";"510.43";"1";"4.23";"BDBM116056";"CCc1ncnc(-c2cc(Cl)c(C(=O)N3CCC(CO)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.59";"nM";"9.23";"";"240668";"UO_0000065";"18.08";"0.36";"5.00";"8.77";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645883";"";"0";"490.56";"0";"3.60";"BDBM116062";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(CC)CC3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"3.58";"nM";"8.45";"";"240674";"UO_0000065";"17.22";"0.32";"4.85";"11.38";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645884";"";"0";"534.61";"1";"3.35";"BDBM116063";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(CC(C)(C)O)CC3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"2.3";"nM";"8.64";"";"240675";"UO_0000065";"16.16";"0.30";"5.29";"9.14";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645889";"";"0";"526.54";"1";"3.84";"BDBM116068";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(CC(F)F)CC3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"7.56";"nM";"8.12";"";"240680";"UO_0000065";"15.42";"0.29";"4.28";"10.94";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645890";"";"0";"491.54";"0";"3.81";"BDBM116069";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCC(C)(O)CC3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"4.69";"nM";"8.33";"";"240681";"UO_0000065";"16.94";"0.32";"4.52";"9.13";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645901";"";"0";"494.52";"0";"3.49";"BDBM116080";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C)CC3)c(C(F)(F)F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"8.85";"nM";"8.05";"";"240692";"UO_0000065";"16.28";"0.31";"4.56";"9.13";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645906";"";"0";"507.01";"1";"4.04";"BDBM116085";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(C(C)C)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.67";"nM";"9.17";"";"240697";"UO_0000065";"18.09";"0.35";"5.13";"10.40";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645909";"";"0";"522.02";"1";"4.50";"BDBM116088";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCC(C(C)(C)O)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.96";"nM";"9.02";"";"240700";"UO_0000065";"17.27";"0.33";"4.52";"8.57";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645916";"";"0";"484.58";"0";"3.53";"BDBM116095";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C4CCC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.47";"nM";"9.33";"";"240707";"UO_0000065";"19.25";"0.35";"5.80";"10.57";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645919";"";"0";"468.50";"0";"2.47";"BDBM116098";"CCc1ncnc(-c2ccc(C(=O)N3CCn4cnnc4C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.18";"nM";"8.93";"";"240710";"UO_0000065";"19.06";"0.35";"6.46";"7.72";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645931";"";"0";"495.56";"0";"3.92";"BDBM116110";"CCNc1ccc(C#Cc2c(CC)ncnc2-c2ccc(C(=O)N3CCn4ccnc4C3)c(F)c2)cn1";"IC50";"'='";"0.81";"nM";"9.09";"";"240722";"UO_0000065";"18.35";"0.34";"5.17";"10.23";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645949";"";"0";"521.04";"1";"4.29";"BDBM116129";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCC(CN(C)C)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"40.26";"nM";"7.39";"";"240741";"UO_0000065";"14.19";"0.27";"3.11";"8.38";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645959";"";"0";"539.62";"1";"3.78";"BDBM116139";"CCc1ncnc(-c2ccc(C(=O)N3CCN(Cc4nc(C)c(C)o4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.53";"nM";"8.81";"";"240751";"UO_0000065";"16.34";"0.30";"5.04";"7.71";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645960";"";"0";"514.61";"1";"2.89";"BDBM116140";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C4CCCC4O)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.68";"nM";"9.17";"";"240752";"UO_0000065";"17.81";"0.33";"6.28";"8.45";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645980";"";"0";"505.02";"1";"2.88";"BDBM116160";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C(C)CO)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.68";"nM";"8.78";"";"240772";"UO_0000065";"17.37";"0.33";"5.89";"8.09";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645986";"";"0";"484.58";"0";"3.57";"BDBM116166";"CCc1ncnc(-c2ccc(C(=O)N3CCC4(CC3)CC(N)C4)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.95";"nM";"8.22";"";"240778";"UO_0000065";"16.97";"0.31";"4.66";"7.41";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645987";"";"0";"600.70";"1";"4.46";"BDBM116167";"CCc1ncnc(-c2ccc(C(=O)N3CCC4(CC3)CN(C(=O)OC(C)(C)C)CCO4)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"8.92";"nM";"8.05";"";"240779";"UO_0000065";"13.40";"0.25";"3.59";"6.50";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643184";"";"0";"472.52";"0";"2.57";"BDBM115827";"CCc1ncnc(-c2ccc(C(=O)NCCN3CCCC3=O)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.0";"nM";"8.30";"";"240439";"UO_0000065";"17.57";"0.32";"5.73";"7.28";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643193";"";"0";"433.44";"0";"1.97";"BDBM115836";"CCc1ncnc(-c2ccc(C(=O)N3CC(O)CO3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"7.0";"nM";"8.15";"";"240448";"UO_0000065";"18.81";"0.35";"6.18";"7.12";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643202";"";"0";"391.41";"0";"2.60";"BDBM115845";"CON(C)C(=O)c1ccc(-c2ncnc(C)c2C#Cc2ccc(N)nc2)cc1F";"IC50";"'='";"12.0";"nM";"7.92";"";"240457";"UO_0000065";"20.24";"0.37";"5.32";"8.41";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643206";"";"0";"407.86";"0";"3.12";"BDBM115849";"CON(C)C(=O)c1ccc(-c2ncnc(C)c2C#Cc2ccc(N)nc2)cc1Cl";"IC50";"'='";"17.0";"nM";"7.77";"";"240461";"UO_0000065";"19.05";"0.37";"4.65";"8.25";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643218";"";"0";"506.56";"1";"2.77";"BDBM115861";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(CCOC)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.15";"nM";"8.67";"";"240473";"UO_0000065";"17.11";"0.32";"5.90";"8.89";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643157";"";"0";"475.00";"0";"3.51";"BDBM115773";"CCc1ncnc(-c2ccc(C(=O)N3CCCN(C)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"22.18";"nM";"7.65";"";"240504";"UO_0000065";"16.11";"0.31";"4.14";"8.67";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643247";"";"0";"470.58";"0";"2.87";"BDBM115912";"CCc1ncnc(-c2ccc(C(=O)N3CC[C@@H](N(C)C)C3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"33.76";"nM";"7.47";"";"240524";"UO_0000065";"15.88";"0.29";"4.60";"7.67";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643280";"";"0";"441.54";"0";"2.99";"BDBM115946";"CCc1ncnc(-c2ccc(C(=O)N3CCCC(O)C3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.69";"nM";"8.57";"";"240558";"UO_0000065";"19.41";"0.35";"5.58";"8.14";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL4288258";"";"0";"478.86";"0";"3.50";"31";"COc1ncc(-c2ccc3ncc(Cl)c(=O)n3c2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"89.2";"nM";"7.05";"";"";"UO_0000065";"14.72";"0.30";"3.55";"6.87";"False";"CHEMBL4255944";"Inhibition of mTOR in human MCF7 cells assessed as reduction in P70S6K phosphorylation after 4 hrs by ADP-Glo assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MCF7";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4251704";"1";"Scientific Literature";"ACS Med Chem Lett";"2018";""
"CHEMBL4295052";"";"0";"444.42";"0";"2.84";"16";"COc1ncc(-c2ccc3nccc(=O)n3c2)cc1NS(=O)(=O)c1cc(F)cc(F)c1";"IC50";"'='";"77.2";"nM";"7.11";"";"";"UO_0000065";"16.00";"0.31";"4.27";"6.93";"False";"CHEMBL4255944";"Inhibition of mTOR in human MCF7 cells assessed as reduction in P70S6K phosphorylation after 4 hrs by ADP-Glo assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MCF7";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4251704";"1";"Scientific Literature";"ACS Med Chem Lett";"2018";""
"CHEMBL3693518";"";"0";"438.53";"0";"2.05";"BDBM174681";"CNCCNc1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(OC)c(CO)c3)nc2n1";"IC50";"'='";"110.0";"nM";"6.96";"";"319962";"UO_0000065";"15.87";"0.30";"4.91";"6.65";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693535";"";"0";"446.51";"0";"2.91";"BDBM174698";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(-n4ccnc4C)nc3n2)cc1CO";"IC50";"'='";"13.0";"nM";"7.89";"";"319980";"UO_0000065";"17.66";"0.33";"4.98";"8.01";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693572";"";"0";"486.57";"0";"4.23";"BDBM174738";"COCc1cccc(-c2nc(N3CCOC[C@@H]3C)c3ccc(-c4ccc(OC)c(CO)c4)nc3n2)c1";"IC50";"'='";"120.0";"nM";"6.92";"";"320017";"UO_0000065";"14.22";"0.26";"2.69";"7.70";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL4284400";"";"0";"444.42";"0";"2.84";"4";"COc1ncc(-c2ccc3nccc(=O)n3c2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"66.0";"nM";"7.18";"";"";"UO_0000065";"16.16";"0.32";"4.34";"6.99";"False";"CHEMBL4255944";"Inhibition of mTOR in human MCF7 cells assessed as reduction in P70S6K phosphorylation after 4 hrs by ADP-Glo assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MCF7";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4251704";"1";"Scientific Literature";"ACS Med Chem Lett";"2018";""
"CHEMBL3688861";"";"0";"458.93";"0";"3.33";"BDBM174320";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccnc(Cl)c3F)nc2n1";"IC50";"'='";"490.0";"nM";"6.31";"";"319636";"UO_0000065";"13.75";"0.27";"2.98";"8.25";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688866";"";"0";"448.53";"0";"2.24";"BDBM174325";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(C(N)=O)cc3)nc2n1";"IC50";"'='";"8.3";"nM";"8.08";"";"319641";"UO_0000065";"18.02";"0.33";"5.84";"7.57";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688888";"";"0";"450.50";"0";"3.05";"BDBM174349";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc([N+](=O)[O-])cc3)nc2n1";"IC50";"'='";"40.0";"nM";"7.40";"";"319665";"UO_0000065";"16.42";"0.31";"4.35";"6.93";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688898";"";"0";"449.56";"0";"3.02";"BDBM174359";"C[C@H]1CN(c2nc(N3CCOC[C@@H]3C)c3ccc(-c4cccc(CO)c4)nc3n2)C[C@@H](C)O1";"IC50";"'='";"38.0";"nM";"7.42";"";"319675";"UO_0000065";"16.51";"0.31";"4.40";"8.85";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688905";"";"0";"420.52";"0";"2.93";"BDBM174366";"C[C@H]1CN(c2nc(N3CCOC[C@@H]3C)c3ccc(-c4ccncc4)nc3n2)C[C@@H](C)O1";"IC50";"'='";"91.0";"nM";"7.04";"";"319682";"UO_0000065";"16.74";"0.31";"4.11";"9.20";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688923";"";"0";"449.52";"0";"1.64";"BDBM174385";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(C(N)=O)nc3)nc2n1";"IC50";"'='";"720.0";"nM";"6.14";"";"319702";"UO_0000065";"13.66";"0.25";"4.50";"5.14";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693589";"";"0";"489.58";"0";"2.30";"BDBM174767";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc4c(c3)NCCNC4=O)nc2n1";"IC50";"'='";"4.9";"nM";"8.31";"";"319708";"UO_0000065";"16.97";"0.32";"6.01";"7.93";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL1801204";"AZD-8055";"1";"465.55";"0";"2.64";"BDBM50348452";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO";"IC50";"'='";"8.9";"nM";"8.05";"";"319604";"UO_0000065";"17.29";"0.32";"5.41";"8.65";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3586559";"";"0";"421.47";"0";"0.72";"12";"Cc1nc(-c2nc[nH]n2)ccc1-c1cnc2c(n1)N(CCN1CCOCC1)C(=O)CN2";"IC50";"'='";"37.0";"nM";"7.43";"";"";"UO_0000065";"17.63";"0.33";"6.71";"5.94";"False";"CHEMBL3587521";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585264";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3393593";"";"0";"480.55";"0";"2.65";"110";"CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3ccc4c(ccn4S(C)(=O)=O)c3n2)cc1";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"18.10";"0.35";"6.05";"7.34";"False";"CHEMBL3395890";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3392967";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL2172626";"";"0";"306.33";"0";"2.15";"20";"Cc1nc(N)cc(-c2c(Nc3cc[nH]n3)nc3ccccn23)n1";"IC50";"'='";"65.0";"nM";"7.19";"";"";"UO_0000065";"23.46";"0.43";"5.04";"6.55";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL3891448";"";"0";"497.55";"0";"3.91";"BDBM245520";"CN(C)CCCOc1ccc(-c2cc3c(cc2F)ncc2c3n([C@H]3CCCOC3)c(=O)n2C)c(F)n1";"IC50";"'='";"23000.0";"nM";"4.64";"";"427930";"UO_0000065";"9.32";"0.18";"0.73";"6.23";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3899194";"";"0";"473.58";"0";"3.78";"BDBM245528";"Cn1c(=O)n(C2COC2)c2c3cc(-c4ccc(OCCCN5CCCCC5)nc4)ccc3ncc21";"IC50";"'='";"12400.0";"nM";"4.91";"";"427938";"UO_0000065";"10.36";"0.19";"1.13";"6.59";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3890876";"";"0";"457.58";"0";"4.54";"BDBM245530";"Cn1c(=O)n(C2CCC2)c2c3cc(-c4ccc(OCCCN5CCCC5)nc4)ccc3ncc21";"IC50";"'='";"7290.0";"nM";"5.14";"";"427940";"UO_0000065";"11.23";"0.21";"0.60";"7.88";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3947316";"";"0";"487.60";"0";"4.17";"BDBM245501";"Cn1c(=O)n([C@H]2CCCOC2)c2c3cc(-c4ccc(OCCCN5CCCC5)nc4)ccc3ncc21";"IC50";"'='";"605.0";"nM";"6.22";"";"427912";"UO_0000065";"12.75";"0.24";"2.05";"8.36";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3957991";"";"0";"451.50";"0";"2.99";"BDBM245482";"CN(C)CCCOc1ccc(-c2cc3c(cc2F)ncc2c3n(C3COC3)c(=O)n2C)cn1";"IC50";"'>'";"21300.0";"nM";"";"";"427892";"UO_0000065";"";"";"";"";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3890490";"";"0";"461.57";"0";"3.63";"BDBM245490";"CN(C)CCCOc1ccc(-c2ccc3ncc4c(c3c2)n([C@H]2CCCOC2)c(=O)n4C)cn1";"IC50";"'='";"1470.0";"nM";"5.83";"";"427900";"UO_0000065";"12.64";"0.23";"2.20";"7.84";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3979811";"";"0";"473.58";"0";"3.77";"BDBM245510";"CO[C@H]1C[C@@H](n2c(=O)n(C)c3cnc4ccc(-c5ccc(OCCCN6CCC6)nc5)cc4c32)C1";"IC50";"'='";"2240.0";"nM";"5.65";"";"427921";"UO_0000065";"11.93";"0.22";"1.88";"7.59";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3693516";"";"0";"427.48";"0";"2.80";"BDBM174679";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(NCCF)nc3n2)cc1CO";"IC50";"'='";"62.0";"nM";"7.21";"";"319960";"UO_0000065";"16.86";"0.32";"4.41";"7.78";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693574";"";"0";"456.55";"0";"4.39";"BDBM174740";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(-c4cccc(C)c4)nc3n2)cc1CO";"IC50";"'='";"220.0";"nM";"6.66";"";"320019";"UO_0000065";"14.58";"0.27";"2.27";"8.26";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688991";"";"0";"478.60";"0";"2.22";"BDBM174472";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(CNCCO)cc3)nc2n1";"IC50";"'='";"1.967";"nM";"8.71";"";"320037";"UO_0000065";"18.19";"0.34";"6.49";"9.08";"False";"CHEMBL3705656";"Biological Assay: For mTOR enzyme activity assays, mTOR protein was isolated from HeLa cell cytoplasmic extract by immunoprecipitation, and activity determined essentially as described previously using recombinant PHAS-1as a substrate (ref 21).";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"HeLa";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";"CHEMBL3308376"
"CHEMBL3688860";"";"0";"464.53";"0";"2.32";"BDBM174319";"COC(=O)c1cncc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"1100.0";"nM";"5.96";"";"319635";"UO_0000065";"12.83";"0.24";"3.64";"5.80";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688929";"";"0";"492.58";"0";"2.51";"BDBM174394";"CNC(=O)c1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1OC";"IC50";"'='";"250.0";"nM";"6.60";"";"319712";"UO_0000065";"13.40";"0.25";"4.09";"6.48";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688942";"";"0";"498.61";"0";"2.51";"BDBM174419";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(NS(C)(=O)=O)cc3)nc2n1";"IC50";"'='";"99.0";"nM";"7.00";"";"319723";"UO_0000065";"14.05";"0.27";"4.49";"6.38";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688839";"";"0";"436.52";"0";"2.55";"BDBM174297";"COc1cncc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"310.0";"nM";"6.51";"";"319613";"UO_0000065";"14.91";"0.28";"3.96";"7.59";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689020";"";"0";"524.64";"1";"3.36";"BDBM174502";"COCCN(C)Cc1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccc1F";"IC50";"'='";"460.0";"nM";"6.34";"";"319803";"UO_0000065";"12.08";"0.23";"2.98";"8.33";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689023";"";"0";"506.65";"1";"3.65";"BDBM174505";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CNC(C)C";"IC50";"'='";"24.0";"nM";"7.62";"";"319806";"UO_0000065";"15.04";"0.28";"3.97";"8.98";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693379";"";"0";"560.74";"1";"4.82";"BDBM174515";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CNC1CCCCC1C";"IC50";"'='";"110.0";"nM";"6.96";"";"319816";"UO_0000065";"12.41";"0.23";"2.14";"8.20";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693578";"";"0";"413.48";"0";"3.47";"BDBM174744";"C[C@H]1COCCN1c1nc(-c2cccnc2)nc2nc(-c3cccc(CO)c3)ccc12";"IC50";"'='";"12.0";"nM";"7.92";"";"320023";"UO_0000065";"19.16";"0.35";"4.45";"9.40";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3946658";"";"0";"431.50";"0";"3.14";"BDBM245470";"COc1ccc(-c2ccc3ncc4c(c3c2)n(C2CCN(C(C)=O)CC2)c(=O)n4C)cn1";"IC50";"'='";"113.0";"nM";"6.95";"";"427981";"UO_0000065";"16.10";"0.30";"3.81";"8.45";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3962107";"";"0";"597.70";"1";"4.77";"BDBM222657";"CSc1c(-c2cccnc2)nc(-c2ccc(NC(=O)Nc3ccc(N4CCOCC4=O)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"5.8";"nM";"8.24";"";"389446";"UO_0000065";"13.78";"0.26";"3.47";"6.76";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3917956";"";"0";"456.96";"0";"4.39";"BDBM222663";"CSc1c(Cl)nc(-c2ccc(NC(=O)Nc3ccncc3)cc2)nc1N1CCOCC1";"IC50";"'='";"193.5";"nM";"6.71";"";"389452";"UO_0000065";"14.69";"0.30";"2.32";"7.28";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3915883";"";"0";"454.92";"0";"4.07";"BDBM222672";"CCOc1c(Cl)nc(-c2ccc(NC(=O)Nc3ccncc3)cc2)nc1N1CCOCC1";"IC50";"'='";"255.5";"nM";"6.59";"";"389461";"UO_0000065";"14.49";"0.28";"2.52";"6.50";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3646484";"";"0";"491.58";"0";"3.53";"BDBM125326";"COc1ccc(Nc2ncc(C(C)c3ccc(S(C)(=O)=O)cc3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255049";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL4069475";"";"0";"583.63";"1";"3.76";"5p";"O=C(Nc1ccc(-c2nc(N3CCOCC3)c3cccnc3n2)cc1)Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1";"IC50";"'='";"9.9";"nM";"8.00";"";"";"UO_0000065";"13.71";"0.26";"4.24";"4.87";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL3649425";"";"0";"495.76";"1";"5.06";"BDBM122448";"Cc1nc2ccc(Br)cn2c1-c1cnc(Cl)c(NS(=O)(=O)c2ccc(F)cc2)c1";"IC50";"'='";"848.0";"nM";"6.07";"";"251052";"UO_0000065";"12.25";"0.29";"1.01";"7.95";"False";"CHEMBL3705287";"In Vitro mTOR Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP 1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639163";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643923";"";"0";"494.59";"0";"1.52";"BDBM125234";"Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2cccc3[nH]ncc23)n1";"IC50";"'>'";"10000.0";"nM";"";"";"254950";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643924";"";"0";"456.54";"1";"0.44";"BDBM125235";"Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2cncnc2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"254952";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643932";"";"0";"376.81";"0";"4.00";"BDBM125250";"Cc1nc(-c2cc(Cl)cnc2Nc2cccc3[nH]ncc23)c2nc[nH]c2n1";"IC50";"'>'";"10000.0";"nM";"";"";"254967";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643943";"";"0";"468.52";"0";"4.49";"BDBM125266";"COc1cccc(NCc2cnc(Nc3ccc(OC)nc3)c(-c3nc(C)nc4[nH]cnc34)c2)c1";"IC50";"'>'";"10000.0";"nM";"";"";"254978";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646436";"";"0";"473.54";"0";"2.53";"BDBM125277";"COc1ccc(Nc2ncc(CN3CCN(C(C)=O)CC3)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'='";"612.0";"nM";"6.21";"";"254989";"UO_0000065";"13.12";"0.24";"3.68";"4.97";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646440";"";"0";"406.45";"0";"2.93";"BDBM125281";"COCCNc1cnc(Nc2ccc(OC)nc2)c(-c2nc(C)nc3[nH]cnc23)c1";"IC50";"'='";"3537.0";"nM";"5.45";"";"254993";"UO_0000065";"13.41";"0.25";"2.52";"4.44";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646521";"";"0";"386.80";"0";"2.79";"BDBM125364";"COC(=O)Nc1ccc(Nc2ncc(Cl)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255093";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646527";"";"0";"311.32";"0";"2.41";"BDBM125370";"Cc1ccc(-c2nc(C)nc(N)n2)c(Nc2cncc(F)c2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255099";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL4084640";"";"0";"400.44";"0";"2.38";"12a";"Nc1ccc(-c2ccc3ncc4ncc(=O)n(C5CCN(C=O)CC5)c4c3c2)cn1";"IC50";"'='";"23.0";"nM";"7.64";"";"";"UO_0000065";"19.07";"0.35";"5.26";"7.14";"False";"CHEMBL4023016";"Inhibition of N-terminal FLAG-tagged recombinant human mTOR (1362 to end residues)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020823";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL4068435";"";"0";"582.65";"1";"4.37";"5o";"O=C(Nc1ccc(-c2nc(N3CCOCC3)c3cccnc3n2)cc1)Nc1ccc(S(=O)(=O)Nc2ccccn2)cc1";"IC50";"'='";"39.8";"nM";"7.40";"";"";"UO_0000065";"12.70";"0.24";"3.03";"4.89";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL3793276";"";"0";"543.02";"1";"4.13";"24";"O=C(Nc1ccc(Cl)c(C(F)(F)F)c1)N1CCN(c2nc3c(c(N4CCOCC4)n2)CSCC3)CC1";"IC50";"'='";"6260.0";"nM";"5.20";"";"";"UO_0000065";"9.58";"0.20";"1.07";"7.05";"False";"CHEMBL3795347";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide substrate incubated for 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3792291";"1";"Scientific Literature";"Eur. J. Med. Chem.";"2016";""
"CHEMBL4089494";"";"0";"483.53";"0";"3.53";"4i";"CNC(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)c4ncccc4n3)cc2)cc1";"IC50";"'='";"40.5";"nM";"7.39";"";"";"UO_0000065";"15.29";"0.28";"3.86";"6.09";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL4102715";"";"0";"470.53";"0";"3.71";"5d";"O=C(Nc1ccc(CCO)cc1)Nc1ccc(-c2nc(N3CCOCC3)c3cccnc3n2)cc1";"IC50";"'='";"36.6";"nM";"7.44";"";"";"UO_0000065";"15.80";"0.29";"3.73";"6.61";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL573339";"PI-103";"0";"348.36";"0";"2.98";"1; PI-103";"Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1";"IC50";"'='";"20.0";"nM";"7.70";"";"";"UO_0000065";"22.10";"0.40";"4.72";"9.11";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL4081617";"";"0";"498.54";"0";"4.35";"4g";"CCOC(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)c4ncccc4n3)cc2)cc1";"IC50";"'='";"1320.0";"nM";"5.88";"";"";"UO_0000065";"11.79";"0.22";"1.53";"4.96";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL2165008";"";"0";"392.47";"0";"2.57";"BDBM50394855";"COc1ccc(Nc2ncc(CN3CCCC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255112";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2336325";"VISTUSERTIB";"2";"462.55";"0";"2.50";"2; AZD2014";"CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"2.8";"nM";"8.55";"";"";"UO_0000065";"18.49";"0.34";"6.05";"9.23";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL3646494";"";"0";"344.33";"0";"3.17";"BDBM125336";"Cc1nc(N)nc(-c2cccnc2Nc2cccc(OC(F)F)c2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255064";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165012";"";"0";"422.49";"0";"1.79";"BDBM50394851";"COc1ccc(Nc2ncc(CN3CC[C@@H](CO)C3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255109";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3577923";"";"0";"516.03";"2";"5.34";"6i";"COc1ncc(-c2cc3c(-c4ccncc4)ncnc3s2)cc1NS(=O)(=O)c1ccc(Cl)s1";"IC50";"'='";"67.9";"nM";"7.17";"";"";"UO_0000065";"13.89";"0.30";"1.83";"6.70";"False";"CHEMBL3579762";"Inhibition of mTOR (unknown origin) using GFP-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3576869";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL3112719";"";"0";"521.51";"1";"3.82";"5g";"COc1ncc(-c2cnc3nc(N)nc(-c4ccncc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"18.4";"nM";"7.74";"";"";"UO_0000065";"14.83";"0.29";"3.92";"5.30";"False";"CHEMBL3579762";"Inhibition of mTOR (unknown origin) using GFP-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3576869";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL3577914";"";"0";"520.52";"1";"4.42";"5h";"COc1ncc(-c2ccc3nc(N)nc(-c4ccncc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"0.29";"nM";"9.54";"";"";"UO_0000065";"18.32";"0.35";"5.12";"7.17";"False";"CHEMBL3579762";"Inhibition of mTOR (unknown origin) using GFP-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3576869";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL3577926";"";"0";"497.96";"1";"5.41";"6l";"O=S(=O)(Nc1cc(-c2cc3c(-c4ccncc4)ncnc3s2)cnc1Cl)c1ccc(F)cc1";"IC50";"'='";"43.7";"nM";"7.36";"";"";"UO_0000065";"14.78";"0.30";"1.95";"7.53";"False";"CHEMBL3579762";"Inhibition of mTOR (unknown origin) using GFP-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3576869";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL3358285";"";"0";"415.48";"0";"1.59";"18";"Cc1nc(N)nc(-c2cc(C(C)(C)O)cnc2Nc2cncc(S(C)(=O)=O)c2)n1";"IC50";"'>'";"16000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3379685";"Inhibition of recombinant N-terminally GST-tagged mTOR (1360 to 2549 aa) (unknown origin) assessed as inhibition of 27BP1 phosphorylation after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352452";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3357867";"";"0";"425.35";"0";"2.71";"6";"COc1ncc(Nc2ncc(C(O)C(F)(F)F)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'='";"2200.0";"nM";"5.66";"";"";"UO_0000065";"13.30";"0.26";"2.95";"4.29";"False";"CHEMBL3379685";"Inhibition of recombinant N-terminally GST-tagged mTOR (1360 to 2549 aa) (unknown origin) assessed as inhibition of 27BP1 phosphorylation after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352452";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3357866";"";"0";"371.38";"0";"2.16";"5";"COc1ncc(Nc2ncc([C@H](C)O)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"25000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3379685";"Inhibition of recombinant N-terminally GST-tagged mTOR (1360 to 2549 aa) (unknown origin) assessed as inhibition of 27BP1 phosphorylation after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352452";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3914157";"";"0";"351.37";"0";"2.76";"11";"CC(=O)Nc1noc2cc(-c3nn(C(C)C)c4ncnc(N)c34)ccc12";"IC50";"'<'";"1000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3882339";"Inhibition of recombinant human GST-tagged mTOR (1360 to 2549 residues) catalytic domain assessed as inhibition of GFP labeled 4EBP1 phosphorylation measured after 1 hr by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3882246";"38";"Patent Bioactivity Data";"";"2010";""
"CHEMBL3982990";"";"0";"635.70";"1";"4.35";"BDBM178404";"COc1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOC[C@@H]4C)nc4c3C(=O)N(C3CCOCC3)CC(C)(C)O4)cc2F)cn1";"IC50";"'='";"62.0";"nM";"7.21";"";"324424";"UO_0000065";"11.34";"0.21";"2.86";"5.14";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3950899";"";"0";"657.77";"1";"4.29";"BDBM178405";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)NCC(C)(C)O)cc4)cc3)c2C1=O";"IC50";"'='";"40.0";"nM";"7.40";"";"324425";"UO_0000065";"11.25";"0.21";"3.11";"4.67";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3973425";"";"0";"722.84";"1";"4.01";"BDBM178450";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(N5CCN(S(C)(=O)=O)CC5)cc4)c(F)c3)c2C1=O";"IC50";"'='";"89.0";"nM";"7.05";"";"324470";"UO_0000065";"9.75";"0.19";"3.04";"4.71";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3985232";"";"0";"586.63";"1";"4.19";"BDBM178462";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(C#N)nc4)c(F)c3)c2C1=O";"IC50";"'='";"26.0";"nM";"7.58";"";"324482";"UO_0000065";"12.93";"0.24";"3.40";"5.21";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3976146";"";"0";"646.72";"1";"4.16";"BDBM178467";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccc(N5C[C@@H]6C[C@H]5CO6)nc4)c(F)c3)c2C1=O";"IC50";"'='";"68.0";"nM";"7.17";"";"324487";"UO_0000065";"11.08";"0.21";"3.01";"5.34";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3969907";"";"0";"658.74";"1";"4.30";"BDBM178468";"CCN1CC(C)(C)Oc2nc(N3C4CCC3COC4)nc(-c3ccc(NC(=O)Nc4ccc(N5C[C@@H]6C[C@H]5CO6)nc4)c(F)c3)c2C1=O";"IC50";"'='";"72.0";"nM";"7.14";"";"324488";"UO_0000065";"10.84";"0.20";"2.84";"5.32";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3970512";"";"0";"674.78";"1";"4.94";"BDBM178472";"CCN1CC(C)(C)Oc2nc(N3C4CCC3COC4)nc(-c3ccc(NC(=O)Nc4ccc(N5CCOCC5(C)C)nc4)c(F)c3)c2C1=O";"IC50";"'='";"142.0";"nM";"6.85";"";"324492";"UO_0000065";"10.15";"0.19";"1.91";"5.10";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3967162";"";"0";"524.62";"1";"2.65";"BDBM178224";"CCNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)nc3c2C(=O)N(CCCO)CC(C)(C)O3)cc1";"IC50";"'='";"65.0";"nM";"7.19";"";"324244";"UO_0000065";"13.70";"0.26";"4.54";"5.56";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3952028";"";"0";"556.64";"1";"3.18";"BDBM178239";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)NCC(C)(C)O)c(F)c3)c2C1=O";"IC50";"'='";"1072.0";"nM";"5.97";"";"324259";"UO_0000065";"10.72";"0.20";"2.79";"4.62";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL4108956";"";"0";"542.61";"1";"2.79";"BDBM178242";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)N[C@H](C)CO)c(F)c3)c2C1=O";"IC50";"'='";"394.0";"nM";"6.41";"";"324262";"UO_0000065";"11.80";"0.22";"3.61";"4.96";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3904337";"";"0";"660.75";"1";"4.55";"BDBM178244";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(N5CCOC[C@@H]5C)nc4)c(F)c3)c2C1=O";"IC50";"'='";"38.0";"nM";"7.42";"";"324264";"UO_0000065";"11.23";"0.21";"2.87";"5.53";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3946609";"";"0";"561.62";"1";"4.32";"BDBM178265";"CCN1CC(C)(C)Oc2nc(N3C4CCC3COC4)nc(-c3ccc(NC(=O)Nc4cccnc4)c(F)c3)c2C1=O";"IC50";"'='";"39.0";"nM";"7.41";"";"324285";"UO_0000065";"13.19";"0.25";"3.09";"6.08";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3932273";"";"0";"559.63";"1";"3.80";"BDBM178269";"COc1ccc(NC(=O)Nc2ccc(-c3nc(N4CC5CCC(C4)O5)nc4c3C(=O)N(C)CC(C)(C)O4)cc2)nc1";"IC50";"'='";"32.0";"nM";"7.50";"";"324289";"UO_0000065";"13.39";"0.25";"3.69";"5.72";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3924065";"";"0";"561.62";"1";"4.24";"BDBM178274";"Cc1cc(NC(=O)Nc2ccc(-c3nc(N4C5CCC4COC5)nc4c3C(=O)N(C)CC(C)(C)O4)cc2F)ccn1";"IC50";"'='";"67.0";"nM";"7.17";"";"324294";"UO_0000065";"12.77";"0.24";"2.93";"5.89";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3897204";"";"0";"561.62";"1";"4.32";"BDBM178290";"CCN1CC(C)(C)Oc2nc(N3C4CCC3COC4)nc(-c3ccc(NC(=O)Nc4ccncc4F)cc3)c2C1=O";"IC50";"'='";"40.0";"nM";"7.40";"";"324310";"UO_0000065";"13.17";"0.25";"3.08";"6.07";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3953002";"";"0";"561.62";"1";"4.32";"BDBM178373";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccccn4)c(F)c3)c2C1=O";"IC50";"'='";"64.0";"nM";"7.19";"";"324393";"UO_0000065";"12.81";"0.24";"2.87";"5.91";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693472";"";"0";"479.58";"0";"2.63";"BDBM174634";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCC(CO)CC4)nc3n2)cc1CO";"IC50";"'='";"14.0";"nM";"7.85";"";"319912";"UO_0000065";"16.38";"0.31";"5.22";"7.55";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689010";"";"0";"536.65";"1";"3.55";"BDBM174491";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(F)c(CNC4CCOCC4)c3)nc2n1";"IC50";"'='";"130.0";"nM";"6.89";"";"319792";"UO_0000065";"12.83";"0.24";"3.34";"8.11";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689015";"";"0";"521.64";"1";"2.69";"BDBM174497";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(F)c(CN4CCNCC4)c3)nc2n1";"IC50";"'='";"160.0";"nM";"6.80";"";"319798";"UO_0000065";"13.03";"0.24";"4.11";"8.62";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689017";"";"0";"535.67";"1";"3.03";"BDBM174499";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(F)c(CN4CCN(C)CC4)c3)nc2n1";"IC50";"'='";"540.0";"nM";"6.27";"";"319800";"UO_0000065";"11.70";"0.22";"3.24";"8.94";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689021";"";"0";"522.63";"1";"2.85";"BDBM174503";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(F)c(CN4CC[C@H](O)C4)c3)nc2n1";"IC50";"'='";"15.0";"nM";"7.82";"";"319804";"UO_0000065";"14.97";"0.28";"4.97";"8.98";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689029";"";"0";"548.73";"1";"4.68";"BDBM174511";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CNCCC(C)(C)C";"IC50";"'='";"91.0";"nM";"7.04";"";"319812";"UO_0000065";"12.83";"0.24";"2.36";"8.30";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689005";"";"0";"497.62";"0";"2.69";"BDBM174486";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(CS(C)(=O)=O)c3)nc2n1";"IC50";"'='";"90.0";"nM";"7.05";"";"319787";"UO_0000065";"14.16";"0.27";"4.36";"7.21";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693452";"";"0";"449.56";"0";"3.41";"BDBM174613";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCCCC4)nc3n2)cc1CO";"IC50";"'='";"66.0";"nM";"7.18";"";"319891";"UO_0000065";"15.97";"0.30";"3.77";"8.56";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL2165048";"";"0";"309.33";"0";"1.97";"28";"COc1ccc(Nc2cccnc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165017";"";"0";"485.57";"1";"1.05";"54";"COc1ccc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"4800.0";"nM";"5.32";"";"";"UO_0000065";"10.95";"0.21";"4.27";"3.49";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165015";"";"0";"465.52";"1";"1.86";"52";"COC(=O)N1CCN(Cc2cnc(Nc3ccc(OC)nc3)c(-c3nc(C)nc(N)n3)c2)CC1";"IC50";"'='";"3700.0";"nM";"5.43";"";"";"UO_0000065";"11.67";"0.22";"3.57";"3.76";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165012";"";"0";"422.49";"0";"1.79";"49";"COc1ccc(Nc2ncc(CN3CC[C@@H](CO)C3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165010";"";"0";"408.47";"0";"1.80";"47";"COc1ccc(Nc2ncc(CN3CCOCC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL3951966";"";"0";"493.58";"0";"3.95";"BDBM245476";"CN(C)CCCOc1ccc(-c2cc3c(cc2F)ncc2c3n(C3(C)CCOCC3)c(=O)n2C)cn1";"IC50";"'='";"4930.0";"nM";"5.31";"";"427886";"UO_0000065";"10.75";"0.20";"1.36";"7.13";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3688843";"";"0";"491.60";"0";"2.37";"BDBM174301";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(N4CCOCC4)nc3)nc2n1";"IC50";"'='";"390.0";"nM";"6.41";"";"319617";"UO_0000065";"13.04";"0.24";"4.04";"7.20";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693522";"";"0";"445.47";"0";"3.09";"BDBM174685";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(NCC(F)F)nc3n2)cc1CO";"IC50";"'='";"10.0";"nM";"8.00";"";"319966";"UO_0000065";"17.96";"0.34";"4.91";"8.64";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693554";"";"0";"437.98";"0";"4.95";"BDBM174717";"C[C@H]1COCCN1c1nc(N2CCCC[C@H]2C)nc2nc(-c3ccc(Cl)cc3)ccc12";"IC50";"'='";"300.0";"nM";"6.52";"";"319999";"UO_0000065";"14.89";"0.29";"1.57";"11.99";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693555";"";"0";"453.97";"0";"4.18";"BDBM174718";"C[C@H]1CN(c2nc(N3CCOC[C@@H]3C)c3ccc(-c4ccc(Cl)cc4)nc3n2)C[C@@H](C)O1";"IC50";"'='";"150.0";"nM";"6.82";"";"320000";"UO_0000065";"15.03";"0.29";"2.64";"10.73";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693556";"";"0";"425.92";"0";"3.41";"BDBM174719";"C[C@H]1COCCN1c1nc(N2CCOCC2)nc2nc(-c3ccc(Cl)cc3)ccc12";"IC50";"'='";"150.0";"nM";"6.82";"";"320001";"UO_0000065";"16.02";"0.31";"3.41";"10.73";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688831";"";"0";"405.50";"0";"3.14";"BDBM174289";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccccc3)nc2n1";"IC50";"'='";"2.45";"nM";"8.61";"";"320036";"UO_0000065";"21.24";"0.39";"5.47";"13.54";"False";"CHEMBL3705656";"Biological Assay: For mTOR enzyme activity assays, mTOR protein was isolated from HeLa cell cytoplasmic extract by immunoprecipitation, and activity determined essentially as described previously using recombinant PHAS-1as a substrate (ref 21).";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"HeLa";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";"CHEMBL3308376"
"CHEMBL3693457";"";"0";"517.55";"1";"4.20";"BDBM174618";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCCC(C(F)(F)F)C4)nc3n2)cc1CO";"IC50";"'='";"230.0";"nM";"6.64";"";"319896";"UO_0000065";"12.83";"0.25";"2.44";"7.92";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693461";"";"0";"558.38";"1";"3.21";"BDBM174622";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(-n4ccnc4I)nc3n2)cc1CO";"IC50";"'='";"97.0";"nM";"7.01";"";"319900";"UO_0000065";"12.56";"0.29";"3.80";"7.13";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688912";"";"0";"476.54";"0";"2.47";"BDBM174373";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc4c(c3)NC(=O)CO4)nc2n1";"IC50";"'='";"160.0";"nM";"6.80";"";"319690";"UO_0000065";"14.26";"0.27";"4.33";"6.67";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL4076574";"";"0";"416.49";"0";"2.22";"12b";"Nc1ccc(-c2ccc3ncc4ncc(=O)n(C5CCN(CCO)CC5)c4c3c2)cn1";"IC50";"'='";"53.0";"nM";"7.28";"";"";"UO_0000065";"17.47";"0.32";"5.06";"6.60";"False";"CHEMBL4023016";"Inhibition of N-terminal FLAG-tagged recombinant human mTOR (1362 to end residues)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020823";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL2165036";"";"0";"371.33";"0";"3.76";"BDBM50394884";"Nc1cc(-c2cccnc2Nc2cccc3[nH]ncc23)nc(C(F)(F)F)n1";"IC50";"'>'";"50000.0";"nM";"";"";"254936";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165010";"";"0";"408.47";"0";"1.80";"BDBM50394853";"COc1ccc(Nc2ncc(CN3CCOCC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"254956";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643929";"";"0";"294.32";"0";"1.55";"BDBM125242";"Cc1nc(N)nc(-c2cccnc2Nc2ccc(N)nc2)n1";"IC50";"'='";"5953.0";"nM";"5.22";"";"254961";"UO_0000065";"17.75";"0.32";"3.68";"4.07";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646474";"";"0";"404.48";"0";"3.37";"BDBM125316";"COc1ccc(Nc2ncc(CNC(C)C)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255035";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL4060651";"";"0";"483.53";"0";"4.13";"4h";"CC(=O)Nc1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)c4ncccc4n3)cc2)cc1";"IC50";"'='";"104.0";"nM";"6.98";"";"";"UO_0000065";"14.44";"0.26";"2.85";"5.75";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL4088957";"";"0";"446.51";"0";"4.32";"9j";"N#CCN1CCC[C@H](n2c(=O)cnc3cnc4ccc(-c5cnc6ccccc6c5)cc4c32)C1";"IC50";"'='";"55.0";"nM";"7.26";"";"";"UO_0000065";"16.26";"0.29";"2.94";"8.28";"False";"CHEMBL4023016";"Inhibition of N-terminal FLAG-tagged recombinant human mTOR (1362 to end residues)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020823";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL4101340";"";"0";"403.42";"0";"2.63";"9v";"N#CCN1CCC(n2c(=O)cnc3cnc4cc(F)c(-c5cn[nH]c5)cc4c32)CC1";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"21.13";"0.39";"5.89";"8.24";"False";"CHEMBL4023016";"Inhibition of N-terminal FLAG-tagged recombinant human mTOR (1362 to end residues)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020823";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL3955316";"";"0";"543.63";"1";"4.10";"BDBM178263";"Cc1ccc(NC(=O)Nc2ccc(-c3nc(N4C5CCC4COC5)nc4c3C(=O)N(C)CC(C)(C)O4)cc2)nc1";"IC50";"'='";"47.0";"nM";"7.33";"";"324283";"UO_0000065";"13.48";"0.25";"3.23";"6.02";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3940347";"";"0";"524.60";"1";"3.57";"BDBM178469";"CCN1CC(C)(C)Oc2nc(N3C4CCC3COC4)nc(-c3ccc(NC(=O)NC4CC4)c(F)c3)c2C1=O";"IC50";"'='";"68.0";"nM";"7.17";"";"324489";"UO_0000065";"13.66";"0.26";"3.60";"6.58";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693415";"";"0";"425.49";"0";"2.23";"BDBM174559";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccoc3CO)nc2n1";"IC50";"'='";"13.0";"nM";"7.89";"";"319852";"UO_0000065";"18.53";"0.35";"5.66";"8.13";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688932";"";"0";"463.54";"0";"2.50";"BDBM174399";"CC(=O)Nc1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccn1";"IC50";"'='";"7.5";"nM";"8.12";"";"319715";"UO_0000065";"17.53";"0.33";"5.62";"7.69";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688938";"";"0";"494.57";"0";"3.03";"BDBM174415";"CCNC(=O)c1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1F";"IC50";"'='";"720.0";"nM";"6.14";"";"319719";"UO_0000065";"12.42";"0.23";"3.11";"6.63";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3964241";"";"0";"487.60";"0";"4.17";"BDBM245527";"Cn1c(=O)n([C@H]2CCOC2)c2c3cc(-c4ccc(OCCCN5CCCCC5)nc4)ccc3ncc21";"IC50";"'='";"3380.0";"nM";"5.47";"";"427937";"UO_0000065";"11.22";"0.21";"1.30";"7.35";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3895113";"";"0";"567.67";"1";"3.16";"BDBM178219";"CCNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)nc3c2C(=O)N(C[C@@H]2CCCN2)CC(C)(C)O3)cc1F";"IC50";"'='";"721.0";"nM";"6.14";"";"324239";"UO_0000065";"10.82";"0.20";"2.98";"5.08";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3951952";"";"0";"545.64";"1";"4.35";"BDBM178251";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4cccc(C)n4)cc3)c2C1=O";"IC50";"'='";"55.0";"nM";"7.26";"";"324271";"UO_0000065";"13.30";"0.25";"2.91";"5.96";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693512";"";"0";"395.46";"0";"2.46";"BDBM174675";"CNc1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(OC)c(CO)c3)nc2n1";"IC50";"'='";"49.0";"nM";"7.31";"";"319956";"UO_0000065";"18.48";"0.34";"4.85";"7.89";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693517";"";"0";"438.49";"0";"1.31";"BDBM174680";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(NCC(N)=O)nc3n2)cc1CO";"IC50";"'='";"47.0";"nM";"7.33";"";"319961";"UO_0000065";"16.71";"0.31";"6.02";"5.40";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693524";"";"0";"452.56";"0";"2.39";"BDBM174687";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(NCCN(C)C)nc3n2)cc1CO";"IC50";"'='";"250.0";"nM";"6.60";"";"319968";"UO_0000065";"14.59";"0.27";"4.21";"6.89";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693534";"";"0";"465.55";"0";"2.38";"BDBM174697";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCC[C@@H]4CO)nc3n2)cc1CO";"IC50";"'='";"29.0";"nM";"7.54";"";"319979";"UO_0000065";"16.19";"0.30";"5.16";"7.24";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693541";"";"0";"466.59";"0";"2.78";"BDBM174704";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(NC(C)CN(C)C)nc3n2)cc1CO";"IC50";"'='";"97.0";"nM";"7.01";"";"319986";"UO_0000065";"15.03";"0.28";"4.23";"7.32";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693543";"";"0";"410.47";"0";"2.82";"BDBM174706";"CCOc1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(OC)c(CO)c3)nc2n1";"IC50";"'='";"43.0";"nM";"7.37";"";"319988";"UO_0000065";"17.95";"0.34";"4.55";"8.20";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693584";"";"0";"417.90";"0";"4.63";"BDBM174750";"C[C@H]1COCCN1c1nc(-c2cccnc2)nc2nc(-c3ccc(Cl)cc3)ccc12";"IC50";"'='";"810.0";"nM";"6.09";"";"320029";"UO_0000065";"14.58";"0.28";"1.46";"9.51";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3896907";"";"0";"579.63";"1";"4.19";"BDBM178457";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4cc(OC)ccn4)cc3F)c2C1=O";"IC50";"'='";"89.0";"nM";"7.05";"";"324477";"UO_0000065";"12.16";"0.23";"2.86";"5.38";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3930603";"";"0";"514.60";"1";"3.67";"BDBM178366";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3CC)nc3c2C(=O)N(CC)CC(C)(C)O3)cc1F";"IC50";"'='";"116.0";"nM";"6.94";"";"324386";"UO_0000065";"13.48";"0.26";"3.27";"6.37";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3958091";"";"0";"522.59";"1";"3.45";"BDBM178367";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(Nc4nnc(C)[nH]4)c(F)c3)c2C1=O";"IC50";"'='";"348.0";"nM";"6.46";"";"324387";"UO_0000065";"12.36";"0.23";"3.01";"5.32";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693568";"";"0";"500.56";"1";"3.87";"BDBM174734";"COC(=O)c1cccc(-c2nc(N3CCOC[C@@H]3C)c3ccc(-c4ccc(OC)c(CO)c4)nc3n2)c1";"IC50";"'='";"770.0";"nM";"6.11";"";"320013";"UO_0000065";"12.21";"0.23";"2.24";"5.72";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3919008";"";"0";"594.71";"1";"4.00";"BDBM178335";"CCNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)nc3c2C(=O)N(CCC(=O)OC(C)(C)C)CC(C)(C)O3)cc1";"IC50";"'='";"351.0";"nM";"6.46";"";"324355";"UO_0000065";"10.85";"0.21";"2.45";"4.77";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL2069328";"";"0";"402.52";"0";"3.75";"26, NVS-P13-4";"CC(=O)c1ccc(-c2sc(NC(=O)NCCC(=O)NC(C)(C)C)nc2C)cc1";"IC50";"'>'";"9100.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2073006";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2069199";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL3903485";"";"0";"684.84";"1";"4.81";"BDBM178238";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)N5CCC(N(C)C)CC5)cc4)cc3)c2C1=O";"IC50";"'='";"51.0";"nM";"7.29";"";"324258";"UO_0000065";"10.65";"0.20";"2.48";"5.50";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3974718";"";"0";"591.64";"1";"4.33";"BDBM178357";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4cccc(OC)n4)c(F)c3)c2C1=O";"IC50";"'='";"495.0";"nM";"6.30";"";"324377";"UO_0000065";"10.66";"0.20";"1.98";"4.81";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3890590";"";"0";"564.62";"1";"3.66";"BDBM178358";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4cnn(C)c4)c(F)c3)c2C1=O";"IC50";"'='";"19.0";"nM";"7.72";"";"324378";"UO_0000065";"13.68";"0.26";"4.06";"6.09";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3956206";"";"0";"592.63";"1";"3.73";"BDBM178359";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccnc(OC)n4)c(F)c3)c2C1=O";"IC50";"'='";"105.0";"nM";"6.98";"";"324379";"UO_0000065";"11.78";"0.22";"3.25";"4.85";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693585";"";"0";"535.63";"1";"3.53";"BDBM174751";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(NS(=O)(=O)c4cccc(C)c4)nc3n2)cc1CO";"IC50";"'='";"1400.0";"nM";"5.85";"";"320030";"UO_0000065";"10.93";"0.21";"2.32";"4.62";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688952";"";"0";"482.59";"0";"3.67";"BDBM174429";"C[C@H]1COCCN1c1nc(N2CCC(c3ccncc3)CC2)nc2nc(-c3ccc(N)nc3)ccc12";"IC50";"'='";"350.0";"nM";"6.46";"";"319733";"UO_0000065";"13.38";"0.24";"2.79";"6.08";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701177";"";"0";"483.62";"0";"3.86";"BDBM172312";"CCc1nccc(-c2ccc(C(=O)N3CCN(C(C)C)CC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"33.0";"nM";"7.48";"";"317236";"UO_0000065";"15.47";"0.28";"3.62";"8.85";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688985";"";"0";"476.58";"0";"2.84";"BDBM174462";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(C(=O)N(C)C)cc3)nc2n1";"IC50";"'='";"1600.0";"nM";"5.80";"";"319767";"UO_0000065";"12.16";"0.23";"2.96";"6.91";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL4110616";"";"0";"487.60";"0";"4.17";"BDBM245526";"Cn1c(=O)n([C@@H]2CCOC2)c2c3cc(-c4ccc(OCCCN5CCCCC5)nc4)ccc3ncc21";"IC50";"'='";"8120.0";"nM";"5.09";"";"427936";"UO_0000065";"10.44";"0.19";"0.92";"6.84";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL4109786";"";"0";"473.58";"0";"3.78";"BDBM245506";"Cn1c(=O)n([C@@H]2CCCOC2)c2c3cc(-c4ccc(OCCCN5CCC5)nc4)ccc3ncc21";"IC50";"'='";"1360.0";"nM";"5.87";"";"427942";"UO_0000065";"12.39";"0.23";"2.09";"7.88";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3701077";"";"0";"429.50";"0";"2.87";"BDBM172211";"CCc1nccc(-c2ccc(C(=O)N3CCNCC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.0";"nM";"8.40";"";"317135";"UO_0000065";"19.55";"0.36";"5.53";"9.98";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701105";"";"0";"414.51";"0";"2.46";"BDBM172240";"Cc1nccc(-c2ccc(C(=O)N(C)CCN(C)C)nc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"35.0";"nM";"7.46";"";"317164";"UO_0000065";"17.99";"0.33";"5.00";"8.45";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3653538";"";"0";"432.49";"0";"2.44";"BDBM136394";"CC(C)[C@H]1CN(CCO)C(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"2.5";"nM";"8.60";"";"270268";"UO_0000065";"19.89";"0.37";"6.16";"7.45";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3688867";"";"0";"528.64";"1";"1.41";"BDBM174326";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(S(=O)(=O)NCCO)c3)nc2n1";"IC50";"'='";"84.0";"nM";"7.08";"";"319643";"UO_0000065";"13.38";"0.26";"5.67";"5.44";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688907";"";"0";"435.53";"0";"3.24";"BDBM174368";"C[C@H]1CN(c2nc(N3CCOC[C@@H]3C)c3ccc(-c4ccc(O)cc4)nc3n2)C[C@@H](C)O1";"IC50";"'='";"0.26";"nM";"9.59";"";"319684";"UO_0000065";"22.01";"0.41";"6.35";"11.43";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3667419";"";"0";"428.47";"0";"1.71";"BDBM150991";"C[C@H]1COCCN1c1nc(N2CCOCC2)nc2[nH]c(-c3ccc(F)c(CO)c3)nc12";"IC50";"'='";"1424.0";"nM";"5.85";"";"290538";"UO_0000065";"13.65";"0.26";"4.14";"5.87";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL3667423";"";"0";"431.50";"0";"2.71";"BDBM150995";"c1cc(-c2nc3c(N4CC5CCC(C4)O5)nc(N4CCOCC4)nc3[nH]2)c2cc[nH]c2c1";"IC50";"'='";"41.0";"nM";"7.39";"";"290541";"UO_0000065";"17.12";"0.32";"4.68";"7.76";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL3667429";"";"0";"433.52";"0";"2.95";"BDBM151001";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2nc(-c3ccc4cc[nH]c4c3)[nH]c2n1";"IC50";"'='";"7.0";"nM";"8.15";"";"290547";"UO_0000065";"18.81";"0.35";"5.20";"8.57";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL3667435";"";"0";"419.49";"0";"2.56";"BDBM151008";"C[C@@H]1COCCN1c1nc(N2CCOCC2)nc2[nH]c(-c3ccc4cc[nH]c4c3)nc12";"IC50";"'='";"237.0";"nM";"6.62";"";"290554";"UO_0000065";"15.79";"0.29";"4.07";"6.96";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL3667437";"";"0";"419.49";"0";"2.56";"BDBM151010";"C[C@H]1COCCN1c1nc(N2CCOCC2)nc2[nH]c(-c3cccc4[nH]ccc34)nc12";"IC50";"'='";"14.0";"nM";"7.85";"";"290556";"UO_0000065";"18.72";"0.35";"5.29";"8.25";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL573339";"PI-103";"0";"348.36";"0";"2.98";"PI103";"Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1";"IC50";"'='";"8.8";"nM";"8.06";"";"";"UO_0000065";"23.12";"0.42";"5.08";"9.53";"True";"CHEMBL3807907";"Inhibition of mTOR (unknown origin) by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3804794";"1";"Scientific Literature";"Eur. J. Med. Chem.";"2016";""
"CHEMBL3960662";"";"0";"461.57";"0";"3.63";"BDBM245474";"CN(C)CCCOc1ccc(-c2ccc3ncc4c(c3c2)n(C2CCOCC2)c(=O)n4C)cn1";"IC50";"'='";"610.0";"nM";"6.21";"";"427884";"UO_0000065";"13.46";"0.25";"2.58";"8.35";"True";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3915261";"";"0";"407.47";"0";"2.49";"BDBM245471";"Cn1c(=O)n(C2CCOCC2)c2c3cc(-c4cnn(CCCO)c4)ccc3ncc21";"IC50";"'='";"2310.0";"nM";"5.64";"";"427982";"UO_0000065";"13.83";"0.26";"3.15";"6.47";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3935310";"";"0";"376.42";"0";"2.28";"BDBM245541";"Cn1c(=O)n(C2CCOCC2)c2c3cc(-c4cnc(N)nc4)ccc3ncc21";"IC50";"'='";"41.4";"nM";"7.38";"";"427986";"UO_0000065";"19.61";"0.36";"5.10";"7.32";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL4114027";"";"0";"461.57";"0";"3.73";"BDBM227491";"CCC[C@@H]1COCCN1c1nc(N2CCOC[C@H]2C)c2nc(-c3cccc4[nH]ccc34)[nH]c2n1";"IC50";"'='";"194.0";"nM";"6.71";"";"397250";"UO_0000065";"14.54";"0.27";"2.98";"7.05";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL4109998";"";"0";"459.55";"0";"3.49";"BDBM227503";"C[C@@H]1COCCN1c1nc(N2CCC23CCOCC3)nc2[nH]c(-c3cccc4[nH]ccc34)nc12";"IC50";"'='";"369.0";"nM";"6.43";"";"397262";"UO_0000065";"14.00";"0.26";"2.94";"6.76";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL3898334";"";"0";"551.58";"1";"3.92";"BDBM178350";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccon4)c(F)c3)c2C1=O";"IC50";"'='";"11.0";"nM";"7.96";"";"324370";"UO_0000065";"14.43";"0.27";"4.04";"5.90";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3958314";"";"0";"575.67";"1";"4.36";"BDBM178411";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccc(OC)nc4)c(C)c3)c2C1=O";"IC50";"'='";"276.0";"nM";"6.56";"";"324431";"UO_0000065";"11.39";"0.21";"2.20";"5.01";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3894827";"";"0";"596.63";"2";"5.25";"BDBM178419";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4cccc(OC(F)F)c4)cc3)c2C1=O";"IC50";"'='";"61.0";"nM";"7.21";"";"324439";"UO_0000065";"12.09";"0.23";"1.96";"6.11";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693481";"";"0";"503.65";"1";"4.43";"BDBM174643";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCC5CCCCC5C4)nc3n2)cc1CO";"IC50";"'='";"250.0";"nM";"6.60";"";"319921";"UO_0000065";"13.11";"0.24";"2.17";"7.87";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701167";"";"0";"499.63";"0";"4.84";"BDBM172302";"CCc1nccc(-c2ccc(C(=O)N3CCN(C(C)(C)C)CC3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"10.0";"nM";"8.00";"";"317226";"UO_0000065";"16.01";"0.30";"3.16";"13.04";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688854";"";"0";"508.60";"1";"3.42";"BDBM174313";"CCCNC(=O)c1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccc1F";"IC50";"'='";"140.0";"nM";"6.85";"";"319629";"UO_0000065";"13.48";"0.25";"3.43";"7.39";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693575";"";"0";"472.55";"0";"4.09";"BDBM174741";"COc1cccc(-c2nc(N3CCOC[C@@H]3C)c3ccc(-c4ccc(OC)c(CO)c4)nc3n2)c1";"IC50";"'='";"96.0";"nM";"7.02";"";"320011";"UO_0000065";"14.85";"0.27";"2.93";"7.81";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693575";"";"0";"472.55";"0";"4.09";"BDBM174741";"COc1cccc(-c2nc(N3CCOC[C@@H]3C)c3ccc(-c4ccc(OC)c(CO)c4)nc3n2)c1";"IC50";"'='";"190.0";"nM";"6.72";"";"320020";"UO_0000065";"14.22";"0.26";"2.63";"7.48";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3958894";"";"0";"574.64";"1";"3.59";"BDBM178243";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4cncc(OC)n4)cc3)c2C1=O";"IC50";"'='";"59.0";"nM";"7.23";"";"324263";"UO_0000065";"12.58";"0.24";"3.64";"5.02";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3976821";"";"0";"529.60";"1";"3.79";"BDBM178254";"CN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccccn4)cc3)c2C1=O";"IC50";"'='";"26.0";"nM";"7.58";"";"324274";"UO_0000065";"14.32";"0.27";"3.80";"6.23";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3965706";"";"0";"595.68";"1";"2.35";"BDBM222558";"COc1c(C(=O)N2CCN(S(C)(=O)=O)CC2)nc(-c2ccc(NC(=O)Nc3ccccc3)cc2)nc1N1CCOCC1";"IC50";"'='";"223.5";"nM";"6.65";"";"389347";"UO_0000065";"11.16";"0.22";"4.30";"4.55";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3912425";"";"0";"596.64";"1";"4.93";"BDBM178423";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4cc(OC)c(F)cc4F)cc3)c2C1=O";"IC50";"'='";"81.0";"nM";"7.09";"";"324443";"UO_0000065";"11.89";"0.23";"2.16";"6.00";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3981126";"";"0";"549.61";"1";"4.18";"BDBM178446";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccncc4)c(F)c3)c2C1=O";"IC50";"'='";"16.0";"nM";"7.80";"";"324466";"UO_0000065";"14.18";"0.27";"3.62";"6.40";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3914269";"";"0";"534.64";"1";"3.82";"BDBM222658";"CSc1cnc(-c2ccc(NC(=O)Nc3ccc(C(=O)N4CCOCC4)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"138.2";"nM";"6.86";"";"389447";"UO_0000065";"12.83";"0.25";"3.04";"6.30";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3940509";"";"0";"591.72";"1";"4.78";"BDBM222660";"CSc1c(-c2cccnc2)nc(-c2ccc(NC(=O)Nc3ccc(NS(C)(=O)=O)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"47.8";"nM";"7.32";"";"389449";"UO_0000065";"12.37";"0.24";"2.54";"5.29";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3983292";"";"0";"554.63";"1";"2.65";"BDBM222664";"COc1cnc(-c2ccc(NC(=O)Nc3ccc(S(=O)(=O)N4CCOCC4)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"252.0";"nM";"6.60";"";"389453";"UO_0000065";"11.90";"0.23";"3.95";"4.88";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3979076";"";"0";"559.63";"1";"3.80";"BDBM178264";"COc1ccc(NC(=O)Nc2ccc(-c3nc(N4C5CCC4COC5)nc4c3C(=O)N(C)CC(C)(C)O4)cc2)nc1";"IC50";"'='";"32.0";"nM";"7.50";"";"324284";"UO_0000065";"13.39";"0.25";"3.69";"5.72";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3890517";"";"0";"573.65";"1";"4.19";"BDBM178294";"CCN1CC(C)(C)Oc2nc(N3C4CCC3COC4)nc(-c3ccc(NC(=O)Nc4cc(OC)ccn4)cc3)c2C1=O";"IC50";"'='";"53.0";"nM";"7.28";"";"324314";"UO_0000065";"12.68";"0.24";"3.09";"5.55";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3928171";"";"0";"600.65";"1";"4.80";"BDBM178301";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccnc5[nH]ccc45)c(F)c3)c2C1=O";"IC50";"'='";"377.0";"nM";"6.42";"";"324321";"UO_0000065";"10.69";"0.20";"1.62";"4.67";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3792866";"";"0";"575.01";"1";"2.81";"27";"O=C(Nc1ccc(Cl)c(C(F)(F)F)c1)N1CCN(c2nc3c(c(N4CCOCC4)n2)CS(=O)(=O)CC3)CC1";"IC50";"'='";"9430.0";"nM";"5.03";"";"";"UO_0000065";"8.74";"0.18";"2.22";"4.65";"False";"CHEMBL3795347";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide substrate incubated for 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3792291";"1";"Scientific Literature";"Eur. J. Med. Chem.";"2016";""
"CHEMBL3701055";"";"0";"377.47";"0";"3.30";"BDBM172189";"CNc1ccc(C#Cc2c(-c3ccc(S(C)(=O)=O)cc3)ccnc2C)cn1";"IC50";"'='";"7.0";"nM";"8.15";"";"317113";"UO_0000065";"21.60";"0.41";"4.85";"11.33";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3360203";"PILARALISIB";"2";"541.03";"1";"4.51";"Compound A";"COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c2cccc(NC(=O)C(C)(C)N)c2)c1";"IC50";"'>'";"15000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3882567";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3882389";"38";"Patent Bioactivity Data";"";"2014";""
"CHEMBL3919132";"";"0";"441.44";"0";"3.91";"BDBM222553";"COc1cnc(-c2ccc(NC(=O)Nc3ccc(F)c(F)c3)cc2)nc1N1CCOCC1";"IC50";"'='";"233.2";"nM";"6.63";"";"389342";"UO_0000065";"15.02";"0.28";"2.72";"7.48";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL573339";"PI-103";"0";"348.36";"0";"2.98";"PI103";"Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1";"IC50";"'='";"19.0";"nM";"7.72";"";"";"UO_0000065";"22.16";"0.41";"4.74";"9.14";"True";"CHEMBL3795347";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide substrate incubated for 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3792291";"1";"Scientific Literature";"Eur. J. Med. Chem.";"2016";""
"CHEMBL2030442";"";"0";"372.45";"0";"2.01";"5";"CS(=O)(=O)Cc1cc(N2CCOCC2)nc(-c2cccc3[nH]ccc23)n1";"IC50";"'='";"5900.0";"nM";"5.23";"";"";"UO_0000065";"14.04";"0.27";"3.22";"5.93";"False";"CHEMBL2330630";"Inhibition of mTOR-mediated AKT phosphorylation at serine 473 in human MDA-MB-468 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MDA-MB-468";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2321758";"1";"Scientific Literature";"J. Med. Chem.";"2013";"CHEMBL3308424"
"CHEMBL3109144";"";"0";"442.48";"0";"3.88";"13e";"O=C(Nc1ccc(O)cc1)Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1";"IC50";"'='";"54.0";"nM";"7.27";"";"";"UO_0000065";"16.42";"0.30";"3.39";"6.46";"False";"CHEMBL3112126";"Inhibition of mTOR (unknown origin) after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3108735";"1";"Scientific Literature";"J. Med. Chem.";"2014";""
"CHEMBL3693540";"";"0";"467.57";"0";"2.62";"BDBM174703";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N(CCO)C(C)C)nc3n2)cc1CO";"IC50";"'='";"4.7";"nM";"8.33";"";"319985";"UO_0000065";"17.81";"0.33";"5.71";"8.00";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3649443";"";"0";"255.28";"0";"2.41";"BDBM122466";"COc1cc(-c2cnc3ccccn23)cnc1OC";"IC50";"'>'";"50000.0";"nM";"";"";"251057";"UO_0000065";"";"";"";"";"False";"CHEMBL3705287";"In Vitro mTOR Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP 1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639163";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649438";"";"0";"428.91";"0";"3.33";"BDBM122461";"CN(C)S(=O)(=O)Nc1cc(-c2cnc3cc(-c4ccncc4)ccn23)cnc1Cl";"IC50";"'='";"258.0";"nM";"6.59";"";"251068";"UO_0000065";"15.36";"0.31";"3.26";"7.12";"False";"CHEMBL3705287";"In Vitro mTOR Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP 1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639163";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646585";"";"0";"510.58";"1";"2.47";"BDBM125439";"COc1ncc(Nc2ncc(C(C)N3CCN(C(=O)N(C)C)CC3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255183";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2170086";"";"0";"531.62";"2";"2.14";"BDBM50396822";"COc1ncc(Nc2ncc([C@@H](C)N3CCN(S(C)(=O)=O)C[C@H]3C)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255251";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2206916";"";"0";"463.96";"0";"2.61";"BDBM50401266";"Cc1nc(N)nc(-c2cccnc2Nc2cnc(Cl)c(NS(=O)(=O)N(C)C(C)C)c2)n1";"IC50";"'='";"420.0";"nM";"6.38";"";"255258";"UO_0000065";"13.74";"0.28";"3.77";"4.20";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165049";"";"0";"310.32";"0";"1.37";"BDBM50394871";"COc1ccc(Nc2ncncc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255017";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646468";"";"0";"495.57";"1";"1.79";"BDBM125310";"Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2ccc3ocnc3c2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255028";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646476";"";"0";"453.51";"0";"3.56";"BDBM125318";"COc1ccc(Nc2ncc(CNCc3ccncc3)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'='";"550.0";"nM";"6.26";"";"255037";"UO_0000065";"13.80";"0.25";"2.70";"4.95";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646482";"";"0";"499.60";"1";"1.61";"BDBM125324";"COc1ccc(Nc2ncc(C(C)N3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"2201.0";"nM";"5.66";"";"255044";"UO_0000065";"11.32";"0.22";"4.05";"3.71";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640948";"";"0";"317.35";"0";"2.23";"BDBM115598";"COc1ccc(-c2ncnc(C)c2C#Cc2ccc(N)nc2)cn1";"IC50";"'='";"63.0";"nM";"7.20";"";"240235";"UO_0000065";"22.69";"0.41";"4.97";"8.29";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640963";"";"0";"391.86";"0";"3.18";"BDBM115613";"Cc1ncnc(-c2cc(Cl)cc(C(=O)N(C)C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"24.0";"nM";"7.62";"";"240250";"UO_0000065";"19.45";"0.37";"4.44";"8.96";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640964";"";"0";"417.44";"0";"2.44";"BDBM115614";"Cc1ncnc(-c2ccc(F)c(C(=O)N3CCOCC3)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"13.0";"nM";"7.89";"";"240251";"UO_0000065";"18.89";"0.35";"5.45";"8.37";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3688991";"";"0";"478.60";"0";"2.22";"BDBM174472";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(CNCCO)cc3)nc2n1";"IC50";"'<'";"2.7";"nM";"";"";"235365";"UO_0000065";"";"";"";"";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL2165034";"";"0";"378.44";"0";"2.18";"BDBM50394856";"COc1ccc(Nc2ncc(CN3CCC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255111";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646524";"";"0";"341.35";"0";"2.42";"BDBM125367";"COc1ncc(Nc2nc(C)ccc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255096";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646429";"";"0";"439.48";"0";"3.88";"BDBM125270";"COc1ccc(Nc2ncc(CNc3ccccn3)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"254982";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3958537";"";"0";"351.37";"0";"2.76";"3";"CC(=O)Nc1nc2ccc(-c3nn(C(C)C)c4ncnc(N)c34)cc2o1";"IC50";"'<'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3882339";"Inhibition of recombinant human GST-tagged mTOR (1360 to 2549 residues) catalytic domain assessed as inhibition of GFP labeled 4EBP1 phosphorylation measured after 1 hr by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3882246";"38";"Patent Bioactivity Data";"";"2010";""
"CHEMBL3799831";"";"0";"467.50";"0";"2.87";"16";"CN(C)C(=O)c1cc(CN2CCOc3c(F)cccc32)c2oc(N3CCOCC3)cc(=O)c2c1";"IC50";"'>'";"50000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3803161";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3797054";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2016";""
"CHEMBL3640936";"";"0";"391.86";"0";"3.10";"BDBM115586";"CCc1ncnc(-c2ccc(C(=O)NC)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.0";"nM";"8.30";"";"240223";"UO_0000065";"21.18";"0.40";"5.20";"8.85";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3639398";"";"0";"540.69";"1";"4.87";"BDBM115647";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CC4CCCCC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1C";"IC50";"'='";"68.0";"nM";"7.17";"";"240284";"UO_0000065";"13.26";"0.24";"2.30";"8.12";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3958903";"";"0";"420.52";"0";"2.72";"BDBM60572";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(N)cc3)nc2n1";"IC50";"'='";"6.865";"nM";"8.16";"";"235369";"UO_0000065";"19.41";"0.36";"5.44";"9.11";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL2172477";"";"0";"453.51";"0";"3.91";"21e";"CC(=O)Nc1cc(-c2c(Nc3ccn(C)n3)nc3ccc(-c4cccnc4C)cn23)nc(C)n1";"IC50";"'='";"15.0";"nM";"7.82";"";"";"UO_0000065";"17.25";"0.31";"3.91";"6.81";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL4107880";"";"0";"384.44";"0";"1.19";"BDBM227490";"C[C@@H]1COCCN1c1nc(N2CCOC[C@H]2C)c2nc(-c3cc[nH]n3)[nH]c2n1";"IC50";"'='";"385.0";"nM";"6.42";"";"397249";"UO_0000065";"16.69";"0.31";"5.22";"5.93";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL4109286";"";"0";"432.53";"0";"2.48";"BDBM227495";"C[C@@H]1COCCN1c1nc(N2CCN(C)CC2)nc2[nH]c(-c3cccc4[nH]ccc34)nc12";"IC50";"'='";"308.0";"nM";"6.51";"";"397254";"UO_0000065";"15.05";"0.28";"4.03";"7.30";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL4107510";"";"0";"485.51";"0";"4.51";"BDBM227501";"C[C@@H]1COCCN1c1nc(N2CCC(C(F)(F)F)CC2)nc2[nH]c(-c3cccc4[nH]ccc34)nc12";"IC50";"'='";"1510.0";"nM";"5.82";"";"397260";"UO_0000065";"11.99";"0.23";"1.31";"6.77";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL4114967";"";"0";"449.52";"0";"1.92";"BDBM227504";"C[C@@H]1COCCN1c1nc(N2CCO[C@H](CO)C2)nc2[nH]c(-c3cccc4[nH]ccc34)nc12";"IC50";"'='";"380.0";"nM";"6.42";"";"397263";"UO_0000065";"14.28";"0.27";"4.50";"5.56";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL3899910";"";"0";"410.48";"0";"1.45";"BDBM227506";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2nc(-c3ccc(N)nc3)[nH]c2n1";"IC50";"'='";"2412.0";"nM";"5.62";"";"397265";"UO_0000065";"13.69";"0.26";"4.17";"4.75";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL3646572";"";"0";"513.63";"2";"1.78";"BDBM125426";"COc1ccc(Nc2ncc(C(C)(C)N3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"1778.0";"nM";"5.75";"";"255168";"UO_0000065";"11.19";"0.22";"3.97";"3.77";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649432";"";"0";"340.34";"0";"2.37";"BDBM122455";"COc1cc(-c2cnc3ccc(N4CCOC4=O)cn23)cnc1OC";"IC50";"'='";"9657.0";"nM";"5.01";"";"251060";"UO_0000065";"14.74";"0.27";"2.65";"6.41";"False";"CHEMBL3705287";"In Vitro mTOR Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP 1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639163";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165011";"";"0";"422.49";"0";"1.93";"BDBM50394852";"COc1ccc(Nc2ncc(CN3CCC(O)CC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255108";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646562";"";"0";"416.49";"0";"1.85";"BDBM125415";"Cc1nc(N)nc(-c2cc(CN3CCNCC3)cnc2Nc2ccc3[nH]cnc3c2)n1";"IC50";"'='";"2213.0";"nM";"5.66";"";"255151";"UO_0000065";"13.58";"0.25";"3.81";"4.23";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646571";"";"0";"384.42";"0";"2.30";"BDBM125425";"COc1ncc(Nc2ncc(C(C)(C)N)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255167";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646495";"";"0";"333.36";"0";"3.02";"BDBM125337";"Cc1nc(N)nc(-c2cccnc2Nc2ccc3oc(C)nc3c2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255065";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3688909";"";"0";"464.53";"0";"3.44";"BDBM174370";"C[C@H]1CN(c2nc(N3CCOC[C@@H]3C)c3ccc(-c4ccc([N+](=O)[O-])cc4)nc3n2)C[C@@H](C)O1";"IC50";"'='";"150.0";"nM";"6.82";"";"319686";"UO_0000065";"14.69";"0.27";"3.38";"6.39";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693388";"";"0";"574.77";"2";"5.35";"BDBM174524";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CNC1CCCCCCC1";"IC50";"'='";"59.0";"nM";"7.23";"";"319825";"UO_0000065";"12.58";"0.24";"1.88";"8.52";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL2165023";"";"0";"388.23";"0";"2.73";"BDBM50394867";"COc1ccc(Nc2ncc(Br)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"254959";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3693418";"";"0";"438.53";"0";"2.45";"BDBM174564";"CNCc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)o1";"IC50";"'='";"94.0";"nM";"7.03";"";"319855";"UO_0000065";"16.02";"0.30";"4.58";"7.91";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3814139";"";"0";"451.55";"0";"3.22";"10b";"CCc1ccc2occ(/C=N/Nc3nc4c(c(N5CCOCC5)n3)CSCC4)c(=O)c2c1";"IC50";"";"";"";"";"";"Not Active";"";"";"";"";"";"False";"CHEMBL3815304";"Inhibition of mTOR (unknown origin) using ULight4E-BP1 peptide as substrate incubated for 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3813678";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2016";""
"CHEMBL4114155";"";"0";"447.54";"0";"3.29";"BDBM245515";"CNCCCOc1ccc(-c2ccc3ncc4c(c3c2)n([C@@H]2CCCOC2)c(=O)n4C)cn1";"IC50";"'='";"262.0";"nM";"6.58";"";"427926";"UO_0000065";"14.71";"0.27";"3.29";"7.91";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL4217549";"";"0";"478.60";"0";"3.35";"12";"C[C@H](Nc1c(C(N)=O)nnc2ccc(-c3ccc(OCCCN(C)C)nc3)cc12)C1CCOCC1";"IC50";"'='";"5300.0";"nM";"5.28";"";"";"UO_0000065";"11.02";"0.21";"1.93";"4.57";"False";"CHEMBL4200474";"Inhibition of truncated FLAG-tagged mTOR (unknown origin) (1362 to 2549 residues) expressed in HEK293 cells using biotinylated P70 peptide as substrate measured after 90 mins by Alphascreen assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4196159";"1";"Scientific Literature";"ACS Med Chem Lett";"2018";""
"CHEMBL3641003";"";"0";"503.05";"1";"4.29";"BDBM115654";"CCCCN1CCN(C(=O)c2ccc(-c3ncnc(CC)c3C#Cc3ccc(N)nc3)cc2Cl)CC1";"IC50";"'='";"1.0";"nM";"9.00";"";"240291";"UO_0000065";"17.89";"0.34";"4.71";"10.20";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649473";"";"0";"548.07";"1";"2.83";"BDBM125512";"Cc1nc(N)cc(-c2cc([C@H](C)N3CCOCC3)cnc2Nc2cnc(Cl)c(NS(=O)(=O)N(C)C)c2)n1";"IC50";"'='";"3190.0";"nM";"5.50";"";"255273";"UO_0000065";"10.03";"0.20";"2.67";"3.63";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2216870";"IDELALISIB";"4";"415.43";"0";"3.75";"34, CAL101, GS1101";"CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3223610";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3217752";"1";"Scientific Literature";"MedChemComm";"2012";""
"CHEMBL3643930";"";"0";"997.99";"";"";"BDBM125244";"COc1ccc(CN(Cc2ccc(OC)cc2)c2nc(C)nc(Cl)n2)cc1.COc1ccc(CNc2nc(C)nc(Cl)n2)cc1.Cc1nc(Cl)nc(Cl)n1.Clc1nc(Cl)nc(Cl)n1";"IC50";"'>'";"10000.0";"nM";"";"";"254979";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649435";"";"0";"340.38";"0";"2.25";"BDBM122458";"COc1cc(-c2cnc3ccc(N4CCOCC4)cn23)cnc1OC";"IC50";"'='";"4519.0";"nM";"5.34";"";"251063";"UO_0000065";"15.70";"0.29";"3.09";"8.75";"False";"CHEMBL3705287";"In Vitro mTOR Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP 1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639163";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649436";"";"0";"496.90";"0";"4.35";"BDBM122459";"CN(C)S(=O)(=O)Nc1cc(-c2cnc3ccc(-c4ccnc(C(F)(F)F)c4)cn23)cnc1Cl";"IC50";"'='";"15.0";"nM";"7.82";"";"251066";"UO_0000065";"15.75";"0.32";"3.47";"8.46";"False";"CHEMBL3705287";"In Vitro mTOR Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP 1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639163";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646535";"";"0";"456.53";"1";"1.20";"BDBM125386";"COc1ccc(Nc2ncc(CN3CC(S(C)(=O)=O)C3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255114";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165004";"";"0";"470.56";"1";"1.59";"BDBM50394841";"COc1ccc(Nc2ncc(CN3CCC(S(C)(=O)=O)C3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"3578.0";"nM";"5.45";"";"255119";"UO_0000065";"11.57";"0.23";"3.86";"3.65";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646550";"";"0";"512.58";"1";"1.66";"BDBM125402";"Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2cc(F)cc3[nH]ncc23)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255135";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649481";"";"0";"440.48";"0";"2.50";"BDBM125520";"COc1ncc(Nc2ncc([C@H](C)N3CCOCC3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'='";"4015.0";"nM";"5.40";"";"255181";"UO_0000065";"12.25";"0.23";"2.90";"4.34";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2206903";"";"0";"436.89";"0";"2.00";"BDBM50401257";"COc1cnc(Nc2cnc(Cl)c(NS(C)(=O)=O)c2)c(-c2nc(C)nc(N)n2)c1";"IC50";"'='";"50.0";"nM";"7.30";"";"255221";"UO_0000065";"16.71";"0.34";"5.30";"4.62";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2206905";"";"0";"507.96";"2";"1.61";"BDBM50401255";"COc1cnc(Nc2cnc(Cl)c(NS(=O)(=O)N3CCOCC3)c2)c(-c2nc(C)nc(N)n2)c1";"IC50";"'='";"585.0";"nM";"6.23";"";"255225";"UO_0000065";"12.27";"0.25";"4.62";"3.66";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640933";"";"0";"375.41";"0";"2.67";"BDBM115583";"Cc1ncnc(-c2ccc(F)c(C(=O)N(C)C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"6.0";"nM";"8.22";"";"240220";"UO_0000065";"21.90";"0.40";"5.55";"9.67";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640997";"";"0";"529.62";"1";"2.38";"BDBM115648";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CC(=O)N(C)C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1C";"IC50";"'='";"2.0";"nM";"8.70";"";"240285";"UO_0000065";"16.42";"0.30";"6.32";"8.01";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640999";"";"0";"520.61";"1";"4.49";"BDBM115650";"CCc1ncnc(-c2ccc(C(=O)N3CCN(c4ccccc4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1C";"IC50";"'='";"26.0";"nM";"7.58";"";"240287";"UO_0000065";"14.57";"0.27";"3.10";"8.60";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3641013";"";"0";"523.04";"1";"4.70";"BDBM115664";"CCc1ncnc(-c2ccc(C(=O)N3CCN(c4ccccc4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.0";"nM";"8.30";"";"240301";"UO_0000065";"15.87";"0.30";"3.60";"9.41";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3641016";"";"0";"489.02";"0";"3.90";"BDBM115667";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C(C)C)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.84";"nM";"9.08";"";"240304";"UO_0000065";"18.56";"0.35";"5.18";"10.29";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3641021";"";"0";"506.56";"1";"3.11";"BDBM115672";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CC(F)F)CC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"240309";"UO_0000065";"17.17";"0.32";"5.59";"8.92";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3586386";"";"0";"420.48";"0";"2.21";"18";"Cc1nc(-c2nc[nH]n2)ccc1-c1cnc2c(n1)N(CCC1CCOCC1)CC(=O)N2";"IC50";"'='";"90.0";"nM";"7.05";"";"";"UO_0000065";"16.76";"0.31";"4.84";"5.78";"True";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3586401";"";"0";"383.45";"0";"1.83";"34";"CC(C)(O)c1ccc(-c2cnc3c(n2)N([C@H]2CC[C@H](O)CC2)C(=O)CN3)cn1";"IC50";"'='";"38.0";"nM";"7.42";"";"";"UO_0000065";"19.35";"0.36";"5.59";"6.66";"False";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3688964";"";"0";"518.62";"1";"2.35";"BDBM174441";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(C(=O)N4CC[C@@H](O)C4)c3)nc2n1";"IC50";"'='";"5.2";"nM";"8.28";"";"319745";"UO_0000065";"15.97";"0.30";"5.93";"7.95";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701106";"";"0";"415.50";"0";"2.94";"BDBM172241";"COCCCN(C)C(=O)c1ccc(-c2ccnc(C)c2C#Cc2ccc(N)nc2)cn1";"IC50";"'='";"10.0";"nM";"8.00";"";"317165";"UO_0000065";"19.25";"0.35";"5.06";"8.49";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3793268";"";"0";"532.99";"1";"3.28";"11";"O=C(Nc1ccc(F)c(Cl)c1)Nc1ccc(-c2nc3c(c(N4CCOCC4)n2)CS(=O)(=O)CC3)cn1";"IC50";"'='";"940.0";"nM";"6.03";"";"";"UO_0000065";"11.31";"0.23";"2.75";"4.77";"False";"CHEMBL3795347";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide substrate incubated for 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3792291";"1";"Scientific Literature";"Eur. J. Med. Chem.";"2016";""
"CHEMBL3670173";"";"0";"351.45";"0";"2.16";"BDBM111647";"CCc1ncnc(N2CCC(O)(CC)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.0";"nM";"8.40";"";"232470";"UO_0000065";"23.90";"0.44";"6.24";"9.53";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670235";"";"0";"432.57";"0";"3.07";"BDBM111711";"Cc1ncnc(N2CCC(CNC(=O)CC3CCCC3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"16.0";"nM";"7.80";"";"232534";"UO_0000065";"18.02";"0.33";"4.73";"8.03";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670182";"";"0";"386.48";"0";"0.50";"BDBM111656";"CCc1ncnc(N2CCN(S(C)(=O)=O)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"16.0";"nM";"7.80";"";"232479";"UO_0000065";"20.17";"0.39";"7.30";"7.40";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670247";"";"0";"376.46";"0";"1.61";"BDBM111723";"Cc1ncnc(N2CCN(C(=O)C3CCC3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"64.0";"nM";"7.19";"";"232546";"UO_0000065";"19.11";"0.35";"5.58";"8.15";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3640956";"";"0";"315.38";"0";"2.79";"BDBM115606";"CCc1ncnc(-c2ccc(C)nc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"22.0";"nM";"7.66";"";"240243";"UO_0000065";"24.28";"0.44";"4.87";"9.87";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3670175";"";"0";"337.43";"0";"1.90";"BDBM111649";"CCC1(O)CCN(c2ncnc(C)c2C#Cc2ccc(N)nc2)CC1";"IC50";"'='";"5.0";"nM";"8.30";"";"232472";"UO_0000065";"24.60";"0.45";"6.40";"9.42";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670249";"";"0";"402.46";"0";"2.03";"BDBM111725";"Cc1ccc(C(=O)N2CCN(c3ncnc(C)c3C#Cc3ccc(N)nc3)CC2)o1";"IC50";"'='";"60.0";"nM";"7.22";"";"232548";"UO_0000065";"17.94";"0.33";"5.19";"7.12";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670254";"";"0";"356.43";"0";"2.37";"BDBM111730";"CCc1ncnc(N2CCc3ncccc3C2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"67.0";"nM";"7.17";"";"232553";"UO_0000065";"20.13";"0.36";"4.80";"8.88";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670273";"";"0";"385.48";"0";"2.14";"BDBM111749";"CCc1ncnc(N2CCN(c3ccncc3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"49.0";"nM";"7.31";"";"232572";"UO_0000065";"18.96";"0.34";"5.17";"8.70";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670164";"";"0";"350.43";"0";"1.27";"BDBM111638";"CC(=O)NC1CCN(c2ncnc(C)c2C#Cc2ccc(N)nc2)CC1";"IC50";"'='";"42.0";"nM";"7.38";"";"232461";"UO_0000065";"21.05";"0.39";"6.11";"7.60";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670188";"";"0";"337.43";"0";"2.03";"BDBM111663";"CCc1ncnc(N2CCOC(C)(C)C2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"30.0";"nM";"7.52";"";"232486";"UO_0000065";"22.29";"0.41";"5.49";"9.75";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670206";"";"0";"350.47";"0";"3.15";"BDBM111682";"CCOC1CCN(c2ncnc(CC)c2C#Cc2ccc(C)nc2)CC1";"IC50";"'='";"168.0";"nM";"6.78";"";"232505";"UO_0000065";"19.33";"0.36";"3.62";"13.25";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670240";"";"0";"365.44";"0";"0.88";"BDBM111716";"CCc1ncnc(N2CCN(C(=O)NC)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"84.0";"nM";"7.08";"";"232539";"UO_0000065";"19.36";"0.36";"6.20";"7.06";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670162";"";"0";"337.43";"0";"1.77";"BDBM111636";"CCc1ncnc(N2CCC(C)(O)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.0";"nM";"8.30";"";"232483";"UO_0000065";"24.60";"0.45";"6.53";"9.42";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670187";"";"0";"337.43";"0";"1.62";"BDBM111662";"CCc1ncnc(N2CCCC(CO)C2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"28.0";"nM";"7.55";"";"232485";"UO_0000065";"22.38";"0.41";"5.93";"8.57";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670275";"";"0";"384.49";"0";"2.74";"BDBM111751";"CCc1ncnc(N2CCN(c3ccccc3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"89.0";"nM";"7.05";"";"232574";"UO_0000065";"18.34";"0.33";"4.31";"9.91";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3109140";"";"0";"364.41";"0";"2.28";"13a";"CNC(=O)Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1";"IC50";"'='";"13.0";"nM";"7.89";"";"";"UO_0000065";"21.64";"0.40";"5.61";"8.55";"False";"CHEMBL3112126";"Inhibition of mTOR (unknown origin) after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3108735";"1";"Scientific Literature";"J. Med. Chem.";"2014";""
"CHEMBL4228946";"";"0";"505.53";"1";"4.11";"9a";"COc1ncc(-c2cc3c(C)nc(NC(C)=O)nc3s2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"10.0";"nM";"8.00";"";"";"UO_0000065";"15.82";"0.32";"3.89";"6.50";"False";"CHEMBL4220376";"Inhibition of recombinant N-terminal FLAG-tagged human mTOR (1362 to end residues) using ULight-4E-BP1 peptide as substrate measured after 1 hr by LANCE assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4219058";"1";"Scientific Literature";"Bioorg Med Chem";"2018";""
"CHEMBL3967736";"";"0";"524.60";"1";"3.57";"BDBM178348";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)NC4CC4)c(F)c3)c2C1=O";"IC50";"'='";"33.0";"nM";"7.48";"";"324368";"UO_0000065";"14.26";"0.27";"3.91";"6.87";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3946500";"";"0";"608.65";"1";"4.69";"BDBM178377";"COCCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(F)cc4F)cc3)c2C1=O";"IC50";"'='";"147.0";"nM";"6.83";"";"324397";"UO_0000065";"11.23";"0.21";"2.14";"5.78";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3930831";"";"0";"659.77";"1";"4.07";"BDBM178410";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(N5CCN(C)CC5)nc4)c(F)c3)c2C1=O";"IC50";"'='";"61.0";"nM";"7.21";"";"324430";"UO_0000065";"10.94";"0.21";"3.14";"5.62";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3355476";"";"0";"366.40";"0";"2.88";"9";"C[C@@H]1COCCN1c1nc(-c2c(F)ncc3[nH]ccc23)cc2c1ncn2C";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL3372424";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352352";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL3355480";"";"0";"349.40";"0";"2.13";"13";"C[C@@H]1COCCN1c1nc(-c2nncc3[nH]ccc23)cc2c1ncn2C";"IC50";"'>'";"13000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3372424";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352352";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL4218854";"";"0";"492.62";"0";"3.61";"21";"CNC(=O)c1nnc2ccc(-c3ccc(OCCCN(C)C)nc3)cc2c1N[C@@H](C)C1CCOCC1";"IC50";"'>'";"19000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4200478";"Inhibition of mTOR in human MDA-MB-231 cells assessed as reduction in AKT phosphorylation at Ser473 residue after 2 hrs by fluorescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MDA-MB-231";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4196159";"1";"Scientific Literature";"ACS Med Chem Lett";"2018";""
"CHEMBL3936477";"";"0";"561.62";"1";"4.32";"BDBM178299";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccccn4)cc3F)c2C1=O";"IC50";"'='";"23.0";"nM";"7.64";"";"324319";"UO_0000065";"13.60";"0.25";"3.32";"6.27";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3965936";"";"0";"440.50";"0";"2.02";"BDBM178309";"CCNC(=O)Nc1ccc(-c2nc(N3CCOCC3)nc3c2C(=O)NCC(C)(C)O3)cc1";"IC50";"'='";"112.0";"nM";"6.95";"";"324329";"UO_0000065";"15.78";"0.30";"4.93";"5.91";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3927688";"";"0";"440.50";"0";"1.98";"BDBM178312";"CCNC(=O)Nc1ccc(-c2nc(N3CCOCC3)nc3c2C(=O)N(CC)CCO3)cc1";"IC50";"'='";"800.0";"nM";"6.10";"";"324332";"UO_0000065";"13.84";"0.26";"4.12";"5.60";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL2336333";"";"0";"464.57";"0";"2.17";"BDBM50429709";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCN(C)CC4)nc3n2)cc1CO";"IC50";"'='";"67.0";"nM";"7.17";"";"319973";"UO_0000065";"15.44";"0.29";"5.00";"8.24";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688833";"";"0";"419.53";"0";"3.45";"BDBM174291";"Cc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1";"IC50";"'='";"5.0";"nM";"8.30";"";"319606";"UO_0000065";"19.79";"0.37";"4.85";"13.05";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688845";"";"0";"409.49";"0";"1.88";"BDBM174303";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cnn(C)c3)nc2n1";"IC50";"'='";"28.0";"nM";"7.55";"";"319619";"UO_0000065";"18.44";"0.34";"5.67";"9.28";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688919";"";"0";"460.54";"0";"2.64";"BDBM174381";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc4c(c3)CC(=O)N4)nc2n1";"IC50";"'='";"42.0";"nM";"7.38";"";"319698";"UO_0000065";"16.02";"0.30";"4.74";"7.96";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688976";"";"0";"516.65";"1";"3.77";"BDBM174453";"CC1CCCN1C(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"380.0";"nM";"6.42";"";"319757";"UO_0000065";"12.43";"0.23";"2.65";"7.65";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688978";"";"0";"494.57";"0";"2.98";"BDBM174455";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(F)c(C(=O)N(C)C)c3)nc2n1";"IC50";"'='";"160.0";"nM";"6.80";"";"319760";"UO_0000065";"13.74";"0.26";"3.82";"8.10";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693463";"";"0";"459.51";"0";"2.95";"BDBM174624";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(Nc4ccncn4)nc3n2)cc1CO";"IC50";"'='";"310.0";"nM";"6.51";"";"319902";"UO_0000065";"14.16";"0.26";"3.56";"5.50";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3889770";"";"0";"447.54";"0";"2.98";"BDBM245478";"CN(C)CCCOc1ccc(-c2ccc3ncc4c(c3c2)n([C@H]2C[C@@H](O)C2)c(=O)n4C)cn1";"IC50";"'='";"1360.0";"nM";"5.87";"";"427888";"UO_0000065";"13.11";"0.24";"2.89";"6.87";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3950905";"";"0";"479.56";"0";"3.77";"BDBM245479";"CO[C@H]1C[C@@H](n2c(=O)n(C)c3cnc4cc(F)c(-c5ccc(OCCCN(C)C)nc5)cc4c32)C1";"IC50";"'>'";"16900.0";"nM";"";"";"427889";"UO_0000065";"";"";"";"";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL4106960";"";"0";"543.60";"1";"3.21";"BDBM178277";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)O[C@H](C)CO)c(F)c3)c2C1=O";"IC50";"'='";"667.0";"nM";"6.18";"";"324297";"UO_0000065";"11.36";"0.22";"2.97";"4.89";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689026";"";"0";"560.72";"1";"4.50";"BDBM174508";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CNCc1cccs1";"IC50";"'='";"110.0";"nM";"6.96";"";"319809";"UO_0000065";"12.41";"0.24";"2.46";"8.20";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL4096651";"";"0";"432.49";"0";"3.93";"9l";"N#CCN1CCC(n2c(=O)cnc3cnc4ccc(-c5cnc6ccccc6c5)cc4c32)C1";"IC50";"'='";"14.0";"nM";"7.85";"";"";"UO_0000065";"18.16";"0.33";"3.92";"8.96";"False";"CHEMBL4023016";"Inhibition of N-terminal FLAG-tagged recombinant human mTOR (1362 to end residues)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020823";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL3643265";"";"0";"433.90";"0";"3.51";"BDBM115930";"CCc1ncnc(-c2ccc(C(=O)N3CCCO3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.27";"nM";"9.57";"";"240542";"UO_0000065";"22.05";"0.42";"6.06";"10.15";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643272";"";"0";"539.06";"1";"2.84";"BDBM115937";"CCc1ncnc(-c2ccc(C(=O)N3CCN(S(=O)(=O)CC)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.36";"nM";"9.44";"";"240549";"UO_0000065";"17.52";"0.35";"6.60";"7.72";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645834";"";"0";"519.02";"1";"4.19";"BDBM116012";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(C4CCC4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"13.63";"nM";"7.87";"";"240624";"UO_0000065";"15.15";"0.29";"3.68";"8.91";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645837";"";"0";"512.55";"1";"2.62";"BDBM116015";"CCc1ncnc(-c2ccc(C(=O)N3CCn4c(COC)nnc4C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.22";"nM";"8.65";"";"240627";"UO_0000065";"16.88";"0.31";"6.03";"6.93";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645844";"";"0";"530.54";"1";"2.76";"BDBM116022";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCn4c(COC)nnc4C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"23.12";"nM";"7.64";"";"240634";"UO_0000065";"14.39";"0.27";"4.88";"6.11";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645846";"";"0";"486.53";"0";"2.75";"BDBM116024";"C#CCN1CCN(C(=O)c2c(F)cc(-c3ncnc(CC)c3C#Cc3ccc(N)nc3)cc2F)CC1";"IC50";"'='";"8.6";"nM";"8.07";"";"240636";"UO_0000065";"16.58";"0.31";"5.32";"9.14";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645870";"";"0";"509.44";"1";"4.17";"BDBM116049";"CCc1ncnc(-c2cc(Cl)c(C(=O)N3CCN(CC)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.4";"nM";"8.85";"";"240661";"UO_0000065";"17.38";"0.35";"4.68";"10.03";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645985";"";"0";"584.70";"2";"5.13";"BDBM116165";"CCc1ncnc(-c2ccc(C(=O)N3CCC4(CC3)CC(NC(=O)OC(C)(C)C)C4)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"9.74";"nM";"8.01";"";"240777";"UO_0000065";"13.70";"0.25";"2.88";"6.50";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3648864";"";"0";"456.53";"0";"2.66";"BDBM116170";"CCc1ncnc(-c2ccc(C(=O)N3CCC4(CNC4)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"13.61";"nM";"7.87";"";"240782";"UO_0000065";"17.23";"0.32";"5.21";"8.11";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3648876";"";"0";"502.57";"1";"3.53";"BDBM116182";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCC4(CC3)CN(C)C4)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.21";"nM";"8.28";"";"240794";"UO_0000065";"16.48";"0.31";"4.75";"9.39";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3648882";"";"0";"529.00";"1";"3.08";"BDBM116188";"CCc1ncnc(-c2ccc(C(=O)N3CCN(Cc4ncon4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.66";"nM";"9.18";"";"240800";"UO_0000065";"17.35";"0.33";"6.10";"7.22";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3648887";"";"0";"458.54";"0";"3.00";"BDBM116193";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C)C[C@H]3C)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.42";"nM";"8.47";"";"240805";"UO_0000065";"18.46";"0.34";"5.47";"9.59";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646556";"";"0";"386.42";"0";"3.03";"BDBM125409";"COc1ccc(Nc2nc(-c3cccnc3)ccc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255144";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646559";"";"0";"377.39";"0";"2.50";"BDBM125412";"Cc1nc(N)nc(-c2cc(-c3cnn(C)c3)cnc2Nc2cncc(F)c2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255148";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646561";"";"0";"494.59";"0";"1.52";"BDBM125414";"Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2ccc3[nH]cnc3c2)n1";"IC50";"'='";"501.0";"nM";"6.30";"";"255150";"UO_0000065";"12.74";"0.25";"4.78";"3.96";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2206911";"";"0";"328.77";"0";"2.20";"BDBM50401249";"Cc1nc(N)nc(-c2cccnc2Nc2cnc(Cl)c(N)c2)n1";"IC50";"'='";"471.0";"nM";"6.33";"";"255155";"UO_0000065";"19.24";"0.38";"4.13";"4.92";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2170088";"";"0";"531.62";"2";"2.14";"BDBM50396820";"COc1ncc(Nc2ncc([C@@H](C)N3CCN(S(C)(=O)=O)C[C@@H]3C)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255162";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646595";"";"0";"516.60";"1";"2.35";"BDBM125450";"COc1ncc(Nc2ncc([C@@H](C)N3CCN(S(C)(=O)=O)CC3)cc2-c2cc(N)nc(C)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255194";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3290305";"";"0";"366.42";"0";"4.25";"16e";"Cc1ccc(-n2c(=O)n(C)c3cnc4ccc(-c5ccncc5)cc4c32)cc1";"IC50";"'='";"468.0";"nM";"6.33";"";"";"UO_0000065";"17.27";"0.31";"2.08";"12.01";"False";"CHEMBL3291527";"Inhibition of human recombinant mTOR assessed as inhibition of 4EBP1 phosphorylation after 30 mins by TR-FRET analysis";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3286093";"1";"Scientific Literature";"J. Med. Chem.";"2014";""
"CHEMBL3693438";"";"0";"493.61";"0";"2.48";"BDBM174588";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(OCCN(C)C)nc3)nc2n1";"IC50";"'='";"330.0";"nM";"6.48";"";"319877";"UO_0000065";"13.13";"0.25";"4.00";"7.29";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3646604";"";"0";"440.48";"0";"2.33";"BDBM125461";"COc1ncc(Nc2ncc(CN3CCOC[C@@H]3C)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255206";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3701117";"";"0";"425.54";"0";"4.23";"BDBM172252";"Cc1nccc(-c2ccc(C(=O)N(C)C3CCCCC3)nc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"60.0";"nM";"7.22";"";"317176";"UO_0000065";"16.97";"0.31";"2.99";"8.50";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688916";"";"0";"473.54";"0";"2.38";"BDBM174378";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc4cn[nH]c(=O)c4c3)nc2n1";"IC50";"'='";"690.0";"nM";"6.16";"";"319695";"UO_0000065";"13.01";"0.24";"3.78";"5.63";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688931";"";"0";"448.50";"0";"3.15";"BDBM174397";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(C#N)c(F)c3)nc2n1";"IC50";"'='";"18.0";"nM";"7.75";"";"319714";"UO_0000065";"17.27";"0.32";"4.59";"8.86";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693434";"";"0";"420.52";"0";"2.85";"BDBM174583";"Cc1ccc(-c2cnc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1";"IC50";"'='";"48.72";"nM";"7.31";"";"319873";"UO_0000065";"17.39";"0.32";"4.46";"9.56";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688838";"";"0";"451.53";"0";"2.25";"BDBM174296";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOCC4)nc3n2)cc1CO";"IC50";"'='";"5.7";"nM";"8.24";"";"319612";"UO_0000065";"18.26";"0.34";"5.99";"8.86";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688840";"";"0";"436.52";"0";"2.55";"BDBM174298";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cn1";"IC50";"'='";"85.0";"nM";"7.07";"";"319614";"UO_0000065";"16.20";"0.30";"4.52";"8.25";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688841";"";"0";"436.52";"0";"2.55";"BDBM174299";"COc1ncccc1-c1ccc2c(N3CCOC[C@@H]3C)nc(N3CCOC[C@@H]3C)nc2n1";"IC50";"'='";"140.0";"nM";"6.85";"";"319615";"UO_0000065";"15.70";"0.29";"4.30";"7.99";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688955";"";"0";"462.55";"0";"2.22";"BDBM174432";"C[C@H]1COCCN1c1nc(N2CCC(CO)CC2)nc2nc(-c3cccc(C(N)=O)c3)ccc12";"IC50";"'='";"290.0";"nM";"6.54";"";"319736";"UO_0000065";"14.13";"0.26";"4.32";"5.55";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693416";"";"0";"468.56";"0";"1.82";"BDBM174562";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(CNCCO)o3)nc2n1";"IC50";"'='";"590.0";"nM";"6.23";"";"319853";"UO_0000065";"13.29";"0.25";"4.41";"5.71";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688922";"";"0";"463.54";"0";"3.05";"BDBM174384";"CC(=O)c1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccc1O";"IC50";"'='";"120.0";"nM";"6.92";"";"319701";"UO_0000065";"14.93";"0.28";"3.87";"6.86";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688917";"";"0";"488.59";"0";"3.80";"BDBM174379";"CC(C)Oc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1C#N";"IC50";"'='";"7500.0";"nM";"5.12";"";"319696";"UO_0000065";"10.49";"0.19";"1.32";"5.30";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688921";"";"0";"506.61";"1";"3.03";"BDBM174383";"CC(C)Oc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1C(N)=O";"IC50";"'='";"490.0";"nM";"6.31";"";"319700";"UO_0000065";"12.45";"0.23";"3.28";"5.44";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693397";"";"0";"520.63";"1";"2.75";"BDBM174538";"COCC(=O)N(C)Cc1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"200.0";"nM";"6.70";"";"319834";"UO_0000065";"12.87";"0.24";"3.95";"7.19";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3639999";"";"0";"471.54";"0";"3.13";"BDBM172224";"CCc1nccc(-c2ccc(C(=O)N3CCN(C(C)=O)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"317148";"UO_0000065";"18.45";"0.34";"5.57";"9.41";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701096";"";"0";"434.93";"0";"3.81";"BDBM172231";"COCCN(C)C(=O)c1cc(-c2ccnc(C)c2C#Cc2ccc(N)nc2)ccc1Cl";"IC50";"'='";"6.0";"nM";"8.22";"";"317155";"UO_0000065";"18.90";"0.36";"4.41";"10.11";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693413";"";"0";"536.65";"1";"3.94";"BDBM174554";"CC(C)CC(=O)NCc1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccc1F";"IC50";"'='";"440.0";"nM";"6.36";"";"319850";"UO_0000065";"11.84";"0.22";"2.42";"6.86";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL4104010";"";"0";"464.50";"0";"4.46";"9b";"N#CCN1CCC(n2c(=O)cnc3cnc4cc(F)c(-c5cnc6ccccc6c5)cc4c32)CC1";"IC50";"'='";"35.0";"nM";"7.46";"";"";"UO_0000065";"16.05";"0.29";"3.00";"8.50";"False";"CHEMBL4023016";"Inhibition of N-terminal FLAG-tagged recombinant human mTOR (1362 to end residues)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020823";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL3649437";"";"0";"399.86";"0";"3.48";"BDBM122460";"CS(=O)(=O)Nc1cc(-c2cnc3cc(-c4cccnc4)ccn23)cnc1Cl";"IC50";"'='";"32.0";"nM";"7.50";"";"251067";"UO_0000065";"18.74";"0.38";"4.01";"8.40";"False";"CHEMBL3705287";"In Vitro mTOR Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP 1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639163";"37";"BindingDB Database";"";"2014";""
"CHEMBL4064699";"";"0";"444.50";"0";"2.40";"12d";"COC(=O)CN1CCC(n2c(=O)cnc3cnc4ccc(-c5ccc(N)nc5)cc4c32)CC1";"IC50";"'='";"4.0";"nM";"8.40";"";"";"UO_0000065";"18.89";"0.35";"6.00";"7.23";"False";"CHEMBL4023016";"Inhibition of N-terminal FLAG-tagged recombinant human mTOR (1362 to end residues)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020823";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL3921955";"";"0";"466.47";"0";"2.87";"BDBM222629";"COc1cnc(-c2ccc(NC(=O)Nc3ccc(C(N)=O)cc3)c(F)c2)nc1N1CCOCC1";"IC50";"'='";"215.0";"nM";"6.67";"";"389418";"UO_0000065";"14.29";"0.27";"3.80";"5.06";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3915379";"";"0";"522.54";"1";"3.14";"BDBM222638";"COc1cnc(-c2ccc(NC(=O)Nc3ccc(N4CCOCC4=O)cc3)cc2F)nc1N1CCOCC1";"IC50";"'='";"179.7";"nM";"6.75";"";"389427";"UO_0000065";"12.91";"0.24";"3.61";"5.71";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3894463";"";"0";"533.63";"1";"3.31";"BDBM222645";"COc1cnc(-c2ccc(NC(=O)Nc3ccc(C(=O)NCCCN(C)C)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"97.7";"nM";"7.01";"";"389434";"UO_0000065";"13.14";"0.25";"3.70";"5.80";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL4103534";"";"0";"483.53";"0";"4.13";"5h";"CC(=O)Nc1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)c4cccnc4n3)cc2)cc1";"IC50";"'='";"30.8";"nM";"7.51";"";"";"UO_0000065";"15.53";"0.28";"3.38";"6.19";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL1236962";"OMIPALISIB";"1";"505.51";"1";"4.84";"4; GSK-2126458";"COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"0.18";"nM";"9.74";"";"";"UO_0000065";"19.28";"0.37";"4.90";"9.11";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL3646538";"";"0";"394.44";"0";"1.15";"BDBM125389";"COc1ccc(Nc2ncc(CN3CC(O)C3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255120";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643122";"";"0";"511.57";"1";"2.04";"BDBM115738";"CCc1ncnc(-c2ccc(C(=O)N3CCN(/C(=N/C)NC#N)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"8.0";"nM";"8.10";"";"240375";"UO_0000065";"15.83";"0.29";"6.06";"5.94";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649482";"";"0";"407.36";"0";"2.57";"BDBM125521";"COc1ccc(Nc2ncc([C@H](O)C(F)(F)F)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"379.0";"nM";"6.42";"";"255214";"UO_0000065";"15.76";"0.30";"3.85";"4.87";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3670156";"";"0";"413.53";"0";"2.99";"BDBM111630";"CCc1ncnc(N2CCC(O)(Cc3ccccc3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"74.0";"nM";"7.13";"";"232453";"UO_0000065";"17.24";"0.31";"4.14";"8.09";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670236";"";"0";"407.52";"0";"1.06";"BDBM111712";"Cc1ncnc(N2CCC(CNC(=O)CN(C)C)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"457.0";"nM";"6.34";"";"232535";"UO_0000065";"15.56";"0.29";"5.28";"6.32";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3645838";"";"0";"471.54";"0";"3.47";"BDBM116016";"CCc1ncnc(-c2ccc(C(=O)N3CCC4(CC3)COC4)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.47";"nM";"8.83";"";"240628";"UO_0000065";"18.73";"0.34";"5.36";"9.37";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645843";"";"0";"459.53";"0";"3.47";"BDBM116021";"CCc1ncnc(-c2ccc(C(=O)N(C)C3CCOCC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.56";"nM";"8.81";"";"240633";"UO_0000065";"19.16";"0.35";"5.34";"9.35";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3639447";"";"0";"491.55";"0";"2.00";"BDBM116026";"CCc1ncnc(-c2cc(F)c(C(=O)NCCN3CCNCC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"17.16";"nM";"7.76";"";"240638";"UO_0000065";"15.80";"0.29";"5.77";"7.12";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645850";"";"0";"501.61";"1";"4.30";"BDBM116029";"CCc1ncnc(-c2ccc(C(=O)N3CCC(C(C)(C)O)CC3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"5.19";"nM";"8.29";"";"240641";"UO_0000065";"16.52";"0.31";"3.98";"9.08";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645854";"";"0";"472.57";"0";"3.46";"BDBM116033";"CCc1ncnc(-c2ccc(C(=O)N3CC[C@H](N(C)C)C3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"2.44";"nM";"8.61";"";"240645";"UO_0000065";"18.23";"0.34";"5.15";"11.60";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645864";"";"0";"475.00";"0";"3.58";"BDBM116043";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C)CC3)c(Cl)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"2.86";"nM";"8.54";"";"240655";"UO_0000065";"17.99";"0.34";"4.96";"11.51";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645866";"";"0";"521.45";"1";"4.31";"BDBM116045";"CCc1ncnc(-c2cc(Cl)c(C(=O)N3CCN4CCC[C@H]4C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.87";"nM";"9.06";"";"240657";"UO_0000065";"17.38";"0.34";"4.75";"10.27";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645871";"";"0";"553.49";"1";"3.92";"BDBM116050";"CCc1ncnc(-c2cc(Cl)c(C(=O)N3CCN(CC(C)(C)O)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.34";"nM";"8.87";"";"240662";"UO_0000065";"16.03";"0.32";"4.95";"8.18";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645892";"";"0";"491.54";"0";"3.67";"BDBM116071";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCC(CO)CC3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"4.33";"nM";"8.36";"";"240683";"UO_0000065";"17.01";"0.32";"4.69";"9.17";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645894";"";"0";"538.57";"1";"4.15";"BDBM116073";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C(C)C)CC3)c(OC(F)(F)F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"21.17";"nM";"7.67";"";"240685";"UO_0000065";"14.25";"0.27";"3.52";"7.87";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645905";"";"0";"478.96";"0";"3.26";"BDBM116084";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(C)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.0";"nM";"9.00";"";"240696";"UO_0000065";"18.79";"0.36";"5.74";"10.20";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645957";"";"0";"502.59";"1";"3.01";"BDBM116137";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C(C)COC)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.7";"nM";"8.57";"";"240749";"UO_0000065";"17.05";"0.32";"5.56";"8.79";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645964";"";"0";"520.58";"1";"3.15";"BDBM116144";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(C(C)COC)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.56";"nM";"9.25";"";"240756";"UO_0000065";"17.77";"0.33";"6.10";"9.49";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645988";"";"0";"500.58";"1";"2.82";"BDBM116168";"CCc1ncnc(-c2ccc(C(=O)N3CCC4(CC3)CNCCO4)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"6.48";"nM";"8.19";"";"240780";"UO_0000065";"16.36";"0.30";"5.37";"7.71";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3648883";"";"0";"475.00";"0";"3.51";"BDBM116189";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C)C[C@H]3C)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.62";"nM";"8.25";"";"240801";"UO_0000065";"17.37";"0.33";"4.74";"9.35";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3648889";"";"0";"502.59";"1";"2.75";"BDBM116195";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CC(C)(C)O)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.03";"nM";"8.99";"";"240807";"UO_0000065";"17.88";"0.33";"6.24";"8.29";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643118";"";"0";"498.61";"0";"3.92";"BDBM115734";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCCC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"17.0";"nM";"7.77";"";"240371";"UO_0000065";"15.58";"0.29";"3.85";"8.81";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643120";"";"0";"541.68";"1";"3.32";"BDBM115736";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CC4CCCN(C)C4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"12.0";"nM";"7.92";"";"240373";"UO_0000065";"14.62";"0.27";"4.60";"8.66";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643121";"";"0";"502.55";"1";"3.14";"BDBM115737";"CCOC(=O)N1CCN(C(=O)c2ccc(-c3ncnc(CC)c3C#Cc3ccc(N)nc3)cc2F)CC1";"IC50";"'='";"16.0";"nM";"7.80";"";"240374";"UO_0000065";"15.51";"0.29";"4.66";"6.81";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643134";"";"0";"486.60";"0";"3.78";"BDBM115750";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C(C)CC)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"10.0";"nM";"8.00";"";"240387";"UO_0000065";"16.44";"0.30";"4.22";"9.07";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643190";"";"0";"474.54";"0";"2.28";"BDBM115833";"CCc1ncnc(-c2ccc(C(=O)NCCN3CCOCC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.0";"nM";"8.40";"";"240445";"UO_0000065";"17.70";"0.33";"6.12";"7.90";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645803";"";"0";"454.58";"0";"3.17";"BDBM115981";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N(C)C)C3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"24.16";"nM";"7.62";"";"240593";"UO_0000065";"16.76";"0.31";"4.45";"8.63";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645811";"";"0";"441.54";"0";"3.25";"BDBM115989";"CCc1ncnc(-c2ccc(C(=O)N3CCCOCC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.16";"nM";"8.38";"";"240601";"UO_0000065";"18.98";"0.35";"5.13";"8.89";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3577911";"";"0";"505.51";"1";"4.84";"5d";"COc1ncc(-c2ccc3ncnc(-c4ccncc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"0.2";"nM";"9.70";"";"";"UO_0000065";"19.19";"0.37";"4.86";"9.07";"False";"CHEMBL3579762";"Inhibition of mTOR (unknown origin) using GFP-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3576869";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL3954673";"";"0";"406.45";"0";"3.03";"BDBM222665";"COc1cnc(-c2ccc(NC(=O)Nc3ccncc3)cc2)nc1N1CCOCC1";"IC50";"'='";"117.4";"nM";"6.93";"";"389454";"UO_0000065";"17.05";"0.32";"3.90";"6.83";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3923182";"";"0";"475.59";"0";"4.02";"BDBM245542";"CO[C@H]1CC[C@H](n2c(=O)n(C)c3cnc4ccc(-c5ccc(OCCCN(C)C)nc5)cc4c32)C1";"IC50";"'='";"360.0";"nM";"6.44";"";"427909";"UO_0000065";"13.55";"0.25";"2.42";"8.66";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL4110389";"";"0";"447.54";"0";"3.24";"BDBM245516";"CN(C)CCCOc1ccc(-c2ccc3ncc4c(c3c2)n([C@@H]2CCOC2)c(=O)n4C)cn1";"IC50";"'='";"2370.0";"nM";"5.62";"";"427927";"UO_0000065";"12.57";"0.23";"2.39";"7.56";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL4079258";"";"0";"344.38";"0";"-0.42";"12";"Nc1cnc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cn1";"IC50";"'='";"817.0";"nM";"6.09";"";"";"UO_0000065";"17.68";"0.33";"6.51";"5.27";"False";"CHEMBL4019299";"Inhibition of mTOR in human A2058 cells assessed as reduction in phosphorylation of S6 at ser235/236 residues after 1 hr by in-cell Western method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017506";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL3640932";"";"0";"364.43";"0";"2.23";"BDBM115582";"Cc1ncnc(-c2ccc(S(C)(=O)=O)cc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"8.0";"nM";"8.10";"";"240219";"UO_0000065";"22.22";"0.43";"5.87";"8.19";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640973";"";"0";"445.95";"0";"4.36";"BDBM115623";"CCc1ncnc(-c2ccc(Cl)c(C(=O)N3CCCCC3)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"28.0";"nM";"7.55";"";"240260";"UO_0000065";"16.94";"0.32";"3.19";"8.89";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643075";"";"0";"458.54";"0";"3.05";"BDBM115690";"CCc1ncnc(-c2ccc(C(=O)NC3CCN(C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"30.0";"nM";"7.52";"";"240327";"UO_0000065";"16.41";"0.30";"4.47";"7.75";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646509";"";"0";"393.84";"0";"4.08";"BDBM125352";"CC(=O)Nc1ccc(Nc2ncccc2-c2nc(C)nc3[nH]cnc23)cc1Cl";"IC50";"'>'";"10000.0";"nM";"";"";"255080";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165017";"";"0";"485.57";"1";"1.05";"BDBM50394846";"COc1ccc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"4763.0";"nM";"5.32";"";"254949";"UO_0000065";"10.96";"0.21";"4.27";"3.49";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165042";"";"0";"342.37";"0";"3.34";"BDBM50394878";"Cc1nc(-c2cccnc2Nc2cccc3n[nH]cc23)c2c[nH]nc2n1";"IC50";"'>'";"50000.0";"nM";"";"";"254963";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646443";"";"0";"418.46";"0";"2.71";"BDBM125285";"COc1ccc(Nc2ncc(N3CCOCC3)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"254997";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646450";"";"0";"510.58";"1";"4.34";"BDBM125292";"Cc1nc(-c2cc(Cc3ccc(S(C)(=O)=O)cc3)cnc2Nc2cccc3[nH]ncc23)c2nc[nH]c2n1";"IC50";"'>'";"10000.0";"nM";"";"";"255004";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL4085859";"";"0";"444.47";"0";"3.31";"9z";"COc1ccc(-c2cc3c(cc2F)ncc2ncc(=O)n(C4CCN(CC#N)CC4)c23)cn1";"IC50";"'='";"32.0";"nM";"7.50";"";"";"UO_0000065";"16.86";"0.31";"4.18";"7.73";"False";"CHEMBL4023016";"Inhibition of N-terminal FLAG-tagged recombinant human mTOR (1362 to end residues)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020823";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL3640977";"";"0";"446.53";"0";"2.86";"BDBM115627";"CCc1ncnc(-c2ccc(C(=O)N(C)CCN(C)C)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"30.0";"nM";"7.52";"";"240264";"UO_0000065";"16.85";"0.31";"4.66";"8.53";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640990";"";"0";"528.63";"1";"3.47";"BDBM115640";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C4CCOCC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1C";"IC50";"'='";"3.0";"nM";"8.52";"";"240277";"UO_0000065";"16.12";"0.30";"5.05";"8.74";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3641008";"";"0";"435.92";"0";"2.80";"BDBM115659";"CCc1ncnc(-c2ccc(C(=O)N(C)CCO)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.0";"nM";"9.00";"";"240296";"UO_0000065";"20.65";"0.40";"6.20";"8.55";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649428";"";"0";"479.92";"1";"5.05";"BDBM122451";"O=S(=O)(Nc1cc(-c2cnc3ccc(-c4cccnc4)cn23)cnc1Cl)c1ccc(F)cc1";"IC50";"'='";"32.0";"nM";"7.50";"";"251055";"UO_0000065";"15.62";"0.31";"2.44";"8.40";"False";"CHEMBL3705287";"In Vitro mTOR Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP 1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639163";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646597";"";"0";"406.86";"0";"1.99";"BDBM125452";"Cc1nc(N)cc(-c2nccnc2Nc2cnc(Cl)c(NS(C)(=O)=O)c2)n1";"IC50";"'='";"3882.0";"nM";"5.41";"";"255196";"UO_0000065";"13.30";"0.27";"3.42";"3.64";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646601";"";"0";"385.40";"0";"2.21";"BDBM125457";"COc1ncc(Nc2ncc(C(C)CO)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255203";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646613";"";"0";"505.61";"1";"2.19";"BDBM125470";"Cc1nc(N)nc(-c2cc(CN3CCN(S(C)(=O)=O)CC3)cnc2Nc2ccc3ccncc3c2)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255217";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646618";"";"0";"544.04";"1";"3.28";"BDBM125475";"Cc1nc(-c2cc(C(C)N3CCOCC3)cnc2Nc2cnc(Cl)c(NS(C)(=O)=O)c2)c2nc[nH]c2n1";"IC50";"'='";"46.0";"nM";"7.34";"";"255230";"UO_0000065";"13.49";"0.27";"4.06";"4.86";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3358287";"";"0";"397.44";"0";"2.21";"BDBM125486";"COc1cc(Nc2ncc(C(C)(C)O)cc2-c2nc(C)nc(N)n2)cnc1OC";"IC50";"'='";"5490.0";"nM";"5.26";"";"255241";"UO_0000065";"13.24";"0.25";"3.05";"3.73";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646631";"";"0";"522.59";"1";"2.44";"BDBM125495";"COc1ncc(Nc2ncc(CN3CCN(C(=O)N(C)C4CC4)CC3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'='";"2990.0";"nM";"5.52";"";"255250";"UO_0000065";"10.57";"0.20";"3.08";"3.99";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2170087";"";"0";"531.62";"2";"2.14";"BDBM50396821";"COc1ncc(Nc2ncc([C@H](C)N3CCN(S(C)(=O)=O)C[C@H]3C)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255252";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640974";"";"0";"391.86";"0";"3.10";"BDBM115624";"CCc1ncnc(-c2ccc(Cl)c(C(=O)NC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"31.0";"nM";"7.51";"";"240261";"UO_0000065";"19.16";"0.37";"4.41";"8.01";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640987";"";"0";"508.55";"1";"3.55";"BDBM115637";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CC(F)F)CC3)c(F)c2)c1C#Cc1ccc(N)nc1C";"IC50";"'='";"3.0";"nM";"8.52";"";"240274";"UO_0000065";"16.76";"0.31";"4.97";"9.66";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640998";"";"0";"534.64";"1";"4.49";"BDBM115649";"CCc1ncnc(-c2ccc(C(=O)N3CCN(Cc4ccccc4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1C";"IC50";"'='";"9.0";"nM";"8.05";"";"240286";"UO_0000065";"15.05";"0.27";"3.56";"9.12";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3641002";"";"0";"487.01";"0";"3.66";"BDBM115653";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C4CC4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.99";"nM";"9.00";"";"240290";"UO_0000065";"18.49";"0.35";"5.34";"10.20";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643074";"";"0";"527.65";"1";"3.07";"BDBM115689";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C4CCN(C)CC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"240326";"UO_0000065";"16.49";"0.30";"5.63";"9.51";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643079";"";"0";"512.63";"1";"4.31";"BDBM115695";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCCCC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.0";"nM";"8.30";"";"240332";"UO_0000065";"16.19";"0.30";"3.99";"9.41";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640935";"";"0";"375.41";"0";"2.67";"BDBM115585";"Cc1ncnc(-c2ccc(C(=O)N(C)C)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"240222";"UO_0000065";"23.17";"0.42";"6.03";"10.23";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640937";"";"0";"300.37";"0";"3.08";"BDBM115587";"CCc1ncnc(-c2ccccc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"64.0";"nM";"7.19";"";"240224";"UO_0000065";"23.95";"0.43";"4.11";"11.12";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640984";"";"0";"460.56";"0";"3.25";"BDBM115634";"CCc1ncnc(-c2ccc(C(=O)N(C)CCCN(C)C)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"33.0";"nM";"7.48";"";"240271";"UO_0000065";"16.24";"0.30";"4.23";"8.48";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643083";"";"0";"458.54";"0";"2.90";"BDBM115699";"CCc1ncnc(-c2ccc(C(=O)NCC3CCN(C)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"33.0";"nM";"7.48";"";"240336";"UO_0000065";"16.32";"0.30";"4.58";"7.71";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643084";"";"0";"486.60";"0";"3.64";"BDBM115700";"CCc1ncnc(-c2ccc(C(=O)N(C)CC3CCN(C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"13.0";"nM";"7.89";"";"240337";"UO_0000065";"16.21";"0.30";"4.25";"8.94";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643086";"";"0";"541.68";"1";"3.46";"BDBM115702";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCN(CC)CC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.0";"nM";"8.30";"";"240339";"UO_0000065";"15.32";"0.28";"4.84";"9.07";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640940";"";"0";"389.43";"0";"2.92";"BDBM115590";"CCc1ncnc(-c2ccc(C(=O)N(C)C)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"240227";"UO_0000065";"22.34";"0.41";"5.78";"10.23";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640929";"";"0";"377.84";"0";"2.84";"BDBM115579";"CNC(=O)c1ccc(-c2ncnc(C)c2C#Cc2ccc(N)nc2)cc1Cl";"IC50";"'='";"3.0";"nM";"8.52";"";"240216";"UO_0000065";"22.56";"0.43";"5.68";"9.09";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3913302";"";"0";"554.58";"1";"3.48";"BDBM178385";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4nnc(C)o4)c(F)c3)c2C1=O";"IC50";"'='";"106.0";"nM";"6.97";"";"324405";"UO_0000065";"12.58";"0.24";"3.49";"4.72";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3960655";"";"0";"561.64";"1";"4.62";"BDBM178408";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Oc4cccc(OC)c4)cc3)c2C1=O";"IC50";"'='";"970.0";"nM";"6.01";"";"324428";"UO_0000065";"10.71";"0.20";"1.39";"5.21";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3954545";"";"0";"528.59";"1";"2.66";"BDBM178425";"CNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)nc3c2C(=O)N(CCOC)CC(C)(C)O3)cc1F";"IC50";"'='";"41.0";"nM";"7.39";"";"324445";"UO_0000065";"13.98";"0.27";"4.73";"6.25";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3892525";"";"0";"629.77";"1";"3.79";"BDBM178433";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccc(N5CCN(C)CC5)cn4)cc3)c2C1=O";"IC50";"'='";"58.0";"nM";"7.24";"";"324453";"UO_0000065";"11.49";"0.21";"3.45";"5.64";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3967825";"";"0";"447.50";"0";"3.36";"BDBM245469";"COC(=O)N1CCC(n2c(=O)n(C)c3cnc4ccc(-c5ccc(OC)nc5)cc4c32)CC1";"IC50";"'='";"72.9";"nM";"7.14";"";"427980";"UO_0000065";"15.95";"0.30";"3.78";"7.80";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3914044";"";"0";"355.40";"0";"3.77";"BDBM245473";"Cn1c(=O)n(C2CC2)c2c3cc(-c4cnc5[nH]ccc5c4)ccc3ncc21";"IC50";"'='";"15.5";"nM";"7.81";"";"427984";"UO_0000065";"21.97";"0.40";"4.04";"11.40";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3670270";"";"0";"452.48";"0";"3.76";"BDBM111746";"CCc1ncnc(N2CCN(c3ccccc3C(F)(F)F)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2000.0";"nM";"5.70";"";"232569";"UO_0000065";"12.59";"0.24";"1.94";"8.01";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670272";"";"0";"385.48";"0";"2.14";"BDBM111748";"CCc1ncnc(N2CCN(c3ccccn3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"33.0";"nM";"7.48";"";"232571";"UO_0000065";"19.41";"0.35";"5.34";"8.90";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670278";"";"0";"442.53";"0";"1.61";"BDBM111754";"CCc1ncnc(N2CCc3c(ncnc3N3CCOCC3)C2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"139.0";"nM";"6.86";"";"232577";"UO_0000065";"15.49";"0.28";"5.25";"6.46";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670217";"";"0";"376.51";"0";"2.47";"BDBM111693";"Cc1ncnc(N2CCC3(CCN(C)CC3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"25.0";"nM";"7.60";"";"232516";"UO_0000065";"20.19";"0.37";"5.13";"10.68";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL4102855";"";"0";"412.38";"0";"0.60";"2";"Nc1ncc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)c(C(F)(F)F)n1";"IC50";"'='";"312.0";"nM";"6.51";"";"";"UO_0000065";"15.78";"0.31";"5.91";"5.64";"False";"CHEMBL4019299";"Inhibition of mTOR in human A2058 cells assessed as reduction in phosphorylation of S6 at ser235/236 residues after 1 hr by in-cell Western method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017506";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL3940140";"";"0";"420.47";"0";"3.42";"BDBM222650";"CCOc1cnc(-c2ccc(NC(=O)Nc3ccncc3)cc2)nc1N1CCOCC1";"IC50";"'='";"56.6";"nM";"7.25";"";"389439";"UO_0000065";"17.24";"0.32";"3.83";"7.14";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3943837";"";"0";"454.92";"0";"4.07";"BDBM222673";"CCOc1c(Cl)nc(-c2ccc(NC(=O)Nc3cccnc3)cc2)nc1N1CCOCC1";"IC50";"'='";"267.7";"nM";"6.57";"";"389462";"UO_0000065";"14.45";"0.28";"2.50";"6.48";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3646605";"";"0";"534.05";"2";"2.09";"BDBM125462";"COc1cc(Nc2ncc(CN3CCN(S(C)(=O)=O)C[C@@H]3C)cc2-c2nc(C)nc(N)n2)cnc1Cl";"IC50";"'>'";"10000.0";"nM";"";"";"255208";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL1879463";"DACTOLISIB";"2";"469.55";"1";"5.89";"5; BEZ235";"Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21";"IC50";"'='";"97.0";"nM";"7.01";"";"";"UO_0000065";"14.94";"0.27";"1.12";"9.17";"False";"CHEMBL4000385";"Inhibition of mTOR (unknown origin) using L-alpha-phosphatidylinositol as substrate after 40 mins by ATP depletion assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4000150";"1";"Scientific Literature";"Bioorg Med Chem";"2015";""
"CHEMBL3894733";"";"0";"471.54";"0";"1.67";"BDBM251586";"CS(=O)(=O)C1(c2nc(-c3cncc4[nH]ccc34)nc3c2OCC2COCCN32)CCOCC1";"IC50";"'='";"3270.0";"nM";"5.49";"";"438482";"UO_0000065";"11.63";"0.23";"3.82";"4.59";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL4112871";"";"0";"470.55";"0";"2.27";"BDBM251587";"CS(=O)(=O)C1(c2nc(-c3cccc4[nH]ccc34)nc3c2OC[C@H]2COCCN32)CCOCC1";"IC50";"'='";"10000.0";"nM";"5.00";"";"438483";"UO_0000065";"10.63";"0.21";"2.73";"4.69";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL4114931";"";"0";"428.51";"0";"2.50";"BDBM251592";"CC(C)(c1nc(-c2cccc3[nH]ccc23)nc2c1OC[C@H]1COCCN21)S(C)(=O)=O";"IC50";"'='";"851.0";"nM";"6.07";"";"438488";"UO_0000065";"14.17";"0.28";"3.57";"6.23";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3973834";"";"0";"469.57";"0";"1.85";"BDBM251632";"CS(=O)(=O)C1(c2nc(-c3cccc4[nH]ccc34)nc3c2OC[C@@H]2COCCN32)CCNCC1";"IC50";"'='";"336.0";"nM";"6.47";"";"438528";"UO_0000065";"13.79";"0.27";"4.62";"5.92";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3983971";"";"0";"492.99";"0";"2.39";"BDBM251643";"CNc1nc2cc(Cl)ccc2n1-c1nc2c(c(C(C)(C)S(C)(=O)=O)n1)OC[C@@H]1COCCN21";"IC50";"'='";"501.0";"nM";"6.30";"";"438539";"UO_0000065";"12.78";"0.26";"3.91";"5.65";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3904072";"";"0";"490.97";"0";"2.14";"BDBM251662";"CNc1nc2ccc(Cl)cc2n1-c1nc2c(c(C3(S(C)(=O)=O)CC3)n1)OC[C@@H]1COCCN21";"IC50";"'='";"10000.0";"nM";"5.00";"";"438544";"UO_0000065";"10.18";"0.21";"2.86";"4.49";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3586387";"";"0";"420.48";"0";"2.21";"11";"Cc1nc(-c2nc[nH]n2)ccc1-c1cnc2c(n1)N(CCC1CCOCC1)C(=O)CN2";"IC50";"'='";"14.0";"nM";"7.85";"";"";"UO_0000065";"18.68";"0.35";"5.64";"6.45";"False";"CHEMBL3587521";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585264";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3586568";"";"0";"392.42";"0";"1.57";"21";"Cc1nc(-c2nc[nH]n2)ccc1-c1cnc2c(n1)N(C1CCOCC1)C(=O)CN2";"IC50";"'='";"26.0";"nM";"7.58";"";"";"UO_0000065";"19.33";"0.36";"6.02";"6.23";"False";"CHEMBL3587521";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585264";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3586569";"";"0";"350.39";"0";"1.80";"22";"Cc1nc(-c2nc[nH]n2)ccc1-c1cnc2c(n1)N(C(C)C)C(=O)CN2";"IC50";"'='";"30.0";"nM";"7.52";"";"";"UO_0000065";"21.47";"0.40";"5.72";"6.68";"False";"CHEMBL3587521";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585264";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL4213003";"";"0";"392.51";"0";"2.53";"7f";"CNc1ncc2c(-c3ccc(N4CCNCC4)nc3)nn(CC3CCCC3)c2n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4188979";"Inhibition of wild-type human partial length MTOR (L1382 to W2549 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4184298";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL3643277";"";"0";"483.62";"0";"4.01";"BDBM115943";"CCc1ncnc(-c2ccc(C(=O)N3CCC(C(C)(C)O)CC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.64";"nM";"8.44";"";"240555";"UO_0000065";"17.45";"0.32";"4.43";"8.02";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645778";"";"0";"454.58";"0";"3.17";"BDBM115956";"CCc1ncnc(-c2ccc(C(=O)N3CC[C@@H](N(C)C)C3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.78";"nM";"8.75";"";"240568";"UO_0000065";"19.25";"0.35";"5.58";"9.92";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645798";"";"0";"454.58";"0";"3.22";"BDBM115976";"CCc1ncnc(-c2ccc(C(=O)NC3CCCN(C)C3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.43";"nM";"8.46";"";"240588";"UO_0000065";"18.62";"0.34";"5.24";"8.72";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645825";"";"0";"489.53";"0";"3.61";"BDBM116003";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCC4(CC3)COC4)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.88";"nM";"9.06";"";"240615";"UO_0000065";"18.50";"0.34";"5.45";"9.61";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645873";"";"0";"538.48";"2";"5.01";"BDBM116052";"CCc1ncnc(-c2cc(Cl)c(C(=O)N3CCC(C(C)(C)O)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.62";"nM";"8.79";"";"240664";"UO_0000065";"16.32";"0.32";"3.78";"8.35";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645896";"";"0";"524.55";"1";"3.76";"BDBM116075";"CCc1ncnc(-c2ccc(C(=O)N3CC[C@@H](N(C)C)C3)c(OC(F)(F)F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"55.47";"nM";"7.26";"";"240687";"UO_0000065";"13.83";"0.26";"3.50";"7.44";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645902";"";"0";"522.58";"1";"4.27";"BDBM116081";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C(C)C)CC3)c(C(F)(F)F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.72";"nM";"8.56";"";"240693";"UO_0000065";"16.39";"0.31";"4.30";"9.71";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645903";"";"0";"508.55";"1";"3.88";"BDBM116082";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CC)CC3)c(C(F)(F)F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"13.62";"nM";"7.87";"";"240694";"UO_0000065";"15.47";"0.29";"3.99";"8.91";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645908";"";"0";"549.05";"1";"3.81";"BDBM116087";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCC(N4CCOCC4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.64";"nM";"9.19";"";"240699";"UO_0000065";"16.74";"0.32";"5.38";"9.43";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645910";"";"0";"505.00";"1";"3.80";"BDBM116089";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN4CCC[C@H]4C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.07";"nM";"10.15";"";"240701";"UO_0000065";"20.11";"0.39";"6.35";"11.51";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645911";"";"0";"492.94";"0";"2.79";"BDBM116090";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(C)C(=O)C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.26";"nM";"9.59";"";"240702";"UO_0000065";"19.44";"0.37";"6.80";"9.10";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645915";"";"0";"518.00";"1";"3.55";"BDBM116094";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(CCC#N)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.73";"nM";"9.14";"";"240706";"UO_0000065";"17.64";"0.34";"5.59";"8.16";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645930";"";"0";"542.66";"1";"4.01";"BDBM116109";"CCNc1ccc(C#Cc2c(CC)ncnc2-c2ccc(C(=O)N3CCC(N4CCOCC4)CC3)c(F)c2)cn1";"IC50";"'='";"1.61";"nM";"8.79";"";"240721";"UO_0000065";"16.20";"0.30";"4.78";"10.53";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645932";"";"0";"496.55";"0";"3.32";"BDBM116111";"CCNc1ccc(C#Cc2c(CC)ncnc2-c2ccc(C(=O)N3CCn4cnnc4C3)c(F)c2)cn1";"IC50";"'='";"1.46";"nM";"8.84";"";"240723";"UO_0000065";"17.79";"0.33";"5.52";"8.69";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645951";"";"0";"492.99";"0";"3.69";"BDBM116131";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCC(CN)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"13.91";"nM";"7.86";"";"240743";"UO_0000065";"15.94";"0.31";"4.17";"7.08";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645956";"";"0";"525.59";"1";"3.48";"BDBM116136";"CCc1ncnc(-c2ccc(C(=O)N3CCN(Cc4cc(C)no4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.51";"nM";"8.82";"";"240748";"UO_0000065";"16.78";"0.31";"5.34";"7.72";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645978";"";"0";"542.04";"1";"3.99";"BDBM116158";"CCc1ncnc(-c2ccc(C(=O)N3CCN(Cc4cc(C)no4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.39";"nM";"9.41";"";"240770";"UO_0000065";"17.36";"0.33";"5.42";"8.23";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643155";"";"0";"446.94";"0";"2.78";"BDBM115771";"CCc1ncnc(-c2ccc(C(=O)N3CCNCC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"8.0";"nM";"8.10";"";"240408";"UO_0000065";"18.12";"0.35";"5.32";"8.34";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643170";"";"0";"466.59";"0";"3.53";"BDBM115811";"Cc1ncnc(-c2ccc(C(=O)N3CCN(C4CCCC4)CC3)cc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.0";"nM";"8.40";"";"240423";"UO_0000065";"18.00";"0.33";"4.87";"9.52";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3973532";"";"0";"464.41";"0";"3.30";"BDBM236558";"Cn1c(=O)c2cnc3ccc(-c4ccc(N)nc4)nc3c2n(-c2cccc(C(F)(F)F)c2)c1=O";"IC50";"'='";"5.4";"nM";"8.27";"";"412062";"UO_0000065";"17.80";"0.33";"4.97";"7.61";"False";"CHEMBL3888698";"mTOR Enzymatic Assay: Agents: 1-fold kinase buffer: 50 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 3 mM MnCl2, 0.01% Tween-20, 2 mM DTT. 4-fold kinase solution: mTOR kinase was added to 1-fold kinase buffer to form 4-fold kinase solution with a final concentration of 2.5 nM. 2-fold substrate and ATP solution: the substrate 4EBP1 and ATP were added to 1-fold kinase buffer to form 2-fold substrate solution with final concentration of 50 nM of 4EBP1 and 10.8 ¿M of ATP. 4-fold test substance solutions: 100-fold test substance solutions in different gradient concentrations were formulated with 100% DMSO, and diluted by 25 folds with 1-fold kinase buffer to form 4-fold test substance solutions in different gradient concentrations. Detection solution: a detection solution containing 2-fold final concentrations of EDTA and 4EBP1 phosphorylated antibody was formulated, wherein the final concentration for EDTA was 8 mM, and the final concentration for the 4EBP phosphorylated antibody was 2 nM. Procedure: To each well of a 384-well plate was added 2.5 ¿L of the 4-fold test substance solutions in gradient concentrations. The replication was made. To each well was added 2.5 ¿L of 4-fold kinase solution, and then the plate was incubated for 10 mins. Then to each well was added 5 ¿L/of 2-fold substrate and ATP solution, and then the plate was incubated at room temperature for 1 hour. Finally, 10 ¿L of the detection solution was added to terminate the reaction. After 60 mins, the data Lance signal (665 nM) was read from Envision.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886794";"37";"BindingDB Database";"";"2016";""
"CHEMBL3958025";"";"0";"451.37";"0";"2.68";"BDBM236560";"Nc1ncc(-c2ccc3ncc4c(=O)[nH]c(=O)n(-c5cccc(C(F)(F)F)c5)c4c3n2)cn1";"IC50";"'='";"2.66";"nM";"8.57";"";"412064";"UO_0000065";"19.00";"0.35";"5.90";"6.47";"False";"CHEMBL3888698";"mTOR Enzymatic Assay: Agents: 1-fold kinase buffer: 50 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 3 mM MnCl2, 0.01% Tween-20, 2 mM DTT. 4-fold kinase solution: mTOR kinase was added to 1-fold kinase buffer to form 4-fold kinase solution with a final concentration of 2.5 nM. 2-fold substrate and ATP solution: the substrate 4EBP1 and ATP were added to 1-fold kinase buffer to form 2-fold substrate solution with final concentration of 50 nM of 4EBP1 and 10.8 ¿M of ATP. 4-fold test substance solutions: 100-fold test substance solutions in different gradient concentrations were formulated with 100% DMSO, and diluted by 25 folds with 1-fold kinase buffer to form 4-fold test substance solutions in different gradient concentrations. Detection solution: a detection solution containing 2-fold final concentrations of EDTA and 4EBP1 phosphorylated antibody was formulated, wherein the final concentration for EDTA was 8 mM, and the final concentration for the 4EBP phosphorylated antibody was 2 nM. Procedure: To each well of a 384-well plate was added 2.5 ¿L of the 4-fold test substance solutions in gradient concentrations. The replication was made. To each well was added 2.5 ¿L of 4-fold kinase solution, and then the plate was incubated for 10 mins. Then to each well was added 5 ¿L/of 2-fold substrate and ATP solution, and then the plate was incubated at room temperature for 1 hour. Finally, 10 ¿L of the detection solution was added to terminate the reaction. After 60 mins, the data Lance signal (665 nM) was read from Envision.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886794";"37";"BindingDB Database";"";"2016";""
"CHEMBL3906903";"";"0";"492.46";"1";"5.37";"BDBM213778";"CC(=O)Nc1ccc(-c2ccc3ncc4c(c3n2)N(c2cccc(C(F)(F)F)c2)C(=O)N(C)C4)cn1";"IC50";"'='";"38.7";"nM";"7.41";"";"375938";"UO_0000065";"15.05";"0.28";"2.04";"8.12";"False";"CHEMBL3888153";"mTOR Activity Assay: 1. Preparation of test reagents {circle around (1)} 1x kinase buffer (50 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 3 mM MnCl, 0.01% Tween-20, 2 mM DTT); {circle around (2)} 4x kinase solution (added mTOR kinase to 1x kinase buffer to provide 4x kinase solution with a final concentration of 2.5 nM); {circle around (3)} 2x substrate solution (added the substrates of 4EBP1 and ATP into 1x kinase buffer to provide 2x substrate solution with 4EBP1 final concentration of 50 nM and ATP final concentration of 10.8 uM); {circle around (4)} 4x test substance solutions (100x test substance solutions with different concentration gradients were prepared using 100% DMSO, and diluted 25-fold with 1x kinase buffer to give 4x test substance solutions with different concentration gradients) {circle around (5)} preparation of test solution (test solution containing EDTA and 4EBP1 phosphorylated antibody was prepared using activity test kit with assay buffer, the final concentration of EDTA was 8 mM, and the final concentration of 4EBP1 phosphorylated antibody was 2 nM) 2. 2.5 uL of 4x test solution was added to a 384-well plate in parallel; 3. added 2.54 uL of 4x kinase solution and incubated for 10 min; 4. then added 5 uL of 2x solutions of 4EBP1 and ATP substrates and incubated for 1 h at room temperature; 5. finally, added 10 uL of test solution to quench the reaction, and read after 60 min; 6. IC50 value was obtained via curve fitting.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886601";"37";"BindingDB Database";"";"2016";""
"CHEMBL3915555";"";"0";"474.45";"1";"5.90";"BDBM213784";"CN1Cc2cnc3ccc(-c4cnc5[nH]ccc5c4)nc3c2N(c2cccc(C(F)(F)F)c2)C1=O";"IC50";"'='";"17.5";"nM";"7.76";"";"375940";"UO_0000065";"16.35";"0.30";"1.86";"9.94";"False";"CHEMBL3888153";"mTOR Activity Assay: 1. Preparation of test reagents {circle around (1)} 1x kinase buffer (50 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 3 mM MnCl, 0.01% Tween-20, 2 mM DTT); {circle around (2)} 4x kinase solution (added mTOR kinase to 1x kinase buffer to provide 4x kinase solution with a final concentration of 2.5 nM); {circle around (3)} 2x substrate solution (added the substrates of 4EBP1 and ATP into 1x kinase buffer to provide 2x substrate solution with 4EBP1 final concentration of 50 nM and ATP final concentration of 10.8 uM); {circle around (4)} 4x test substance solutions (100x test substance solutions with different concentration gradients were prepared using 100% DMSO, and diluted 25-fold with 1x kinase buffer to give 4x test substance solutions with different concentration gradients) {circle around (5)} preparation of test solution (test solution containing EDTA and 4EBP1 phosphorylated antibody was prepared using activity test kit with assay buffer, the final concentration of EDTA was 8 mM, and the final concentration of 4EBP1 phosphorylated antibody was 2 nM) 2. 2.5 uL of 4x test solution was added to a 384-well plate in parallel; 3. added 2.54 uL of 4x kinase solution and incubated for 10 min; 4. then added 5 uL of 2x solutions of 4EBP1 and ATP substrates and incubated for 1 h at room temperature; 5. finally, added 10 uL of test solution to quench the reaction, and read after 60 min; 6. IC50 value was obtained via curve fitting.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886601";"37";"BindingDB Database";"";"2016";""
"CHEMBL1879463";"DACTOLISIB";"2";"469.55";"1";"5.89";"NVP-BEZ235";"Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21";"IC50";"'='";"3.23";"nM";"8.49";"";"375941";"UO_0000065";"18.08";"0.32";"2.60";"11.10";"False";"CHEMBL3888153";"mTOR Activity Assay: 1. Preparation of test reagents {circle around (1)} 1x kinase buffer (50 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 3 mM MnCl, 0.01% Tween-20, 2 mM DTT); {circle around (2)} 4x kinase solution (added mTOR kinase to 1x kinase buffer to provide 4x kinase solution with a final concentration of 2.5 nM); {circle around (3)} 2x substrate solution (added the substrates of 4EBP1 and ATP into 1x kinase buffer to provide 2x substrate solution with 4EBP1 final concentration of 50 nM and ATP final concentration of 10.8 uM); {circle around (4)} 4x test substance solutions (100x test substance solutions with different concentration gradients were prepared using 100% DMSO, and diluted 25-fold with 1x kinase buffer to give 4x test substance solutions with different concentration gradients) {circle around (5)} preparation of test solution (test solution containing EDTA and 4EBP1 phosphorylated antibody was prepared using activity test kit with assay buffer, the final concentration of EDTA was 8 mM, and the final concentration of 4EBP1 phosphorylated antibody was 2 nM) 2. 2.5 uL of 4x test solution was added to a 384-well plate in parallel; 3. added 2.54 uL of 4x kinase solution and incubated for 10 min; 4. then added 5 uL of 2x solutions of 4EBP1 and ATP substrates and incubated for 1 h at room temperature; 5. finally, added 10 uL of test solution to quench the reaction, and read after 60 min; 6. IC50 value was obtained via curve fitting.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886601";"37";"BindingDB Database";"";"2016";""
"CHEMBL3643154";"";"0";"515.06";"1";"4.44";"BDBM115770";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCCC4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"10.0";"nM";"8.00";"";"240407";"UO_0000065";"15.53";"0.30";"3.56";"9.07";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643171";"";"0";"458.54";"0";"3.05";"BDBM115813";"CCc1ncnc(-c2ccc(C(=O)NC3CCCN(C)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"31.0";"nM";"7.51";"";"240425";"UO_0000065";"16.38";"0.30";"4.46";"7.74";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643176";"";"0";"431.47";"0";"2.43";"BDBM115819";"CCc1ncnc(-c2ccc(C(=O)N3CC[C@H](O)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.0";"nM";"9.00";"";"240431";"UO_0000065";"20.86";"0.38";"6.57";"8.55";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643177";"";"0";"431.47";"0";"2.43";"BDBM115820";"CCc1ncnc(-c2ccc(C(=O)N3CC[C@@H](O)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"240432";"UO_0000065";"20.16";"0.37";"6.27";"8.27";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643191";"";"0";"417.44";"0";"3.00";"BDBM115834";"CCc1ncnc(-c2ccc(C(=O)N3CCCO3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.0";"nM";"8.30";"";"240446";"UO_0000065";"19.89";"0.37";"5.30";"8.81";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643214";"";"0";"462.50";"0";"2.75";"BDBM115857";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.29";"nM";"8.89";"";"240469";"UO_0000065";"19.22";"0.36";"6.14";"10.07";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643224";"";"0";"433.46";"0";"3.60";"BDBM115867";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCCC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.94";"nM";"9.03";"";"240479";"UO_0000065";"20.83";"0.39";"5.43";"10.62";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643125";"";"0";"459.53";"0";"3.47";"BDBM115741";"CCc1ncnc(-c2ccc(C(=O)N3CCOC(C)(C)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"8.89";"nM";"8.05";"";"240483";"UO_0000065";"17.52";"0.32";"4.58";"8.54";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643228";"";"0";"456.53";"0";"2.75";"BDBM115872";"CCc1ncnc(-c2ccc(C(=O)N3C[C@H]4C[C@@H]3CN4C)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"20.91";"nM";"7.68";"";"240484";"UO_0000065";"16.82";"0.31";"4.93";"8.70";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643150";"";"0";"461.95";"0";"3.33";"BDBM115766";"CCc1ncnc(-c2ccc(C(=O)N3CCCC(O)C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.14";"nM";"8.50";"";"240497";"UO_0000065";"18.41";"0.35";"5.17";"8.08";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643152";"";"0";"489.02";"0";"3.90";"BDBM115768";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N(C)C)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"29.7";"nM";"7.53";"";"240499";"UO_0000065";"15.39";"0.29";"3.63";"8.53";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643153";"";"0";"475.00";"0";"3.51";"BDBM115769";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N(C)C)C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"19.76";"nM";"7.70";"";"240500";"UO_0000065";"16.22";"0.31";"4.19";"8.73";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643236";"";"0";"539.68";"1";"2.94";"BDBM115901";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"10.2";"nM";"7.99";"";"240513";"UO_0000065";"14.81";"0.27";"5.05";"7.94";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643244";"";"0";"524.67";"1";"4.04";"BDBM115909";"CCc1ncnc(-c2ccc(C(=O)N3CCC4(CCN(C)CC4)CC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"51.12";"nM";"7.29";"";"240521";"UO_0000065";"13.90";"0.26";"3.25";"7.48";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643253";"";"0";"514.59";"1";"3.01";"BDBM115918";"CCOC(=O)N1CCN(C(=O)c2ccc(-c3ncnc(CC)c3C#Cc3ccc(N)nc3)cc2OC)CC1";"IC50";"'='";"19.5";"nM";"7.71";"";"240530";"UO_0000065";"14.98";"0.28";"4.70";"6.23";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643257";"";"0";"496.62";"0";"3.26";"BDBM115922";"CCc1ncnc(-c2ccc(C(=O)N3CCC4(CCN(C)C4)C3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"53.75";"nM";"7.27";"";"240534";"UO_0000065";"14.64";"0.27";"4.01";"7.46";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3693483";"";"0";"518.66";"1";"3.48";"BDBM174645";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCC(N5CCCC5)CC4)nc3n2)cc1CO";"IC50";"'='";"63.0";"nM";"7.20";"";"319923";"UO_0000065";"13.88";"0.26";"3.72";"8.27";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693489";"";"0";"478.55";"0";"1.87";"BDBM174651";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCC[C@H]4C(N)=O)nc3n2)cc1CO";"IC50";"'='";"73.0";"nM";"7.14";"";"319929";"UO_0000065";"14.91";"0.28";"5.27";"5.62";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693492";"";"0";"531.62";"2";"3.49";"BDBM174654";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCCC(c5nc(C)no5)C4)nc3n2)cc1CO";"IC50";"'='";"79.0";"nM";"7.10";"";"319932";"UO_0000065";"13.36";"0.25";"3.61";"5.79";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693498";"";"0";"490.52";"1";"2.39";"BDBM174660";"COC(=O)c1cncn1-c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(OC)c(CO)c3)nc2n1";"IC50";"'='";"92.0";"nM";"7.04";"";"319940";"UO_0000065";"14.34";"0.27";"4.65";"5.64";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3892328";"";"0";"569.64";"1";"3.60";"BDBM222620";"CCOC(=O)c1nc(-c2ccc(NC(=O)Nc3ccc(S(C)(=O)=O)cc3)cc2)nc(N2CCOCC2)c1OCC";"IC50";"'='";"179.9";"nM";"6.75";"";"389409";"UO_0000065";"11.84";"0.23";"3.14";"4.53";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3947264";"";"0";"514.63";"1";"3.72";"BDBM222625";"CSc1cnc(-c2ccc(NC(=O)Nc3ccc(NS(C)(=O)=O)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"130.3";"nM";"6.88";"";"389414";"UO_0000065";"13.38";"0.27";"3.17";"5.48";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3923593";"";"0";"597.70";"1";"4.77";"BDBM222632";"CSc1c(-c2ccncc2)nc(-c2ccc(NC(=O)Nc3ccc(N4CCOCC4=O)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"5.4";"nM";"8.27";"";"389421";"UO_0000065";"13.83";"0.26";"3.50";"6.79";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3896445";"";"0";"541.64";"1";"4.51";"BDBM222633";"CSc1c(-c2ccncc2)nc(-c2ccc(NC(=O)Nc3ccc(C(N)=O)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"19.6";"nM";"7.71";"";"389422";"UO_0000065";"14.23";"0.27";"3.20";"5.69";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3918959";"";"0";"462.51";"0";"3.59";"BDBM222644";"COc1cnc(-c2ccc(NC(=O)Nc3cccc(NC(C)=O)c3)cc2)nc1N1CCOCC1";"IC50";"'='";"173.9";"nM";"6.76";"";"389433";"UO_0000065";"14.62";"0.27";"3.17";"5.74";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3890827";"";"0";"462.53";"0";"1.87";"BDBM115812";"CCc1ncnc(-c2ccc(C(=O)NCC(O)CN(C)C)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"19.0";"nM";"7.72";"";"240424";"UO_0000065";"16.69";"0.31";"5.85";"6.58";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643180";"";"0";"498.61";"0";"3.97";"BDBM115823";"CCc1ncnc(-c2ccc(C(=O)NC3CC(N4CCCCC4)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"10.0";"nM";"8.00";"";"240435";"UO_0000065";"16.04";"0.30";"4.03";"8.24";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643186";"";"0";"500.62";"1";"4.26";"BDBM115829";"CCc1ncnc(-c2ccc(C(=O)NC3CC(C)(C)NC(C)(C)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"18.0";"nM";"7.75";"";"240441";"UO_0000065";"15.47";"0.29";"3.48";"7.32";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643198";"";"0";"387.44";"0";"2.72";"BDBM115841";"CCc1ncnc(-c2ccc(C(=O)N(C)OC)cc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"16.0";"nM";"7.80";"";"240453";"UO_0000065";"20.12";"0.37";"5.08";"8.27";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643201";"";"0";"419.42";"0";"1.72";"BDBM115844";"Cc1ncnc(-c2ccc(C(=O)N3CC(O)CO3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"8.0";"nM";"8.10";"";"240456";"UO_0000065";"19.31";"0.36";"6.38";"7.07";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643215";"";"0";"490.56";"0";"3.53";"BDBM115858";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(C(C)C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.18";"nM";"8.66";"";"240470";"UO_0000065";"17.66";"0.33";"5.13";"9.82";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643266";"";"0";"489.02";"0";"3.90";"BDBM115931";"CCc1ncnc(-c2ccc(C(=O)N3CCCC(N(C)C)C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"12.36";"nM";"7.91";"";"240543";"UO_0000065";"16.17";"0.31";"4.01";"8.96";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645783";"";"0";"489.60";"0";"2.65";"BDBM115961";"CCc1ncnc(-c2ccc(C(=O)N(C)C3CCS(=O)(=O)C3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.92";"nM";"9.04";"";"240573";"UO_0000065";"18.46";"0.35";"6.39";"7.58";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645799";"";"0";"459.58";"0";"2.60";"BDBM115977";"CCc1ncnc(-c2ccc(C(=O)N3CC[S+]([O-])CC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.86";"nM";"8.23";"";"240589";"UO_0000065";"17.91";"0.34";"5.63";"8.07";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640943";"";"0";"370.46";"0";"3.51";"BDBM115593";"CCc1ncnc(-c2ccc(C(=O)N(C)C)cc2)c1C#Cc1ccc(C)nc1";"IC50";"'='";"29.0";"nM";"7.54";"";"240230";"UO_0000065";"20.35";"0.37";"4.03";"12.78";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645831";"";"0";"515.98";"1";"4.04";"BDBM116009";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCn4c(C)cnc4C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.22";"nM";"8.65";"";"240621";"UO_0000065";"16.77";"0.32";"4.61";"8.42";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645842";"";"0";"458.54";"0";"2.95";"BDBM116020";"CCc1ncnc(-c2ccc(C(=O)NCC3CCNCC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"6.8";"nM";"8.17";"";"240632";"UO_0000065";"17.81";"0.33";"5.22";"7.72";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645853";"";"0";"472.57";"0";"3.46";"BDBM116032";"CCc1ncnc(-c2ccc(C(=O)N3CC[C@@H](N(C)C)C3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"8.83";"nM";"8.05";"";"240644";"UO_0000065";"17.04";"0.31";"4.59";"10.85";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643197";"";"0";"415.45";"0";"1.83";"BDBM115840";"CCc1ncnc(-c2ccc(C(=O)N3CC(O)CO3)cc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"12.0";"nM";"7.92";"";"240452";"UO_0000065";"19.07";"0.35";"6.09";"6.92";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643209";"";"0";"458.54";"0";"3.00";"BDBM115852";"CCc1ncnc(-c2ccc(C(=O)N3CC[C@@H](N(C)C)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"8.0";"nM";"8.10";"";"240464";"UO_0000065";"17.66";"0.33";"5.10";"9.18";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643222";"";"0";"532.60";"1";"3.30";"BDBM115865";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCC(N4CCOCC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.4";"nM";"9.40";"";"240477";"UO_0000065";"17.65";"0.33";"6.10";"9.64";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643235";"";"0";"499.62";"0";"3.71";"BDBM115900";"CCc1ncnc(-c2ccc(C(=O)N3CCC(C(C)(C)O)CC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"11.35";"nM";"7.95";"";"240512";"UO_0000065";"15.90";"0.29";"4.24";"6.94";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645779";"";"0";"480.62";"0";"3.70";"BDBM115957";"CCc1ncnc(-c2ccc(C(=O)N3CCN4CCCCC4C3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"7.8";"nM";"8.11";"";"240569";"UO_0000065";"16.87";"0.31";"4.41";"9.19";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645787";"";"0";"508.67";"1";"4.48";"BDBM115965";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCCCC4)CC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.5";"nM";"8.46";"";"240577";"UO_0000065";"16.62";"0.30";"3.98";"9.58";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645794";"";"0";"480.62";"0";"3.56";"BDBM115972";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CC4CC4)CC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"11.03";"nM";"7.96";"";"240584";"UO_0000065";"16.56";"0.30";"4.40";"9.02";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645796";"";"0";"455.56";"0";"3.64";"BDBM115974";"CCc1ncnc(-c2ccc(C(=O)N3CCC(OC)CC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"10.94";"nM";"7.96";"";"240586";"UO_0000065";"17.48";"0.32";"4.32";"8.45";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645818";"";"0";"501.03";"1";"4.05";"BDBM115996";"CCc1ncnc(-c2ccc(C(=O)N3CCN4CCCC[C@H]4C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.98";"nM";"8.53";"";"240608";"UO_0000065";"17.02";"0.32";"4.48";"9.66";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645827";"";"0";"502.57";"1";"3.67";"BDBM116005";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(C4CCC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.7";"nM";"9.15";"";"240617";"UO_0000065";"18.22";"0.34";"5.48";"10.38";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645830";"";"0";"502.94";"1";"3.12";"BDBM116008";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCn4cnnc4C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.59";"nM";"9.23";"";"240620";"UO_0000065";"18.35";"0.35";"6.11";"7.98";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645858";"";"0";"545.09";"1";"4.13";"BDBM116037";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCOCC4)CC3)c(Cl)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"0.68";"nM";"9.17";"";"240649";"UO_0000065";"16.82";"0.32";"5.04";"10.98";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645863";"";"0";"489.02";"0";"3.97";"BDBM116042";"CCc1ncnc(-c2ccc(C(=O)N3CC[C@H](N(C)C)C3)c(Cl)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"5.16";"nM";"8.29";"";"240654";"UO_0000065";"16.95";"0.32";"4.32";"11.16";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645872";"";"0";"524.45";"1";"4.62";"BDBM116051";"CCc1ncnc(-c2cc(Cl)c(C(=O)N3CCC(C(C)O)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.11";"nM";"8.96";"";"240663";"UO_0000065";"17.07";"0.34";"4.33";"8.51";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645876";"";"0";"509.40";"1";"3.30";"BDBM116055";"CCc1ncnc(-c2cc(Cl)c(C(=O)N3CCN(C=O)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.92";"nM";"8.41";"";"240667";"UO_0000065";"16.50";"0.33";"5.11";"7.98";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645879";"";"0";"502.57";"1";"3.74";"BDBM116058";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN4CCC[C@H]4C3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"2.51";"nM";"8.60";"";"240670";"UO_0000065";"17.11";"0.32";"4.86";"11.58";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645898";"";"0";"524.55";"1";"3.76";"BDBM116077";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CC)CC3)c(OC(F)(F)F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"14.41";"nM";"7.84";"";"240689";"UO_0000065";"14.95";"0.28";"4.08";"8.04";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645907";"";"0";"492.99";"0";"3.65";"BDBM116086";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(CC)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.24";"nM";"8.91";"";"240698";"UO_0000065";"18.07";"0.35";"5.26";"10.09";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645914";"";"0";"493.97";"0";"3.72";"BDBM116093";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCC(CO)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.2";"nM";"9.70";"";"240705";"UO_0000065";"19.63";"0.38";"5.98";"9.22";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645917";"";"0";"551.65";"1";"1.53";"BDBM116096";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CCNS(C)(=O)=O)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.13";"nM";"8.95";"";"240708";"UO_0000065";"16.22";"0.31";"7.42";"6.66";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645921";"";"0";"550.66";"1";"2.41";"BDBM116100";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CCCS(C)(=O)=O)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.36";"nM";"8.36";"";"240712";"UO_0000065";"15.18";"0.29";"5.95";"6.83";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645922";"";"0";"487.01";"0";"3.56";"BDBM116101";"CCc1ncnc(-c2ccc(C(=O)N3CCC4(CC3)CNC4)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"7.99";"nM";"8.10";"";"240713";"UO_0000065";"16.63";"0.32";"4.54";"8.35";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645923";"";"0";"501.03";"1";"4.05";"BDBM116102";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C4CCC4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.57";"nM";"9.24";"";"240714";"UO_0000065";"18.45";"0.35";"5.19";"10.48";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645926";"";"0";"484.95";"0";"2.98";"BDBM116105";"CCc1ncnc(-c2ccc(C(=O)N3CCn4cnnc4C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.46";"nM";"9.34";"";"240717";"UO_0000065";"19.25";"0.36";"6.36";"8.07";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645934";"";"0";"499.59";"0";"4.32";"BDBM116113";"CCNc1ccc(C#Cc2c(CC)ncnc2-c2ccc(C(=O)N3CCC4(CC3)COC4)c(F)c2)cn1";"IC50";"'='";"2.09";"nM";"8.68";"";"240725";"UO_0000065";"17.37";"0.32";"4.36";"10.82";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645935";"";"0";"579.70";"1";"2.38";"BDBM116114";"CCNc1ccc(C#Cc2c(CC)ncnc2-c2ccc(C(=O)N3CCN(CCNS(C)(=O)=O)CC3)c(F)c2)cn1";"IC50";"'='";"1.39";"nM";"8.86";"";"240726";"UO_0000065";"15.28";"0.30";"6.48";"7.36";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645938";"";"0";"570.67";"1";"4.76";"BDBM116117";"CCNc1ccc(C#Cc2c(CC)ncnc2-c2ccc(C(=O)N3CC4(CN(C(=O)OC(C)(C)C)C4)C3)c(F)c2)cn1";"IC50";"'='";"9.26";"nM";"8.03";"";"240729";"UO_0000065";"14.08";"0.26";"3.27";"7.99";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645947";"";"0";"500.62";"1";"3.94";"BDBM116127";"CCc1ncnc(-c2ccc(C(=O)N3CCC(CN(C)C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1C";"IC50";"'='";"144.8";"nM";"6.84";"";"240739";"UO_0000065";"13.66";"0.25";"2.90";"7.75";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640970";"";"0";"405.89";"0";"3.44";"BDBM115620";"CCc1ncnc(-c2ccc(Cl)c(C(=O)N(C)C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.0";"nM";"8.40";"";"240257";"UO_0000065";"20.69";"0.40";"4.96";"9.88";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3648867";"";"0";"584.70";"2";"5.09";"BDBM116173";"CCc1ncnc(-c2ccc(C(=O)N3CCC4(CCN(C(=O)OC(C)(C)C)CC4)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"7.08";"nM";"8.15";"";"240785";"UO_0000065";"13.94";"0.26";"3.06";"7.12";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3648880";"";"0";"476.53";"0";"3.14";"BDBM116186";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(C)C[C@H]3C)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.86";"nM";"8.23";"";"240798";"UO_0000065";"17.28";"0.32";"5.09";"9.33";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640992";"";"0";"562.67";"1";"2.48";"BDBM115642";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C4CCS(=O)(=O)C4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1C";"IC50";"'='";"7.0";"nM";"8.15";"";"240279";"UO_0000065";"14.49";"0.28";"5.67";"6.66";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640996";"";"0";"458.54";"0";"2.92";"BDBM115646";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1C";"IC50";"'='";"8.0";"nM";"8.10";"";"240283";"UO_0000065";"17.66";"0.33";"5.18";"9.18";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643137";"";"0";"458.54";"0";"3.04";"BDBM115753";"CCc1ncnc(-c2ccc(C(=O)N3CC(C)NC(C)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"26.0";"nM";"7.58";"";"240390";"UO_0000065";"16.54";"0.30";"4.55";"7.82";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643219";"";"0";"532.60";"1";"3.30";"BDBM115862";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(C4CCOCC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.35";"nM";"9.46";"";"240474";"UO_0000065";"17.75";"0.33";"6.16";"9.70";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643156";"";"0";"407.86";"0";"3.20";"BDBM115772";"CCc1ncnc(-c2ccc(C(=O)N(C)O)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"16.87";"nM";"7.77";"";"240503";"UO_0000065";"19.06";"0.37";"4.57";"7.39";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643162";"";"0";"537.07";"1";"4.69";"BDBM115778";"CCc1ncnc(-c2ccc(C(=O)N3CCN(Cc4ccccc4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"29.33";"nM";"7.53";"";"240510";"UO_0000065";"14.03";"0.26";"2.84";"8.54";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643240";"";"0";"445.48";"0";"1.84";"BDBM115905";"CCc1ncnc(-c2ccc(C(=O)N3CC(O)CO3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"6.64";"nM";"8.18";"";"240517";"UO_0000065";"18.36";"0.34";"6.34";"6.61";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643241";"";"0";"429.48";"0";"2.87";"BDBM115906";"CCc1ncnc(-c2ccc(C(=O)N3CCCO3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"8.86";"nM";"8.05";"";"240518";"UO_0000065";"18.75";"0.34";"5.18";"7.78";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643245";"";"0";"560.68";"1";"2.04";"BDBM115910";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C4CCS(=O)(=O)C4)CC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"7.24";"nM";"8.14";"";"240522";"UO_0000065";"14.52";"0.28";"6.10";"6.19";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643256";"";"0";"498.59";"0";"2.79";"BDBM115921";"CCc1ncnc(-c2ccc(C(=O)N(C)CCN3CCCC3=O)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"15.76";"nM";"7.80";"";"240533";"UO_0000065";"15.65";"0.29";"5.01";"6.81";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643263";"";"0";"447.93";"0";"3.21";"BDBM115928";"CCc1ncnc(-c2ccc(C(=O)N3CCOCC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.46";"nM";"9.34";"";"240540";"UO_0000065";"20.85";"0.40";"6.13";"9.91";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643276";"";"0";"482.63";"0";"3.95";"BDBM115942";"CCCCN1CCN(C(=O)c2ccc(-c3ncnc(CC)c3C#Cc3ccc(N)nc3)cc2C)CC1";"IC50";"'='";"1.52";"nM";"8.82";"";"240554";"UO_0000065";"18.27";"0.33";"4.87";"9.99";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645774";"";"0";"508.67";"1";"4.34";"BDBM115952";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCC(C)CC4)C3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"10.41";"nM";"7.98";"";"240564";"UO_0000065";"15.69";"0.29";"3.64";"9.05";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3960573";"";"0";"500.58";"1";"3.28";"BDBM178218";"CCNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)nc3c2C(=O)N(CC)CC(C)(C)O3)cc1F";"IC50";"'='";"18.0";"nM";"7.75";"";"324238";"UO_0000065";"15.47";"0.29";"4.46";"7.11";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3890939";"";"0";"494.60";"0";"3.29";"BDBM178225";"CCNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)nc3c2C(=O)N(CC)CC(C)(C)O3)cc1";"IC50";"'='";"344.0";"nM";"6.46";"";"324245";"UO_0000065";"13.07";"0.25";"3.17";"5.93";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3934130";"";"0";"547.59";"1";"3.93";"BDBM178297";"CN1CC(C)(C)Oc2nc(N3C4CCC3COC4)nc(-c3ccc(NC(=O)Nc4ccncc4)c(F)c3)c2C1=O";"IC50";"'='";"21.0";"nM";"7.68";"";"324317";"UO_0000065";"14.02";"0.26";"3.75";"6.30";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL4108332";"";"0";"646.72";"1";"4.16";"BDBM178302";"C[C@@H]1COCCN1c1ccc(NC(=O)Nc2ccc(-c3nc(N4CC5CCC(C4)O5)nc4c3C(=O)N(C)CC(C)(C)O4)cc2F)cn1";"IC50";"'='";"57.0";"nM";"7.24";"";"324322";"UO_0000065";"11.20";"0.21";"3.08";"5.39";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3890695";"";"0";"442.52";"0";"2.11";"BDBM178315";"CCN1CC(C)(C)Oc2nc(N3CCOCC3)nc(-c3ccc(OC)c(CO)c3)c2C1=O";"IC50";"'='";"7285.0";"nM";"5.14";"";"324335";"UO_0000065";"11.61";"0.22";"3.03";"5.28";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3983141";"";"0";"424.51";"0";"2.12";"BDBM178322";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(N)nc3)c2C1=O";"IC50";"'='";"2648.0";"nM";"5.58";"";"324342";"UO_0000065";"13.14";"0.25";"3.46";"5.23";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3963623";"";"0";"543.63";"1";"4.18";"BDBM178327";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4cccnc4)cc3)c2C1=O";"IC50";"'='";"20.0";"nM";"7.70";"";"324347";"UO_0000065";"14.16";"0.26";"3.52";"6.32";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3906075";"";"0";"524.62";"1";"2.65";"BDBM178334";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)NCCCO)cc3)c2C1=O";"IC50";"'='";"104.0";"nM";"6.98";"";"324354";"UO_0000065";"13.31";"0.25";"4.33";"5.41";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3912820";"";"0";"512.59";"1";"3.24";"BDBM178338";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)NCCF)cc3)c2C1=O";"IC50";"'='";"22.0";"nM";"7.66";"";"324358";"UO_0000065";"14.94";"0.28";"4.42";"7.03";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3959624";"";"0";"596.63";"1";"4.55";"BDBM178403";"COCCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccc(F)cc4F)cc3)c2C1=O";"IC50";"'='";"63.0";"nM";"7.20";"";"324423";"UO_0000065";"12.07";"0.23";"2.65";"6.09";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3974594";"";"0";"646.72";"1";"4.16";"BDBM178415";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(N5CCOCC5)nc4)c(F)c3)c2C1=O";"IC50";"'='";"52.0";"nM";"7.28";"";"324435";"UO_0000065";"11.26";"0.21";"3.12";"5.42";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3914913";"";"0";"554.55";"1";"3.82";"BDBM178364";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)NCC(F)(F)F)c(F)c3)c2C1=O";"IC50";"'='";"113.0";"nM";"6.95";"";"324384";"UO_0000065";"12.53";"0.24";"3.13";"6.38";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3960354";"";"0";"628.63";"2";"5.95";"BDBM178369";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(C(F)(F)F)cc4F)cc3)c2C1=O";"IC50";"'='";"182.0";"nM";"6.74";"";"324389";"UO_0000065";"10.72";"0.20";"0.79";"6.19";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3907841";"";"0";"545.64";"1";"4.35";"BDBM178383";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccc(C)cn4)cc3)c2C1=O";"IC50";"'='";"18.0";"nM";"7.75";"";"324403";"UO_0000065";"14.19";"0.26";"3.39";"6.36";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3966167";"";"0";"639.80";"2";"5.77";"BDBM178418";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(CN5CCCCC5)cc4)cc3)c2C1=O";"IC50";"'='";"96.0";"nM";"7.02";"";"324438";"UO_0000065";"10.97";"0.20";"1.25";"6.26";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3899745";"";"0";"640.79";"1";"4.54";"BDBM178420";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(N5CCN(C)CC5)cc4)cc3)c2C1=O";"IC50";"'='";"63.0";"nM";"7.20";"";"324440";"UO_0000065";"11.24";"0.21";"2.66";"6.24";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3929564";"";"0";"626.66";"1";"4.87";"BDBM178431";"COCCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4cccc(OC(F)F)c4)cc3)c2C1=O";"IC50";"'='";"125.0";"nM";"6.90";"";"324451";"UO_0000065";"11.02";"0.21";"2.03";"5.42";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3976288";"";"0";"516.57";"1";"2.52";"BDBM178440";"CNC(=O)Nc1ccc(-c2nc(N3CCOC[C@@H]3C)nc3c2C(=O)N(CCOC)CC(C)(C)O3)cc1F";"IC50";"'='";"36.0";"nM";"7.44";"";"324460";"UO_0000065";"14.41";"0.27";"4.92";"6.30";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3895683";"";"0";"629.61";"2";"5.34";"BDBM178445";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(C(F)(F)F)nc4)c(F)c3)c2C1=O";"IC50";"'='";"77.0";"nM";"7.11";"";"324465";"UO_0000065";"11.30";"0.22";"1.77";"5.84";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3893570";"";"0";"589.67";"1";"4.94";"BDBM178456";"CCN1CC(C)(C)Oc2nc(N3C4CCC3COC4)nc(-c3ccc(NC(=O)Nc4cc(C)nc(C)c4)c(F)c3)c2C1=O";"IC50";"'='";"165.0";"nM";"6.78";"";"324476";"UO_0000065";"11.50";"0.22";"1.84";"5.57";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3961960";"";"0";"628.73";"1";"4.02";"BDBM178465";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(N5CCOCC5)cn4)cc3)c2C1=O";"IC50";"'='";"36.0";"nM";"7.44";"";"324485";"UO_0000065";"11.84";"0.22";"3.42";"5.54";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693487";"";"0";"541.65";"1";"3.91";"BDBM174649";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCC(O)(c5ccccc5)CC4)nc3n2)cc1CO";"IC50";"'='";"77.0";"nM";"7.11";"";"319927";"UO_0000065";"13.13";"0.24";"3.20";"6.84";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693573";"";"0";"510.52";"2";"5.10";"BDBM174739";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(-c4cccc(C(F)(F)F)c4)nc3n2)cc1CO";"IC50";"'='";"410.0";"nM";"6.39";"";"320018";"UO_0000065";"12.51";"0.24";"1.29";"7.92";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL4110596";"";"0";"479.56";"0";"3.77";"BDBM245483";"CN(C)CCCOc1ccc(-c2cc3c(cc2F)ncc2c3n([C@@H]3CCCOC3)c(=O)n2C)cn1";"IC50";"'='";"5900.0";"nM";"5.23";"";"427893";"UO_0000065";"10.90";"0.20";"1.46";"7.03";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3927821";"";"0";"479.56";"0";"3.77";"BDBM245494";"CN(C)CCCOc1ccc(-c2ccc3ncc4c(c3c2)n(C2CCOCC2)c(=O)n4C)c(F)n1";"IC50";"'='";"797.0";"nM";"6.10";"";"427904";"UO_0000065";"12.72";"0.24";"2.33";"8.20";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL573339";"PI-103";"0";"348.36";"0";"2.98";"PI-103";"Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1";"IC50";"'='";"111.0";"nM";"6.96";"";"";"UO_0000065";"19.96";"0.37";"3.97";"8.23";"False";"CHEMBL4050194";"Inhibition of human mTOR/FRAP1 using 4EBP1 as substrate in presence of [gamma-32P]ATP";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049399";"1";"Scientific Literature";"Bioorg Med Chem";"2017";""
"CHEMBL4088600";"";"0";"336.42";"0";"0.86";"6b";"OCc1cc2nc(N3CCOCC3)nc(N3CCOCC3)c2s1";"IC50";"'>'";"2000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL4104267";"";"0";"349.46";"0";"0.77";"6c";"CN1CCN(c2nc(N3CCOCC3)c3sc(CO)cc3n2)CC1";"IC50";"'>'";"2000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL4063923";"";"0";"384.46";"0";"2.55";"6f";"OCc1cc2nc(N3CCOc4ccccc43)nc(N3CCOCC3)c2s1";"IC50";"'='";"336.0";"nM";"6.47";"";"";"UO_0000065";"16.84";"0.33";"3.92";"9.12";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL4098035";"";"0";"411.53";"0";"3.20";"14c";"C[C@H]1CN(c2nc(N3CCOCC3)c3sc(-c4ccccn4)cc3n2)C[C@@H](C)O1";"IC50";"'='";"270.0";"nM";"6.57";"";"";"UO_0000065";"15.96";"0.31";"3.37";"10.33";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL4086949";"";"0";"400.50";"0";"3.40";"14k";"C[C@H]1CN(c2nc(N3CCOCC3)c3sc(-c4ccco4)cc3n2)C[C@@H](C)O1";"IC50";"'='";"109.0";"nM";"6.96";"";"";"UO_0000065";"17.38";"0.34";"3.56";"10.90";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL4115205";"";"0";"451.51";"0";"3.09";"BDBM227484";"C[C@H]1COCCN1c1nc(N2CCOC[C@H]2C)c2nc(-c3cc(F)cc4[nH]ccc34)[nH]c2n1";"IC50";"'='";"21.0";"nM";"7.68";"";"397243";"UO_0000065";"17.00";"0.32";"4.59";"8.07";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL4108459";"";"0";"447.54";"0";"3.34";"BDBM227494";"CC[C@@H]1COCCN1c1nc(N2CCOC[C@H]2C)c2nc(-c3cccc4[nH]ccc34)[nH]c2n1";"IC50";"'='";"60.0";"nM";"7.22";"";"397253";"UO_0000065";"16.14";"0.30";"3.88";"7.59";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL4106480";"";"0";"459.55";"0";"3.20";"BDBM227499";"C[C@@H]1COCCN1c1nc(N2CCC3COCC3C2)nc2[nH]c(-c3cccc4[nH]ccc34)nc12";"IC50";"'='";"484.0";"nM";"6.32";"";"397258";"UO_0000065";"13.74";"0.25";"3.12";"6.63";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL4111608";"";"0";"410.48";"0";"1.45";"BDBM227507";"C[C@@H]1COCCN1c1nc(N2CCOC[C@H]2C)c2nc(-c3ccc(N)nc3)[nH]c2n1";"IC50";"'='";"754.0";"nM";"6.12";"";"397266";"UO_0000065";"14.92";"0.28";"4.67";"5.18";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL3899388";"";"0";"488.54";"0";"2.41";"BDBM251605";"CS(=O)(=O)C1(c2nc(-c3cc(F)cc4[nH]ccc34)nc3c2OC[C@@H]2COCCN32)CCOCC1";"IC50";"'='";"785.0";"nM";"6.11";"";"438501";"UO_0000065";"12.50";"0.25";"3.70";"5.72";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3951757";"";"0";"472.57";"0";"2.12";"BDBM251627";"CCNc1nc2ccccc2n1-c1nc2c(c(C(C)(C)S(C)(=O)=O)n1)OC[C@@H]1COCCN21";"IC50";"'='";"505.0";"nM";"6.30";"";"438523";"UO_0000065";"13.32";"0.26";"4.18";"5.65";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3969134";"";"0";"486.60";"0";"2.51";"BDBM251628";"CCCNc1nc2ccccc2n1-c1nc2c(c(C(C)(C)S(C)(=O)=O)n1)OC[C@@H]1COCCN21";"IC50";"'='";"921.0";"nM";"6.04";"";"438524";"UO_0000065";"12.40";"0.24";"3.53";"5.41";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3981377";"";"0";"470.56";"0";"1.88";"BDBM251646";"CNc1nc2ccccc2n1-c1nc2c(c(C3(S(C)(=O)=O)CCC3)n1)OC[C@@H]1COCCN21";"IC50";"'='";"1240.0";"nM";"5.91";"";"438545";"UO_0000065";"12.55";"0.24";"4.03";"5.30";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3646570";"";"0";"366.43";"0";"2.17";"BDBM125424";"COc1ccc(Nc2ncc(C(C)(C)N)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"517.0";"nM";"6.29";"";"255166";"UO_0000065";"17.16";"0.32";"4.12";"4.56";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646465";"";"0";"404.41";"0";"3.17";"BDBM125307";"COc1ccc(Nc2nc(-c3ccc(F)cc3)ncc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255025";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3921669";"";"0";"470.55";"0";"2.27";"BDBM251580";"CS(=O)(=O)C1(c2nc(-c3cccc4[nH]ccc34)nc3c2OC[C@@H]2COCCN32)CCOCC1";"IC50";"'='";"1860.0";"nM";"5.73";"";"438476";"UO_0000065";"12.18";"0.24";"3.46";"5.37";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3897391";"";"0";"541.63";"1";"2.71";"BDBM251631";"CCOC(=O)N1CCC(c2nc(-c3cccc4[nH]ccc34)nc3c2OC[C@@H]2COCCN32)(S(C)(=O)=O)CC1";"IC50";"'='";"2080.0";"nM";"5.68";"";"438527";"UO_0000065";"10.49";"0.20";"2.97";"4.48";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3948778";"";"0";"444.49";"0";"2.40";"BDBM251637";"CS(=O)(=O)C1(c2nc(-c3cc(F)cc4[nH]ccc34)nc3c2OC[C@@H]2COCCN32)CC1";"IC50";"'='";"152.0";"nM";"6.82";"";"438533";"UO_0000065";"15.34";"0.30";"4.42";"7.00";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3646485";"";"0";"509.57";"1";"3.67";"BDBM125327";"COc1ncc(Nc2ncc(C(C)c3ccc(S(C)(=O)=O)cc3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255050";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646489";"";"0";"422.45";"0";"1.33";"BDBM125331";"COc1ccc(Nc2ncc(CN3CCOCC3=O)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"3030.0";"nM";"5.52";"";"255054";"UO_0000065";"13.06";"0.24";"4.19";"3.91";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL4112870";"";"0";"475.59";"0";"4.02";"BDBM245498";"CO[C@@H]1CC[C@@H](n2c(=O)n(C)c3cnc4ccc(-c5ccc(OCCCN(C)C)nc5)cc4c32)C1";"IC50";"'='";"1190.0";"nM";"5.92";"";"427908";"UO_0000065";"12.46";"0.23";"1.90";"7.96";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3942682";"";"0";"572.67";"1";"4.80";"BDBM178342";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4cccc(OC)c4)cc3)c2C1=O";"IC50";"'='";"16.0";"nM";"7.80";"";"324362";"UO_0000065";"13.61";"0.25";"3.00";"6.60";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3972628";"";"0";"563.63";"1";"4.49";"BDBM178376";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccc(C)nc4)c(F)c3)c2C1=O";"IC50";"'='";"38.0";"nM";"7.42";"";"324396";"UO_0000065";"13.17";"0.25";"2.93";"6.09";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3919139";"";"0";"515.64";"1";"2.91";"BDBM178326";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NS(=O)(=O)CC)cc3)c2C1=O";"IC50";"'='";"6349.0";"nM";"5.20";"";"324346";"UO_0000065";"10.08";"0.20";"2.29";"4.56";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3907841";"";"0";"545.64";"1";"4.35";"BDBM178383";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccc(C)cn4)cc3)c2C1=O";"IC50";"'='";"31.0";"nM";"7.51";"";"324404";"UO_0000065";"13.76";"0.26";"3.16";"6.16";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3932385";"";"0";"629.77";"1";"3.79";"BDBM178389";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccc(N5CCN(C)CC5)nc4)cc3)c2C1=O";"IC50";"'='";"22.0";"nM";"7.66";"";"324409";"UO_0000065";"12.16";"0.23";"3.87";"5.97";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3970894";"";"0";"484.53";"0";"2.64";"BDBM178421";"CCN1CC(C)(C)Oc2nc(N3C[C@@H]4C[C@H]3CO4)nc(-c3ccc(NC(=O)NC)c(F)c3)c2C1=O";"IC50";"'='";"145.0";"nM";"6.84";"";"324441";"UO_0000065";"14.11";"0.27";"4.20";"6.28";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3965674";"";"0";"578.65";"1";"4.79";"BDBM178428";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4cc(OC)ccc4F)cc3)c2C1=O";"IC50";"'='";"48.0";"nM";"7.32";"";"324448";"UO_0000065";"12.65";"0.24";"2.53";"6.19";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3908330";"";"0";"486.55";"0";"2.89";"BDBM178217";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)NC)c(F)c3)c2C1=O";"IC50";"'='";"22.0";"nM";"7.66";"";"324237";"UO_0000065";"15.74";"0.30";"4.77";"7.03";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3646490";"";"0";"499.60";"1";"1.44";"BDBM125332";"COc1ccc(Nc2ncc(CN3CCN(S(C)(=O)=O)C[C@H]3C)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"3284.0";"nM";"5.48";"";"255058";"UO_0000065";"10.98";"0.21";"4.04";"3.60";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3781792";"";"0";"471.56";"1";"6.95";"10";"CC(=O)Nc1cnc2ccc(-c3cnc4ccccc4c3)cc2c1Nc1ccc(C(C)(C)C#N)cc1";"IC50";"'='";"114.0";"nM";"6.94";"";"";"UO_0000065";"14.72";"0.26";"-0.01";"7.66";"False";"CHEMBL3784491";"Inhibition of human mTOR using ULight-4E-BP1 peptide as substrate after 1 hr by Lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3779897";"1";"Scientific Literature";"MedChemComm";"2016";""
"CHEMBL3928694";"";"0";"579.61";"1";"4.46";"BDBM178291";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccncc4F)c(F)c3)c2C1=O";"IC50";"'='";"28.0";"nM";"7.55";"";"324311";"UO_0000065";"13.03";"0.25";"3.09";"6.20";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3891738";"";"0";"646.72";"2";"5.10";"BDBM178292";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(OC5CCOC5)cc4)c(F)c3)c2C1=O";"IC50";"'='";"56.0";"nM";"7.25";"";"324312";"UO_0000065";"11.21";"0.21";"2.15";"5.69";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3906150";"";"0";"703.78";"2";"4.21";"BDBM178296";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(N5CCN(C(=O)OC)CC5)nc4)c(F)c3)c2C1=O";"IC50";"'='";"124.0";"nM";"6.91";"";"324316";"UO_0000065";"9.81";"0.18";"2.70";"4.47";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3937154";"";"0";"525.61";"1";"3.07";"BDBM178303";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)OC[C@H](C)O)cc3)c2C1=O";"IC50";"'='";"198.0";"nM";"6.70";"";"324323";"UO_0000065";"12.75";"0.24";"3.63";"5.31";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3643106";"";"0";"506.59";"1";"4.18";"BDBM115722";"CCc1ncnc(-c2ccc(C(=O)N3CCN(c4ccccc4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"10.0";"nM";"8.00";"";"240359";"UO_0000065";"15.79";"0.29";"3.82";"9.07";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643919";"";"0";"327.35";"0";"3.64";"BDBM125229";"c1cnc(Nc2cccc3[nH]ccc23)c(-c2ncnc3[nH]cnc23)c1";"IC50";"'>'";"50000.0";"nM";"";"";"254934";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165014";"";"0";"421.51";"0";"1.72";"BDBM50394849";"COc1ccc(Nc2ncc(CN3CCN(C)CC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255057";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646520";"";"0";"370.80";"0";"2.57";"BDBM125363";"CC(=O)Nc1ccc(Nc2ncc(Cl)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255092";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646529";"";"0";"440.53";"0";"1.54";"BDBM125372";"COc1ccc(Nc2ncc(CN3CC[S+]([O-])CC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255101";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646533";"";"0";"418.46";"0";"2.44";"BDBM125376";"COc1ccc(Nc2ncc(N3CC[C@@H](O)C3)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'='";"594.0";"nM";"6.23";"";"255105";"UO_0000065";"14.88";"0.27";"3.79";"4.98";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643145";"";"0";"479.99";"0";"2.94";"BDBM115761";"CCc1ncnc(-c2ccc(C(=O)N3CC[S+]([O-])CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"240398";"UO_0000065";"17.76";"0.35";"5.58";"8.35";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165041";"";"0";"319.33";"0";"2.56";"BDBM50394879";"COc1ccc(Nc2ncccc2-c2ncnc3nc[nH]c23)cn1";"IC50";"'='";"5124.0";"nM";"5.29";"";"254935";"UO_0000065";"16.57";"0.30";"2.73";"5.21";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643933";"";"0";"421.26";"0";"4.11";"BDBM125253";"Cc1nc(-c2cc(Br)cnc2Nc2cccc3[nH]ncc23)c2nc[nH]c2n1";"IC50";"'>'";"10000.0";"nM";"";"";"254968";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643936";"";"0";"491.56";"1";"5.67";"BDBM125259";"COc1ccc(COCc2cnc(Nc3cccc4[nH]ccc34)c(-c3nc(C)nc4[nH]cnc34)c2)cc1";"IC50";"'>'";"50000.0";"nM";"";"";"254971";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646437";"";"0";"454.49";"0";"4.62";"BDBM125278";"COc1ccc(Nc2cnc(Nc3ccc(OC)nc3)c(-c3nc(C)nc4[nH]cnc34)c2)cc1";"IC50";"'='";"743.0";"nM";"6.13";"";"254990";"UO_0000065";"13.49";"0.25";"1.51";"4.99";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3891331";"";"0";"466.38";"0";"3.11";"BDBM236559";"COc1ncc(-c2ccc3ncc4c(=O)[nH]c(=O)n(-c5cccc(C(F)(F)F)c5)c4c3n2)cn1";"IC50";"'='";"39.3";"nM";"7.41";"";"412063";"UO_0000065";"15.88";"0.30";"4.30";"6.40";"False";"CHEMBL3888698";"mTOR Enzymatic Assay: Agents: 1-fold kinase buffer: 50 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 3 mM MnCl2, 0.01% Tween-20, 2 mM DTT. 4-fold kinase solution: mTOR kinase was added to 1-fold kinase buffer to form 4-fold kinase solution with a final concentration of 2.5 nM. 2-fold substrate and ATP solution: the substrate 4EBP1 and ATP were added to 1-fold kinase buffer to form 2-fold substrate solution with final concentration of 50 nM of 4EBP1 and 10.8 ¿M of ATP. 4-fold test substance solutions: 100-fold test substance solutions in different gradient concentrations were formulated with 100% DMSO, and diluted by 25 folds with 1-fold kinase buffer to form 4-fold test substance solutions in different gradient concentrations. Detection solution: a detection solution containing 2-fold final concentrations of EDTA and 4EBP1 phosphorylated antibody was formulated, wherein the final concentration for EDTA was 8 mM, and the final concentration for the 4EBP phosphorylated antibody was 2 nM. Procedure: To each well of a 384-well plate was added 2.5 ¿L of the 4-fold test substance solutions in gradient concentrations. The replication was made. To each well was added 2.5 ¿L of 4-fold kinase solution, and then the plate was incubated for 10 mins. Then to each well was added 5 ¿L/of 2-fold substrate and ATP solution, and then the plate was incubated at room temperature for 1 hour. Finally, 10 ¿L of the detection solution was added to terminate the reaction. After 60 mins, the data Lance signal (665 nM) was read from Envision.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886794";"37";"BindingDB Database";"";"2016";""
"CHEMBL3670141";"";"0";"352.44";"0";"0.93";"BDBM111615";"COCCN1CCN(c2ncnc(C)c2C#Cc2ccc(N)nc2)CC1";"IC50";"'='";"32.0";"nM";"7.50";"";"232438";"UO_0000065";"21.27";"0.39";"6.56";"9.32";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670238";"";"0";"432.57";"0";"3.07";"BDBM111714";"Cc1ncnc(N2CCC(CNC(=O)C3CCCCC3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"78.0";"nM";"7.11";"";"232537";"UO_0000065";"16.43";"0.30";"4.04";"7.33";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3643922";"";"0";"470.56";"0";"1.47";"BDBM125233";"COc1ccc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3)cc2-c2ncnc(C)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"254948";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165050";"";"0";"310.32";"0";"1.37";"BDBM50394870";"COc1ccc(Nc2nccnc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255014";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646511";"";"0";"333.36";"0";"2.87";"BDBM125354";"COc1cncc(Nc2ncccc2-c2nc(C)nc3[nH]cnc23)c1";"IC50";"'>'";"10000.0";"nM";"";"";"255082";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3693557";"";"0";"466.97";"0";"3.27";"BDBM174720";"C[C@H]1COCCN1c1nc(N2CCC(C(N)=O)CC2)nc2nc(-c3ccc(Cl)cc3)ccc12";"IC50";"'='";"52.0";"nM";"7.28";"";"320002";"UO_0000065";"15.60";"0.30";"4.01";"7.47";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3670158";"";"0";"391.40";"0";"2.31";"BDBM111632";"CCc1ncnc(N2CCC(O)(C(F)(F)F)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.0";"nM";"9.00";"";"232455";"UO_0000065";"22.99";"0.44";"6.69";"10.21";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670167";"";"0";"399.50";"0";"2.74";"BDBM111641";"Cc1ncnc(N2CCC(O)(Cc3ccccc3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"50.0";"nM";"7.30";"";"232464";"UO_0000065";"18.28";"0.33";"4.56";"8.28";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670177";"";"0";"323.40";"0";"1.78";"BDBM111651";"COC1CCN(c2ncnc(C)c2C#Cc2ccc(N)nc2)CC1";"IC50";"'='";"18.0";"nM";"7.75";"";"232474";"UO_0000065";"23.95";"0.44";"5.96";"10.04";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670183";"";"0";"337.43";"0";"2.03";"BDBM111657";"CCc1ncnc(N2CCC(OC)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"10.0";"nM";"8.00";"";"232480";"UO_0000065";"23.71";"0.44";"5.97";"10.37";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670211";"";"0";"391.52";"0";"3.07";"BDBM111687";"Cc1ncnc(N2CCC(O)(C3CCCCC3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"30.0";"nM";"7.52";"";"232510";"UO_0000065";"19.21";"0.35";"4.45";"8.53";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670233";"";"0";"364.45";"0";"1.51";"BDBM111709";"CC(=O)NCC1CCN(c2ncnc(C)c2C#Cc2ccc(N)nc2)CC1";"IC50";"'='";"15.0";"nM";"7.82";"";"232532";"UO_0000065";"21.47";"0.40";"6.31";"8.06";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670234";"";"0";"420.56";"0";"3.07";"BDBM111710";"CCCCCC(=O)NCC1CCN(c2ncnc(C)c2C#Cc2ccc(N)nc2)CC1";"IC50";"'='";"31.0";"nM";"7.51";"";"232533";"UO_0000065";"17.85";"0.33";"4.44";"7.74";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670237";"";"0";"408.51";"0";"1.53";"BDBM111713";"COCCC(=O)NCC1CCN(c2ncnc(C)c2C#Cc2ccc(N)nc2)CC1";"IC50";"'='";"18.0";"nM";"7.75";"";"232536";"UO_0000065";"18.96";"0.35";"6.21";"7.29";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670261";"";"0";"405.55";"0";"1.63";"BDBM111737";"CCc1ncnc(N2CCN(C3CCN(C)CC3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1569.0";"nM";"5.80";"";"232560";"UO_0000065";"14.31";"0.26";"4.17";"7.80";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670269";"";"0";"415.50";"0";"3.00";"BDBM111745";"CCc1ncnc(N2CCc3cc(OC)c(OC)cc3C2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"83.0";"nM";"7.08";"";"232568";"UO_0000065";"17.04";"0.31";"4.08";"8.20";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3986418";"";"0";"466.42";"0";"4.82";"BDBM213782";"COc1ncc(-c2ccc3ncc4c(c3n2)N(c2cccc(C(F)(F)F)c2)C(=O)N(C)C4)cn1";"IC50";"'='";"30.3";"nM";"7.52";"";"375948";"UO_0000065";"16.12";"0.30";"2.70";"8.91";"False";"CHEMBL3888153";"mTOR Activity Assay: 1. Preparation of test reagents {circle around (1)} 1x kinase buffer (50 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 3 mM MnCl, 0.01% Tween-20, 2 mM DTT); {circle around (2)} 4x kinase solution (added mTOR kinase to 1x kinase buffer to provide 4x kinase solution with a final concentration of 2.5 nM); {circle around (3)} 2x substrate solution (added the substrates of 4EBP1 and ATP into 1x kinase buffer to provide 2x substrate solution with 4EBP1 final concentration of 50 nM and ATP final concentration of 10.8 uM); {circle around (4)} 4x test substance solutions (100x test substance solutions with different concentration gradients were prepared using 100% DMSO, and diluted 25-fold with 1x kinase buffer to give 4x test substance solutions with different concentration gradients) {circle around (5)} preparation of test solution (test solution containing EDTA and 4EBP1 phosphorylated antibody was prepared using activity test kit with assay buffer, the final concentration of EDTA was 8 mM, and the final concentration of 4EBP1 phosphorylated antibody was 2 nM) 2. 2.5 uL of 4x test solution was added to a 384-well plate in parallel; 3. added 2.54 uL of 4x kinase solution and incubated for 10 min; 4. then added 5 uL of 2x solutions of 4EBP1 and ATP substrates and incubated for 1 h at room temperature; 5. finally, added 10 uL of test solution to quench the reaction, and read after 60 min; 6. IC50 value was obtained via curve fitting.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886601";"37";"BindingDB Database";"";"2016";""
"CHEMBL3929946";"";"0";"404.47";"0";"2.82";"BDBM213788";"COc1ccc(-c2ccc3ncc4c(c3n2)N(C2CCNCC2)C(=O)N(C)C4)cn1";"IC50";"'='";"732.3";"nM";"6.13";"";"375952";"UO_0000065";"15.17";"0.28";"3.32";"7.35";"False";"CHEMBL3888153";"mTOR Activity Assay: 1. Preparation of test reagents {circle around (1)} 1x kinase buffer (50 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 3 mM MnCl, 0.01% Tween-20, 2 mM DTT); {circle around (2)} 4x kinase solution (added mTOR kinase to 1x kinase buffer to provide 4x kinase solution with a final concentration of 2.5 nM); {circle around (3)} 2x substrate solution (added the substrates of 4EBP1 and ATP into 1x kinase buffer to provide 2x substrate solution with 4EBP1 final concentration of 50 nM and ATP final concentration of 10.8 uM); {circle around (4)} 4x test substance solutions (100x test substance solutions with different concentration gradients were prepared using 100% DMSO, and diluted 25-fold with 1x kinase buffer to give 4x test substance solutions with different concentration gradients) {circle around (5)} preparation of test solution (test solution containing EDTA and 4EBP1 phosphorylated antibody was prepared using activity test kit with assay buffer, the final concentration of EDTA was 8 mM, and the final concentration of 4EBP1 phosphorylated antibody was 2 nM) 2. 2.5 uL of 4x test solution was added to a 384-well plate in parallel; 3. added 2.54 uL of 4x kinase solution and incubated for 10 min; 4. then added 5 uL of 2x solutions of 4EBP1 and ATP substrates and incubated for 1 h at room temperature; 5. finally, added 10 uL of test solution to quench the reaction, and read after 60 min; 6. IC50 value was obtained via curve fitting.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886601";"37";"BindingDB Database";"";"2016";""
"CHEMBL3902079";"";"0";"549.61";"1";"4.18";"BDBM178227";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccncc4)cc3F)c2C1=O";"IC50";"'='";"17.0";"nM";"7.77";"";"324247";"UO_0000065";"14.14";"0.27";"3.59";"6.38";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3905118";"";"0";"550.66";"1";"3.44";"BDBM178229";"CCNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)nc3c2C(=O)N(C2CCOCC2)CC(C)(C)O3)cc1";"IC50";"'='";"41.0";"nM";"7.39";"";"324249";"UO_0000065";"13.42";"0.25";"3.95";"6.25";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3900695";"";"0";"543.63";"1";"4.10";"BDBM178257";"Cc1ccc(NC(=O)Nc2ccc(-c3nc(N4CC5CCC(C4)O5)nc4c3C(=O)N(C)CC(C)(C)O4)cc2)nc1";"IC50";"'='";"43.0";"nM";"7.37";"";"324277";"UO_0000065";"13.55";"0.25";"3.27";"6.05";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3928536";"";"0";"543.60";"1";"3.21";"BDBM178276";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)O[C@@H](C)CO)c(F)c3)c2C1=O";"IC50";"'='";"993.0";"nM";"6.00";"";"324296";"UO_0000065";"11.04";"0.21";"2.79";"4.75";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3929170";"";"0";"511.58";"1";"2.69";"BDBM178280";"CCN1CC(C)(C)Oc2nc(N3C4CCC3COC4)nc(-c3ccc(NC(=O)OCCO)cc3)c2C1=O";"IC50";"'='";"27.0";"nM";"7.57";"";"324300";"UO_0000065";"14.79";"0.28";"4.88";"5.99";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3943611";"";"0";"529.60";"1";"3.79";"BDBM178284";"CN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccncc4)cc3)c2C1=O";"IC50";"'='";"6.0";"nM";"8.22";"";"324304";"UO_0000065";"15.52";"0.29";"4.43";"6.75";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3907351";"";"0";"587.68";"1";"4.50";"BDBM178390";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(OC)nc4)c(C)c3)c2C1=O";"IC50";"'='";"585.0";"nM";"6.23";"";"324410";"UO_0000065";"10.61";"0.20";"1.73";"4.76";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3953184";"";"0";"552.61";"1";"3.52";"BDBM178397";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4cn(C)cn4)c(F)c3)c2C1=O";"IC50";"'='";"26.0";"nM";"7.58";"";"324417";"UO_0000065";"13.73";"0.26";"4.07";"5.98";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3957262";"";"0";"564.65";"1";"3.01";"BDBM178416";"COCCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4cnn(C)c4)cc3)c2C1=O";"IC50";"'='";"48.0";"nM";"7.32";"";"324436";"UO_0000065";"12.96";"0.24";"4.31";"5.38";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3911420";"";"0";"511.58";"1";"2.68";"BDBM178453";"C[C@@H](CO)OC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)nc3c2C(=O)N(C)CC(C)(C)O3)cc1";"IC50";"'='";"678.0";"nM";"6.17";"";"324473";"UO_0000065";"12.06";"0.23";"3.49";"4.88";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3903725";"";"0";"450.38";"0";"3.29";"BDBM236557";"Nc1ccc(-c2ccc3ncc4c(=O)[nH]c(=O)n(-c5cccc(C(F)(F)F)c5)c4c3n2)cn1";"IC50";"'='";"2.5";"nM";"8.60";"";"412061";"UO_0000065";"19.10";"0.36";"5.31";"7.20";"False";"CHEMBL3888698";"mTOR Enzymatic Assay: Agents: 1-fold kinase buffer: 50 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 3 mM MnCl2, 0.01% Tween-20, 2 mM DTT. 4-fold kinase solution: mTOR kinase was added to 1-fold kinase buffer to form 4-fold kinase solution with a final concentration of 2.5 nM. 2-fold substrate and ATP solution: the substrate 4EBP1 and ATP were added to 1-fold kinase buffer to form 2-fold substrate solution with final concentration of 50 nM of 4EBP1 and 10.8 ¿M of ATP. 4-fold test substance solutions: 100-fold test substance solutions in different gradient concentrations were formulated with 100% DMSO, and diluted by 25 folds with 1-fold kinase buffer to form 4-fold test substance solutions in different gradient concentrations. Detection solution: a detection solution containing 2-fold final concentrations of EDTA and 4EBP1 phosphorylated antibody was formulated, wherein the final concentration for EDTA was 8 mM, and the final concentration for the 4EBP phosphorylated antibody was 2 nM. Procedure: To each well of a 384-well plate was added 2.5 ¿L of the 4-fold test substance solutions in gradient concentrations. The replication was made. To each well was added 2.5 ¿L of 4-fold kinase solution, and then the plate was incubated for 10 mins. Then to each well was added 5 ¿L/of 2-fold substrate and ATP solution, and then the plate was incubated at room temperature for 1 hour. Finally, 10 ¿L of the detection solution was added to terminate the reaction. After 60 mins, the data Lance signal (665 nM) was read from Envision.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886794";"37";"BindingDB Database";"";"2016";""
"CHEMBL3970627";"";"0";"608.65";"2";"5.39";"BDBM178233";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4cccc(OC(F)F)c4)cc3)c2C1=O";"IC50";"'='";"25.0";"nM";"7.60";"";"324253";"UO_0000065";"12.49";"0.24";"2.21";"6.43";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3890540";"";"0";"573.65";"1";"4.19";"BDBM178259";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(OC)cn4)cc3)c2C1=O";"IC50";"'='";"34.0";"nM";"7.47";"";"324279";"UO_0000065";"13.02";"0.24";"3.28";"5.70";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3941267";"";"0";"559.60";"1";"4.07";"BDBM178267";"CCN1CC(C)(C)Oc2nc(N3CC4CC35CC5O4)nc(-c3ccc(NC(=O)Nc4ccncc4)c(F)c3)c2C1=O";"IC50";"'='";"18.0";"nM";"7.75";"";"324287";"UO_0000065";"13.84";"0.26";"3.67";"6.36";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3956322";"";"0";"539.63";"1";"3.46";"BDBM178268";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)O[C@H]4CCC[C@H]4O)cc3)c2C1=O";"IC50";"'='";"222.0";"nM";"6.65";"";"324288";"UO_0000065";"12.33";"0.23";"3.19";"5.27";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3929469";"";"0";"510.60";"1";"2.26";"BDBM178332";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)NCCO)cc3)c2C1=O";"IC50";"'='";"25.0";"nM";"7.60";"";"324352";"UO_0000065";"14.89";"0.28";"5.34";"5.89";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3968766";"";"0";"568.65";"1";"3.58";"BDBM178343";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)NCC4CCCO4)c(F)c3)c2C1=O";"IC50";"'='";"3475.0";"nM";"5.46";"";"324363";"UO_0000065";"9.60";"0.18";"1.88";"4.62";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3970027";"";"0";"547.62";"1";"4.08";"BDBM178380";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccon4)c(C)c3)c2C1=O";"IC50";"'='";"180.0";"nM";"6.75";"";"324400";"UO_0000065";"12.32";"0.23";"2.66";"5.00";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3670221";"";"0";"362.44";"0";"1.27";"BDBM111697";"Cc1ncnc(N2CCC3(CCNC3=O)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"19.0";"nM";"7.72";"";"232520";"UO_0000065";"21.30";"0.39";"6.45";"7.96";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL4064318";"";"0";"428.47";"0";"3.49";"9aa";"N#CCN1CCC(n2c(=O)cnc3cnc4cc(F)c(-c5ccc(N)cc5)cc4c32)CC1";"IC50";"'='";"29.0";"nM";"7.54";"";"";"UO_0000065";"17.59";"0.32";"4.05";"7.48";"False";"CHEMBL4023016";"Inhibition of N-terminal FLAG-tagged recombinant human mTOR (1362 to end residues)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020823";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL3970095";"";"0";"617.71";"1";"3.59";"BDBM222598";"CCOC(=O)c1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)N4CCN(C)CC4)cc3)cc2)nc(N2CCOCC2)c1OCC";"IC50";"'='";"105.6";"nM";"6.98";"";"389387";"UO_0000065";"11.29";"0.21";"3.39";"5.04";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3917024";"";"0";"604.66";"1";"3.67";"BDBM222600";"CCOC(=O)c1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)N4CCOCC4)cc3)cc2)nc(N2CCOCC2)c1OCC";"IC50";"'='";"67.0";"nM";"7.17";"";"389389";"UO_0000065";"11.86";"0.22";"3.50";"4.97";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3969697";"";"0";"498.57";"0";"3.00";"BDBM222651";"COc1cnc(-c2ccc(NC(=O)Nc3ccc(NS(C)(=O)=O)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"79.2";"nM";"7.10";"";"389440";"UO_0000065";"14.24";"0.28";"4.10";"5.27";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3894495";"";"0";"422.51";"0";"3.74";"BDBM222570";"CSc1cnc(-c2ccc(NC(=O)Nc3cccnc3)cc2)nc1N1CCOCC1";"IC50";"'='";"101.2";"nM";"7.00";"";"389359";"UO_0000065";"16.56";"0.32";"3.25";"7.58";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3930890";"";"0";"406.45";"0";"3.03";"BDBM222573";"COc1cnc(-c2ccc(NC(=O)Nc3cccnc3)cc2)nc1N1CCOCC1";"IC50";"'='";"82.6";"nM";"7.08";"";"389362";"UO_0000065";"17.43";"0.32";"4.05";"6.98";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3928366";"";"0";"506.63";"1";"4.19";"BDBM222591";"COc1cnc(-c2ccc(NC(=O)Nc3ccc(N4CCSCC4)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"8.0";"nM";"8.10";"";"389380";"UO_0000065";"15.98";"0.31";"3.91";"8.82";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3903444";"";"0";"530.63";"1";"4.65";"BDBM222551";"CCOc1c(C(=O)N2CCCCC2)nc(-c2ccc(NC(=O)Nc3ccccc3)cc2)nc1N1CCOCC1";"IC50";"'='";"257.3";"nM";"6.59";"";"389340";"UO_0000065";"12.42";"0.23";"1.94";"6.05";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3932641";"";"0";"477.52";"0";"3.81";"BDBM222556";"CCOC(=O)c1nc(-c2ccc(NC(=O)Nc3ccccc3)cc2)nc(N2CCOCC2)c1OC";"IC50";"'='";"275.3";"nM";"6.56";"";"389345";"UO_0000065";"13.74";"0.26";"2.75";"5.71";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3949307";"";"0";"343.39";"0";"1.74";"BDBM222574";"CNC(=O)Nc1ccc(-c2ncc(OC)c(N3CCOCC3)n2)cc1";"IC50";"'='";"241.0";"nM";"6.62";"";"389363";"UO_0000065";"19.27";"0.36";"4.88";"7.47";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3952626";"";"0";"478.58";"0";"4.30";"BDBM222627";"CSc1cnc(-c2ccc(NC(=O)Nc3ccc(NC(C)=O)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"221.2";"nM";"6.66";"";"389416";"UO_0000065";"13.91";"0.27";"2.36";"6.13";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3963896";"";"0";"507.62";"1";"3.58";"BDBM222592";"CSc1cnc(-c2ccc(NC(=O)Nc3ccc(N4CCOCC4)nc3)cc2)nc1N1CCOCC1";"IC50";"'='";"171.9";"nM";"6.76";"";"389381";"UO_0000065";"13.33";"0.26";"3.18";"6.46";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3960400";"";"0";"534.57";"1";"3.30";"BDBM222582";"CCOC(=O)c1nc(-c2ccc(NC(=O)Nc3ccc(C(N)=O)cc3)cc2)nc(N2CCOCC2)c1OCC";"IC50";"'='";"18.0";"nM";"7.75";"";"389371";"UO_0000065";"14.49";"0.27";"4.44";"4.90";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3921978";"";"0";"490.56";"0";"3.47";"BDBM222590";"COc1cnc(-c2ccc(NC(=O)Nc3ccc(N4CCOCC4)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"86.8";"nM";"7.06";"";"389379";"UO_0000065";"14.39";"0.27";"3.59";"6.99";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3965896";"";"0";"524.62";"1";"4.32";"BDBM222571";"CSc1cnc(-c2ccc(NC(=O)Nc3ccc(N4CCOCC4)c(F)c3)cc2)nc1N1CCOCC1";"IC50";"'='";"212.6";"nM";"6.67";"";"389360";"UO_0000065";"12.72";"0.25";"2.35";"7.26";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3670209";"";"0";"336.44";"0";"2.35";"BDBM111685";"CCc1ncnc(N2CCC(CO)CC2)c1C#Cc1ccc(C)nc1";"IC50";"'='";"70.0";"nM";"7.16";"";"232508";"UO_0000065";"21.27";"0.39";"4.80";"11.51";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670204";"";"0";"323.40";"0";"1.37";"BDBM111680";"Cc1ncnc(N2CCC(O)C(C)C2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"43.0";"nM";"7.37";"";"232503";"UO_0000065";"22.78";"0.42";"6.00";"8.36";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3643143";"";"0";"543.12";"1";"4.93";"BDBM115759";"CCc1ncnc(-c2ccc(C(=O)N3CCC(C4CCN(C)CC4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"7.0";"nM";"8.15";"";"240396";"UO_0000065";"15.01";"0.29";"3.22";"9.24";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643105";"";"0";"520.61";"1";"4.18";"BDBM115721";"CCc1ncnc(-c2ccc(C(=O)N3CCN(Cc4ccccc4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"12.0";"nM";"7.92";"";"240358";"UO_0000065";"15.21";"0.28";"3.74";"8.98";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3951024";"";"0";"465.44";"1";"5.42";"BDBM213775";"COc1ccc(-c2ccc3ncc4c(c3n2)N(c2cccc(C(F)(F)F)c2)C(=O)N(C)C4)cn1";"IC50";"'='";"54.3";"nM";"7.26";"";"375942";"UO_0000065";"15.61";"0.29";"1.85";"10.17";"False";"CHEMBL3888153";"mTOR Activity Assay: 1. Preparation of test reagents {circle around (1)} 1x kinase buffer (50 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 3 mM MnCl, 0.01% Tween-20, 2 mM DTT); {circle around (2)} 4x kinase solution (added mTOR kinase to 1x kinase buffer to provide 4x kinase solution with a final concentration of 2.5 nM); {circle around (3)} 2x substrate solution (added the substrates of 4EBP1 and ATP into 1x kinase buffer to provide 2x substrate solution with 4EBP1 final concentration of 50 nM and ATP final concentration of 10.8 uM); {circle around (4)} 4x test substance solutions (100x test substance solutions with different concentration gradients were prepared using 100% DMSO, and diluted 25-fold with 1x kinase buffer to give 4x test substance solutions with different concentration gradients) {circle around (5)} preparation of test solution (test solution containing EDTA and 4EBP1 phosphorylated antibody was prepared using activity test kit with assay buffer, the final concentration of EDTA was 8 mM, and the final concentration of 4EBP1 phosphorylated antibody was 2 nM) 2. 2.5 uL of 4x test solution was added to a 384-well plate in parallel; 3. added 2.54 uL of 4x kinase solution and incubated for 10 min; 4. then added 5 uL of 2x solutions of 4EBP1 and ATP substrates and incubated for 1 h at room temperature; 5. finally, added 10 uL of test solution to quench the reaction, and read after 60 min; 6. IC50 value was obtained via curve fitting.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886601";"37";"BindingDB Database";"";"2016";""
"CHEMBL3984179";"";"0";"459.55";"0";"3.12";"BDBM245487";"Cn1c(=O)n([C@H]2C[C@@H](O)C2)c2c3cc(-c4ccc(OCCCN5CCC5)nc4)ccc3ncc21";"IC50";"'='";"1040.0";"nM";"5.98";"";"427897";"UO_0000065";"13.02";"0.24";"2.86";"7.00";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL4111966";"";"0";"461.57";"0";"3.63";"BDBM245489";"CN(C)CCCOc1ccc(-c2ccc3ncc4c(c3c2)n([C@@H]2CCCOC2)c(=O)n4C)cn1";"IC50";"'='";"714.0";"nM";"6.15";"";"427899";"UO_0000065";"13.32";"0.25";"2.52";"8.26";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL4109786";"";"0";"473.58";"0";"3.78";"BDBM245506";"Cn1c(=O)n([C@@H]2CCCOC2)c2c3cc(-c4ccc(OCCCN5CCC5)nc4)ccc3ncc21";"IC50";"'='";"505.0";"nM";"6.30";"";"427917";"UO_0000065";"13.30";"0.25";"2.52";"8.46";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3972478";"";"0";"487.60";"0";"4.55";"BDBM245508";"O=c1[nH]c2cnc3ccc(-c4ccc(OCCCN5CCCCC5)nc4)cc3c2n1C1CCOCC1";"IC50";"'='";"10600.0";"nM";"4.97";"";"427919";"UO_0000065";"10.20";"0.19";"0.42";"5.83";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3929864";"";"0";"493.58";"0";"4.16";"BDBM245543";"CO[C@H]1CC[C@H](n2c(=O)n(C)c3cnc4cc(F)c(-c5ccc(OCCCN(C)C)nc5)cc4c32)C1";"IC50";"'='";"10800.0";"nM";"4.97";"";"427944";"UO_0000065";"10.06";"0.19";"0.81";"6.67";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL4208852";"";"0";"406.54";"0";"2.87";"13b";"CNc1ncc2c(-c3ccc(N4CCN(C)CC4)nc3)nn(CC3CCCC3)c2n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4188979";"Inhibition of wild-type human partial length MTOR (L1382 to W2549 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4184298";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL4205191";"";"0";"531.61";"2";"1.82";"10d";"CNc1ncc2c(-c3ccc(N4CCNCC4)nc3)nn(Cc3cn(-c4ccsc4C(=O)OC)nn3)c2n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4188979";"Inhibition of wild-type human partial length MTOR (L1382 to W2549 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4184298";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL3970915";"";"0";"443.50";"0";"2.70";"BDBM222546";"CCNC(=O)Nc1ccc(-c2nc(C(=O)OCC)c(OCC)c(N3CCOCC3)n2)cc1";"IC50";"'='";"292.3";"nM";"6.53";"";"389335";"UO_0000065";"14.73";"0.28";"3.83";"5.69";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3923670";"";"0";"532.60";"1";"3.50";"BDBM222642";"CCOc1cnc(-c2ccc(NC(=O)Nc3ccc(C(=O)N4CCOCC4)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"58.8";"nM";"7.23";"";"389431";"UO_0000065";"13.58";"0.25";"3.73";"6.12";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3900052";"";"0";"518.57";"1";"3.11";"BDBM222628";"COc1cnc(-c2ccc(NC(=O)Nc3ccc(C(=O)N4CCOCC4)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"67.7";"nM";"7.17";"";"389417";"UO_0000065";"13.83";"0.26";"4.06";"6.07";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3978070";"";"0";"534.06";"1";"4.40";"BDBM222630";"CSc1c(Cl)nc(-c2ccc(NC(=O)Nc3ccc(S(C)(=O)=O)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"140.8";"nM";"6.85";"";"389419";"UO_0000065";"12.83";"0.27";"2.45";"6.04";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3960662";"";"0";"461.57";"0";"3.63";"64";"CN(C)CCCOc1ccc(-c2ccc3ncc4c(c3c2)n(C2CCOCC2)c(=O)n4C)cn1";"IC50";"'='";"200.0";"nM";"6.70";"";"";"UO_0000065";"14.51";"0.27";"3.07";"9.00";"False";"CHEMBL4153804";"Inhibition of human m-TOR (L1382 to W2549 residues) expressed in mammalian expression system";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4152224";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL3327146";"";"0";"462.94";"0";"3.50";"2s";"COc1ncc(-c2cnc3nc(N)nc(C)c3c2)cc1NS(=O)(=O)c1ccc(Cl)s1";"IC50";"'='";"37.6";"nM";"7.42";"";"";"UO_0000065";"16.04";"0.34";"3.92";"5.58";"False";"CHEMBL3380578";"Inhibition of mTOR (unknown origin) assessed as inhibition of 4EBP-1 phosphorylation preincubated for 15 mins before substrate addition by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3351642";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3653616";"";"0";"525.55";"1";"3.43";"BDBM136473";"O=C1OCC(c2ccccc2N2CCNCC2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"10.1";"nM";"8.00";"";"270347";"UO_0000065";"15.21";"0.28";"4.57";"6.86";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653628";"";"0";"456.44";"0";"3.72";"BDBM136485";"Cc1ccc([C@H]2COC(=O)N2c2ccn3ncc(-c4ccc(-c5nc[nH]n5)c(F)c4)c3n2)nc1";"IC50";"'='";"9.3";"nM";"8.03";"";"270359";"UO_0000065";"17.60";"0.32";"4.31";"7.03";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643090";"";"0";"486.55";"0";"2.83";"BDBM115706";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C(C)=O)CC3)c(F)c2)c1C#Cc1ccc(N)nc1C";"IC50";"'='";"4.0";"nM";"8.40";"";"240343";"UO_0000065";"17.26";"0.32";"5.57";"7.97";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3650234";"";"0";"499.42";"0";"2.70";"BDBM136377";"CC(C)[C@H]1COC(=O)N1c1ccn2ncc(-c3ccc(-c4ncn(COP(=O)(O)O)n4)cc3)c2n1";"IC50";"'='";"12.3";"nM";"7.91";"";"270251";"UO_0000065";"15.84";"0.31";"5.21";"5.03";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653551";"";"0";"485.60";"0";"3.45";"BDBM136407";"CC(C)[C@H]1CN(CC2CCNCC2)C(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"20.4";"nM";"7.69";"";"270281";"UO_0000065";"15.84";"0.29";"4.24";"7.16";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653588";"";"0";"389.42";"0";"3.31";"BDBM136445";"CCC[C@H]1COC(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"6.4";"nM";"8.19";"";"270319";"UO_0000065";"21.04";"0.39";"4.88";"8.09";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653611";"";"0";"477.41";"0";"4.30";"BDBM136468";"O=C1OC[C@@H](c2ccc(F)cc2F)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"88.7";"nM";"7.05";"";"270342";"UO_0000065";"14.77";"0.28";"2.75";"6.96";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653623";"";"0";"459.42";"0";"4.16";"BDBM136480";"O=C1OC[C@H](c2ccccc2F)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"36.0";"nM";"7.44";"";"270354";"UO_0000065";"16.20";"0.30";"3.28";"7.35";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL4096248";"";"0";"446.51";"0";"4.32";"9n";"N#CCN1CCC(n2c(=O)cnc3cnc4ccc(-c5cnc6ccccc6c5)cc4c32)CC1";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"19.09";"0.34";"4.20";"9.72";"False";"CHEMBL4023016";"Inhibition of N-terminal FLAG-tagged recombinant human mTOR (1362 to end residues)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020823";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL4084564";"";"0";"422.53";"0";"3.87";"10d";"CCCn1cnc2c(N3CCOC[C@@H]3C)cc(-c3ccc(NC(=O)NCC)cc3)nc21";"IC50";"'='";"290.0";"nM";"6.54";"";"";"UO_0000065";"15.47";"0.29";"2.67";"7.75";"False";"CHEMBL4056088";"Inhibition of mTOR (unknown origin) by Kinase-Glo plus luminescence kinase assay or and ADP-Glo Plus luminescence kinase assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052688";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL4068688";"";"0";"438.53";"0";"3.11";"10g";"CCNC(=O)Nc1ccc(-c2cc(N3CCOC[C@@H]3C)c3ncn(CCOC)c3n2)cc1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL4056088";"Inhibition of mTOR (unknown origin) by Kinase-Glo plus luminescence kinase assay or and ADP-Glo Plus luminescence kinase assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052688";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL521851";"PICTILISIB";"2";"513.65";"1";"2.15";"1, GDC-0941";"CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL3371129";"Inhibition of mTOR (unknown origin) using poly (Glu, Tyr) 4:1 substrate incubated for 30 mins by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352345";"1";"Scientific Literature";"Eur. J. Med. Chem.";"2014";""
"CHEMBL4069454";"";"0";"436.56";"0";"4.26";"10e";"CCCCn1cnc2c(N3CCOC[C@@H]3C)cc(-c3ccc(NC(=O)NCC)cc3)nc21";"IC50";"'='";"425.0";"nM";"6.37";"";"";"UO_0000065";"14.60";"0.27";"2.11";"7.56";"False";"CHEMBL4056088";"Inhibition of mTOR (unknown origin) by Kinase-Glo plus luminescence kinase assay or and ADP-Glo Plus luminescence kinase assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052688";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL3908758";"";"0";"522.54";"1";"3.14";"BDBM222637";"COc1cnc(-c2ccc(NC(=O)Nc3ccc(N4CCOCC4=O)cc3)c(F)c2)nc1N1CCOCC1";"IC50";"'='";"49.5";"nM";"7.30";"";"389426";"UO_0000065";"13.98";"0.26";"4.17";"6.18";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3895669";"";"0";"497.58";"0";"3.43";"BDBM222643";"CCOc1cnc(-c2ccc(NC(=O)Nc3ccc(S(C)(=O)=O)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"30.1";"nM";"7.52";"";"389432";"UO_0000065";"15.12";"0.29";"4.09";"6.13";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3970265";"";"0";"499.00";"0";"4.10";"BDBM222589";"CSc1c(Cl)nc(-c2ccc(NC(=O)Nc3ccc(C(N)=O)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"74.4";"nM";"7.13";"";"389378";"UO_0000065";"14.29";"0.29";"3.03";"5.82";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3904646";"";"0";"518.57";"1";"3.11";"BDBM222557";"COc1c(C(=O)N2CCOCC2)nc(-c2ccc(NC(=O)Nc3ccccc3)cc2)nc1N1CCOCC1";"IC50";"'='";"102.3";"nM";"6.99";"";"389346";"UO_0000065";"13.48";"0.25";"3.88";"5.92";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3892534";"";"0";"448.48";"0";"2.73";"BDBM222601";"COc1cnc(-c2ccc(NC(=O)Nc3ccc(C(N)=O)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"47.7";"nM";"7.32";"";"389390";"UO_0000065";"16.33";"0.30";"4.59";"5.56";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3953862";"";"0";"465.54";"0";"4.04";"BDBM222609";"CSc1cnc(-c2ccc(NC(=O)Nc3ccc(C(=O)O)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"93.9";"nM";"7.03";"";"389398";"UO_0000065";"15.10";"0.29";"2.99";"6.02";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3946141";"";"0";"548.60";"1";"4.16";"BDBM222623";"CCOC(=O)c1nc(-c2ccc(NC(=O)Nc3ccc(NC(C)=O)cc3)cc2)nc(N2CCOCC2)c1OCC";"IC50";"'='";"86.0";"nM";"7.07";"";"389412";"UO_0000065";"12.88";"0.24";"2.91";"4.91";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3905285";"";"0";"590.64";"1";"3.56";"BDBM222569";"CCOC(=O)c1nc(-c2ccc(NC(=O)Nc3ccc(N4CCOCC4=O)cc3)cc2)nc(N2CCOCC2)c1OCC";"IC50";"'='";"11.5";"nM";"7.94";"";"389358";"UO_0000065";"13.44";"0.25";"4.38";"5.50";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL4092947";"";"0";"348.43";"0";"1.57";"11";"CC(=O)c1cc2nc(N3CCOCC3)nc(N3CCOCC3)c2s1";"IC50";"'>'";"2000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL3650230";"";"0";"422.45";"0";"4.48";"BDBM136373";"O=C1OC[C@H](c2ccccc2)N1c1ccn2ncc(-c3ccc(-c4ncc[nH]4)cc3)c2n1";"IC50";"'='";"2.5";"nM";"8.60";"";"270247";"UO_0000065";"20.36";"0.37";"4.12";"9.73";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3650237";"";"0";"403.45";"0";"3.47";"BDBM136380";"Cc1nnc(-c2ccc(-c3cnn4ccc(N5C(=O)OC[C@@H]5C(C)C)nc34)cc2)[nH]1";"IC50";"'='";"6.1";"nM";"8.21";"";"270254";"UO_0000065";"20.36";"0.37";"4.74";"8.11";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653532";"";"0";"399.46";"0";"3.63";"BDBM136388";"O=C1N[C@H]2CCCC[C@@H]2N1c1ccn2ncc(-c3ccc(-c4ncc[nH]4)cc3)c2n1";"IC50";"'='";"18.3";"nM";"7.74";"";"270262";"UO_0000065";"19.37";"0.35";"4.11";"8.48";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653533";"";"0";"461.53";"0";"2.41";"BDBM136389";"CC(C)[C@H]1CN(C[C@H](O)CO)C(=O)N1c1ccn2ncc(-c3ccc(-c4ncc[nH]4)cc3)c2n1";"IC50";"'='";"2.7";"nM";"8.57";"";"270263";"UO_0000065";"18.57";"0.34";"6.16";"6.97";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653571";"";"0";"433.47";"0";"2.63";"BDBM136428";"CC(C)[C@H]1COC(=O)N1c1ccn2ncc(-c3ccc(-c4ncnn4CCO)cc3)c2n1";"IC50";"'='";"2046.0";"nM";"5.69";"";"270302";"UO_0000065";"13.12";"0.24";"3.06";"5.14";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653589";"";"0";"437.46";"0";"3.75";"BDBM136446";"O=C1OC[C@H](Cc2ccccc2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"17.1";"nM";"7.77";"";"270320";"UO_0000065";"17.75";"0.32";"4.02";"7.67";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653619";"";"0";"424.42";"0";"3.27";"BDBM136476";"O=C1OC[C@@H](c2ccccn2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"495.0";"nM";"6.30";"";"270350";"UO_0000065";"14.86";"0.27";"3.04";"5.52";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3577918";"";"0";"413.48";"0";"3.20";"6d";"COc1ncc(-c2cc3c(-c4ccncc4)ncnc3s2)cc1NS(C)(=O)=O";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL3579762";"Inhibition of mTOR (unknown origin) using GFP-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3576869";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL3903978";"";"0";"422.51";"0";"3.25";"BDBM222631";"CSc1c(-c2ccncc2)nc(-c2ccc(NC(N)=O)cc2)nc1N1CCOCC1";"IC50";"'='";"79.6";"nM";"7.10";"";"389420";"UO_0000065";"16.80";"0.32";"3.85";"6.68";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3897508";"";"0";"617.71";"1";"2.81";"BDBM222654";"O=C(Nc1ccc(C(=O)N2CCOCC2)cc1)Nc1ccc(-c2ncc(OCCN3CCOCC3)c(N3CCOCC3)n2)cc1";"IC50";"'='";"110.9";"nM";"6.96";"";"389443";"UO_0000065";"11.26";"0.21";"4.15";"5.32";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3912522";"";"0";"499.60";"0";"4.80";"BDBM222661";"CSc1c(-c2cccnc2)nc(-c2ccc(NC(=O)Nc3cccnc3)cc2)nc1N1CCOCC1";"IC50";"'='";"75.1";"nM";"7.12";"";"389450";"UO_0000065";"14.26";"0.27";"2.32";"6.77";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3969114";"";"0";"450.57";"0";"3.91";"BDBM222667";"CCNC(=O)Nc1ccc(-c2nc(-c3ccncc3)c(SC)c(N3CCOCC3)n2)cc1";"IC50";"'='";"23.7";"nM";"7.62";"";"389456";"UO_0000065";"16.92";"0.33";"3.72";"8.26";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3921359";"";"0";"446.92";"0";"3.99";"BDBM222670";"CSc1c(Cl)nc(-c2ccc(NC(=O)Nc3ccon3)cc2)nc1N1CCOCC1";"IC50";"'='";"58.1";"nM";"7.24";"";"389459";"UO_0000065";"16.19";"0.33";"3.25";"6.86";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL4112797";"";"0";"395.47";"0";"1.87";"BDBM227486";"C[C@H]1COCCN1c1nc(N2CCOC[C@H]2C)c2nc(-c3ccccn3)[nH]c2n1";"IC50";"'='";"184.0";"nM";"6.74";"";"397245";"UO_0000065";"17.03";"0.32";"4.87";"7.30";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL3643161";"";"0";"461.95";"0";"3.50";"BDBM115777";"CCc1ncnc(-c2ccc(C(=O)NCC3(C)COC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"7.0";"nM";"8.15";"";"240414";"UO_0000065";"17.65";"0.34";"4.65";"7.92";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643158";"";"0";"524.03";"1";"4.09";"BDBM115774";"CCc1ncnc(-c2ccc(C(=O)N3CCN(c4ccncc4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"10.0";"nM";"8.00";"";"240411";"UO_0000065";"15.27";"0.29";"3.91";"7.91";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643162";"";"0";"537.07";"1";"4.69";"BDBM115778";"CCc1ncnc(-c2ccc(C(=O)N3CCN(Cc4ccccc4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"29.0";"nM";"7.54";"";"240415";"UO_0000065";"14.03";"0.26";"2.85";"8.54";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643167";"";"0";"516.63";"1";"1.77";"BDBM115808";"Cc1ncnc(-c2ccc(C(=O)N3CCN(C4CCS(=O)(=O)C4)CC3)cc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.0";"nM";"8.40";"";"240420";"UO_0000065";"16.26";"0.31";"6.63";"6.86";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643183";"";"0";"527.65";"1";"3.12";"BDBM115826";"CCc1ncnc(-c2ccc(C(=O)NC3CCN(C4CCN(C)CC4)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"7.0";"nM";"8.15";"";"240438";"UO_0000065";"15.46";"0.29";"5.03";"8.13";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643196";"";"0";"413.48";"0";"3.25";"BDBM115839";"CCc1ncnc(-c2ccc(C(=O)N3CCCCO3)cc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"13.0";"nM";"7.89";"";"240451";"UO_0000065";"19.07";"0.35";"4.64";"8.37";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643161";"";"0";"461.95";"0";"3.50";"BDBM115777";"CCc1ncnc(-c2ccc(C(=O)NCC3(C)COC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"6.99";"nM";"8.16";"";"240509";"UO_0000065";"17.65";"0.34";"4.66";"7.92";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643234";"";"0";"498.63";"0";"3.65";"BDBM115899";"CCCCN1CCN(C(=O)c2ccc(-c3ncnc(CC)c3C#Cc3ccc(N)nc3)cc2OC)CC1";"IC50";"'='";"4.52";"nM";"8.35";"";"240511";"UO_0000065";"16.74";"0.31";"4.69";"8.56";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645797";"";"0";"522.70";"1";"4.59";"BDBM115975";"CCc1ncnc(-c2ccc(C(=O)N3CCC(C4CCN(C)CC4)CC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"73.02";"nM";"7.14";"";"240587";"UO_0000065";"13.65";"0.25";"2.55";"8.09";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645823";"";"0";"486.49";"0";"2.61";"BDBM116001";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCn4cnnc4C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.89";"nM";"9.05";"";"240613";"UO_0000065";"18.60";"0.34";"6.44";"7.82";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643114";"";"0";"460.51";"0";"2.54";"BDBM115730";"CCc1ncnc(-c2ccc(C(=O)N3CCN(OC)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"9.0";"nM";"8.05";"";"240367";"UO_0000065";"17.47";"0.32";"5.51";"8.25";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643156";"";"0";"407.86";"0";"3.20";"BDBM115772";"CCc1ncnc(-c2ccc(C(=O)N(C)O)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"17.0";"nM";"7.77";"";"240409";"UO_0000065";"19.05";"0.37";"4.57";"7.38";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643164";"";"0";"456.55";"0";"2.23";"BDBM115805";"COCCN1CCN(C(=O)c2ccc(-c3ncnc(C)c3C#Cc3ccc(N)nc3)cc2)CC1";"IC50";"'='";"3.0";"nM";"8.52";"";"240417";"UO_0000065";"18.67";"0.34";"6.29";"8.74";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL1236962";"OMIPALISIB";"1";"505.51";"1";"4.84";"GSK-2126458";"COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"0.31";"nM";"9.51";"";"";"UO_0000065";"18.81";"0.36";"4.67";"8.89";"True";"CHEMBL3867034";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide as substrate after 1 hr in presence of ATP by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3865829";"1";"Scientific Literature";"Eur J Med Chem";"2016";""
"CHEMBL573339";"PI-103";"0";"348.36";"0";"2.98";"PI-103";"Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1";"IC50";"'='";"8.8";"nM";"8.06";"";"";"UO_0000065";"23.12";"0.42";"5.08";"9.53";"False";"CHEMBL3867034";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide as substrate after 1 hr in presence of ATP by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3865829";"1";"Scientific Literature";"Eur J Med Chem";"2016";""
"CHEMBL3640942";"";"0";"377.47";"0";"3.21";"BDBM115592";"CCc1ncnc(-c2ccc(S(C)(=O)=O)cc2)c1C#Cc1ccc(C)nc1";"IC50";"'='";"69.0";"nM";"7.16";"";"240229";"UO_0000065";"18.97";"0.36";"3.95";"9.84";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640944";"";"0";"388.45";"0";"3.65";"BDBM115594";"CCc1ncnc(-c2ccc(C(=O)N(C)C)c(F)c2)c1C#Cc1ccc(C)nc1";"IC50";"'='";"19.0";"nM";"7.72";"";"240231";"UO_0000065";"19.88";"0.36";"4.07";"13.09";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645839";"";"0";"468.54";"0";"2.61";"BDBM116017";"C#CCN1CCN(C(=O)c2ccc(-c3ncnc(CC)c3C#Cc3ccc(N)nc3)cc2F)CC1";"IC50";"'='";"2.49";"nM";"8.60";"";"240629";"UO_0000065";"18.36";"0.34";"5.99";"9.75";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645840";"";"0";"465.48";"0";"4.09";"BDBM116018";"CCc1ncnc(-c2ccc(C(=O)N3CCC(F)(F)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"21.06";"nM";"7.68";"";"240630";"UO_0000065";"16.49";"0.31";"3.59";"9.03";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645847";"";"0";"483.47";"0";"4.23";"BDBM116025";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCC(F)(F)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"18.75";"nM";"7.73";"";"240637";"UO_0000065";"15.98";"0.30";"3.50";"9.09";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640969";"";"0";"399.50";"0";"3.57";"BDBM115619";"CCc1ncnc(-c2cccc(C(=O)N(CC)CC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"109.0";"nM";"6.96";"";"240256";"UO_0000065";"17.43";"0.32";"3.39";"8.19";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645955";"";"0";"490.97";"0";"3.26";"BDBM116135";"CCc1ncnc(-c2cc(F)c(C(=O)N3CC4(CN(C)C4)C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.54";"nM";"8.26";"";"240747";"UO_0000065";"16.82";"0.32";"5.00";"9.36";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640971";"";"0";"431.47";"0";"2.69";"BDBM115621";"CCc1ncnc(-c2ccc(F)c(C(=O)N3CCOCC3)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"31.0";"nM";"7.51";"";"240258";"UO_0000065";"17.40";"0.32";"4.82";"7.97";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640988";"";"0";"484.58";"0";"3.45";"BDBM115638";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C4CC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1C";"IC50";"'='";"4.0";"nM";"8.40";"";"240275";"UO_0000065";"17.33";"0.32";"4.95";"9.52";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3641023";"";"0";"482.59";"0";"3.01";"BDBM115674";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C4CC4)CC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"240311";"UO_0000065";"18.03";"0.33";"5.69";"8.92";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643061";"";"0";"526.64";"1";"3.03";"BDBM115676";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C4CCOCC4)CC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.0";"nM";"9.00";"";"240313";"UO_0000065";"17.09";"0.32";"5.97";"8.43";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643094";"";"0";"548.64";"1";"2.17";"BDBM115710";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C4CCS(=O)(=O)C4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.0";"nM";"8.40";"";"240347";"UO_0000065";"15.31";"0.29";"6.23";"6.86";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643108";"";"0";"472.57";"0";"3.39";"BDBM115724";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N(C)C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"16.0";"nM";"7.80";"";"240361";"UO_0000065";"16.50";"0.30";"4.41";"8.83";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643140";"";"0";"445.50";"0";"2.82";"BDBM115756";"CCc1ncnc(-c2ccc(C(=O)N3CCC[C@H]3CO)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"240393";"UO_0000065";"19.13";"0.35";"5.70";"8.10";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643142";"";"0";"505.02";"1";"3.22";"BDBM115758";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C(C)(C)O)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.0";"nM";"8.30";"";"240395";"UO_0000065";"16.44";"0.31";"5.08";"7.65";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643166";"";"0";"452.56";"0";"3.14";"BDBM115807";"Cc1ncnc(-c2ccc(C(=O)N3CCN4CCCCC4C3)cc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"17.0";"nM";"7.77";"";"240419";"UO_0000065";"17.17";"0.31";"4.63";"8.81";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL4088969";"";"0";"549.63";"1";"4.06";"(S)-C8";"COc1ncc(-c2ccc3ncn([C@H]4CCN(CC5CC5)C4)c(=O)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1";"IC50";"'='";"114.0";"nM";"6.94";"";"";"UO_0000065";"12.63";"0.24";"2.88";"6.52";"False";"CHEMBL4000385";"Inhibition of mTOR (unknown origin) using L-alpha-phosphatidylinositol as substrate after 40 mins by ATP depletion assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4000150";"1";"Scientific Literature";"Bioorg Med Chem";"2015";""
"CHEMBL4286023";"";"0";"467.51";"0";"3.78";"14";"CCOC(=O)C1=C(CSc2nc3cc([N+](=O)[O-])ccc3[nH]2)N(C)C(=O)NC1c1ccccc1";"IC50";"'='";"720.0";"nM";"6.14";"";"";"UO_0000065";"13.14";"0.25";"2.36";"4.71";"False";"CHEMBL4272807";"Inhibition of mTOR (unknown origin) incubated for 1 hr by ELISA";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4270553";"1";"Scientific Literature";"Eur J Med Chem";"2018";""
"CHEMBL4071702";"";"0";"454.60";"0";"3.42";"12b";"C[C@H]1CN(c2nc(N3CCOCC3)c3sc(C(O)Cc4ccccc4)cc3n2)C[C@@H](C)O1";"IC50";"'>'";"2000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL4068220";"";"0";"426.55";"0";"2.79";"14g";"C[C@H]1CN(c2nc(N3CCOCC3)c3sc(-c4ccc(N)nc4)cc3n2)C[C@@H](C)O1";"IC50";"'='";"70.0";"nM";"7.16";"";"";"UO_0000065";"16.77";"0.33";"4.36";"7.98";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL4062102";"";"0";"416.57";"0";"3.87";"14m";"C[C@H]1CN(c2nc(N3CCOCC3)c3sc(-c4ccsc4)cc3n2)C[C@@H](C)O1";"IC50";"'>'";"2000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL2322239";"";"0";"313.38";"0";"3.36";"26";"O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)csc12";"IC50";"'='";"610.0";"nM";"6.21";"";"";"UO_0000065";"19.83";"0.39";"2.85";"14.56";"False";"CHEMBL2330617";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2321770";"1";"Scientific Literature";"J. Med. Chem.";"2013";""
"CHEMBL4291436";"";"0";"442.55";"0";"2.12";"21";"CNc1nc2ccccc2n1-c1nc(N2CCOC[C@H]2C)cc(C2(S(C)(=O)=O)CC2)n1";"IC50";"'='";"1500.0";"nM";"5.82";"";"";"UO_0000065";"13.16";"0.26";"3.70";"5.70";"False";"CHEMBL4269701";"Inhibition of mTOR in human MDA-MB-468 cells assessed as decrease in 70S6K S235/236 phosphorylation";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MDA-MB-468";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4266018";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL2087490";"";"0";"487.59";"1";"0.07";"30";"CCS(=O)(=O)N1CCN(Cc2cn3cc(-c4cnc(N)nc4)nc(N4CCOCC4)c3n2)CC1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL2092092";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2086238";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2087491";"";"0";"552.46";"2";"0.44";"31";"CS(=O)(=O)N1CCN(Cc2nc3c(N4CCOCC4)nc(-c4cnc(N)nc4)cn3c2Br)CC1";"IC50";"'='";"5100.0";"nM";"5.29";"";"";"UO_0000065";"9.58";"0.21";"4.85";"3.92";"False";"CHEMBL2092092";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2086238";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL4087892";"";"0";"450.57";"0";"3.68";"14j";"C[C@H]1CN(c2nc(N3CCOCC3)c3sc(-c4cccc5[nH]ncc45)cc3n2)C[C@@H](C)O1";"IC50";"'>'";"2000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL4101802";"";"0";"400.51";"0";"2.53";"14r";"C[C@H]1CN(c2nc(N3CCOCC3)c3sc(-c4cn[nH]c4)cc3n2)C[C@@H](C)O1";"IC50";"'='";"427.0";"nM";"6.37";"";"";"UO_0000065";"15.90";"0.31";"3.84";"8.02";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL3586386";"";"0";"420.48";"0";"2.21";"10";"Cc1nc(-c2nc[nH]n2)ccc1-c1cnc2c(n1)N(CCC1CCOCC1)CC(=O)N2";"IC50";"'='";"90.0";"nM";"7.05";"";"";"UO_0000065";"16.76";"0.31";"4.84";"5.78";"False";"CHEMBL3587521";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585264";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL1539483";"";"0";"474.57";"1";"6.11";"5";"c1ccc(-c2c(-c3ccccc3)n(Cc3ccco3)c3ncnc(NCCCn4ccnc4)c23)cc1";"IC50";"'='";"54100.0";"nM";"4.27";"";"";"UO_0000065";"8.99";"0.16";"-1.84";"5.79";"False";"CHEMBL3116603";"Inhibition of mTOR (unknown origin) by KINOMEscan assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112406";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL3112866";"";"0";"354.41";"0";"1.13";"28, SAR260301";"C[C@H]1Cc2ccccc2N1C(=O)Cc1nc(N2CCOCC2)cc(=O)[nH]1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3119734";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3112424";"1";"Scientific Literature";"J. Med. Chem.";"2014";""
"CHEMBL3407730";"";"0";"451.46";"0";"2.78";"III";"O=C(O)c1ccc2occ(/C=N/Nc3nc(N4CCOCC4)c4ccsc4n3)c(=O)c2c1";"IC50";"'='";"160.0";"nM";"6.80";"";"";"UO_0000065";"15.05";"0.29";"4.02";"5.22";"False";"CHEMBL3815304";"Inhibition of mTOR (unknown origin) using ULight4E-BP1 peptide as substrate incubated for 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3813678";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2016";""
"CHEMBL4239931";"";"0";"395.42";"0";"1.13";"3b";"COc1ccc(-c2ccc3c(N4CCOCC4)nc(C(N)=O)nc3n2)cc1CO";"IC50";"'='";"48.0";"nM";"7.32";"";"";"UO_0000065";"18.51";"0.34";"6.19";"5.92";"False";"CHEMBL4233142";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide substrate measured after 1 hr by Lance Ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4229417";"1";"Scientific Literature";"Bioorg Med Chem";"2018";""
"CHEMBL521851";"PICTILISIB";"2";"513.65";"1";"2.15";"Pictilisib";"CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1";"IC50";"'='";"580.0";"nM";"6.24";"";"";"UO_0000065";"12.14";"0.24";"4.09";"5.80";"False";"CHEMBL3815304";"Inhibition of mTOR (unknown origin) using ULight4E-BP1 peptide as substrate incubated for 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3813678";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2016";""
"CHEMBL3984611";"";"0";"538.61";"1";"3.85";"BDBM222626";"CSc1cnc(-c2ccc(NC(=O)Nc3ccc(N4CCOCC4=O)cc3)cc2F)nc1N1CCOCC1";"IC50";"'='";"133.2";"nM";"6.88";"";"389415";"UO_0000065";"12.77";"0.25";"3.03";"6.31";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3932615";"";"0";"553.04";"1";"3.79";"BDBM222640";"CSc1c(Cl)nc(-c2ccc(NC(=O)Nc3ccc(S(N)(=O)=O)cc3)cc2F)nc1N1CCOCC1";"IC50";"'='";"136.93";"nM";"6.86";"";"389429";"UO_0000065";"12.41";"0.26";"3.07";"4.92";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3938111";"";"0";"610.18";"2";"5.17";"BDBM222646";"CSc1c(Cl)nc(-c2ccc(NC(=O)Nc3ccc(C(=O)N4CCC(N(C)C)CC4)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"69.4";"nM";"7.16";"";"389435";"UO_0000065";"11.73";"0.23";"1.99";"6.95";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3940430";"";"0";"477.53";"0";"3.38";"BDBM222648";"CCOc1cnc(-c2ccc(NC(=O)Nc3ccc(NC(C)=O)nc3)cc2)nc1N1CCOCC1";"IC50";"'='";"39.0";"nM";"7.41";"";"389437";"UO_0000065";"15.52";"0.29";"4.03";"5.67";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL1236962";"OMIPALISIB";"1";"505.51";"1";"4.84";"GSK2126458";"COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"0.3";"nM";"9.52";"";"";"UO_0000065";"18.84";"0.36";"4.68";"8.90";"False";"CHEMBL3766570";"Inhibition of mTOR kinase (unknown origin) assessed as suppression of ULight-4E-BP1 substrate phosphorylation incubated for 1 hr by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3763019";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2016";""
"CHEMBL3651966";"";"0";"440.47";"1";"5.04";"8; PIM447";"C[C@@H]1C[C@H](N)C[C@H](c2ccncc2NC(=O)c2ccc(F)c(-c3c(F)cccc3F)n2)C1";"IC50";"'>'";"9100.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3749778";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3745712";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL4210320";"";"0";"417.41";"0";"1.52";"1";"CS(=O)(=O)Cc1cc(-c2cnc(N)cc2C(F)(F)F)nc(N2CCOCC2)n1";"IC50";"'='";"13980.0";"nM";"4.85";"";"";"UO_0000065";"11.63";"0.24";"3.33";"4.36";"False";"CHEMBL4199839";"Inhibition of recombinant human GST-tagged mTOR catalytic domain (1360 to 2549 residues) expressed in baculovirus expression system using GFP-4EBP1 as substrate measured after 1 hr by Lathascreen method";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4196123";"1";"Scientific Literature";"ACS Med Chem Lett";"2018";""
"CHEMBL4211915";"";"0";"407.47";"0";"1.52";"26";"C[C@H]1COCCN1c1nc(-c2cnc(N)cc2F)cc(C2(S(C)(=O)=O)CC2)n1";"IC50";"'='";"186.0";"nM";"6.73";"";"";"UO_0000065";"16.52";"0.33";"5.21";"6.05";"False";"CHEMBL4199839";"Inhibition of recombinant human GST-tagged mTOR catalytic domain (1360 to 2549 residues) expressed in baculovirus expression system using GFP-4EBP1 as substrate measured after 1 hr by Lathascreen method";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4196123";"1";"Scientific Literature";"ACS Med Chem Lett";"2018";""
"CHEMBL3109141";"";"0";"456.51";"0";"3.66";"13b";"O=C(Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1)Nc1cccc(CO)c1";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"19.71";"0.36";"5.34";"8.00";"True";"CHEMBL3112126";"Inhibition of mTOR (unknown origin) after 2 hrs by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3108735";"1";"Scientific Literature";"J. Med. Chem.";"2014";""
"CHEMBL3648329";"";"0";"441.56";"0";"2.75";"35";"CNc1nc2ccccc2n1-c1nc(N2CCOC[C@H]2C)cc(C2([S@](C)(=N)=O)CC2)n1";"IC50";"'='";"9800.0";"nM";"5.01";"";"";"UO_0000065";"11.34";"0.22";"2.26";"4.59";"False";"CHEMBL4269700";"Inhibition of mTOR in human MDA-MB-468 cells assessed as decrease in AKT phosphorylation at S473 residue";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MDA-MB-468";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4266018";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL2325697";"";"0";"412.52";"0";"2.88";"1; AZ20";"C[C@@H]1COCCN1c1cc(C2(S(C)(=O)=O)CC2)nc(-c2cccc3[nH]ccc23)n1";"IC50";"'='";"720.0";"nM";"6.14";"";"";"UO_0000065";"14.89";"0.29";"3.26";"6.97";"False";"CHEMBL4269701";"Inhibition of mTOR in human MDA-MB-468 cells assessed as decrease in 70S6K S235/236 phosphorylation";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MDA-MB-468";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4266018";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL1879463";"DACTOLISIB";"2";"469.55";"1";"5.89";"1; BEZ-235";"Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21";"IC50";"'='";"21.0";"nM";"7.68";"";"";"UO_0000065";"16.35";"0.29";"1.79";"10.04";"True";"CHEMBL3784491";"Inhibition of human mTOR using ULight-4E-BP1 peptide as substrate after 1 hr by Lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3779897";"1";"Scientific Literature";"MedChemComm";"2016";""
"CHEMBL4211308";"";"0";"480.58";"0";"2.63";"12a";"CNc1ncc2c(-c3ccc(N4CCNCC4)cc3)nn(Cc3cn(Cc4ccccc4)nn3)c2n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4188979";"Inhibition of wild-type human partial length MTOR (L1382 to W2549 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4184298";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL3913555";"";"0";"394.40";"0";"0.66";"17";"Nc1noc2ccc(-c3nn(CC(=O)N4CCOCC4)c4ncnc(N)c34)cc12";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3882339";"Inhibition of recombinant human GST-tagged mTOR (1360 to 2549 residues) catalytic domain assessed as inhibition of GFP labeled 4EBP1 phosphorylation measured after 1 hr by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3882246";"38";"Patent Bioactivity Data";"";"2010";""
"CHEMBL3962632";"";"0";"309.33";"0";"2.38";"4";"CC(C)n1nc(-c2ccc3nc(N)oc3c2)c2c(N)ncnc21";"IC50";"'<'";"1000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3882339";"Inhibition of recombinant human GST-tagged mTOR (1360 to 2549 residues) catalytic domain assessed as inhibition of GFP labeled 4EBP1 phosphorylation measured after 1 hr by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3882246";"38";"Patent Bioactivity Data";"";"2010";""
"CHEMBL3925171";"";"0";"434.50";"0";"2.61";"6";"Nc1nc2cc(-c3nn(C4CCC(N5CCOCC5)CC4)c4ncnc(N)c34)ccc2o1";"IC50";"'<'";"100.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3882339";"Inhibition of recombinant human GST-tagged mTOR (1360 to 2549 residues) catalytic domain assessed as inhibition of GFP labeled 4EBP1 phosphorylation measured after 1 hr by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3882246";"38";"Patent Bioactivity Data";"";"2010";""
"CHEMBL3653644";"";"0";"475.87";"0";"4.67";"BDBM136501";"O=C1OC[C@H](c2cccc(Cl)c2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"1.6";"nM";"8.80";"";"270375";"UO_0000065";"18.48";"0.35";"4.13";"8.68";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL4251185";"";"0";"450.54";"0";"3.31";"3m";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(C4CCOCC4)nc3n2)cc1CO";"IC50";"'='";"53.0";"nM";"7.28";"";"";"UO_0000065";"16.15";"0.30";"3.97";"8.10";"False";"CHEMBL4233142";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide substrate measured after 1 hr by Lance Ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4229417";"1";"Scientific Literature";"Bioorg Med Chem";"2018";""
"CHEMBL4240170";"";"0";"380.45";"0";"2.73";"3h";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(C)nc3n2)cc1CO";"IC50";"'='";"95.0";"nM";"7.02";"";"";"UO_0000065";"18.46";"0.34";"4.29";"8.71";"False";"CHEMBL4233142";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide substrate measured after 1 hr by Lance Ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4229417";"1";"Scientific Literature";"Bioorg Med Chem";"2018";""
"CHEMBL573339";"PI-103";"0";"348.36";"0";"2.98";"PI-103";"Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1";"IC50";"'='";"16.0";"nM";"7.80";"";"";"UO_0000065";"22.38";"0.41";"4.82";"9.22";"True";"CHEMBL3738862";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide as substrate after 1 hr by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3734757";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2015";""
"CHEMBL4064622";"";"0";"380.45";"0";"2.61";"10a";"CCNC(=O)Nc1ccc(-c2cc(N3CCOCC3)c3ncn(C)c3n2)cc1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL4056088";"Inhibition of mTOR (unknown origin) by Kinase-Glo plus luminescence kinase assay or and ADP-Glo Plus luminescence kinase assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052688";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL4090667";"";"0";"422.53";"0";"3.79";"10n";"CCNC(=O)Nc1ccc(-c2cc(N3CCOC[C@@H]3C)c3nc(C)n(CC)c3n2)cc1";"IC50";"'='";"330.0";"nM";"6.48";"";"";"UO_0000065";"15.34";"0.29";"2.69";"7.69";"False";"CHEMBL4056088";"Inhibition of mTOR (unknown origin) by Kinase-Glo plus luminescence kinase assay or and ADP-Glo Plus luminescence kinase assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052688";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL4096679";"";"0";"438.53";"0";"3.46";"10f";"CCNC(=O)Nc1ccc(-c2cc(N3CCOC[C@@H]3C)c3ncn(COCC)c3n2)cc1";"IC50";"'='";"403.0";"nM";"6.39";"";"";"UO_0000065";"14.58";"0.27";"2.93";"6.84";"False";"CHEMBL4056088";"Inhibition of mTOR (unknown origin) by Kinase-Glo plus luminescence kinase assay or and ADP-Glo Plus luminescence kinase assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052688";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL4059467";"";"0";"479.63";"0";"3.81";"10j";"CCNC(=O)Nc1ccc(-c2cc(N3CCOC[C@@H]3C)c3ncn(CCN(CC)CC)c3n2)cc1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL4056088";"Inhibition of mTOR (unknown origin) by Kinase-Glo plus luminescence kinase assay or and ADP-Glo Plus luminescence kinase assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052688";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL3670251";"";"0";"448.57";"0";"2.27";"BDBM111727";"CCc1ncnc(N2CCC3(CCN(C(=O)COC)CC3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"32.0";"nM";"7.50";"";"232550";"UO_0000065";"16.71";"0.31";"5.22";"7.69";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670257";"";"0";"350.47";"0";"1.95";"BDBM111733";"CCc1ncnc(N2CCN(C(C)C)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"91.0";"nM";"7.04";"";"232556";"UO_0000065";"20.09";"0.37";"5.09";"9.89";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL4073531";"";"0";"408.51";"0";"3.31";"10m";"CCNC(=O)Nc1ccc(-c2cc(N3CCOC[C@@H]3C)c3nc(C)n(C)c3n2)cc1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL4056088";"Inhibition of mTOR (unknown origin) by Kinase-Glo plus luminescence kinase assay or and ADP-Glo Plus luminescence kinase assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052688";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL1879463";"DACTOLISIB";"2";"469.55";"1";"5.89";"1; NVP-BEZ235";"Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21";"IC50";"'='";"21.0";"nM";"7.68";"";"";"UO_0000065";"16.35";"0.29";"1.79";"10.04";"True";"CHEMBL3868759";"Inhibition of mTOR (unknown origin) expressed in baculovirus after 60 mins by kinase-glo assay";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3868583";"1";"Scientific Literature";"Eur J Med Chem";"2016";""
"CHEMBL3650235";"";"0";"405.42";"0";"3.01";"BDBM136378";"CC(C)[C@H]1COC(=O)N1c1ccn2ncc(-c3ccc(-c4nnc(N)o4)cc3)c2n1";"IC50";"'='";"6.5";"nM";"8.19";"";"270252";"UO_0000065";"20.19";"0.37";"5.18";"6.57";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3650236";"";"0";"421.49";"0";"3.48";"BDBM136379";"CC(C)[C@H]1COC(=O)N1c1ccn2ncc(-c3ccc(-c4nnc(N)s4)cc3)c2n1";"IC50";"'='";"6.6";"nM";"8.18";"";"270253";"UO_0000065";"19.41";"0.37";"4.70";"7.33";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653575";"";"0";"415.34";"0";"3.07";"BDBM136432";"O=C1OC(C(F)(F)F)CN1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"56.7";"nM";"7.25";"";"270306";"UO_0000065";"17.45";"0.33";"4.18";"7.15";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653586";"";"0";"531.64";"1";"4.46";"BDBM136443";"CC(C)[C@H]1CN(C[C@H]2CCCN2C(C)C)C(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"14.0";"nM";"7.85";"";"270317";"UO_0000065";"14.77";"0.28";"3.39";"7.97";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653649";"";"0";"457.43";"0";"3.87";"BDBM136506";"Nc1nnc(-c2ccc(-c3cnn4ccc(N5C(=O)OC[C@@H]5c5ccc(F)cc5)nc34)cc2)o1";"IC50";"'='";"4.5";"nM";"8.35";"";"270380";"UO_0000065";"18.25";"0.34";"4.48";"6.70";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653652";"";"0";"474.43";"0";"3.56";"BDBM136510";"Cn1ncnc1-c1ccc(-c2cnn3ccc(N4C(=O)OC[C@@H]4c4ccc(F)cn4)nc23)cc1F";"IC50";"'='";"859.0";"nM";"6.07";"";"270384";"UO_0000065";"12.79";"0.24";"2.51";"5.87";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3670250";"";"0";"418.55";"0";"2.64";"BDBM111726";"CCc1ncnc(N2CCC3(CCN(C(C)=O)CC3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"30.0";"nM";"7.52";"";"232549";"UO_0000065";"17.97";"0.33";"4.88";"8.53";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670266";"";"0";"428.56";"0";"0.97";"BDBM111742";"CCc1ncnc(N2CCN(CCCS(C)(=O)=O)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"25.0";"nM";"7.60";"";"232565";"UO_0000065";"17.74";"0.35";"6.63";"7.22";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670271";"";"0";"366.47";"0";"0.92";"BDBM111747";"CCc1ncnc(N2CCN(CC(C)O)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"51.0";"nM";"7.29";"";"232570";"UO_0000065";"19.90";"0.37";"6.37";"7.98";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670274";"";"0";"385.48";"0";"2.14";"BDBM111750";"CCc1ncnc(N2CCN(c3cccnc3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"14.0";"nM";"7.85";"";"232573";"UO_0000065";"20.37";"0.37";"5.71";"9.34";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3653541";"";"0";"446.52";"0";"2.83";"BDBM136397";"CC(C)[C@H]1CN(CCCO)C(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"8.3";"nM";"8.08";"";"270271";"UO_0000065";"18.10";"0.33";"5.25";"6.99";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653556";"";"0";"499.62";"0";"3.93";"BDBM136412";"CCN1CCC(N2C[C@H](C(C)C)N(c3ccn4ncc(-c5ccc(-c6nc[nH]n6)cc5)c4n3)C2=O)CC1";"IC50";"'='";"59.1";"nM";"7.23";"";"270286";"UO_0000065";"14.47";"0.27";"3.30";"7.33";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653557";"";"0";"471.57";"0";"3.20";"BDBM136413";"CC(C)[C@H]1CN(C[C@H]2CCCN2)C(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"40.6";"nM";"7.39";"";"270287";"UO_0000065";"15.67";"0.29";"4.19";"6.89";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653581";"";"0";"424.42";"0";"3.27";"BDBM136438";"O=C1OCC(c2ccccn2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"49.2";"nM";"7.31";"";"270312";"UO_0000065";"17.22";"0.31";"4.04";"6.40";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653599";"";"0";"456.44";"0";"3.72";"BDBM136456";"Cc1cccc([C@H]2COC(=O)N2c2ccn3ncc(-c4ccc(-c5nc[nH]n5)c(F)c4)c3n2)n1";"IC50";"'='";"3.4";"nM";"8.47";"";"270330";"UO_0000065";"18.55";"0.34";"4.75";"7.42";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653612";"";"0";"459.42";"0";"4.16";"BDBM136469";"O=C1OC[C@@H](c2ccc(F)c(F)c2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"593.0";"nM";"6.23";"";"270343";"UO_0000065";"13.55";"0.25";"2.07";"6.15";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653625";"";"0";"459.42";"0";"4.16";"BDBM136482";"O=C1OC[C@H](c2cccc(F)c2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"1.3";"nM";"8.89";"";"270356";"UO_0000065";"19.34";"0.36";"4.73";"8.77";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653626";"";"0";"442.41";"0";"3.41";"BDBM136483";"O=C1OC[C@H](c2ccc(F)cn2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"2.7";"nM";"8.57";"";"270357";"UO_0000065";"19.37";"0.35";"5.16";"7.50";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653630";"";"0";"471.45";"0";"4.03";"BDBM136487";"COc1ccccc1[C@H]1COC(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"1.7";"nM";"8.77";"";"270361";"UO_0000065";"18.60";"0.34";"4.74";"7.93";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653635";"";"0";"456.44";"0";"3.72";"BDBM136492";"Cc1ccnc([C@H]2COC(=O)N2c2ccn3ncc(-c4ccc(-c5nc[nH]n5)c(F)c4)c3n2)c1";"IC50";"'='";"10.8";"nM";"7.97";"";"270366";"UO_0000065";"17.45";"0.32";"4.25";"6.98";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL4246481";"";"0";"454.53";"0";"2.58";"3g";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(CC(OC)OC)nc3n2)cc1CO";"IC50";"'='";"29.0";"nM";"7.54";"";"";"UO_0000065";"16.58";"0.31";"4.96";"7.61";"False";"CHEMBL4233142";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide substrate measured after 1 hr by Lance Ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4229417";"1";"Scientific Literature";"Bioorg Med Chem";"2018";""
"CHEMBL4238656";"";"0";"422.53";"0";"3.72";"3j";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(C(C)(C)C)nc3n2)cc1CO";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"20.59";"0.38";"4.98";"10.79";"False";"CHEMBL4233142";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide substrate measured after 1 hr by Lance Ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4229417";"1";"Scientific Literature";"Bioorg Med Chem";"2018";""
"CHEMBL4066648";"";"0";"410.54";"0";"3.81";"14a";"C[C@H]1CN(c2nc(N3CCOCC3)c3sc(-c4ccccc4)cc3n2)C[C@@H](C)O1";"IC50";"'>'";"2000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL2332032";"";"0";"670.18";"3";"-1.03";"12";"O=P(O)(O)O[C@@H]1[C@H](OP(=O)(O)O)[C@@H](OP(=O)(O)O)[C@H](OP(=O)(O)O)[C@@H](OP(=O)(O)O)[C@@H]1OCc1ccccc1";"IC50";"'='";"1300.0";"nM";"5.89";"";"";"UO_0000065";"8.78";"0.21";"6.92";"1.72";"False";"CHEMBL2343763";"Inhibition of MTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331244";"1";"Scientific Literature";"J. Med. Chem.";"2013";""
"CHEMBL3984896";"";"0";"577.66";"1";"4.88";"BDBM178252";"CC[C@H]1COCCN1c1nc2c(c(-c3ccc(NC(=O)Nc4ccc(C)nc4)c(F)c3)n1)C(=O)N(CC)CC(C)(C)O2";"IC50";"'='";"122.0";"nM";"6.91";"";"324272";"UO_0000065";"11.97";"0.22";"2.03";"5.68";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3969786";"";"0";"484.53";"0";"2.64";"BDBM178261";"CNC(=O)Nc1ccc(-c2nc(N3C4CCC3COC4)nc3c2C(=O)N(C)CC(C)(C)O3)cc1F";"IC50";"'='";"26.0";"nM";"7.58";"";"324281";"UO_0000065";"15.65";"0.30";"4.95";"6.96";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3920568";"";"0";"546.63";"1";"3.52";"BDBM178330";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccnn4C)cc3)c2C1=O";"IC50";"'='";"147.0";"nM";"6.83";"";"324350";"UO_0000065";"12.50";"0.23";"3.31";"5.39";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3911954";"";"0";"540.60";"1";"2.80";"BDBM178352";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)NC4COC4)c(F)c3)c2C1=O";"IC50";"'='";"29.0";"nM";"7.54";"";"324372";"UO_0000065";"13.94";"0.26";"4.74";"6.38";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3932628";"";"0";"574.64";"1";"3.59";"BDBM178361";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(OC)nn4)cc3)c2C1=O";"IC50";"'='";"35.0";"nM";"7.46";"";"324381";"UO_0000065";"12.97";"0.24";"3.87";"5.18";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3908213";"";"0";"564.62";"1";"3.88";"BDBM178382";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4cnc(C)cn4)c(F)c3)c2C1=O";"IC50";"'='";"62.0";"nM";"7.21";"";"324402";"UO_0000065";"12.77";"0.24";"3.33";"5.35";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3944480";"";"0";"561.64";"1";"4.05";"BDBM178399";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4cc(OC)ccn4)cc3)c2C1=O";"IC50";"'='";"12.0";"nM";"7.92";"";"324419";"UO_0000065";"14.10";"0.26";"3.87";"6.04";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3979520";"";"0";"498.56";"0";"3.03";"BDBM178422";"CCN1CC(C)(C)Oc2nc(N3C4CCC3COC4)nc(-c3ccc(NC(=O)NC)c(F)c3)c2C1=O";"IC50";"'='";"18.0";"nM";"7.75";"";"324442";"UO_0000065";"15.53";"0.29";"4.71";"7.11";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3933002";"";"0";"658.80";"1";"4.28";"BDBM178430";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccc(C(=O)N(C)CCN(C)C)cc4)cc3)c2C1=O";"IC50";"'='";"48.0";"nM";"7.32";"";"324450";"UO_0000065";"11.11";"0.21";"3.04";"5.52";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3976753";"";"0";"529.57";"1";"2.82";"BDBM178437";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)OCCO)c(F)c3)c2C1=O";"IC50";"'='";"123.0";"nM";"6.91";"";"324457";"UO_0000065";"13.05";"0.25";"4.09";"5.47";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3904381";"";"0";"561.64";"1";"4.05";"BDBM178388";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccc(OC)cn4)cc3)c2C1=O";"IC50";"'='";"12.0";"nM";"7.92";"";"324408";"UO_0000065";"14.10";"0.26";"3.87";"6.04";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3981934";"";"0";"579.63";"1";"4.19";"BDBM178396";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4cc(OC)ccn4)c(F)c3)c2C1=O";"IC50";"'='";"74.0";"nM";"7.13";"";"324416";"UO_0000065";"12.30";"0.23";"2.94";"5.44";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3941599";"";"0";"647.71";"2";"3.55";"BDBM178448";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4cnc(N5CCOCC5)cn4)c(F)c3)c2C1=O";"IC50";"'='";"68.0";"nM";"7.17";"";"324468";"UO_0000065";"11.07";"0.21";"3.62";"4.87";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3894647";"";"0";"658.73";"1";"4.87";"BDBM178459";"CN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Oc4ccc(N5CC6CCC(C5)O6)cc4)c(F)c3)c2C1=O";"IC50";"'='";"60.0";"nM";"7.22";"";"324479";"UO_0000065";"10.96";"0.21";"2.35";"6.09";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3982081";"";"0";"662.77";"1";"4.80";"BDBM178463";"CC[C@H]1COCCN1c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOC[C@@H]4C)nc4c3C(=O)N(CC)CC(C)(C)O4)cc2F)cn1";"IC50";"'='";"68.0";"nM";"7.17";"";"324483";"UO_0000065";"10.81";"0.20";"2.37";"5.34";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3892946";"";"0";"674.78";"1";"4.94";"BDBM178464";"CC[C@H]1COCCN1c1ccc(NC(=O)Nc2ccc(-c3nc(N4C5CCC4COC5)nc4c3C(=O)N(CC)CC(C)(C)O4)cc2F)cn1";"IC50";"'='";"365.0";"nM";"6.44";"";"324484";"UO_0000065";"9.54";"0.18";"1.50";"4.79";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3894665";"";"0";"672.76";"1";"4.69";"BDBM178475";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccnc(N5CC6CCC(C5)O6)c4)c(F)c3)c2C1=O";"IC50";"'='";"174.0";"nM";"6.76";"";"324495";"UO_0000065";"10.05";"0.19";"2.07";"5.03";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL4166594";"";"0";"571.61";"1";"4.69";"37";"CNc1nc(C)c2cc(-c3cnc(OC)c(NS(=O)(=O)c4ccc(F)cc4F)c3)cc(OC3CCOCC3)c2n1";"IC50";"'='";"43.0";"nM";"7.37";"";"";"UO_0000065";"12.89";"0.25";"2.68";"5.91";"False";"CHEMBL4150392";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide as substrate after 30 mins by Lance Ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4145625";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL3954271";"";"0";"674.78";"1";"4.80";"BDBM178237";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(OC5CCN(C)CC5)nc4)c(F)c3)c2C1=O";"IC50";"'='";"76.0";"nM";"7.12";"";"324257";"UO_0000065";"10.55";"0.20";"2.32";"5.30";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3963046";"";"0";"466.54";"0";"2.51";"BDBM178258";"CNC(=O)Nc1ccc(-c2nc(N3C4CCC3COC4)nc3c2C(=O)N(C)CC(C)(C)O3)cc1";"IC50";"'='";"27.0";"nM";"7.57";"";"324278";"UO_0000065";"16.22";"0.30";"5.06";"6.95";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3948113";"";"0";"498.56";"0";"3.03";"BDBM178262";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)NC)cc3F)c2C1=O";"IC50";"'='";"34.0";"nM";"7.47";"";"324282";"UO_0000065";"14.98";"0.28";"4.44";"6.86";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3951769";"";"0";"561.62";"1";"4.24";"BDBM178275";"Cc1cc(NC(=O)Nc2ccc(-c3nc(N4CC5CCC(C4)O5)nc4c3C(=O)N(C)CC(C)(C)O4)cc2F)ccn1";"IC50";"'='";"58.0";"nM";"7.24";"";"324295";"UO_0000065";"12.89";"0.24";"3.00";"5.94";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3939461";"";"0";"512.59";"1";"3.42";"BDBM178365";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)NC4CC4)c(F)c3)c2C1=O";"IC50";"'='";"40.0";"nM";"7.40";"";"324385";"UO_0000065";"14.43";"0.27";"3.98";"6.79";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3952325";"";"0";"617.71";"2";"3.27";"BDBM178447";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4cnc(N5CCOCC5)cn4)cc3)c2C1=O";"IC50";"'='";"32.0";"nM";"7.50";"";"324467";"UO_0000065";"12.13";"0.23";"4.22";"5.09";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL4060108";"";"0";"427.53";"0";"2.18";"14i";"C[C@H]1CN(c2nc(N3CCOCC3)c3sc(-c4cnc(N)nc4)cc3n2)C[C@@H](C)O1";"IC50";"'='";"424.0";"nM";"6.37";"";"";"UO_0000065";"14.91";"0.29";"4.19";"6.22";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL4066144";"";"0";"350.40";"0";"1.06";"9";"O=C(O)c1cc2nc(N3CCOCC3)nc(N3CCOCC3)c2s1";"IC50";"'>'";"2000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL3975159";"";"0";"510.64";"1";"3.78";"BDBM178324";"CCNC(=O)Nc1ccc(-c2nc(N3C[C@H](C)O[C@H](C)C3)nc3c2C(=O)N(CC)CC(C)(C)CO3)cc1";"IC50";"'='";"7770.0";"nM";"5.11";"";"324344";"UO_0000065";"10.01";"0.19";"1.33";"4.69";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3897756";"";"0";"647.76";"1";"3.93";"BDBM178386";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccc(N5CCN(C)CC5)nc4)c(F)c3)c2C1=O";"IC50";"'='";"37.0";"nM";"7.43";"";"324406";"UO_0000065";"11.47";"0.22";"3.50";"5.79";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3899980";"";"0";"628.73";"1";"3.75";"BDBM178287";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(N5CCC(O)C5)cn4)cc3)c2C1=O";"IC50";"'='";"23.0";"nM";"7.64";"";"324307";"UO_0000065";"12.15";"0.23";"3.89";"5.26";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3914396";"";"0";"392.42";"0";"1.98";"7";"CC(=O)N1CCC(n2nc(-c3ccc4oc(N)nc4c3)c3c(N)ncnc32)CC1";"IC50";"'<'";"100.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3882339";"Inhibition of recombinant human GST-tagged mTOR (1360 to 2549 residues) catalytic domain assessed as inhibition of GFP labeled 4EBP1 phosphorylation measured after 1 hr by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3882246";"38";"Patent Bioactivity Data";"";"2010";""
"CHEMBL3919788";"";"0";"604.69";"1";"4.39";"BDBM178293";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccnc(N(C)C)c4)c(F)c3)c2C1=O";"IC50";"'='";"90.0";"nM";"7.05";"";"324313";"UO_0000065";"11.65";"0.22";"2.66";"5.63";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3670267";"";"0";"421.51";"0";"0.99";"BDBM111743";"CCc1ncnc(N2CCN(C(=O)N3CCOCC3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"22.0";"nM";"7.66";"";"232566";"UO_0000065";"18.17";"0.34";"6.67";"7.60";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670180";"";"0";"375.40";"0";"3.19";"BDBM111654";"CCc1ncnc(N2CCC(C(F)(F)F)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"9.0";"nM";"8.05";"";"232477";"UO_0000065";"21.43";"0.41";"4.86";"11.84";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670192";"";"0";"336.40";"0";"0.74";"BDBM111667";"CCc1ncnc(N2CCNC(=O)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"14.0";"nM";"7.85";"";"232490";"UO_0000065";"23.35";"0.43";"7.11";"8.09";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670207";"";"0";"322.41";"0";"2.10";"BDBM111683";"CCc1ncnc(N2CCC(O)CC2)c1C#Cc1ccc(C)nc1";"IC50";"'='";"141.0";"nM";"6.85";"";"232506";"UO_0000065";"21.25";"0.39";"4.75";"11.02";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670147";"";"0";"308.39";"0";"0.91";"BDBM111621";"Cc1ncnc(N2CCN(C)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"56.0";"nM";"7.25";"";"232444";"UO_0000065";"23.52";"0.43";"6.34";"10.19";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670148";"";"0";"323.40";"0";"1.78";"BDBM111622";"Cc1ncnc(N2C[C@H](C)O[C@H](C)C2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"11.0";"nM";"7.96";"";"232445";"UO_0000065";"24.61";"0.45";"6.18";"10.31";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670153";"";"0";"379.51";"0";"2.79";"BDBM111627";"CCc1ncnc(N2CCC(CC(C)(C)O)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"9.0";"nM";"8.05";"";"232450";"UO_0000065";"21.20";"0.39";"5.26";"9.13";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670155";"";"0";"399.50";"0";"2.90";"BDBM111629";"CCc1ncnc(N2CCC(O)(c3ccccc3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"7.0";"nM";"8.15";"";"232452";"UO_0000065";"20.41";"0.37";"5.25";"9.25";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670157";"";"0";"351.45";"0";"2.01";"BDBM111631";"CCc1ncnc(N2CCC(CCO)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.0";"nM";"8.30";"";"232454";"UO_0000065";"23.62";"0.44";"6.29";"9.42";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670241";"";"0";"413.49";"0";"1.77";"BDBM111717";"CCc1ncnc(N2CCN(C(=O)c3ccccn3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"90.0";"nM";"7.05";"";"232540";"UO_0000065";"17.04";"0.31";"5.28";"6.97";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670172";"";"0";"350.47";"0";"2.88";"BDBM111646";"CCc1ncnc(N2CCC(O)(CC)CC2)c1C#Cc1ccc(C)nc1";"IC50";"'='";"51.0";"nM";"7.29";"";"232469";"UO_0000065";"20.81";"0.38";"4.41";"11.74";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670179";"";"0";"350.43";"0";"1.08";"BDBM111653";"CCc1ncnc(N2CCN(C(C)=O)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"32.0";"nM";"7.50";"";"232476";"UO_0000065";"21.39";"0.39";"6.41";"8.49";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3736275";"";"0";"436.52";"0";"4.78";"9e";"CNC(=O)c1cnc2ccc(-c3ccc(N)nc3)cc2c1Nc1ccc(C(C)(C)C#N)cc1";"IC50";"'='";"280.0";"nM";"6.55";"";"";"UO_0000065";"15.01";"0.27";"1.77";"5.61";"False";"CHEMBL3738862";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide as substrate after 1 hr by lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3734757";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2015";""
"CHEMBL3670170";"";"0";"390.41";"0";"3.04";"BDBM111644";"CCc1ncnc(N2CCC(O)(C(F)(F)F)CC2)c1C#Cc1ccc(C)nc1";"IC50";"'='";"37.0";"nM";"7.43";"";"232467";"UO_0000065";"19.04";"0.36";"4.39";"11.96";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670218";"";"0";"380.50";"0";"1.31";"BDBM111694";"CCc1ncnc(N2CCN(CC(C)(C)O)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"7.0";"nM";"8.15";"";"232517";"UO_0000065";"21.43";"0.40";"6.84";"8.92";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670232";"";"0";"421.55";"0";"1.45";"BDBM111708";"Cc1ncnc(N2CCC(CC(=O)NCCN(C)C)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"261.0";"nM";"6.58";"";"232531";"UO_0000065";"15.62";"0.29";"5.13";"6.57";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670242";"";"0";"375.44";"0";"0.98";"BDBM111718";"CCc1ncnc(N2CCN(C(=O)CC#N)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"91.0";"nM";"7.04";"";"232541";"UO_0000065";"18.75";"0.34";"6.06";"6.28";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3911008";"";"0";"464.55";"0";"3.45";"BDBM222594";"CSc1cnc(-c2ccc(NC(=O)Nc3ccc(C(N)=O)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"109.1";"nM";"6.96";"";"389383";"UO_0000065";"14.99";"0.29";"3.51";"5.68";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3936961";"";"0";"518.57";"1";"3.39";"BDBM222612";"CCOc1cnc(-c2ccc(NC(=O)Nc3ccc(N4CCOCC4=O)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"24.8";"nM";"7.61";"";"389401";"UO_0000065";"14.67";"0.27";"4.22";"6.44";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3903006";"";"0";"547.62";"1";"2.43";"BDBM222656";"NC(=O)c1ccc(NC(=O)Nc2ccc(-c3ncc(OCCN4CCOCC4)c(N4CCOCC4)n3)cc2)cc1";"IC50";"'='";"119.3";"nM";"6.92";"";"389445";"UO_0000065";"12.64";"0.24";"4.49";"4.80";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3966107";"";"0";"605.70";"1";"3.49";"BDBM222599";"CCOC(=O)c1nc(-c2ccc(NC(=O)Nc3ccc(C(=O)NCCN(C)C)cc3)cc2)nc(N2CCOCC2)c1OCC";"IC50";"'='";"78.3";"nM";"7.11";"";"389388";"UO_0000065";"11.73";"0.22";"3.62";"4.83";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL4280989";"";"0";"433.45";"0";"2.44";"10";"COc1ncc(-c2ccc3nccc(=O)n3c2)cc1NS(=O)(=O)c1ccc(C#N)cc1";"IC50";"'='";"245.7";"nM";"6.61";"";"";"UO_0000065";"15.25";"0.29";"4.17";"5.23";"False";"CHEMBL4255944";"Inhibition of mTOR in human MCF7 cells assessed as reduction in P70S6K phosphorylation after 4 hrs by ADP-Glo assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MCF7";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4251704";"1";"Scientific Literature";"ACS Med Chem Lett";"2018";""
"CHEMBL3960662";"";"0";"461.57";"0";"3.63";"64";"CN(C)CCCOc1ccc(-c2ccc3ncc4c(c3c2)n(C2CCOCC2)c(=O)n4C)cn1";"IC50";"'='";"610.0";"nM";"6.21";"";"";"UO_0000065";"13.46";"0.25";"2.58";"8.35";"False";"CHEMBL4153812";"Inhibition of m-TOR in human MDA-MB-468 cells assessed as decrease in AKT phosphorylation at Ser 473 after 2 hrs by immunofluorescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MDA-MB-468";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4152224";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL4102513";"";"0";"408.51";"0";"3.49";"10c";"CCCn1cnc2c(N3CCOCC3)cc(-c3ccc(NC(=O)NCC)cc3)nc21";"IC50";"'='";"399.0";"nM";"6.40";"";"";"UO_0000065";"15.66";"0.29";"2.91";"7.59";"False";"CHEMBL4056088";"Inhibition of mTOR (unknown origin) by Kinase-Glo plus luminescence kinase assay or and ADP-Glo Plus luminescence kinase assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052688";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL2325697";"";"0";"412.52";"0";"2.88";"1; AZ20";"C[C@@H]1COCCN1c1cc(C2(S(C)(=O)=O)CC2)nc(-c2cccc3[nH]ccc23)n1";"IC50";"'='";"38.0";"nM";"7.42";"";"";"UO_0000065";"17.99";"0.35";"4.54";"8.41";"False";"CHEMBL4269699";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4266018";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL4079746";"";"0";"411.47";"0";"2.75";"9m";"N#CCN1CCC(n2c(=O)cnc3cnc4ccc(-c5ccc(N)nc5)cc4c32)CC1";"IC50";"'='";"7.0";"nM";"8.15";"";"";"UO_0000065";"19.82";"0.36";"5.40";"7.17";"False";"CHEMBL4023016";"Inhibition of N-terminal FLAG-tagged recombinant human mTOR (1362 to end residues)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020823";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL4093606";"";"0";"453.43";"0";"3.50";"9x";"N#CCN1CCC(n2c(=O)cnc3cnc4cc(F)c(-c5cnn(C(F)F)c5)cc4c32)CC1";"IC50";"'='";"56.0";"nM";"7.25";"";"";"UO_0000065";"15.99";"0.30";"3.75";"7.83";"False";"CHEMBL4023016";"Inhibition of N-terminal FLAG-tagged recombinant human mTOR (1362 to end residues)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020823";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL3109142";"";"0";"456.51";"0";"3.66";"A; 13c";"O=C(Nc1ccc(CO)cc1)Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1";"IC50";"'='";"5.0";"nM";"8.30";"";"";"UO_0000065";"18.18";"0.33";"4.64";"7.38";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL3653540";"";"0";"402.46";"0";"3.08";"BDBM136396";"CC(C)[C@H]1CN(C)C(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"9.4";"nM";"8.03";"";"270270";"UO_0000065";"19.94";"0.37";"4.95";"8.42";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653562";"";"0";"462.51";"0";"1.80";"BDBM136418";"CC(C)[C@H]1CN(C[C@@H](O)CO)C(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"11.5";"nM";"7.94";"";"270292";"UO_0000065";"17.17";"0.32";"6.14";"5.85";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3639524";"";"0";"447.46";"0";"2.72";"BDBM136426";"CC(C)[C@H]1COC(=O)N1c1ccn2ncc(-c3ccc(-c4ncn(CC(=O)O)n4)cc3)c2n1";"IC50";"'='";"279.0";"nM";"6.55";"";"270300";"UO_0000065";"14.65";"0.27";"3.83";"5.13";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646448";"";"0";"359.39";"0";"3.43";"BDBM125290";"CC(=O)Nc1ccc(Nc2ncccc2-c2nc(C)nc3[nH]cnc23)cc1";"IC50";"'='";"35.0";"nM";"7.46";"";"255002";"UO_0000065";"20.75";"0.38";"4.03";"6.87";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646463";"";"0";"393.46";"0";"2.36";"BDBM125305";"COc1ccc(Nc2nc(N3CCCCC3)ncc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255023";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646464";"";"0";"387.41";"0";"2.43";"BDBM125306";"COc1ccc(Nc2nc(-c3ccncc3)ncc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255024";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646467";"";"0";"367.80";"0";"3.52";"BDBM125309";"COc1ccc(Nc2ncc(Cl)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255027";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2170095";"";"0";"486.56";"1";"0.44";"BDBM50396813";"COc1ncc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"1138.0";"nM";"5.94";"";"255106";"UO_0000065";"12.22";"0.24";"5.50";"3.60";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653568";"";"0";"403.45";"0";"3.47";"BDBM136424";"Cc1cc(-c2nc[nH]n2)ccc1-c1cnn2ccc(N3C(=O)OC[C@@H]3C(C)C)nc12";"IC50";"'='";"19.2";"nM";"7.72";"";"270298";"UO_0000065";"19.13";"0.35";"4.25";"7.62";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653583";"";"0";"441.43";"0";"4.02";"BDBM136440";"O=C1OC[C@H](c2ccccc2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"2.0";"nM";"8.70";"";"270314";"UO_0000065";"19.71";"0.36";"4.68";"8.59";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653585";"";"0";"489.56";"0";"3.34";"BDBM136442";"CC(C)[C@H]1CN(C[C@H]2CCCN2)C(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"11.0";"nM";"7.96";"";"270316";"UO_0000065";"16.26";"0.30";"4.62";"7.41";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653609";"";"0";"433.45";"0";"3.84";"BDBM136466";"O=C1OC[C@H](C2CCCC2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"1.7";"nM";"8.77";"";"270340";"UO_0000065";"20.23";"0.37";"4.93";"8.66";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653615";"";"0";"477.41";"0";"4.30";"BDBM136472";"O=C1OC[C@H](c2ccc(F)c(F)c2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"0.87";"nM";"9.06";"";"270346";"UO_0000065";"18.98";"0.35";"4.76";"8.94";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653622";"";"0";"441.43";"0";"4.02";"BDBM136479";"O=C1OC[C@H](c2ccc(F)cc2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"2.3";"nM";"8.64";"";"270353";"UO_0000065";"19.57";"0.36";"4.62";"8.53";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653629";"";"0";"460.40";"0";"3.55";"BDBM136486";"O=C1OC[C@@H](c2ccc(F)cn2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"12.6";"nM";"7.90";"";"270360";"UO_0000065";"17.16";"0.32";"4.35";"6.92";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653655";"";"0";"552.42";"2";"2.95";"BDBM136513";"O=C1OC[C@H](c2ccccn2)N1c1ccn2ncc(-c3ccc(-c4ncn(COP(=O)(O)O)n4)c(F)c3)c2n1";"IC50";"'='";"36.9";"nM";"7.43";"";"270387";"UO_0000065";"13.46";"0.26";"4.48";"4.37";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649475";"";"0";"486.56";"0";"3.44";"BDBM125514";"Cc1nc(-c2cc(Cc3ccc(S(C)(=O)=O)cc3)cnc2Nc2ccc(N)nc2)c2nc[nH]c2n1";"IC50";"'='";"84.0";"nM";"7.08";"";"255006";"UO_0000065";"14.54";"0.28";"3.64";"4.64";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646452";"";"0";"317.36";"0";"3.05";"BDBM125294";"Cc1nc(N)cc(-c2cnccc2Nc2cccc3[nH]ncc23)n1";"IC50";"'>'";"50000.0";"nM";"";"";"255007";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646453";"";"0";"358.41";"0";"4.03";"BDBM125295";"CC(=O)Nc1cc(-c2cnccc2Nc2cccc3[nH]ccc23)nc(C)n1";"IC50";"'>'";"50000.0";"nM";"";"";"255008";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165040";"";"0";"328.34";"0";"3.03";"BDBM50394880";"c1cnc(Nc2cccc3n[nH]cc23)c(-c2ncnc3nc[nH]c23)c1";"IC50";"'>'";"50000.0";"nM";"";"";"254933";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643926";"";"0";"331.38";"0";"3.36";"BDBM125239";"Cc1cnc(Nc2cccc3[nH]ccc23)c(-c2nc(C)nc(N)n2)c1";"IC50";"'='";"6992.0";"nM";"5.16";"";"254957";"UO_0000065";"15.56";"0.28";"1.80";"4.89";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165037";"";"0";"342.37";"0";"3.34";"BDBM50394883";"Cc1nc(-c2cccnc2Nc2cccc3n[nH]cc23)c2[nH]cnc2n1";"IC50";"'='";"534.0";"nM";"6.27";"";"254965";"UO_0000065";"18.32";"0.33";"2.93";"5.80";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL573339";"PI-103";"0";"348.36";"0";"2.98";"PI-103";"Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1";"IC50";"'='";"31.0";"nM";"7.51";"";"";"UO_0000065";"21.55";"0.39";"4.53";"8.88";"False";"CHEMBL4009793";"Inhibition of human N-terminal FLAG-tagged mTOR (1362-end residues) in presence of [gamma33P]ATP after 40 mins";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4007445";"1";"Scientific Literature";"Eur J Med Chem";"2017";""
"CHEMBL3667417";"";"0";"381.44";"0";"2.00";"BDBM150989";"Oc1cccc(-c2cc3c(N4CCOCC4)nc(N4CCOCC4)nc3[nH]2)c1";"IC50";"'='";"40.0";"nM";"7.40";"";"290536";"UO_0000065";"19.39";"0.36";"5.40";"8.53";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL3667434";"";"0";"419.49";"0";"2.56";"BDBM151007";"C[C@@H]1COCCN1c1nc(N2CCOCC2)nc2[nH]c(-c3cccc4[nH]ccc34)nc12";"IC50";"'='";"6.0";"nM";"8.22";"";"290553";"UO_0000065";"19.60";"0.36";"5.66";"8.64";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688994";"";"0";"434.54";"0";"2.60";"BDBM174475";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(CN)c3)nc2n1";"IC50";"'='";"27.0";"nM";"7.57";"";"319776";"UO_0000065";"17.42";"0.32";"4.97";"8.44";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688997";"";"0";"448.57";"0";"2.86";"BDBM174478";"CNCc1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"9.1";"nM";"8.04";"";"319779";"UO_0000065";"17.93";"0.33";"5.18";"10.63";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689019";"";"0";"508.64";"1";"4.12";"BDBM174501";"CC(C)N(C)Cc1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccc1F";"IC50";"'='";"220.0";"nM";"6.66";"";"319802";"UO_0000065";"13.09";"0.25";"2.54";"9.96";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3650233";"";"0";"403.45";"0";"3.47";"BDBM136376";"Cc1cc(-c2cnn3ccc(N4C(=O)OC[C@@H]4C(C)C)nc23)ccc1-c1nc[nH]n1";"IC50";"'='";"15.9";"nM";"7.80";"";"270250";"UO_0000065";"19.33";"0.36";"4.33";"7.70";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653539";"";"0";"388.44";"0";"2.74";"BDBM136395";"CC(C)[C@H]1CNC(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"4.7";"nM";"8.33";"";"270269";"UO_0000065";"21.44";"0.39";"5.59";"8.00";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653544";"";"0";"503.59";"1";"3.49";"BDBM136400";"CC(C)[C@H]1CN(CCN2CC[C@H](F)C2)C(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"19.4";"nM";"7.71";"";"270274";"UO_0000065";"15.31";"0.28";"4.22";"7.83";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653553";"";"0";"513.65";"1";"4.18";"BDBM136409";"CC(C)[C@H]1CN(CCC2CCCN(C)C2)C(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"72.7";"nM";"7.14";"";"270283";"UO_0000065";"13.90";"0.26";"2.96";"7.24";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653567";"";"0";"531.64";"1";"4.32";"BDBM136423";"CCN1CCC(CN2CC(C(C)C)N(c3ccn4ncc(-c5ccc(-c6nc[nH]n6)c(F)c5)c4n3)C2=O)CC1";"IC50";"'='";"21.5";"nM";"7.67";"";"270297";"UO_0000065";"14.42";"0.27";"3.35";"7.78";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653592";"";"0";"419.42";"0";"3.45";"BDBM136449";"O=C1OC[C@H](CC2CC2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"2.3";"nM";"8.64";"";"270323";"UO_0000065";"20.60";"0.38";"5.19";"8.53";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653600";"";"0";"456.44";"0";"3.72";"BDBM136457";"Cc1ccc([C@H]2COC(=O)N2c2ccn3ncc(-c4ccc(-c5nc[nH]n5)c(F)c4)c3n2)cn1";"IC50";"'='";"21.3";"nM";"7.67";"";"270331";"UO_0000065";"16.81";"0.31";"3.95";"6.72";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653614";"";"0";"437.46";"0";"4.05";"BDBM136471";"C[C@]1(c2ccccc2)COC(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"12.2";"nM";"7.91";"";"270345";"UO_0000065";"18.09";"0.33";"3.86";"7.81";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653651";"";"0";"570.41";"2";"3.09";"BDBM136508";"O=C1OC[C@H](c2ccc(F)cn2)N1c1ccn2ncc(-c3ccc(-c4ncn(COP(=O)(O)O)n4)c(F)c3)c2n1";"IC50";"'='";"11.3";"nM";"7.95";"";"270382";"UO_0000065";"13.93";"0.27";"4.86";"4.67";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3904568";"";"0";"436.54";"0";"3.52";"BDBM222668";"CNC(=O)Nc1ccc(-c2nc(-c3ccncc3)c(SC)c(N3CCOCC3)n2)cc1";"IC50";"'='";"25.1";"nM";"7.60";"";"389457";"UO_0000065";"17.41";"0.33";"4.08";"8.24";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3975395";"";"0";"505.58";"1";"2.73";"BDBM222669";"O=C(Nc1ccncc1)Nc1ccc(-c2ncc(OCCN3CCOCC3)c(N3CCOCC3)n2)cc1";"IC50";"'='";"169.3";"nM";"6.77";"";"389458";"UO_0000065";"13.39";"0.25";"4.04";"5.94";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL4215969";"";"0";"443.45";"0";"2.01";"6";"CS(=O)(=O)C1(c2cc(-c3cnc(N)cc3C(F)(F)F)nc(N3CCOCC3)n2)CC1";"IC50";"'='";"1680.0";"nM";"5.78";"";"";"UO_0000065";"13.02";"0.26";"3.76";"5.19";"False";"CHEMBL4199839";"Inhibition of recombinant human GST-tagged mTOR catalytic domain (1360 to 2549 residues) expressed in baculovirus expression system using GFP-4EBP1 as substrate measured after 1 hr by Lathascreen method";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4196123";"1";"Scientific Literature";"ACS Med Chem Lett";"2018";""
"CHEMBL3911465";"";"0";"460.42";"1";"5.96";"BDBM213777";"[C-]#[N+]c1ccc(-c2ccc3ncc4c(c3n2)N(c2cccc(C(F)(F)F)c2)C(=O)N(C)C4)cn1";"IC50";"'='";"24.0";"nM";"7.62";"";"375944";"UO_0000065";"16.55";"0.31";"1.66";"11.44";"False";"CHEMBL3888153";"mTOR Activity Assay: 1. Preparation of test reagents {circle around (1)} 1x kinase buffer (50 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 3 mM MnCl, 0.01% Tween-20, 2 mM DTT); {circle around (2)} 4x kinase solution (added mTOR kinase to 1x kinase buffer to provide 4x kinase solution with a final concentration of 2.5 nM); {circle around (3)} 2x substrate solution (added the substrates of 4EBP1 and ATP into 1x kinase buffer to provide 2x substrate solution with 4EBP1 final concentration of 50 nM and ATP final concentration of 10.8 uM); {circle around (4)} 4x test substance solutions (100x test substance solutions with different concentration gradients were prepared using 100% DMSO, and diluted 25-fold with 1x kinase buffer to give 4x test substance solutions with different concentration gradients) {circle around (5)} preparation of test solution (test solution containing EDTA and 4EBP1 phosphorylated antibody was prepared using activity test kit with assay buffer, the final concentration of EDTA was 8 mM, and the final concentration of 4EBP1 phosphorylated antibody was 2 nM) 2. 2.5 uL of 4x test solution was added to a 384-well plate in parallel; 3. added 2.54 uL of 4x kinase solution and incubated for 10 min; 4. then added 5 uL of 2x solutions of 4EBP1 and ATP substrates and incubated for 1 h at room temperature; 5. finally, added 10 uL of test solution to quench the reaction, and read after 60 min; 6. IC50 value was obtained via curve fitting.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886601";"37";"BindingDB Database";"";"2016";""
"CHEMBL4217549";"";"0";"478.60";"0";"3.35";"12";"C[C@H](Nc1c(C(N)=O)nnc2ccc(-c3ccc(OCCCN(C)C)nc3)cc12)C1CCOCC1";"IC50";"'>'";"15000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4200478";"Inhibition of mTOR in human MDA-MB-231 cells assessed as reduction in AKT phosphorylation at Ser473 residue after 2 hrs by fluorescence assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MDA-MB-231";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4196159";"1";"Scientific Literature";"ACS Med Chem Lett";"2018";""
"CHEMBL3693387";"";"0";"558.69";"1";"3.21";"BDBM174523";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CNCCc1cnc[nH]1";"IC50";"'='";"49.0";"nM";"7.31";"";"319824";"UO_0000065";"13.08";"0.24";"4.10";"6.44";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3648329";"";"0";"441.56";"0";"2.75";"35";"CNc1nc2ccccc2n1-c1nc(N2CCOC[C@H]2C)cc(C2([S@](C)(=N)=O)CC2)n1";"IC50";"'='";"150.0";"nM";"6.82";"";"";"UO_0000065";"15.45";"0.30";"4.07";"6.26";"False";"CHEMBL4269699";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4266018";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL4166144";"";"0";"557.58";"1";"4.23";"19";"COc1ncc(-c2cc(OC3CCOCC3)c3nc(N)nc(C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"7.9";"nM";"8.10";"";"";"UO_0000065";"14.53";"0.28";"3.87";"5.85";"False";"CHEMBL4150392";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide as substrate after 30 mins by Lance Ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4145625";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL3781549";"";"0";"593.05";"2";"6.58";"17";"CC(=O)Nc1cnc2ccc(-c3cnc4ccccc4c3)cc2c1Nc1ccc(N2CCNCC2)c(C(F)(F)F)c1.Cl";"IC50";"'='";"22.0";"nM";"7.66";"";"";"UO_0000065";"13.76";"0.26";"1.08";"9.32";"False";"CHEMBL3784491";"Inhibition of human mTOR using ULight-4E-BP1 peptide as substrate after 1 hr by Lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3779897";"1";"Scientific Literature";"MedChemComm";"2016";""
"CHEMBL3781247";"";"0";"640.71";"2";"7.87";"26";"CC(=O)N1CCN(c2ccc(Nc3c(NC(=O)C(C)(C)C)cnc4ccc(-c5cnc6ccccc6c5)cc34)cc2C(F)(F)F)CC1";"IC50";"'='";"36.0";"nM";"7.44";"";"";"UO_0000065";"11.62";"0.22";"-0.43";"8.23";"False";"CHEMBL3784491";"Inhibition of human mTOR using ULight-4E-BP1 peptide as substrate after 1 hr by Lance ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3779897";"1";"Scientific Literature";"MedChemComm";"2016";""
"CHEMBL4294612";"";"0";"444.42";"0";"2.84";"17";"COc1ncc(-c2ccc3nccc(=O)n3c2)cc1NS(=O)(=O)c1cc(F)ccc1F";"IC50";"'='";"108.5";"nM";"6.96";"";"";"UO_0000065";"15.67";"0.31";"4.12";"6.78";"False";"CHEMBL4255944";"Inhibition of mTOR in human MCF7 cells assessed as reduction in P70S6K phosphorylation after 4 hrs by ADP-Glo assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MCF7";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4251704";"1";"Scientific Literature";"ACS Med Chem Lett";"2018";""
"CHEMBL4291436";"";"0";"442.55";"0";"2.12";"21";"CNc1nc2ccccc2n1-c1nc(N2CCOC[C@H]2C)cc(C2(S(C)(=O)=O)CC2)n1";"IC50";"'='";"52.0";"nM";"7.28";"";"";"UO_0000065";"16.46";"0.32";"5.16";"7.12";"False";"CHEMBL4269699";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4266018";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL3586390";"";"0";"343.39";"0";"1.17";"22";"COCCN1CC(=O)Nc2ncc(-c3ccc(C(C)(C)O)nc3)nc21";"IC50";"'='";"436.0";"nM";"6.36";"";"";"UO_0000065";"18.52";"0.35";"5.19";"6.33";"False";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL1236962";"OMIPALISIB";"1";"505.51";"1";"4.84";"Omipalisib";"COc1ncc(-c2ccc3nccc(-c4ccnnc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"0.68";"nM";"9.17";"";"";"UO_0000065";"18.14";"0.35";"4.33";"8.57";"False";"CHEMBL4255949";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1(Thr37/46) peptide as substrate measured after 2 hrs by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4251704";"1";"Scientific Literature";"ACS Med Chem Lett";"2018";""
"CHEMBL4284400";"";"0";"444.42";"0";"2.84";"4";"COc1ncc(-c2ccc3nccc(=O)n3c2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"19.2";"nM";"7.72";"";"";"UO_0000065";"17.36";"0.34";"4.88";"7.52";"False";"CHEMBL4255949";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1(Thr37/46) peptide as substrate measured after 2 hrs by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4251704";"1";"Scientific Literature";"ACS Med Chem Lett";"2018";""
"CHEMBL4281223";"";"0";"408.44";"0";"2.57";"7";"COc1ncc(-c2ccc3nccc(=O)n3c2)cc1NS(=O)(=O)c1ccccc1";"IC50";"'='";"197.9";"nM";"6.70";"";"";"UO_0000065";"16.41";"0.32";"4.13";"6.53";"False";"CHEMBL4255944";"Inhibition of mTOR in human MCF7 cells assessed as reduction in P70S6K phosphorylation after 4 hrs by ADP-Glo assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MCF7";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4251704";"1";"Scientific Literature";"ACS Med Chem Lett";"2018";""
"CHEMBL3586393";"";"0";"369.43";"0";"1.70";"25";"CC(C)(O)c1ccc(-c2cnc3c(n2)N(C2CCOCC2)C(=O)CN3)cn1";"IC50";"'='";"168.0";"nM";"6.78";"";"";"UO_0000065";"18.34";"0.34";"5.07";"6.74";"False";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3586385";"";"0";"406.45";"0";"1.90";"17";"O=C1CN(CCC2CCOCC2)c2nc(-c3ccc(-c4nc[nH]n4)nc3)cnc2N1";"IC50";"'='";"18.0";"nM";"7.75";"";"";"UO_0000065";"19.05";"0.35";"5.84";"6.36";"False";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3905605";"";"0";"646.72";"1";"4.16";"BDBM178288";"C[C@H]1COCCN1c1ccc(NC(=O)Nc2ccc(-c3nc(N4CC5CCC(C4)O5)nc4c3C(=O)N(C)CC(C)(C)O4)cc2F)cn1";"IC50";"'='";"71.0";"nM";"7.15";"";"324308";"UO_0000065";"11.05";"0.21";"2.99";"5.32";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3902096";"";"0";"512.59";"1";"3.42";"BDBM178325";"CCNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)nc3c2C(=O)N(CC)CC(C)(C)O3)cc1F";"IC50";"'='";"45.0";"nM";"7.35";"";"324345";"UO_0000065";"14.33";"0.27";"3.93";"6.75";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3984147";"";"0";"496.61";"0";"3.53";"BDBM178329";"CCNC(=O)Nc1ccc(-c2nc(N3C[C@H](C)O[C@H](C)C3)nc3c2C(=O)N(CC)CC(C)(C)O3)cc1";"IC50";"'='";"1220.0";"nM";"5.91";"";"324349";"UO_0000065";"11.91";"0.22";"2.38";"5.43";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL4291436";"";"0";"442.55";"0";"2.12";"21";"CNc1nc2ccccc2n1-c1nc(N2CCOC[C@H]2C)cc(C2(S(C)(=O)=O)CC2)n1";"IC50";"'='";"4000.0";"nM";"5.40";"";"";"UO_0000065";"12.20";"0.24";"3.28";"5.28";"False";"CHEMBL4269700";"Inhibition of mTOR in human MDA-MB-468 cells assessed as decrease in AKT phosphorylation at S473 residue";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MDA-MB-468";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4266018";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL3646539";"";"0";"462.47";"1";"0.37";"BDBM125390";"COc1ccc(Nc2ncc(CN3CC4(C3)NC(=O)NC4=O)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255121";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL1879463";"DACTOLISIB";"2";"469.55";"1";"5.89";"Dactolisib";"Cn1c(=O)n(-c2ccc(C(C)(C)C#N)cc2)c2c3cc(-c4cnc5ccccc5c4)ccc3ncc21";"IC50";"'='";"6.0";"nM";"8.22";"";"";"UO_0000065";"17.51";"0.31";"2.33";"10.75";"False";"CHEMBL4235179";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4229497";"1";"Scientific Literature";"Bioorg Med Chem";"2018";""
"CHEMBL3688949";"";"0";"438.96";"0";"3.32";"BDBM174426";"C[C@H]1COCCN1c1nc(N2CCN(C)CC2)nc2nc(-c3ccc(Cl)cc3)ccc12";"IC50";"'='";"560.0";"nM";"6.25";"";"319730";"UO_0000065";"14.24";"0.28";"2.93";"10.85";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688953";"";"0";"462.55";"0";"2.37";"BDBM174430";"C[C@H]1COCCN1c1nc(N2CCCCC2CO)nc2nc(-c3cccc(C(N)=O)c3)ccc12";"IC50";"'='";"170.0";"nM";"6.77";"";"319734";"UO_0000065";"14.64";"0.27";"4.40";"5.75";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688958";"";"0";"514.59";"1";"3.12";"BDBM174435";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(C(=O)Nc4cc[nH]n4)c3)nc2n1";"IC50";"'='";"48.0";"nM";"7.32";"";"319739";"UO_0000065";"14.22";"0.26";"4.20";"6.03";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688973";"";"0";"502.62";"1";"3.40";"BDBM174450";"C=CCN(C)C(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"560.0";"nM";"6.25";"";"319754";"UO_0000065";"12.44";"0.23";"2.85";"7.45";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693485";"";"0";"588.11";"2";"5.17";"BDBM174647";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCC(C(=O)c5ccc(Cl)cc5)CC4)nc3n2)cc1CO";"IC50";"'='";"420.0";"nM";"6.38";"";"319925";"UO_0000065";"10.84";"0.21";"1.21";"6.32";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3643413";"LENIOLISIB";"2";"450.47";"0";"2.88";"CDZ173; 3h";"CCC(=O)N1CC[C@H](Nc2ncnc3c2CN(c2cnc(OC)c(C(F)(F)F)c2)CC3)C1";"IC50";"'>'";"9100.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4134233";"Inhibition of recombinant mTOR (unknown origin) using 4EBP1 as substrate by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4130456";"1";"Scientific Literature";"ACS Med Chem Lett";"2017";""
"CHEMBL4288517";"";"0";"426.43";"0";"2.71";"8";"COc1ncc(-c2ccc3nccc(=O)n3c2)cc1NS(=O)(=O)c1ccc(F)cc1";"IC50";"'='";"105.8";"nM";"6.98";"";"";"UO_0000065";"16.36";"0.32";"4.27";"6.79";"False";"CHEMBL4255944";"Inhibition of mTOR in human MCF7 cells assessed as reduction in P70S6K phosphorylation after 4 hrs by ADP-Glo assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MCF7";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4251704";"1";"Scientific Literature";"ACS Med Chem Lett";"2018";""
"CHEMBL4288222";"";"0";"426.43";"0";"2.71";"13";"COc1ncc(-c2ccc3nccc(=O)n3c2)cc1NS(=O)(=O)c1cccc(F)c1";"IC50";"'='";"64.0";"nM";"7.19";"";"";"UO_0000065";"16.87";"0.33";"4.48";"7.01";"False";"CHEMBL4255944";"Inhibition of mTOR in human MCF7 cells assessed as reduction in P70S6K phosphorylation after 4 hrs by ADP-Glo assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MCF7";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4251704";"1";"Scientific Literature";"ACS Med Chem Lett";"2018";""
"CHEMBL3357874";"";"0";"355.38";"0";"2.33";"13";"Cc1nc(N)nc(-c2cc(C(C)(C)O)cnc2Nc2cncc(F)c2)n1";"IC50";"'='";"2500.0";"nM";"5.60";"";"";"UO_0000065";"15.76";"0.29";"3.27";"4.56";"False";"CHEMBL3379685";"Inhibition of recombinant N-terminally GST-tagged mTOR (1360 to 2549 aa) (unknown origin) assessed as inhibition of 27BP1 phosphorylation after 90 mins by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3352452";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2014";""
"CHEMBL4285417";"";"0";"412.52";"0";"2.91";"2; AZD6738";"C[C@@H]1COCCN1c1cc(C2([S@](C)(=N)=O)CC2)nc(-c2ccnc3[nH]ccc23)n1";"IC50";"'='";"370.0";"nM";"6.43";"";"";"UO_0000065";"15.59";"0.30";"3.52";"5.96";"False";"CHEMBL4269699";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4266018";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL4242668";"";"0";"444.51";"0";"1.57";"3e";"COc1ccc(-c2ccc3c(N4CCOCC4)nc(CS(C)(=O)=O)nc3n2)cc1CO";"IC50";"'>'";"500.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4233142";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide substrate measured after 1 hr by Lance Ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4229417";"1";"Scientific Literature";"Bioorg Med Chem";"2018";""
"CHEMBL4246121";"";"0";"448.52";"0";"3.22";"3l";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(C4=CCOCC4)nc3n2)cc1CO";"IC50";"'='";"30.0";"nM";"7.52";"";"";"UO_0000065";"16.77";"0.31";"4.30";"8.37";"False";"CHEMBL4233142";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide substrate measured after 1 hr by Lance Ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4229417";"1";"Scientific Literature";"Bioorg Med Chem";"2018";""
"CHEMBL4170185";"";"0";"572.07";"2";"5.18";"9b";"O=C(Nc1ccc(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cc1)Nc1ccc(Cl)c(-c2cccnc2)c1";"IC50";"'='";"330.0";"nM";"6.48";"";"";"UO_0000065";"11.33";"0.22";"1.30";"6.19";"False";"CHEMBL4141549";"Inhibition of mTOR (unknown origin) using Ulight-4EBP1 peptide as substrate measured after 1 hr by Lance Ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4138149";"1";"Scientific Literature";"Eur J Med Chem";"2017";""
"CHEMBL3931472";"";"0";"608.63";"1";"3.70";"BDBM222610";"CCOC(=O)c1nc(-c2ccc(NC(=O)Nc3ccc(N4CCOCC4=O)cc3)cc2F)nc(N2CCOCC2)c1OCC";"IC50";"'='";"93.0";"nM";"7.03";"";"389399";"UO_0000065";"11.55";"0.22";"3.33";"4.87";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3586382";"";"0";"405.46";"0";"2.50";"14";"O=C1CNc2ncc(-c3ccc(-c4nc[nH]n4)cc3)nc2N1CCC1CCOCC1";"IC50";"'='";"4.0";"nM";"8.40";"";"";"UO_0000065";"20.71";"0.38";"5.90";"7.71";"False";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3915415";"";"0";"491.55";"0";"4.20";"BDBM222545";"CCOC(=O)c1nc(-c2ccc(NC(=O)Nc3ccccc3)cc2)nc(N2CCOCC2)c1OCC";"IC50";"'='";"142.6";"nM";"6.85";"";"389334";"UO_0000065";"13.93";"0.26";"2.65";"5.96";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3895307";"";"0";"559.07";"1";"4.98";"BDBM222564";"CSc1c(Cl)nc(-c2ccc(NC(=O)Nc3ccc(N4CCOCC4)c(F)c3)cc2)nc1N1CCOCC1";"IC50";"'='";"226.9";"nM";"6.64";"";"389353";"UO_0000065";"11.88";"0.24";"1.66";"7.23";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3954563";"";"0";"554.12";"1";"4.75";"BDBM222565";"CSc1c(Cl)nc(-c2ccc(NC(=O)Nc3ccc(N4CCN(C)CC4)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"52.5";"nM";"7.28";"";"389354";"UO_0000065";"13.14";"0.26";"2.53";"8.48";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3889828";"";"0";"557.15";"2";"5.55";"BDBM222566";"CSc1c(Cl)nc(-c2ccc(NC(=O)Nc3ccc(N4CCSCC4)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"133.9";"nM";"6.87";"";"389355";"UO_0000065";"12.34";"0.25";"1.32";"8.32";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3933978";"";"0";"506.63";"1";"4.18";"BDBM222584";"CSc1cnc(-c2ccc(NC(=O)Nc3ccc(N4CCOCC4)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"96.4";"nM";"7.02";"";"389373";"UO_0000065";"13.85";"0.27";"2.84";"7.64";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3961469";"";"0";"428.54";"0";"3.80";"BDBM222585";"CSc1cnc(-c2ccc(NC(=O)Nc3nccs3)cc2)nc1N1CCOCC1";"IC50";"'='";"116.7";"nM";"6.93";"";"389374";"UO_0000065";"16.18";"0.33";"3.13";"7.51";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3962603";"";"0";"448.48";"0";"2.73";"BDBM222607";"COc1cnc(-c2ccc(NC(=O)Nc3cccc(C(N)=O)c3)cc2)nc1N1CCOCC1";"IC50";"'='";"214.3";"nM";"6.67";"";"389396";"UO_0000065";"14.87";"0.28";"3.94";"5.06";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3979425";"";"0";"412.48";"0";"3.09";"BDBM222608";"COc1cnc(-c2ccc(NC(=O)Nc3nccs3)cc2)nc1N1CCOCC1";"IC50";"'='";"169.7";"nM";"6.77";"";"389397";"UO_0000065";"16.41";"0.32";"3.68";"6.67";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3958976";"";"0";"462.51";"0";"3.12";"BDBM222611";"CCOc1cnc(-c2ccc(NC(=O)Nc3ccc(C(N)=O)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"50.1";"nM";"7.30";"";"389400";"UO_0000065";"15.78";"0.29";"4.18";"5.54";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3983186";"";"0";"491.55";"0";"2.86";"BDBM222617";"COc1cnc(-c2ccc(NC(=O)Nc3ccc(N4CCOCC4)nc3)cc2)nc1N1CCOCC1";"IC50";"'='";"194.6";"nM";"6.71";"";"389406";"UO_0000065";"13.65";"0.25";"3.85";"5.89";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3915639";"";"0";"498.61";"1";"5.41";"BDBM222647";"CSc1c(-c2cccnc2)nc(-c2ccc(NC(=O)Nc3ccccc3)cc2)nc1N1CCOCC1";"IC50";"'='";"51.1";"nM";"7.29";"";"389436";"UO_0000065";"14.62";"0.28";"1.88";"7.90";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3945842";"";"0";"503.61";"1";"3.38";"BDBM222614";"COc1cnc(-c2ccc(NC(=O)Nc3ccc(N4CCN(C)CC4)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"272.2";"nM";"6.57";"";"389403";"UO_0000065";"13.04";"0.24";"3.19";"6.90";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3961305";"";"0";"476.54";"0";"3.98";"BDBM222621";"CCOc1cnc(-c2ccc(NC(=O)Nc3ccc(NC(C)=O)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"83.4";"nM";"7.08";"";"389410";"UO_0000065";"14.85";"0.28";"3.10";"6.01";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3586388";"";"0";"377.45";"0";"3.20";"20";"O=C1CN(CCC2CCOCC2)c2nc(-c3ccc4[nH]ccc4c3)cnc2N1";"IC50";"'='";"122.0";"nM";"6.91";"";"";"UO_0000065";"18.32";"0.34";"3.71";"8.32";"False";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3594042";"";"0";"509.59";"2";"6.09";"7h";"CC(=O)Nc1ccc(S(=O)(=O)N(c2ccccc2)c2ccnc3ccc(-c4ccc(O)cc4)cc23)cc1";"IC50";"'='";"613.0";"nM";"6.21";"";"";"UO_0000065";"12.19";"0.23";"0.12";"6.24";"False";"CHEMBL3595885";"Inhibition of mTOR (unknown origin) assessed as p70S6K phosphorylation after 30 mins by ELISA";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3593172";"1";"Scientific Literature";"Bioorg. Med. Chem.";"2015";""
"CHEMBL3586391";"";"0";"343.39";"0";"1.17";"23";"COCCN1C(=O)CNc2ncc(-c3ccc(C(C)(C)O)nc3)nc21";"IC50";"'='";"175.0";"nM";"6.76";"";"";"UO_0000065";"19.68";"0.37";"5.59";"6.73";"False";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL4113535";"";"0";"395.47";"0";"1.87";"BDBM227480";"C[C@@H]1COCCN1c1nc(N2CCOC[C@H]2C)c2nc(-c3ccccn3)[nH]c2n1";"IC50";"'='";"139.0";"nM";"6.86";"";"397239";"UO_0000065";"17.34";"0.32";"4.99";"7.43";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL4107741";"";"0";"463.54";"0";"2.44";"BDBM227485";"C[C@@H]1COCCN1c1nc(N2CCOC[C@H]2C)c2nc(-c3cc(CO)cc4[nH]ccc34)[nH]c2n1";"IC50";"'='";"66.0";"nM";"7.18";"";"397244";"UO_0000065";"15.49";"0.29";"4.74";"6.22";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL3925592";"";"0";"603.68";"1";"2.70";"BDBM222655";"O=C(Nc1ccc(-c2ncc(OCCN3CCOCC3)c(N3CCOCC3)n2)cc1)Nc1ccc(N2CCOCC2=O)cc1";"IC50";"'='";"42.3";"nM";"7.37";"";"389444";"UO_0000065";"12.21";"0.23";"4.67";"5.65";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL1765602";"";"0";"432.41";"1";"5.20";"9";"Nc1ccc(-c2ccc3ncc4ccc(=O)n(-c5cccc(C(F)(F)F)c5)c4c3c2)cn1";"IC50";"'='";"0.25";"nM";"9.60";"";"";"UO_0000065";"22.21";"0.41";"4.40";"13.01";"False";"CHEMBL4235179";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4229497";"1";"Scientific Literature";"Bioorg Med Chem";"2018";""
"CHEMBL3586396";"";"0";"411.51";"0";"2.73";"29";"CO[C@H]1CC[C@@H](CN2CC(=O)Nc3ncc(-c4ccc(C(C)(C)O)nc4)nc32)CC1";"IC50";"'='";"149.0";"nM";"6.83";"";"";"UO_0000065";"16.59";"0.31";"4.10";"6.79";"False";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3586383";"";"0";"419.49";"0";"2.81";"15";"Cc1cc(-c2nc[nH]n2)ccc1-c1cnc2c(n1)N(CCC1CCOCC1)CC(=O)N2";"IC50";"'='";"4.0";"nM";"8.40";"";"";"UO_0000065";"20.02";"0.37";"5.59";"7.71";"False";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL4285417";"";"0";"412.52";"0";"2.91";"2; AZD6738";"C[C@@H]1COCCN1c1cc(C2([S@](C)(=N)=O)CC2)nc(-c2ccnc3[nH]ccc23)n1";"IC50";"'='";"5700.0";"nM";"5.24";"";"";"UO_0000065";"12.71";"0.25";"2.33";"4.86";"False";"CHEMBL4269701";"Inhibition of mTOR in human MDA-MB-468 cells assessed as decrease in 70S6K S235/236 phosphorylation";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MDA-MB-468";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4266018";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL4064842";"";"0";"456.51";"0";"3.66";"5b";"O=C(Nc1ccc(CO)cc1)Nc1ccc(-c2nc(N3CCOCC3)c3cccnc3n2)cc1";"IC50";"'='";"54.3";"nM";"7.26";"";"";"UO_0000065";"15.91";"0.29";"3.61";"6.46";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL4065735";"";"0";"502.96";"1";"4.59";"5j";"O=C(Nc1ccc(C(=O)CCl)cc1)Nc1ccc(-c2nc(N3CCOCC3)c3cccnc3n2)cc1";"IC50";"'='";"1190.0";"nM";"5.92";"";"";"UO_0000065";"11.78";"0.22";"1.33";"5.42";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL4065390";"";"0";"306.39";"0";"1.36";"3a";"c1cc2nc(N3CCOCC3)nc(N3CCOCC3)c2s1";"IC50";"'>'";"2000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL4218369";"";"0";"495.60";"1";"2.37";"12b";"CNc1ncc2c(-c3ccc(N4CCN(C)CC4)nc3)nn(Cc3cn(Cc4ccccc4)nn3)c2n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4188979";"Inhibition of wild-type human partial length MTOR (L1382 to W2549 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4184298";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL4210084";"";"0";"481.57";"1";"2.03";"10a";"CNc1ncc2c(-c3ccc(N4CCNCC4)nc3)nn(Cc3cn(Cc4ccccc4)nn3)c2n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4188979";"Inhibition of wild-type human partial length MTOR (L1382 to W2549 residues) expressed in mammalian expression system using poly [Glu, Try] 4:1 as substrate in presence of [gamma-33P]ATP";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4184298";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL4294409";"";"0";"430.85";"0";"3.35";"28";"O=c1ccnc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccccc4F)c3)cn12";"IC50";"'>'";"400.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4255944";"Inhibition of mTOR in human MCF7 cells assessed as reduction in P70S6K phosphorylation after 4 hrs by ADP-Glo assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MCF7";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4251704";"1";"Scientific Literature";"ACS Med Chem Lett";"2018";""
"CHEMBL4280614";"";"0";"442.88";"0";"3.22";"9";"COc1ncc(-c2ccc3nccc(=O)n3c2)cc1NS(=O)(=O)c1ccc(Cl)cc1";"IC50";"'='";"223.4";"nM";"6.65";"";"";"UO_0000065";"15.02";"0.30";"3.43";"6.48";"False";"CHEMBL4255944";"Inhibition of mTOR in human MCF7 cells assessed as reduction in P70S6K phosphorylation after 4 hrs by ADP-Glo assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MCF7";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4251704";"1";"Scientific Literature";"ACS Med Chem Lett";"2018";""
"CHEMBL4277571";"";"0";"438.47";"0";"2.57";"12";"COc1ccc(S(=O)(=O)Nc2cc(-c3ccc4nccc(=O)n4c3)cnc2OC)cc1";"IC50";"'='";"138.0";"nM";"6.86";"";"";"UO_0000065";"15.65";"0.30";"4.29";"6.13";"False";"CHEMBL4255944";"Inhibition of mTOR in human MCF7 cells assessed as reduction in P70S6K phosphorylation after 4 hrs by ADP-Glo assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MCF7";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4251704";"1";"Scientific Literature";"ACS Med Chem Lett";"2018";""
"CHEMBL4279898";"";"0";"422.47";"0";"2.87";"15";"COc1ncc(-c2ccc3nccc(=O)n3c2)cc1NS(=O)(=O)c1ccccc1C";"IC50";"'='";"153.4";"nM";"6.81";"";"";"UO_0000065";"16.13";"0.31";"3.94";"6.64";"False";"CHEMBL4255944";"Inhibition of mTOR in human MCF7 cells assessed as reduction in P70S6K phosphorylation after 4 hrs by ADP-Glo assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MCF7";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4251704";"1";"Scientific Literature";"ACS Med Chem Lett";"2018";""
"CHEMBL3577912";"";"0";"506.49";"1";"4.24";"5e";"COc1ncc(-c2cnc3ncnc(-c4ccncc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"62.3";"nM";"7.21";"";"";"UO_0000065";"14.23";"0.27";"2.97";"6.01";"False";"CHEMBL3579762";"Inhibition of mTOR (unknown origin) using GFP-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3576869";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL3577909";"";"0";"505.51";"1";"4.84";"5b";"COc1ncc(-c2cnc3nccc(-c4ccncc4)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"66.7";"nM";"7.18";"";"";"UO_0000065";"14.20";"0.27";"2.34";"6.71";"False";"CHEMBL3579762";"Inhibition of mTOR (unknown origin) using GFP-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3576869";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL3577925";"";"0";"515.95";"2";"5.55";"6k";"O=S(=O)(Nc1cc(-c2cc3c(-c4ccncc4)ncnc3s2)cnc1Cl)c1ccc(F)cc1F";"IC50";"'='";"53.6";"nM";"7.27";"";"";"UO_0000065";"14.09";"0.29";"1.72";"7.44";"False";"CHEMBL3579762";"Inhibition of mTOR (unknown origin) using GFP-4E-BP1 as substrate after 1 hr by TR-FRET assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3576869";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL4291635";"";"0";"476.44";"0";"3.58";"11";"COc1ncc(-c2ccc3nccc(=O)n3c2)cc1NS(=O)(=O)c1ccc(C(F)(F)F)cc1";"IC50";"'='";"163.3";"nM";"6.79";"";"";"UO_0000065";"14.25";"0.28";"3.21";"6.61";"False";"CHEMBL4255944";"Inhibition of mTOR in human MCF7 cells assessed as reduction in P70S6K phosphorylation after 4 hrs by ADP-Glo assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MCF7";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4251704";"1";"Scientific Literature";"ACS Med Chem Lett";"2018";""
"CHEMBL4206442";"";"0";"457.48";"0";"2.40";"11";"C[C@H]1COCCN1c1nc(-c2cnc(N)cc2C(F)(F)F)cc(C2(S(C)(=O)=O)CC2)n1";"IC50";"'='";"2120.0";"nM";"5.67";"";"";"UO_0000065";"12.40";"0.25";"3.27";"5.10";"False";"CHEMBL4199839";"Inhibition of recombinant human GST-tagged mTOR catalytic domain (1360 to 2549 residues) expressed in baculovirus expression system using GFP-4EBP1 as substrate measured after 1 hr by Lathascreen method";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4196123";"1";"Scientific Literature";"ACS Med Chem Lett";"2018";""
"CHEMBL4218854";"";"0";"492.62";"0";"3.61";"21";"CNC(=O)c1nnc2ccc(-c3ccc(OCCCN(C)C)nc3)cc2c1N[C@@H](C)C1CCOCC1";"IC50";"'='";"21000.0";"nM";"4.68";"";"";"UO_0000065";"9.50";"0.18";"1.07";"4.61";"False";"CHEMBL4200474";"Inhibition of truncated FLAG-tagged mTOR (unknown origin) (1362 to 2549 residues) expressed in HEK293 cells using biotinylated P70 peptide as substrate measured after 90 mins by Alphascreen assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4196159";"1";"Scientific Literature";"ACS Med Chem Lett";"2018";""
"CHEMBL4106998";"";"0";"472.57";"0";"2.12";"BDBM251625";"CNc1nc2ccccc2n1-c1nc2c(c(C(C)(C)S(C)(=O)=O)n1)OCC[C@@H]1COCCN21";"IC50";"'='";"6600.0";"nM";"5.18";"";"438521";"UO_0000065";"10.96";"0.21";"3.06";"4.65";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3355073";"";"0";"414.54";"0";"2.31";"6";"C[C@@H]1Cn2ncc(C3CCN(S(C)(=O)=O)CC3)c2CN1c1ccnc2[nH]ccc12";"IC50";"'>'";"2300.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL3379631";"Inhibition of mTOR (unknown origin) by alphascreen SureFire p70 S6K (p-Thr389) assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3351372";"1";"Scientific Literature";"ACS Med. Chem. Lett.";"2015";""
"CHEMBL3646584";"";"0";"539.69";"2";"3.20";"BDBM125438";"Cc1nc(N)nc(-c2cc([C@@H](C)N3CCN(S(C)(=O)=O)C[C@@H]3C)cnc2Nc2ccc3scnc3c2)n1";"IC50";"'='";"252.0";"nM";"6.60";"";"255182";"UO_0000065";"12.23";"0.24";"3.40";"4.61";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646630";"";"0";"564.55";"1";"2.84";"BDBM125494";"COc1ncc(Nc2ncc(CN3CCN(C(=O)N(C)CC(F)(F)F)CC3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'='";"1745.0";"nM";"5.76";"";"255249";"UO_0000065";"10.20";"0.20";"2.92";"4.16";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649466";"";"0";"549.06";"2";"2.23";"BDBM125505";"Cc1nc(N)nc(-c2cc([C@H](C)N3CCOCC3)cnc2Nc2cnc(Cl)c(NS(=O)(=O)N(C)C)c2)n1";"IC50";"'='";"388.0";"nM";"6.41";"";"255265";"UO_0000065";"11.68";"0.24";"4.18";"3.90";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646590";"";"0";"382.40";"0";"2.06";"BDBM125445";"COc1ncc(Nc2ncc(C3(N)CC3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255189";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL4276933";"";"0";"458.45";"0";"3.15";"30";"COc1ncc(-c2ccc3ncc(C)c(=O)n3c2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"119.0";"nM";"6.92";"";"";"UO_0000065";"15.10";"0.30";"3.77";"6.75";"False";"CHEMBL4255944";"Inhibition of mTOR in human MCF7 cells assessed as reduction in P70S6K phosphorylation after 4 hrs by ADP-Glo assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MCF7";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4251704";"1";"Scientific Literature";"ACS Med Chem Lett";"2018";""
"CHEMBL2170090";"";"0";"531.62";"2";"1.92";"BDBM50396818";"COc1ncc(Nc2ncc(C(C)(C)N3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255169";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646592";"";"0";"541.68";"2";"2.73";"BDBM125447";"COc1ncc(Nc2ncc([C@@H](C)N3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cc1C(C)C";"IC50";"'>'";"10000.0";"nM";"";"";"255191";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646608";"";"0";"421.38";"0";"2.74";"BDBM125465";"COc1ccc(Nc2ncc(C(C)(O)C(F)(F)F)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"263.0";"nM";"6.58";"";"255211";"UO_0000065";"15.62";"0.30";"3.84";"4.99";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653576";"";"0";"423.44";"0";"3.88";"BDBM136433";"O=C1OC[C@H](c2ccccc2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"4.2";"nM";"8.38";"";"270307";"UO_0000065";"19.78";"0.36";"4.50";"8.27";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653584";"";"0";"407.41";"0";"3.45";"BDBM136441";"CCC[C@H]1COC(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"1.6";"nM";"8.80";"";"270315";"UO_0000065";"21.59";"0.40";"5.35";"8.68";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653587";"";"0";"375.39";"0";"2.92";"BDBM136444";"CC[C@H]1COC(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"14.9";"nM";"7.83";"";"270318";"UO_0000065";"20.85";"0.38";"4.91";"7.73";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653591";"";"0";"455.45";"0";"3.89";"BDBM136448";"O=C1OC[C@H](Cc2ccccc2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"7.8";"nM";"8.11";"";"270322";"UO_0000065";"17.80";"0.33";"4.22";"8.00";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653602";"";"0";"462.47";"0";"3.78";"BDBM136459";"Cc1nc([C@H]2COC(=O)N2c2ccn3ncc(-c4ccc(-c5nc[nH]n5)c(F)c4)c3n2)cs1";"IC50";"'='";"6.5";"nM";"8.19";"";"270333";"UO_0000065";"17.70";"0.34";"4.41";"7.17";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653636";"";"0";"438.45";"0";"3.58";"BDBM136493";"Cc1ccnc([C@H]2COC(=O)N2c2ccn3ncc(-c4ccc(-c5nc[nH]n5)cc4)c3n2)c1";"IC50";"'='";"11.4";"nM";"7.94";"";"270367";"UO_0000065";"18.12";"0.33";"4.36";"6.96";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653647";"";"0";"486.47";"0";"3.20";"BDBM136504";"CCn1cccc([C@H]2COC(=O)N2c2ccn3ncc(-c4ccc(-c5nc[nH]n5)c(F)c4)c3n2)c1=O";"IC50";"'='";"49.5";"nM";"7.30";"";"270378";"UO_0000065";"15.02";"0.28";"4.11";"5.92";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653648";"";"0";"474.43";"0";"3.86";"BDBM136505";"Cc1ccc(F)c([C@H]2COC(=O)N2c2ccn3ncc(-c4ccc(-c5nc[nH]n5)c(F)c4)c3n2)n1";"IC50";"'='";"6.5";"nM";"8.19";"";"270379";"UO_0000065";"17.26";"0.32";"4.33";"7.17";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653617";"";"0";"460.40";"0";"3.55";"BDBM136474";"O=C1OC[C@H](c2ccc(F)cn2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"3.5";"nM";"8.46";"";"270383";"UO_0000065";"18.37";"0.34";"4.91";"7.41";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646507";"";"0";"484.59";"0";"1.65";"BDBM125350";"COc1ccc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3)cc2-c2cc(N)nc(C)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255077";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653530";"";"0";"445.53";"0";"3.70";"BDBM136386";"COCCN1C[C@H](C(C)C)N(c2ccn3ncc(-c4ccc(-c5ncc[nH]5)cc4)c3n2)C1=O";"IC50";"'='";"5.2";"nM";"8.28";"";"270260";"UO_0000065";"18.59";"0.34";"4.58";"9.04";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653534";"";"0";"484.61";"0";"4.05";"BDBM136390";"CC(C)[C@H]1CN(CC2CCNCC2)C(=O)N1c1ccn2ncc(-c3ccc(-c4ncc[nH]4)cc3)c2n1";"IC50";"'='";"17.7";"nM";"7.75";"";"270264";"UO_0000065";"16.00";"0.29";"3.70";"8.21";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653549";"";"0";"514.59";"1";"1.88";"BDBM136405";"CC(C)[C@H]1CN(CCN2CCNC(=O)C2)C(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"8.0";"nM";"8.10";"";"270279";"UO_0000065";"15.73";"0.29";"6.22";"6.34";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165018";"";"0";"514.62";"2";"0.90";"BDBM50394845";"COc1ccc(Nc2ncc(CN3CCN(S(=O)(=O)N(C)C)CC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255107";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643917";"";"0";"346.35";"0";"2.51";"BDBM125227";"CC(=O)Nc1ccc(Nc2ncccc2-c2ncnc3[nH]cnc23)cn1";"IC50";"'='";"1686.0";"nM";"5.77";"";"254931";"UO_0000065";"16.67";"0.30";"3.26";"4.76";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3649478";"";"0";"499.60";"1";"1.61";"BDBM125517";"COc1ccc(Nc2ncc([C@@H](C)N3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"3249.0";"nM";"5.49";"";"255046";"UO_0000065";"10.99";"0.21";"3.88";"3.60";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646505";"";"0";"404.41";"0";"3.17";"BDBM125347";"COc1ncc(Nc2nc(-c3ccncc3)ccc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255075";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646526";"";"0";"439.37";"0";"3.19";"BDBM125369";"COc1ncc(Nc2nc(COCC(F)(F)F)ccc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255098";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165009";"";"0";"406.49";"0";"2.96";"BDBM50394854";"COc1ccc(Nc2ncc(CN3CCCCC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255113";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646486";"";"0";"422.45";"0";"1.44";"BDBM125328";"COc1ccc(Nc2ncc(C(=O)N3CCOCC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"5390.0";"nM";"5.27";"";"255051";"UO_0000065";"12.47";"0.23";"3.83";"3.73";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2165006";"";"0";"399.46";"0";"3.56";"BDBM50394839";"COc1ccc(Nc2ncc(Cc3ccccc3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255056";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646525";"";"0";"426.46";"0";"1.94";"BDBM125368";"COc1ncc(Nc2nc(CN3CCOCC3)ccc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255097";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646528";"";"0";"424.53";"0";"2.52";"BDBM125371";"COc1ccc(Nc2ncc(CN3CCSCC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255100";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3667428";"";"0";"420.48";"0";"1.96";"BDBM151000";"C[C@H]1COCCN1c1nc(N2CCOCC2)nc2[nH]c(-c3cnc4cc[nH]c4c3)nc12";"IC50";"'='";"469.0";"nM";"6.33";"";"290546";"UO_0000065";"15.05";"0.28";"4.37";"5.86";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL3667430";"";"0";"433.52";"0";"2.69";"BDBM151003";"C[C@H]1COCCN1c1nc(N2CCC(O)CC2)nc2[nH]c(-c3cccc4[nH]ccc34)nc12";"IC50";"'='";"160.0";"nM";"6.80";"";"290549";"UO_0000065";"15.68";"0.29";"4.11";"6.40";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL3643918";"";"0";"304.32";"0";"2.14";"BDBM125228";"Nc1ccc(Nc2ncccc2-c2ncnc3[nH]cnc23)cn1";"IC50";"'='";"17548.0";"nM";"4.76";"";"254932";"UO_0000065";"15.63";"0.28";"2.62";"4.02";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643941";"";"0";"363.38";"0";"2.36";"BDBM125264";"COc1ccc(Nc2ncc(CO)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'='";"924.0";"nM";"6.03";"";"254976";"UO_0000065";"16.61";"0.31";"3.67";"4.96";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646432";"";"0";"509.60";"1";"1.95";"BDBM125273";"COc1ccc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"254985";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2170098";"";"0";"485.57";"1";"1.05";"BDBM50396810";"COc1cncc(Nc2ncc(CN3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)c1";"IC50";"'>'";"10000.0";"nM";"";"";"255062";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL4174909";"";"0";"557.58";"1";"4.30";"43";"CNc1nc(C)c2cc(-c3cnc(OC)c(NS(=O)(=O)c4ccc(F)cc4F)c3)cc(O[C@@H]3CCOC3)c2n1";"IC50";"'='";"56.0";"nM";"7.25";"";"";"UO_0000065";"13.01";"0.25";"2.95";"5.82";"False";"CHEMBL4150392";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide as substrate after 30 mins by Lance Ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4145625";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL3927003";"";"0";"474.40";"0";"4.18";"BDBM236561";"O=c1[nH]c(=O)n(-c2cccc(C(F)(F)F)c2)c2c1cnc1ccc(-c3cnc4[nH]ccc4c3)nc12";"IC50";"'='";"1.12";"nM";"8.95";"";"412065";"UO_0000065";"18.87";"0.35";"4.77";"8.19";"False";"CHEMBL3888698";"mTOR Enzymatic Assay: Agents: 1-fold kinase buffer: 50 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 3 mM MnCl2, 0.01% Tween-20, 2 mM DTT. 4-fold kinase solution: mTOR kinase was added to 1-fold kinase buffer to form 4-fold kinase solution with a final concentration of 2.5 nM. 2-fold substrate and ATP solution: the substrate 4EBP1 and ATP were added to 1-fold kinase buffer to form 2-fold substrate solution with final concentration of 50 nM of 4EBP1 and 10.8 ¿M of ATP. 4-fold test substance solutions: 100-fold test substance solutions in different gradient concentrations were formulated with 100% DMSO, and diluted by 25 folds with 1-fold kinase buffer to form 4-fold test substance solutions in different gradient concentrations. Detection solution: a detection solution containing 2-fold final concentrations of EDTA and 4EBP1 phosphorylated antibody was formulated, wherein the final concentration for EDTA was 8 mM, and the final concentration for the 4EBP phosphorylated antibody was 2 nM. Procedure: To each well of a 384-well plate was added 2.5 ¿L of the 4-fold test substance solutions in gradient concentrations. The replication was made. To each well was added 2.5 ¿L of 4-fold kinase solution, and then the plate was incubated for 10 mins. Then to each well was added 5 ¿L/of 2-fold substrate and ATP solution, and then the plate was incubated at room temperature for 1 hour. Finally, 10 ¿L of the detection solution was added to terminate the reaction. After 60 mins, the data Lance signal (665 nM) was read from Envision.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886794";"37";"BindingDB Database";"";"2016";""
"CHEMBL3586403";"";"0";"397.48";"0";"2.48";"36";"CO[C@H]1CC[C@H](N2CC(=O)Nc3ncc(-c4ccc(C(C)(C)O)nc4)nc32)CC1";"IC50";"'='";"103.0";"nM";"6.99";"";"";"UO_0000065";"17.58";"0.33";"4.51";"6.95";"False";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3586402";"";"0";"397.48";"0";"2.48";"35";"CO[C@H]1CC[C@@H](N2CC(=O)Nc3ncc(-c4ccc(C(C)(C)O)nc4)nc32)CC1";"IC50";"'='";"300.0";"nM";"6.52";"";"";"UO_0000065";"16.41";"0.31";"4.04";"6.49";"False";"CHEMBL3587365";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585315";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3891810";"";"0";"586.70";"1";"4.25";"BDBM178279";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(N(C)C)cn4)cc3)c2C1=O";"IC50";"'='";"24.0";"nM";"7.62";"";"324299";"UO_0000065";"12.99";"0.24";"3.37";"6.09";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3913268";"";"0";"468.55";"0";"2.65";"BDBM178316";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(OC)c(CO)c3)c2C1=O";"IC50";"'='";"4045.0";"nM";"5.39";"";"324336";"UO_0000065";"11.51";"0.22";"2.74";"5.55";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3922289";"";"0";"495.58";"0";"3.71";"BDBM178321";"CCOC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)nc3c2C(=O)N(CC)CC(C)(C)O3)cc1";"IC50";"'='";"442.0";"nM";"6.36";"";"324341";"UO_0000065";"12.82";"0.24";"2.64";"5.99";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3906651";"";"0";"479.58";"0";"3.49";"BDBM178323";"CCC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)nc3c2C(=O)N(CC)CC(C)(C)O3)cc1";"IC50";"'='";"472.0";"nM";"6.33";"";"324343";"UO_0000065";"13.19";"0.25";"2.84";"6.53";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3915060";"";"0";"521.65";"1";"4.05";"BDBM178336";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(Nc4nnc(C)s4)cc3)c2C1=O";"IC50";"'='";"66.0";"nM";"7.18";"";"324356";"UO_0000065";"13.76";"0.27";"3.13";"6.80";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3943892";"";"0";"616.72";"1";"2.84";"BDBM178344";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)NCC4CCS(=O)(=O)C4)c(F)c3)c2C1=O";"IC50";"'='";"1384.0";"nM";"5.86";"";"324364";"UO_0000065";"9.50";"0.19";"3.02";"4.10";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3912834";"";"0";"592.63";"1";"3.73";"BDBM178354";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4cncc(OC)n4)c(F)c3)c2C1=O";"IC50";"'='";"251.0";"nM";"6.60";"";"324374";"UO_0000065";"11.14";"0.21";"2.87";"4.59";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3982586";"";"0";"548.62";"1";"4.78";"BDBM178417";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccccc4F)cc3)c2C1=O";"IC50";"'='";"19.0";"nM";"7.72";"";"324437";"UO_0000065";"14.07";"0.26";"2.94";"7.09";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL4062723";"";"0";"475.27";"0";"2.39";"21";"FC(F)(F)c1cc(Br)ncc1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL4019299";"Inhibition of mTOR in human A2058 cells assessed as reduction in phosphorylation of S6 at ser235/236 residues after 1 hr by in-cell Western method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017506";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL4084907";"BIMIRALISIB";"2";"411.39";"0";"1.21";"1; PQR309";"Nc1cc(C(F)(F)F)c(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cn1";"IC50";"'='";"205.0";"nM";"6.69";"";"";"UO_0000065";"16.26";"0.31";"5.48";"6.52";"False";"CHEMBL4019299";"Inhibition of mTOR in human A2058 cells assessed as reduction in phosphorylation of S6 at ser235/236 residues after 1 hr by in-cell Western method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017506";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL3945702";"";"0";"578.62";"2";"5.07";"BDBM178234";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(F)cc4F)cc3)c2C1=O";"IC50";"'='";"32.0";"nM";"7.50";"";"324254";"UO_0000065";"12.95";"0.24";"2.42";"6.88";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL4115263";"";"0";"433.52";"0";"2.95";"BDBM227482";"C[C@@H]1COCCN1c1nc(N2CCCOCC2)nc2[nH]c(-c3cccc4[nH]ccc34)nc12";"IC50";"'='";"164.0";"nM";"6.79";"";"397241";"UO_0000065";"15.65";"0.29";"3.84";"7.13";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL3901534";"";"0";"384.44";"0";"1.19";"BDBM227489";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2nc(-c3cc[nH]n3)[nH]c2n1";"IC50";"'='";"343.0";"nM";"6.46";"";"397248";"UO_0000065";"16.82";"0.32";"5.27";"5.98";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL4114022";"";"0";"445.53";"0";"2.81";"BDBM227498";"C[C@@H]1COCCN1c1nc(N2CC3COCC3C2)nc2[nH]c(-c3cccc4[nH]ccc34)nc12";"IC50";"'='";"296.0";"nM";"6.53";"";"397257";"UO_0000065";"14.65";"0.27";"3.72";"6.86";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL3981458";"";"0";"567.67";"1";"2.71";"BDBM222671";"COc1cnc(-c2ccc(NC(=O)Nc3ccc(N4CCN(S(C)(=O)=O)CC4)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"86.7";"nM";"7.06";"";"389460";"UO_0000065";"12.44";"0.24";"4.35";"5.46";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL3912756";"";"0";"512.59";"1";"3.39";"BDBM222634";"CCOc1cnc(-c2ccc(NC(=O)Nc3ccc(NS(C)(=O)=O)cc3)cc2)nc1N1CCOCC1";"IC50";"'='";"70.4";"nM";"7.15";"";"389423";"UO_0000065";"13.95";"0.27";"3.76";"5.31";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL2158851";"";"0";"358.41";"0";"2.99";"9i";"N#Cc1cccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)c1";"IC50";"'>'";"4000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2161544";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2157945";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2158848";"";"0";"347.42";"0";"3.43";"9f";"Cc1cccc(Nc2nccc(-c3ccnc(N4CCOCC4)c3)n2)c1";"IC50";"'>'";"20000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2161544";"Inhibition of mTOR";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2157945";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2172480";"";"0";"398.43";"0";"2.91";"7";"Cc1nc(N)nc(-c2c(Nc3cc[nH]n3)nc3ccc(-c4cccnc4C)cn23)n1";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"21.39";"0.39";"5.61";"6.29";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2172490";"";"0";"388.40";"0";"2.51";"17";"Cc1cc(-c2ccc3nc(Nc4cc[nH]n4)c(-c4nc(C)nc(N)n4)n3c2)on1";"IC50";"'='";"3.0";"nM";"8.52";"";"";"UO_0000065";"21.94";"0.40";"6.01";"5.73";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2172489";"";"0";"413.45";"0";"2.74";"16";"Cc1nc(N)nc(-c2c(Nc3cc[nH]n3)nc3ccc(-c4cnn(C5CC5)c4)cn23)n1";"IC50";"'='";"2.0";"nM";"8.70";"";"";"UO_0000065";"21.04";"0.38";"5.96";"6.19";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2172481";"";"0";"397.45";"0";"3.52";"8";"Cc1nc(N)nc(-c2c(Nc3cc[nH]n3)nc3ccc(-c4ccccc4C)cn23)n1";"IC50";"'='";"21.0";"nM";"7.68";"";"";"UO_0000065";"19.32";"0.35";"4.16";"6.26";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2172639";"";"0";"401.41";"0";"3.35";"4";"Cc1nc(N)nc(-c2c(Nc3cc[nH]n3)nc3ccc(-c4cccc(F)c4)cn23)n1";"IC50";"'='";"27.0";"nM";"7.57";"";"";"UO_0000065";"18.86";"0.34";"4.22";"6.17";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2336322";"";"0";"506.61";"1";"2.85";"BDBM50429704";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1C(=O)N(C)C";"IC50";"'='";"42.0";"nM";"7.38";"";"319758";"UO_0000065";"14.56";"0.27";"4.53";"7.92";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688981";"";"0";"510.57";"1";"2.91";"BDBM174458";"CON(C)C(=O)c1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccc1F";"IC50";"'='";"740.0";"nM";"6.13";"";"319763";"UO_0000065";"12.01";"0.23";"3.22";"6.58";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688995";"";"0";"474.61";"0";"3.39";"BDBM174476";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(CNC4CC4)c3)nc2n1";"IC50";"'='";"54.0";"nM";"7.27";"";"319777";"UO_0000065";"15.31";"0.28";"3.88";"9.61";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693427";"";"0";"522.61";"1";"1.87";"BDBM174573";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1C(=O)NCCO";"IC50";"'='";"79.0";"nM";"7.10";"";"319865";"UO_0000065";"13.59";"0.26";"5.23";"5.81";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693411";"";"0";"522.63";"1";"3.55";"BDBM174552";"CC(C)C(=O)NCc1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccc1F";"IC50";"'='";"160.0";"nM";"6.80";"";"319848";"UO_0000065";"13.00";"0.24";"3.25";"7.33";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693412";"";"0";"534.64";"1";"3.70";"BDBM174553";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(F)c(CNC(=O)C4CCC4)c3)nc2n1";"IC50";"'='";"290.0";"nM";"6.54";"";"319849";"UO_0000065";"12.23";"0.23";"2.84";"7.05";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693419";"";"0";"452.56";"0";"2.84";"BDBM174565";"CCNCc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)o1";"IC50";"'='";"97.0";"nM";"7.01";"";"319856";"UO_0000065";"15.50";"0.29";"4.17";"7.90";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693423";"";"0";"482.59";"0";"2.47";"BDBM174569";"COCCNCc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)o1";"IC50";"'='";"330.0";"nM";"6.48";"";"319860";"UO_0000065";"13.43";"0.25";"4.01";"6.61";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3958463";"";"0";"551.60";"1";"3.26";"BDBM178395";"COCCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccon4)cc3)c2C1=O";"IC50";"'='";"11.0";"nM";"7.96";"";"324415";"UO_0000065";"14.43";"0.27";"4.70";"5.52";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3890939";"";"0";"494.60";"0";"3.29";"BDBM178328";"CCNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)nc3c2C(=O)N(CC)CC(C)(C)O3)cc1";"IC50";"'='";"31.0";"nM";"7.51";"";"324334";"UO_0000065";"15.18";"0.28";"4.22";"6.89";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3916088";"";"0";"591.64";"1";"4.33";"BDBM178339";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(OC)nc4)c(F)c3)c2C1=O";"IC50";"'='";"20.0";"nM";"7.70";"";"324359";"UO_0000065";"13.01";"0.24";"3.37";"5.88";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3919993";"";"0";"470.53";"0";"2.30";"BDBM178319";"CCN1CC(C)(C)Oc2nc(N3CCOCC3)nc(-c3ccc(NC(=O)NOC)cc3)c2C1=O";"IC50";"'='";"1494.0";"nM";"5.83";"";"324339";"UO_0000065";"12.38";"0.23";"3.53";"4.93";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3957873";"";"0";"544.62";"1";"3.58";"BDBM178340";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4cnccn4)cc3)c2C1=O";"IC50";"'='";"16.0";"nM";"7.80";"";"324360";"UO_0000065";"14.31";"0.27";"4.22";"5.79";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3890939";"";"0";"494.60";"0";"3.29";"BDBM178328";"CCNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)nc3c2C(=O)N(CC)CC(C)(C)O3)cc1";"IC50";"'='";"3960.0";"nM";"5.40";"";"324348";"UO_0000065";"10.92";"0.20";"2.11";"4.96";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3975621";"";"0";"512.59";"1";"3.42";"BDBM178470";"CCNC(=O)Nc1ccc(-c2nc(N3C4CCC3COC4)nc3c2C(=O)N(CC)CC(C)(C)O3)cc1F";"IC50";"'='";"72.0";"nM";"7.14";"";"324490";"UO_0000065";"13.93";"0.26";"3.72";"6.56";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3899327";"";"0";"660.75";"1";"4.55";"BDBM178473";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccc(N5CC6CCC(C5)O6)nc4)c(F)c3)c2C1=O";"IC50";"'='";"53.0";"nM";"7.28";"";"324493";"UO_0000065";"11.01";"0.21";"2.73";"5.42";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693513";"";"0";"409.49";"0";"2.85";"BDBM174676";"CCNc1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(OC)c(CO)c3)nc2n1";"IC50";"'='";"72.0";"nM";"7.14";"";"319957";"UO_0000065";"17.44";"0.33";"4.29";"7.71";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688914";"";"0";"474.57";"0";"3.41";"BDBM174376";"CCOc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1C#N";"IC50";"'='";"1000.0";"nM";"6.00";"";"319693";"UO_0000065";"12.64";"0.23";"2.59";"6.21";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688918";"";"0";"451.53";"0";"2.34";"BDBM174380";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(O)c(CO)c3)nc2n1";"IC50";"'='";"24.0";"nM";"7.62";"";"319697";"UO_0000065";"16.88";"0.32";"5.28";"7.32";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693405";"";"0";"476.58";"0";"2.78";"BDBM174546";"CC(=O)NCc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1";"IC50";"'='";"91.0";"nM";"7.04";"";"319842";"UO_0000065";"14.77";"0.27";"4.26";"7.59";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693454";"";"0";"478.60";"0";"2.74";"BDBM174615";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCCCC(N)C4)nc3n2)cc1CO";"IC50";"'='";"39.0";"nM";"7.41";"";"319893";"UO_0000065";"15.48";"0.29";"4.67";"6.74";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL4071370";"";"0";"411.39";"0";"1.21";"15";"Nc1ncc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1C(F)(F)F";"IC50";"'='";"1638.0";"nM";"5.79";"";"";"UO_0000065";"14.06";"0.27";"4.58";"5.64";"False";"CHEMBL4019299";"Inhibition of mTOR in human A2058 cells assessed as reduction in phosphorylation of S6 at ser235/236 residues after 1 hr by in-cell Western method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017506";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL3667432";"";"0";"433.52";"0";"2.95";"BDBM151005";"C[C@H]1COCCN1c1nc(N2CCOC[C@H]2C)nc2[nH]c(-c3cccc4[nH]ccc34)nc12";"IC50";"'='";"46.0";"nM";"7.34";"";"290551";"UO_0000065";"16.92";"0.31";"4.39";"7.71";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693565";"";"0";"472.55";"0";"3.58";"BDBM174729";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(-c4cccc(CO)c4)nc3n2)cc1CO";"IC50";"'='";"52.0";"nM";"7.28";"";"320008";"UO_0000065";"15.41";"0.28";"3.70";"7.22";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3978752";"";"0";"498.56";"0";"3.03";"BDBM178216";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)NC)c(F)c3)c2C1=O";"IC50";"'='";"23.0";"nM";"7.64";"";"324236";"UO_0000065";"15.32";"0.29";"4.61";"7.01";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3983092";"";"0";"557.66";"1";"4.49";"BDBM178249";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(C)cn4)cc3)c2C1=O";"IC50";"'='";"43.0";"nM";"7.37";"";"324269";"UO_0000065";"13.21";"0.25";"2.88";"6.05";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3909708";"";"0";"575.65";"1";"4.63";"BDBM178270";"CCN1CC(C)(C)Oc2nc(N3C4CCC3COC4)nc(-c3ccc(NC(=O)Nc4ccnc(C)c4)c(F)c3)c2C1=O";"IC50";"'='";"66.0";"nM";"7.18";"";"324290";"UO_0000065";"12.47";"0.23";"2.55";"5.89";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3936252";"";"0";"603.68";"1";"3.82";"BDBM178412";"COCCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(OC)nc4)cc3)c2C1=O";"IC50";"'='";"117.0";"nM";"6.93";"";"324432";"UO_0000065";"11.48";"0.22";"3.11";"4.94";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3945169";"";"0";"563.63";"1";"4.49";"BDBM178414";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccnc(C)c4)c(F)c3)c2C1=O";"IC50";"'='";"39.0";"nM";"7.41";"";"324434";"UO_0000065";"13.15";"0.25";"2.92";"6.08";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688925";"";"0";"466.52";"0";"2.38";"BDBM174387";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(C(N)=O)c(F)c3)nc2n1";"IC50";"'='";"1800.0";"nM";"5.75";"";"319704";"UO_0000065";"12.31";"0.23";"3.36";"5.38";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3689004";"";"0";"504.64";"1";"2.71";"BDBM174485";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(CN4CC[C@H](O)C4)c3)nc2n1";"IC50";"'='";"29.0";"nM";"7.54";"";"319786";"UO_0000065";"14.94";"0.28";"4.83";"8.66";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688868";"";"0";"406.49";"0";"2.54";"BDBM174327";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccncc3)nc2n1";"IC50";"'='";"6.0";"nM";"8.22";"";"319644";"UO_0000065";"20.23";"0.37";"5.68";"10.75";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688875";"";"0";"463.54";"0";"2.93";"BDBM174336";"COC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"440.0";"nM";"6.36";"";"319652";"UO_0000065";"13.71";"0.26";"3.43";"7.07";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688879";"";"0";"506.61";"1";"2.52";"BDBM174340";"COCCNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"180.0";"nM";"6.75";"";"319656";"UO_0000065";"13.31";"0.25";"4.22";"6.62";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688924";"";"0";"436.52";"0";"1.82";"BDBM174386";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccnc(NN)c3)nc2n1";"IC50";"'='";"66.0";"nM";"7.18";"";"319703";"UO_0000065";"16.45";"0.31";"5.36";"6.27";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL2206921";"";"0";"470.35";"0";"2.49";"BDBM50401261";"Cc1nc(N)nc(-c2cc(Cl)cnc2Nc2cnc(Cl)c(NS(=O)(=O)N(C)C)c2)n1";"IC50";"'='";"163.0";"nM";"6.79";"";"255275";"UO_0000065";"14.43";"0.31";"4.30";"4.47";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646636";"";"0";"520.02";"2";"2.38";"BDBM125500";"Cc1nc(N)nc(-c2cc(C(C)N3CCOCC3)cnc2Nc2cnc(Cl)c(NS(C)(=O)=O)c2)n1";"IC50";"'='";"472.0";"nM";"6.33";"";"255260";"UO_0000065";"12.17";"0.25";"3.95";"3.93";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3689027";"";"0";"548.69";"1";"3.42";"BDBM174509";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CNC1CCOCC1";"IC50";"'='";"12.0";"nM";"7.92";"";"319810";"UO_0000065";"14.44";"0.27";"4.50";"8.42";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693394";"";"0";"518.66";"1";"3.80";"BDBM174535";"CC(C)CC(=O)NCc1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1";"IC50";"'='";"370.0";"nM";"6.43";"";"319831";"UO_0000065";"12.40";"0.23";"2.63";"6.94";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701063";"";"0";"390.87";"0";"3.79";"BDBM172197";"Cc1nccc(-c2ccc(C(=O)N(C)C)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.0";"nM";"9.00";"";"317121";"UO_0000065";"23.03";"0.44";"5.21";"12.48";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701071";"";"0";"366.47";"0";"4.49";"BDBM172205";"CCc1nccc(-c2ccc(C(C)(C)C#N)cc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"93.0";"nM";"7.03";"";"317129";"UO_0000065";"19.19";"0.34";"2.54";"9.30";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701089";"";"0";"527.64";"1";"4.22";"BDBM172223";"CCc1nccc(-c2ccc(C(=O)N3CCN(C4CCOCC4)CC3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"5.0";"nM";"8.30";"";"317147";"UO_0000065";"15.73";"0.29";"4.08";"11.76";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701092";"";"0";"375.86";"0";"4.17";"BDBM172227";"CNC(=O)c1cc(-c2ccnc(C)c2C#Cc2ccc(C)nc2)ccc1Cl";"IC50";"'='";"497.0";"nM";"6.30";"";"317151";"UO_0000065";"16.77";"0.32";"2.13";"11.49";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701098";"";"0";"275.31";"0";"2.16";"BDBM172233";"Cc1nccc(-c2cn[nH]c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"97.0";"nM";"7.01";"";"317157";"UO_0000065";"25.47";"0.46";"4.85";"8.71";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701099";"";"0";"497.62";"0";"4.53";"BDBM172234";"CCc1nccc(-c2ccc(C(=O)N3CCN(C4CCCC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.0";"nM";"8.40";"";"317158";"UO_0000065";"16.88";"0.31";"3.87";"11.15";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701115";"";"0";"471.58";"0";"4.13";"BDBM172250";"CCN1CCC(N(C)C(=O)c2cc(-c3ccnc(C)c3C#Cc3ccc(N)nc3)ccc2F)CC1";"IC50";"'='";"33.0";"nM";"7.48";"";"317174";"UO_0000065";"15.86";"0.29";"3.35";"9.93";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701131";"";"0";"444.51";"0";"3.42";"BDBM172266";"CCc1nccc(-c2ccc(C(=O)N3CCC(O)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"317190";"UO_0000065";"19.57";"0.36";"5.28";"9.42";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701134";"";"0";"514.61";"1";"2.67";"BDBM172269";"CCc1nccc(-c2ccc(C(=O)N3CCN(CC(=O)N(C)C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"317193";"UO_0000065";"16.90";"0.31";"6.03";"9.09";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701151";"";"0";"457.55";"0";"3.52";"BDBM172286";"CCc1nccc(-c2ccc(C(=O)N3CCN(C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1C";"IC50";"'='";"5.0";"nM";"8.30";"";"317210";"UO_0000065";"18.14";"0.33";"4.78";"11.02";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701154";"";"0";"501.61";"1";"3.54";"BDBM172289";"CCc1nccc(-c2ccc(C(=O)N3CCN(CCOC)CC3)c(F)c2)c1C#Cc1ccc(N)nc1C";"IC50";"'='";"21.0";"nM";"7.68";"";"317213";"UO_0000065";"15.31";"0.28";"4.14";"9.08";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701158";"";"0";"354.34";"0";"3.85";"BDBM172293";"Cc1nccc(-c2ccc(C(F)(F)F)nc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"27.0";"nM";"7.57";"";"317217";"UO_0000065";"21.36";"0.40";"3.72";"11.70";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701180";"";"0";"483.62";"0";"3.86";"BDBM172315";"CCCN1CCN(C(=O)c2ccc(-c3ccnc(CC)c3C#Cc3ccc(N)nc3)cc2OC)CC1";"IC50";"'='";"11.0";"nM";"7.96";"";"317239";"UO_0000065";"16.46";"0.30";"4.10";"9.41";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688920";"";"0";"480.54";"0";"2.64";"BDBM174382";"CNC(=O)c1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1F";"IC50";"'='";"300.0";"nM";"6.52";"";"319699";"UO_0000065";"13.57";"0.25";"3.88";"7.04";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693456";"";"0";"493.61";"0";"3.02";"BDBM174617";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCC(CCO)CC4)nc3n2)cc1CO";"IC50";"'='";"31.0";"nM";"7.51";"";"319895";"UO_0000065";"15.21";"0.28";"4.49";"7.21";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693478";"";"0";"464.57";"0";"2.35";"BDBM174640";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCC(N)CC4)nc3n2)cc1CO";"IC50";"'='";"78.0";"nM";"7.11";"";"319918";"UO_0000065";"15.30";"0.29";"4.76";"6.47";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3649480";"";"0";"439.50";"0";"3.11";"BDBM125519";"COc1ncc(Nc2ncc([C@@H](C)N3CCOCC3)cc2-c2cc(N)nc(C)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255165";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3923382";"";"0";"484.53";"0";"2.64";"BDBM178260";"CNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)nc3c2C(=O)N(C)CC(C)(C)O3)cc1F";"IC50";"'='";"24.0";"nM";"7.62";"";"324280";"UO_0000065";"15.73";"0.30";"4.98";"7.00";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3943113";"";"0";"543.63";"1";"4.18";"BDBM178278";"CCN1CC(C)(C)Oc2nc(N3C4CCC3COC4)nc(-c3ccc(NC(=O)Nc4ccccn4)cc3)c2C1=O";"IC50";"'='";"31.0";"nM";"7.51";"";"324298";"UO_0000065";"13.81";"0.26";"3.33";"6.16";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3975060";"";"0";"543.60";"1";"3.21";"BDBM178235";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)OC[C@H](C)O)c(F)c3)c2C1=O";"IC50";"'='";"286.0";"nM";"6.54";"";"324255";"UO_0000065";"12.04";"0.23";"3.33";"5.18";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3946655";"";"0";"612.74";"1";"4.78";"BDBM178240";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(N5CCCC5)cn4)cc3)c2C1=O";"IC50";"'='";"130.0";"nM";"6.89";"";"324260";"UO_0000065";"11.24";"0.21";"2.11";"5.51";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3909760";"";"0";"617.71";"1";"4.21";"BDBM178255";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(OCCOC)cn4)cc3)c2C1=O";"IC50";"'='";"56.0";"nM";"7.25";"";"324275";"UO_0000065";"11.74";"0.22";"3.04";"5.17";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3646581";"";"0";"518.65";"1";"3.54";"BDBM125435";"Cc1nc(N)nc(-c2cc(C(C)N3CCN(C(=O)N(C)C)CC3)cnc2Nc2ccc3scnc3c2)n1";"IC50";"'='";"326.0";"nM";"6.49";"";"255178";"UO_0000065";"12.51";"0.24";"2.95";"5.02";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646599";"";"0";"504.02";"1";"2.25";"BDBM125454";"Cc1nc(N)nc(-c2cc([C@@H](C)N3CCN(S(C)(=O)=O)CC3)cnc2Nc2ccc(Cl)nc2)n1";"IC50";"'='";"2674.0";"nM";"5.57";"";"255198";"UO_0000065";"11.06";"0.22";"3.32";"3.89";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646541";"";"0";"445.49";"1";"1.58";"BDBM125393";"COc1ccc(Nc2ncc(CN3CCn4ncnc4C3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"4801.0";"nM";"5.32";"";"255124";"UO_0000065";"11.94";"0.22";"3.74";"3.65";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646619";"";"0";"573.08";"1";"3.13";"BDBM125476";"Cc1nc(-c2cc(C(C)N3CCOCC3)cnc2Nc2cnc(Cl)c(NS(=O)(=O)N(C)C)c2)c2nc[nH]c2n1";"IC50";"'='";"81.0";"nM";"7.09";"";"255231";"UO_0000065";"12.37";"0.25";"3.96";"4.60";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646469";"";"0";"434.53";"0";"3.01";"BDBM125311";"Cc1nc(N)nc(-c2cc(CN3CCOCC3)cnc2Nc2ccc3scnc3c2)n1";"IC50";"'='";"1344.0";"nM";"5.87";"";"255029";"UO_0000065";"13.51";"0.26";"2.86";"5.11";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646479";"";"0";"523.62";"1";"2.51";"BDBM125321";"COc1ccc(Nc2ncc(C(C)N3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'='";"476.0";"nM";"6.32";"";"255040";"UO_0000065";"12.07";"0.23";"3.81";"4.45";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3955193";"";"0";"563.63";"1";"4.49";"BDBM178379";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccc(C)cn4)c(F)c3)c2C1=O";"IC50";"'='";"85.0";"nM";"7.07";"";"324399";"UO_0000065";"12.54";"0.24";"2.58";"5.80";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3967784";"";"0";"633.73";"1";"4.62";"BDBM178442";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccc(N5CCOCC5)cc4)c(F)c3)c2C1=O";"IC50";"'='";"76.0";"nM";"7.12";"";"324462";"UO_0000065";"11.23";"0.21";"2.50";"5.86";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3902420";"";"0";"702.79";"1";"4.82";"BDBM178451";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(N5CCN(C(=O)OC)CC5)cc4)c(F)c3)c2C1=O";"IC50";"'='";"112.0";"nM";"6.95";"";"324471";"UO_0000065";"9.89";"0.19";"2.13";"4.91";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3983518";"";"0";"573.63";"1";"4.38";"BDBM178271";"CCN1CC(C)(C)Oc2nc(N3CC4CC35CC5O4)nc(-c3ccc(NC(=O)Nc4ccnc(C)c4)c(F)c3)c2C1=O";"IC50";"'='";"41.0";"nM";"7.39";"";"324291";"UO_0000065";"12.88";"0.24";"3.01";"6.06";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3924494";"";"0";"561.62";"1";"4.32";"BDBM178286";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccncc4)cc3F)c2C1=O";"IC50";"'='";"21.0";"nM";"7.68";"";"324306";"UO_0000065";"13.67";"0.26";"3.36";"6.30";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3916167";"";"0";"610.64";"2";"5.81";"BDBM178362";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c2C1=O";"IC50";"'='";"182.0";"nM";"6.74";"";"324382";"UO_0000065";"11.04";"0.21";"0.93";"6.19";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3944119";"";"0";"629.72";"1";"4.35";"BDBM178363";"COc1ccc(NC(=O)Nc2ccc(-c3nc(N4CC5CCC(C4)O5)nc4c3C(=O)N(C3CCOCC3)CC(C)(C)O4)cc2)cn1";"IC50";"'='";"68.0";"nM";"7.17";"";"324383";"UO_0000065";"11.38";"0.21";"2.82";"5.11";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3892916";"";"0";"581.61";"1";"3.54";"BDBM178394";"COCCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccon4)c(F)c3)c2C1=O";"IC50";"'='";"58.0";"nM";"7.24";"";"324414";"UO_0000065";"12.44";"0.24";"3.70";"5.02";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3945623";"";"0";"549.61";"1";"4.18";"BDBM178407";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccccn4)c(F)c3)c2C1=O";"IC50";"'='";"29.0";"nM";"7.54";"";"324427";"UO_0000065";"13.71";"0.26";"3.36";"6.19";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3936728";"";"0";"564.62";"1";"3.66";"BDBM178409";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4cn(C)cn4)c(F)c3)c2C1=O";"IC50";"'='";"27.0";"nM";"7.57";"";"324429";"UO_0000065";"13.40";"0.25";"3.91";"5.97";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3943617";"";"0";"574.65";"1";"2.66";"BDBM178441";"COCCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)NCC(C)(C)O)c(F)c3)c2C1=O";"IC50";"'='";"1280.0";"nM";"5.89";"";"324461";"UO_0000065";"10.25";"0.20";"3.23";"4.26";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3915648";"";"0";"559.63";"1";"3.80";"BDBM178285";"COc1ccnc(NC(=O)Nc2ccc(-c3nc(N4C5CCC4COC5)nc4c3C(=O)N(C)CC(C)(C)O4)cc2)c1";"IC50";"'='";"27.0";"nM";"7.57";"";"324305";"UO_0000065";"13.52";"0.25";"3.77";"5.78";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3936062";"";"0";"572.67";"1";"4.20";"BDBM178308";"CCN1CC(C)(C)Oc2nc(N3C4CCC3COC4)nc(-c3ccc(NC(=O)Nc4cc(C)nc(C)n4)cc3)c2C1=O";"IC50";"'='";"72.0";"nM";"7.14";"";"324328";"UO_0000065";"12.47";"0.23";"2.94";"5.30";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3892574";"";"0";"547.62";"1";"4.08";"BDBM178331";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4cc(C)on4)cc3)c2C1=O";"IC50";"'='";"42.0";"nM";"7.38";"";"324351";"UO_0000065";"13.47";"0.25";"3.30";"5.47";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3922301";"";"0";"563.62";"1";"3.40";"BDBM178387";"COCCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccon4)cc3)c2C1=O";"IC50";"'='";"20.0";"nM";"7.70";"";"324407";"UO_0000065";"13.66";"0.26";"4.30";"5.34";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693501";"";"0";"525.41";"1";"3.67";"BDBM174663";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(-n4cc(Br)nc4C)nc3n2)cc1CO";"IC50";"'='";"43.0";"nM";"7.37";"";"319943";"UO_0000065";"14.02";"0.30";"3.70";"7.48";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3899047";"";"0";"658.78";"1";"4.68";"BDBM178228";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(N5CCN(C)CC5)cc4)c(F)c3)c2C1=O";"IC50";"'='";"132.0";"nM";"6.88";"";"324248";"UO_0000065";"10.44";"0.20";"2.20";"5.96";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3970833";"";"0";"561.62";"1";"4.32";"BDBM178266";"CCN1CC(C)(C)Oc2nc(N3C4CCC3COC4)nc(-c3ccc(NC(=O)Nc4ccncc4)c(F)c3)c2C1=O";"IC50";"'='";"20.0";"nM";"7.70";"";"324286";"UO_0000065";"13.71";"0.26";"3.38";"6.32";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688830";"";"0";"477.61";"0";"4.19";"BDBM174288";"CCC1CCCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(OC)c(CO)c3)nc2n1";"IC50";"'='";"1.84";"nM";"8.73";"";"320035";"UO_0000065";"18.29";"0.34";"4.55";"10.42";"False";"CHEMBL3705656";"Biological Assay: For mTOR enzyme activity assays, mTOR protein was isolated from HeLa cell cytoplasmic extract by immunoprecipitation, and activity determined essentially as described previously using recombinant PHAS-1as a substrate (ref 21).";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"HeLa";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";"CHEMBL3308376"
"CHEMBL3935750";"";"0";"527.62";"1";"3.32";"BDBM178429";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)OCC(C)(C)O)cc3)c2C1=O";"IC50";"'='";"2448.0";"nM";"5.61";"";"324449";"UO_0000065";"10.63";"0.20";"2.29";"4.44";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3984825";"";"0";"652.70";"2";"5.25";"BDBM178435";"COCCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4cccc(OC(C)F)c4)c(F)c3)c2C1=O";"IC50";"'='";"348.0";"nM";"6.46";"";"324455";"UO_0000065";"9.89";"0.19";"1.21";"5.07";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3938220";"";"0";"500.58";"1";"3.28";"BDBM178443";"CC[C@H]1COCCN1c1nc2c(c(-c3ccc(NC(=O)NC)c(F)c3)n1)C(=O)N(CC)CC(C)(C)O2";"IC50";"'='";"70.0";"nM";"7.16";"";"324463";"UO_0000065";"14.29";"0.27";"3.87";"6.57";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3920179";"";"0";"575.65";"1";"4.63";"BDBM178444";"CCN1CC(C)(C)Oc2nc(N3C4CCC3COC4)nc(-c3ccc(NC(=O)Nc4ccc(C)nc4)c(F)c3)c2C1=O";"IC50";"'='";"43.0";"nM";"7.37";"";"324464";"UO_0000065";"12.80";"0.24";"2.74";"6.05";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3906633";"";"0";"658.74";"1";"4.30";"BDBM178460";"CN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(N5C6CCC5COC6)nc4)c(F)c3)c2C1=O";"IC50";"'='";"63.0";"nM";"7.20";"";"324480";"UO_0000065";"10.93";"0.20";"2.90";"5.36";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3896468";"";"0";"595.72";"1";"3.75";"BDBM178345";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)NCC4CCN(C)CC4)c(F)c3)c2C1=O";"IC50";"'='";"2120.0";"nM";"5.67";"";"324365";"UO_0000065";"9.52";"0.18";"1.92";"5.06";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3958472";"";"0";"608.65";"2";"5.08";"BDBM178353";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(F)c(OC)c4)c(F)c3)c2C1=O";"IC50";"'='";"299.0";"nM";"6.52";"";"324373";"UO_0000065";"10.72";"0.20";"1.44";"5.52";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688945";"";"0";"465.55";"0";"2.64";"BDBM174422";"COc1ccc(-c2ccc3c(N4CCOC[C@H]4C)nc(N4CCOC[C@H]4C)nc3n2)cc1CO";"IC50";"'='";"13.0";"nM";"7.89";"";"319726";"UO_0000065";"16.94";"0.32";"5.25";"8.47";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL2336321";"";"0";"492.58";"0";"2.51";"BDBM50429705";"CNC(=O)c1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccc1OC";"IC50";"'='";"66.0";"nM";"7.18";"";"319768";"UO_0000065";"14.58";"0.27";"4.67";"7.04";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688851";"";"0";"424.51";"0";"2.75";"BDBM174310";"Cc1noc(C)c1-c1ccc2c(N3CCOC[C@@H]3C)nc(N3CCOC[C@@H]3C)nc2n1";"IC50";"'='";"370.0";"nM";"6.43";"";"319626";"UO_0000065";"15.15";"0.28";"3.68";"7.18";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688856";"";"0";"480.54";"0";"2.64";"BDBM174315";"CNC(=O)c1cc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)ccc1F";"IC50";"'='";"380.0";"nM";"6.42";"";"319631";"UO_0000065";"13.36";"0.25";"3.78";"6.93";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688870";"";"0";"498.61";"0";"2.51";"BDBM174329";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(NS(C)(=O)=O)c3)nc2n1";"IC50";"'='";"34.0";"nM";"7.47";"";"319646";"UO_0000065";"14.98";"0.29";"4.96";"6.80";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688873";"";"0";"449.51";"0";"2.84";"BDBM174333";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(C(=O)O)c3)nc2n1";"IC50";"'='";"9.2";"nM";"8.04";"";"319650";"UO_0000065";"17.88";"0.33";"5.20";"7.96";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688880";"";"0";"531.66";"1";"2.53";"BDBM174341";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cccc(C(=O)N4CCN(C)CC4)c3)nc2n1";"IC50";"'='";"60.0";"nM";"7.22";"";"319657";"UO_0000065";"13.58";"0.25";"4.69";"8.29";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688883";"";"0";"473.54";"0";"2.32";"BDBM174344";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(-c4nnn[nH]4)cc3)nc2n1";"IC50";"'='";"32.0";"nM";"7.50";"";"319660";"UO_0000065";"15.83";"0.29";"5.17";"6.35";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3688908";"";"0";"458.57";"0";"4.01";"BDBM174369";"C[C@H]1CN(c2nc(N3CCOC[C@@H]3C)c3ccc(-c4ccc5[nH]ccc5c4)nc3n2)C[C@@H](C)O1";"IC50";"'='";"220.0";"nM";"6.66";"";"319685";"UO_0000065";"14.52";"0.27";"2.65";"8.38";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693548";"";"0";"488.57";"0";"1.84";"BDBM174711";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(OCCS(C)(=O)=O)nc3n2)cc1CO";"IC50";"'='";"710.0";"nM";"6.15";"";"319993";"UO_0000065";"12.59";"0.25";"4.31";"4.96";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693549";"";"0";"439.52";"0";"2.02";"BDBM174712";"CNCCOc1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(OC)c(CO)c3)nc2n1";"IC50";"'='";"3.1";"nM";"8.51";"";"319994";"UO_0000065";"19.36";"0.36";"6.49";"8.35";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693588";"";"0";"366.42";"0";"2.42";"BDBM174755";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)ncnc3n2)cc1CO";"IC50";"'='";"200.0";"nM";"6.70";"";"320033";"UO_0000065";"18.28";"0.34";"4.28";"8.31";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3941033";"";"0";"561.62";"1";"4.32";"BDBM178438";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4cccnc4)c(F)c3)c2C1=O";"IC50";"'='";"20.0";"nM";"7.70";"";"324458";"UO_0000065";"13.71";"0.26";"3.38";"6.32";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3898823";"";"0";"552.61";"1";"3.52";"BDBM178381";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccn(C)n4)c(F)c3)c2C1=O";"IC50";"'='";"86.0";"nM";"7.07";"";"324401";"UO_0000065";"12.79";"0.24";"3.55";"5.57";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3916088";"";"0";"591.64";"1";"4.33";"BDBM178455";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(OC)nc4)c(F)c3)c2C1=O";"IC50";"'='";"61.0";"nM";"7.21";"";"324475";"UO_0000065";"12.19";"0.23";"2.88";"5.51";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693510";"";"0";"479.58";"0";"2.77";"BDBM174673";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCCCC4CO)nc3n2)cc1CO";"IC50";"'='";"25.0";"nM";"7.60";"";"319953";"UO_0000065";"15.85";"0.30";"4.83";"7.30";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693542";"";"0";"396.45";"0";"2.43";"BDBM174705";"COc1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(OC)c(CO)c3)nc2n1";"IC50";"'='";"80.0";"nM";"7.10";"";"319987";"UO_0000065";"17.90";"0.33";"4.67";"7.90";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693546";"";"0";"453.54";"0";"2.36";"BDBM174709";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(OCCN(C)C)nc3n2)cc1CO";"IC50";"'='";"120.0";"nM";"6.92";"";"319991";"UO_0000065";"15.26";"0.29";"4.56";"7.44";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693442";"";"0";"431.50";"0";"2.41";"BDBM174592";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3ccc(C#N)nc3)nc2n1";"IC50";"'='";"160.0";"nM";"6.80";"";"319881";"UO_0000065";"15.75";"0.29";"4.39";"6.78";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693470";"";"0";"492.58";"0";"2.12";"BDBM174632";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCC(C(N)=O)CC4)nc3n2)cc1CO";"IC50";"'='";"14.0";"nM";"7.85";"";"319910";"UO_0000065";"15.94";"0.30";"5.73";"6.19";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL4090324";"";"0";"411.53";"0";"3.20";"14e";"C[C@H]1CN(c2nc(N3CCOCC3)c3sc(-c4ccncc4)cc3n2)C[C@@H](C)O1";"IC50";"'>'";"2000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL4071150";"";"0";"357.42";"0";"0.50";"13";"Cc1cc(N)ncc1-c1nc(N2CCOCC2)nc(N2CCOCC2)n1";"IC50";"'='";"939.0";"nM";"6.03";"";"";"UO_0000065";"16.86";"0.32";"5.53";"5.88";"False";"CHEMBL4019299";"Inhibition of mTOR in human A2058 cells assessed as reduction in phosphorylation of S6 at ser235/236 residues after 1 hr by in-cell Western method";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4017506";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL4281240";"";"0";"413.50";"0";"2.28";"15";"C[C@@H]1COCCN1c1cc(C2(S(C)(=O)=O)CC2)nc(-c2cncc3[nH]ccc23)n1";"IC50";"'='";"34.0";"nM";"7.47";"";"";"UO_0000065";"18.06";"0.35";"5.19";"7.39";"False";"CHEMBL4269699";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4266018";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL3667418";"";"0";"434.50";"0";"2.35";"BDBM150990";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2nc(-c3ccnc4[nH]ccc34)[nH]c2n1";"IC50";"'='";"510.0";"nM";"6.29";"";"290537";"UO_0000065";"14.48";"0.27";"3.94";"5.82";"False";"CHEMBL3705815";"TR-FRET Tracer Assay: IC50s for mTOR interacting compounds were assessed using the FRAP1/mTOR TR-FRET tracer assay (Invitrogen by Life Technologies). FRAP1/mTOR (PV4753) and LanthaScreen Eu-Anti-GST Antibody (PV5594) (total volume of 14 uL) were added to each well of a ProxiPlate-384 Plus (Perkin-Elmer) 384-well plate. Compounds were serially diluted in DMSO (12-point, 4x dilution factor) and 1 uL of diluted compound was then added to each well and mixed by pipetting using a Biomek FX (Beckman Coulter). 5 uL of mTOR Kinase Tracer 314 (PV6087) was added to each well, mixed and plates were incubated at room temperature for 1 hour. Final concentrations of components are: 6 nM FRAP1/3 nM LanthaScreen Eu-Anti-GST Antibody/50 nM mTOR Kinase Tracer 314/unlabeled compounds, 4.8*10^-6-20 uM. Final assay buffer composition is: 50 mM HEPES (pH 7.5), 50 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Plates were measured in plate reader (Perkin Elmer, EnVision) using 340 nm excitation.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639085";"37";"BindingDB Database";"";"2015";""
"CHEMBL2165038";"";"0";"341.38";"0";"3.95";"BDBM50394882";"Cc1nc(-c2cccnc2Nc2cccc3[nH]ccc23)c2[nH]cnc2n1";"IC50";"'='";"621.0";"nM";"6.21";"";"254964";"UO_0000065";"18.18";"0.33";"2.26";"6.52";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643935";"";"0";"334.34";"0";"2.27";"BDBM125255";"COc1ncc(Nc2ncccc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'='";"426.0";"nM";"6.37";"";"254970";"UO_0000065";"19.05";"0.35";"4.10";"5.57";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646445";"";"0";"495.57";"0";"1.95";"BDBM125287";"COc1ccc(Nc2ncc(N3CCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'='";"186.0";"nM";"6.73";"";"254999";"UO_0000065";"13.58";"0.26";"4.78";"4.74";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646498";"";"0";"358.31";"0";"2.89";"BDBM125340";"Cc1nc(N)nc(-c2cccnc2Nc2ccc3c(c2)OC(F)(F)O3)n1";"IC50";"'>'";"10000.0";"nM";"";"";"255068";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646502";"";"0";"386.42";"0";"3.03";"BDBM125344";"COc1ccc(Nc2ncc(-c3ccccn3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"255072";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3688850";"";"0";"440.94";"0";"3.19";"BDBM174309";"C[C@H]1COCCN1c1nc(N2CCOC[C@@H]2C)c2ccc(-c3cncc(Cl)c3)nc2n1";"IC50";"'='";"180.0";"nM";"6.75";"";"319622";"UO_0000065";"15.30";"0.30";"3.55";"8.82";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3961518";"";"0";"524.62";"1";"2.91";"BDBM178432";"CCNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)nc3c2C(=O)N(CCOC)CC(C)(C)O3)cc1";"IC50";"'='";"59.0";"nM";"7.23";"";"324452";"UO_0000065";"13.78";"0.26";"4.32";"6.12";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3944530";"";"0";"495.58";"0";"2.68";"BDBM178232";"CCNC(=O)Nc1ccc(-c2nc(N3CC4CCC(C3)O4)nc3c2C(=O)N(CC)CC(C)(C)O3)cn1";"IC50";"'='";"2487.0";"nM";"5.60";"";"324252";"UO_0000065";"11.31";"0.21";"2.92";"4.60";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL4115267";"";"0";"660.75";"1";"4.55";"BDBM178245";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4ccc(N5CCOC[C@H]5C)nc4)c(F)c3)c2C1=O";"IC50";"'='";"21.0";"nM";"7.68";"";"324265";"UO_0000065";"11.62";"0.22";"3.13";"5.72";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3927742";"";"0";"573.65";"1";"4.19";"BDBM178250";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4cc(OC)ccn4)cc3)c2C1=O";"IC50";"'='";"37.0";"nM";"7.43";"";"324270";"UO_0000065";"12.96";"0.24";"3.24";"5.67";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3963551";"";"0";"587.66";"1";"4.69";"BDBM178273";"CCN1CC(C)(C)Oc2nc(N3CC4CC35CC5O4)nc(-c3ccc(NC(=O)Nc4cc(C)nc(C)c4)c(F)c3)c2C1=O";"IC50";"'='";"28.0";"nM";"7.55";"";"324293";"UO_0000065";"12.85";"0.24";"2.86";"6.20";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3890547";"";"0";"634.71";"1";"4.02";"BDBM178402";"CCN1CC(C)(C)Oc2nc(N3CCOC[C@@H]3C)nc(-c3ccc(NC(=O)Nc4ccc(N5CCOCC5)nc4)c(F)c3)c2C1=O";"IC50";"'='";"37.0";"nM";"7.43";"";"324422";"UO_0000065";"11.71";"0.22";"3.41";"5.53";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693406";"";"0";"490.61";"0";"3.12";"BDBM174547";"CC(=O)N(C)Cc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1";"IC50";"'='";"560.0";"nM";"6.25";"";"319843";"UO_0000065";"12.74";"0.24";"3.13";"7.45";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701084";"";"0";"471.58";"0";"4.06";"BDBM172218";"CCc1nccc(-c2ccc(C(=O)N3CCN(CC)CC3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"9.0";"nM";"8.05";"";"317142";"UO_0000065";"17.06";"0.31";"3.99";"13.11";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701133";"";"0";"487.58";"0";"3.23";"BDBM172268";"CCc1nccc(-c2ccc(C(=O)N3CCN(CCOC)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.0";"nM";"8.70";"";"317192";"UO_0000065";"17.84";"0.33";"5.47";"10.28";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701175";"";"0";"342.45";"0";"4.01";"BDBM172310";"CCc1nccc(-c2cc(C)nc(C)c2)c1C#Cc1ccc(N)nc1C";"IC50";"'='";"15.0";"nM";"7.82";"";"317234";"UO_0000065";"22.85";"0.41";"3.81";"12.09";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701165";"";"0";"485.61";"0";"4.44";"BDBM172300";"Cc1nc(N)ccc1C#Cc1c(-c2ccc(C(=O)N3CCN(C(C)(C)C)CC3)c(F)c2)ccnc1C";"IC50";"'='";"5.0";"nM";"8.30";"";"317224";"UO_0000065";"17.09";"0.31";"3.86";"11.02";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3701178";"";"0";"495.63";"0";"3.86";"BDBM172313";"CCc1nccc(-c2ccc(C(=O)N3CCN(CC4CC4)CC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"27.0";"nM";"7.57";"";"317237";"UO_0000065";"15.27";"0.28";"3.71";"8.95";"False";"CHEMBL3706375";"TR-FRET Assay: Kinase reaction conditions:400 nM GFP-4E-BP1, 8 uM ATP, -150 ng/mL mTOR, 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, 10 mM MnC12, and variable amounts of test compounds.Preparation of Reagents:Note: Thaw and keep mTOR, the substrate, ATP, and the antibody on ice prior to making working dilutions. Working dilutions of these components can be kept at room temperature for short periods of time the day of use.1. Add 2 ml of 5X Assay Buffer to 8 ml water to prepare 10 ml of IX Assay Buffer. Note: The concentration of IX Assay Buffer is 50 mM HEPES pH 7.5, 0.01% Polysorbate 20, 1 mM EGTA, and 10 mM MnC12.2. Prepare Antibody/EDTA Solution by first adding 2.75 ul of Tb-anti p4E-BPl Antibody to 2397 ul of LanthaScreenTM TR-FRET Dilution Buffer. Then, add 100 ul of 0.5 M EDTA. 3. Prepare 4X Substrate/Enzyme Solution by first adding 72 ul of GFP-4E-BP1 (22 uM) to 926 ul of IX Assay Buffer. Then, add 1.6 ul of mTOR (0.45 mg/mL). 4.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639133";"37";"BindingDB Database";"";"2015";""
"CHEMBL3966219";"";"0";"592.63";"1";"3.73";"BDBM178351";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4cnc(OC)nc4)c(F)c3)c2C1=O";"IC50";"'='";"34.0";"nM";"7.47";"";"324371";"UO_0000065";"12.60";"0.24";"3.74";"5.19";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693539";"";"0";"439.52";"0";"1.85";"BDBM174702";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N(C)CCO)nc3n2)cc1CO";"IC50";"'='";"6.3";"nM";"8.20";"";"319984";"UO_0000065";"18.66";"0.35";"6.35";"7.88";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693499";"";"0";"474.52";"0";"2.72";"BDBM174661";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(-n4cnc(C)c4C=O)nc3n2)cc1CO";"IC50";"'='";"160.0";"nM";"6.80";"";"319941";"UO_0000065";"14.32";"0.27";"4.08";"5.88";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3693484";"";"0";"479.58";"0";"3.03";"BDBM174646";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCCC(OC)C4)nc3n2)cc1CO";"IC50";"'='";"22.0";"nM";"7.66";"";"319924";"UO_0000065";"15.97";"0.30";"4.63";"8.23";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3646617";"";"0";"430.88";"0";"2.89";"BDBM125474";"Cc1nc(-c2cccnc2Nc2cnc(Cl)c(NS(C)(=O)=O)c2)c2nc[nH]c2n1";"IC50";"'='";"17.0";"nM";"7.77";"";"255229";"UO_0000065";"18.03";"0.37";"4.88";"5.61";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646552";"";"0";"390.45";"0";"2.35";"BDBM125405";"COc1ccc(Nc2ncc(C3=CCNCC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'='";"2614.0";"nM";"5.58";"";"255139";"UO_0000065";"14.30";"0.26";"3.23";"4.51";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646583";"";"0";"440.48";"0";"2.50";"BDBM125437";"COc1ncc(Nc2ncc([C@@H](C)N3CCOCC3)cc2-c2nc(C)nc(N)n2)cc1F";"IC50";"'>'";"10000.0";"nM";"";"";"255180";"UO_0000065";"";"";"";"";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646591";"";"0";"412.47";"0";"3.08";"BDBM125446";"CCC(N)(CC)c1cnc(Nc2cnc(OC)c(F)c2)c(-c2nc(C)nc(N)n2)c1";"IC50";"'='";"4875.0";"nM";"5.31";"";"255190";"UO_0000065";"12.88";"0.24";"2.23";"3.86";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL2206908";"";"0";"505.99";"2";"1.82";"BDBM50401252";"Cc1nc(N)nc(-c2cc(CN3CCOCC3)cnc2Nc2cnc(Cl)c(NS(C)(=O)=O)c2)n1";"IC50";"'='";"154.0";"nM";"6.81";"";"255223";"UO_0000065";"13.46";"0.27";"4.99";"4.23";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL3950980";"";"0";"559.63";"1";"3.80";"BDBM178236";"COc1ccnc(NC(=O)Nc2ccc(-c3nc(N4CC5CCC(C4)O5)nc4c3C(=O)N(C)CC(C)(C)O4)cc2)c1";"IC50";"'='";"15.0";"nM";"7.82";"";"324256";"UO_0000065";"13.98";"0.26";"4.02";"5.97";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3914585";"";"0";"591.64";"1";"4.33";"BDBM178304";"CCN1CC(C)(C)Oc2nc(N3C4CCC3COC4)nc(-c3ccc(NC(=O)Nc4cc(OC)ccn4)cc3F)c2C1=O";"IC50";"'='";"84.0";"nM";"7.08";"";"324324";"UO_0000065";"11.96";"0.22";"2.75";"5.40";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3942601";"";"0";"590.66";"1";"4.33";"BDBM178305";"CCN1CC(C)(C)Oc2nc(N3CC4CCC(C3)O4)nc(-c3ccc(NC(=O)Nc4cc(C)nc(C)n4)c(F)c3)c2C1=O";"IC50";"'='";"450.0";"nM";"6.35";"";"324325";"UO_0000065";"10.75";"0.20";"2.02";"4.71";"False";"CHEMBL3887223";"Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) Assay: The test detects the phosphorylation of the substrate GFP-4EBP1 using a terbium-labelled antibody that is specific for the phospho-Thr46 epitope. Binding of the Tb-antibody to the phosphorylated GFP peptide allows the transfer of energy from Tb, excited at 340 nm, to GFP with an increase in the fluorescence emission of the GFP at 520 nm. The test is performed in 96-well format (Corning/Costar 96 black flat-bottomed half-wells plate, ref. 3694) in a total volume of 30 ul. To 1 ul of inhibitor in 100% DMSO are added (final concentrations) 400 nM of GFP-4EBP1 (Invitrogen PV4759), 8 uM of ATP, 200 ng/ml of enzyme (human recombinant aa mTOR 1360-2549, Invitrogen PV4753) in a buffer of HEPES 50 mM pH 7.5, EGTA 1 mM, MnCl2 10 mM, BSA 0.1 mg/ml, glycerol 0.5%, NV-10 0.1 mg/ml, DTT 2 mM. The mixture is incubated for 30 minutes at room temperature. 10 ul of solution are taken up and the reaction is quenched by adding 10 ul of Tb-antibody solution (Invitrogen PV4757)/EDTA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886220";"37";"BindingDB Database";"";"2015";""
"CHEMBL3670228";"";"0";"408.51";"0";"1.53";"BDBM111704";"COCCNC(=O)CC1CCN(c2ncnc(C)c2C#Cc2ccc(N)nc2)CC1";"IC50";"'='";"144.0";"nM";"6.84";"";"232527";"UO_0000065";"16.75";"0.31";"5.31";"6.44";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670246";"";"0";"402.46";"0";"1.97";"BDBM111722";"CCc1ncnc(N2CCN(C(=O)c3ccco3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"60.0";"nM";"7.22";"";"232545";"UO_0000065";"17.94";"0.33";"5.25";"7.12";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670248";"";"0";"389.42";"0";"1.11";"BDBM111724";"Cc1ncnc(N2CCN(C(=O)c3ccno3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"55.0";"nM";"7.26";"";"232547";"UO_0000065";"18.64";"0.34";"6.15";"6.35";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670161";"";"0";"365.44";"0";"1.76";"BDBM111635";"CCc1ncnc(N2CCC3(CC2)OCCO3)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.0";"nM";"8.40";"";"232458";"UO_0000065";"22.98";"0.42";"6.64";"9.72";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670210";"";"0";"336.44";"0";"2.49";"BDBM111686";"CCc1ncnc(N2CCC(C)(O)CC2)c1C#Cc1ccc(C)nc1";"IC50";"'='";"30.0";"nM";"7.52";"";"232509";"UO_0000065";"22.36";"0.41";"5.03";"12.11";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670146";"";"0";"350.43";"0";"1.22";"BDBM111620";"CC(=O)N1CCCN(c2ncnc(C)c2C#Cc2ccc(N)nc2)CC1";"IC50";"'='";"94.0";"nM";"7.03";"";"232443";"UO_0000065";"20.05";"0.37";"5.81";"7.96";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670154";"";"0";"361.49";"0";"3.60";"BDBM111628";"CCc1ncnc(N2CCC(C=C(C)C)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"64.0";"nM";"7.19";"";"232451";"UO_0000065";"19.90";"0.36";"3.59";"10.59";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670245";"";"0";"366.43";"0";"1.30";"BDBM111721";"CCc1ncnc(N2CCN(C(=O)OC)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"101.0";"nM";"7.00";"";"232544";"UO_0000065";"19.09";"0.35";"5.70";"7.18";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670143";"";"0";"295.35";"0";"1.00";"BDBM111617";"Cc1ncnc(N2CCOCC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"38.0";"nM";"7.42";"";"232440";"UO_0000065";"25.12";"0.46";"6.42";"9.62";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670243";"";"0";"376.46";"0";"1.47";"BDBM111719";"CCc1ncnc(N2CCN(C(=O)C3CC3)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"113.0";"nM";"6.95";"";"232542";"UO_0000065";"18.45";"0.34";"5.48";"7.87";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670195";"";"0";"309.37";"0";"1.25";"BDBM111670";"CCc1ncnc(N2CCOCC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"93.0";"nM";"7.03";"";"232493";"UO_0000065";"22.73";"0.42";"5.78";"9.11";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL2165006";"";"0";"399.46";"0";"3.56";"61";"COc1ccc(Nc2ncc(Cc3ccccc3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165003";"";"0";"499.60";"1";"1.44";"58";"COc1ccc(Nc2ncc(CN3CCCN(S(C)(=O)=O)CC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165030";"";"0";"391.44";"0";"2.78";"40";"COc1ccc(Nc2ncc(C3=CCOCC3)cc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165049";"";"0";"310.32";"0";"1.37";"29";"COc1ccc(Nc2ncncc2-c2nc(C)nc(N)n2)cn1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL3643151";"";"0";"543.12";"2";"5.22";"BDBM115767";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCCCCC4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"42.96";"nM";"7.37";"";"240498";"UO_0000065";"13.56";"0.26";"2.15";"8.35";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643246";"";"0";"470.58";"0";"2.87";"BDBM115911";"CCc1ncnc(-c2ccc(C(=O)N3CC[C@H](N(C)C)C3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"61.95";"nM";"7.21";"";"240523";"UO_0000065";"15.32";"0.28";"4.34";"7.40";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643271";"";"0";"510.02";"1";"3.00";"BDBM115936";"CCc1ncnc(-c2ccc(C(=O)N(C)C3CCS(=O)(=O)C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"2.64";"nM";"8.58";"";"240548";"UO_0000065";"16.82";"0.33";"5.58";"7.20";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645804";"";"0";"494.64";"0";"4.09";"BDBM115982";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCCC4)CC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"11.91";"nM";"7.92";"";"240594";"UO_0000065";"16.02";"0.29";"3.83";"8.98";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645813";"";"0";"502.62";"1";"4.35";"BDBM115991";"CCc1ncnc(-c2ccc(C(=O)N3CCN(c4ccccc4)CC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.15";"nM";"8.50";"";"240603";"UO_0000065";"16.91";"0.31";"4.15";"9.63";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645857";"";"0";"518.06";"1";"4.82";"BDBM116036";"CCc1ncnc(-c2ccc(C(=O)N3CCC(C(C)(C)O)CC3)c(Cl)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"3.43";"nM";"8.46";"";"240648";"UO_0000065";"16.34";"0.31";"3.64";"9.28";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645878";"";"0";"534.45";"1";"4.06";"BDBM116057";"CCc1ncnc(-c2cc(Cl)c(C(=O)N3CCN(CCC#N)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.38";"nM";"8.86";"";"240669";"UO_0000065";"16.58";"0.33";"4.80";"7.91";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643099";"";"0";"474.54";"0";"1.97";"BDBM115715";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CCO)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.0";"nM";"8.40";"";"240352";"UO_0000065";"17.70";"0.33";"6.43";"7.74";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643116";"";"0";"445.50";"0";"2.82";"BDBM115732";"CCc1ncnc(-c2ccc(C(=O)N3CCCC(O)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"6.0";"nM";"8.22";"";"240369";"UO_0000065";"18.46";"0.34";"5.40";"7.81";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3890706";"";"0";"480.59";"0";"2.58";"BDBM60569";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCSCC4)nc3n2)cc1C(N)=O";"IC50";"'='";"5.5";"nM";"8.26";"";"235366";"UO_0000065";"17.19";"0.33";"5.68";"7.74";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3986415";"";"0";"477.57";"0";"1.78";"BDBM60570";"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCN(C)CC4)nc3n2)cc1C(N)=O";"IC50";"'='";"30.0";"nM";"7.52";"";"235367";"UO_0000065";"15.75";"0.29";"5.74";"6.84";"False";"CHEMBL3705655";"Alternative Enzyme Assay: The assay used AlphaScreen technology (Gray et al., Analytical Biochemistry, 2003, 313: 234-245) to determine the ability of test compounds to inhibit phosphorylation by recombinant mTOR.Test compounds were prepared as 10 mM stock solutions in DMSO and diluted into water as required to give a range of final assay concentrations. Aliquots (2 ul) of each compound dilution were placed into a well of a Greiner 384-well low volume (LV) white polystyrene plate (Greiner Bio-one). A 10 ul mixture of recombinant purified mTOR enzyme, 1 uM biotinylated peptide substrate (Biotin-Ahx-Lys-Lys-Ala-Asn-Gln-Val-Phe-Leu-Gly-Phe-Thr-Tyr-Val-Ala-Pro-Ser-Val-Leu-Glu-Ser-Val-Lys-Glu-NH2; Bachem UK Ltd), ATP (20 uM) in a buffer solution [comprising Tris-HCl pH7.4 buffer (50 mM), EGTA (0.1 mM), bovine serum albumin (0.5 mg/ml), DTT (1.25 mM) and manganese chloride (10 mM)] were added to the assay plates and incubated with compound for 2 hours at room temperature.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638644";"37";"BindingDB Database";"";"2015";""
"CHEMBL3643144";"";"0";"475.00";"0";"3.56";"BDBM115760";"CCc1ncnc(-c2ccc(C(=O)NC3CCCN(C)C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"56.51";"nM";"7.25";"";"240490";"UO_0000065";"15.26";"0.29";"3.69";"7.47";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643148";"";"0";"447.93";"0";"2.94";"BDBM115764";"CCc1ncnc(-c2ccc(C(=O)N3CC[C@H](O)C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"1.99";"nM";"8.70";"";"240495";"UO_0000065";"19.43";"0.37";"5.76";"8.27";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643233";"";"0";"501.03";"1";"3.90";"BDBM115896";"CCc1ncnc(-c2ccc(C(=O)N3CCC4(CCN(C)C4)C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"40.09";"nM";"7.40";"";"240508";"UO_0000065";"14.76";"0.28";"3.50";"8.38";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645806";"";"0";"387.44";"0";"2.85";"BDBM115984";"CCc1ncnc(-c2ccc(C(=O)N(C)O)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"27.44";"nM";"7.56";"";"240596";"UO_0000065";"19.52";"0.36";"4.71";"7.19";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645855";"";"0";"458.54";"0";"3.07";"BDBM116034";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C)CC3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"4.7";"nM";"8.33";"";"240646";"UO_0000065";"18.16";"0.33";"5.26";"11.22";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643152";"";"0";"489.02";"0";"3.90";"BDBM115768";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N(C)C)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"30.0";"nM";"7.52";"";"240405";"UO_0000065";"15.38";"0.29";"3.62";"8.53";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643165";"";"0";"454.58";"0";"3.39";"BDBM115806";"CCCCN1CCN(C(=O)c2ccc(-c3ncnc(C)c3C#Cc3ccc(N)nc3)cc2)CC1";"IC50";"'='";"8.0";"nM";"8.10";"";"240418";"UO_0000065";"17.81";"0.33";"4.71";"9.18";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643225";"";"0";"393.40";"0";"2.72";"BDBM115868";"CCc1ncnc(-c2cc(F)c(C(=O)NC)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.42";"nM";"8.47";"";"240480";"UO_0000065";"21.52";"0.40";"5.75";"9.03";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643143";"";"0";"543.12";"1";"4.93";"BDBM115759";"CCc1ncnc(-c2ccc(C(=O)N3CCC(C4CCN(C)CC4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"6.99";"nM";"8.16";"";"240489";"UO_0000065";"15.02";"0.29";"3.23";"9.24";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643238";"";"0";"526.64";"1";"3.03";"BDBM115903";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCOCC4)CC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"12.48";"nM";"7.90";"";"240515";"UO_0000065";"15.01";"0.28";"4.87";"7.41";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643249";"";"0";"538.70";"1";"4.57";"BDBM115914";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCCCCC4)CC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"50.49";"nM";"7.30";"";"240526";"UO_0000065";"13.55";"0.25";"2.73";"7.49";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645777";"";"0";"454.58";"0";"3.17";"BDBM115955";"CCc1ncnc(-c2ccc(C(=O)N3CC[C@H](N(C)C)C3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"11.05";"nM";"7.96";"";"240567";"UO_0000065";"17.50";"0.32";"4.79";"9.02";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645800";"";"0";"455.56";"0";"3.38";"BDBM115978";"CCc1ncnc(-c2ccc(C(=O)N3CCC(C)(O)CC3)c(C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"6.62";"nM";"8.18";"";"240590";"UO_0000065";"17.95";"0.33";"4.80";"7.77";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645814";"";"0";"487.01";"0";"3.66";"BDBM115992";"CCc1ncnc(-c2ccc(C(=O)N3CCN4CCC[C@@H]4C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.99";"nM";"9.00";"";"240604";"UO_0000065";"18.49";"0.35";"5.34";"10.20";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645829";"";"0";"501.95";"1";"3.73";"BDBM116007";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCn4ccnc4C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.51";"nM";"9.29";"";"240619";"UO_0000065";"18.51";"0.35";"5.56";"9.04";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645859";"";"0";"545.09";"1";"4.13";"BDBM116038";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C4CCOCC4)CC3)c(Cl)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"1.93";"nM";"8.71";"";"240650";"UO_0000065";"15.99";"0.31";"4.58";"10.44";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643063";"";"0";"470.58";"0";"2.87";"BDBM115678";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CC)CC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"240315";"UO_0000065";"18.11";"0.33";"5.65";"8.74";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643093";"";"0";"515.59";"1";"2.07";"BDBM115709";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CC(=O)N(C)C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"7.0";"nM";"8.15";"";"240346";"UO_0000065";"15.82";"0.29";"6.08";"7.51";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643107";"";"0";"501.61";"1";"2.54";"BDBM115723";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CCN(C)C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"16.0";"nM";"7.80";"";"240360";"UO_0000065";"15.54";"0.29";"5.26";"8.52";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643123";"";"0";"458.54";"0";"3.00";"BDBM115739";"CCc1ncnc(-c2ccc(C(=O)N3CCCN(C)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"17.0";"nM";"7.77";"";"240376";"UO_0000065";"16.94";"0.31";"4.77";"8.81";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643125";"";"0";"459.53";"0";"3.47";"BDBM115741";"CCc1ncnc(-c2ccc(C(=O)N3CCOC(C)(C)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"9.0";"nM";"8.05";"";"240378";"UO_0000065";"17.51";"0.32";"4.58";"8.54";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3670168";"";"0";"350.47";"0";"2.74";"BDBM111642";"CCc1ncnc(N2CCC(CCO)CC2)c1C#Cc1ccc(C)nc1";"IC50";"'='";"67.0";"nM";"7.17";"";"232465";"UO_0000065";"20.47";"0.38";"4.43";"11.54";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670169";"";"0";"337.43";"0";"1.76";"BDBM111643";"Cc1ncnc(N2CCC(CCO)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"9.0";"nM";"8.05";"";"232466";"UO_0000065";"23.84";"0.44";"6.29";"9.13";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670176";"";"0";"381.48";"0";"2.05";"BDBM111650";"CCc1ncnc(N2CCC(OCCOC)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"36.0";"nM";"7.44";"";"232473";"UO_0000065";"19.51";"0.36";"5.39";"8.62";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670208";"";"0";"336.44";"0";"2.35";"BDBM111684";"CCc1ncnc(N2CCCC(CO)C2)c1C#Cc1ccc(C)nc1";"IC50";"'='";"108.0";"nM";"6.97";"";"232507";"UO_0000065";"20.71";"0.38";"4.62";"11.21";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3639690";"";"0";"337.43";"0";"1.62";"BDBM111677";"CCc1ncnc(N2CCC(O)C(C)C2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"10.0";"nM";"8.00";"";"232500";"UO_0000065";"23.71";"0.44";"6.38";"9.07";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670225";"";"0";"378.48";"0";"1.86";"BDBM111701";"Cc1ncnc(N2CCC(CC(=O)N(C)C)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"45.0";"nM";"7.35";"";"232524";"UO_0000065";"19.41";"0.36";"5.49";"8.33";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670178";"";"0";"351.45";"0";"2.28";"BDBM111652";"CCc1ncnc(N2CCC(COC)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"19.0";"nM";"7.72";"";"232475";"UO_0000065";"21.97";"0.41";"5.44";"10.01";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670201";"";"0";"365.48";"0";"2.40";"BDBM111676";"CCc1ncnc(N2CCC(O)(C(C)C)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.61";"nM";"9.21";"";"232499";"UO_0000065";"25.21";"0.47";"6.81";"10.45";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670216";"";"0";"366.47";"0";"1.05";"BDBM111692";"Cc1ncnc(N2CCN(CC(C)(C)O)CC2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"18.0";"nM";"7.75";"";"232515";"UO_0000065";"21.13";"0.39";"6.69";"8.47";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL3670231";"";"0";"392.51";"0";"2.25";"BDBM111707";"CCN(C)C(=O)CC1CCN(c2ncnc(C)c2C#Cc2ccc(N)nc2)CC1";"IC50";"'='";"53.0";"nM";"7.28";"";"232530";"UO_0000065";"18.54";"0.34";"5.03";"8.25";"False";"CHEMBL3705850";"Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself is divided into two phases: the reaction phase and the detection phase. In the reaction phase, all components required for the kinase reaction are added to the well, including the labeled protein substrate. The reaction is allowed to incubate for 60 minutes. After the reaction, EDTA is added to stop the kinase reaction, and terbium-labeled antibody is added to bind phosphorylated product. Because the terbium chelate is stable at the EDTA concentrations used to stop a kinase assay, the antibody and EDTA can be pre-mixed prior to addition to minimize pipetting steps. Binding of the terbium labeled antibody to the fluorophore-labeled phosphorylated product brings the terbium and GFP into proximity, resulting in an increase in TR-FRET.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638997";"37";"BindingDB Database";"";"2013";""
"CHEMBL2165028";"";"0";"396.46";"0";"1.71";"38";"COCCNCc1cnc(Nc2ccc(OC)nc2)c(-c2nc(C)nc(N)n2)c1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"True";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL2165268";"";"0";"317.36";"0";"3.05";"11";"Cc1nc(N)nc(-c2cccnc2Nc2cccc3[nH]ccc23)n1";"IC50";"'='";"7200.0";"nM";"5.14";"";"";"UO_0000065";"16.20";"0.29";"2.09";"4.88";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL4281240";"";"0";"413.50";"0";"2.28";"15";"C[C@@H]1COCCN1c1cc(C2(S(C)(=O)=O)CC2)nc(-c2cncc3[nH]ccc23)n1";"IC50";"'='";"1400.0";"nM";"5.85";"";"";"UO_0000065";"14.16";"0.28";"3.57";"5.79";"False";"CHEMBL4269700";"Inhibition of mTOR in human MDA-MB-468 cells assessed as decrease in AKT phosphorylation at S473 residue";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MDA-MB-468";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4266018";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL2325697";"";"0";"412.52";"0";"2.88";"1; AZ20";"C[C@@H]1COCCN1c1cc(C2(S(C)(=O)=O)CC2)nc(-c2cccc3[nH]ccc23)n1";"IC50";"'='";"2400.0";"nM";"5.62";"";"";"UO_0000065";"13.62";"0.26";"2.74";"6.37";"False";"CHEMBL4269700";"Inhibition of mTOR in human MDA-MB-468 cells assessed as decrease in AKT phosphorylation at S473 residue";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MDA-MB-468";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4266018";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL4281240";"";"0";"413.50";"0";"2.28";"15";"C[C@@H]1COCCN1c1cc(C2(S(C)(=O)=O)CC2)nc(-c2cncc3[nH]ccc23)n1";"IC50";"'='";"270.0";"nM";"6.57";"";"";"UO_0000065";"15.89";"0.31";"4.29";"6.50";"False";"CHEMBL4269701";"Inhibition of mTOR in human MDA-MB-468 cells assessed as decrease in 70S6K S235/236 phosphorylation";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MDA-MB-468";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4266018";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL3648329";"";"0";"441.56";"0";"2.75";"35";"CNc1nc2ccccc2n1-c1nc(N2CCOC[C@H]2C)cc(C2([S@](C)(=N)=O)CC2)n1";"IC50";"'='";"3100.0";"nM";"5.51";"";"";"UO_0000065";"12.48";"0.24";"2.76";"5.05";"False";"CHEMBL4269701";"Inhibition of mTOR in human MDA-MB-468 cells assessed as decrease in 70S6K S235/236 phosphorylation";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MDA-MB-468";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4266018";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL4291192";"";"0";"529.77";"2";"6.19";"19";"CCOC(=O)C1=C(CSC(=S)N(C2CCCCC2)C2CCCCC2)N(C)C(=O)NC1c1ccccc1";"IC50";"'='";"640.0";"nM";"6.19";"";"";"UO_0000065";"11.69";"0.23";"0.00";"10.01";"False";"CHEMBL4272807";"Inhibition of mTOR (unknown origin) incubated for 1 hr by ELISA";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4270553";"1";"Scientific Literature";"Eur J Med Chem";"2018";""
"CHEMBL3900163";"";"0";"400.46";"0";"1.77";"BDBM251584";"CS(=O)(=O)Cc1nc(-c2cccc3[nH]ccc23)nc2c1OCC1COCCN21";"IC50";"'='";"1620.0";"nM";"5.79";"";"438480";"UO_0000065";"14.46";"0.28";"4.02";"5.94";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3916419";"";"0";"446.50";"0";"2.64";"BDBM251591";"CC(C)(c1nc(-c2c(F)ccc3[nH]ccc23)nc2c1OCC1COCCN21)S(C)(=O)=O";"IC50";"'='";"2190.0";"nM";"5.66";"";"438487";"UO_0000065";"12.68";"0.25";"3.02";"5.81";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3943001";"";"0";"456.53";"0";"1.49";"BDBM251629";"CNc1nc2ccccc2n1-c1nc2c(c(C3(S(C)(=O)=O)CC3)n1)OC[C@@H]1COCCN21";"IC50";"'='";"854.0";"nM";"6.07";"";"438525";"UO_0000065";"13.29";"0.26";"4.58";"5.44";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL4110558";"";"0";"445.53";"0";"0.69";"BDBM251633";"CC(C)(c1nc(-[n+]2c(N)[nH]c3ccccc32)nc2c1OC[C@@H]1COCCN21)S(C)(=O)=O";"IC50";"'='";"226.0";"nM";"6.65";"";"438529";"UO_0000065";"14.92";"0.29";"5.96";"5.22";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3943875";"";"0";"490.97";"0";"2.14";"BDBM251645";"CNc1nc2cc(Cl)ccc2n1-c1nc2c(c(C3(S(C)(=O)=O)CC3)n1)OC[C@@H]1COCCN21";"IC50";"'='";"3410.0";"nM";"5.47";"";"438543";"UO_0000065";"11.14";"0.23";"3.33";"4.90";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL4110591";"";"0";"446.50";"0";"2.64";"BDBM251603";"CC(C)(c1nc(-c2c(F)ccc3[nH]ccc23)nc2c1OC[C@H]1COCCN21)S(C)(=O)=O";"IC50";"'='";"10000.0";"nM";"5.00";"";"438499";"UO_0000065";"11.20";"0.22";"2.36";"5.13";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3897015";"";"0";"396.45";"0";"2.46";"BDBM251623";"COc1cc(-c2nc3c(c(C(C)(C)O)n2)OC[C@@H]2COCCN32)c2cc[nH]c2c1";"IC50";"'='";"38.0";"nM";"7.42";"";"438519";"UO_0000065";"18.72";"0.35";"4.96";"8.00";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3908893";"";"0";"488.54";"0";"2.41";"BDBM251654";"CS(=O)(=O)C1(c2nc(-c3ccc(F)c4[nH]ccc34)nc3c2OC[C@@H]2COCCN32)CCOCC1";"IC50";"'='";"10000.0";"nM";"5.00";"";"438555";"UO_0000065";"10.23";"0.20";"2.59";"4.69";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL4173271";"";"0";"573.06";"1";"4.57";"9i";"O=C(Nc1ccc(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cc1)Nc1ccc(Cl)c(-c2ccncc2)c1";"IC50";"'='";"180.0";"nM";"6.75";"";"";"UO_0000065";"11.77";"0.22";"2.17";"5.73";"False";"CHEMBL4141549";"Inhibition of mTOR (unknown origin) using Ulight-4EBP1 peptide as substrate measured after 1 hr by Lance Ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4138149";"1";"Scientific Literature";"Eur J Med Chem";"2017";""
"CHEMBL3936734";"";"0";"461.57";"0";"3.63";"BDBM245475";"CO[C@H]1C[C@@H](n2c(=O)n(C)c3cnc4ccc(-c5ccc(OCCCN(C)C)nc5)cc4c32)C1";"IC50";"'='";"1170.0";"nM";"5.93";"";"427885";"UO_0000065";"12.85";"0.24";"2.30";"7.97";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3986918";"";"0";"479.56";"0";"3.77";"BDBM245481";"CN(C)CCCOc1ccc(-c2cc3c(cc2F)ncc2c3n(C3CCOCC3)c(=O)n2C)cn1";"IC50";"'='";"14000.0";"nM";"4.85";"";"427891";"UO_0000065";"10.12";"0.19";"1.08";"6.52";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3890119";"";"0";"505.59";"1";"4.31";"BDBM245496";"Cn1c(=O)n([C@H]2CCCOC2)c2c3cc(-c4ccc(OCCCN5CCCC5)nc4)c(F)cc3ncc21";"IC50";"'='";"18200.0";"nM";"4.74";"";"427906";"UO_0000065";"9.38";"0.17";"0.43";"6.37";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3936943";"";"0";"487.60";"0";"4.16";"BDBM245500";"CO[C@H]1C[C@@H](n2c(=O)n(C)c3cnc4ccc(-c5ccc(OCCCN6CCCC6)nc5)cc4c32)C1";"IC50";"'='";"2770.0";"nM";"5.56";"";"427911";"UO_0000065";"11.40";"0.21";"1.40";"7.47";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3955034";"";"0";"473.58";"0";"4.15";"BDBM245507";"CO[C@H]1C[C@@H](n2c(=O)[nH]c3cnc4ccc(-c5ccc(OCCCN6CCCC6)nc5)cc4c32)C1";"IC50";"'='";"579.0";"nM";"6.24";"";"427918";"UO_0000065";"13.17";"0.24";"2.09";"7.31";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3954517";"";"0";"447.54";"0";"3.29";"BDBM245514";"CNCCCOc1ccc(-c2ccc3ncc4c(c3c2)n([C@H]2C[C@@H](OC)C2)c(=O)n4C)cn1";"IC50";"'='";"214.0";"nM";"6.67";"";"427925";"UO_0000065";"14.90";"0.28";"3.38";"8.02";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3932222";"";"0";"447.54";"0";"3.24";"BDBM245517";"CN(C)CCCOc1ccc(-c2ccc3ncc4c(c3c2)n([C@H]2CCOC2)c(=O)n4C)cn1";"IC50";"'='";"1190.0";"nM";"5.92";"";"427928";"UO_0000065";"13.24";"0.25";"2.68";"7.96";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3932835";"";"0";"451.50";"0";"2.99";"BDBM245524";"CN(C)CCCOc1ccc(-c2ccc3ncc4c(c3c2)n(C2COC2)c(=O)n4C)c(F)n1";"IC50";"'='";"12100.0";"nM";"4.92";"";"427934";"UO_0000065";"10.89";"0.20";"1.93";"6.61";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3946515";"";"0";"519.62";"1";"4.70";"BDBM245525";"Cn1c(=O)n(C2CCOCC2)c2c3cc(-c4ccc(OCCCN5CCCCC5)nc4)c(F)cc3ncc21";"IC50";"'>'";"29300.0";"nM";"";"";"427935";"UO_0000065";"";"";"";"";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL4114446";"";"0";"493.58";"0";"4.16";"BDBM245534";"CO[C@@H]1CC[C@@H](n2c(=O)n(C)c3cnc4cc(F)c(-c5ccc(OCCCN(C)C)nc5)cc4c32)C1";"IC50";"'>'";"30000.0";"nM";"";"";"427943";"UO_0000065";"";"";"";"";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL4115552";"";"0";"514.67";"1";"4.98";"BDBM245535";"CO[C@@H]1CC[C@@H](n2c(=O)n(C)c3cnc4ccc(-c5ccc(NCCCN6CCCCC6)nc5)cc4c32)C1";"IC50";"'='";"12000.0";"nM";"4.92";"";"427945";"UO_0000065";"9.56";"0.18";"-0.06";"6.37";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3904625";"";"0";"501.63";"1";"4.55";"BDBM245536";"CO[C@H]1CC[C@H](n2c(=O)n(C)c3cnc4ccc(-c5ccc(OCCCN6CCCC6)nc5)cc4c32)C1";"IC50";"'='";"3320.0";"nM";"5.48";"";"427947";"UO_0000065";"10.92";"0.20";"0.93";"7.36";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3968419";"";"0";"332.37";"0";"2.26";"BDBM245540";"Cn1c(=O)n(C2CC2)c2c3cc(-c4cnc(N)nc4)ccc3ncc21";"IC50";"'='";"287.0";"nM";"6.54";"";"427985";"UO_0000065";"19.68";"0.36";"4.28";"7.14";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3970131";"";"0";"465.54";"0";"3.20";"BDBM245467";"COc1ncc(-c2ccc3ncc4c(c3c2)n(C2CC2)c(=O)n4C)cc1NS(=O)(=O)C1CC1";"IC50";"'='";"46.9";"nM";"7.33";"";"427987";"UO_0000065";"15.74";"0.30";"4.13";"6.78";"False";"CHEMBL3888994";"Cellular Assay: Assay d) MDA-MB-468 cells (human breast adenocarcinoma ##ATCC HTB 132) were seeded at 1500 cells/well in 40 ¿l of DMEM containing 10% FBS and 1% glutamine into Greiner 384 well black flat-bottomed plates. Cell plates were incubated for 18 h in a 37° C. incubator before dosing with compounds of formula (I) in 100% DMSO using acoustic dispensing. Compounds were dosed in a 12 point concentration range into a randomised plate map. Control wells were generated either by dosing of 100% DMSO (max signal) or addition of a reference compound (a PI3K-ß inhibitor) that completely eliminated the pAKT signal (min control). Plates were incubated, at 37° C. for 2 h, cells were then fixed by the addition of 10 ¿l of a 3.7% formaldehyde solution. After 30 minutes the plates were washed with PBS using a Tecan PW384 plate washer. Wells were blocked and cells permeabilised with the addition of 40 ¿l of PBS containing 0.5% Tween20 and 1% Marvel¿ (dried milk powder) and incubated for 60 minutes at r.t. The plates were washed with PBS containing 0.5% (v/v) Tween20 and 20 ¿l rabbit anti-phospho AKT Ser473 (Cell Signalling Technologies, #3787) in same PBS-Tween+1% Marvel¿ was added and incubated overnight at 4° C. Plates were washed 3 times with PBS 0.05% Tween 20 using a Tecan PW384. 20 ¿l of secondary antibody Alexa Fluor 488 anti-Rabbit (Molecular Probes, #A11008) diluted in PBS+0.05% Tween20 containing 1% Marvel¿ was added to each well and incubated for 1 h at r.t. Plates were washed three times as before then 20 ¿l PBS added to each well and plates sealed with a black plate sealer. The plates were read on an Acumen plate reader as soon as possible, measuring green fluorescence after excitation with 488 nm laser.";"B";"BAO_0000218";"organism-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886912";"37";"BindingDB Database";"";"2016";""
"CHEMBL3109141";"";"0";"456.51";"0";"3.66";"13b";"O=C(Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1)Nc1cccc(CO)c1";"IC50";"'='";"1.0";"nM";"9.00";"";"";"UO_0000065";"19.71";"0.36";"5.34";"8.00";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL4104902";"";"0";"547.60";"1";"2.34";"4m";"N=C(N)NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(-c3nc(N4CCOCC4)c4ncccc4n3)cc2)cc1";"IC50";"'='";"3.57";"nM";"8.45";"";"";"UO_0000065";"15.43";"0.30";"6.11";"4.49";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL4092840";"";"0";"582.65";"1";"4.37";"4o";"O=C(Nc1ccc(-c2nc(N3CCOCC3)c3ncccc3n2)cc1)Nc1ccc(S(=O)(=O)Nc2ccccn2)cc1";"IC50";"'='";"274.0";"nM";"6.56";"";"";"UO_0000065";"11.26";"0.21";"2.19";"4.34";"False";"CHEMBL4022584";"Competitive inhibition of human mTOR using 4EBP1 as substrate in presence of [33gammaP]-ATP after 120 mins by filter binding method";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4020805";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL2165043";"";"0";"317.35";"0";"3.70";"23";"Cc1cc(-c2cccnc2Oc2cccc3[nH]ccc23)nc(N)n1";"IC50";"'>'";"10000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL3640934";"";"0";"357.42";"0";"2.53";"BDBM115584";"Cc1ncnc(-c2cccc(C(=O)N(C)C)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"17.0";"nM";"7.77";"";"240221";"UO_0000065";"21.74";"0.39";"5.24";"9.14";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640949";"";"0";"301.35";"0";"2.53";"BDBM115599";"Cc1ccc(-c2ncnc(C)c2C#Cc2ccc(N)nc2)cn1";"IC50";"'='";"34.0";"nM";"7.47";"";"240236";"UO_0000065";"24.78";"0.44";"4.94";"9.63";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640953";"";"0";"369.35";"0";"3.50";"BDBM115603";"CCc1ncnc(-c2ccc(C(F)(F)F)nc2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"50.0";"nM";"7.30";"";"240240";"UO_0000065";"19.77";"0.37";"3.80";"9.41";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640976";"";"0";"447.51";"0";"3.33";"BDBM115626";"CCc1ncnc(-c2ccc(C(=O)N(C)CCCOC)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"240263";"UO_0000065";"19.05";"0.35";"5.19";"9.04";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3641001";"";"0";"532.09";"1";"3.36";"BDBM115652";"CCc1ncnc(-c2ccc(C(=O)N3CCN(CCN(C)C)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1C";"IC50";"'='";"5.0";"nM";"8.30";"";"240289";"UO_0000065";"15.60";"0.30";"4.94";"9.07";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3641005";"";"0";"531.06";"1";"3.67";"BDBM115656";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C4CCOCC4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.88";"nM";"9.06";"";"240293";"UO_0000065";"17.05";"0.33";"5.39";"9.29";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3641022";"";"0";"498.63";"0";"3.65";"BDBM115673";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C(C)(C)C)CC3)c(OC)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"240310";"UO_0000065";"17.09";"0.31";"4.87";"8.74";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643207";"";"0";"500.58";"1";"2.77";"BDBM115850";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCOCC4)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"8.0";"nM";"8.10";"";"240462";"UO_0000065";"16.18";"0.30";"5.33";"8.31";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643212";"";"0";"431.47";"0";"2.69";"BDBM115855";"CCc1ncnc(-c2ccc(C(=O)N3CCOCC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.0";"nM";"8.52";"";"240467";"UO_0000065";"19.75";"0.36";"5.83";"9.04";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643220";"";"0";"502.57";"1";"3.53";"BDBM115863";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(CC4CC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.94";"nM";"9.03";"";"240475";"UO_0000065";"17.96";"0.33";"5.50";"10.23";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645881";"";"0";"490.56";"0";"3.60";"BDBM116060";"CCc1ncnc(-c2cc(F)c(C(=O)N3CC[C@@H](N(C)C)C3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"5.71";"nM";"8.24";"";"240672";"UO_0000065";"16.80";"0.31";"4.64";"11.10";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645887";"";"0";"546.62";"1";"3.76";"BDBM116066";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCC(N4CCOCC4)CC3)c(F)c2)c1C#Cc1ccc(NC)nc1";"IC50";"'='";"1.96";"nM";"8.71";"";"240678";"UO_0000065";"15.93";"0.30";"4.95";"10.43";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645895";"";"0";"536.56";"1";"3.90";"BDBM116074";"CCc1ncnc(-c2ccc(C(=O)N3CCN4CCC[C@H]4C3)c(OC(F)(F)F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"9.33";"nM";"8.03";"";"240686";"UO_0000065";"14.97";"0.28";"4.13";"8.24";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645912";"";"0";"537.04";"1";"3.40";"BDBM116091";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(CC(C)(C)O)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.29";"nM";"9.54";"";"240703";"UO_0000065";"17.76";"0.34";"6.14";"8.79";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645927";"";"0";"483.96";"0";"3.59";"BDBM116106";"CCc1ncnc(-c2ccc(C(=O)N3CCn4ccnc4C3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.67";"nM";"9.17";"";"240718";"UO_0000065";"18.96";"0.36";"5.58";"8.92";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645933";"";"0";"509.59";"1";"4.23";"BDBM116112";"CCNc1ccc(C#Cc2c(CC)ncnc2-c2ccc(C(=O)N3CCn4c(C)cnc4C3)c(F)c2)cn1";"IC50";"'='";"1.63";"nM";"8.79";"";"240724";"UO_0000065";"17.24";"0.32";"4.56";"9.89";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645946";"";"0";"504.54";"1";"2.52";"BDBM116125";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(C4COC4)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"3.07";"nM";"8.51";"";"240737";"UO_0000065";"16.87";"0.31";"5.99";"8.73";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3648865";"";"0";"600.70";"1";"4.46";"BDBM116171";"CCc1ncnc(-c2ccc(C(=O)N3CCOC4(CCN(C(=O)OC(C)(C)C)CC4)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"67.77";"nM";"7.17";"";"240783";"UO_0000065";"11.93";"0.22";"2.71";"5.79";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643185";"";"0";"479.54";"0";"2.14";"BDBM115828";"CCc1ncnc(-c2ccc(C(=O)NC3CCS(=O)(=O)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"5.0";"nM";"8.30";"";"240440";"UO_0000065";"17.31";"0.33";"6.16";"6.49";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3640945";"";"0";"301.35";"0";"2.53";"BDBM115595";"Cc1cc(-c2ncnc(C)c2C#Cc2ccc(N)nc2)ccn1";"IC50";"'='";"40.0";"nM";"7.40";"";"240232";"UO_0000065";"24.55";"0.44";"4.87";"9.54";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3641012";"";"0";"515.06";"1";"4.44";"BDBM115663";"CCc1ncnc(-c2ccc(C(=O)N3CCN(C4CCCC4)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"4.0";"nM";"8.40";"";"240300";"UO_0000065";"16.30";"0.31";"3.96";"9.52";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643147";"";"0";"475.98";"0";"3.72";"BDBM115763";"CCc1ncnc(-c2ccc(C(=O)N3CCC(C)(O)CC3)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"6.0";"nM";"8.22";"";"240400";"UO_0000065";"17.27";"0.33";"4.50";"7.81";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643208";"";"0";"484.58";"0";"3.53";"BDBM115851";"CCc1ncnc(-c2ccc(C(=O)N3CCC(N4CCCC4)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"17.0";"nM";"7.77";"";"240463";"UO_0000065";"16.03";"0.29";"4.24";"8.81";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645937";"";"0";"598.72";"2";"5.54";"BDBM116116";"CCNc1ccc(C#Cc2c(CC)ncnc2-c2ccc(C(=O)N3CCC4(CC3)CN(C(=O)OC(C)(C)C)C4)c(F)c2)cn1";"IC50";"'='";"11.46";"nM";"7.94";"";"240728";"UO_0000065";"13.26";"0.25";"2.40";"7.90";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3645967";"";"0";"532.60";"1";"3.03";"BDBM116147";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCN(C4CCCC4O)CC3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"0.28";"nM";"9.55";"";"240759";"UO_0000065";"17.94";"0.33";"6.52";"8.81";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3648877";"";"0";"519.02";"1";"4.04";"BDBM116183";"CCc1ncnc(-c2cc(F)c(C(=O)N3CCC4(CC3)CN(C)C4)c(Cl)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"10.07";"nM";"8.00";"";"240795";"UO_0000065";"15.41";"0.30";"3.96";"9.06";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL3643175";"";"0";"514.65";"1";"4.60";"BDBM115818";"CCc1ncnc(-c2ccc(C(=O)NC3CC(C)(C)N(C)C(C)(C)C3)c(F)c2)c1C#Cc1ccc(N)nc1";"IC50";"'='";"16.0";"nM";"7.80";"";"240430";"UO_0000065";"15.15";"0.28";"3.20";"8.03";"False";"CHEMBL3706089";"mTOR Kinase Activity Assay: The mTOR kinase TR-FRET assay utilizes a physiologically relevant protein substrate for mTOR (4E-BP1, labeled with an acceptor fluorophore (Green Fluorescent Protein) and paired with a corresponding Tb-labeled phospho-specific antibody. The assay itself can be divided into two phases: the reaction phase and the detection phase.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638592";"37";"BindingDB Database";"";"2014";""
"CHEMBL2172631";"";"0";"384.41";"0";"3.10";"19f";"Cc1nc(Nc2cccnc2)cc(-c2c(Nc3cc[nH]n3)nc3cccnn23)n1";"IC50";"'='";"147.0";"nM";"6.83";"";"";"UO_0000065";"17.77";"0.32";"3.73";"5.62";"False";"CHEMBL2175555";"Inhibition of mTOR by LanthaScreen assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2169744";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2012";""
"CHEMBL2165038";"";"0";"341.38";"0";"3.95";"18";"Cc1nc(-c2cccnc2Nc2cccc3[nH]ccc23)c2[nH]cnc2n1";"IC50";"'='";"560.0";"nM";"6.25";"";"";"UO_0000065";"18.31";"0.33";"2.30";"6.57";"False";"CHEMBL2169664";"Inhibition of recombinant GST-tagged mTOR-mediated 4EBP1 phosphorylation after 90 mins by FRET assay";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2163268";"1";"Scientific Literature";"J. Med. Chem.";"2012";""
"CHEMBL4110853";"";"0";"429.50";"0";"1.90";"BDBM251598";"CC(C)(c1nc(-c2cccc3[nH]ncc23)nc2c1OC[C@H]1COCCN21)S(C)(=O)=O";"IC50";"'='";"5580.0";"nM";"5.25";"";"438494";"UO_0000065";"12.23";"0.24";"3.35";"4.76";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3913428";"";"0";"470.55";"0";"2.27";"BDBM251579";"CS(=O)(=O)C1(c2nc(-c3cccc4[nH]ccc34)nc3c2OCC2COCCN32)CCOCC1";"IC50";"'='";"2720.0";"nM";"5.57";"";"438475";"UO_0000065";"11.83";"0.23";"3.30";"5.22";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL3985847";"";"0";"458.54";"0";"1.73";"BDBM251588";"CNc1nc2ccccc2n1-c1nc2c(c(C(C)(C)S(C)(=O)=O)n1)OC[C@@H]1COCCN21";"IC50";"'='";"604.0";"nM";"6.22";"";"438484";"UO_0000065";"13.56";"0.27";"4.49";"5.58";"False";"CHEMBL3889163";"LanthaScreen Kinase Activity Assay: The enzymatic mTOR activity was measured using a LanthaScreen kinase activity assay (Invitrogen). The enzyme was purchased from Invitrogen (PV4754), as well as the GFP-labelled substrate (4EBP1-GFP; PV4759) and the Tb-antip4EBP1(pThr46) antibody (PV4757). The assay was performed in 50 Mm HEPES buffer, pH 7.5, containing 1.5 mM MnCl2, 10 mM MgCl2, 1 mM EGTA, 2.5 mM DTT and 0.01% Tween-20. The concentration of the assay components were the following: 0.24 nM mTOR kinase, 400 nM 4EBP1-GFP, 10 mM ATP and serial dilutions of the compound (inhibitor) to be evaluated. After 1 h incubation at room temperature, 20 mM EDTA was used to stop the reaction and terbium-labelled antibody (4 nM) added to detect phosphorylated product. The antibody associates with the phosphorylated product resulting in an increased TR-FRET value. The TR-FRET value (a dimensionless number) was calculated as the ratio of the acceptor signal (GFP, emission at 520 nm) to the donor signal (terbium, emission at 495 nm).";"B";"BAO_0000357";"single protein format";"";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886972";"37";"BindingDB Database";"";"2016";""
"CHEMBL1078983";"AZD-2014";"0";"465.55";"0";"2.64";"Ku-0063794";"COc1ccc(-c2ccc3c(N4CCOCC4)nc(N4C[C@H](C)O[C@H](C)C4)nc3n2)cc1CO";"IC50";"'='";"2.5";"nM";"8.60";"";"";"UO_0000065";"18.48";"0.35";"5.96";"9.24";"False";"CHEMBL2338832";"Inhibition of recombinant FLAG-tagged mTOR (1362 to 2549) (unknown origin) expressed in HEK293 cells";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"HEK293";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL2331448";"1";"Scientific Literature";"Bioorg. Med. Chem. Lett.";"2013";"CHEMBL3307715"
"CHEMBL3586572";"";"0";"336.36";"0";"1.41";"25";"CCN1CC(=O)Nc2ncc(-c3ccc(-c4nc[nH]n4)nc3C)nc21";"IC50";"'='";"90.0";"nM";"7.05";"";"";"UO_0000065";"20.95";"0.38";"5.64";"6.26";"False";"CHEMBL3587521";"Inhibition of mTOR (unknown origin) by HTR-FRET substrate phosphorylation assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3585264";"1";"Scientific Literature";"J. Med. Chem.";"2015";""
"CHEMBL3650239";"";"0";"507.60";"2";"5.26";"BDBM136382";"COc1ccc(CN2C[C@H](C(C)C)N(c3ccn4ncc(-c5ccc(-c6ncc[nH]6)cc5)c4n3)C2=O)cc1";"IC50";"'='";"46.0";"nM";"7.34";"";"270256";"UO_0000065";"14.45";"0.26";"2.08";"8.01";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653554";"";"0";"487.57";"0";"2.44";"BDBM136410";"CC(C)[C@H]1CN(C[C@@H]2COCCN2)C(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"16.3";"nM";"7.79";"";"270284";"UO_0000065";"15.97";"0.30";"5.35";"6.68";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653555";"";"0";"471.57";"0";"3.20";"BDBM136411";"CC(C)[C@H]1CN(C2CCNCC2)C(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"22.4";"nM";"7.65";"";"270285";"UO_0000065";"16.22";"0.30";"4.45";"7.13";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653559";"";"0";"487.57";"0";"2.44";"BDBM136415";"CC(C)[C@H]1CN(C[C@H]2CNCCO2)C(=O)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)cc3)c2n1";"IC50";"'='";"37.0";"nM";"7.43";"";"270289";"UO_0000065";"15.24";"0.28";"4.99";"6.38";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3653574";"";"0";"447.47";"0";"4.23";"BDBM136431";"O=C1OC[C@H](C2CCCCC2)N1c1ccn2ncc(-c3ccc(-c4nc[nH]n4)c(F)c3)c2n1";"IC50";"'='";"1.6";"nM";"8.80";"";"270305";"UO_0000065";"19.66";"0.36";"4.57";"8.68";"False";"CHEMBL3706278";"Kinase Assay: The ability of compounds of Formula I to inhibit mTOR was determined in a radioactive filtration assay that measures the transfer of radiolabeled phosphate from [gamma-33P]ATP to the protein substrate 4E-BP1. Compounds were first prepared at 50x the top dose of 10,000 nM and serially diluted 3-fold in DMSO to give ten dose dilution series. Assays were conducted in 96-well polypropylene U-bottom plates in 40 uL (final volume) assay mixtures that contained 50 mM K+HEPES, pH 7.5, 1 mM EGTA, 0.005% Tween-20, 10 mM MnCl2, 2.5 mM DTT, 2% DMSO (final concentration with compound), 10 uM [gamma-33P]ATP (50 uCi/mL), 5 uM 4E-BP1 and 5 nM mTOR, which was added last to initiate the assay. Each plate contained appropriate high (uninhibited) and low (prequenched) controls as well as a reference compound. Incubations were carried out at 22 C. for 45 minutes, after which the reaction was stopped by the addition of 100 uL aliquots of 25% TCA.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3639211";"37";"BindingDB Database";"";"2014";""
"CHEMBL3646477";"";"0";"453.51";"0";"3.56";"BDBM125319";"COc1ccc(Nc2ncc(CNCc3cccnc3)cc2-c2nc(C)nc3[nH]cnc23)cn1";"IC50";"'='";"1397.0";"nM";"5.86";"";"255038";"UO_0000065";"12.91";"0.24";"2.29";"4.63";"False";"CHEMBL3706289";"In Vitro Inhibition Assay: The Invitrogen (Carlsbad, Calif.) mammalian target of rapamycin (mTOR) Lanthascreen assay can be used to quantitate mTOR kinase activity in an in vitro setting. Active mTOR phosphorylates eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) on residue threonine 46. This phosphorylation event can be detected with a phospho-specific terbium (Tb) labeled Ab, in turn bringing the Tb label in close proximity to the GFP tagged 4E-BP1 and allowing for time-resolved fluorescence resonance energy transfer (TR-FRET), which correlates 4E-BP1 phosphorylation levels with mTOR kinase activity.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3638541";"37";"BindingDB Database";"";"2014";""
"CHEMBL4060768";"";"0";"525.55";"1";"3.72";"10";"O=C(c1cc([C@H]2CCCN2c2cc(F)cc(F)c2)c2oc(N3CCOCC3)cc(=O)c2c1)N1CCOCC1";"IC50";"'='";"42000.0";"nM";"4.38";"";"";"UO_0000065";"8.33";"0.16";"0.66";"5.80";"False";"CHEMBL4015080";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4014298";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL4100890";"";"0";"290.33";"0";"0.03";"3b";"c1nc2c(N3CCOCC3)nc(N3CCOCC3)nc2[nH]1";"IC50";"'>'";"2000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL4084177";"";"0";"289.34";"0";"0.63";"3c";"c1cc2c(N3CCOCC3)nc(N3CCOCC3)nc2[nH]1";"IC50";"'>'";"2000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4051856";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as reduction in ULight-4E-BP1 phosphorylation after 30 mins by lance ultra assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4049442";"1";"Scientific Literature";"J Med Chem";"2017";""
"CHEMBL3894117";"";"0";"501.47";"2";"5.60";"BDBM213780";"CN1Cc2cnc3ccc(-c4ccc(-n5cccn5)nc4)nc3c2N(c2cccc(C(F)(F)F)c2)C1=O";"IC50";"'='";"43.7";"nM";"7.36";"";"375946";"UO_0000065";"14.68";"0.27";"1.76";"9.19";"False";"CHEMBL3888153";"mTOR Activity Assay: 1. Preparation of test reagents {circle around (1)} 1x kinase buffer (50 mM HEPES, pH 7.5, 10 mM MgCl2, 1 mM EGTA, 3 mM MnCl, 0.01% Tween-20, 2 mM DTT); {circle around (2)} 4x kinase solution (added mTOR kinase to 1x kinase buffer to provide 4x kinase solution with a final concentration of 2.5 nM); {circle around (3)} 2x substrate solution (added the substrates of 4EBP1 and ATP into 1x kinase buffer to provide 2x substrate solution with 4EBP1 final concentration of 50 nM and ATP final concentration of 10.8 uM); {circle around (4)} 4x test substance solutions (100x test substance solutions with different concentration gradients were prepared using 100% DMSO, and diluted 25-fold with 1x kinase buffer to give 4x test substance solutions with different concentration gradients) {circle around (5)} preparation of test solution (test solution containing EDTA and 4EBP1 phosphorylated antibody was prepared using activity test kit with assay buffer, the final concentration of EDTA was 8 mM, and the final concentration of 4EBP1 phosphorylated antibody was 2 nM) 2. 2.5 uL of 4x test solution was added to a 384-well plate in parallel; 3. added 2.54 uL of 4x kinase solution and incubated for 10 min; 4. then added 5 uL of 2x solutions of 4EBP1 and ATP substrates and incubated for 1 h at room temperature; 5. finally, added 10 uL of test solution to quench the reaction, and read after 60 min; 6. IC50 value was obtained via curve fitting.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886601";"37";"BindingDB Database";"";"2016";""
"CHEMBL3890850";"";"0";"555.11";"1";"4.15";"BDBM222595";"CSc1c(Cl)nc(-c2ccc(NC(=O)Nc3ccc(N4CCN(C)CC4)cn3)cc2)nc1N1CCOCC1";"IC50";"'='";"237.7";"nM";"6.62";"";"389384";"UO_0000065";"11.93";"0.24";"2.47";"6.71";"False";"CHEMBL3888310";"mTOR Kinase Assay: The activity of the compound against mTOR was examined by measuring the incorporation of 33P from [¿-33P]-ATP into 4EBP1. His-tagged, recombinant human 4EBP1 was expressed in E. coli, purified by nickel-nitrilotriacetic acid (Ni-NTA) resins, and stored at ¿80 °C. Phosphorylation of 4EBP1 by mTOR was assayed in the presence or absence of the compound and performed in a final volume of 25 ¿l reaction buffer containing 300 ng 4EBP1, 50 ng recombinant mTOR (Invitrogen), 50 mM HEPES (pH 7.5), 1 mM EGTA, 0.01% Polysorbate 20, 10 mM MnCl2, 2.5 mM DTT, 10 ¿M ATP, and 0.5 ¿Ci [Î³-33P]-ATP (PerkinElmir) for 30 min at 30 °C. The reactions were terminated by adding 3% phosphoric acid. The 33P labeled 4EBP1 was transferred onto UniFilter-96 GF/B plate (PerkinElmer) and quantified by Top Count Microplate Scintillation Counter (PerkinElmer). For primary screening of kinase activity inhibition, each test compound was evaluated at 10 M in duplicate.";"B";"BAO_0000019";"assay format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886650";"37";"BindingDB Database";"";"2016";""
"CHEMBL4109896";"";"0";"461.57";"0";"3.59";"BDBM227500";"CC(C)[C@@H]1COCCN1c1nc(N2CCOC[C@H]2C)c2nc(-c3cccc4[nH]ccc34)[nH]c2n1";"IC50";"'='";"122.0";"nM";"6.91";"";"397259";"UO_0000065";"14.98";"0.28";"3.32";"7.26";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL3934178";"";"0";"367.41";"0";"1.09";"BDBM227488";"c1ccc(-c2nc3c(N4CCOCC4)nc(N4CCOCC4)nc3[nH]2)nc1";"IC50";"'='";"860.0";"nM";"6.07";"";"397247";"UO_0000065";"16.51";"0.31";"4.98";"6.57";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL4115534";"";"0";"460.54";"0";"2.86";"BDBM227483";"C[C@@H]1COCCN1c1nc(N2CCOC[C@H]2C)c2nc(-c3ccc(-c4ncc[nH]4)cc3)[nH]c2n1";"IC50";"'='";"2122.0";"nM";"5.67";"";"397242";"UO_0000065";"12.32";"0.23";"2.81";"5.25";"False";"CHEMBL3888391";"mTOR ATP-Binding Assay: 1. 8-point serial dilutions of compounds (10 mM stock) are performed in 90% DMSO in a 384-well 'masterplate' and 50 nL is transferred onto 384-well assay plates (white polystyrene small volume; Matrix/Thermo Scientific Cat. No. #4365). 2. The final volume of the assay is 10 ¿L and the order of addition is as follows: 50 nL of compounds dilution; 5 ¿L of a mixture of GST-mTOR and Europium anti-GST antibody with or without the PI3K/mTOR inhibitor P1-103 (3-(4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol, Calbiochem); 5 ¿L of tracer-314. Incubated for 60 minutes at room temperature. TR-FRET measured in Biotek Synergy2 reader at: Excitation 340 nm/emission 665 nm; Excitation 340 nm/emission 620 nm. The assay buffer consists of 50 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM EGTA, 0.01% Pluronic F-127. Tracer-314 (Alexa Fluor® 647-labeled ATP-competitive kinase inhibitor; Cat. No. PV6087), Europium anti-GST antibody (Cat. No PV5594) and N-terminally GST-tagged truncated human mTOR (FRAP1) (Cat. No PV4754) are available from Invitrogen. The following final concentrations are used: 3 nM GST-mTOR; 1 nM Europium anti-GST antibody; +/¿ 10 ¿M P1-103; and 10 nM tracer-314. The final concentrations of diluted compounds are 9091; 2730; 910; 273; 91; 27; 9; and 3 nM. The final concentration of DMSO is 0.45%. The following controls are used: High signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, tracer-314; Low signal: solvent vehicle, GST-mTOR, Eu-anti-GST antibody, P1-103, tracer-314.";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL3886692";"37";"BindingDB Database";"";"2016";""
"CHEMBL4176771";"";"0";"543.55";"1";"3.84";"20";"COc1ncc(-c2cc(O[C@@H]3CCOC3)c3nc(N)nc(C)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"9.9";"nM";"8.00";"";"";"UO_0000065";"14.73";"0.29";"4.16";"5.78";"False";"CHEMBL4150392";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide as substrate after 30 mins by Lance Ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4145625";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL4098391";"";"0";"470.58";"0";"4.43";"10l";"CCNC(=O)Nc1ccc(-c2cc(N3CCOCC3)c3nc(C)n(Cc4ccccc4)c3n2)cc1";"IC50";"";"";"";"";"";"Not Determined";"";"";"";"";"";"False";"CHEMBL4056088";"Inhibition of mTOR (unknown origin) by Kinase-Glo plus luminescence kinase assay or and ADP-Glo Plus luminescence kinase assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052688";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL2331680";"RG-7603";"1";"452.56";"0";"2.27";"GDC-0349";"CCNC(=O)Nc1ccc(-c2nc3c(c(N4CCOC[C@@H]4C)n2)CCN(C2COC2)C3)cc1";"IC50";"'='";"39.0";"nM";"7.41";"";"";"UO_0000065";"16.37";"0.31";"5.14";"8.07";"False";"CHEMBL4056088";"Inhibition of mTOR (unknown origin) by Kinase-Glo plus luminescence kinase assay or and ADP-Glo Plus luminescence kinase assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4052688";"1";"Scientific Literature";"Bioorg Med Chem Lett";"2017";""
"CHEMBL4285417";"";"0";"412.52";"0";"2.91";"2; AZD6738";"C[C@@H]1COCCN1c1cc(C2([S@](C)(=N)=O)CC2)nc(-c2ccnc3[nH]ccc23)n1";"IC50";"'>'";"23000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4269700";"Inhibition of mTOR in human MDA-MB-468 cells assessed as decrease in AKT phosphorylation at S473 residue";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MDA-MB-468";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4266018";"1";"Scientific Literature";"J Med Chem";"2018";""
"CHEMBL4097625";"";"0";"563.61";"1";"3.59";"(S)-C5";"COc1ncc(-c2ccc3ncn([C@H]4CCN(C(=O)C5CC5)C4)c(=O)c3c2)cc1NS(=O)(=O)c1ccc(F)cc1";"IC50";"'='";"208.0";"nM";"6.68";"";"";"UO_0000065";"11.86";"0.23";"3.09";"5.41";"False";"CHEMBL4000385";"Inhibition of mTOR (unknown origin) using L-alpha-phosphatidylinositol as substrate after 40 mins by ATP depletion assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4000150";"1";"Scientific Literature";"Bioorg Med Chem";"2015";""
"CHEMBL4288258";"";"0";"478.86";"0";"3.50";"31";"COc1ncc(-c2ccc3ncc(Cl)c(=O)n3c2)cc1NS(=O)(=O)c1ccc(F)cc1F";"IC50";"'='";"4.7";"nM";"8.33";"";"";"UO_0000065";"17.39";"0.36";"4.83";"8.11";"False";"CHEMBL4255949";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1(Thr37/46) peptide as substrate measured after 2 hrs by HTRF assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4251704";"1";"Scientific Literature";"ACS Med Chem Lett";"2018";""
"CHEMBL4287809";"";"0";"426.43";"0";"2.71";"14";"COc1ncc(-c2ccc3nccc(=O)n3c2)cc1NS(=O)(=O)c1ccccc1F";"IC50";"'>'";"400.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4255944";"Inhibition of mTOR in human MCF7 cells assessed as reduction in P70S6K phosphorylation after 4 hrs by ADP-Glo assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MCF7";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4251704";"1";"Scientific Literature";"ACS Med Chem Lett";"2018";""
"CHEMBL4280265";"";"0";"448.84";"0";"3.49";"27";"O=c1ccnc2ccc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4F)c3)cn12";"IC50";"'>'";"400.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4255944";"Inhibition of mTOR in human MCF7 cells assessed as reduction in P70S6K phosphorylation after 4 hrs by ADP-Glo assay";"B";"BAO_0000219";"cell-based format";"Homo sapiens";"";"";"MCF7";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4251704";"1";"Scientific Literature";"ACS Med Chem Lett";"2018";""
"CHEMBL4246563";"";"0";"407.43";"0";"4.92";"16b";"C=CC(=O)Nc1ccc(-n2c(=O)ccc3oc4ccc(-c5cccnc5)cc4c32)cc1";"IC50";"'='";"228.0";"nM";"6.64";"";"";"UO_0000065";"16.30";"0.29";"1.72";"8.61";"False";"CHEMBL4235194";"Inhibition of recombinant human N-terminal FLAG-tagged mTOR (1362-end residues)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4229497";"1";"Scientific Literature";"Bioorg Med Chem";"2018";""
"CHEMBL4244147";"";"0";"381.44";"0";"1.49";"3c";"COc1ccc(-c2ccc3c(N4CCOCC4)nc(CN)nc3n2)cc1CO";"IC50";"'='";"146.0";"nM";"6.84";"";"";"UO_0000065";"17.92";"0.33";"5.35";"6.41";"False";"CHEMBL4233142";"Inhibition of mTOR (unknown origin) using ULight-4E-BP1 peptide substrate measured after 1 hr by Lance Ultra assay";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4229417";"1";"Scientific Literature";"Bioorg Med Chem";"2018";""
"CHEMBL4276946";"";"0";"284.15";"0";"3.41";"3a";"CC(=O)n1nc(C)c(-c2ccc(Cl)c(Cl)c2)c1N";"IC50";"'>'";"100000.0";"nM";"";"";"";"UO_0000065";"";"";"";"";"False";"CHEMBL4259095";"Inhibition of mTOR (unknown origin)";"B";"BAO_0000357";"single protein format";"Homo sapiens";"";"";"";"";"CHEMBL2842";"Serine/threonine-protein kinase mTOR";"Homo sapiens";"SINGLE PROTEIN";"CHEMBL4257503";"1";"Scientific Literature";"MedChemComm";"2018";""
